<SEC-DOCUMENT>0001193125-16-660212.txt : 20160727
<SEC-HEADER>0001193125-16-660212.hdr.sgml : 20160727
<ACCEPTANCE-DATETIME>20160727170512
ACCESSION NUMBER:		0001193125-16-660212
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		14
FILED AS OF DATE:		20160727
DATE AS OF CHANGE:		20160727

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bioventus Inc.
		CENTRAL INDEX KEY:			0001665988
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				810980861
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-212329
		FILM NUMBER:		161787436

	BUSINESS ADDRESS:	
		STREET 1:		4721 EMPEROR BOULEVARD, SUITE 100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		(919) 474-6700

	MAIL ADDRESS:	
		STREET 1:		4721 EMPEROR BOULEVARD, SUITE 100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d22578ds1a.htm
<DESCRIPTION>AMENDMENT NO. 3 TO FORM S-1
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No. 3 to Form S-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>As filed with the Securities and Exchange Commission on July&nbsp;27, 2016 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Registration No. 333-212329 </B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>SECURITIES
AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>Washington, D.C. 20549 </B></FONT></P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>Amendment No. 3 to </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>FORM S-1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>REGISTRATION
STATEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B><I>UNDER </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>THE SECURITIES ACT OF 1933 </I></B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="6">Bioventus Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(Exact name of registrant as specified in its charter) </B></FONT></P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Delaware<BR></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>3841<BR></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>81-0980861<BR></B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(State or other jurisdiction of<BR>incorporation or organization)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(Primary Standard Industrial<BR>Classification Code Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(I.R.S. Employer<BR>Identification No.)</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>4721 Emperor Boulevard, Suite 100 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>Durham, North Carolina 27703 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(919) 474-6700 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></FONT></P>
<P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Anthony P. Bihl III </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Chief
Executive Officer </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Bioventus Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>4721 Emperor Boulevard, Suite 100 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Durham, North Carolina 27703 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(919) 474-6700 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>(Name,
address, including zip code, and telephone number, including area code, of agent for service) </B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B><I>Copies to:
</I></B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Charles K. Ruck, Esq.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>Wesley C. Holmes, Esq.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Latham&nbsp;&amp; Watkins LLP</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>885 Third Avenue</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>New York,
New York 10022</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Telephone: (212) 906-1200</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>Fax: (212)&nbsp;751-4864</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Arthur D. Robinson, Esq.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="1"><B>Simpson Thacher&nbsp;&amp; Bartlett LLP</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>425 Lexington Avenue</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>New York, New York 10017</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Telephone: (212)&nbsp;455-2000</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Fax: (212)&nbsp;455-2502</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement is declared effective. </FONT></P>
<P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933,
check the following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="1"></FONT> </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1">If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="1"></FONT> </FONT></P>
<P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="1"></FONT> </FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1">If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective
registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="1"></FONT> </FONT></P>
<P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the
definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. </FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="1"></FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">Accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="1"></FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">Non-accelerated filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="1"></FONT>&nbsp;&nbsp;(Do not check if a
smaller reporting company)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="1"></FONT></FONT></TD></TR>
</TABLE> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>CALCULATION OF REGISTRATION FEE </B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Title of each class of<BR>securities to be registered</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Proposed</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>maximum</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>aggregate</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>offering
price(1)</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Amount of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>registration fee(2)(3)</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Class A Common Stock, $0.001 par value per share</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1">$182,647,044</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1">$18,392.56</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The registration fee was previously paid by the Registrant. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><B>The Registrant hereby amends this
Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in
accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></FONT></P>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2" COLOR="#8b3f4e"><B>The information in this preliminary prospectus is not complete and may be changed. These securities
may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any
state or other jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2" COLOR="#8b3f4e"><B>Subject to completion, dated July&nbsp;27, 2016 </B></FONT></P>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Preliminary prospectus </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><I>8,823,529&nbsp;Shares </I></B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g22578g45y56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><I>Class&nbsp;A common stock </I></B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">This is the initial public offering of
shares of Class&nbsp;A common stock of Bioventus Inc. We are selling 8,823,529&nbsp;shares of our Class&nbsp;A common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Prior to this offering,
there has been no public market for our Class&nbsp;A common stock. The estimated initial public offering price is between $16.00&nbsp;and $18.00 per share. We expect to list our Class&nbsp;A common stock on The NASDAQ Global Market, or NASDAQ, under
the symbol &#147;BIOV&#148;. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We will use the net proceeds that we receive from this offering to purchase from Bioventus LLC <FONT
STYLE="white-space:nowrap">newly-issued</FONT> common membership interests of Bioventus LLC, which we refer to as the &#147;LLC Interests.&#148; There is no public market for the&nbsp;LLC Interests. The purchase price for the <FONT
STYLE="white-space:nowrap">newly-issued&nbsp;LLC</FONT> Interests will be equal to the public offering price of our Class&nbsp;A common stock, less the underwriting discounts and commissions referred to below. We intend to cause Bioventus LLC to use
the net proceeds it receives from us in connection with this offering as described in &#147;Use of proceeds.&#148; Simultaneous with this offering, certain of the indirect owners of membership interests in Bioventus LLC, whom we refer to as
&#147;Former LLC Owners,&#148; will exchange their indirect ownership interests for shares of Class&nbsp;A common stock and certain other holders of membership interests in Bioventus LLC, whom we refer to as &#147;Continuing LLC Owners,&#148; will
retain their membership interests in Bioventus LLC. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We will have two classes of common stock outstanding after this offering: Class&nbsp;A common stock
and Class B common stock. Each share of Class&nbsp;A common stock and Class B common stock entitles its holder to one vote on all matters presented to our stockholders generally. All of our Class B common stock will be held by the Continuing LLC
Owners, on a one-to-one basis with the number of LLC Interests they own. Immediately following this offering, the holders of our Class&nbsp;A common stock issued in this offering collectively will hold 37.2% of the economic interests in us and 26.5%
of the voting power in us, the Former LLC Owners, through their ownership of Class&nbsp;A common stock, collectively will hold 62.8% of the economic interests in us and 44.8% of the voting power in us, and the Continuing LLC Owners, through their
ownership of all of the outstanding Class B common stock, collectively will hold no economic interest in us and the remaining 28.7% of the voting power in us. We will be a holding company, and upon consummation of this offering and the application
of proceeds therefrom, our principal asset will be the LLC Interests we purchase from Bioventus LLC and acquire from the Former LLC Owners, representing an aggregate 71.3% economic interest in Bioventus LLC. The remaining 28.7% economic interest in
Bioventus LLC will be owned by the Continuing LLC Owners through their ownership of LLC Interests. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We will be the sole managing member of Bioventus LLC.
We will operate and control all of the business and affairs of Bioventus LLC and, through Bioventus LLC and its subsidiaries, conduct our business. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">Following this offering, we will be a &#147;controlled company&#148; within the meaning of the corporate governance rules for NASDAQ-listed companies. See
&#147;Transactions&#148; and &#147;Management&#151;Corporate governance.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">We are an &#147;emerging growth company&#148; as defined under the
federal securities laws and, as such, may elect to comply with certain reduced public company reporting requirements for future filings. See &#147;Prospectus summary&#151;Implications of being an emerging growth company.&#148; </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Per share</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Initial public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Underwriting discounts and commissions&nbsp;(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Proceeds to us, before expenses</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">See &#147;Underwriting&#148; for additional information regarding underwriting compensation. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1">We have granted the underwriters an over-allotment option for a period of 30 days to purchase up to 1,323,529 additional shares of Class&nbsp;A common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1"><B>Investing in shares of our Class&nbsp;A common stock involves risks. See &#147;<A HREF="#rom22578_2">Risk factors</A>&#148; beginning on page 23. </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to
the contrary is a criminal offense. </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">The underwriters expect to deliver the shares against payment in New York, New York on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="5"><B>J.P. Morgan</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="5"><B>Piper Jaffray</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="4"><B>Stifel</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="4"><B>Leerink Partners</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1">The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g22578ifc.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc"></A>Table of contents </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_1">Prospectus summary</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_2">Risk factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_3">Special note regarding forward-looking statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">70</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_4">Use of proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">72</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_5">Dividend policy</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">73</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_6">Transactions</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">74</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_7">Capitalization</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">78</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_8">Dilution</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">79</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_9">Unaudited pro forma consolidated financial information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">82</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_10">Selected financial data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">92</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_11">Management&#146;s discussion and analysis of financial condition and results of operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">94</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_12">Industry</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">131</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_13">Business</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">139</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_14">Management</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">177</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_15">Executive compensation</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">185</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_16">Certain relationships and related party transactions</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">199</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_17">Principal stockholders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">206</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_18">Description of capital stock</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">208</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_19">Description of indebtedness</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">214</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_20">Shares eligible for future sale</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">218</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_21">Material U.S. federal income tax consequences to non-U.S. holders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">221</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_22">Underwriting</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">225</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_23">Legal matters</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">230</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_24">Experts</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">230</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_25">Where you can find more information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">230</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom22578_26">Index to financial statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-1</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those contained in this
prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This
prospectus is an offer to sell only the shares of Class&nbsp;A common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing
prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our Class&nbsp;A common stock. Our business, financial condition, results of operations and prospects may have changed since that date.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For investors outside the United States: Neither we nor any of the underwriters have taken any action that would permit this offering or possession or
distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons who have come into possession of this prospectus in a jurisdiction outside the United States are required to
inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">i </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Basis of presentation </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In connection with the closing of this offering, we will effect certain organizational transactions. Unless otherwise stated or the context otherwise requires, all information in this prospectus reflects the
consummation of the organizational transactions and this offering, which we refer to collectively as the &#147;Transactions.&#148; See &#147;Transactions&#148; for additional information regarding the Transactions. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:arial" SIZE="2">As used in this prospectus, unless the context otherwise requires, references to: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#147;we,&#148; &#147;us,&#148; &#147;our,&#148; the &#147;Company,&#148; &#147;Bioventus,&#148; &#147;Bioventus Inc.&#148; and similar references refer:
(i)&nbsp;following the consummation of the Transactions, including this offering, to Bioventus&nbsp;Inc., and, unless otherwise stated, all of its subsidiaries, including Bioventus LLC, which we refer to as &#147;Bioventus LLC,&#148; and, unless
otherwise stated, all of its subsidiaries, and (ii)&nbsp;on or prior to the completion of the Transactions, including this offering, to Bioventus LLC and, unless otherwise stated, all of its subsidiaries. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>&#147;Acquisition&#148;</I> refers to our acquisition of BioStructures, LLC, or BioStructures, on November&nbsp;24, 2015. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>&#147;Continuing LLC Owners&#148;</I> refers to our chief executive officer and Smith&nbsp;&amp; Nephew, Inc., each of whom will continue to own&nbsp;LLC
Interests (as defined below) after the Transactions and who may, following the consummation of this offering, exchange their&nbsp;LLC Interests for shares of our Class&nbsp;A common stock (upon redemption or cancellation of the same number of their
shares of our Class B common stock) or a cash payment (if mutually agreed) as described in &#147;Certain relationships and related party transactions&#151;Bioventus LLC Agreement.&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>&#147;Essex Woodlands Health Ventures&#148;</I> refers to Essex Woodlands Health Ventures Fund VIII, L.P., Essex Woodlands Health Ventures Fund VIII-A, L.P.
and Essex Woodlands Health Ventures Fund VIII-B, L.P. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>&#147;Former LLC Owners&#148;</I> refers to all of the Original LLC Owners (including Essex Woodlands Health Ventures, but excluding the Continuing LLC
Owners) who will exchange their&nbsp;indirect ownership interests in Bioventus LLC for shares of our Class&nbsp;A common stock in connection with the consummation of this offering. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>&#147;LLC Interests&#148;</I> refer to the single class of <FONT STYLE="white-space:nowrap">newly-issued</FONT> common membership interests of Bioventus LLC.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>&#147;Original LLC Owners&#148;</I> refer to the direct and certain indirect owners of Bioventus LLC, collectively, prior to the Transactions, including the
members of the Voting Group (as defined below). </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>&#147;Phantom Plan Participants&#148;</I> refer to certain individuals who hold existing awards under the Phantom Profits Interest Plan, which we refer to as
the &#147;Phantom Plan,&#148; and will, in connection with this offering, receive rights to receive shares of Class&nbsp;A common stock upon settlement of their awards as described in &#147;Executive compensation&#151;Narrative to summary
compensation table&#151;Elements of compensation&#151;Equity-based compensation&#151;Phantom profits interest units.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>&#147;Voting Group&#148;</I> refers collectively to (i)&nbsp;Essex Woodlands Health Ventures, (ii)&nbsp;Smith&nbsp;&amp; Nephew, Inc., a U.S. based subsidiary
of Smith&nbsp;&amp; Nephew plc, or Smith&nbsp;&amp; Nephew or S&amp;N and (iii)&nbsp;certain other Original LLC Owners, all of whom will be parties to the Stockholders Agreement as described in &#147;Description of capital stock&#151;Stockholders
Agreement.&#148; The Voting Group will hold Class&nbsp;A common stock and Class&nbsp;B common stock representing in the aggregate a majority of the combined voting power of our common stock. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We will be a holding company and the sole managing member of Bioventus LLC, and upon completion of this offering and the application of proceeds therefrom, our
principal asset will be LLC Interests of Bioventus LLC. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">ii </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Bioventus LLC is the predecessor of the issuer, Bioventus Inc., for financial reporting purposes. Bioventus Inc. will be the audited financial reporting entity following this offering.
Accordingly, this prospectus contains the following historical financial statements: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Bioventus Inc.</I> The historical financial information of Bioventus Inc. has not been included in this prospectus as it is a newly incorporated entity, has
no business transactions or activities to date and had no assets or liabilities during the periods presented in this prospectus. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Bioventus LLC.</I> As we will have no other interest in any operations other than those of Bioventus LLC and its subsidiaries, the historical consolidated
financial information included in this prospectus is that of Bioventus LLC and its subsidiaries. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The unaudited pro forma financial
information of Bioventus Inc. presented in this prospectus has been derived by the application of pro forma adjustments to the historical consolidated financial statements of Bioventus LLC and its subsidiaries included elsewhere in this prospectus.
These pro forma adjustments give effect to the Acquisition and the Transactions as described in &#147;Transactions,&#148; including the completion of this offering, as if all such transactions had occurred on January&nbsp;1, 2015, in the case of the
unaudited pro forma consolidated statements of operations data for the year ended December 31, 2015 and the three month periods ended March 28, 2015 and April 2, 2016, and as of April 2, 2016, in the case of the unaudited pro forma consolidated
balance sheet data. See &#147;Unaudited pro forma consolidated financial information&#148; for a complete description of the adjustments and assumptions underlying the pro forma financial information included in this prospectus. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Numerical figures included in this prospectus have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be
arithmetic aggregations of the figures that precede them. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Trademarks, trade names and service marks </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">This prospectus includes our trademarks and trade names, such as Bioventus, Durolane, Exogen, Exponent, OsteoAMP, OsteoPlus, PureBone,
Signafuse and our logo. This prospectus also includes trademarks, trade names and service marks that are the property of other organizations. Solely for convenience, trademarks and trade names referred to in this prospectus appear without any
&#147;&#153;&#148; or &#147;<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>&#148; symbol, but those references are not intended to indicate, in any way, that we will
not assert, to the fullest extent under applicable law, our rights to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#146; trademarks, trade names or service marks to imply, and such use or
display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Market and industry data
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Unless otherwise indicated, information contained in this prospectus concerning our industry and the markets in which we operate is based on
information from iData Research, Inc., or iData. Other information concerning our industry and the markets in which we operate is based on independent industry and research organizations, other <FONT STYLE="white-space:nowrap">third-party</FONT>
sources (including industry publications, surveys and forecasts), and management estimates. Management estimates are derived from publicly available information released by independent industry analysts and
<FONT STYLE="white-space:nowrap">third-party</FONT> sources, as well as data from our internal research, and are based on assumptions made by us upon reviewing such data and our knowledge of such industry and markets which we believe to be
reasonable. In addition, projections, assumptions and estimates of the future performance of the industry in which we operate and our future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those
described in &#147;Risk factors&#148; and &#147;Special note regarding <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements.&#148; These and other factors could cause results to differ materially from those expressed in the estimates
made by the independent parties and by us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">iii </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_1"></A>Prospectus summary </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>The following summary highlights information contained elsewhere in this prospectus. This summary is not complete and may not contain all the information you should consider before investing in our Class&nbsp;A
common stock. You should read this entire prospectus carefully, including the risks of investing in our Class&nbsp;A common stock discussed under the heading &#147;Risk factors,&#148; and the financial statements and related notes included elsewhere
in this prospectus before making an investment decision. </I></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Overview </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are a global medical technology company focused on developing and commercializing innovative and proprietary orthobiologic products for the treatment of patients suffering from a broad array of musculoskeletal
conditions. Our products address the growing need for clinically effective, cost efficient and minimally invasive solutions that enhance the body&#146;s natural healing processes. For the year ended December&nbsp;31, 2015 and the three months ended
April 2, 2016, we generated $253.7 million and $65.4 million of net sales, respectively. We operate our business through four reportable segments: Active Healing Therapies&#151;U.S., Active Healing Therapies&#151;International, Surgical and BMP.
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Active Healing Therapies&#151;U.S. and International.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our Active Healing Therapies segments offer two types of non-surgical
products: our market-leading, non-invasive Exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. Our Exogen system is a U.S. Food and Drug
Administration premarket approved, or PMA, product that offers significant advantages over competitors&#146; long bone stimulation systems, including shorter treatment times, superior nonunion heal rates based on a comparison of available PMA
clinical data and a broader label that is the only label for a long bone growth stimulator for certain fresh fractures. Our two PMA approved HA viscosupplementation therapies are: Supartz FX, a five injection therapy, which we market in the United
States, and GelSyn-3, a three injection therapy, which we expect to launch in the United States in the second half of 2016. We also market Durolane, a single injection therapy, outside the United States and own certain related assets.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Surgical.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our Surgical segment offers a portfolio of advanced bone graft substitutes with 510(k) clearance or regulated as HCT/Ps
in the United States that are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries. These products include our OsteoAMP allogeneic growth factor, a range of bioactive synthetics, a collagen ceramic matrix, a
demineralized bone matrix, or DBM, and allograft comprising demineralized cancellous bone in different preparations. Our development pipeline includes additional bone graft substitutes. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>BMP.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our BMP segment is comprised of proprietary next-generation bone morphogenetic protein, or BMP. Our next-generation BMP
product candidates are designed to offer at least equivalent efficacy at a lower dose administration and provide a better-controlled release to address the safety concerns associated with Infuse Bone Graft, or Infuse, the current market-leading bone
graft. Our pre-clinical data are based on animal models, including non-human primate studies, which may not be indicative of results that we will experience in clinical trials with human subjects. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We were founded in May 2012, when a group led by Essex Woodlands Health Ventures Inc. acquired a majority stake in the biologics business of Smith&nbsp;&amp; Nephew
plc, which included Exogen, exclusive U.S. distribution rights to Supartz and exclusive distribution rights to Durolane outside the United States. Our investors believed that the biologics business would provide a platform from which to build a
global leader in the rapidly evolving </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
orthobiologics market. Since our founding, we have assembled an experienced senior executive team to execute this vision. This team has successfully accomplished the following: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Established our Surgical business through the acquisition and integration of the OsteoAMP product line in 2014 and the BioStructures business in 2015.</I>
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Accelerated the research and development of our next-generation BMP product candidates by obtaining an exclusive worldwide license to an intellectual property
portfolio.</I> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Enhanced our Active Healing Therapies business by securing distribution rights to commercialize a broader set of HA viscosupplementation therapies.</I>
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We currently market and sell our products in the United States and 29 other countries. Our Exogen system and Supartz FX, which
accounted for the majority of our revenue for the year ended December 31, 2015, have regulatory approvals to be marketed and sold in the United States. In addition, we also have regulatory approval to market and sell our Exogen system in key
international markets, such as the European Union and Canada. As of April 2, 2016, our sales organization consisted of approximately 232 direct sales representatives and 124 independent distributors in the United States and approximately
57&nbsp;direct sales representatives and 12 independent distributors internationally. In the United States, our Active Healing Therapies sales organization markets our products to orthopedists, musculoskeletal and sports medicine physicians and
podiatrists. Our Surgical sales organization is composed of a sales management team that markets our surgical products primarily to neurosurgeons and orthopedic spine surgeons. In international markets, we market and sell our Active Healing
Therapies through direct sales representatives in twelve countries and through independent distributors in an additional 17&nbsp;countries. Our products are typically covered and reimbursed by third-party payors, including government authorities,
such as Medicare and Medicaid, managed care providers and private health insurers. We have grown our total net sales from $232.4 million for the year ended December&nbsp;31, 2013 to $242.9 million for the year ended December 31, 2014 and to $253.7
million for the year ended December&nbsp;31, 2015, at a compound annual growth rate, or CAGR, of 4.5%. We have grown our total net sales from $53.4&nbsp;million for the three months ended March 28, 2015, to $65.4 million for the three months ended
April 2, 2016, at an annual growth rate of 22.5%. For the years ended December 31, 2013, 2014 and 2015 and the three months ended March&nbsp;28, 2015 and April 2, 2016, we had net losses of $22.4 million, $12.9 million, $34.1 million,
$21.0&nbsp;million and $6.0 million, respectively. We have grown our Adjusted EBITDA from $32.5&nbsp;million for the year ended December&nbsp;31, 2013 to $36.2&nbsp;million for the year ended December&nbsp;31, 2014 and to $42.2&nbsp;million for the
year ended December&nbsp;31, 2015, at a CAGR of 14.0%. Also, we have grown our Adjusted EBITDA from $2.3&nbsp;million for the three months ended March 28, 2015, to $10.7&nbsp;million for the three months ended April 2, 2016, at an annual growth rate
of 365.2%. Adjusted EBITDA is burdened by BMP program costs of $0.7 million, $6.7 million and $11.3 million, for the years ended December 31, 2013, 2014 and 2015, respectively, and $2.5 million and $2.5 million for the three months ended March 28,
2015 and April 2, 2016, respectively. For a reconciliation of net loss to Adjusted EBITDA, see Note&nbsp;3 to the information contained in &#147;&#151;Summary historical and pro forma financial information.&#148; </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Industry background </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Market opportunity
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Orthobiologics are used to accelerate the healing of, or reduce pain experienced in, bones, joints or damaged musculoskeletal tissue by
harnessing the body&#146;s natural healing processes. We believe the current U.S. annual total market opportunity for orthobiologic products is approximately $3.0 billion and will grow at approximately 4&#150;5% annually for the next five to seven
years. There is additional opportunity outside the </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
United States, particularly in HA viscosupplementation. These estimates for the U.S. market include non-surgical products, such as long bone growth stimulation and HA viscosupplementation
therapies; surgical bone graft substitutes such as allografts, DBMs, synthetics, stem cells, BMPs/growth factors; spinal stimulation; cell therapies and orthopedic cartilage repair products. Market growth is being driven by improving technologies
and unaddressed market needs, an aging population, increased incidence of spinal disorders driving the need for spinal fusion surgery and increased incidence of osteoarthritis leading to the need for HA viscosupplementation therapy or surgery.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The chart below summarizes the U.S. orthobiologics market, key product categories and our products in each of those categories: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>U.S&nbsp;current<BR>market&nbsp;size<BR>(in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014&#150;2021<BR>Market<BR>CAGR</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Primary applications</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Bioventus product<BR>offerings&nbsp;(1)</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="13"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" COLSPAN="13"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B><U>Non-surgical</U></B></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Long bone stimulation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">300</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I></I>&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><I>1.9%</I></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I></I>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Fracture repair</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Exogen</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">HA viscosupplementation&nbsp;(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">873</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I></I>&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><I>6.1%</I></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I></I>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Alleviation&nbsp;of osteoarthritis pain through single, three or five injection viscosupplementation
regimens</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Supartz&nbsp;FX, Durolane&#043;, <FONT STYLE="white-space:nowrap">GelSyn-3*</FONT></FONT></P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="10" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Subtotal</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="10" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B><U>Surgical&#151;Bone graft substitutes</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Allografts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">132</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I></I>&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><I>(0.9)%</I></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I></I>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Spinal fusion, trauma and other bone repair applications</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Purebone</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">DBMs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">365</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I></I>&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><I>2.3%</I></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I></I>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Spinal fusion, trauma and other bone repair applications</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Exponent</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Synthetics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">361</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I></I>&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><I>5.7%</I></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I></I>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Spinal fusion, trauma and other bone repair applications</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Signafuse, Interface, Osteoplus</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Stem cells</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">178</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I></I>&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><I>16.9%</I></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I></I>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Spinal fusion, trauma and other bone repair applications</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;No offerings</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">BMPs/growth factors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">372</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I></I>&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><I>0.6%</I></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I></I>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Spinal fusion, trauma and other bone repair applications</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;OsteoAMP</FONT></P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="10" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Subtotal</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>1,408</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B></B><I></I><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B></B><I>5.2%</I><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B></B><I></I><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="10" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B><U>Other markets</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Spinal stimulation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">250</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">N/A</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Spinal fusion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;No offerings</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Cell therapy</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">143</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I></I>&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><I>4.0%</I></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I></I>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Injectable platelet-rich plasma used for soft tissue repair</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;No offerings</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Orthopedic cartilage repair</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">92</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I></I>&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><I>3.8%</I></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I></I>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Autograft-, allograft- and microfracture-based cartilage repair</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;No offerings</FONT></P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="10" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Subtotal</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>485</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B></B>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="10" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Total</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>3,066</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B></B>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="13" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">Source:</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">iData 2015 U.S. Market for Orthopedic Biomaterials, except spinal stimulation data. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">See &#147;Business&#148; for additional information regarding our products. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The HA viscosupplementation market is comprised of single injection ($279 million market), three injection ($431 million market) and five injection ($163 million market)
products. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">&#043;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">We do not market this product in the United States. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">We expect to launch GelSyn-3 in the United States in the second half of 2016. </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe the orthobiologics market is characterized by a set of specific product development, regulatory, sales
and marketing and purchasing dynamics that include the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Lack of focus resulting in inadequate allocation of resources by existing orthobiologics competitors;</I> </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Increasing regulatory complexity and scrutiny;</I> </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Historical lack of investment in clinical data and clinical education; and</I> </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Hospitals increasingly favoring end-to-end orthobiologics providers.</I> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As a result of these factors, we believe there is an opportunity for a company to achieve leadership in the global orthobiologics market by focusing on developing and commercializing a portfolio of clinically
validated, cost-effective products for use both in and out of the surgical suite. Additionally, we believe there is room to grow the worldwide orthobiologics market opportunity beyond its current size of approximately $4.5&nbsp;billion, by
developing therapies that are superior to, or have a broader label than, existing bone graft substitutes or HA viscosupplementation therapies. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our
competitive strengths </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:arial" SIZE="2">We believe we have the following competitive strengths: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Sufficient scale combined with an exclusive focus on orthobiologics</I>.<I>&nbsp;&nbsp;&nbsp;&nbsp; </I>We believe we are the only company exclusively focused
on the orthobiologics market with annual net sales over $100 million. We believe we have sufficient scale and resources to be competitive and relevant in the marketplace, but are small enough to respond quickly to internal and external
opportunities. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Leadership and strong competitive positions in Active Healing Therapies</I>.<I></I>&nbsp;&nbsp;&nbsp;&nbsp; Our Active Healing Therapies segments generated
all of their $227.9 million in net sales in 2015 from PMA approved products, including our market-leading Exogen system and the HA viscosupplementation therapies that we own or distribute. We believe our direct salesforce of over 300 representatives
is among the largest sales forces in our industry. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Portfolio of advanced orthobiologics that address a variety of surgeon needs</I>.<I></I>&nbsp;&nbsp;&nbsp;&nbsp; We offer a portfolio of advanced
orthobiologics products that enables us to fulfill a greater portion of the orthobiologics needs of neurosurgeons and orthopedic spine surgeons than many of our competitors. We believe our current product portfolio, combined with our pipeline that
includes next-generation and additional indications and formulations of our products, positions us to be a portfolio provider of surgical orthobiologic solutions. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Next-generation BMP product candidates in development</I><B></B>.<B></B><I>&nbsp;&nbsp;&nbsp;&nbsp; </I>Infuse revolutionized certain types of spinal fusion
by enabling faster recovery time and improved bone healing, but safety concerns have limited its ability to be used across a broader range of procedures. In more than 80 non-human primate studies, our next-generation BMP product candidates have
demonstrated at least equivalent efficacy to Infuse at one-tenth the dosage. However, non-human primate studies may not be indicative of results that we will experience in clinical trials with human subjects. Clinical testing is expensive, is
difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Seasoned management focused on profitable growth</I>.<I></I>&nbsp;&nbsp;&nbsp;&nbsp; Our senior leadership team has been involved in growing large businesses
or business lines, major acquisitions and integrations, public company sale transactions, as well as the development, approval and launch of transformative medical devices and orthobiologics. We have grown net sales from $232.4 million as of
December 31, 2013 to $253.7 million as of December&nbsp;31, 2015 and made significant investments in our product pipeline, while growing Adjusted EBITDA. </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our strategy </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I></I><I>Grow our Surgical business by investing in our portfolio and expanding our distribution network</I><B></B>.<B></B><I></I>&nbsp;&nbsp;&nbsp;&nbsp;
Through the acquisition of BioStructures, we expanded our existing distribution network and broadened our product portfolio. We intend to sell both OsteoAMP and BioStructures products through this expanded distribution network of approximately 135
independent distributors. Additionally, we are continuing to invest in product development and clinical studies. Over the long term, we believe we can be a portfolio provider of orthobiologics to hospitals by offering bone graft substitutes backed
by clinical and economic data. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Advance our next-generation BMP product candidates</I><B></B>.<B>&nbsp;&nbsp;&nbsp;&nbsp;</B><I></I>We are investing significant resources into our
next-generation BMP product candidates. We intend to enter clinical trials for transforaminal lumbar interbody fusion, or TLIF, posterior lumbar interbody fusion, or PLIF, and open tibial fractures, which we believe represent an approximately $240
million market for BMP-2 products in the United States in the aggregate. We intend to enter a Phase 1 clinical trial within 18&nbsp;months and expect to demonstrate advancement of our product candidates through a number of milestones over the next
two years. However, we cannot determine with certainty the timing of initiation, duration or completion of future clinical trials of our BMP product candidates. Upon the first commercial sale of a product candidate, Pfizer Inc., or Pfizer, will
assign us certain intellectual property rights covered by our license agreement. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Grow our Active Healing Therapies business through new product introductions and selling strategies</I>.<I></I>&nbsp;&nbsp;&nbsp;&nbsp;We intend to grow our
HA viscosupplementation therapies business by commercializing GelSyn-3, a three injection therapy, to which we recently obtained the U.S. distribution rights from Institut Biochimique SA, or IBSA. We believe this will enable us to contract with a
broader set of payors. In addition, we intend to continue to grow sales of our Exogen system by introducing new technology-based decision-making tools that assist physicians in deciding when to prescribe long bone growth stimulators, as well as
highlighting our Exogen system&#146;s shorter treatment times, superior nonunion heal rates based on a comparison of available PMA clinical data and its broader label which is the only label for a long bone growth stimulator that includes certain
fresh fractures. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Selectively pursue</I><B></B> <I>business development opportunities</I>.<B></B><I>&nbsp;&nbsp;&nbsp;&nbsp;</I>We have completed five acquisitions, licensing
and distribution agreements since our founding in 2012. We intend to continue to selectively pursue business development opportunities that add to our Surgical business as well as broaden our Active Healing Therapies business. We will continue to be
disciplined when evaluating opportunities and look for products that have clinical differentiation and cost-effectiveness. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Focus on continued Adjusted EBITDA growth</I><B></B>.<B></B><I></I>&nbsp;&nbsp;&nbsp;&nbsp; We have increased our Adjusted EBITDA, while making significant
investments in our development pipeline. Additionally, we are focused on continuing to increase our Adjusted EBITDA over time by leveraging the investments we have made to date, as well as maintaining our cost focus. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Summary of risks associated with our business </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are
subject to a number of risks, including risks that may prevent us from achieving our business objectives or that may adversely affect our business, financial condition, results of operations and cash flows. You should carefully consider the risks
discussed in the section entitled &#147;Risk factors,&#148; including the following risks, before investing in our Class&nbsp;A common stock: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we are highly dependent on a limited number of products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we compete and may compete in the future against other companies, some of which have longer operating histories, more established products or greater resources
than we do, which may prevent us from achieving increased market penetration or improved operating results; </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">clinical trials of our next-generation BMP product candidates may fail to satisfactorily demonstrate safety and efficacy or we may be unable to obtain regulatory
approval for, or successfully commercialize our next-generation BMP product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our long-term growth depends on our ability to develop, acquire and commercialize additional orthobiologic products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our HCT/P products are subject to extensive government regulation and our failure to comply with these requirements could cause our business to suffer;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we have incurred significant net losses since inception, and we may not be able to achieve or sustain profitability; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we have identified material weaknesses in our internal control over financial reporting. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Summary of the transactions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Prior to the consummation of
this offering and the organizational transactions described below, the Original LLC Owners are the only owners of Bioventus LLC. Bioventus&nbsp;Inc. was incorporated as a Delaware corporation on December&nbsp;22, 2015 to serve as the issuer of the
Class&nbsp;A common stock offered hereby. In connection with the closing of this offering, we will consummate the following organizational transactions: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we will amend and restate the amended and restated limited liability company agreement of Bioventus LLC, as amended, effective as of the completion of this
offering, or the Bioventus LLC Agreement, to, among other things, (i)&nbsp;provide for&nbsp;LLC Interests that will be the single class of common membership interests in Bioventus LLC, (ii)&nbsp;exchange all of the existing membership interests
(including profit interests awarded under the Bioventus LLC Management Incentive Plan, or MIP) in Bioventus LLC for&nbsp;LLC Interests and (iii)&nbsp;appoint Bioventus Inc. as the sole managing member of Bioventus LLC; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we will amend and restate Bioventus Inc.&#146;s certificate of incorporation to, among other things, (i)&nbsp;provide for Class&nbsp;A common stock and
Class&nbsp;B common stock, each share of which entitles its holders to one vote per share on all matters presented to Bioventus Inc.&#146;s stockholders and (ii)&nbsp;issue shares of Class&nbsp;B common stock to the Continuing LLC Owners, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> basis with the number of&nbsp;LLC interests they own; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we will issue 8,823,529&nbsp;shares of our Class&nbsp;A common stock to the purchasers in this offering (or 10,147,058&nbsp;shares of our Class&nbsp;A common
stock if the underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common stock); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we will use all of the net proceeds from this offering (including any net proceeds received upon exercise of the underwriters&#146; option to purchase additional
shares of Class&nbsp;A common stock) to acquire <FONT STYLE="white-space:nowrap">newly-issued&nbsp;LLC</FONT> Interests from Bioventus LLC at a purchase price per interest equal to the initial public offering price per share of Class&nbsp;A common
stock, less underwriting discounts and commissions, collectively representing 26.5% of Bioventus LLC&#146;s outstanding&nbsp;LLC Interests (or 29.3%, if the underwriters exercise in full their option to purchase additional shares of Class&nbsp;A
common stock); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Bioventus LLC will use the proceeds from the sale of&nbsp;LLC Interests to Bioventus as described in &#147;Use of proceeds;&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Former LLC Owners will exchange their&nbsp;indirect ownership interests in Bioventus LLC for shares of Class&nbsp;A common stock on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> basis, representing (i)&nbsp;approximately 44.8% of the combined voting power of all of Bioventus Inc.&#146;s common stock (or approximately 43.0%, if the
underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common stock) and (ii)&nbsp;approximately 44.8% of the economic </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
interest in the business of Bioventus LLC and its subsidiaries (or approximately 43.0%, if the underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common
stock); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Phantom Plan will be terminated and the Phantom Plan Participants will receive rights to receive up to 513,117&nbsp;shares of Class&nbsp;A common stock upon
settlement of their awards under the Phantom Plan, with such settlement expected to take place on the twelve month anniversary following the date of termination of the Phantom Plan as described in &#147;Executive compensation&#151;Narrative to
summary compensation table&#151;Equity-based compensation&#151;Phantom profits interest units&#148; (settlement may result in a change in the timing over which compensation expense is recognized as described in &#147;Management&#146;s discussion and
analysis of financial condition and results of operations &#151; Components of our results of operations &#151; Selling, general and administrative expenses&#148; and Bioventus will receive a corresponding number of&nbsp;LLC Interests from Bioventus
LLC upon settlement); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Continuing LLC Owners will continue to own the&nbsp;LLC Interests they received in exchange for their existing membership interests in Bioventus LLC,
which&nbsp;LLC Interests, following this offering, will be redeemable, at the election of such members, for <FONT STYLE="white-space:nowrap">newly-issued</FONT> shares of Class&nbsp;A common stock on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis or, if Bioventus Inc. and such members agree, a cash payment equal to a volume weighted average market price of one share of Class&nbsp;A common stock for each&nbsp;LLC Interest redeemed
(subject to customary adjustments, including for stock splits, stock dividends and reclassifications) in accordance with the terms of the Bioventus LLC Agreement; provided that, at Bioventus Inc.&#146;s election, Bioventus Inc. may effect a direct
exchange of such Class&nbsp;A common stock or such cash (if mutually agreed) for such LLC Interests. Shares of Class&nbsp;B common stock will be cancelled on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis if we, at the election of a Continuing LLC Owner, redeem or exchange&nbsp;LLC Interests of such Continuing LLC Owners pursuant to the terms of the
Bioventus LLC Agreement; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Bioventus Inc. will enter into (i)&nbsp;a tax receivable agreement, or Tax Receivable Agreement, with the Continuing LLC Owners, (ii)&nbsp;a stockholders
agreement, or the Stockholders Agreement, with the Voting Group and (iii)&nbsp;a registration rights agreement, or the Registration Rights Agreement, with the Original LLC Owners. Upon the consummation of this offering, the Continuing LLC Owners
will own (x)&nbsp;9,571,764&nbsp;shares of Bioventus&#146; Class&nbsp;B common stock (which will not have any liquidation or distribution rights), representing approximately 28.7% of the combined voting power of all of Bioventus&#146; common stock
(or approximately 27.6%, if the underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common stock) and (y)&nbsp;LLC Interests, representing approximately 28.7% of the economic interest in the business of Bioventus
LLC and its subsidiaries (or approximately 27.6%, if the underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common stock). </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We refer to the foregoing transactions collectively as the &#147;Transactions.&#148; For more information regarding our structure after the completion of the
Transactions, including this offering, see &#147;Transactions.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Immediately following this offering, Bioventus Inc. will be a holding company and its principal asset will be the LLC&nbsp;Interests it purchases from Bioventus
LLC and acquires from the Former LLC Owners. As the sole managing member of Bioventus LLC, we will operate and control all of the business and affairs of Bioventus LLC and, through Bioventus LLC and its subsidiaries, conduct our business.
Accordingly, we will have the sole voting interest in, and control the management of, Bioventus LLC. As a result, we will consolidate Bioventus LLC in our consolidated financial statements and will report a
<FONT STYLE="white-space:nowrap">non-controlling</FONT> interest related to the&nbsp;LLC Interests held by the Continuing LLC Owners on our consolidated financial statements. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">See &#147;Description of capital stock&#148; for more information about our certificate of incorporation and the terms of the Class A common stock and Class B common stock. See &#147;Certain relationships and
related party transactions&#148; for more information about (i) the Bioventus LLC Agreement, including the terms of the LLC Interests and the </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
redemption right of the Continuing LLC Owners; (ii) the Tax Receivable Agreement; (iii) the Registration Rights Agreement; and (iv) the Stockholders Agreement.&nbsp;Under the Stockholders
Agreement, any increase or decrease in the size of our board of directors or any committee, and any amendment to our organizational documents, will in each case require the approval of Essex Woodlands Health Ventures and certain other members of the
Voting Group, for so long as they collectively own at least 10% of the total shares of our Class A common stock owned by them as of the date this offering is consummated, and will also require the approval of Smith &amp; Nephew, for so long as Smith
&amp; Nephew collectively owns at least 10% of the total shares of our Class B common stock owned by them as of the date this offering is consummated. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The diagram below depicts our organizational structure after giving effect to the Transactions, including this
offering, assuming no exercise by the underwriters of their option to purchase additional shares of Class A common stock. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g22578g81g02.jpg" ALT="LOGO">
 </P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Recent Developments </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Selected preliminary financial results for the three months ended July 2, 2016 </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We estimate that for the three
months ended July&nbsp;2, 2016: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Net sales will be between $69.6&nbsp;million and $72.5&nbsp;million, an increase of approximately 8.0% at the midpoint of the range as compared to $65.8 million
for the three months ended June&nbsp;27, 2015. The estimated increase in net sales is primarily due to an increase in net sales from our Surgical segment partially attributable to the BioStructures acquisition in the fourth quarter of 2015 as well
as higher sales from other surgical products. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Net (loss) income will be between $(0.7)&nbsp;million and $1.9&nbsp;million as compared to net loss of $(4.1)&nbsp;million for the three months ended
June&nbsp;27, 2015. The estimated improvement in our net (loss) income compared to the corresponding period in 2015 is primarily due to an increase in operating income from our Surgical segment driven by increased sales and a lower change in the
fair value of contingent consideration. These increases were partially offset by increased BMP expenses. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Adjusted EBITDA will be between $12.8&nbsp;million and $15.3&nbsp;million, which includes $3.2&nbsp;million of BMP expenses, an increase of 12.8% at the midpoint
of the range, as compared to $12.5 million, which includes $2.3&nbsp;million of BMP expenses, for the three months ended June&nbsp;27, 2015. The estimated increase in Adjusted EBITDA is primarily due to an increase in operating income from our
Surgical segment partially offset by increased BMP expenses. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Net sales for our Active Healing Therapies&#151;U.S. segment will be between $49.0 million and $51.0 million, a slight increase of approximately 0.2% at the
midpoint of the range as compared to $49.9&nbsp;million for the three months ended June&nbsp;27, 2015. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Net sales for our Active Healing Therapies&#151;International segment will be between $10.0 million and $10.4&nbsp;million, a slight decrease of approximately
0.9% at the midpoint of the range as compared to $10.3&nbsp;million for the three months ended June&nbsp;27, 2015. The estimated decrease in net sales is primarily due to the termination of our Russian distributor relationship and fluctuations in
demand in several markets partially offset by favorable foreign currency translation adjustments. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Net sales for our Surgical segment will be between $10.6 million and $11.1 million, an increase of approximately 93.8% at the midpoint of the range as compared
to $5.6&nbsp;million for the three months ended June&nbsp;27, 2015. The estimated increase in net sales is primarily attributable to the BioStructures acquisition. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We include Adjusted EBITDA in this prospectus for the reasons as described in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operation &#150; Components of Our Results of
Operations&#151;Adjusted EBITDA.&#148; Adjusted EBITDA has certain limitations in that it does not reflect all expense items that affect our results. These and other limitations are described in Footnote 3 to the table under &#147;Prospectus
summary&#151;Summary historical and pro forma financial data.&#148; We encourage you to review our financial information in its entirety and not rely on a single financial measure. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">10 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table reconciles net loss to Adjusted EBITDA for the three months ended June 27, 2015 and
July&nbsp;2, 2016: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Three Months Ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(Dollars in millions)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>June&nbsp;27,&nbsp;2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>July&nbsp;2,&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Low</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>High</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net (loss) income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest expense, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization(a)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">EBITDA</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Non-cash equity compensation(b)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Restructuring costs(c)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Contingent consideration(d)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other corporate expenses(e)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Inventory step up(f)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Adjusted EBITDA</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Includes depreciation and amortization recorded in cost of sales of $5.8&nbsp;million and $5.1&nbsp;million for the three months ended June&nbsp;27, 2015 and July&nbsp;2, 2016,
respectively, in addition to depreciation and amortization in the consolidated statements of operations and comprehensive loss of $2.6&nbsp;million and $2.9&nbsp;million for the three months ended June&nbsp;27, 2015 and July&nbsp;2, 2016,
respectively. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Represents non-cash equity compensation resulting from two equity-based compensation plans, the MIP and the Phantom Plan. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(c)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Represents expenses relating to the restructuring and relocating of certain U.S. finance functions and headcount reductions in our international business to improve operating
efficiency. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(d)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Represents expense related to changes in the fair value of contingent consideration related to the OsteoAMP acquisition. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(e)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Represents expenses associated with Bioventus LLC preparing to become a public company, primarily accounting and legal fees. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(f)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Represents non-cash expense recorded in cost of sales for BioStructures inventory subject to valuation step-up as a result of purchase accounting. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have provided a range for our preliminary results described above because our financial closing procedures for the three months ended July&nbsp;2, 2016 are not
yet complete. We currently expect that our final results will be within the ranges described above. However, these estimates are preliminary and are based upon our estimates and the information available to management as of the date of this
prospectus. Therefore, it is possible that our actual results may differ materially from these estimates due to the completion of our financial closing procedures, final adjustments and other developments which may arise between now and the time our
financial results for the three months ended July&nbsp;2, 2016 are finalized. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Accordingly, you should not place undue reliance on these preliminary
estimates. In addition, the estimated data is not necessarily indicative of our results for the full fiscal year or future period. The preliminary estimated range of unaudited financial data for the three months ended July&nbsp;2, 2016 included in
this prospectus have been prepared by, and are the responsibility of, our management and have not been reviewed or audited </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
or subjected to any other procedures by our independent registered public accounting firm. Accordingly, our independent registered public accounting firm does not express an opinion or any other
form of assurance with respect to the preliminary estimated range of unaudited financial data. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Implications of being an emerging growth company
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and are eligible to
take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. These include, but are not limited to: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reduced obligations with respect to financial data, including presenting only two years of audited financial statements and only two years of selected financial
data in the registration statement on Form S-1 of which this prospectus is a part; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">exemptions from the requirements of holding a non-binding advisory vote on executive compensation and the requirement to obtain stockholder approval of any
golden parachute payments not previously approved. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may take advantage of these exemptions until the last day of our fiscal year
following the fifth anniversary of the completion of this offering or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company if we have more than $1.0 billion in annual revenue, we are
deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or SEC, or we issue more than $1.0 billion of non-convertible debt over a three-year period. We may choose to take advantage of some, but not all, of
the available exemptions. We have taken advantage of certain reduced reporting burdens in this prospectus. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold
stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, Section&nbsp;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period
provided in Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, or the Securities Act, for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until
those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are
not emerging growth companies. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Corporate information </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Bioventus Inc., the issuer of the Class&nbsp;A common stock in this offering, was incorporated in Delaware on December&nbsp;22, 2015. Bioventus LLC was organized in Delaware as a limited liability company in
November&nbsp;23, 2011. Our principal executive offices are located at 4721 Emperor Boulevard, Suite 100, Durham, NC 27703. Our telephone number is (919)&nbsp;474-6700. Our corporate website is www.bioventusglobal.com. The information contained on
or that can be accessed through our website is not incorporated by reference into this prospectus, and you should not consider information on our website to be part of this prospectus or in deciding to purchase our Class&nbsp;A common stock.
</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">12 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>The offering </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Issuer </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">Bioventus Inc. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Class&nbsp;A common stock offered by us </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">8,823,529&nbsp;shares (or 10,147,058&nbsp;shares if the underwriters exercise in full their option to purchase additional shares) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Underwriters&#146; option to purchase additional shares of Class&nbsp;A common stock </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">1,323,529&nbsp;shares </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Class&nbsp;A common stock to be issued to Former LLC Owners </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">14,904,090&nbsp;shares </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Class&nbsp;A common stock to be outstanding immediately after this offering </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">23,727,619&nbsp;shares (or 25,051,148&nbsp;shares if the underwriters exercise in full their option to purchase additional shares) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Class B common stock to be outstanding immediately after this offering </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">9,571,764&nbsp;shares, all of which will be owned by the Continuing LLC Owners. </FONT></TD></TR></TABLE> <P STYLE="font-size:16px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Voting Rights </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">Holders of our Class&nbsp;A common stock and Class&nbsp;B common stock will vote together as a single class on all matters presented to stockholders for their vote or approval, except as otherwise
required by law. Each share of Class&nbsp;A common stock and Class&nbsp;B common stock will entitle its holder to one vote per share on all such matters. See &#147;Description of capital stock.&#148; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Voting power held by purchasers in this offering </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">26.5% (or 29.3%, if the underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common stock). </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Voting power held by the Former LLC Owners </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">44.8% (or 43.0%, if the underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common stock). </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Voting power held by all holders of Class&nbsp;A common stock after giving effect to this offering </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">71.3% (or 72.4%, if the underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common stock). </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Voting power held by all holders of Class&nbsp;B common stock after giving effect to this offering </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">28.7% (or 27.6%, if the underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common stock). </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">13 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Voting power held by the Original LLC Owners after giving effect to this offering </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">73.5% (or 70.7%, if the underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common stock). </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Ratio of shares of Class&nbsp;A common stock to&nbsp;LLC Interests </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation and the Bioventus LLC Agreement will require that we at all times maintain a ratio of one LLC Interest owned by us for each share of Class&nbsp;A
common stock (subject to certain exceptions for treasury shares and shares underlying certain convertible or exchangeable securities) and Bioventus LLC at all times maintain a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> ratio between the number of shares of Class&nbsp;A common stock issued by us and the number of&nbsp;LLC Interests owned by us, as well as a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> ratio between the number of shares of Class&nbsp;B common stock owned by the Continuing LLC Owners and the number of&nbsp;LLC Interests owned by the Continuing LLC
Owners. This construct is intended to result in the Continuing LLC Owners having a voting interest in Bioventus Inc. that is substantially the same as the Continuing LLC Owners&#146; percentage economic interest in Bioventus LLC. The Continuing LLC
Owners will own all of our outstanding Class&nbsp;B common stock. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Use of proceeds </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">We estimate that the net proceeds to us from this offering, after deducting underwriting discounts and commissions and estimated offering expenses, will be approximately $135.6&nbsp;million (or
approximately $156.5&nbsp;million if the underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common stock), assuming the shares are offered at $17.00 per share (the midpoint of the price range listed on the cover
page of this prospectus). </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">We intend to use the net proceeds that we receive from this offering to purchase 8,823,529 <FONT STYLE="white-space:nowrap">newly-issued&nbsp;LLC</FONT> Interests from Bioventus
LLC at a purchase price per interest equal to the initial public offering price per share of Class&nbsp;A common stock less underwriting discounts and commissions and estimated offering expenses payable thereon. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">We intend to cause Bioventus LLC to use such proceeds (i)&nbsp;to repay all of the outstanding borrowings under our second lien term loan facility, together with a prepayment
premium and accrued and unpaid interest thereon, (ii)&nbsp;to repay a $23.5&nbsp;million promissory note and a $5.0&nbsp;million deferred payment relating to the Acquisition when due in 2016, (iii) to repay all of the outstanding borrowings under
our first lien revolving facility and (iv)&nbsp;with any remaining net proceeds used&nbsp;for general corporate purposes. See &#147;Use of proceeds.&#148; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Redemption rights of holders of&nbsp;LLC Interests </B></FONT></P></TD>
<TD> <P><FONT STYLE="font-family:arial" SIZE="2">The Continuing LLC Owners, from time to time following the offering, may require Bioventus LLC to redeem all or a portion of their&nbsp;LLC Interests for
<FONT STYLE="white-space:nowrap">newly-issued</FONT> shares of Class&nbsp;A common stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis or, if Bioventus and such members agree, a cash payment
equal to the volume </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">14 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:0%"><FONT STYLE="font-family:arial" SIZE="2">
weighted average market price of one share of our Class&nbsp;A common stock for each&nbsp;LLC Interest redeemed (subject to customary adjustments, including for </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">stock splits, stock dividends and reclassifications) in accordance with the terms of the Bioventus LLC Agreement; provided that, at Bioventus Inc.&#146;s election, we may effect a direct exchange of such
Class&nbsp;A common stock or such cash (if mutually agreed) for such LLC Interests. See &#147;Certain relationships and related party transactions&#151;Bioventus&nbsp;LLC Agreement.&#148; Shares of our Class&nbsp;B common stock will be cancelled on
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis if we, at the election of a Continuing LLC Owner, redeem or exchange LLC Interests of such Continuing LLC Owner pursuant to the terms of the
Bioventus LLC Agreement. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Registration Rights Agreement </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">Pursuant to the Registration Rights Agreement, we will, subject to the terms and conditions thereof, agree to register the resale of the shares of our Class&nbsp;A common stock that are issuable to the
Continuing LLC Owners upon redemption or exchange of their&nbsp;LLC Interests and the shares of our Class&nbsp;A common stock that are issued to the Former&nbsp;LLC Owners in connection with the Transactions. See &#147;Certain relationships and
related party transactions&#151;Registration Rights Agreement.&#148; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Controlled company </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">Following this offering we will be a &#147;controlled company&#148; within the meaning of the corporate governance rules of The NASDAQ Global Market. See &#147;Management&#151;Corporate governance.&#148;
By becoming a stockholder, you will be deemed to have notice of and consented to provisions of our amended and restated certificate of incorporation that allocate certain corporate opportunities between us and our Original LLC Owners. See
&#147;Description of capital stock&#151;Corporate opportunities.&#148; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Dividend policy </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">We currently intend to retain all available funds and any future earnings for use in the operation of our business, and therefore we do not currently expect to pay any cash dividends on our Class&nbsp;A
common stock. Any future determination to pay dividends to holders of Class&nbsp;A common stock will be at the discretion of our board of directors and will depend upon many factors, including our results of operations, financial condition, capital
requirements, restrictions in Bioventus LLC&#146;s debt agreements and other factors that our board of directors deems relevant. We are a holding company, and substantially all of our operations are carried out by Bioventus LLC and its subsidiaries,
and therefore we will only be able to pay dividends from funds we receive from Bioventus LLC. Our ability to pay dividends may also be restricted by the terms of any credit agreement or any debt or preferred equity securities of ours or of our
subsidiaries. See &#147;Dividend policy.&#148; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Tax Receivable Agreement </B></FONT></P></TD>
<TD> <P><FONT STYLE="font-family:arial" SIZE="2">We will enter into the Tax Receivable Agreement with Bioventus LLC and the Continuing LLC Owners that will provide for the payment by us to the Continuing LLC Owners of 85% of the amount of tax
benefits, if any, that we actually realize (or in some circumstances are deemed to realize) as a result of (i)&nbsp;increases in the tax basis of assets of Bioventus LLC resulting from any redemptions or
</FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">15 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
exchanges of&nbsp;LLC Interests described above under &#147;&#151;The offering&#151;Redemption rights of holders of&nbsp;LLC interests&#148; and (ii)&nbsp;certain other tax benefits related to
our making payments under the Tax Receivable Agreement. See &#147;Certain relationships and related party transactions&#151;Tax Receivable Agreement.&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Stockholders Agreement </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">Pursuant to the Stockholders Agreement, the Voting Group will hold Class&nbsp;A common stock and Class B common stock representing approximately 72.9% of the combined voting power of all of our common
stock. Until such time as Essex Woodlands Health Ventures and certain other members of the Voting Group own less than 10% of the total shares of our Class&nbsp;A common stock owned by them as of the date this offering is consummated, and
Smith&nbsp;&amp; Nephew collectively owns less than 10% of the total shares of our Class B common stock owned by them as of the date this offering is consummated, or the Stockholders Agreement is otherwise terminated in accordance with its terms,
the parties to the Stockholders Agreement will agree to vote their shares of Class&nbsp;A common stock and Class B common stock in favor of the election of the nominees of certain members of the Voting Group to our board of directors upon their
nomination by the nominating and corporate governance committee of our board of directors. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Risk Factors </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">Investing in shares of our Class&nbsp;A common stock involves a high degree of risk. See &#147;Risk factors&#148; for a discussion of factors you should carefully consider before investing in shares of
our Class&nbsp;A common stock. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>NASDAQ Global Market symbol </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">&#147;BIOV&#148; </FONT></TD></TR></TABLE> <P STYLE="margin-top:24px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:arial" SIZE="2">The number of shares of Class&nbsp;A common stock to be
outstanding after this offering is based on the membership interests of Bioventus LLC outstanding as of July&nbsp;2, 2016, and excludes: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">2,981,436 shares of Class&nbsp;A common stock reserved for issuance under our 2016 Incentive Award Plan as described in &#147;Executive compensation&#151;New
incentive arrangements&#148;, consisting of (i)&nbsp;2,514,265 shares of Class&nbsp;A common stock issuable upon the exercise of options to purchase shares of Class&nbsp;A common stock granted on the date of this prospectus to our directors and
certain employees, including the named executive officers, in connection with this offering as described in &#147;Executive Compensation&#151;Director Compensation&#148; and &#147;Executive Compensation&#151;New Equity Awards,&#148; and
(ii)&nbsp;467,171 additional shares of Class&nbsp;A common stock reserved for future issuance (exclusive of the additional shares available for issuance under the 2016 Incentive Award Plan pursuant to the annual increase each calendar year beginning
in 2017 and ending in 2026 as described in &#147;Executive compensation&#151;New incentive arrangements&#148;); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">513,117 shares of Class&nbsp;A common stock reserved as of the closing date of this offering for future issuance to the Phantom Plan Participants upon settlement
of their awards as described in &#147;Executive compensation&#151;Narrative to summary compensation table&#151;Elements of compensation&#151;Equity-based compensation&#151;Phantom profits interest units&#148;; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">373,616 shares of Class A common stock reserved for issuance under our Employee Stock Purchase Plan as described in &#147;Executive compensation&#151;New
incentive arrangements&#148;; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">9,571,764&nbsp;shares of Class&nbsp;A common stock reserved as of the closing date of this offering for future issuance upon redemption or exchange of&nbsp;LLC
Interests by the Continuing LLC Owners. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Unless otherwise indicated, this prospectus assumes the shares of Class A common stock are
offered at $17.00 per share (the midpoint of the price range listed on the cover page of this prospectus). Certain share </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">16 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
information presented in this prospectus will vary depending on the initial public offering price in this offering, as well as the number of shares being offered hereby to the public. For
example, the amount of shares of Class A common stock reserved for issuance under our 2016 Incentive Award Plan and our Employee Stock Purchase Plan, the amount of shares of Class A common stock issuable upon the exercise of options to purchase
shares of Class A common stock granted on the date of this prospectus, and the relative allocation of the shares of common stock issued in the Transactions as among the Continuing LLC Owners, the Former LLC Owners and the Phantom Plan Participants
will vary, depending on the initial public offering price in this offering. In addition, the relative allocation of the shares of common stock issued in the Transactions as between the Original LLC Owners and the Phantom Plan Participants, on the
one hand, and the investors in this offering, on the other hand, will vary, depending on the initial public offering price in this offering and the number of shares being offered hereby to the public. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Unless otherwise indicated, this prospectus assumes no exercise by the underwriters of their option to purchase additional shares of Class&nbsp;A common stock and
no exercise of outstanding options after July&nbsp;2, 2016. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">17 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Summary historical and pro forma financial data </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following tables present the summary historical and pro forma financial data for Bioventus LLC and its subsidiaries for the periods and at the dates indicated. Bioventus LLC is the predecessor of the issuer,
Bioventus Inc., for financial reporting purposes. The summary statements of operations data for the years ended December&nbsp;31, 2013, 2014 and 2015 are derived from the Bioventus LLC audited financial statements included elsewhere in this
prospectus. The summary statements of operations data for the three months ended March 28, 2015 and April 2, 2016, and the summary balance sheet data as of April 2, 2016 are derived from the Bioventus LLC unaudited financial statements included
elsewhere in this prospectus. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, include all adjustments, consisting only
of normal and recurring adjustments, necessary for a fair presentation of the information set forth herein. You should read this data together with our audited and unaudited financial statements and related notes appearing elsewhere in this
prospectus and the information under the captions &#147;Capitalization,&#148; &#147;Selected financial data&#148; and &#147;Management&#146;s discussion and analysis of financial condition and results of operations.&#148; Our historical results are
not necessarily indicative of our future results and results of interim periods are not necessarily indicative of results for the entire year. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
summary unaudited pro forma consolidated financial data of Bioventus Inc. presented below have been derived from our unaudited pro forma consolidated financial statements included elsewhere in this prospectus. The summary unaudited pro forma balance
sheet data as of April 2, 2016 give effect to the Acquisition and the Transactions as described in &#147;Transactions&#148;, including the completion of this offering, as if all such transactions had occurred on that date and the summary unaudited
pro forma statement of operations data for the year ended December&nbsp;31, 2015 and the three months ended March 28, 2015 and April 2, 2016 gives effect to the Transactions, as if all such transactions had occurred January 1, 2015. The unaudited
pro forma financial information includes various estimates which are subject to material change and may not be indicative of what our operations or financial position would have been had this offering and related transactions taken place on the
dates indicated, or that may be expected to occur in the future. See &#147;Unaudited pro forma consolidated financial information&#148; for a complete description of the adjustments and assumptions underlying the summary unaudited pro forma
consolidated financial data. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">18 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The summary historical data of Bioventus&nbsp;Inc. have not been presented as Bioventus&nbsp;Inc. is a newly
incorporated entity, has had no business transactions or activities to date and had no assets or liabilities during the periods presented in this section. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="20" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Historical Bioventus&nbsp;LLC</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Pro&nbsp;forma<BR>Bioventus&nbsp;Inc.(1)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>Year&nbsp;ended</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Three&nbsp;months&nbsp;ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>Year&nbsp;ended</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>Three&nbsp;months&nbsp;ended</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>(in thousands, except per share and share<BR>amounts)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>December&nbsp;31,<BR>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>December&nbsp;31,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>2014</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>December&nbsp;31,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>2015</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>March&nbsp;28,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>2015</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>April 2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>December&nbsp;31,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>2015</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>April 2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Consolidated statements of operations data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">232,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">242,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">253,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">53,362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">65,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">265,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">65,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Cost of sales (including depreciation and amortization of $16,693, $19,622, $22,474, $5,741, and $6,300, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">71,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">75,792</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">74,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">16,807</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">19,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">80,598</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">19,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Gross profit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">161,003</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">167,101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">179,106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">36,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">46,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">185,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">46,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Selling, general and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">150,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">147,058</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">148,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">37,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">40,184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">160,265</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">41,724</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">10,936</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">9,465</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">14,747</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,966</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">15,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,766</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Change in fair value of contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">19,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">8,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">19,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Restructuring costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151; </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">7,765</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">8,968</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">10,570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">12,124</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Operating income (loss)(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(8,068</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(16,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(16,299</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(2,038</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(24,275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(3,626</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">11,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">11,969</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">14,229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">6,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,641</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Other (income) expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(596</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,154</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">496</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Other expense, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">12,172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">11,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">15,383</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,408</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">8,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,494</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Loss before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(20,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(11,353</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(31,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(20,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(5,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(32,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(5,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Income tax expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">603</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">603</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(22,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(12,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(34,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(21,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(34,528</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(5,723</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Less: Net (loss) income attributable to non-controlling interests</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(9,909</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net (loss) income attributable to Bioventus</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(24,618</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(4,080</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accumulated and unpaid preferred distributions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(3,610</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(3,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(3,997</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(953</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,042</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net loss attributable to common unit holders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(25,977</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(16,618</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(38,108</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(21,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(7,091</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net loss per common unit, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(5.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(3.39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(7.78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(4.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Weighted average common units outstanding, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Pro forma weighted average shares of Class A common stock outstanding:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="25"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">23,727,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">23,727,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" COLSPAN="25"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">23,727,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">23,727,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Pro forma net loss per share of Class&nbsp;A common stock outstanding:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" COLSPAN="25"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(0.17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="25"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1.04</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(0.17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Other Financial Data:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Adjusted EBITDA(3)(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">32,485</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">36,193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">42,186</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">10,677</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">45,861</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(5)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">10,677</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="32" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Years ended </B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Three&nbsp;months&nbsp;ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April 2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Consolidated statements of cash flows data:</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Net cash (used in) provided by:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">15,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">18,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(3,821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,162</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(10,999</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(31,376</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(60,185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(306</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(6,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">6,801</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(6,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">31,246</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">5,495</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Effect of exchange rate changes on cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(805</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net (decrease) increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,963</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(24,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(10,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(745</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,216</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="22" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">19 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Pro&nbsp;forma&nbsp;Bioventus&nbsp;Inc.</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;As&nbsp;of&nbsp;April&nbsp;2,&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;As&nbsp;of&nbsp;April&nbsp;2,&nbsp;2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Balance sheet data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">486,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">510,591</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">299,962</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">191,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(97,975</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151; </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total members&#146;/stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">186,302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">318,691</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Gives pro forma effect to the Acquisition and the Transactions. See &#147;Unaudited pro forma consolidated financial information.&#148; </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">During the year ended December&nbsp;31, 2013, in connection with our divesture from S&amp;N, we recorded $4,690 of transition expenses, such as product rebranding, legal fees and
consulting expenses. During the year ended December&nbsp;31, 2015 and the three months ended March 28, 2015 and April 2, 2016, we recorded an expense of $19,493, $8,971 and $1,301, respectively related to changes in the fair value of contingent
consideration related to the OsteoAmp acquisition. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">We define EBITDA as net loss plus interest expense, income tax expense, and depreciation and amortization. We define Adjusted EBITDA as net income before depreciation and
amortization, interest expense and provision for income taxes, adjusted for the impact of certain cash and non-cash and other items that we do not consider in our evaluation of ongoing operating performance. These items include non-cash equity
compensation, restructuring costs, contingent consideration, transition costs, severance, OsteoAMP inventory step-up, and purchased in-process R&amp;D. We present EBITDA and Adjusted EBITDA because we believe they are useful indicators of our
operating performance. Our management uses EBITDA and Adjusted EBITDA principally as measures of our operating performance and believes that EBITDA and Adjusted EBITDA are useful to our investors because they are frequently used by securities
analysts, investors and other interested parties in their evaluation of the operating performance of companies in industries similar to ours. Our management also uses EBITDA and Adjusted EBITDA for planning purposes, including the preparation of our
annual operating budget and financial projections. Adjusted EBITDA is burdened by BMP program costs of $650, $6,682, and $11,309, for the years ended December 31, 2013, 2014, and 2015, respectively, and $2,491 and $2,535 for the three months ended
March 28, 2015 and April 2, 2016, respectively. We have incurred development costs related to our BMP product candidates in each of the past three years, and we expect to incur significant costs related to our BMP product candidates in future
periods. Such costs are not added back in the calculation of our Adjusted EBITDA. See &#147;Management&#146;s discussion and analysis of financial condition and results of operations &#151;Strategic Transactions &#151; BMP portfolio.&#148;
</FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">EBITDA and Adjusted EBITDA are not measurements of financial performance under U.S. generally accepted accounting
principles, or GAAP. EBITDA and Adjusted EBITDA should not be considered in isolation or as substitutes for a measure of our liquidity or operating performance prepared in accordance with GAAP, and are not indicative of net loss from operations as
determined under GAAP. In addition, EBITDA and Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. EBITDA, Adjusted EBITDA and other non-GAAP financial measures have
limitations that should be considered before using these measures to evaluate our liquidity or financial performance. Some of these limitations are as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">EBITDA and Adjusted EBITDA exclude certain tax payments that may require a reduction in cash available to us; </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">20 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">EBITDA and Adjusted EBITDA do not reflect our cash expenditures, or future requirements, for capital expenditures (including capitalized software developmental
costs) or contractual commitments; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">EBITDA and Adjusted EBITDA do not reflect changes in, or cash requirements for, our working capital needs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">EBITDA and Adjusted EBITDA do not reflect the cash requirements necessary to service interest or principal payments on our debt; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Adjusted EBITDA excludes certain purchase accounting adjustments related to the Acquisition. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">In addition, our definition and calculation of EBITDA and Adjusted EBITDA may differ from that of other companies. We compensate for these
limitations by relying primarily on our GAAP results and by using non-GAAP financial measures only supplementally. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table presents a
reconciliation of net loss to EBITDA and Adjusted EBITDA for the periods presented: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Pro&nbsp;Forma&nbsp;Bioventus&nbsp;Inc.<BR></B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended </B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Three&nbsp;months&nbsp;ended</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended </B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Three<BR>months<BR>ended</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands, except per<BR>share and share amounts)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(22,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(34,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(34,528</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,723</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest expense, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,969</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,641</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">603</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">603</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization(a)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">24,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28,820</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">33,078</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,394</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">38,054</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>EBITDA</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>15,677</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>29,436</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>15,336</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>(8,401</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>7,246</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>12,659</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>5,658</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Non-cash equity compensation(b)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">576</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,325</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,677</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,876</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Restructuring costs(c)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Contingent consideration(d)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Transition costs(e)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,690</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other corporate expenses(f)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Severance(g)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,542</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Inventory step-up(h)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,629</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">280</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">164</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">280</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Purchased in-process <FONT STYLE="white-space:nowrap">R&amp;D-BMP(i)</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Adjusted EBITDA</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>32,485</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>36,193</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>42,186</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2,339</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>10,677</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>45,861</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>10,677</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes depreciation and amortization recorded in cost of sales of $16,693, $19,622 and $22,474 for the years ended December 31, 2013, 2014, and 2015, respectively, and
depreciation and amortization recorded in R&amp;D expenses of $0, $230 and $34 for the years ended December 31, 2013, 2014 and 2015, respectively, in addition to depreciation and amortization shown on the consolidated statements of operations and
comprehensive loss of $7,765, $8,968 and $10,570 for the years ended December 31, 2013, 2014 and 2015, respectively. Includes depreciation and amortization recorded in cost of sales of $5,741 and $6,300 for the three months ended March 28, 2015 and
April 2, 2016, respectively, and depreciation and amortization recorded in R&amp;D expenses of $82 and $7 for the three months ended March 28, 2015 and April 2, 2016, respectively, in addition to depreciation and amortization shown on the
consolidated statements of operations and comprehensive loss of $2,571 and $2,830 for the three months ended March 28, 2015 and April 2, 2016, respectively. On a pro forma basis the year ended December 31, 2015 includes an incremental $4,976 of
amortization expense, of which $3,459 is included in pro forma cost of cost of sales and $1,517 in pro forma R&amp;D expenses.</FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents non-cash equity compensation resulting from two equity-based compensation plans, the MIP and the Phantom Plan. On a pro forma basis includes incremental compensation
expense of $6,352 for the year ended December 31, 2015 and $1,588 for the three months ended April 2, 2016 for new awards intended to be granted under the 2016 Incentive Award Plan in connection with this offering. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(c)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">Represents restructuring expenses associated with a plan to no longer sell a diagnostic ultrasound product, including employee severance. Additionally, this
includes a provision for inventory related to this product of $1,183 and $202 in 2014 and 2015, respectively, which is included </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">21 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="1">
in cost of sales. Also included are restructuring and relocation costs of certain U.S. finance functions and headcount reductions in our international business to improve operating efficiency.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(d)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents expense related to changes in the fair value of contingent consideration related to the OsteoAMP acquisition. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(e)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents expenses related to the transition of Bioventus LLC to become a separate entity as a result of the divestiture from Smith &amp; Nephew, such as product rebranding,
legal fees and consulting expenses. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(f)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents expenses associated with Bioventus LLC preparing to become a public company, primarily accounting and legal fees. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(g)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents 2013 severance costs related to headcount reductions as a result of the divestiture from Smith &amp; Nephew. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(h)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents non-cash expense recorded in cost of sales for OsteoAMP and BioStructures inventory subject to valuation step-up as a result of purchase accounting.
</FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(i)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents initial expense paid to Pfizer to acquire certain rights related to our next-generation BMP product candidates. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Adjusted EBITDA is burdened by BMP program costs of $650, $6,682, and $11,309 for the years ended December 31, 2013, 2014, and 2015, respectively, and $2,491 and $2,535 for the
three months ended March 28, 2015 and April 2, 2016, respectively. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Gives pro forma effect to the Acquisition, but not the Transactions. The pro forma effect of the Transactions would reduce Adjusted EBITDA by the amount of the results of
operations attributable to the non-controlling interests for the applicable period. </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">22 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_2"></A>Risk factors </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Investing in our Class&nbsp;A common stock involves a high degree of risk. These risks include, but are not limited to, those described below, each of which may be relevant to an investment decision. You should
carefully consider the risks described below, together with all of the other information in this prospectus, including our financial statements and related notes, before investing in our Class&nbsp;A common stock. The realization of any of these
risks could have a significant adverse effect on our reputation, business, including our financial condition, results of operations and growth, which we refer to collectively in this section as our business, and ability to accomplish our strategic
objectives. In that event, the trading price of our Class&nbsp;A common stock could decline, and you may lose part or all of your investment. </I></FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to our business </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We are highly dependent
on a limited number of products. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our Exogen system and Supartz FX accounted for 89%, 87%, 83%, 85% and 77% of our total revenue for the years
ended December&nbsp;31, 2013, 2014 and 2015 and the three months ended March 28, 2015 and April 2, 2016, respectively. We expect that sales of our Active Healing Therapies products will continue to account for a majority of our revenue while we
continue to expand and develop our product offerings for our Surgical business. Therefore, our ability to execute our growth strategy and become profitable will depend upon the continued demand for these products. In addition, the term of our
distribution agreement for Supartz FX ends in May 2019. If our distribution agreement for Supartz FX is terminated, our revenue may be impaired if we are unable to introduce a product that effectively replaces or improves upon Supartz FX. If our
Exogen system or Supartz FX fail to maintain their market acceptance for any reason, or if we do not renew our distribution agreement with respect to Supartz FX on commercially reasonable terms or at all, our business, results of operations and
financial condition may be adversely affected. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may be unable to launch and successfully commercialize GelSyn-3. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We plan to launch GelSyn-3, a three injection HA viscosupplementation therapy, in the United States during the second half of 2016. Even if we are able to launch
GelSyn-3, the commercial success of GelSyn-3 will depend upon the awareness and acceptance of GelSyn-3 among the medical community, including physicians and patients. Market acceptance will depend on a number of factors, including, among others:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the perceived advantages and disadvantages of GelSyn-3 over existing HA viscosupplementation therapies and other competitive treatments for knee osteoarthritis;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">availability of alternative treatments; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the extent to which physicians prescribe GelSyn-3; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the willingness of the target patient population to try new therapies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the strength of marketing and distribution support and timing of market introduction of GelSyn-3 and competitive products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">publicity concerning GelSyn-3, our existing products or competing products and treatments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">pricing and cost effectiveness of GelSyn-3; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the effectiveness of our sales and marketing strategies; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the willingness of patients to pay out-of-pocket in the absence of third party reimbursement. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">23 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our efforts to educate the medical community about the benefits of GelSyn-3 may require significant resources and we
may never be successful. In addition, we may be ineffective at marketing GelSyn-3 to existing patients and customers in such a manner that would effectively replace any loss of revenue associated with any discontinuance of our distribution agreement
for Supartz FX. If GelSyn-3 does not achieve an adequate level of acceptance by patients and physicians, our net sales may be adversely affected. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our commercial success depends on our ability to differentiate the HA viscosupplementation therapies that we own or distribute from alternative therapies for
the treatment of osteoarthritis. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our ability to achieve commercial success will, at least in part, depend on our ability to differentiate the HA
viscosupplementation therapies that we own or distribute in such a way that physicians and patients will select them. The HA viscosupplementation therapies that we own or distribute could face competition from steroid injections, single injection HA
viscosupplementation therapies and a number of combination HA viscosupplementation/steroid therapies currently in development. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We expect that the HA
viscosupplementation therapies that we own or distribute will continue to be used primarily after simple analgesics and steroid injections no longer provide adequate pain relief. In addition, the five and three injection HA viscosupplementation
therapies that we distribute or plan to distribute face competition from single injection therapies. Due to the convenience associated with the single injection treatments, it is expected that these products will capture increasing market share of
the HA viscosupplementation therapies market, which may adversely affect our business, results of operations and financial condition. There are also a number of combination HA viscosupplementation/steroid therapies currently in development. The
American Association of Orthopedic Surgeons, since the release of their 2013 clinical practice guidelines, does not recommend the use of HA for patients with symptomatic knee osteoarthritis because clinical studies have reached inconsistent results
on its efficacy. To the extent that any therapies receive approval or alternative therapies receive positive support from the American Association of Orthopedic Surgeons or other physicians, they could reduce the market share represented by HA
viscosupplementation therapies for osteoarthritis treatment and adversely affect our commercial success. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we are unable to differentiate the HA
viscosupplementation therapies we own or distribute from other therapies, physicians and patients may not be willing to use them or be willing to switch from existing therapies with which they are familiar. Once physicians incorporate a particular
treatment into their practice they may not alter their practice absent compelling clinical evidence of safety and/or effectiveness and/or significant pricing reimbursement advantages. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>We compete and may compete in the future against other companies, some of which have longer operating histories, more established products or greater resources than we do, which may prevent us from achieving
increased market penetration or improved operating results. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The medical technology industries are characterized by intense competition, subject
to rapid change and significantly affected by market activities of industry participants, new product introductions and other technological advancements. We believe that our competitors have historically dedicated and will continue to dedicate
significant resources to promote their products or to develop new products for orthobiologics. We have competitors in the United States and internationally, including major medical device and pharmaceutical companies, biotechnology companies and
universities and other research institutions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These companies and other industry participants may develop alternative treatments, products or procedures
that compete directly or indirectly with our products. If alternative treatments are, or are perceived to be, superior to our products, sales of our products could be negatively affected and our results of operations could suffer. Our competitors
may also develop and patent processes or products earlier than we can or obtain </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">24 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
regulatory clearance or approvals for competing products more rapidly than we can, which could impair our ability to develop and commercialize similar processes or products. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Many of our current and potential competitors are major medical device and pharmaceutical companies that have substantially greater financial, technical and
marketing resources than we do, and they may succeed in developing products that would render our products obsolete or noncompetitive. It is also possible that our competition will be able to leverage their large market share to set prices at a
level below that which is profitable for us. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Some of our competitors enjoy several competitive advantages over us, including: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">greater financial, human and other resources for product R&amp;D, sales and marketing and litigation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">significantly greater name recognition; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">control of intellectual property and more expansive portfolios of intellectual property rights, which could impact future products under development;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">greater experience in obtaining and maintaining regulatory clearances or approvals for products and product enhancements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">established relationships with hospitals and other healthcare providers, physicians, suppliers, customers and third-party payors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">additional lines of products, and the ability to bundle products to offer greater incentives to gain a competitive advantage; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">more established sales, marketing and worldwide distribution networks. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The potential introduction by competitors of products that compete with our existing or planned products may also make it difficult to market or sell our products. In addition, the entry of multiple new products
and competitors may lead some of our competitors to employ pricing strategies that could adversely affect the pricing of our products and pricing in the market generally. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As a result, our ability to compete successfully will depend on our ability to develop proprietary products that reach the market in a timely manner, receive adequate coverage and reimbursement from third-party
payors, and are safer, less invasive and more effective than alternatives available for similar purposes. If we are unable to do so, our sales or margins could decrease, which would adversely affect our business. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If clinical trials of our next-generation BMP product candidates fail to satisfactorily demonstrate safety and efficacy or we are unable to obtain regulatory
approval for, or successfully commercialize our next-generation BMP product candidates,&nbsp;our&nbsp;future growth prospects could be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Clinical testing is expensive, is difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. We expect to commence a Phase 1 clinical trial of one of our
next-generation BMP product candidates within 18 months. Over the next several years, we expect to increase our R&amp;D expenses significantly for our next-generation BMP product candidates as we undergo clinical trials to demonstrate the safety and
efficacy of our product candidates in order to gain regulatory approvals. Such increased R&amp;D expenses on our next-generation BMP product candidates could potentially be multiples of our current R&amp;D expenses on the BMP product candidates. We
cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. Our pre-clinical data are based on animal models, including non-human primate studies, which may not be indicative of results that we will
experience in clinical trials with human subjects. The clinical development of our next-generation BMP product candidates is susceptible to the risk of failure inherent at any stage of product development, including failure to demonstrate
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">25 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
efficacy in a clinical trial or across a broad population of patients, the occurrence of adverse events that are severe or medically or commercially unacceptable, failure to comply with protocols
or applicable regulatory requirements and determination by the FDA or any comparable foreign regulatory authority that a product candidate may not continue development or is not approvable. Our failure to successfully complete clinical trials of any
of our next-generation BMP product candidates and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market any of our next-generation BMP product candidates could adversely affect our future growth prospects.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our long-term growth depends on our ability to develop, acquire and commercialize additional orthobiologic products. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our industry is highly competitive and subject to rapid change and technological advancements. Therefore, it is important to our business that we continue to
enhance our product offerings and introduce new products. Developing, acquiring and commercializing products is expensive, time-consuming and could divert management&#146;s attention away from our existing orthobiologics business. Even if we are
successful in developing additional products, the success of any new product offering or enhancements to existing products will depend on several factors, including our ability to: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">properly identify and anticipate the needs of healthcare professionals and patients; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">develop and introduce new products or product enhancements in a timely manner; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">distinguish our products from those of our competitors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">avoid infringing upon the intellectual property rights of third-parties and maintain necessary intellectual property licenses from third-parties;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">demonstrate, if required, the safety and efficacy of new products with data from preclinical studies and clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtain clearance or approval, if required, from the FDA and other regulatory agencies, for such new products or enhancements to existing products, and maintain
full compliance with FDA and other regulatory requirements applicable to new devices or products or modifications of existing devices or products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">provide adequate training to potential users of our products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">receive adequate coverage and reimbursement for our products; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">maintain an effective and dedicated sales and marketing team. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If we are unsuccessful in developing, acquiring and commercializing new products, our ability to increase our net sales may be impaired. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Our Surgical business depends on the continued and future acceptance of our bone graft substitutes by the medical community. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">New allograft, DBMs, synthetics, BMPs/growth factors, or other enhancements to our existing implants may never achieve broad market acceptance, which can be affected by numerous factors, including lack of clinical
acceptance of bone graft substitutes and technologies, introduction of competitive treatment options which render bone graft substitutes and technologies too expensive or obsolete and difficulty training surgeons in the use of bone graft substitutes
and technologies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Market acceptance will also depend on our ability to demonstrate that our existing and new bone graft substitutes and technologies are
an attractive alternative to existing treatment options. Our ability to do so will depend on surgeons&#146; evaluations of the clinical safety, efficacy, ease of use, reliability and cost-effectiveness of
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">26 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
these treatment options and technologies. For example, we believe that some in the medical community have lingering concerns over the risk of disease transmission through the use of allografts.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Media reports or other negative publicity concerning both methods of tissue recovery from donors and actual or potential disease transmission from
donated tissue may limit widespread acceptance by the medical community of our allografts, BMPs/growth factor and DBMs, whether directed at these products generally or our products specifically. Unfavorable reports of improper or illegal tissue
recovery practices by any participant in the industry, both in the United States and internationally, as well as incidents of improperly processed tissue leading to transmission of disease, may broadly affect the rate of future tissue donation and
market acceptance of allograft based technologies by the medical community. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Furthermore, we believe that even if the medical community generally accepts
our bone graft substitutes and technologies, acceptance and recommendations by influential members of the medical community will be important to their broad commercial success. If our bone graft substitutes and technologies are not broadly accepted
by the medical community, we may not remain competitive in the market. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our future growth depends on physician awareness of the distinctive
characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We focus our sales, marketing and training efforts
on physicians, surgeons and other health care professionals. The acceptance of our products depends in part on our ability to educate physicians as to the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our
products compared to alternative products, procedures and therapies. We support our sales force and distributors through in-person educational programs and an online medical education platform, among other things. We also produce marketing
materials, including materials outlining our products, for our sales and marketing team in a variety of languages using printed, video and multimedia formats. However, we may not be successful in our efforts to educate physicians and surgeons. If
physicians or surgeons are not properly trained, they may misuse or ineffectively use our products, which may result in unsatisfactory patient outcomes, patient injury, negative publicity or lawsuits against us. In addition, a failure to educate
physicians or surgeons regarding our products may impair our ability to achieve market acceptance of our products. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We have incurred significant
net losses since inception, and we may not be able to achieve or sustain profitability. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have incurred net losses since our inception. For the
years ended December 31, 2013, 2014 and 2015 and the three months ended March 28, 2015 and April 2, 2016, we had net losses of $22.4 million, $12.9 million, $34.1&nbsp;million,<B><I> </I></B>$21.0 million and $6.0 million, respectively. As a result
of ongoing losses, we had an accumulated deficit of $91.8&nbsp;million and $98.0 million as of December 31,<B><I> </I></B>2015 and April 2, 2016, respectively. Our ability to generate sufficient net sales from our existing products or from any of
our products in<B><I> </I></B>development or products that we acquire, in order to transition to profitability, is uncertain. Following this<B><I> </I></B>offering, we expect that our operating expenses will continue to increase as we continue to
develop, enhance<B><I> </I></B>and commercialize new products and incur additional operational costs associated with being a public company, such that we may never achieve profitability. Furthermore, even if we do achieve profitability, we may not
be able to<B><I> </I></B>sustain or increase profitability on an ongoing basis. If we do not achieve profitability, it will be more difficult<B><I> </I></B>for us to finance our business and accomplish our strategic objectives. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Pricing pressure from our competitors or hospitals may affect our ability to sell our products at prices necessary to support our current business strategies.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Medical technology companies, healthcare systems and group purchasing organizations have intensified competitive pricing pressure as a result of
industry trends and new technologies. Purchasing decisions are </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">27 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
gradually shifting to hospitals, integrated delivery networks and other hospital groups, with surgeons and other physicians increasingly acting only as &#147;employees.&#148; Because hospitals
that typically bill various third-party payors generally purchase our Surgical products, changes in the purchasing behavior of such hospitals or the amount such payors are willing to reimburse our customers for procedures using our products,
including those as a result of healthcare reform initiatives, could create additional pricing pressure on us. In addition to these competitive forces, we continue to see pricing pressure as hospitals introduce new pricing structures into their
contracts and agreements, including fixed price formulas, capitated pricing and episodic or bundled payments intended to contain healthcare costs. If such trends continue to drive down the prices we are able to charge for our products, our profit
margins will shrink, adversely affecting our ability to invest in and grow our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Healthcare costs have risen significantly over the past decade,
which has resulted in or led to numerous cost reform initiatives by legislators, regulators and third-party payors. Cost reform has triggered a consolidation trend in the healthcare industry to aggregate purchasing power, which may create more
requests for pricing concessions in the future. Additionally, group purchasing organizations, independent delivery networks and large single accounts may continue to use their market power to consolidate purchasing decisions for physicians. We
expect that market demand, government regulation, third-party coverage and reimbursement policies and societal pressures will continue to change the healthcare industry worldwide, resulting in further business consolidations and alliances among our
customers, which may exert further downward pressure on the prices of our products. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we are unable to achieve and maintain adequate levels of
coverage and/or reimbursement for the procedures using our products, or any future products we may seek to commercialize, their commercial success may be severely hindered. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our products, except our Exogen system, are purchased by healthcare providers and customers who typically bill third-party payors, such as government programs, including Medicare and Medicaid, or private insurance
plans and healthcare networks, to cover all or a portion of the costs and fees associated with our products. These third-party payors may in turn bill patients for any deductibles or co-payments. For our Exogen system, we typically bill third-party
payors and collect co-payments from patients. These third-party payors and insurers may deny reimbursement if they determine that a device or product provided to a patient or used in a procedure does not meet applicable payment criteria or if the
policyholder&#146;s healthcare insurance benefits are limited. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Limits put on reimbursement by third-party payors, whether foreign or domestic,
governmental or commercial, could make it more difficult to buy our products and substantially reduce, or possibly eliminate, patient access to our products. The healthcare industry in the United States has experienced a trend toward cost
containment as government and private insurers seek to control rising healthcare costs by imposing lower payment rates and negotiating reduced contract rates with providers. In addition, there is no uniform policy of coverage and reimbursement for
our products or procedures using our products among third-party payors in the United States, and coverage and reimbursement for our products and procedures using our products can differ significantly from payor to payor. Payors regularly review new
and existing technologies for possible coverage and can, without notice, deny or reverse coverage for new or existing products and treatments. We may also be required to conduct expensive clinical studies to justify coverage and reimbursement or the
level of reimbursement relative to other therapies. In addition, should governmental authorities continue to enact legislation or adopt regulations that affect third-party coverage and reimbursement, access to our products and coverage by private or
public insurers may be reduced. If third-party payors or insurers that currently cover or reimburse our products or the procedures in which they are used limit their coverage or reimbursement in the future, or if other third-party payors or insurers
issue similar policies, this could impact our ability to sell our products, force us to lower the price we charge for our products, and adversely affect our business, results of operations and financial condition. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">28 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our ability to market and sell our products could be harmed by future actions by the Centers for Medicare and Medicaid
Services, or CMS (which administers the Medicare program), other government agencies or private payors to diminish payments to healthcare providers. Private payors may adopt coverage decisions and payment amounts determined by CMS as guidelines in
setting their coverage and reimbursement policies. In addition, for some governmental programs, such as Medicaid, coverage and reimbursement differs from state to state. Medicaid payments to physicians, facilities and other providers are often lower
than payments by other third-party payors and some state Medicaid programs may not pay an adequate amount for the procedures performed with our products, if any payment is made at all. If CMS, other government agencies or private payors lower their
reimbursement rates, the commercial success of our products may be severely hindered. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our ability to maintain our competitive position depends on
our ability to attract, retain and motivate our senior management team and highly qualified personnel, and our failure to do so could have an adverse effect on our results of operations. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that our continued success depends to a significant extent upon the skill, experience and performance of members of our senior management team, who have
been critical to the management of our operations and implementation of our strategy, as well as our ability to continue to attract, retain and motivate additional executive officers, and other key employees and consultants, such as those
individuals who are engaged in our R&amp;D efforts. The replacement of any of our key personnel likely would involve significant time and costs and may significantly delay or prevent the achievement of our business objectives and could therefore
have an adverse impact on our business. In addition, we do not carry any &#147;key person&#148; insurance policies that could offset potential loss of service under applicable circumstances. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Competition for experienced employees in the medical technology industry can be intense. To attract, retain and motivate qualified employees, we plan to utilize stock-based incentive awards such as employee stock
options. If the value of such stock awards does not appreciate as measured by the performance of the price of our Class&nbsp;A common stock and ceases to be viewed as a valuable benefit, our ability to attract, retain and motivate our employees
could be adversely impacted, which could negatively affect our results of operations and/or require us to increase the amount we expend on cash and other forms of compensation. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Governments outside the United States may not provide coverage or reimbursement of our products, which may adversely affect our net sales. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Acceptance of our products in international markets may depend, in part, upon the availability of coverage and reimbursement within prevailing healthcare payment systems. Reimbursement and healthcare payment
systems in international markets vary significantly by country, and include both government-sponsored healthcare and private insurance. Our products may not obtain international coverage and reimbursement approvals in a timely manner, if at all,
which may require consumers desiring our product to purchase them directly. Third-party coverage and reimbursement for our products or any of our products in development for which we may receive regulatory approval may not be available or adequate
in international markets, which could have an adverse impact on our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We face the risk of product liability claims that could be
expensive, divert management&#146;s attention and harm our reputation and business. We may not be able to maintain adequate product liability insurance. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our business exposes us to the risk of product liability claims that are inherent in the testing, manufacturing and marketing of our products. This risk exists even if a product is cleared or approved for
commercial sale by the FDA and manufactured in facilities regulated by the FDA or an applicable foreign regulatory authority. Our products are designed to affect, and any future products will be designed to affect, important bodily functions and
processes. Any side effects, manufacturing defects, misuse or abuse associated with our products or our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">29 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
products in development could result in patient injury or death. The medical technology industry has historically been subject to extensive litigation over product liability claims, and we cannot
assure you that we will not face product liability suits. We may be subject to product liability claims if our products or products in development cause, or merely appear to have caused, patient injury or death, even if such injury or death was as a
result of supplies or components that are produced by third-party suppliers. Product liability claims may be brought against us by consumers, healthcare providers or others selling or otherwise coming into contact with our products, among others. If
we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities and reputational harm. In addition, regardless of merit or eventual outcome, product liability claims may result in: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">costs of litigation; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">distraction of management&#146;s attention from our primary business; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the inability to commercialize existing or new products; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">decreased demand for our products or, if cleared or approved, products in development; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">damage to our business reputation; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">product recalls or withdrawals from the market; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">withdrawal of clinical trial participants; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">substantial monetary awards to patients or other claimants; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">loss of net sales. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">While we may attempt to
manage our product liability exposure by proactively recalling or withdrawing from the market any defective products, any recall or market withdrawal of our products may delay the supply of those products to our customers and may impact our
reputation. We cannot assure you that we will be successful in initiating appropriate market recall or market withdrawal efforts that may be required in the future or that these efforts will have the intended effect of preventing product
malfunctions and the accompanying product liability that may result. Such recalls and withdrawals may also be used by our competitors to harm our reputation for product safety or be perceived by patients as a safety risk when considering the use of
our products, either of which could have an adverse impact on our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, although we have product liability and clinical study liability
insurance that we believe is appropriate, this insurance is subject to deductibles and coverage limitations. Our current product liability insurance may not continue to be available to us on acceptable terms, if at all, and, if available, coverage
may not be adequate to protect us against any future product liability claims. If we are unable to obtain insurance at an acceptable cost or on acceptable terms or otherwise protect against potential product liability claims, we could be exposed to
significant liabilities. A product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could have an adverse impact on our business. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Fluctuations in the demand for our products or our inability to forecast demand accurately may influence the ability of our suppliers to meet our delivery
needs or result in excess product inventory. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are required by some of our contracts with suppliers of our products to forecast future product
demand or meet minimum purchase requirements. Our distribution agreement for Supartz FX is subject to certain annual minimum purchase requirements based on a percentage of our Supartz FX annual forecast and our supply agreement for Durolane is
subject to a minimum order volume for each order and purchase amounts are also based in part on forecasts. We will also be subject to certain annual minimum purchase requirements for GelSyn-3 and purchase amounts will be based on rolling forecasts.
Our forecasts are based on multiple assumptions of product and market demand, which may cause our estimates to be inaccurate. If we underestimate demand, we may not have adequate supplies and could have reduced control over pricing, availability and
delivery schedules with our suppliers, which could prevent us from meeting increased customer </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">30 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
or consumer demand and harm our business. However, if we overestimate our demand, we may have underutilized assets and may experience reduced margins. If we do not accurately align our supplies
with demand, our business, financial condition and results of operations may be adversely affected. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may face issues with respect to the supply
of our products or their components, including increased costs, disruptions of supply, shortages, contaminations or mislabeling. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are
dependent on a limited number of suppliers for the supply of products and components used in the manufacturing process of our products. Our top three suppliers provide us with products and components that constituted 46%, 44% and 48% of our total
net sales for the years ended December&nbsp;31, 2013, 2014 and 2015, respectively. For the three month periods ended March 28, 2015 and April 2, 2016, our top two suppliers provide us with products and components that constitute 42% and 38%,
respectively, of our total net sales. Our Exogen system undergoes final assembly with components procured from various suppliers, including a transducer, which is a key component that is supplied by a single source supplier. GelSyn-3, Supartz FX and
Durolane are supplied by single-source third-party manufacturers. We also have a supply agreement with Advanced Biologics LLC, or Advanced Biologics, through October 2018 to purchase our OsteoAMP product. We may not be able to renew or enter into
new contracts with our existing suppliers following the expiration of such contracts on commercially reasonable terms, or at all. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In particular, the
success of our Surgical business, which, among other things, markets and develops <FONT STYLE="white-space:nowrap">tissue-based</FONT> bone biologic product will depend on our suppliers continuing to have access to donated human cadaveric tissue, as
well as the maintenance of high standards in their processing methodology. The supply of such donors can fluctuate over time. We cannot be certain that our current suppliers who rely on allograft bone tissue, plus any additional sources that our
suppliers identify in the future, will be sufficient to meet our product needs. Our dependence on a limited number of third-party suppliers and the challenges that they may face in obtaining adequate supplies of allograft bone tissue involve several
risks, including limited control over pricing, availability, quality and delivery schedules. We may be unable to find an alternative supplier in a reasonable time period or on commercially reasonable terms, if at all, which would have a material
adverse effect on our business, results of operations and financial condition. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If any of our products or the components used in our products are alleged
or proven to include quality or product defects, including as a result of improper methods of tissue recovery from donors and disease transmission from donated tissue or illegal harvesting, we may need to find alternate supplies, delay production of
our products, discard or otherwise dispose of our products, or engage in a product recall, all of which may have a materially adverse effect on our business, financial condition and results of operations. If our products or the components in our
products are affected by adverse prices or quality or other concerns, we may not be able to identify alternate sources of components or other supplies that meet our quality controls and standards to sustain our sales volumes or on commercially
reasonable terms, or at all. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We rely on a limited number of third-party manufacturers to manufacture certain of our products. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have developed in-house assembly capabilities for our Exogen system. Exogen components, Supartz FX, GelSyn-3, Durolane and our Surgical products are generally
manufactured by third-party manufacturers. We and our third-party manufacturers are required to comply with the Quality System Regulation, or QSR, which is a set of FDA regulations that establishes current Good Manufacturing Practices, or cGMP,
requirements for medical devices and covers the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of such devices. There are a limited number of
suppliers and third-party manufacturers that operate under FDA&#146;s QSR requirements and that have the necessary expertise and capacity to manufacture our products or components for our products. As a result, it may be difficult for us to locate
manufacturers for our anticipated future needs, and our anticipated growth </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">31 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
could strain the ability of our current suppliers and third-party manufacturers to deliver products, materials and components to us. Upon expiration of our existing agreements with these
third-party manufacturers, we may not be able to renegotiate the terms of our agreements with these third-party manufacturers on a commercially reasonable basis, or at all. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If we or our third-party manufacturers fail to maintain facilities in accordance with the FDA&#146;s QSR, the noncomplying party could lose the ability to manufacture our products on a commercial scale. Loss of
this manufacturing capability would limit our ability to sell our products, including Supartz FX, Durolane and our Surgical products, which are manufactured by single-source third-party manufacturers. See &#147;Business&#151;Manufacturing and
supply.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The manufacture of our products may not be easily transferable to other sites in the event that any of our third-party manufacturers
experience breakdown, failure or substandard performance of equipment, disruption of supply or shortages of, or quality issues with, components of our products and other supplies, labor problems, power outages, adverse weather conditions and natural
disasters or the need to comply with environmental and other directives of governmental agencies. From time to time, a third-party manufacturer may experience financial difficulties, bankruptcy or other business disruptions, which could disrupt our
supply of finished goods or require that we incur additional expense by providing financial accommodations to the third-party manufacturer or taking other steps to seek to minimize or avoid supply disruption, such as establishing a new third-party
manufacturing arrangement with another provider. The loss of any of these third-party manufacturers or the failure for any reason of any of these third-party manufacturers to fulfill their obligations under their agreements with us, including a
failure to meet our quality controls and standards, may result in disruptions to our supply of finished goods. We may be unable to locate an additional or alternate third-party manufacturing arrangement that meets our quality controls and standards
in a timely manner or on commercially reasonable terms, if at all. If this occurs, our business, financial condition and results of operations will be adversely affected. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>If our facilities are damaged or become inoperable, we will be unable to continue to research, develop and manufacture our products and, as a result, there will be an adverse impact on our business until we
are able to secure a new facility. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We do not have redundant facilities for the final assembly of our Exogen system. Our other facilities and
equipment would be costly to replace and could require substantial lead time to repair or replace. Our facilities may be harmed or rendered inoperable by natural or man-made disasters, including, but not limited to, tornadoes, flooding, fire and
power outages, which may render it difficult or impossible for us to perform our research, development, manufacturing and commercialization activities for some period of time. The inability to perform those activities, combined with our limited
inventory of supplies, components and finished product, may result in the inability to continue manufacturing or supplying our products during such periods and the loss of customers or harm to our reputation. Although we possess insurance for damage
to our facilities and the disruption of our business, this insurance may not be sufficient to cover all of our potential losses and this insurance may not continue to be available to us on acceptable terms, or at all. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we fail to maintain our numerous contractual relationships, our business, financial condition or results of operations could be adversely affected.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are party to numerous contracts in the normal course of our business, including our distribution agreement for Supartz FX which has a current
term expiring in May 2019. We have contractual relationships with suppliers, distributors and agents, as well as service providers. In the aggregate, these contractual relationships are necessary for us to operate our business. From time to time, we
amend, terminate or negotiate our contracts. We may also periodically be subject to, or make claims of breach of contract, or threaten legal action relating to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">32 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
our contracts. These actions may result in litigation. At any one time, we have a number of negotiations under way for new or amended commercial agreements. We devote substantial time, effort and
expense to the administration and negotiation of contracts involved in our business. However, these contracts may not continue in effect past their current term or we may not be able to negotiate satisfactory contracts in the future with current or
new business partners, which may adversely affect our business, financial condition or results of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we are unable to manage, maintain
and expand our network of direct sales representatives and independent distributors, we may not be able to generate anticipated sales. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our
operating results are directly dependent upon the sales and marketing efforts of not only our direct sales representatives, but also our independent distributors. If our direct sales representatives or independent distributors fail to adequately
promote, market and sell our products, our sales could significantly decrease. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We face significant challenges and risks in managing our geographically
dispersed distribution network and retaining the individuals who make up that network. If any of our direct sales representatives were to leave us, or if any of our independent distributors were to cease to do business with us, our sales could be
adversely affected. In such a situation, we may need to seek alternative independent distributors or increase our reliance on our direct sales representatives, which may not prevent our sales from being adversely affected. If a direct sales
representative or independent distributor were to depart and be retained by one of our competitors, we may be unable to prevent them from helping competitors solicit business from our existing customers, which could further adversely affect our
sales. Because of the competition for their services, we may be unable to recruit or retain additional qualified independent distributors or to hire additional direct sales representatives to work with us on favorable or commercially reasonable
terms, if at all. Failure to hire or retain qualified direct sales representatives or independent distributors would prevent us from maintaining or expanding our business and generating sales. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If we launch new products or increase our marketing efforts with respect to existing products, we will need to expand the reach of our marketing and sales networks. Our future success will depend largely on our
ability to continue to hire, train, retain and motivate skilled direct sales representatives and independent distributors with significant technical knowledge in orthobiologics. New hires require training and take time to achieve full productivity.
If we fail to train new hires adequately, or if we experience high turnover in our sales force in the future, we cannot be certain that new hires will become as productive as may be necessary to maintain or increase our sales. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we are unable to expand our sales and marketing capabilities domestically and internationally, we may not be able to effectively commercialize our products,
which would adversely affect our business, results of operations and financial condition. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we choose to acquire or invest in new businesses,
products or technologies, we may be unable to complete these acquisitions or to successfully integrate them in a cost-effective and non-disruptive manner. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our success depends on our ability to enhance and broaden our product offerings in response to changing customer demands, competitive pressures and advances in technologies. In November&nbsp;2015, we acquired
BioStructures, a proprietary developer and marketer of bioresorbable bone graft products for a broad range of spinal and orthopedic surgical applications. We continue to search for viable acquisition candidates or strategic alliances that would
expand our market sector or global presence, as well as additional products appropriate for current distribution channels. Accordingly, we may in the future pursue the acquisition of, or joint ventures relating to, new businesses, products or
technologies instead of developing them ourselves. Potential and completed acquisitions and strategic investments involve numerous risks, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">risks associated with conducting due diligence; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">33 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">problems integrating the purchased technologies, products or business operations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">inability to achieve the anticipated synergies and overpaying for acquisitions or unanticipated costs associated with acquisitions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">invalid net sales assumptions for potential acquisitions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">issues maintaining uniform standards, procedures, controls and policies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">diversion of management&#146;s attention from our core business; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">adverse effects on existing business relationships with suppliers, distributors and customers; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">risks associated with entering new markets in which we have limited or no experience; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">potential loss of key employees of acquired businesses; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">increased legal, accounting and compliance costs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We compete with other companies for these opportunities, and we may be unable to consummate such acquisitions or joint ventures on commercially reasonable terms, or at all. In addition, acquired businesses may have
ongoing or potential liabilities, legal claims (including tort and/or personal injury claims) or adverse operating issues that we fail to discover through due diligence prior to the acquisition. Even if we are aware of such liabilities, claims or
issues, we may not be able to accurately estimate the magnitude of the related liabilities and damages. In particular, to the extent that prior owners of any acquired businesses or properties failed to comply with or otherwise violated applicable
laws or regulations, failed to fulfill their contractual obligations to their customers, or failed to satisfy legal obligations to employees or third parties, we, as the successor, may be financially responsible for these violations and failures and
may suffer reputational harm or otherwise be adversely affected. Acquisitions also frequently result in the recording of goodwill and other intangible assets which are subject to potential impairment in the future that could harm our financial
results. If we were to issue additional equity in connection with such acquisitions, this may dilute our stockholders. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Actual or attempted
breaches of security, unauthorized disclosure of information, denial of service attacks or the perception that personal and/or other sensitive or confidential information in our possession is not secure, could result in a material loss of business,
substantial legal liability or significant harm to our reputation. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We receive, collect, process, use and store a large amount of information,
including personally identifiable, protected health and other sensitive and confidential information. This data is often accessed by us through transmissions over public and private networks, including the Internet. The secure transmission of such
information over the Internet and other mechanisms is essential to maintain confidence in our IT systems. Despite the privacy and security measures we have in place to ensure compliance with applicable laws, regulations and contractual requirements,
our facilities and systems, and those of our third-party vendors and service providers, are vulnerable to privacy and security incidents including, but not limited to, computer hacking, breaches, acts of vandalism or theft, computer viruses or other
forms of cyber-attack, misplaced or lost data, programming and/or human errors or other similar events. A party, whether internal or external, that is able to circumvent our security systems could, among other things, misappropriate or misuse
sensitive or confidential information, user information or other proprietary information, or cause significant interruptions in our operations. Internal or external parties may attempt to circumvent our security systems, and we expect that we may in
the future experience external attacks on our network, such as, for example, reconnaissance probes, denial of service attempts, malicious software attacks and phishing attacks. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Because the techniques used to circumvent security systems can be highly sophisticated and change frequently, often are not recognized until launched against a target and may originate from less regulated and
remote </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">34 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
areas around the world, we may be unable to proactively address all possible techniques or implement adequate preventive measures for all situations. Recent, well-publicized attacks on prominent
companies have resulted in the theft of significant amounts of sensitive and personal information and demonstrate the sophistication of the perpetrators and magnitude of the threat posed to companies across the nation, including the health care
industry. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If someone is able to circumvent or breach our security systems, they could steal any information located therein or cause interruptions to
our operations. Security breaches or attempts thereof could also damage our reputation and expose us to a risk of monetary loss and/or litigation, fines and sanctions. We also face risks associated with security breaches affecting third parties that
conduct business with us or our customers and others who interact with our data. While we maintain insurance that covers certain security and privacy breaches, we may not carry appropriate insurance or maintain sufficient coverage to compensate for
all potential liability. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are subject to diverse laws and regulations relating to data privacy and security, including the federal Health Insurance
Portability and Accountability Act of 1996, or HIPAA, and the EU Data Protection Directive (95/46/EC). Complying with these numerous and complex regulations is expensive and difficult, and failure to comply with any privacy laws or data security
laws or any security incident or breach involving the misappropriation, loss or other unauthorized use or disclosure of sensitive or confidential patient or consumer information, whether by us, one of our business associates or another third-party,
could have a material adverse effect on our business, reputation, financial condition and results of operations, including but not limited to: material fines and penalties; compensatory, special, punitive, and statutory damages; litigation; consent
orders regarding our privacy and security practices; requirements that we provide notices, credit monitoring services and/or credit restoration services or other relevant services to impacted individuals; adverse actions against our licenses to do
business; and injunctive relief. Furthermore, these rules are constantly changing; for example, the US-EU Safe Harbor framework has been declared invalid and other methods to permit transfer are now under review. Additionally, the costs incurred to
remediate any data security or privacy incident could be substantial. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We cannot assure you that any of our third-party service providers with access to
our or our customers and/or employees&#146; personally identifiable and other sensitive or confidential information will maintain appropriate policies and practices regarding data privacy and security in compliance with all applicable laws or that
they will not experience data security breaches or attempts thereof, which could have a corresponding effect on our business. While we attempt to address the associated risks by requiring all such third-party providers with data access to sign
agreements, including business associate agreements, if necessary, obligating them to take security measures to protect such data, we cannot assure you that these contractual measures and our own privacy and security-related safeguards will protect
us from the risks associated with the third-party storage and transmission of such information. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Failure of a key information technology and
communication system, process or site could adversely affect our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We rely extensively on information technology and communication
systems and software and hardware products, including those of external providers to conduct business. These systems and software and hardware impact, among other things, ordering and managing components of our products from suppliers, shipping
products to customers on a timely basis, processing transactions, coordinating our sales activities across all of our products, summarizing and reporting results of operations, complying with regulatory, legal or tax requirements, data security and
other processes necessary to manage our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Despite any precautions we may take, our systems and software and hardware could be exposed to damage
or interruption from circumstances beyond our control, such as fire, natural disasters, systems failures, power </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">35 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
outages, cyber-attacks, terrorism, energy loss, telecommunications failure, security breaches and attempts thereof, computer viruses and similar disruptions affecting the global Internet.
Although we have taken steps to prevent system failures and have back-up systems and procedures to prevent or reduce disruptions, such steps may not prevent an interruption of services and our disaster recovery planning may not be adequate or
account for all contingencies. Additionally, our insurance may not adequately compensate us for all losses or failures that may occur. If our systems or software and hardware are damaged or cease to function properly and our business continuity
plans do not effectively compensate on a timely basis, we may suffer interruptions in our operations, which could adversely affect our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We will
need to improve and upgrade our systems and infrastructure as our operations grow in scale in order to maintain the reliability and integrity of our systems and infrastructure. The expansion of our systems and infrastructure will require us to
commit substantial financial, operational and technical resources before the volume of our business increases, with no assurance that the volume of business will increase. Any service outages or delays due to the installation of any new or upgraded
technology (and customer issues therewith), or the impact on the reliability of our data from any new or upgraded technology could adversely affect our cash flows, operating results and financial condition. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our business subjects us to economic, political, regulatory and other risks associated with international sales and operations that could materially adversely
affect our business, financial condition or results of operations. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Since we sell our products in many different jurisdictions outside the United
States, our business is subject to risks associated with conducting business internationally. We anticipate that net sales from international operations will continue to represent a portion of our total net sales. In addition, a number of our
third-party manufacturing facilities and suppliers of our products are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">economic weakness, including inflation, or political instability in particular foreign economies and markets; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in
another country; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">customers in some foreign countries potentially having longer payment cycles; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">disadvantages of competing against companies from countries that are not subject to U.S. laws and regulations, including the U.S. Foreign Corrupt Practices Act,
or FCPA, regulations of the U.S. Office of Foreign Assets Controls, and U.S. anti-money laundering regulations, as well as exposure of our foreign operations to liability under these regulatory regimes; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">training of third-parties on our products and the procedures in which they are used; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reduced protection for and greater difficulty enforcing our intellectual property rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">unexpected changes in tariffs, trade barriers and regulatory requirements, export licensing requirements or other restrictive actions by foreign governments;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">difficulty in staffing and managing widespread operations, including compliance with tax, employment, immigration and labor laws for employees living or
traveling abroad; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">foreign taxes, including withholding of payroll taxes; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">workforce uncertainty in countries where labor unrest is more common than in the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">international regulators and third-party payors requiring additional clinical studies prior to approving or allowing reimbursement for our products;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">36 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">production shortages resulting from any events affecting material supply or manufacturing capabilities abroad; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, further expansion into new international markets may require significant resources and the efforts and attention of our
management and other personnel, which may divert resources from our existing business operations. As we expand our business internationally, our success will depend, in large part, on our ability to&nbsp;anticipate and effectively manage these and
other risks associated with our operations outside of the United&nbsp;States. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Failure to comply with the FCPA and laws associated with our
activities outside the United States could adversely affect our business, financial condition or results of operations. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are subject to the
FCPA and other anti-bribery legislation around the world. The FCPA generally prohibits covered entities and their intermediaries from engaging in bribery or making other prohibited payments, offers or promises to foreign officials for the purpose of
obtaining or retaining business or other advantages. In addition, the FCPA imposes recordkeeping and internal controls requirements on publicly traded corporations and their foreign affiliates, which are intended to, among other things, prevent the
diversion of corporate funds to the payment of bribes and other improper payments, and to prevent the establishment of &#147;off books&#148; slush funds from which such improper payments can be made. As we conduct our business in jurisdictions
outside of the United States, we face significant risks if we fail to comply with the FCPA and other laws that prohibit improper payments, offers or promises of payment to foreign governments and their officials and political parties by us and other
business entities for the purpose of obtaining or retaining business or other advantages. In many foreign countries, particularly in countries with developing economies, it may be a local custom that businesses operating in such countries engage in
business practices that are prohibited by the FCPA or other laws and regulations. Although we have implemented a company policy requiring our employees and consultants to comply with the FCPA and similar laws, such policy may not be effective at
preventing all potential FCPA or other violations. Although our agreements with our international distributors clearly state our expectations for our distributors&#146; compliance with U.S. laws, including the FCPA, and provide us with various
remedies upon any non-compliance, including the ability to terminate the agreement, we also cannot guarantee our distributors&#146; compliance with U.S. laws, including the FCPA. Therefore there can be no assurance that none of our employees and
agents, or those companies to which we outsource certain of our business operations, have not and will not take actions that violate our policies or applicable laws, for which we may be ultimately held responsible. Any violation of the FCPA and
related policies could result in severe criminal or civil sanctions, which could have a material and adverse effect on our business, financial condition or results of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Furthermore, we are subject to the export controls and economic embargo rules and regulations of the United States, including, but not limited to, the Export Administration Regulations and trade sanctions against
embargoed countries, which are administered by the Office of Foreign Assets Control within the Department of the Treasury, as well as the laws and regulations administered by the Department of Commerce. These regulations limit our ability to market,
sell, distribute or otherwise transfer our products or technology to prohibited countries or persons. A determination that we have failed to comply, whether knowingly or inadvertently, may result in substantial penalties, including fines,
enforcement actions, civil and/or criminal sanctions, the disgorgement of profits, the imposition of a court-appointed monitor, as well as the denial of export privileges, and may have an adverse effect on our business, financial condition or
results of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">37 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We are exposed to foreign currency risks, which may materially adversely affect our business, financial
condition or results of operations. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our financial statements are presented in U.S. dollars. Because some of our revenue, expenses, assets and
liabilities are denominated in foreign currencies, we are subject to exchange rate and currency risks. In preparing our financial statements, we must convert all non-U.S. dollar financial results to U.S. dollars at varying exchange rates. This may
ultimately result in currency gain or loss, the outcome of which we cannot predict. Furthermore, to the extent that we incur expenses or earn revenue in currencies other than in U.S. dollars, any change in the values of those foreign currencies
relative to the U.S. dollar could cause our profits to decrease or our products to be less competitive against those of our competitors. To the extent that our current assets denominated in foreign currency are greater or less than our current
liabilities denominated in foreign currencies, we face potential foreign exchange exposure. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To minimize such exposures, we have entered, and may in the
future enter, into derivative instruments related to forecasted foreign currency transactions or currency hedges from time to time. Losses from changes in the value of the Euro or other foreign currencies relative to the U.S. dollar could materially
affect our business, financial condition or results of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We are subject to differing tax rates in several jurisdictions in which we
operate, which may adversely affect our results of operations. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have subsidiaries in several countries. Our business outside of the United
States is conducted primarily through a subsidiary in the Netherlands. Income taxes in the Netherlands are imposed on a negotiated percentage of sales. We have an agreement with the Dutch taxing authorities that is subject to renewal every five
years where our subsidiary in the Netherlands will incur, but not have to pay income taxes in years when the subsidiary is operating at a loss. As a result, based on the net sales for the year ended December&nbsp;31, 2013, we recorded a deferred tax
liability of about $0.3 million which is still outstanding at December&nbsp;31, 2015. If our tax treatment were to change, we may be subject to additional tax liability or penalty, which could adversely affect our profitability. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The results of the United Kingdom&#146;s referendum on withdrawal from the European Union may have a negative effect on global economic conditions, financial
markets and our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In June 2016, a majority of voters in the United Kingdom elected to withdraw from the European Union in a national
referendum. The referendum was advisory, and the terms of any withdrawal are subject to a negotiation period that could last at least two years after the government of the United Kingdom formally initiates a withdrawal process. Nevertheless, the
referendum has created significant uncertainty about the future relationship between the United Kingdom and the European Union, including with respect to the laws and regulations that will apply as the United Kingdom determines which European Union
laws to replace or replicate in the event of a withdrawal. The referendum has also given rise to calls for the governments of other European Union member states to consider withdrawal. These developments, or the perception that any of them could
occur, have had and may continue to have a material adverse effect on global economic conditions and the stability of global financial markets, and may significantly reduce global market liquidity and restrict the ability of key market participants
to operate in certain financial markets. Any of these factors could depress economic activity and restrict our access to capital, which could have a material adverse effect on our business, financial condition and results of operations and reduce
the price of our Class A common stock. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">38 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our credit agreements contain financial and operating restrictions that may limit our access to credit. If we
fail to comply with financial or other covenants in our credit agreements, we may be required to repay indebtedness to our existing lenders, which may harm our liquidity. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As of April 2, 2016, we had outstanding indebtedness of $19.5 million under our revolving credit facility (leaving availability of $20.5 million) and $159.9 million under our term loan facilities (net of
unamortized original issue discount and deferred financing costs). Our secured credit facilities contain certain covenants, including, but not limited to: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a minimum fixed charge ratio and a maximum debt leverage ratio requirement as defined in the credit agreements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">restrictions on the declaration or payment of certain distributions on or in respect of our equity interests; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">restrictions on acquisitions, investments and certain other payments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">limitations on the incurrence of new indebtedness; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">limitations on transfers, sales and other dispositions; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">limitations on making any material change in any of our business objectives that could reasonably be expected to have a material adverse effect on the repayment
of our credit facilities. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Such indebtedness could have significant consequences, including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">requiring a substantial portion of our cash flows to be dedicated to debt service payments instead of funding growth, working capital, capital expenditures,
investments or other cash requirements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reducing our flexibility to adjust to changing business conditions or obtain additional financing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">exposing us to the risk of increased interest rates as certain of our borrowings, including borrowings under our term loan facilities, are at variable rates,
making it more difficult for us to make payments on our indebtedness; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">restricting us from making strategic acquisitions or causing us to make non-strategic divestitures; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">subjecting us to restrictive covenants that may limit our flexibility in operating our business; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">limiting our ability to obtain additional financing for working capital, capital expenditures, debt service requirements and general corporate or other purposes.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, we may not be able to comply with the financial covenants in the future. In the absence of a waiver from our lenders, any
failure by us to comply with these covenants in the future may result in the declaration of an event of default under our secured credit facilities, which could adversely affect our financial position. See &#147;Description of indebtedness.&#148;
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to government regulation </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The risk
factors listed below describe the risks we face related to government regulation. The companies who manufacture or produce certain of the products we distribute face similar risks with respect to government regulation relating to such products. If
such suppliers are unable to comply with government regulations, they may not be able to continue to supply us with products, which could have a material adverse effect on our business, results of operations and financial condition. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">39 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our products and operations are subject to extensive governmental regulation, and our failure to comply with
applicable requirements could cause our business to suffer. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The healthcare industry, and in particular the medical device industry, are
regulated extensively by governmental authorities, principally the FDA and corresponding state and foreign regulatory agencies and authorities. The FDA and other U.S. and foreign governmental agencies and authorities regulate and oversee, among
other things: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">design, development and manufacturing; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">testing, labeling, content and language of instructions for use and storage; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">clinical trials; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">product safety; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">marketing, sales and distribution; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">premarket clearance and approval; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">conformity assessment procedures; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">record-keeping procedures; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">advertising and promotion; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">recalls and other field safety corrective actions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">postmarket surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury;
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">postmarket studies; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">product import and export. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The regulations to
which we are subject are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The failure to comply with applicable regulations could jeopardize our ability to sell our products and result in enforcement actions such as:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">administrative or judicially imposed sanctions; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">unanticipated expenditures to address or defend such actions; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">injunctions, consent decrees or the imposition of civil penalties or fines; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">recall or seizure of our products; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">total or partial suspension of production or distribution; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">refusal to grant pending or future clearances or approvals for our products; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">withdrawal or suspension of regulatory clearances or approvals; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">clinical holds; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">untitled letters or warning letters; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">refusal to permit the import or export of our products; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">criminal prosecution of us or our employees. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and harm our reputation, business, financial condition and
results of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The FDA regulatory process is expensive, time-consuming and uncertain, and the failure to obtain and maintain required
regulatory clearances and approvals could prevent us from commercializing our products. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Before we can market or sell a new medical device or a
new use of or a claim for or significant modification to an existing medical device in the United States, we must obtain either clearance from the FDA under Section&nbsp;510(k) of the Federal Food, Drug, and Cosmetic Act, or FDCA, or approval of a
PMA, unless an exemption </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">40 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
applies. In the United States, we have obtained 510(k) premarket clearance from the FDA to market products such as Signafuse Bioactive Bone Graft Putty, Interface Bioactive Bone Graft and
Signafuse Mineralized Collagen Scaffold. Our Active Healing Therapies, including our Exogen system, Supartz FX and GelSyn-3, have obtained PMA approval. In the 510(k) clearance process, before a device may be marketed, the FDA must determine that a
proposed device is &#147;substantially equivalent&#148; to a legally-marketed &#147;predicate&#148; device, which includes a device that has been previously cleared through the 510(k) process, a device that was legally marketed prior to May&nbsp;28,
1976 (preamendments device), a device that was originally on the U.S. market pursuant to an approved PMA application and later downclassified, or a 510(k)-exempt device. To be &#147;substantially equivalent,&#148; the proposed device must have the
same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate
device. Clinical data are sometimes required to support substantial equivalence. In the PMA process, the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not
limited to, technical, preclinical, clinical trial, manufacturing and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Modifications to products that are approved through a PMA application generally require FDA approval. Similarly, certain modifications made to products
cleared through a 510(k) may require a new 510(k) clearance. Both the PMA approval and the 510(k) clearance process can be expensive, lengthy and uncertain. The FDA&#146;s 510(k) clearance process usually takes from three to twelve months, but can
last longer. The process of obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years, or even longer, from the time the application is filed with the FDA. In addition, a PMA
generally requires the performance of one or more clinical trials. Despite the time, effort and cost, we cannot assure you that any particular device will be approved or cleared by the FDA. Any delay or failure to obtain necessary regulatory
approvals could harm our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any modification to one of our 510(k) cleared products that would constitute a major change in its intended use, or
any change that could significantly affect the safety or effectiveness of the device would require us to obtain a new 510(k) marketing clearance and may even, in some circumstances, require the submission of a PMA application, if the change raises
complex or novel scientific issues or the product has a new intended use. The FDA requires every manufacturer to make the determination regarding the need for a new 510(k) submission in the first instance, but the FDA may review any
manufacturer&#146;s decision. We may make changes to our 510(k)-cleared products in the future that we may determine do not require a new 510(k) clearance or PMA approval. If the FDA disagrees with our decision not to seek a new 510(k) or PMA
approval for changes or modifications to existing devices and requires new clearances or approvals, we may be required to recall and stop marketing our products as modified, which could require us to redesign our products, conduct clinical trials to
support any modifications, and pay significant regulatory fines or penalties. If there is any delay or failure in obtaining required clearances or approvals or if the FDA requires us to go through a lengthier, more rigorous examination for future
products or modifications to existing products than we had expected, our ability to introduce new or enhanced products in a timely manner would be adversely affected, which in turn would result in delayed or no realization of revenue from such
product enhancements or new products and could also result in substantial additional costs which could decrease our profitability. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The FDA can delay,
limit or deny clearance or approval of a device for many reasons, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may not be able to demonstrate to the FDA&#146;s satisfaction that the product or modification is substantially equivalent to the proposed predicate device or
safe and effective for its intended use; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the data from our preclinical studies and clinical trials may be insufficient to support clearance or approval, where required; and </FONT></P></TD></TR></TABLE>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">41 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the manufacturing process or facilities we use may not meet applicable requirements. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our
future products under development or impact our ability to modify our currently cleared product on a timely basis. For example, in response to industry and healthcare provider concerns regarding the predictability, consistency and rigor of the
510(k) clearance process, the FDA initiated an evaluation, and in January 2011, announced several proposed actions intended to reform the 510(k) clearance process. The FDA intends these reform actions to improve the efficiency and transparency of
the clearance process, as well as bolster patient safety. In addition, as part of the Food and Drug Administration Safety and Innovation Act enacted in 2012, Congress reauthorized the Medical Device User Fee Amendments with various FDA performance
goal commitments and enacted several &#147;Medical Device Regulatory Improvements&#148; and miscellaneous reforms, which are further intended to clarify and improve medical device regulation both pre- and post-clearance and approval. Some of these
proposals and reforms could impose additional regulatory requirements upon us that could delay our ability to obtain new 510(k) clearances, increase the costs of compliance or restrict our ability to maintain our current clearances. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Even after clearance or approval for our products is obtained, we are subject to extensive postmarket regulation by the FDA. For example, the FDA has the power to
require us to conduct postmarket studies. These studies can be very expensive and time-consuming to conduct. Failure to complete such studies in a timely manner could result in the revocation of clearance or approval and the recall or withdrawal of
the product, which could prevent us from generating sales from that product in the United States. Our failure to meet strict regulatory requirements could require us to pay fines, incur other costs or even close our facilities. We cannot assure you
that we will successfully maintain the clearances or approvals we have received or may receive in the future. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our HCT/P products are subject to
extensive government regulation and our failure to comply with these requirements could cause our business to suffer. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the United States, we
sell human tissue-derived bone graft substitutes, such as PureBone and OsteoAMP, which are referred to by the FDA as HCT/Ps. Certain HCT/Ps are regulated by the FDA solely under Section 361 of the Public Health Service Act and are referred to as
&#147;Section 361 HCT/Ps,&#148; while other HCT/Ps are subject to FDA&#146;s regulatory requirements applicable to medical devices or biologics. Section 361 HCT/Ps do not require 510(k) clearance, PMA approval, biologics license application, or BLA,
or other premarket authorization from FDA before marketing. We believe our HCT/Ps are regulated solely under Section 361 of the PHSA, and therefore, we have not sought or obtained 510(k) clearance, PMA approval, or licensure through a BLA. The FDA
could disagree with our determination that our human tissue products are Section 361 HCT/Ps and could determine that these products are biologics requiring a BLA or medical devices requiring 510(k) clearance or PMA approval, and could require that
we cease marketing such products and/or recall them pending appropriate clearance, approval or license from the FDA. For example, the FDA&#146;s Center for Devices and Radiological Health, or CDRH, issued us a letter in March 2016 in which it
asserted that OsteoAMP meets the definition of a medical device, and requested that we provide CDRH with information in support of our position that OsteoAMP does not require 510(k) clearance or PMA approval. We provided CDRH with the requested
information in support of this position in May 2016 and we have received no further inquiries to date. We believe that CDRH&#146;s assertion is unfounded and inconsistent with a 2011 letter from the FDA concluding that OsteoAMP meets the criteria
for regulation solely as a Section 361 HCT/P. However, if the FDA were to disagree, and if we are otherwise unsuccessful in asserting our position, the FDA may then require that we obtain 510(k) clearance or PMA approval and that we cease marketing
OsteoAMP and/or recall OsteoAMP unless and until we receive clearance or approval. We estimate that if we were to cease marketing OsteoAmp and/or recall OsteoAmp that our net sales would decrease, which would adversely affect our results of
operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">42 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Even though we believe that our HCT/Ps are not subject to premarket approval or review, HCT/Ps are subject to donor
eligibility and screening, current Good Tissue Practices, or cGTPs, product labeling, and postmarket reporting requirements. If we or our suppliers fail to comply with these requirements, we could be subject to FDA enforcement action, including, for
example, warning letters, fines, injunctions, product recalls or seizures, and, in the most serious cases, criminal penalties. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may be subject
to enforcement action if we engage in improper marketing or promotion of our products, and the misuse or off-label use of our products may harm our image in the marketplace, result in injuries that lead to product liability suits or result in costly
investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The medical devices that we currently market have been cleared or approved by the FDA and other foreign regulatory bodies for specific treatments. However, we cannot prevent a physician from using our products
outside of such cleared or approved indications for use, known as &#147;off-label uses&#148;, when in the physician&#146;s independent professional medical judgment, he or she deems it appropriate. There may be increased risk of injury to patients
if physicians attempt to use our products off-label. Furthermore, the use of our products for indications other than those cleared or approved by the FDA or any foreign regulatory body may not effectively treat such conditions, which could harm our
reputation in the marketplace among physicians and patients. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, physicians may misuse our products or use improper techniques if they are not
adequately trained, potentially leading to injury and an increased risk of product liability. If our products are misused or used with improper technique, we may become subject to costly litigation by our customers or their patients. Product
liability claims could divert management&#146;s attention from our core business, be expensive to defend and result in sizeable damage awards against us that may not be covered by insurance. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Further, our promotional materials and training methods must comply with FDA and other applicable laws and regulations, including the prohibition of the promotion of off-label use. If the FDA or any foreign
regulatory body determines that our promotional materials or training constitute promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the
issuance of an untitled letter, a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our business activities to
constitute promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare
programs, and the curtailment of our operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our products may cause or contribute to adverse medical events that we are required to report to
the FDA, and if we fail to do so, we would be subject to sanctions that could materially harm our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Some of our marketed products are
subject to Medical Device Reporting, or MDR, obligations, which require that we report to the FDA any incident in which our products may have caused or contributed to a death or serious injury, or in which our products malfunctioned and, if the
malfunction were to recur, it could likely cause or contribute to a death or serious injury. The timing of our obligation to report under the MDR regulations is triggered by the date we become aware of the adverse event as well as the nature of the
event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event
or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA could take action including warning letters, untitled letters, administrative actions,
criminal prosecution, imposition of civil monetary penalties, revocation of our device clearances, seizure of our products, or delay in clearance of future products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">43 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We and our third-party manufacturers and suppliers are subject to various governmental regulations related to
the manufacturing of our products. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any product for which we obtain clearance or approval, and the manufacturing processes, reporting
requirements, post-approval clinical data and promotional activities for such product, will be subject to continued regulatory review, oversight and periodic inspection by the FDA and other domestic and foreign regulatory bodies. In particular, the
methods used in, and the facilities used for, the manufacture of the medical device products that we own and distribute must comply with the FDA&#146;s QSR, which covers the procedures and documentation of the design, testing, production, control,
quality assurance, labeling, packaging, sterilization, storage and shipping of medical devices. The FDA enforces the QSR through periodic announced or unannounced inspections of manufacturing facilities, and both we and our third-party manufacturers
and suppliers are subject to such inspections. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Failure to comply with applicable FDA requirements, or later discovery of previously unknown problems
with our products or the manufacturing processes of our third-party manufacturers and suppliers, including any failure to take satisfactory corrective action in response to an adverse QSR inspection, can result in, among other things: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">administrative or judicially imposed sanctions; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">injunctions or the imposition of civil penalties or fines; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">recall or seizure of our products; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">total or partial suspension of production or distribution; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">refusal to grant pending or future clearances or approvals for our products; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">withdrawal or suspension of regulatory clearances or approvals; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">clinical holds; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">untitled letters or warning letters; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">refusal to permit the import or export of our products; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">criminal prosecution of us or our employees. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any of these actions could prevent or delay us from marketing, distributing or selling our products and would likely harm our business. Furthermore, our suppliers
may not currently be or may not continue to be in compliance with all applicable regulatory requirements, which could result in our failure to produce our products on a timely basis and in the required quantities, if at all. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our products may be subject to product recalls. A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority,
or the discovery of serious safety issues with our products, could have a significant adverse impact on us. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The FDA and similar foreign
governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in their design or manufacture. The FDA&#146;s authority to require a recall must be based on a finding
that there is reasonable probability that the device would cause serious injury or death. We have in the past instituted a voluntary recall for certain of our products and we may also choose to voluntarily recall a product if any material deficiency
is found. A government-mandated or voluntary recall could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of any of our
products would divert managerial and financial resources and could adversely affect our reputation and business, which could impair our ability to produce our products in a cost-effective and timely manner in order to meet our customers&#146;
demands. We may also be subject to liability claims, be required to bear other costs, or take other actions that may have a negative impact on our future sales and our ability to generate profits. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">44 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the
FDA. We may initiate voluntary recalls or corrections for our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to report those actions as recalls and
we may be subject to enforcement action. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>As we conduct clinical studies designed to generate long-term data on some of our existing products, the
data we generate may not be consistent with our existing data and may demonstrate less favorable safety or efficacy. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are currently collecting
and plan to continue collecting long-term clinical data regarding the quality, safety and effectiveness of some of our existing products. The clinical data collected and generated as part of these studies will further strengthen our clinical
evaluation concerning safety and performance of these products. We believe that this additional data will help with the marketing of our products by providing surgeons and physicians with additional confidence in their long-term safety and efficacy.
If the results of these clinical studies are negative, these results could reduce demand for our products and significantly reduce our ability to achieve expected net sales. We do not expect to undertake such studies for all of our products and will
only do so in the future where we anticipate the benefits will outweigh the costs and risks. For these reasons, surgeons and physicians could be less likely to purchase our products than competing products for which longer-term clinical data are
available. Also, we may not choose or be able to generate the comparative data that some of our competitors have or are generating and we may be subject to greater regulatory and product liability risks. If we are unable to or unwilling to collect
sufficient long-term clinical data supporting the quality, safety and effectiveness of our existing products, our business, results of operations and financial condition could be adversely affected. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may rely on third parties to conduct our clinical studies and to assist us with preclinical development and if they fail to perform as contractually
required or expected, we may not be able to obtain regulatory clearance or approval for or commercialize our products. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may rely on third
parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to assist in conducting our clinical studies. If these third parties fail to successfully carry out their contractual duties,
comply with applicable regulatory obligations, meet expected deadlines, or if these third parties must be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to clinical protocols or applicable
regulatory requirements or for other reasons, our pre-clinical development activities or clinical studies may be extended, delayed, suspended or terminated. Under these circumstances we may not be able to obtain regulatory clearance or approval for,
or successfully commercialize, our products on a timely basis, if at all, and our business may be adversely affected. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If clinical studies of our
future products do not produce results necessary to support regulatory clearance or approval in the United States or elsewhere, we will be unable to expand the indications for or commercialize these products. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We will likely need to conduct additional clinical studies in the future to support new indications for our products or for clearances or approvals of new product
lines, or for the approval of the use of our products in some foreign countries. Clinical testing can take many years, can be expensive and carries uncertain outcomes. The initiation and completion of any of these studies may be prevented, delayed,
or halted for numerous reasons. Conducting successful clinical studies requires the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and completion of
patient participation and follow-up depends on many factors, including the size of the patient population, the nature of the trial protocol, the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled
subjects, the availability of appropriate clinical trial investigators and support staff, proximity of patients to clinical sites, patient ability to meet the eligibility and exclusion criteria for
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">45 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
participation in the clinical trial and patient compliance. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive
post-treatment procedures or follow-up to assess the safety and effectiveness of our products or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts. Patients may
also not participate in our clinical trials if they choose to participate in contemporaneous clinical trials of competitive products. In addition, patients participating in clinical trials may die before completion of the trial or suffer adverse
medical events unrelated to investigational products. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Clinical failure can occur at any stage of testing. Our clinical studies may produce negative or
inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical and non-clinical studies in addition to those we have planned. Our failure to adequately demonstrate the safety and efficacy of any of our devices
would prevent receipt of regulatory clearance or approval and, ultimately, the commercialization of that device or indication for use. Even if our future products are cleared in the United States, commercialization of our products in foreign
countries would require approval by regulatory authorities in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States,
including additional preclinical studies or clinical trials. Any of these occurrences could have an adverse impact on our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Healthcare
regulatory reform may affect our ability to sell our products profitably and could have a material adverse effect on our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the United
States and in certain foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the regulatory and healthcare systems in ways that could prevent or delay marketing approval of our products in development,
restrict or regulate post-approval activities of our products and impact our ability to sell our products profitably. In the United States in recent years, new legislation has been proposed and adopted at the federal and state level that is
effecting major changes in the healthcare system. In addition, new regulations and interpretations of existing healthcare statutes and regulations are frequently adopted. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, were signed into law. While the goal of
healthcare reform is to expand coverage to more individuals, it also involves increased government price controls, additional regulatory mandates and other measures designed to constrain medical costs. The Affordable Care Act substantially changes
the way healthcare is financed by both governmental and private insurers, encourages improvements in the quality of healthcare items and services and significantly impacts the medical technology industry. Among other things, the Affordable Care Act:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">imposed an annual excise tax of 2.3% on any entity that manufactures or imports prescription drugs, biologic agents and medical devices offered for sale in the
United States, which was suspended from January&nbsp;1, 2016, to December&nbsp;31, 2017, by the Consolidated Appropriations Act of 2016, but will be reinstated starting January&nbsp;1, 2018, absent further action; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused,
instilled, implanted or injected; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">extended manufacturers&#146; Medicaid rebate liability to individuals enrolled in Medicaid managed care organizations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">expanded eligibility criteria for Medicaid programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">established a new Patient-Centered Outcomes Research Institute to oversee and identify priorities in comparative clinical effectiveness research in an effort to
coordinate and develop such research; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">46 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the
coordination, quality and efficiency of certain healthcare services through bundled payment models; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">created an independent payment advisory board that will submit recommendations to Congress to reduce Medicare spending if projected Medicare spending exceeds a
specified growth rate. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, third-party payors regularly update payments to physicians and hospitals where our products are
used. For example, on April&nbsp;16, 2015, President Obama signed into law the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA. Among other things, MACRA extended existing payment rates through June&nbsp;30, 2015, with a 0.5% update
for July&nbsp;1, 2015 through December&nbsp;31, 2015, and for each calendar year through 2019, after which there will be a 0% annual update each year through 2025. In addition, the Budget Control Act of 2011 and the Bipartisan Budget Act of 2015
imposed reductions to Medicare payments to providers of up to 2%&nbsp;per fiscal year, which went into effect on April&nbsp;1, 2013, and, due to subsequent legislative amendments to the statute, will remain in effect through 2025 unless additional
Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several types of providers, and increased the statute of
limitations period for the government to recover overpayments to providers from three to five years. These payment updates could directly impact the demand for our products or any products we may develop in the future, if cleared or approved.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We expect that the Affordable Care Act, as well as other healthcare reform measures that may be adopted in the future, may result in additional
reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we receive for any cleared or approved products. Furthermore, we believe that many
individuals who have obtained insurance coverage through the health insurance exchanges which arose as a result of the Affordable Care Act have done so with policies that have significantly higher deductibles than policies they may have obtained
prior to its enactment. Because the out-of-pocket costs of undergoing a treatment for patients who have not met their deductible for a given year would be significantly higher than they historically would have been, these patients may be discouraged
from undergoing such a treatment due to the cost. Any reluctance on the part of patients to undergo treatment due to cost could impact our ability to expand sales of our products and could adversely impact our business. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for cleared or approved
products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our products, if any,
may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#146;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and postmarketing testing and other
requirements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may be subject to federal, state and foreign laws and regulations relating to our healthcare business, and could face substantial
penalties if we are determined not to have fully complied with such laws, which would have an adverse impact on our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may be subject
to healthcare fraud and abuse regulation and enforcement by federal, state and foreign governments, which could adversely impact our business. Healthcare fraud and abuse and health information privacy and security laws potentially applicable to our
operations include: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the federal Anti-Kickback Statute, which applies to our marketing practices, educational programs, pricing and discounting policies and relationships with
healthcare providers, by prohibiting, among other things, </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">47 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
persons and entities from knowingly and willfully soliciting, receiving, offering or providing remuneration intended to induce or reward, or in return for, either the referral of an individual
for, or the purchase, order or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare or Medicaid programs. A person or entity does not need to have actual knowledge of this statute or specific
intent to violate it to have committed a violation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the federal civil and criminal false claims laws and civil monetary penalties laws, including the False Claims Act, which impose civil and criminal penalties
through governmental, civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval to the federal government that are false or
fraudulent, knowingly making a false statement material to an obligation to pay or transmit money or property to the federal government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay or transmit money
or property to the federal government. The government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims
statutes; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">HIPAA and its implementing regulations, which created federal criminal laws that prohibit, among other things, executing or attempting to execute a scheme to
defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it
to have committed a violation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, which also imposes
certain regulatory and contractual requirements regarding the privacy, security and transmission of personal health information; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the federal Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under
Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the government information related to certain payments or other &#147;transfers of value&#148; made to physicians (defined to include
doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and requires applicable manufacturers to report annually to the government ownership and investment interests held by the physicians described above and their
immediate family members and payments or other &#147;transfers of value&#148; to such physician owners; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government
programs, and where the failure to report such prices may expose us to potential liability; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">state and foreign law equivalents of each of the above federal laws and regulations, such as anti-kickback and false claims laws that may apply to items or
services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical and device companies to comply with the industry&#146;s voluntary compliance guidelines and the relevant compliance guidance
promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state laws that require drug and device manufacturers to report information related to payments and other transfers of value to physicians
and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of certain health information, many of which differ from each other in significant ways and some of which may be more stringent
than HIPAA or HITECH. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">48 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The risk of our being found in violation of these laws and regulations is increased by the fact that many of them have
not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. We are unable to predict what additional federal, state or foreign legislation or regulatory initiatives may be
enacted in the future regarding our business or the healthcare industry in general, or what effect such legislation or regulations may have on us. Federal, state or foreign governments may impose additional restrictions or adopt interpretations of
existing laws that could have a material adverse effect on us. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Because of the breadth of these laws and the narrowness of the statutory exceptions and
safe harbors available under such laws, it is possible that some of our business activities, including certain sales and marketing practices and financial arrangements with physicians and other healthcare providers, some of whom recommend, use,
prescribe or purchase our products, and other customers, could be subject to challenge under one or more of such laws. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant
legal expenses and divert our management&#146;s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject
to penalties, including civil and criminal penalties, damages, fines, exclusion from governmental healthcare programs, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring
of our operations, any of which could adversely impact our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we fail to meet Medicare accreditation and surety bond requirements or
DMEPOS supplier standards, it could negatively affect our business operations. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our Exogen system is classified by CMS and third-party payors as
durable medical equipment. Suppliers of Medicare durable medical equipment, prosthetics, orthotics and supplies, or DMEPOS, must be accredited by an approved accreditation organization as meeting DMEPOS quality standards adopted by CMS and are
required to meet surety bond requirements. In addition, Medicare DMEPOS suppliers must comply with Medicare supplier standards in order to obtain and retain billing privileges, including meeting all applicable federal and state licensure and
regulatory requirements. CMS periodically expands or otherwise clarifies the Medicare DMEPOS supplier standards, and states periodically change licensure requirements, including licensure rules imposing more stringent requirements on out-of-state
DMEPOS suppliers. We believe we currently are in compliance with these requirements. If we fail to maintain our Medicare accreditation status and/or do not comply with Medicare surety bond or supplier standard requirements or state licensure
requirements in the future, or if these requirements are changed or expanded, it could adversely affect our profits and results of operations. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Audits or denials of our claims by government agencies could reduce our net sales or profits. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In connection with our Exogen system, we submit claims on behalf of patients directly to, and receive payments directly from, the Medicare and Medicaid programs and private payors. Therefore, we are subject to
extensive government regulation, including detailed requirements for submitting reimbursement claims under appropriate codes and maintaining certain documentation to support our claims. Medicare contractors and Medicaid agencies periodically conduct
pre- and post-payment reviews and other audits of claims and are under increasing pressure to more closely scrutinize healthcare claims and supporting documentation. We may be subject to pre-payment and post-payment reviews, as well as audits of
claims in the future. Private payors may from time to time conduct similar reviews and audits. Such reviews and similar audits of our claims could result in material delays in payment, material recoupments, overpayments, or claim denials, or
exclusion from participation in the Medicare or Medicaid programs, all of which could reduce our net sales and profitability. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">49 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our operations involve the use of hazardous and toxic materials, and we must comply with environmental, health
and safety laws and regulations, which can be expensive, and could have an adverse affect on our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are subject to a variety of
federal, state, local and foreign laws and regulations relating to the protection of the environment or of human health and safety, including laws pertaining to the use, handling, storage, disposal and human exposure to hazardous and toxic
materials. Liability under environmental laws can be imposed on a joint and several basis (which could result in an entity paying more than its fair share) and without regard to comparative fault, and environmental laws are likely to become more
stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations, which could have an adverse affect on our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Our employees, independent distributors, independent contractors, suppliers and other third parties may engage in misconduct or other improper activities, including noncompliance with regulatory standards and
requirements, which could expose us to liability and hurt our reputation. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are exposed to the risk that our employees, independent
distributors, independent contractors, suppliers and others may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities
to us that violates: (1)&nbsp;FDA laws and regulations, including those laws that require the reporting of true, complete and accurate information to the FDA, (2)&nbsp;manufacturing standards, (3)&nbsp;healthcare fraud and abuse laws, or
(4)&nbsp;laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials,
creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter
misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other
actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant
impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other
federal healthcare programs, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to intellectual property matters </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The risk
factors listed below describe the risks we face related to intellectual property matters. The companies who own certain of the products we distribute face similar risks with respect to intellectual property relating to such products. If such
suppliers are unable to protect their intellectual property rights, they may not be able to continue to supply us with products, which could have a material adverse effect on our business, results of operations and financial condition. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Protection of our intellectual property rights may be difficult and costly, and our inability to protect our intellectual property could adversely affect our
competitive position. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our success depends significantly on our ability to protect our proprietary rights to the technologies and inventions used
in, or embodied by, our products. To protect our proprietary technology, we rely on patent </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">50 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
protection, as well as a combination of copyright, trade secret and trademark laws, as well as nondisclosure, confidentiality and other contractual restrictions in our consulting and employment
agreements. These legal means afford only limited protection, however, and may not adequately protect our rights or permit us to gain or keep any competitive advantage. Our existing confidentiality and/or invention assignment agreements with
employees, contractors, and others who participate in IP development activities could be breached, or we may not enter into sufficient and adequate agreements with those individuals in the first instance, and we may not have adequate remedies for
such breaches. Furthermore, we may be subject to, and forced to defend against, third-party claims of ownership to our intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights, such as exclusive ownership of, or rights to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims,
litigation could result in substantial costs and be a distraction to management and other employees. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Patents </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The process of applying for patent protection itself is time-consuming and expensive and we cannot assure you that all of our patent applications will issue as
patents or that, if issued, they will issue in a form that will be advantageous to us. The rights granted to us under our patents, including prospective rights sought in our pending patent applications, may not be meaningful or provide us with any
commercial advantage, and they could be opposed, contested, narrowed, or circumvented by our competitors or declared invalid or unenforceable in judicial or administrative proceedings. We may not be able to file and prosecute all necessary or
desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our R&amp;D output before it is too late to obtain patent protection. We may not have the right to
control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to us by third-parties. Therefore, these patents and applications may not be prosecuted or enforced in a manner consistent with the
best interests of our business. If such licensors fail to maintain such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated, which could also have a material adverse effect on our business. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We own numerous issued patents and pending patent applications relating to our technology and products. The rights granted to us under these patents, including
prospective rights sought in our pending patent applications, could be opposed, contested or circumvented by our competitors or declared invalid or unenforceable in judicial or administrative proceedings. If any of our patents are challenged,
invalidated or legally circumvented by third-parties, and if we do not own other enforceable patents protecting our products, competitors could market products and use processes that are substantially similar to, or superior to, ours, and our
business will suffer. In&nbsp;addition, the patents we own may not be of sufficient scope or strength to provide us with any meaningful&nbsp;protection or commercial advantage, and competitors may be able to design around our patents or develop
products that provide outcomes comparable to ours without infringing on our intellectual property rights. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Recent patent reform legislation could
increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act was signed into
law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation, and switch the U.S. patent
system from a &#147;first-to-invent&#148; system to a &#147;first-to-file&#148; system. Under a &#147;first-to-file&#148; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally
will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The U.S. Patent and Trademark Office, or USPTO, recently developed new regulations and procedures to govern administration of
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">51 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first-to-file provisions, only became effective on
March&nbsp;16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the
prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. In addition, patent reform legislation may pass in the future
that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement, and defense of our patents and applications. We may be subject to a third-party preissuance submission of prior art to the USPTO, or become
involved in opposition, derivation, reexamination, inter partes review, post-grant review or other patent office proceedings or litigation, in the United States or elsewhere, challenging our patent rights. An adverse determination in any such
submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third-parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to
manufacture or commercialize products without infringing third-party patent rights. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Moreover, the USPTO and various foreign governmental patent agencies
require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent
agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in
abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include,
but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our
products or procedures, we may not be able to stop a competitor from marketing products that are the same as or similar to our products, which would have a material adverse effect on our business. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Furthermore, we do not have patent rights in certain foreign countries in which a market may exist in the future, and the laws of many foreign countries may not
protect our intellectual property rights or provide mechanisms for the enforcement of same to the same extent as the laws of the United States. We may need to expend additional resources to defend our intellectual property rights in these countries,
and the inability to defend the same could impair our brand or adversely affect the growth of our business internationally. For example, we may not be able to stop a competitor from marketing and selling in foreign countries products that are the
same as or similar to our products. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Trademarks </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We rely on our trademarks as one means to distinguish our products from the products of our competitors, and have registered or applied to register many of these
trademarks. However, we may not be able to successfully secure trademark registrations for all such applications. Third-parties may oppose our trademark applications, or otherwise challenge our use of both registered and unregistered trademarks. In
the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors
may infringe our trademarks and we may not have adequate resources to enforce our trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks, then we may not be able to compete effectively and our business
may be adversely affected. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">52 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Trade secrets and know-how </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by consultants, vendors, former employees or current employees, despite the existence generally of
confidentiality agreements and other contractual restrictions. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be
effective. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. For example, the FDA, as part of its
Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at
the present time how the FDA&#146;s disclosure policies may change in the future, if at all. Our competitors could use any of the information we may be required to disclose by the FDA to develop independently technology similar to ours. Competitors
could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own
competitive technologies that fall outside of our intellectual property rights. If our intellectual property is not adequately protected so as to protect our market against competitors&#146; products and methods, our competitive position could be
adversely affected, as could our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we were to enforce a claim that a third-party had illegally obtained, misappropriated or was using our
trade secrets, it would be expensive and time consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. If any of the technology or information that we protect as
trade secrets were to be independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. Misappropriation or unauthorized disclosure of our trade secrets could impair our
competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade
secret. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We depend on certain technologies that are licensed to us. We do not control the intellectual property rights covering these technologies
and any loss of our rights to these technologies or the rights licensed to us could prevent us from selling our products, which could adversely impact our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are a party to license agreements under which we are granted rights to intellectual property that is important to our business, and we may need to enter into additional license agreements in the future. For
example, we expect that we will be dependent on our licensing arrangements with Pfizer relating to our next-generation BMP product candidates. We rely on these licenses in order to be able to use and sell various proprietary technologies that are
material to our business, as well as technologies which we intend to use in our future commercial activities. Our rights to use these technologies and the inventions claimed in the licensed patents are subject to the continuation of and our
compliance with the terms of those licenses. Our existing license agreements impose, and we expect that future license agreements will impose on us, various diligence obligations, payment of milestones or royalties and other obligations. If we fail
to comply with our obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which case we would not be able to market products covered by the license, which would adversely
affect our financial condition. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As we have done previously, we may need to obtain licenses from third parties to advance our research or allow
commercialization of our products and technologies. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to
the same technologies licensed to us. In the event that we are not able </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">53 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
to acquire a license, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or
commercialize the affected products and technologies, which could materially harm our business. In addition, the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our
sales, an obligation on our part to pay royalties or other forms of compensation and damages. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In some cases, we may not have the right to control the
prosecution, maintenance, or filing of the patents that are licensed to us, or the enforcement of these patents against infringement by third parties. Some of our patents and patent applications were not filed by us, but were either acquired by us
or are licensed from third parties. Thus, these patents and patent applications were not drafted by us or our attorneys, and we did not control or have any input into the prosecution of these patents and patent applications prior to our acquisition
of, or our entry into a license with respect to, such patents and patent applications. We cannot be certain that the drafting or prosecution of the patents and patent applications licensed to us will result or has resulted in valid and enforceable
patents. Further, we do not always retain complete control over our ability to enforce our licensed patent rights against third-party infringement. In those cases, we cannot be certain that our licensor will elect to enforce these patents to the
extent that we would choose to do so, or in a way that will ensure that we retain the rights we currently have under our license. If our licensor fails to properly enforce the patents subject to our license in the event of third-party infringement,
our ability to retain our competitive advantage with respect to our products may be materially and adversely affected. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Licensing of intellectual
property is an important part of our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property that is subject to a license agreement, including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the scope of rights granted under the license agreement and other interpretation-related issues; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our right to sublicense patent and other rights to third parties under collaborative development relationships; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our products and
technologies, and what activities satisfy those diligence obligations; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, we may become the owner of intellectual property that was obtained through assignments which may be subject to
re-assignment back to the original assignor upon our failure to prosecute or maintain such intellectual property, upon our breach of the agreement pursuant to which such intellectual property was assigned, or upon our bankruptcy. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, or if
intellectual property is re-assigned back to the original assignor, we may be unable to successfully develop and commercialize the affected products and technologies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>We may in the future be a party to patent and other intellectual property litigation and administrative proceedings that could be costly and could interfere with our ability to successfully market our
products. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The medical technology industry has been characterized by frequent and extensive intellectual property litigation and is highly
competitive. Our competitors or other patent holders may assert that our products and/</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">54 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
or the methods employed in our products are covered by their patents or that we are infringing, misappropriating, or misusing their trademark, copyright, trade secret, and/or other proprietary
rights. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If our products or methods are found to infringe, we could be prevented from manufacturing or marketing our products. In the event that we
become involved in such a dispute, we may incur significant costs and expenses and may need to devote resources to resolving any claims, which would reduce the cash we have available for operations and may be distracting to management and other
employees, including those involved in the development of intellectual property. We do not know whether our competitors or potential competitors have applied for, will apply for, or will obtain patents that will prevent, limit or interfere with our
ability to make, use, sell, import or export our products. Because patent applications can take many years to issue, third parties may have currently pending patent applications which may later result in issued patents that our products and
technologies may infringe, or which such third parties claim are infringed by the use of our products or technologies. There is no guarantee that patents will not issue in the future from currently pending applications that may be infringed by our
technology or products. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases, and
difficulty in assessing the meaning of patent claims. Moreover, as the medical technology industry expands and more patents are issued in this area, the risk increases that we may be subject to claims of infringement of the patent rights of third
parties. We cannot assure you that we will prevail in such actions, or that other actions alleging misappropriation or misuse by us of third-party trade secrets or infringement by us of third-party patents, copyrights, trademarks or other rights or
challenging the validity of our patents, copyrights, trademarks or other rights will not be asserted against us. Competing products may also be sold in other countries in which our patent coverage might not exist or be as strong. If we lose a
foreign patent lawsuit alleging our infringement of a competitor&#146;s patents, we could be prevented from marketing our products in one or more foreign countries. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We may also initiate litigation against third-parties to enforce our patent and proprietary rights or to determine the scope, enforceability or validity of the proprietary rights of others. Our intellectual
property has not been tested in litigation. If we initiate litigation to protect our rights, we run the risk of having our patents and other proprietary rights invalidated, canceled or narrowed, which could undermine our competitive position.
Further, if the scope of protection provided by our patents or patent applications or other proprietary rights is threatened or reduced as a result of litigation, it could discourage third parties from entering into collaborations with us that are
important to the commercialization of our products. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Litigation related to infringement and other intellectual property claims, with or without merit, is
unpredictable, can be expensive and time-consuming and can divert management&#146;s attention from our core business. If we lose this kind of litigation, a court could require us to pay substantial damages, treble damages and attorneys&#146; fees
and could prohibit us from using technologies essential to our products, any of which would have a material adverse effect on our business. If relevant patents are upheld as valid and enforceable and we are found to infringe, we could be prevented
from selling our products unless we can obtain licenses to use technology or ideas covered by such patents. We do not know whether any necessary licenses would be available to us on satisfactory terms, if at all. If we cannot obtain these licenses,
we could be forced to design around those patents at additional cost or abandon the product altogether. As a result, our ability to grow our business and compete in the market may be harmed. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure
during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If these results are perceived to be
negative, the price of our Class&nbsp;A common stock could be adversely affected. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">55 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, certain of our agreements with suppliers, distributors, customers and other entities with whom we do
business may require us to defend or indemnify these parties to the extent they become involved in infringement claims relating to our technologies or products, or rights licensed to them by us. We could also voluntarily agree to defend or indemnify
third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify any of these third parties in connection with any infringement
claims, we could incur significant costs and expenses that could adversely affect our business, operating results, or financial condition. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may
be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our competitors or former employers or are in breach of non-competition or non-solicitation agreements with our
competitors or former employers. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or
disclosed alleged trade secrets or other proprietary information of former employers or competitors. In addition, we may in the future be subject to claims that we caused an employee to breach the terms of his or her non-competition or
non-solicitation agreement. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management. If our
defense to those claims fails, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our products, if such technologies or features are found to incorporate or be derived from the
trade secrets or other proprietary information of the competitors or former employers. An inability to incorporate technologies or features that are important or essential to our products could have an adverse impact on our business, and may prevent
us from selling our products. In addition, we may lose valuable intellectual property rights or personnel. Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A
loss of key personnel or their work product could hamper or prevent our ability to commercialize our products, which could have an adverse impact on our business. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Risks related to our company and our organizational structure </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our principal asset after the completion
of this offering will be our interest in Bioventus LLC, and, accordingly, we will depend on distributions from Bioventus LLC to pay our taxes and expenses, including payments under the Tax Receivable Agreement. Bioventus LLC&#146;s ability to make
such distributions may be subject to various limitations and restrictions. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Upon the consummation of this offering, we will be a holding company
and will have no material assets other than our ownership of&nbsp;LLC Interests of Bioventus LLC. As such, we will have no independent means of generating net sales or cash flow, and our ability to pay our taxes and operating expenses or declare and
pay dividends in the future, if any, will be dependent upon the financial results and cash flows of Bioventus LLC and its subsidiaries and distributions we receive from Bioventus LLC. There can be no assurance that our subsidiaries will generate
sufficient cash flow to distribute funds to us or that applicable state law and contractual restrictions, including negative covenants in our debt instruments, will permit such distributions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Bioventus LLC will continue to be treated as a partnership for U.S. federal income tax purposes and, as such, will not be subject to any <FONT STYLE="white-space:nowrap">entity-level&nbsp;U.S.</FONT> federal income
tax. Instead, taxable income will be allocated to holders of&nbsp;LLC Interests, including us. Accordingly, we will incur income taxes on our allocable share of any net taxable income of Bioventus LLC. Under the terms of the Bioventus
LLC&nbsp;Agreement, Bioventus LLC will be obligated to make tax distributions to holders of&nbsp;LLC Interests, including us, subject to any limitations or restrictions in our debt arrangements. In addition to tax expenses, we will also incur
expenses related to our operations, including payments under the Tax Receivable Agreement, which we expect could be significant. See &#147;Certain relationships and related party transactions&#151;Tax Receivable Agreement.&#148; We intend, as its
managing </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">56 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
member, to cause Bioventus LLC to make cash distributions to the owners of&nbsp;LLC Interests in an amount sufficient to (i)&nbsp;fund their tax obligations in respect of taxable income allocated
to them and (ii)&nbsp;cover our operating expenses, including payments under the Tax Receivable Agreement. However, Bioventus LLC&#146;s ability to make such distributions may be subject to various limitations and restrictions, such as restrictions
on distributions that would either violate any contract or agreement to which Bioventus LLC is then a party, including debt agreements, or any applicable law, or that would have the effect of rendering Bioventus LLC insolvent. If we do not have
sufficient funds to pay taxes or other liabilities or to fund our operations, we may have to borrow funds, which could materially adversely affect our liquidity and financial condition and subject us to various restrictions imposed by any such
lenders. To the extent that we are unable to make payments under the Tax Receivable Agreement for any reason, such payments generally will be deferred and will accrue interest until paid; provided, however, that nonpayment for a specified period may
constitute a material breach of a material obligation under the Tax Receivable Agreement and therefore accelerate payments due under the Tax Receivable Agreement. See &#147;Certain relationships and related party transactions&#151;Tax Receivable
Agreement.&#148; In addition, if Bioventus LLC does not have sufficient funds to make distributions, our ability to declare and pay cash dividends will also be restricted or impaired. See &#147;&#151;Risks related to this offering and ownership of
our Class&nbsp;A common stock&#148; and &#147;Dividend policy.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The Tax Receivable Agreement with the Continuing LLC Owners requires us to
make cash payments to them in respect of certain tax benefits to which we may become entitled, and we expect that the payments we will be required to make could be significant. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Upon the closing of this offering, we will be a party to the Tax Receivable Agreement with the Continuing LLC Owners. Under the Tax Receivable Agreement, we will be required to make cash payments to the Continuing
LLC Owners equal to 85% of the tax benefits, if any, that we actually realize, or in certain circumstances are deemed to realize, as a result of (1)&nbsp;the increases in the tax basis of assets of Bioventus LLC resulting from any future redemptions
or exchanges of&nbsp;LLC Interests described under &#147;Certain relationships and related party transactions&#151;Bioventus&nbsp;LLC Agreement&#151;LLC Interest Redemption Right,&#148; and (2)&nbsp;certain other tax benefits related to our making
payments under the Tax Receivable Agreement. We expect the amount of the cash payments that we will be required to make under the Tax Receivable Agreement will be significant. The actual amount and timing of any payments under the Tax Receivable
Agreement will vary depending upon a number of factors, including the timing of redemptions or exchanges by the holders of&nbsp;LLC Interests, the amount of gain recognized by such holders of&nbsp;LLC Interests, the amount and timing of the taxable
income we generate in the future, and the federal tax rates then applicable. Any payments made by us to the Continuing LLC Owners under the Tax Receivable Agreement will generally reduce the amount of overall cash flow that might have otherwise been
available to us. To the extent that we are unable to make timely payments under the Tax Receivable Agreement for any reason, the unpaid amounts will be deferred and will accrue interest until paid by us. Furthermore, our future obligation to make
payments under the Tax Receivable Agreement could make us a less attractive target for an acquisition, particularly in the case of an acquirer that cannot use some or all of the tax benefits that are the subject of the Tax Receivable Agreement.
Payments under the Tax Receivable Agreement are not conditioned on any Continuing LLC Owner&#146;s continued ownership of&nbsp;LLC Interests or our Class&nbsp;A common stock after this offering. For more information, see &#147;Certain relationships
and related party transactions&#151;Tax Receivable Agreement.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our organizational structure, including the Tax Receivable Agreement, confers
certain tax benefits upon the Continuing LLC Owners that may not benefit Class&nbsp;A common stockholders to the same extent as they will benefit the Continuing LLC Owners. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our organizational structure, including the Tax Receivable Agreement, confers certain tax benefits upon the Continuing LLC Owners that may not benefit the holders of our Class&nbsp;A common stock to the same extent
as they will benefit the Continuing LLC Owners. We will enter into the Tax Receivable Agreement with Bioventus </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">57 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
LLC and the Continuing LLC Owners that will provide for our payment to the Continuing LLC Owners of 85% of the amount of tax benefits, if any, that we actually realize (or in some circumstances
are deemed to realize) as a result of (i)&nbsp;increases in the tax basis of assets of Bioventus LLC resulting from any future redemptions or exchanges of&nbsp;LLC Interests described under &#147;Certain relationships and related party
transactions&#151;Bioventus&nbsp;LLC Agreement&#151;LLC Interest Redemption Right,&#148; and (ii)&nbsp;certain other tax benefits related to our making payments under the Tax Receivable Agreement. Although Bioventus will retain 15% of such tax
benefits, this and other aspects of our organizational structure may adversely impact the future trading market for the Class&nbsp;A common stock. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>In certain cases, payments under the Tax Receivable Agreement to the Continuing LLC Owners may be accelerated or significantly exceed the actual benefits we
realize in respect of the tax attributes subject to the Tax Receivable Agreement. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Tax Receivable Agreement provides that if (i)&nbsp;we
materially breach any of our material obligations under the Tax Receivable Agreement, (ii)&nbsp;certain mergers, asset sales, other forms of business combinations or other changes of control were to occur on or before December 31, 2017 or
(iii)&nbsp;we elect an early termination of the Tax Receivable Agreement, then our obligations or our successor&#146;s obligations under the Tax Receivable Agreement to make payments thereunder would be based on certain assumptions, including an
assumption that we would have sufficient taxable income to fully utilize all potential future tax benefits that are subject to the Tax Receivable Agreement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As a result of the foregoing, (i)&nbsp;we could be required to make payments under the Tax Receivable Agreement that are greater than the specified percentage of the actual benefits we ultimately realize in respect
of the tax benefits that are subject to the Tax Receivable Agreement and (ii)&nbsp;if we materially breach any of our material obligations under the Tax Receivable Agreement or if we elect to terminate the Tax Receivable Agreement early, we would be
required to make an immediate cash payment equal to the present value of the anticipated future tax benefits that are the subject of the Tax Receivable Agreement, which payment may be made significantly in advance of the actual realization, if any,
of such future tax benefits. In these situations, our obligations under the Tax Receivable Agreement could have a substantial negative impact on our liquidity and could have the effect of delaying, deferring or preventing certain mergers, asset
sales, other forms of business combinations or other changes of control. There can be no assurance that we will be able to fund or finance our obligations under the Tax Receivable Agreement. See &#147;Certain relationships and related party
transactions&#151;Tax Receivables Agreement.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may make payments to the Continuing LLC Owners under the Tax Receivable Agreement that
exceed the tax benefits initially claimed by us in the event that any tax benefits are disallowed by a taxing authority. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Payments under the Tax
Receivable Agreement will be based on the tax reporting positions that we determine, and the Internal Revenue Service, or the IRS, or another tax authority may challenge all or part of the tax basis increases, as well as other related tax positions
we take, and a court could sustain such challenge. Pursuant to the Tax Receivable Agreement, the Continuing LLC Owners are required to reimburse us for any cash payments previously made to the Continuing LLC Owners under the Tax Receivable Agreement
in the event that any tax benefits initially claimed by us and for which payment has been made to a Continuing LLC Owner are subsequently challenged by a taxing authority and are ultimately disallowed. In addition, but without duplication of any
amounts previously reimbursed by any Continuing LLC Owner, any excess cash payments made by us to a Continuing LLC Owner will be netted against any future cash payments that we might otherwise be required to make to such Continuing LLC Owner under
the terms of the Tax Receivable Agreement. However, we might not determine that we have effectively made an excess cash payment to a Continuing LLC Owner for a number of years following the initial time of such payment. Moreover, there can be no
assurance that any excess cash payments for which the Continuing LLC Owners have a reimbursement obligation under the Tax </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">58 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Receivable Agreement will be repaid to us. As a result, payments could be made under the Tax Receivable Agreement in excess of the tax savings that we realize in respect of the tax attributes
with respect to a Continuing LLC Owner that are the subject of the Tax Receivable Agreement. See &#147;Certain relationships and related party transactions&#151;Tax Receivable Agreement.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Unanticipated changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns could adversely affect our results of operations and financial condition.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are subject to taxes by the U.S. federal, state, local and foreign tax authorities, and our tax liabilities will be affected by the
allocation of expenses to differing jurisdictions. Our future effective tax rates could be subject to volatility or adversely affected by a number of factors, including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">changes in the valuation of our deferred tax assets and liabilities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">expected timing and amount of the release of any tax valuation allowances; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">tax effects of <FONT STYLE="white-space:nowrap">stock-based</FONT> compensation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">changes in tax laws, regulations or interpretations thereof; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">future earnings being lower than anticipated in countries where we have lower statutory tax rates and higher than anticipated earnings in countries where we have
higher statutory tax rates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, we may be subject to audits of our income, sales and other transaction taxes by U.S. federal,
state, local and foreign taxing authorities. Outcomes from these audits could have an adverse effect on our operating results and financial condition. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we were deemed to be an investment company under the Investment Company Act of 1940, as amended, or the 1940 Act, as a result of our ownership of Bioventus
LLC, applicable restrictions could make it impractical for us to continue our business as contemplated and could have a material adverse effect on our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Under Sections&nbsp;3(a)(1)(A) and (C)&nbsp;of the 1940 Act, a company generally will be deemed to be an &#147;investment company&#148; for purposes of the 1940 Act if (i)&nbsp;it is, or holds itself out as being,
engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities or (ii)&nbsp;it engages, or proposes to engage, in the business of investing, reinvesting, owning, holding or trading in
securities and it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis. We do not believe that we are an
&#147;investment company,&#148; as such term is defined in either of those sections of the 1940 Act. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As the sole managing member of Bioventus LLC, we
will control and operate Bioventus LLC. On that basis, we believe that our interest in Bioventus LLC is not an &#147;investment security&#148; as that term is used in the 1940 Act. However, if we were to cease participation in the management of
Bioventus LLC, our interest in Bioventus LLC could be deemed an &#147;investment security&#148; for purposes of the 1940 Act. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We and Bioventus LLC
intend to conduct our operations so that we will not be deemed an investment company. However, if we were to be deemed an investment company, restrictions imposed by the 1940 Act, including limitations on our capital structure and our ability to
transact with affiliates, could make it impractical for us to continue our business as contemplated and could have a material adverse effect on our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Bioventus is controlled by the Original LLC Owners, whose interests may differ from those of our public stockholders. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Immediately following this offering and the application of net proceeds from this offering, the Original LLC Owners will control approximately 73.5% of the combined voting power of our common stock through their
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">59 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
ownership of both Class&nbsp;A common stock and Class&nbsp;B common stock. The Original LLC Owners will, for the foreseeable future, have significant influence over corporate management and
affairs, and will be able to control virtually all matters requiring stockholder approval. The Original LLC Owners are able to, subject to applicable law, and the voting arrangements described in &#147;Certain relationships and related party
transactions,&#148; elect a majority of the members of our board of directors and control actions to be taken by us and our board of directors, including amendments to our certificate of incorporation and bylaws and approval of significant corporate
transactions, including mergers and sales of substantially all of our assets. The directors so elected will have the authority, subject to the terms of our indebtedness and applicable rules and regulations, to issue additional stock, implement stock
repurchase programs, declare dividends and make other decisions. It is possible that the interests of the Original LLC Owners may in some circumstances conflict with our interests and the interests of our other stockholders, including you. For
example, the Continuing LLC Owners may have different tax positions from us, especially in light of the Tax Receivable Agreement that could influence their decisions regarding whether and when to dispose of assets, whether and when to incur new or
refinance existing indebtedness, and whether and when Bioventus should terminate the Tax Receivable Agreement and accelerate its obligations thereunder. In addition, the determination of future tax reporting positions and the structuring of future
transactions may take into consideration these Continuing LLC Owners&#146; tax or other considerations, which may differ from the considerations of us or our other stockholders. See &#147;Certain relationships and related party transactions&#151;Tax
Receivable Agreement.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our amended and restated certificate of incorporation will, to the extent permitted by applicable law, contain
provisions renouncing our interest and expectation to participate in certain corporate opportunities identified or presented to certain of our Original LLC Owners. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Certain of the Original LLC Owners are in the business of making or advising on investments in companies and these Original LLC owners may hold, and may, from time to time in the future, acquire interests in or
provide advice to businesses that directly or indirectly compete with certain portions of our business or the business of our suppliers. Our amended and restated certificate of incorporation will provide that, to the fullest extent permitted by law,
none of the Original LLC Owners or any director who is not employed by us or his or her affiliates will have any duty to refrain from engaging in a corporate opportunity in the same or similar lines of business as us. The Original LLC Owners may
also pursue acquisitions that may be complementary to our business, and, as a result, those acquisition opportunities may not be available to us. As a result, these arrangements could adversely affect our business, financial condition, results of
operations or prospects if attractive business opportunities are allocated to any of the Original LLC Owners instead of to us. See &#147;Description of capital stock&#151;Corporate opportunities.&#148; </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We are a &#147;controlled company&#148; within the meaning of The NASDAQ Global Market listing standards and, as a result, will qualify for, and intend to
rely on, exemptions from certain corporate governance requirements. You will not have the same protections afforded to stockholders of companies that are subject to such requirements. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Substantially concurrent with the closing of this offering, the Voting Group, which will hold Class&nbsp;A common stock and Class&nbsp;B common stock representing approximately 72.9% of the combined voting power of
our common stock, intends to enter into the Stockholders Agreement. Pursuant to the terms of the Stockholders Agreement, until such time as Essex Woodlands Health Ventures and certain other members of the Voting Group own less than 10% of the total
shares of our Class&nbsp;A common stock owned by them as of the date this offering is consummated, and Smith&nbsp;&amp; Nephew collectively owns less than 10% of the total shares of our Class&nbsp;B common stock owned by them as of the date this
offering is consummated, or the Stockholders Agreement is otherwise terminated in accordance with its terms, the parties to the Stockholders Agreement will agree to vote their shares of Class&nbsp;A common stock and Class&nbsp;B common stock in
favor of the election of the nominees of certain members of the Voting Group to our board of directors upon their nomination by the nominating and corporate governance committee of our board of directors. See &#147;Description of capital
stock&#151;Stockholders Agreement.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">60 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Because of the Stockholders Agreement and the aggregate voting power over our Class&nbsp;A common stock and
Class&nbsp;B common stock held by the parties to the Stockholders Agreement, we are considered a &#147;controlled company&#148; for the purposes of The NASDAQ Global Market. As such, we are exempt from certain corporate governance requirements of
The NASDAQ Global Market, including (1)&nbsp;the requirement that a majority of the board of directors consist of independent directors, (2)&nbsp;the requirement that we have a nominating and corporate governance committee that is composed entirely
of independent directors and (3)&nbsp;the requirement that we have a compensation committee that is composed entirely of independent directors. Following this offering, we intend to rely on some or all of these exemptions. As a result, we will not
have a majority of independent directors and our compensation and nominating and corporate governance committees will not consist entirely of independent directors. Accordingly, you will not have the same protections afforded to stockholders of
companies that are subject to all of the corporate governance requirements of The NASDAQ Global Market. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our
<FONT STYLE="white-space:nowrap">anti-takeover</FONT> provisions could prevent or delay a change in control of our Company, even if such change in control would be beneficial to our stockholders. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Provisions of our amended and restated certificate of incorporation and amended and restated bylaws as well as provisions of Delaware law could discourage, delay or
prevent a merger, acquisition or other change in control of our Company, even if such change in control would be beneficial to our stockholders. These provisions include: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">authorizing the issuance of &#147;blank check&#148; preferred stock that could be issued by our board of directors to increase the number of outstanding shares
and thwart a takeover attempt; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">establishing a classified board of directors so that not all members of our board of directors are elected at one time; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the removal of directors only for cause; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">prohibiting the use of cumulative voting for the election of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">limiting the ability of stockholders to call special meetings or amend our bylaws; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">requiring all stockholder actions to be taken at a meeting of our stockholders; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">establishing advance notice and duration of ownership requirements for nominations for election to the board of directors or for proposing matters that can be
acted upon by stockholders at stockholder meetings. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These provisions could also discourage proxy contests and make it more difficult
for you and other stockholders to elect directors of your choosing and to cause us to take other corporate actions you desire. In addition, because our board of directors is responsible for appointing the members of our management team, these
provisions could in turn affect any attempt by our stockholders to replace current members of our management team. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, the Delaware General
Corporation Law, or DGCL, to which we are subject, prohibits us, except under specified circumstances, from engaging in any mergers, significant sales of stock or assets or business combinations with any stockholder or group of stockholders who owns
at least 15% of our common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may issue shares of preferred stock in the future, which could make it difficult for another company to
acquire us or could otherwise adversely affect holders of our Class&nbsp;A common stock, which could depress the price of our Class&nbsp;A common stock. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation will authorize us to issue one or more series of preferred stock. Our board of directors will have the authority to determine the preferences, limitations and
relative </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">61 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
rights of the shares of preferred stock and to fix the number of shares constituting any series and the designation of such series, without any further vote or action by our stockholders. Our
preferred stock could be issued with voting, liquidation, dividend and other rights superior to the rights of our Class&nbsp;A common stock. The potential issuance of preferred stock may delay or prevent a change in control of us, discourage bids
for our Class&nbsp;A common stock at a premium to the market price, and materially and adversely affect the market price and the voting and other rights of the holders of our Class&nbsp;A common stock. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The provision of our certificate of incorporation requiring exclusive venue in the Court of Chancery in the State of Delaware for certain types of lawsuits
may have the effect of discouraging lawsuits against our directors and officers. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation will
require, to the fullest extent permitted by law, that (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees
to us or our stockholders, (iii)&nbsp;any action asserting a claim against us arising pursuant to any provision of the DGCL or our amended and restated certificate of incorporation or the bylaws or (iv)&nbsp;any action asserting a claim against us
governed by the internal affairs doctrine will have to be brought only in the Court of Chancery in the State of Delaware. Although we believe this provision benefits us by providing increased consistency in the application of Delaware law in the
types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against our directors and officers. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related
to this offering and ownership of our Class&nbsp;A common stock </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We have identified material weaknesses in our internal control over financial
reporting. If we are unable to remediate these material weaknesses, or if we experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely
report our financial condition or results of operations, or comply with the accounting and reporting requirements applicable to public companies, which may adversely affect investor confidence in us and, as a result, the value of our common stock.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with the audit of our consolidated financial statements as of and for the years ended December&nbsp;31, 2015, 2014 and 2013, we
identified material weaknesses in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a
material misstatement of our financial statements will not be prevented or detected on a timely basis. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our material weaknesses include the following:
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We did not design and maintain an effective control environment with the sufficient number of professionals with an appropriate level of accounting
knowledge, training and experience to properly analyze, record and disclose accounting matters commensurate with our accounting and financial reporting requirements. This material weakness contributed to additional material weaknesses in which,
specifically, we did not design and maintain effective internal control over: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Accuracy and presentation and disclosure of sales allowances, distributor fees and bad debt expenses; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Cutoff and presentation and disclosures of revenue recognition, including the impact on cost of sales and selling, general and administrative expenses (sales
commissions) and sales allowances; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Completeness, accuracy and presentation and disclosure of intangible asset amortization expense, including impact on inventories and cost of sales;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">62 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Completeness, accuracy, valuation and presentation and disclosure of the contingent consideration liability related to business combinations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Completeness, accuracy, and presentation and disclosure of foreign currency transaction and translation gains and losses; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Completeness, existence, accuracy and presentation and disclosure of quarterly income tax provisions and deferred tax accounting; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Completeness, accuracy and presentation and disclosure of the statement of cash flows, specifically as it relates to excess partner distributions, payment of
in-kind interest and the impact of foreign currency; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Accuracy and presentation and disclosure of the financial statements, commensurate with our financial reporting requirements. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These material weaknesses resulted in adjustments to accounts receivable, inventories, goodwill, accrued sales commissions, contingent consideration liabilities,
equity, net sales, cost of sales, selling, general and administrative expenses, restructuring costs, depreciation and amortization, foreign currency transaction gains and losses and income tax expense in our consolidated financial statements for the
years ended December&nbsp;31, 2013, 2014 and 2015. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a public company, we will be required to maintain internal control over financial reporting and to
report any material weaknesses in such internal controls. However, neither our management nor an independent registered public accounting firm has ever performed an evaluation of our internal control over financial reporting in accordance with the
rules of the SEC because no such evaluation has been required. Had we or our independent registered public accounting firm performed an evaluation of our internal control over financial reporting, additional material weaknesses may have been
identified. Further, due to a transition period established by the rules of the SEC for newly public companies, our management will not be required to provide a management report on internal control over financial reporting until our second annual
report following this offering, which will be our fiscal year ending December&nbsp;31, 2017, and our independent registered public accounting firm will not be required to attest to our management report on internal control over financial reporting
until we are no longer an EGC. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have implemented and are still in the process of implementing measures designed to improve our internal control over
financial reporting and remediate our material weaknesses, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The augmentation and training of our accounting staff, including the appointment of a U.S. Controller at our headquarters in January 2015;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The continued centralization of accounting operations, including the transition of the U.S. accounts receivable, inventory and accounts payables functions to our
headquarters during the first half of 2015; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The commissioning of a third-party specialist to provide recommendations for improvement and to assist us in formalizing the documentation of our accounting
policies and internal controls; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The hiring of a Chief Accounting Officer in April 2016. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, during 2016, we plan to review our finance and accounting function to evaluate whether we have a sufficient number of appropriately trained and experienced personnel and plan to add new personnel as we
deem necessary. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Although we plan to complete these remediation activities as quickly as possible, we cannot at this time estimate how long the
remediation will take or cost to achieve, and our initiatives may not prove to be </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">63 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
successful in remediating these weaknesses and deficiencies. We cannot assure you that the measures we have taken to date, together with any measures we may take in the future, will be sufficient
to remediate our material weaknesses in our internal control over financial reporting or to avoid potential future material weaknesses. If the steps we take do not correct the material weaknesses in a timely manner, we will be unable to conclude
that we maintain effective internal control over financial reporting, and as a public company, we may have difficulties reporting on a quarterly basis with a review from our independent registered auditors in a timely manner. Accordingly, there
could continue to be a reasonable possibility that a material misstatement of our financial statements would not be prevented or detected on a timely basis. As we have not fully completed the updates to our control structure and have not completed
our evaluation and testing of these controls, we cannot be certain that these material weaknesses will be fully remediated or that other material weaknesses and any significant deficiencies or internal control deficiencies will not be discovered in
the future. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we are unable to successfully remediate our existing or any future material weaknesses in our internal control over financial reporting,
or identify any additional existing material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic
reports in addition to applicable stock exchange listing requirements, our reported financial results may be materially misstated, investors may lose confidence in our financial reporting and our stock price may decline as a result. As a result of
such failures, we could also become subject to investigations by the stock exchange on which our securities are listed, the SEC or other regulatory authorities, and become subject to litigation from investors and stockholders, which could harm our
reputation, business, financial condition and divert financial and management resources from our core business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Immediately following the
consummation of this offering, the Continuing LLC Owners will have the right to have their&nbsp;LLC Interests redeemed pursuant to the terms of the Bioventus&nbsp;LLC Agreement, which may dilute the owners of the Class&nbsp;A common stock.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">After this offering, we will have an aggregate of 126,272,381 shares of Class&nbsp;A common stock authorized but unissued, including
approximately 9,571,764 shares of Class&nbsp;A common stock issuable upon redemption of&nbsp;LLC Interests that will be held by the Continuing LLC Owners. Bioventus LLC will enter into the Bioventus LLC Agreement and, subject to certain restrictions
set forth therein and as described elsewhere in this prospectus, the Continuing LLC Owners will be entitled to have their&nbsp;LLC Interests redeemed for shares of our Class&nbsp;A common stock. We also intend to enter into a Registration Rights
Agreement pursuant to which the shares of Class&nbsp;A common stock issued to the Original LLC Owners upon redemption of&nbsp;LLC Interests and the shares of Class&nbsp;A common stock issued to the Former LLC Owners in connection with the
Transactions will be eligible for resale, subject to certain limitations set forth therein. See &#147;Certain relationships and related party transactions&#151;Registration Rights Agreement.&#148; </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We cannot predict the size of future issuances of our Class&nbsp;A common stock or the effect, if any, that future issuances and sales of shares of our Class&nbsp;A
common stock may have on the market price of our Class&nbsp;A common stock. Sales or distributions of substantial amounts of our Class&nbsp;A common stock, including shares issued in connection with an acquisition, or the perception that such sales
or distributions could occur, may cause the market price of our Class&nbsp;A common stock to decline. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If you purchase shares of Class&nbsp;A
common stock in this offering, you will incur immediate and substantial dilution. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Dilution is the difference between the offering price per
share and the pro forma net tangible book value per share of our Class&nbsp;A common stock immediately after the offering. The price you pay for shares of our Class&nbsp;A common stock sold in this offering is substantially higher than our pro forma
net tangible book value per share immediately after this offering. If you purchase shares of Class&nbsp;A common stock in this offering, you will incur </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">64 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
immediate and substantial dilution in the amount of $18.75&nbsp;per share based upon an assumed initial public offering price of $17.00&nbsp;per share (the midpoint of the price range listed on
the cover page of this prospectus). In addition, you may also experience additional dilution, or potential dilution, upon future equity issuances to investors or to our employees and directors under our stock option plan and any other equity
incentive plans we may adopt. As a result of this dilution, investors purchasing shares of Class&nbsp;A common stock in this offering may receive significantly less than the full purchase price that they paid for the stock purchased in this offering
in the event of liquidation. See &#147;Dilution.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We do not know whether a market will develop for our Class&nbsp;A common stock or what the
market price of our Class&nbsp;A common stock will be and as a result it may be difficult for you to sell your shares of our Class&nbsp;A common stock. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Before this offering, there was no public trading market for our Class&nbsp;A common stock. If a market for our Class&nbsp;A common stock does not develop or is not sustained, it may be difficult for you to sell
your shares of Class&nbsp;A common stock at an attractive price or at all. We cannot predict the prices at which our Class&nbsp;A common stock will trade. It is possible that in one or more future periods our results of operations may be below the
expectations of public market analysts and investors and, as a result of these and other factors, the price of our Class&nbsp;A common stock may fall. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our Class&nbsp;A common stock, the
price of our Class&nbsp;A common stock could decline. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The trading market for our Class&nbsp;A common stock will rely in part on the research and
reports that industry or securities analysts publish about us or our business. We do not currently have and may never obtain research coverage by industry or securities analysts. If no or few analysts commence coverage of us, the trading price of
our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our Class&nbsp;A common stock could decline. If one or more of these
analysts cease to cover our Class&nbsp;A common stock, we could lose visibility in the market for our stock, which in turn could cause our Class&nbsp;A common stock price to decline. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>We expect that the price of our Class&nbsp;A common stock will fluctuate substantially and you may not be able to sell the shares you purchase in this offering at or above the offering price.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The initial public offering price for the shares of our Class&nbsp;A common stock sold in this offering is determined by negotiation between the
representatives of the underwriters and us. This price may not reflect the market price of our Class&nbsp;A common stock following this offering. In addition, the market price of our Class&nbsp;A common stock is likely to be highly volatile and may
fluctuate substantially due to many factors, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the volume and timing of sales of our products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the introduction of new products or product enhancements by us or our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">disputes or other developments with respect to our or others&#146; intellectual property rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to develop, obtain regulatory clearance or approval for, and market new and enhanced products on a timely basis; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">product liability claims or other litigation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">quarterly variations in our results of operations or those of our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">media exposure of our products or our competitors; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">65 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">changes in governmental regulations or in reimbursement; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">changes in earnings estimates or recommendations by securities analysts; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">general market conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In recent years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or
disproportionate to the operating performance of those companies. Broad market and industry factors may significantly affect the market price of our Class&nbsp;A common stock, regardless of our actual operating performance. These fluctuations may be
even more pronounced in the trading market for our Class&nbsp;A common stock shortly following this offering. If the market price of shares of our Class&nbsp;A common stock after this offering does not ever exceed the initial public offering price,
you may not realize any return on your investment in us and may lose some or all of your investment. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, in the past, class action litigation
has often been instituted against companies whose securities have experienced periods of volatility in market price. Securities litigation brought against us following volatility in our stock price, regardless of the merit or ultimate results of
such litigation, could result in substantial costs, which would hurt our financial condition and operating results and divert management&#146;s attention and resources from our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Substantial future sales of our Class&nbsp;A common stock, or the perception in the public markets that these sales may occur, may depress our stock price. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Sales of substantial amounts of our Class&nbsp;A common stock in the public market after this offering, or the perception that these sales could occur, could
adversely affect the price of our Class&nbsp;A common stock and could impair our ability to raise capital through the sale of additional shares. Upon the closing of this offering, we will have 23,727,619 shares of Class&nbsp;A common stock
outstanding (or 25,051,148 if the underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common stock) and 9,571,764 shares of Class&nbsp;A common stock that would be issuable upon redemption or exchange of&nbsp;LLC
Interests authorized but unissued. The shares of Class&nbsp;A common stock offered in this offering will be freely tradable without restriction under the Securities Act, except for any shares of our common stock that may be held or acquired by our
directors, executive officers and other affiliates, as that term is defined in the Securities Act, which will be restricted securities under the Securities Act. Restricted securities may not be sold in the public market unless the sale is registered
under the Securities Act or an exemption from registration is available. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The remaining outstanding 14,904,090 shares of Class&nbsp;A common stock held
by the Former LLC Owners will be subject to certain restrictions on sale. We and each of our executive officers and directors and the Original LLC Owners, which collectively will hold 73.5% of our outstanding capital stock (including shares of
Class&nbsp;A common stock issuable upon redemption or exchange of&nbsp;LLC Interests) upon the closing of this offering, have agreed with the underwriters, subject to certain exceptions, not to dispose of or hedge any shares of common stock or
securities convertible into or exchangeable for (including the&nbsp;LLC Interests), or that represent the right to receive, shares of common stock during the period from the date of this prospectus continuing through the date 180&nbsp;days after the
date of this prospectus, except with the prior written consent of J.P.&nbsp;Morgan Securities&nbsp;LLC. See &#147;Underwriting.&#148; All of our shares of common stock outstanding as of the date of this prospectus (and shares of Class&nbsp;A common
stock issuable upon redemption or exchange of&nbsp;LLC Interests) may be sold in the public market by existing stockholders following the expiration of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> period, subject to applicable
limitations imposed under federal securities laws. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We also intend to enter into a Registration Rights Agreement pursuant to which the shares of
Class&nbsp;A common stock issued upon redemption or exchange of&nbsp;LLC Interests held by certain of the Continuing LLC Owners and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">66 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
the shares of Class&nbsp;A common stock issued to the Former LLC Owners in connection with the Transactions will be eligible for resale, subject to certain limitations set forth therein. See
&#147;Certain relationships and related party transactions&#151;Registration Rights Agreement.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We intend to file one or more registration
statements on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities Act to register all shares of Class&nbsp;A common stock subject to outstanding options and Class&nbsp;A common stock (a) issued or issuable under our stock
plans and (b) issuable to the Phantom Plan Participants under the Phantom Plan. Any such <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> registration statements will automatically become effective upon filing. Accordingly, shares registered
under such registration statements will be available for sale in the open market following the expiration of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> period. We expect that the initial registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> will cover 3,868,169 shares of our Class&nbsp;A common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">See &#147;Shares eligible for future
sale&#148; for a more detailed description of the restrictions on selling shares of our common stock after this offering. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the future, we may also
issue additional securities if we need to raise capital, which could constitute a material portion of our <FONT STYLE="white-space:nowrap">then-outstanding</FONT> shares of common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Taking advantage of the reduced disclosure requirements applicable to &#147;emerging growth companies&#148; may make our Class&nbsp;A common stock less attractive to investors. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The JOBS Act provides that, so long as a company qualifies as an &#147;emerging growth company,&#148; it will, among other things: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">be exempt from the provisions of Section&nbsp;404(b) of the <FONT STYLE="white-space:nowrap">Sarbanes-Oxley</FONT> Act requiring that its independent registered
public accounting firm provide an attestation report on the effectiveness of its internal control over financial reporting; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">be exempt from the &#147;say on pay&#148; and &#147;say on golden parachute&#148; advisory vote requirements of the
<FONT STYLE="white-space:nowrap">Dodd-Frank</FONT> Wall Street Reform and Customer Protection Act, or the <FONT STYLE="white-space:nowrap">Dodd-Frank</FONT> Act; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">be exempt from certain disclosure requirements of the <FONT STYLE="white-space:nowrap">Dodd-Frank</FONT> Act relating to compensation of its executive officers
and be permitted to omit the detailed compensation discussion and analysis from proxy statements and reports filed under the Securities Exchange Act of 1934, as amended, or the Exchange Act; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">be permitted to provide a reduced level of disclosure concerning executive compensation and be exempt from any rules that may be adopted by the Public Company
Accounting Oversight Board requiring mandatory audit firm rotations or a supplement to the auditor&#146;s report on the financial statements. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We currently intend to take advantage of the reduced disclosure requirements regarding executive compensation. We have irrevocably elected not to take advantage of the extension of time to comply with new or
revised financial accounting standards available under Section&nbsp;107(b) of the JOBS Act. We could be an emerging growth company for up to five years after this offering. If we remain an &#147;emerging growth company&#148; after fiscal 2015, we
may take advantage of other exemptions, including the exemptions from the advisory vote requirements and executive compensation disclosures under the <FONT STYLE="white-space:nowrap">Dodd-Frank</FONT> Act and the exemption from the provisions of
Section&nbsp;404(b) of the <FONT STYLE="white-space:nowrap">Sarbanes-Oxley</FONT> Act. We cannot predict if investors will find our Class&nbsp;A common stock less attractive if we elect to rely on these exemptions, or if taking advantage of these
exemptions would result in less active trading or more volatility in the price of our Class&nbsp;A common stock. Also, as a result of our intention to take advantage of some or all of the reduced regulatory and reporting requirements that will be
available to us as long as we qualify as an &#147;emerging growth company,&#148; our financial statements may not be comparable to those of companies that fully comply with regulatory and reporting requirements upon the public company effective
dates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">67 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We will incur increased costs as a result of becoming a public company and in the administration of our
organizational structure. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a public company, we will incur significant legal, accounting, insurance and other expenses that we have not
incurred as a private company, including costs associated with public company reporting requirements. We also have incurred and will incur costs associated with the <FONT STYLE="white-space:nowrap">Sarbanes-Oxley</FONT> Act and related rules
implemented by the SEC. Following the completion of this offering, we will incur ongoing periodic expenses in connection with the administration of our organizational structure. The expenses incurred by public companies generally for reporting and
corporate governance purposes have been increasing. We expect these rules and regulations to increase our legal and financial compliance costs and to make some activities more <FONT STYLE="white-space:nowrap">time-consuming</FONT> and costly,
although we are currently unable to estimate these costs with any degree of certainty. In estimating these costs, we took into account expenses related to insurance, legal, accounting, and compliance activities, as well as other expenses not
currently incurred. These laws and regulations could also make it more difficult or costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and
coverage or incur substantially higher costs to obtain the same or similar coverage. These laws and regulations could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees
or as our executive officers. Furthermore, if we are unable to satisfy our obligations as a public company, we could be subject to delisting of our common stock, fines, sanctions and other regulatory action and potentially civil litigation.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Failure to establish and maintain effective internal controls in accordance with Section&nbsp;404 of the
<FONT STYLE="white-space:nowrap">Sarbanes-Oxley</FONT> Act could have a material adverse effect on our business and stock price. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are not
currently required to comply with the rules of the SEC implementing Section&nbsp;404 of the <FONT STYLE="white-space:nowrap">Sarbanes-Oxley</FONT> Act and are therefore not required to make a formal assessment of the effectiveness of our internal
control over financial reporting for that purpose. Upon becoming a public company, we will be required to comply with the SEC&#146;s rules implementing Sections&nbsp;302 and 404 of the <FONT STYLE="white-space:nowrap">Sarbanes-Oxley</FONT> Act,
which will require management to certify financial and other information in our quarterly and annual reports and provide an annual management report on the effectiveness of controls over financial reporting. Though we will be required to disclose
changes made in our internal controls and procedures on a quarterly basis, we will not be required to make our first annual assessment of our internal control over financial reporting pursuant to Section&nbsp;404 until the year following our first
annual report required to be filed with the SEC. However, as an emerging growth company, our independent registered public accounting firm will not be required to formally attest to the effectiveness of our internal control over financial reporting
pursuant to Section&nbsp;404 until the later of the year following our first annual report required to be filed with the SEC or the date we are no longer an emerging growth company. At such time, our independent registered public accounting firm may
issue a report that is adverse in the event it is not satisfied with the level at which our controls are documented, designed or operating. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To comply
with the requirements of being a public company, we have undertaken various actions, and may need to take additional actions, such as implementing new internal controls and procedures and hiring additional accounting or internal audit staff. Testing
and maintaining internal controls can divert our management&#146;s attention from other matters that are important to the operation of our business. Additionally, when evaluating our internal controls over financial reporting, we may identify
material weaknesses that we may not be able to remediate in time to meet the applicable deadline imposed upon us for compliance with the requirements of Section&nbsp;404. For example, material weaknesses were identified during fiscal 2014 relating
to prior period financial statement close procedures. If we identify any additional material weaknesses in our internal controls over financial reporting or are unable to comply with the requirements of Section&nbsp;404 in a timely manner or assert
that our internal controls over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal controls
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">68 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
over financial reporting once we are no longer an emerging growth company, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our
Class&nbsp;A common stock could be negatively affected, and we could become subject to investigations by the stock exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial and
management resources. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We do not currently expect to pay any cash dividends. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The continued operation and expansion of our business will require substantial funding. Accordingly, we do not currently expect to pay any cash dividends on shares of our Class&nbsp;A common stock. Any
determination to pay dividends in the future will be at the discretion of our board of directors and will depend upon results of operations, financial condition, contractual restrictions, restrictions imposed by applicable law and other factors our
board of directors deems relevant. We are a holding company, and substantially all of our operations are carried out by Bioventus LLC and its subsidiaries. Therefore our ability to generate cash to make future dividend payments, if any, is highly
dependent on the earnings and the receipt of funds from our subsidiaries via dividends or intercompany loans. Under our secured credit facilities, Bioventus LLC is restricted from paying cash dividends, and we expect these restrictions to continue
in the future. Our ability to pay dividends may also be restricted by the terms of any future credit agreement or any future debt or preferred equity securities of ours or of our subsidiaries. In addition, Delaware law may impose requirements that
may restrict our ability to pay dividends to holders of our common stock. Accordingly, if you purchase shares in this offering, realization of a gain on your investment will depend on the appreciation of the price of our Class&nbsp;A common stock,
which may never occur. Investors seeking cash dividends in the foreseeable future should not purchase our Class&nbsp;A common stock. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">69 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_3"></A>Special note regarding forward-looking statements </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This prospectus contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives
and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;assume,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;due,&#148; &#147;estimate,&#148;
&#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;positioned,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148;
&#147;will,&#148; &#147;would&#148; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements
contain these words. These forward-looking statements include, but are not limited to, statements about: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our dependence on a limited number of products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">competition against other companies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">clinical trials of our next-generation BMP product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to differentiate the HA viscosupplementation therapies we own or distribute; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to develop and commercialize additional orthobiologic products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">physician awareness of our products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our net losses; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">risk of product liability claims; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the continued and future acceptance of our bone graft substitutes by the medical community and the public; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">acquisition or investment in new businesses, products or technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the FDA regulatory process; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">various governmental regulations related to the manufacturing of our products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">healthcare regulatory reform; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Voting Group&#146;s control of us; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the other risks identified in this prospectus including, without limitation, those under the sections titled &#147;Risk factors,&#148; &#147;Management&#146;s
discussion and analysis of financial condition and results of operations&#148; and &#147;Business.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Forward-looking statements
are based on management&#146;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management&#146;s beliefs and assumptions are not guarantees of future performance or development
and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this prospectus may turn out to be inaccurate. Furthermore, if the
forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">70 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Factors that may cause actual results to differ materially from current expectations
include, among other things, those described in the section entitled &#147;Risk factors&#148; and elsewhere in this prospectus. Potential investors are urged to consider these factors carefully in evaluating these forward-looking statements. These
forward-looking statements speak only as of the date of this prospectus. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
You should, however, review the factors and risks and other information we describe in the reports we will file from time to time with the SEC after the date of this prospectus. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">71 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_4"></A>Use of proceeds </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We estimate the net proceeds from this initial public offering of shares of Class&nbsp;A common stock will be approximately $135.6 million, or $156.5&nbsp;million if the underwriters exercise their option to
purchase additional shares in full, assuming an initial public offering price of $17.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the underwriting discounts and commissions and
estimated offering expenses payable by us. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each $1.00 increase (decrease) in the assumed initial public offering price of $17.00 per share, the midpoint
of the price range set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us by approximately $8.2&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this
prospectus, remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Each increase (decrease) of 1,000,000
shares in the number of shares offered by us would increase (decrease) the net proceeds to us by approximately $15.8&nbsp;million, assuming that the assumed initial public offering price remains the same, and after deducting the underwriting
discounts and commissions and estimated offering expenses payable by us. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We intend to use the net proceeds to us from this offering to purchase
8,823,529 <FONT STYLE="white-space:nowrap">newly-issued&nbsp;LLC</FONT> Interests from Bioventus LLC at a purchase price per LLC Interest equal to the initial public offering price per share of Class&nbsp;A common stock less the underwriting
discounts and commissions and estimated offering expenses payable thereon. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We intend to cause Bioventus LLC to use such proceeds (i)&nbsp;to repay all
of the outstanding borrowings under our second lien term loan facility, together with a prepayment premium and accrued and unpaid interest thereon, (ii) to&nbsp;repay a $23.5&nbsp;million promissory note and a $5.0&nbsp;million deferred payment
relating to the Acquisition when due in 2016, (iii) to repay all of the outstanding borrowings under our first lien revolving facility and (iv)&nbsp;with any remaining net proceeds used&nbsp;for general corporate purposes. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of April 2, 2016, we had outstanding indebtedness of $60.0&nbsp;million under our second lien term loan, which matures on April&nbsp;10, 2020. The interest rate
on borrowings under the second lien term loan facility was 11.0% as of April 2, 2016. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of April 2, 2016 there was $19.5 million outstanding under our
revolving credit facility, which matures on October 10, 2019. The interest rate on borrowings under our revolving credit facility was 3.18% as of April 2, 2016. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We will use the net proceeds we receive pursuant to any exercise of the underwriters&#146; option to purchase additional shares of Class&nbsp;A common stock to purchase additional&nbsp;LLC Interests from Bioventus
LLC to maintain the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> ratio between the number of shares of Class&nbsp;A common stock issued by us and the number of&nbsp;LLC Interests owned by us. We intend
to cause Bioventus LLC to use any such proceeds it receives for general corporate purposes. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of the date of this prospectus, since we cannot specify
with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering, our management will have broad discretion over the use of any net proceeds from this offering that are to be applied for general
corporate purposes. Pending the use of the proceeds from this offering, we intend to invest the net proceeds in short-term, interest-bearing, investment grade securities, certificates of deposit or governmental securities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">72 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_5"></A>Dividend policy </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We currently intend to retain all available funds and any future earnings for use in the operation of our business, and therefore we do not currently expect to pay any cash dividends on our Class&nbsp;A common
stock. Holders of our Class&nbsp;B common stock are not entitled to participate in any dividends declared by our board of directors. Any future determination to pay dividends to holders of Class&nbsp;A common stock will be at the discretion of our
board of directors and will depend upon many factors, including our results of operations, financial condition, capital requirements, restrictions in Bioventus LLC&#146;s debt agreements and other factors that our board of directors deems relevant.
We are a holding company, and substantially all of our operations are carried out by Bioventus LLC and its subsidiaries, and therefore we will only be able to pay dividends from funds we receive from Bioventus LLC. Under our credit agreements,
Bioventus LLC is currently restricted from paying certain distributions, and we expect these restrictions to continue in the future, which may in turn limit our ability to pay dividends on our Class&nbsp;A common stock. Our ability to pay dividends
may also be restricted by the terms of any future credit agreement or any future debt or preferred equity securities of us or our subsidiaries. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">73 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_6"></A>Transactions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Existing organization </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Prior to the consummation of this offering and the organizational transactions
described below, the Original LLC Owners are the only owners of Bioventus LLC. Bioventus LLC is treated as a partnership for U.S. federal income tax purposes and, as such, is not subject to any U.S. federal
<FONT STYLE="white-space:nowrap">entity-level</FONT> income taxes. Rather, taxable income or loss is included in the U.S. federal income tax returns of Bioventus LLC&#146;s members. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Bioventus Inc. was incorporated as a Delaware corporation on December&nbsp;22, 2015 to serve as the issuer of the Class&nbsp;A common stock offered hereby. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Transactions </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with the closing of this offering we will consummate the following
transactions, which we refer to as the &#147;Transactions&#148;: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we will amend and restate the Bioventus LLC Agreement, to, among other things, (i)&nbsp;provide for&nbsp;LLC Interests that will be the single class of common
membership interests in Bioventus LLC, (ii)&nbsp;exchange all of the existing membership interests (including profit interests awarded under our MIP) in Bioventus LLC for&nbsp;LLC Interests and (iii)&nbsp;appoint Bioventus Inc. as the sole managing
member of Bioventus LLC; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we will amend and restate Bioventus Inc.&#146;s certificate of incorporation to, among other things, (i)&nbsp;provide for Class&nbsp;A common stock and
Class&nbsp;B common stock, each share of which entitles its holders to one vote per share on all matters presented to Bioventus Inc.&#146;s stockholders and (ii)&nbsp;issue shares of Class&nbsp;B common stock to the Continuing LLC Owners, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> basis with the number of&nbsp;LLC Interests they own; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we will issue 8,823,529&nbsp;shares of our Class&nbsp;A common stock to the purchasers in this offering (or 10,147,058&nbsp;shares if the underwriters exercise
in full their option to purchase additional shares of Class&nbsp;A common stock) in exchange for net proceeds of approximately $139.5 million (or approximately $160.4&nbsp;million if the underwriters exercise in full their option to purchase
additional shares of Class&nbsp;A common stock), assuming the shares are offered at $17.00 per share (the midpoint of the price range listed on the cover page of this prospectus), after deducting underwriting discounts and commissions but before
offering expenses; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we will use all of the net proceeds from this offering (including any net proceeds received upon exercise of the underwriters&#146; option to purchase additional
shares of Class&nbsp;A common stock) to acquire <FONT STYLE="white-space:nowrap">newly-issued&nbsp;LLC</FONT> Interests from Bioventus LLC at a purchase price per interest equal to the initial public offering price of Class&nbsp;A common stock, less
underwriting discounts and commissions, collectively representing 26.5% of Bioventus LLC&#146;s outstanding&nbsp;LLC Interests (or 29.3%, if the underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common stock);
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Bioventus LLC will use the proceeds from the sale of&nbsp;LLC Interests as set forth under &#147;Use of proceeds;&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Former LLC Owners will exchange their&nbsp;indirect ownership interests in Bioventus LLC for
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of Class&nbsp;A common stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> basis;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Phantom Plan will be terminated and the Phantom Plan Participants will receive the right to receive up to 513,117 shares of Class&nbsp;A common stock upon
settlement of their awards under the Phantom Plan, with such settlement expected to take place on the twelve month anniversary following the date of termination of the Phantom Plan as described in &#147;Executive compensation &#151; Narrative to
summary compensation table &#151; Equity-based compensation &#151; Phantom profits interest units&#148; (settlement may result in a change in the </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">74 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
timing over which compensation expense is recognized as described in &#147;Management&#146;s discussion and analysis of financial condition and results of operations &#151; Components of our
results of operations &#151; Selling, general and administrative expenses&#148; and Bioventus will receive a corresponding number of&nbsp;LLC Interests from Bioventus LLC upon settlement); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Continuing LLC Owners will continue to own the&nbsp;LLC Interests they received in exchange for their existing membership interests in Bioventus LLC; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Bioventus will enter into (i) the Tax Receivable Agreement with the Continuing LLC Owners, (ii) the Stockholders Agreement with the Voting Group and (iii) the
Registration Rights Agreement with the Original LLC Owners who, upon the consummation of this offering, will own 24,475,854&nbsp;shares of Bioventus&#146; Class A and Class&nbsp;B common stock (which will not have any liquidation or distribution
rights). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Organizational structure following this offering </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Immediately following the completion of the Transactions, including this offering: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Bioventus will be a holding company and the principal asset of Bioventus will be&nbsp;LLC Interests of Bioventus LLC; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Bioventus will be the sole managing member of Bioventus LLC and will control the business and affairs of Bioventus LLC and its subsidiaries;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our amended and restated certificate of incorporation and the Bioventus LLC Agreement will require that we and Bioventus LLC at all times maintain a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> ratio between the number of shares of Class&nbsp;A common stock issued by us and the number of&nbsp;LLC Interests owned by us, as well as a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> ratio between the number of shares of Class&nbsp;B common stock owned by the Continuing LLC Owners and the number of&nbsp;LLC Interests owned by the Continuing LLC
Owners; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Bioventus will own&nbsp;LLC Interests representing 71.3% of the economic interest in Bioventus LLC (or 72.4%, if the underwriters exercise in full their option
to purchase additional shares of Class&nbsp;A common stock); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the purchasers in this offering (i)&nbsp;will own 8,823,529&nbsp;shares of Class&nbsp;A common stock, representing approximately 26.5% of the combined voting
power of all of Bioventus&#146; common stock (or approximately 29.3%, if the underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common stock), (ii)&nbsp;will own 37.2% of the economic interest in Bioventus (or
40.5%, if the underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common stock) and (iii)&nbsp;through Bioventus&#146; ownership of&nbsp;LLC Interests, indirectly will hold (applying the percentages in the
preceding clause&nbsp;(ii) to Bioventus&#146; percentage economic interest in Bioventus LLC) approximately 26.5% of the economic interest in Bioventus LLC (or 29.3%, if the underwriters exercise in full their option to purchase additional shares of
Class&nbsp;A common stock); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Former LLC Owners (i)&nbsp;will own 14,904,090&nbsp;shares of Class&nbsp;A common stock, representing approximately 44.8% of the combined voting power of all
of Bioventus&#146; common stock (or approximately 43.0%, if the underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common stock), (ii)&nbsp;will own 62.8% of the economic interest in Bioventus (or 59.5%, if the
underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common stock) and (iii)&nbsp;through Bioventus&#146; ownership of&nbsp;LLC Interests, indirectly will hold (applying the percentages in the preceding
clause&nbsp;(ii) to Bioventus&#146; percentage economic interest in Bioventus LLC) approximately 44.8% of the economic interest in Bioventus LLC (or 43.0%, if the underwriters exercise in full their option to purchase additional shares of
Class&nbsp;A common stock); </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">75 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Continuing LLC Owners will own (i)&nbsp;LLC Interests, representing 28.7% of the economic interest in Bioventus LLC (or 27.6%, if the underwriters exercise
in full their option to purchase additional shares of Class&nbsp;A common stock) and (ii)&nbsp;through their ownership of Class&nbsp;B common stock, approximately 28.7% of the voting power in Bioventus (or approximately 27.6%, if the underwriters
exercise in full their option to purchase additional shares of Class&nbsp;A common stock). Following the offering, each&nbsp;LLC Interest held by the Continuing LLC Owners will be redeemable, at the election of such members, for, at Bioventus&#146;
option, as determined by Bioventus&#146; board of directors, <FONT STYLE="white-space:nowrap">newly-issued</FONT> shares of Class&nbsp;A common stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT>
basis or a cash payment (if mutually agreed) equal to a volume weighted average market price of one share of Class&nbsp;A common stock for each&nbsp;LLC Interest redeemed (subject to customary adjustments, including for stock splits, stock dividends
and reclassifications) in accordance with the terms of the Bioventus LLC Agreement. See &#147;Certain relationships and related party transactions&#151;Bioventus LLC Agreement;&#148; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Original LLC Owners collectively (i)&nbsp;will own Class&nbsp;A and Class&nbsp;B common stock representing approximately 73.5% of the combined voting power
of all of Bioventus&#146; common stock (or approximately 70.7%, if the underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common stock) and (ii)&nbsp;will own 73.5% of the economic interest in Bioventus LLC (or
70.7%, if the underwriters exercise in full their option to purchase additional shares of Class&nbsp;A common stock), representing both a direct interest through the Continuing LLC Owners&#146; ownership of&nbsp;LLC Interests and an indirect
interest through the Former LLC Owners&#146; ownership of Class&nbsp;A common stock. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Immediately following this offering, we will be a
holding company and our principal asset will be the LLC&nbsp;Interests we purchase from Bioventus LLC and acquire from the Former LLC Owners. As the sole managing member of Bioventus LLC, we will operate and control all of the business and affairs
of Bioventus LLC and, through Bioventus LLC and its subsidiaries, conduct our business. Accordingly, we will have the sole voting interest in, and control the management of, Bioventus LLC. As a result, we will consolidate Bioventus LLC in our
consolidated financial statements and will report a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest related to the&nbsp;LLC Interests held by the Continuing LLC Owners on our consolidated financial statements. Bioventus Inc. will
have a board of directors and executive officers, but will have no employees. The functions of all of our employees are expected to reside at or under Bioventus LLC. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">76 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following diagram shows our organizational structure after giving effect to the Transactions, including this
offering, assuming no exercise by the underwriters of their option to purchase additional shares of Class&nbsp;A common stock: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g22578g81g02.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">77 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_7"></A>Capitalization </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following table sets forth the cash and cash equivalents and capitalization as of April&nbsp;2,&nbsp;2016: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">of Bioventus LLC and its subsidiaries on an actual basis; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">of Bioventus and its subsidiaries on a pro forma basis to give effect to the Transactions, including our issuance and sale of 8,823,529&nbsp;shares of
Class&nbsp;A common stock in this offering at an assumed initial public offering price of $17.00 per share, the midpoint of the price range listed on the cover page of this prospectus, after (i)&nbsp;deducting the estimated underwriting discounts
and commissions and estimated offering expenses payable by us and (ii)&nbsp;the application of the proceeds from the offering, each as described under &#147;Use of proceeds.&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">You should read this information together with the financial statements and related notes appearing elsewhere in this prospectus and the information set forth under
the headings &#147;Prospectus summary&#151;Summary historical and pro forma financial data,&#148; &#147;Transactions,&#148; &#147;Use of proceeds,&#148; &#147;Selected financial data,&#148; and &#147;Management&#146;s discussion and analysis of
financial condition and results of operations&#148;. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of April&nbsp;2,&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Bioventus&nbsp;LLC</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>actual</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Bioventus&nbsp;Inc.<BR>pro forma(1)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Long-term indebtedness</B>:<B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2014 revolver(3) </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">First lien term loan(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">102,310</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">102,310</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Second lien term loan(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">57,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Stockholders&#146; equity (deficit)</B>:<B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Class&nbsp;A common stock, par value $0.001&nbsp;per share; no shares authorized, issued and outstanding, actual; 150,000,000 shares
authorized, 22,263,466 shares issued and outstanding, Bioventus Inc. pro forma</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Class&nbsp;B common stock, par value $0.001&nbsp;per share; no shares authorized, issued and outstanding, actual; 10,000,000 shares
authorized, 11,046,822 shares issued and outstanding, Bioventus Inc. pro forma</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Members&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">284,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated other comprehensive income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">227,193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(97,975</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Non-controlling interest in subsidiary</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">91,464</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total members&#146; equity, actual; stockholders&#146; equity, pro forma</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">186,302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">318,691</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total capitalization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">365,712</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">421,001</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">A $1.00 increase (decrease) in the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range listed on the cover page of this
prospectus, would increase (decrease) the pro forma amount of each of cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity and total capitalization by approximately $8.2
million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
</FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Excludes $0.3&nbsp;million of restricted cash. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">For more information regarding the 2014 Revolver, first lien term loan and second lien term loan, see &#147;Description of indebtedness.&#148; As of April&nbsp;2, 2016, we had
$20.5&nbsp;million of availability under the 2014 revolver (after giving effect to $0 of outstanding letters of credit) and on a pro forma basis to give effect to the Transactions, we will have $40.0 million of availability under the 2014 revolver
(after giving effect to $0 of outstanding letters of credit). </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">78 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_8"></A>Dilution </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Continuing LLC Owners will maintain their LLC Interests in Bioventus LLC after the Transactions. Because the Continuing LLC Owners do not own any Class&nbsp;A common stock or have any right to receive
distributions from Bioventus, we have presented dilution in pro forma net tangible book value per share after this offering assuming that all of the holders of&nbsp;LLC Interests (other than Bioventus) had their&nbsp;LLC Interests redeemed or
exchanged for <FONT STYLE="white-space:nowrap">newly-issued</FONT> shares of Class&nbsp;A common stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis (rather than for cash), and the
cancellation for no consideration of all of their shares of Class B common stock (which are not entitled to distributions from Bioventus), in order to more meaningfully present the dilutive impact on the investors in this offering. We refer to the
assumed redemption or exchange of all&nbsp;LLC Interests for shares of Class&nbsp;A common stock as described in the previous sentence as the &#147;Assumed Redemption.&#148; We also note that the effect of the Assumed Redemption is to increase the
assumed number of shares of Class A common stock outstanding before the offering, thereby decreasing the pro forma net tangible book value per share before the offering and correspondingly increasing the dilution per share to new Class A common
stock investors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Dilution is the amount by which the offering price paid by the purchasers of the Class&nbsp;A common stock in this offering exceeds the
pro forma net tangible book value per share of Class&nbsp;A common stock after the offering. Bioventus LLC&#146;s net tangible book value as of April 2, 2016 was ($190.5)&nbsp;million. Net tangible book value per share is determined at any date by
subtracting our total liabilities from the total book value of our tangible assets and dividing the difference by the number of shares of Class&nbsp;A common stock deemed to be outstanding at that date. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If you invest in our Class&nbsp;A common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the
initial public offering price per share and the pro forma net tangible book value per share of our Class&nbsp;A common stock after this offering. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pro
forma net tangible book value per share is determined at any date by subtracting our total liabilities from the total book value of our tangible assets and dividing the difference by the number of shares of Class&nbsp;A common stock, after giving
effect to the Transactions, including this offering, and the Assumed Redemption. Our pro forma net tangible book value as of April 2, 2016 would have been approximately ($58.1)&nbsp;million, or ($1.75)&nbsp;per share of Class&nbsp;A common stock.
This amount represents an immediate increase in pro forma net tangible book value of $5.94 per share to our existing stockholders and an immediate dilution in pro forma net tangible book value of approximately $18.75 per share to new investors
purchasing shares of Class&nbsp;A common stock in this offering. We determine dilution by subtracting the pro forma net tangible book value per share after this offering from the amount of cash that a new investor paid for a share of Class&nbsp;A
common stock. The following table illustrates this dilution: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Assumed initial public offering price per share</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17.00</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pro forma net tangible book value per share as of April 2, 2016 before this offering(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(7.69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Increase per share attributable to investors in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pro forma net tangible book value per share after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Dilution per share to new Class&nbsp;A common stock investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18.75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">79 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The computation of pro forma net tangible book value per share as of April 2, 2016 before this offering is set forth below: </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Numerator:</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Book value of tangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">109.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Less: total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(297.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Pro forma net tangible book value(a)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(188.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Denominator:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Shares of Class&nbsp;A common stock outstanding immediately prior to this offering and after Assumed Redemption</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">24,475,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Pro forma net tangible book value per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(7.69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Gives pro forma effect to the Transactions (other than this offering) and the Assumed Redemption. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If the underwriters exercise their option to purchase additional shares of our Class&nbsp;A common stock in full in this offering, the pro forma net tangible book value after the offering would be ($1.07)&nbsp;per
share, the increase in pro forma net tangible book value per share to existing stockholders would be $6.21 and the dilution per share to new investors would be $18.07 per share, in each case assuming an initial public offering price of
$17.00&nbsp;per share, which is the midpoint of the price range listed on the cover page of this prospectus. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table summarizes, as of April
2, 2016 after giving effect to this offering, the Transactions and the Acquisition the differences between the Original LLC Owners and new investors in this offering with regard to: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the number of shares of Class&nbsp;A common stock purchased from us by investors in this offering and the number of shares issued to the Original LLC Owners
after giving effect to the Assumed Redemption, </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the total consideration paid to us in cash by investors purchasing shares of Class&nbsp;A common stock in this offering and by the Original LLC Owners, and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the average price per share of Class&nbsp;A common stock that such Original LLC Owners and new investors paid. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The calculation below is based on an assumed initial public offering price of $17.00 per share, which is the midpoint of the price range listed on the cover page of
this prospectus, before deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Shares purchased</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total&nbsp;consideration</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Average&nbsp;price</B></FONT><br><FONT
STYLE="font-family:arial" SIZE="2"><B>per&nbsp;share</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Original LLC Owners</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">24,475,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">73.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">281.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">65.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11.49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">New investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,823,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">26.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">150.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34.8%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">33,299,383</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">431.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12.95</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="20" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Except as otherwise indicated, the discussion and the tables above assume no exercise of the underwriters&#146; option to purchase
additional shares of Class&nbsp;A common stock. The number of shares of our Class&nbsp;A common stock outstanding after this offering as shown in the tables above is based on the number of shares outstanding as of April 2, 2016, after giving effect
to the Transactions and the Assumed Redemption, and excludes: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">2,981,436 shares of Class&nbsp;A common stock reserved for future issuance under our 2016 Incentive Award Plan (as described in &#147;Executive
compensation<B>&#151;</B>New incentive arrangements&#148;), consisting of (i)&nbsp;2,514,265 shares of Class A common stock relating to stock options granted in connection with this offering and (ii)&nbsp;467,171 additional shares of Class&nbsp;A
common stock reserved for future issuance (exclusive of the additional shares available for issuance under the 2016 Incentive Award Plan pursuant to the annual increase each calendar year beginning in 2017 and ending in 2026 as described in
&#147;Executive compensation&#151;New incentive arrangements&#148;); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">513,117 shares of Class&nbsp;A common stock expected to be available for future issuance to the Phantom Plan Participants upon settlement of their awards as
described in &#147;Executive compensation&#151;Narrative to summary compensation table&#151;Elements of compensation&#151;Equity-based compensation&#151;Phantom profits interests units&#148;; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">373,616 shares of Class A common stock reserved for issuance under our Employee Stock Purchase Plan as described in &#147;Executive compensation&#151;New
incentive arrangements&#148;. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">80 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To the extent any of these outstanding options are exercised, and upon the issuance of shares of Class&nbsp;A common
stock to Phantom Plan Participants upon settlement of their awards, there will be further dilution to new investors. To the extent all of such outstanding options had been exercised and all settlement shares issued to the Phantom Plan Participants
as of April&nbsp;2, 2016, the pro forma net tangible book value per share after this offering would be $(1.58), and total dilution per share to new investors would be $18.58, which does not include the proceeds from the exercise of any outstanding
options or repurchases of any shares of Class A common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the underwriters exercise their option to purchase additional shares of Class&nbsp;A
common stock in full, after giving effect to the Transactions and Assumed Redemption: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the percentage of shares of Class&nbsp;A common stock held by Original LLC Owners will decrease to approximately 70.7% of the total number of shares of our
Class&nbsp;A common stock outstanding after this offering; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the number of shares held by new investors will increase to 10,147,058, or approximately 29.3% of the total number of shares of our Class&nbsp;A common stock
outstanding after this offering. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">81 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_9"></A>Unaudited pro forma consolidated financial information </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following statements set forth unaudited pro forma consolidated financial data for Bioventus Inc. for the year ended December 31, 2015 and as of April 2, 2016
and for the three months ended March 28, 2015 and April 2, 2016. The unaudited pro forma consolidated balance sheet as of April 2, 2016 gives effect to the Transactions as if they had occurred on that date. The unaudited pro forma consolidated
statements of operations for the fiscal year ended December 31, 2015 and the three month periods ended March 28, 2015 and April 2, 2016 have been prepared to illustrate the effects of the Acquisition and the Transactions as if they occurred on
January 1, 2015. The unaudited pro forma consolidated financial statements have been developed by applying pro forma adjustments to the historical audited consolidated financial statements of Bioventus LLC included elsewhere in this prospectus.
Assumptions underlying the pro forma adjustments are described in the accompanying notes, which should be read in conjunction with these unaudited pro forma consolidated financial statements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Bioventus Inc. was incorporated on December&nbsp;22, 2015 and has no business transactions, activities, assets or liabilities to date, and therefore its historical financial information is not shown in a separate
column in the unaudited pro forma consolidated balance sheet and unaudited pro forma consolidated statement of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The pro forma adjustments
related to the Acquisition, which we refer to as Acquisition Adjustments, are described in the notes to the unaudited pro forma consolidated financial information and include those related to the acquisition of BioStructures, LLC on
November&nbsp;24, 2015. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The pro forma adjustments related to the Transactions other than this offering, which we refer to as Reorganization Adjustments,
are described in the notes to the unaudited pro forma consolidated financial information, and principally include those transactions as listed within the &#147;Transactions&#148; section of this prospectus. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The pro forma adjustments related to this offering, which we refer to as the Offering Adjustments, are described in the notes to the unaudited pro forma
consolidated financial information, and principally include those items listed within &#147;The offering&#148; and &#147;Use of proceeds&#148; sections of this prospectus. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Except as otherwise indicated, the unaudited pro forma consolidated financial information presented assumes no exercise by the underwriters of their option to purchase additional shares of Class&nbsp;A common stock
from us. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Bioventus LLC has been, and following the Transactions will continue to be, treated as a partnership for U.S. federal income tax purposes and,
as such, is not subject to any U.S. federal entity-level income taxes. Rather, taxable income or loss is included in the U.S. federal income tax returns of Bioventus LLC&#146;s members, including Bioventus Inc. Bioventus Inc. will be subject to U.S.
federal, state and local income taxes with respect to our allocable share of any taxable income of Bioventus LLC. For the purposes of the unaudited pro forma financial statements, Bioventus Inc. has not recorded pro forma adjustments to income tax
expense or deferred income taxes as it is not more likely than not that Bioventus Inc. will be able to realize the benefit from the reorganization. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As
described in greater detail under &#145;&#145;Certain relationships and related party transactions&#151;Tax Receivable Agreement,&#146;&#146; in connection with the closing of this offering, we will enter into the Tax Receivable Agreement with
Continuing LLC Owners that will provide for the payment by Bioventus Inc. to such persons of 85% of the amount of tax benefits, if any, that Bioventus Inc. actually realizes (or in some circumstances is deemed to realize) as a result of
(i)&nbsp;increases in the tax basis of assets of Bioventus LLC resulting from any future redemptions or exchanges of LLC Interests described under &#147;Certain relationships and related party transactions&#151;Bioventus LLC Agreement&#151;LLC
Interest Redemption Right,&#148; and (ii)&nbsp;certain other tax benefits </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">82 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
related to our making payments under the Tax Receivable Agreement. Due to the uncertainty in the amount and timing of future redemptions or exchanges of LLC Interests by the Continuing LLC
Owners, the unaudited pro forma consolidated financial information assumes that no redemptions or exchanges of LLC Interests have occurred and therefore no increases in tax basis in Bioventus LLC&#146;s assets or other tax benefits that may be
realized thereunder have been assumed in the unaudited pro forma consolidated financial information. However, if all of the Continuing LLC Owners were to exchange or redeem their LLC Interests, we would recognize a deferred tax asset of
approximately $105.0 million and a related liability for payments under the Tax Receivable Agreement of approximately $89.3 million, assuming, among other factors, (i)&nbsp;all exchanges occurred on the same day; (ii)&nbsp;a price of $17.00&nbsp;per
share of Class&nbsp;A common stock (which is the midpoint of the price range set forth on the cover of this prospectus), (iii)&nbsp;a constant corporate tax rate of 38.50%; (iv)&nbsp;we will have sufficient taxable income to fully utilize the tax
benefits; (v)&nbsp;Bioventus LLC is able to fully depreciate or amortize its assets; and (vi)&nbsp;no material changes in tax law. For each 5% increase (decrease) in the amount of LLC Interests exchanged by the Continuing LLC Owners, our deferred
tax asset would increase (decrease) by approximately $5.0 million and the related liability for payments under the Tax Receivable Agreement would increase (decrease) by approximately $4.3 million, assuming that the price per share and corporate tax
rate remain the same. These amounts are estimates and have been prepared for informational purposes only. The actual amount of deferred tax assets and related liabilities that we will recognize will differ based on, among other things, the timing of
the redemptions or exchanges, the price of our shares of Class&nbsp;A common stock at the time of the redemptions or exchanges and the tax rates then in effect. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Under the Tax Receivable Agreement, we may elect to terminate the Tax Receivable Agreement early by making an immediate cash payment equal to the present value of all of the tax benefit payments that would be
required to be paid by us to the Continuing LLC Owners under the Tax Receivable Agreement. The calculation of such cash payment would be based on certain assumptions, including, among others (i) that any Continuing LLC Owners&#146; LLC Interests
that have not been exchanged are deemed exchanged, in general, for the market value of our Class A common stock that would be received by such Continuing LLC Owner if such LLC Interests had been exchanged at the time of termination, (ii)&nbsp;we
will have sufficient taxable income in each future taxable year to fully realize all potential tax savings, (iii) the tax rates for future years will be those specified in the law as in effect at the time of termination and (iv)&nbsp;certain
non-amortizable assets are deemed disposed of within specified time periods. In addition, the present value of such tax benefit payments are discounted at a rate equal to the lessor of (i) 6.50% per annum, compounded annually and (ii) LIBOR plus 100
basis points. Assuming that the market value of our Class A common stock were to be equal to $17.00, the midpoint of the price range set forth on the cover of this prospectus and that LIBOR were to be 1.23%, we estimate that the aggregate amount of
these termination payments would be approximately $71.9 million if we were to exercise our termination right immediately following this offering. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
pro forma adjustments are based upon available information and methodologies that are factually supportable and directly related to the Acquisition and the Transactions and are presented for illustrative purposes only. The unaudited pro forma
consolidated financial information includes various estimates which are subject to material change and may not be indicative of what our operations or financial position would have been had the Acquisition and the Transactions, including this
offering, taken place on the dates indicated, or that may be expected to occur in the future. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The pro forma financial information should be read in
conjunction with, &#147;Risk factors,&#148; &#147;Summary historical and unaudited pro forma consolidated financial and other data,&#148; &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; and the
historical consolidated financial statements and related notes included elsewhere in this prospectus. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">83 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Unaudited pro forma consolidated financial information </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Bioventus Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Unaudited pro forma consolidated balance sheet </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>As of April 2, 2016 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(Dollar amounts in thousands)
</B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Bioventus<BR>LLC<BR>historical</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Reorganization<BR>adjustments<BR>(note 2)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Offering<BR>adjustments<BR>(note 3)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Bioventus<BR>Inc.&nbsp;<BR>pro&nbsp;forma</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">26,327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3c</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>
</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">343</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">343</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts receivable, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">51,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">51,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Inventories, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">37,119</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">37,119</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Prepaid expenses and other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,248</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3a</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>
</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,248</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="21" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">99,985</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">24,327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">124,312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,984</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,984</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT><BR></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Goodwill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">58,694</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">58,694</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intangibles assets, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">318,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">318,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">371</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">371</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred tax asset</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">89</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">89</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="21" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">486,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">24,327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">510,591</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="21" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="9"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" COLSPAN="8"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Liabilities and members&#146;/stockholders&#146; equity</B></FONT></P></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accrued liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">30,534</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3c</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>
</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25,558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Note payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(23,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3c</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>
</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current portion of contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current portion of long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current portion of capital lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="21" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">86,799</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(28,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">58,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Long-term debt, less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">145,535</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(57,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3c</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>
</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">87,935</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Long-term revolver</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(19,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3c</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>
</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Contingent consideration, less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">31,136</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">31,136</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Capital lease obligations, less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,030</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,030</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other long-term liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,313</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2a</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>
</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,924</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred tax liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="21" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">299,962</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(105,673</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">191,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="24" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Class&nbsp;A Common Stock </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2a</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>
</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3c</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>
</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Class B Common Stock </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2a</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>
</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Membership equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">284,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(284,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2a</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>
</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Additional paid in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">97,202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2a</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>
</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">129,991</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3c</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>
</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">227,193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated other comprehensive income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2a</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>
</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated (deficit) income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(97,975</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">97,975</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2a</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>
</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Non-controlling interest in subsidiary</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">91,464</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2b</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>
</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">&nbsp;
&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">91,464</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="21" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total members&#146;/stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">186,302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">130,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">318,691</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="21" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total liabilities and equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">486,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">24,327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">510,591</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="24" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>See Notes to the Unaudited Pro Forma Consolidated Financial Information. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">84 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Bioventus Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Unaudited pro forma consolidated statement of operations </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the year ended December 31, 2015 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(Dollar amounts in
thousands, except per share amounts) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Bioventus<BR>LLC<BR>historical</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>Historical</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>BioStructures<BR>LLC from<BR>January&nbsp;1,<BR>2015</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:arial" SIZE="1"><B>through<BR>November&nbsp;24,<BR>2015</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Acquisition<BR>adjustments<BR>(note 1)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Combined<BR>pro forma</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Reorganization<BR>adjustments<BR>(note 2)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Offering<BR>adjustments<BR>(note 3)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Bioventus&nbsp;Inc.<BR>pro&nbsp;forma</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">253,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">12,174</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">265,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">265,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Cost of sales (including depreciation and amortization)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">74,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,595</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1a</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">80,598</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">80,598</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="44" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Gross profit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">179,106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">9,579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(3,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">185,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">185,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Selling, general and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">148,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">6,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(525</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1b</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">154,104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">6,161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3e</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">160,265</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">14,747</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">14,985</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3e</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">15,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Change in fair value of contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">19,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">19,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">19,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Restructuring costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">10,570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,517</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1a</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">12,124</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">12,124</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="44" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Operating income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(16,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,116</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(4,451</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(17,923</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(6,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(24,275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">14,229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">14,243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(7,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3c</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">6,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Other (income) expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,154</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="44" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Other expense, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">15,383</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">15,363</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(7,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">8,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="44" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Loss (income) before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(31,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,136</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(4,451</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(33,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">898</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(32,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="44" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net (loss) income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(34,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,136</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(4,451</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(35,426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2b</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">898</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(34,528</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Less: Net (loss) income attributable to non-controlling interests</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(10,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2b</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">258</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2b</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(9,909</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="44" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net (loss) income attributable to Bioventus</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(34,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,136</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(4,451</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(35,426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">10,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">640</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(24,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="44" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net (loss) income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(34,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,136</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(4,451</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(35,426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accumulated and unpaid preferred distributions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(3,997</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(3,997</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="21" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net loss attributable to common unit holders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(38,108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,136</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(4,451</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(39,423</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="21" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Pro forma net (loss) income per share attributable to Bioventus:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3d</SUP></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3d</SUP></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Pro forma weighted average common shares outstanding:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">23,727,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3d</SUP></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">23,727,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3d</SUP></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="47" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>See Notes to the Unaudited Pro Forma Consolidated Financial Information. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">85 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Bioventus Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Unaudited pro forma consolidated statement of operations </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the three months ended April 2, 2016 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(Dollar amounts
in thousands, except per share amounts) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Bioventus<BR>LLC<BR>historical</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Reorganization<BR>adjustments<BR>(note 2)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Offering<BR>adjustments<BR>(note 3)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Bioventus&nbsp;Inc.<BR>pro&nbsp;forma</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">65,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">65,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Cost of sales (including depreciation and amortization)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">19,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">19,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Gross profit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">46,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">46,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Selling, general and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">40,184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3e</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">41,724</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3e</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,766</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Change in fair value of contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Restructuring costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Operating income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(2,038</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(3,626</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,914</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3c</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,641</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Other (income) expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Other expense, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,408</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,914</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,494</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Loss (income) before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(5,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">326</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(5,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">603</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">603</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net (loss) income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2b</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">326</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(5,723</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Less: Net (loss) income attributable to non-controlling interests</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,736</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2b</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2b</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net (loss) income attributable to Bioventus</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,736</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">232</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(4,080</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net (loss) income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accumulated and unpaid preferred distribution</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,042</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net (loss) attributable to common unit holders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(7,091</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Pro forma net (loss) income per share attributable to Bioventus:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(0.17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3d</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(0.17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3d</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Pro forma weighted average common shares outstanding:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">23,727,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3d</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">23,727,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3d</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="28" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>See Notes to the Unaudited Pro Forma Consolidated Financial Information. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">86 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Bioventus Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Unaudited pro forma consolidated statement of operations </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the three months ended March 28, 2015 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(Dollar amounts
in thousands, except per share amounts) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Bioventus<BR>LLC<BR>historical</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>Historical</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>BioStructures<BR>LLC from<BR>January&nbsp;1,<BR>2015</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:arial" SIZE="1"><B>through<BR>March&nbsp;28,</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>2015</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Acquisition<BR>adjustments<BR>(note 1)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Combined<BR>pro&nbsp;forma</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Reorganization<BR>adjustments<BR>(note 2)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Offering<BR>adjustments<BR>(note 3)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Bioventus&nbsp;Inc.<BR>pro&nbsp;forma</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">53,362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,099</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">56,461</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">56,461</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Cost of sales (including depreciation and amortization)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">16,807</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">603</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">865</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">18,275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">18,275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="33" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Gross profit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">36,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,496</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(865</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">38,186</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">38,186</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Selling, general and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">37,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,453</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">38,723</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3e</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">40,263</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,966</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3e</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,064</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Change in fair value of contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">8,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">8,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">8,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Restructuring costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">379</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="33" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Operating income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(16,299</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">985</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,244</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(16,558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(18,146</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,857</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,727</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3c</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,130</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Other (income) expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">496</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">517</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">517</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="33" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Other expense, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,374</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,727</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="33" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Loss (income) before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(20,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">961</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,244</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(20,932</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(20,793</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="33" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net (loss) income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(21,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">961</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,244</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(21,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2b</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(21,162</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Less: Net (loss) income attributable to non-controlling interests</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(6,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2b</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2b</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(6,073</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="33" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net (loss) income attributable to Bioventus</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(21,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">961</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,244</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(21,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">6,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(15,088</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net (loss) income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(21,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">961</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,244</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(21,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accumulated and unpaid preferred distributions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(953</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(953</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net (loss) attributable to common unit holders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(21,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">961</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,244</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(22,254</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Pro forma net (loss) income per share attributable to Bioventus:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(0.64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3d</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>(0.64</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3d</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Pro forma weighted average common shares outstanding:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">23,727,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3d</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">23,727,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3d</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="36" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>See Notes to the Unaudited Pro Forma Consolidated Financial Information. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">87 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Notes to unaudited pro forma consolidated financial information </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(Dollar amounts in thousands) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>1. BioStructures
acquisition adjustments </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On November&nbsp;24, 2015, Bioventus LLC acquired 100% of the membership interests of BioStructures, LLC, a medical device
company focused on developing innovative propriety platforms in bio-resorbable bone graft products for a broad range of spinal surgical applications. The Acquisition has been accounted for using the acquisition method of accounting in accordance
with ASC 805, Business Combinations, which requires, among other things, that the assets acquired and liabilities assumed be recognized at their acquisition date fair values, with any excess of the consideration transferred over the estimated fair
values of the identifiable net assets acquired recorded as goodwill. The purchase price consisted of cash paid to shareholders on the closing date, a $23,528 note payable to the former BioStructures owners, a $4,960 deferred payment and contingent
consideration of up to $4,542 to be paid upon the receipt of certain premarket notification 510(k) clearances with the FDA. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The accounting for the
Acquisition is preliminary and subject to change. The final accounting for the business combination may differ materially from that presented in these unaudited pro forma consolidated financial statements. As the valuation work is being completed,
any increases or decreases in the fair value of relevant statement of financial position amounts will result in adjustments to the balance sheet and/or statements of operations until the accounting for the business combination is finalized.
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><I>Intangible assets and amortization expense</I>&#151;Adjustment to intangibles reflects the preliminary fair market value related to the change in fair value of identifiable
intangible assets acquired in the transaction. The preliminary fair market value was determined using an income approach. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">The preliminary amounts assigned to identifiable intangible assets and the related amortization expense is as follows (dollar amounts in thousands):
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="95%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Intangible asset</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Estimated<BR>useful life<BR>(years)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Preliminary<BR>fair value</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Amortization<BR>expense
for<BR>the&nbsp;year&nbsp;ended<BR>December&nbsp;31,<BR>2015(ii)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Amortization<BR>expense for
the<BR>three&nbsp;months<BR>ended&nbsp;March&nbsp;28,<BR>2015(iii)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intellectual property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">45,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,523</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">881</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Distributor relationships</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,517</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">379</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">IPR&amp;D</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Trade name</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">73,350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,040</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less: BioStructures historical amounts(i)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Pro forma adjustment</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>4,976</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>1,244</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(i)</FONT></TD>
<TD WIDTH="2%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">BioStructures historical amortization expenses were recorded within cost of sales in the historical financial statements. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(ii)</FONT></TD>
<TD WIDTH="2%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The pro forma adjustment for amortization for the year ended December&nbsp;31, 2015 includes an increase of $3,459 recorded in cost of sales and an increase of $1,517 recorded in
depreciation and amortization. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(iii)</FONT></TD>
<TD WIDTH="2%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The pro forma adjustment for the three months ended March 28, 2015 includes an increase of $865 recorded in cost of sales and an increase of $379 recorded in depreciation and
amortization. </FONT></TD></TR></TABLE> <P STYLE="margin-top:4px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">The fair value of the acquired IPR&amp;D will be an indefinite-lived intangible asset. Once the associated
product is available for sale, the asset is amortized over its remaining estimated useful life. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">The estimated fair value of amortizable
intangible assets is expected to be amortized on a <FONT STYLE="white-space:nowrap">straight-line</FONT> basis over the estimated useful lives. The amortizable lives reflect the periods over which the assets are
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">88 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">
expected to provide economic benefit. With other assumptions held constant, a 10% change in the fair value adjustment for amortizable intangible assets would increase annual pro forma
amortization by approximately $504. In addition, with other assumptions held constant, a one year increase in the estimated useful lives would decrease annual amortization expense by approximately $631 and a one year decrease in the estimated useful
lives would increase amortization expense by approximately $1,052. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><I>Selling, general and administrative expenses</I>&#151;Adjustment reflects the removal of transaction expenses incurred in relation to the Acquisition. These expenses are
directly attributable to the Acquisition and are not expected to have a continuing impact on Bioventus Inc. and therefore have been removed for the purposes of the pro forma consolidated statement of operations. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>2. Reorganization adjustments </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following adjustments are
related to the reorganization of the Company as described in the section entitled &#147;Transactions&#148;. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">As a C-corporation, we will no longer record a members&#146; equity in the consolidated balance sheet. The preferred units of Bioventus LLC, along with their related preferred
return (collectively the liquidation preference), as well as the Equity Participation Right held by one of the Continuing LLC Owners will convert to common units in Bioventus LLC immediately prior to the Transactions. To reflect the <FONT
STYLE="white-space:nowrap">C-corporation</FONT> structure of our equity, we will separately present the value of our Class&nbsp;A common stock, Class B common stock, non-controlling interest in subsidiary, additional paid-in capital and accumulated
deficit. This adjustment represents the issuance of 14,904,090&nbsp;shares of Class&nbsp;A common stock with a par value of $0.001 per share and the issuance of 9,571,764&nbsp;shares of Class B common stock with a par value of $0.001 per share.
Additionally, this adjustment includes the elimination of previously recorded accumulated other comprehensive income (loss) and accumulated (deficit) income of Bioventus LLC and the elimination of the liability of $2,389 previously recorded for the
Equity Participation Right. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">As described in &#147;Transactions&#148;, Bioventus Inc. will become the sole managing member of, own the sole voting interest in, and control the management of Bioventus LLC. As
a result, we will consolidate the financial results of Bioventus LLC and will report a non-controlling interest related to the LLC Interest held by the Continuing LLC Owners on our consolidated balance sheet. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">The computation of the non-controlling interest following the consummation of this offering is as follows: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Units</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">LLC Interests in Bioventus LLC held by Bioventus Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23,727,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">71.3%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Non-controlling interest in Bioventus LLC held by Continuing LLC Owners</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,571,764</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">33,299,383</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0%</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">If the underwriters were to exercise their option to purchase additional shares of our Class&nbsp;A common
stock, Bioventus Inc. would own 72.4% of the economic interest of Bioventus LLC and the Continuing LLC Owners would own the remaining 27.6% of the economic interest of Bioventus LLC. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">In connection with the Transactions, Class B common stock and LLC Interests will be issued to Continuing LLC Owners and their ownership will be
presented as non-controlling interest in Bioventus Inc.&#146;s consolidated financial statements. We will contribute all of the net proceeds of this offering (after deducting underwriting commissions and discounts and certain offering expenses) to
Bioventus LLC in exchange for LLC Interests equal in number to the shares of 23,727,619 Class&nbsp;A common stock issued, representing a controlling interest. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">89 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">The balance of the non-controlling interest and total member&#146;s equity as of April 2, 2016 on a
pro forma basis were calculated as follows (in thousands of dollars): </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Historical Bioventus LLC equity</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">186,302</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net adjustments from the reorganization and this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">132,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total members&#146; equity of Bioventus LLC after the Transactions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">318,691<B></B></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><B></B>&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total Continuing LLC Owners ownership percentage in Bioventus LLC after the Transactions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28.7%</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Non-controlling interest as of April 2, 2016 on a pro forma basis</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">91,464</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Stockholders&#146; equity attributable to common stock on a pro forma basis</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">227,227</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total stockholders&#146; equity at April 2, 2016 on a pro forma basis</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">318,691</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">The Continuing LLC Owners, from time to time following the offering, may require Bioventus LLC to redeem or
exchange all or a portion of their&nbsp;LLC Interests for <FONT STYLE="white-space:nowrap">newly-issued</FONT> shares of Class&nbsp;A common stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis
or, if Bioventus and such members agree, a cash payment equal to the volume weighted average market price of one share of our Class&nbsp;A common stock for each&nbsp;LLC Interest redeemed in accordance with the terms of the Bioventus LLC Agreement;
provided that, at Bioventus&#146; election, Bioventus may effect a direct exchange of such Class&nbsp;A common stock or such cash (if mutually agreed) for such LLC Interests. See &#147;Certain relationships and related party
transactions&#151;Bioventus&nbsp;LLC Agreement.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">The pro forma net (loss) attributable to non-controlling interest is computed as
follows (dollar amounts in thousands): </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Year ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Three&nbsp;months ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>December&nbsp;31, 2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>March&nbsp;28, 2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>April&nbsp;2, 2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Reorganization</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>Offering</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>adjustment</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Reorganization</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>Offering</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>adjustment</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Reorganization</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>Offering</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>adjustment</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net (loss) income(i)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(35,426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">898</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">326</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Non-controlling interests ownership percentage</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="21" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net (loss) income attributable to non-controlling interests</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(10,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">258</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,736</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="24" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(i)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Net (loss) income presented for the Reorganization reflects the combined pro forma net income (loss) after giving effect to the Acquisition. Net (loss) income presented for the
Offering presents the impact on net (loss) income of the Offering adjustments. </FONT></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>3. Offering related adjustments </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">We have been deferring certain costs in our historical financial statements directly associated with this offering, including certain legal, accounting and other related
expenses, which have been recorded in other assets on our consolidated balance sheet. Some of these costs directly associated with this offering were incurred prior to April 2, 2016 and others were incurred subsequent to April 2, 2016. Upon
completion of this offering, approximately $2.0 million of deferred costs will be reversed out of other assets and charged against the proceeds from this offering as a reduction to additional paid-in capital. The total amount of estimated offering
expenses is $3.9&nbsp;million. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We estimate that the net proceeds from this offering, after deducting underwriting discounts and commissions but before estimated offering expenses, will be
approximately $139.5 million, based on an assumed initial public offering price of $17.00 per share, the midpoint of the price range set forth on the cover page of this prospectus. If the underwriters exercise their option to purchase additional
shares in </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">90 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
full, we estimate that the net proceeds will be approximately $160.4 million after deducting underwriting discounts and commissions but before estimated offering expenses.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Assumed initial public offering price per share</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17.00</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Shares of Class&nbsp;A common stock issued in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,823,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Gross proceeds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less: underwriting discounts and commissions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(10,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less: offering expenses (including amounts previously deferred)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash proceeds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">135,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(c)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">We intend to use the proceeds from this offering to purchase 8,823,529 newly issued LLC interests from Bioventus LLC at a purchase price per interest equal to the initial public
offering price per share of Class&nbsp;A common stock less underwriting discounts and commissions and estimated offering expenses payable thereon. We intend to cause Bioventus LLC to use such proceeds (i) to repay all of the outstanding borrowings
under our second lien term loan facility totaling $61.2 million, which includes an estimated early prepayment penalty as well as the write-off of original issue discount and debt issuance costs, (ii) to repay a $23.5 million promissory note and a
$5.0 million deferred payment relating to the Acquisition when due in 2016, (iii) to repay all of the outstanding borrowings under our first lien revolving facility and (iv) with any remaining net proceeds used for general corporate purposes.
Accordingly pro forma adjustments have been made to eliminate previously recorded interest expense of $7.3 million, $1.9&nbsp;million and $1.7 million for the year ended December 31, 2015, the three months ended April 2, 2016 and the three months
ended March 28, 2015, respectively. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(d)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Pro forma basic net income (loss) per share is calculated by dividing net income (loss) attributable to common stockholders by the number of weighted average Class&nbsp;A common
stock outstanding. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year&nbsp;Ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Three&nbsp;months&nbsp;ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share, basic and diluted:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Numerator</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(34,528</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,162</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,723</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less: Net loss attributable to non-controlling interests</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(9,909</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,073</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss attributable to Class A common stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,618</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(15,088</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,080</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Denominator</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Shares of Class A common stock issued in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,823,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,823,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,823,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Shares of Class A common stock held by the Former LLC Owners</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,904,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,904,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,904,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted-average shares of Class A common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23,727,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23,727,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23,727,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In computing the dilutive effect, if any, that the aforementioned exchange would have on earnings per share, we considered that the
net income available to holders of Class&nbsp;A common stock would increase due to elimination of the non-controlling interest in consolidated entities associated with the Class B common stock held (including any tax impact). </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(e)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">In connection with the Transactions we intend to grant new stock based compensation awards to certain of our employees and directors. Accordingly this adjustment reflects
estimated compensation expense of $6,352 for the year ended December 31, 2015, $1,588 for the three months ended March 28, 2015, and $1,588 for the three months ended April 2, 2016, which has been recorded in selling, general and administrative
expenses and research and development expenses. The settlement of the awards under the Phantom Plan is expected to take place on the twelve month anniversary following the date of termination of the Phantom Plan. Our unaudited pro forma consolidated
statements of operations do not include compensation expense related to the settlement of the awards under the Phantom Plan, which is expected to be recognized during the third quarter of 2016. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">91 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_10"></A>Selected financial data </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following table presents the selected financial data for Bioventus LLC and its subsidiaries for the periods and at the dates indicated. Bioventus LLC is the predecessor of the issuer, Bioventus&nbsp;Inc., for
financial reporting purposes. The selected statements of operations data for the years ended December&nbsp;31, 2013, 2014 and 2015 and the selected balance sheet data as of December&nbsp;31, 2014 and 2015 are derived from the Bioventus LLC audited
financial statements appearing elsewhere in this prospectus. The selected statements of operations data for the three months ended March 28, 2015 and April 2, 2016, and the selected balance sheet data as of April 2, 2016 are derived from the
Bioventus LLC unaudited financial statements included elsewhere in this prospectus. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of
management, include all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of the information set forth herein. You should read this data together with our audited and unaudited financial statements
and related notes appearing elsewhere in this prospectus and the information under the captions &#147;Capitalization&#148; and &#147;Management&#146;s discussion and analysis of financial condition and results of operations.&#148; Our historical
results are not necessarily indicative of our future results or any other period and results of interim periods are not necessarily indicative of results for the entire year. The selected financial data included in this section are not intended to
replace the financial statements and the related notes included elsewhere in this prospectus. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have elected to present three years of selected
financial data as permitted under the reduced disclosure requirements available to emerging growth companies. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Years&nbsp;ended&nbsp;December&nbsp;31, </B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Three&nbsp;months&nbsp;ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands, except per share and share<BR>amounts)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2, 2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">232,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">242,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">253,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">53,362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">65,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Cost of sales (including depreciation and amortization of $16,693, $19,622, $22,474, $5,741, and $6,300, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">71,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">75,792</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">74,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">16,807</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">19,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Gross profit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">161,003</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">167,101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">179,106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">36,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">46,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Selling, general and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">150,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">147,058</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">148,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">37,270</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">40,184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">10,936</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">9,465</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">14,747</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,966</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Change in fair value of contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">19,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">8,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,301</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Restructuring costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">7,765</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">8,968</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">10,570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Operating income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(8,068</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(16,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(16,299</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(2,038</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">11,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">11,969</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">14,229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Other (income) expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(596</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,154</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">496</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Other expense, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">12,172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">11,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">15,383</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,408</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Loss before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(20,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(11,353</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(31,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(20,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(5,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">603</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(22,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(12,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(34,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(21,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accumulated and unpaid preferred distributions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(3,610</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(3,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(3,992</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(953</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,042</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net loss attributable to common unit holders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(25,977</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(16,618</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(38,108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(21,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(7,091</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net loss per unit, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(5.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(3.39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(7.78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(4.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Weighted average common units outstanding, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Unaudited pro forma net loss per share:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net loss per share, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(0.64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(0.17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Weighted average shares, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">23,727,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">23,727,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">23,727,619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="22" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">92 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Years ended </B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Three&nbsp;months&nbsp;ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>April 2,<BR>2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Consolidated statement of cash flow data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash (used in) provided by:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> 2,162</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(10,999</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(31,376</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(60,185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(306</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,801</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">31,246</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,495</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Effect of exchange rate changes on cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,428</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(805</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(470</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">197</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net (decrease) increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,963</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,340</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(10,824</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(745</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,216</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of </B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,<BR>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April 2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Balance sheet data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">430,421</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">487,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">486,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">252,932</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">295,014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">299,962</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(56,495</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(91,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(97,975</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total members&#146; equity</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">177,489</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">192,338</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">186,302</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">93 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_11"></A>Management&#146;s discussion and analysis of financial condition and results of
operations </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>The following discussion and analysis of our financial condition and results of operations should be read in conjunction with
&#147;Risk factors,&#148; &#147;Selected financial data&#148; and our consolidated financial statements and the related notes to those statements included elsewhere in this prospectus. In addition to historical consolidated financial information,
the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. Our actual results may differ
materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under &#147;Risk factors&#148; and elsewhere in this prospectus</I>. <I>The following discussion does not give effect to the
Transactions. See &#147;Transactions&#148; and &#147;Unaudited pro forma consolidated financial information&#148; included elsewhere in this prospectus for a description of the Transactions and their effect on our historical results of operations.
</I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Overview </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are a global medical technology
company focused on developing and commercializing innovative and proprietary orthobiologic products for the treatment of patients suffering from a broad array of musculoskeletal conditions. Our products address the growing need for clinically
effective, cost efficient and minimally invasive solutions that enhance the body&#146;s natural healing processes. For the year ended December&nbsp;31, 2015 and three months ended April 2, 2016, we generated $253.7 million and $65.4 million of net
sales, respectively. We operate our business through four reportable segments: Active Healing Therapies&#151;U.S., Active Healing Therapies&#151;International, Surgical and BMP. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our Active Healing Therapies segments offer two types of non-surgical products: our market-leading, non-invasive Exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA,
viscosupplementation therapies for osteoarthritis pain relief. Our Exogen system is a U.S. Food and Drug Administration premarket approved, or PMA, product that offers significant advantages over competitors&#146; long bone stimulation systems,
including shorter treatment times, superior nonunion heal rates based on a comparison of available PMA clinical data and a broader label that is the only label for a long bone growth stimulator for certain fresh fractures. Our two PMA approved HA
viscosupplementation therapies are: Supartz FX, a five injection therapy, which we market in the United States, and GelSyn-3, a three injection therapy, which we expect to launch in the United States in the second half of 2016. We also market
Durolane, a single injection therapy, outside the United States and own certain related assets. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our Surgical segment offers a portfolio of advanced bone
graft substitutes with 510(k) clearance or regulated as HCT/Ps in the United States designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries. These products include our OsteoAMP allogeneic growth factor, a range
of bioactive synthetics, a collagen ceramic matrix, a demineralized bone matrix, or DBM, and allograft comprising demineralized cancellous bone in different preparations. Our development pipeline includes additional bone graft substitute products.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our BMP segment is comprised of proprietary next-generation bone morphogenetic protein, or BMP. Our next-generation BMP product candidates are designed
to offer at least equivalent efficacy at a lower dose administration and provide a better-controlled release to address the safety concerns associated with Infuse, the current market-leading bone graft. Our pre-clinical data are based on animal
models, including non-human primate studies, which may not be indicative of results that we will experience in clinical trials with human subjects. We intend to enter one of our next-generation BMP candidates into Phase 1 clinical trials within 18
months and expect to demonstrate advancement of our product candidates through a number of milestones </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">94 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
over the next two years. However, we cannot determine with certainty the timing of initiation, duration or completion of future clinical trials of our BMP product candidates. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We currently market and sell our products in the United States and 29 other countries. Our Exogen system and Supartz FX, which accounted for the majority of our
revenue for the year ended December 31, 2015, have regulatory approvals to be marketed and sold in the United States. In addition, we also have regulatory approval to market and sell our Exogen system in key international markets, such as the
European Union and Canada. As of April 2, 2016, our sales organization consisted of approximately 232 direct sales representatives and 124 independent distributors in the United States and approximately 57&nbsp;direct sales representatives and 12
independent distributors internationally. In the United States, our Active Healing Therapies sales organization markets our products to orthopedists, musculoskeletal and sports medicine physicians and podiatrists. Our Surgical sales organization is
composed of a sales management team that markets our surgical products primarily to neurosurgeons and orthopedic spine surgeons. In international markets, we market and sell our Active Healing Therapies through direct sales representatives in twelve
countries and through independent distributors in an additional 17 countries. Our products are typically covered and reimbursed by third-party payors, including government authorities, such as Medicare and Medicaid, managed care providers and
private health insurers. We have grown our total net sales from $232.4 million for the year ended December&nbsp;31, 2013, to $242.9 million for the year ended December 31, 2014 and to $253.7&nbsp;million for the year ended December&nbsp;31, 2015, at
a CAGR, of 4.5%. We have grown our total net sales from $53.4 million for the three months ended March 28, 2015, to $65.4 million for the three months ended April 2, 2016, at an annual growth rate of 22.5%. For the years ended December 31, 2013,
2014 and 2015 and the three months ended March 28, 2015 and April 2, 2016, we had net losses of $22.4 million, $12.9 million, $34.1 million, $21.0 million and $6.0 million, respectively. We have grown our Adjusted EBITDA from $32.5&nbsp;million for
the year ended December&nbsp;31, 2013, to $36.2 million for the year ended December 31, 2014 and to $42.2 million for the year ended December&nbsp;31, 2015 at a CAGR of 14.0%. Also, we have grown our Adjusted EBITDA from $2.3 million for the three
months ended March 28, 2015, to $10.7 million for the three months ended April 2, 2016, at an annual growth rate of 365.2%. Adjusted EBITDA is burdened by BMP program costs of $0.7&nbsp;million, $6.7&nbsp;million and $11.3&nbsp;million, for the
years ended December&nbsp;31, 2013, 2014 and 2015, respectively, and $2.5&nbsp;million and $2.5&nbsp;million for the three months ended March&nbsp;28, 2015 and April&nbsp;2, 2016, respectively. For a reconciliation of net loss to Adjusted EBITDA,
see Note&nbsp;3 to the information contained in &#147;Prospectus summary&#151;Summary historical and pro forma financial information.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition
to marketing and selling our existing products, we are engaged in ongoing R&amp;D efforts. Our R&amp;D efforts are focused on our next-generation BMP product candidates as well as bone graft substitutes, including several programs that we recently
acquired through our BioStructures acquisition. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Strategic transactions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Since our inception in May 2012, we have engaged in a series of acquisitions and other strategic transactions to grow the business and broaden our product portfolio. Below is a summary of these transactions.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>BMP portfolio</I></B><B></B>.<B></B>&nbsp;&nbsp;&nbsp;&nbsp;On June&nbsp;27, 2013, we entered into an agreement with Pfizer for an
exclusive, worldwide license to certain parts of Pfizer&#146;s BMP IP portfolio, subject to certain field of use and other restrictions. As part of the license agreement, Pfizer transferred to us certain existing development work for their BMP
assets and agreed to undertake certain early-development activities relating to the next-generation BMP product candidates. Pfizer has also agreed to assign to us, upon the first commercial sale of a product containing next-generation BMP, certain
IP rights relating to next-generation BMP, though we will continue to license certain material background IP from Pfizer under the agreement. Under the terms of the license agreement, we paid Pfizer an upfront cash milestone payment, which was
recorded as an R&amp;D expense in 2013. Additionally, with respect to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">95 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
our next-generation BMP product candidates, we will be obligated to make cash payments upon Phase I of $3.0&nbsp;million, Phase II of $5.0 million, Phase III of $10.0 million, the first
commercial sale in a major market of $25.0 million and a cash payment of $30.0 million upon achieving annual net sales of a product equal to or greater than $300 million. We will also be obligated to make low double digit percentage royalty payments
to Pfizer on sales upon commercialization of any next-generation BMP product covered by the license. Over the next several years, we expect to increase our R&amp;D expenses for our next-generation BMP product candidates as we undergo clinical trials
to demonstrate the safety and efficacy of the product. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Durolane</I></B>.<B><I></I></B>&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;31, 2013, we
entered into an agreement with Galderma S.A. and Q-Med AB to acquire the exclusive distribution rights to Durolane outside the United States. Under the terms of the agreement, we made payments to Galderma S.A. and Q-Med AB of $19.7 million in 2014
and $5.3 million in 2015, including implicit interest. The agreement included an option for us to acquire certain Durolane assets outside the United States, including the Durolane trademark and product registrations and clinical data. We exercised
this option </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">on November&nbsp;16, 2015. Prior to exercising this option, we served as the exclusive distributor of Durolane in Europe, Canada and
Australia. As a result of this acquisition, our Durolane cost of sales have decreased significantly, resulting in a higher gross margin for the product. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>OsteoAMP</I>.&nbsp;&nbsp;&nbsp;&nbsp;On October&nbsp;3, 2014, we entered the surgical orthobiologics market with the asset acquisition of the OsteoAMP product
line, intellectual property and commercial business from Advanced Biologics for a purchase price of approximately $17.7 million in upfront cash ($10.5 million of which was paid upon closing with the remainder paid in February 2015), plus contingent
consideration. This transaction was accounted for using the acquisition method of accounting. The contingent consideration consists of (i)&nbsp;up to $12.0 million for cash earn-out payments upon the achievement of certain net sales targets through
December&nbsp;31, 2019, (ii) a royalty on certain future net sales of OsteoAMP beginning January 1, 2019 and ending December 31, 2023, and (iii)&nbsp;the payment of above-market rate prices for tissue used for the OsteoAMP product pursuant to a
supply agreement with Advanced Biologics ending in October 2018. Based on management assumptions for market rates and future contract revenues, the estimated fair value of the contingent cash consideration payable under the supply agreement is $20.8
million as of December 31, 2015. We will recognize any subsequent changes in the fair value of the contingent consideration in our consolidated statements of operations in the period of the change. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>BioStructures</I>.&nbsp;&nbsp;&nbsp;&nbsp;On November&nbsp;24, 2015, we acquired BioStructures, a developer and marketer of a proprietary range of advanced
bioactive synthetics and other bone graft substitutes for various spinal and orthopedic surgical applications, as well as a pipeline of bone graft substitute products. The purchase price was $81.4 million, including $48.4 million paid in cash at
closing, a $23.5 million note payable to the former BioStructures owners and a deferred payment of $5.0 million, both due on the twelve-month anniversary of the acquisition, and contingent consideration of $4.5 million based on the achievement of
certain regulatory milestones. We expect sales from these acquired bone graft substitutes to increase in the next several years as we grow our Surgical business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>GelSyn-3</I>.&nbsp;&nbsp;&nbsp;&nbsp;On February&nbsp;9, 2016, we entered into an agreement with IBSA where we obtained the exclusive distribution rights for GelSyn-3 in the United States, as well as an
assignment of the related GelSyn-3 trademark. Under the agreement, IBSA will supply <FONT STYLE="white-space:nowrap">GelSyn-3</FONT> on a purchase order basis, based on the amounts of <FONT STYLE="white-space:nowrap">GelSyn-3</FONT> that we require
as set forth in rolling forecasts. We will also be subject to certain annual minimum purchase requirements. We are obligated to use commercially reasonable efforts to launch GelSyn-3 and to diligently market GelSyn-3 in the United States.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain of the foregoing transactions have had a significant impact on our consolidated financial statements for the periods in which they occurred and
they have affected the comparability of these statements for the corresponding comparative periods. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">96 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Outlook </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We
plan to continue to expand our business, increase our net sales and achieve profitability by executing on the following strategies: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Grow our Surgical business by investing in our portfolio and expanding our distribution network. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Advance our next-generation BMP product candidates. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Grow our Active Healing Therapies business through new product introductions and selling strategies. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Selectively pursue business development opportunities. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Focus on continued Adjusted EBITDA growth. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We
expect our Surgical business to be a significant contribution to our growth going forward as we continue to grow our OsteoAMP product at a faster rate than the rest of our business, as well as leverage our recent BioStructures acquisition.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We expect to face challenges as we execute on our business strategy. Our industry is highly competitive, subject to rapid change and significantly
affected by market activities of industry participants, new product introductions and other technological advancements. We believe our experienced management team positions us for success in facing these and other challenges. However, there are a
number of factors affecting our business that are beyond our control. For example, we expect that market demand, government regulation, third-party coverage and reimbursement policies and societal pressures will continue to change the healthcare
industry worldwide, resulting in further business consolidations and alliances among our customers, which may exert further downward pressure on the prices of our products. For information about additional factors that may affect our outlook, see
the &#147;Risk factors&#148; section of this prospectus. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Components of our results of operations </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Net sales </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We generate net sales from a portfolio of
orthobiologic products that meet the needs of our orthopedist, musculoskeletal and sports medicine physician, podiatrist, neurosurgeon and orthopedic spine surgeon customers and their patients. We operate our business through four operating and
reportable segments, Active Healing Therapies &#151; U.S., Active Healing Therapies &#151; International, Surgical and BMP. Within our Active Healing Therapies segment in the United States and certain international markets, we sell our products
through direct sales representatives who manage and maintain the sales relationship with physician practices. In certain international markets, we also sell our Active Healing Therapies to independent distributors on pre-arranged business terms, who
manage or maintain the sales relationship with their physician customers. See Note&nbsp;15 to our consolidated financial statements for the years ended December&nbsp;31, 2015, 2014 and 2013. We recognize revenue when these products are shipped to
the independent stocking distributors and transfer of title to the goods and the risk of loss related to those goods are transferred. Within our Surgical segment in the United States, we consign or loan our products to hospitals so our neurosurgeon
and orthopedic spine surgeon customers can use them in procedures. We recognize revenue based upon the date that our consigned products have been used in a surgical procedure. Our sales are reported net of customer allowances, rebates and returns.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Cost of sales and gross margin </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our cost
of sales primarily consist of costs of products purchased from our third-party suppliers (which includes the entities whose products we distribute), amortization of intellectual property related to our products, direct labor and allocated overhead
associated with the assembly of our Exogen system, excess and obsolete inventory charges, shipping, inspection and related costs incurred in making our products available for sale or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">97 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
use. Our products are generally manufactured by third-party suppliers located in Japan, Sweden and the United States. We receive the components for our Exogen system from suppliers and assemble
each system in-house at our Cordova, Tennessee facility. In the future, we expect our cost of sales to increase in absolute terms due primarily to increased sales volume. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We calculate gross margin as gross profit divided by net sales. Our gross margin has been and will continue to be affected by a variety of factors, including production volumes, costs of products purchased from our
third-party suppliers, product reliability, and implementation over time of cost-reduction strategies. We expect net sales to vary quarter by quarter and therefore our gross profit will likely fluctuate from quarter to quarter. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Selling, general and administrative expenses </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our
selling, general and administrative, or SG&amp;A, expenses primarily consist of salaries, benefits and other related costs, including stock-based compensation, for personnel employed in sales, marketing, finance, legal, compliance, administrative,
information technology, medical education and training, quality and human resource departments. SG&amp;A expenses also include marketing, supply chain and distribution, information technology, legal, human resources, insurance and facilities
expenses. SG&amp;A expenses also include commissions, generally based on a percentage of sales, to direct sales representatives and independent distributors. We expect our SG&amp;A expenses will increase in absolute terms with the continued
expansion of our sales organization and commercialization of our current and pipeline products. We plan to hire more personnel to support the growth of our business. In addition, as a public company, we will be implementing additional procedures and
processes for the purpose of addressing the standards and requirements applicable to public companies. We expect to incur additional annual SG&amp;A expenses related to these additional procedures and processes including, among other things,
increased liability insurance for our directors and officers, director fees, reporting requirements of the SEC, transfer agent fees, hiring additional accounting, legal and administrative personnel, increased auditing and legal fees and similar
expenses. We also expect a change in the timing over which compensation expense is recognized as a result of the termination of the Phantom Plan and the receipt by Phantom Plan participants of shares of Class A common stock upon settlement of their
awards, which settlement is expected to take place on the twelve month anniversary of the date of such termination. However, over time, as we grow our net sales, we expect SG&amp;A expenses to decline slightly as a percentage of net sales.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Research and development expenses </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our
R&amp;D expenses primarily consist of employee compensation, stock-based compensation and related expenses, and contract research organization services related to clinical trials, primarily related to our next-generation BMP product candidates.
Internal R&amp;D costs are expensed as incurred. R&amp;D costs incurred by third parties are expensed as the contracted work is performed. Our R&amp;D expenses may vary substantially from period to period based on the timing of our R&amp;D
activities. Over the next several years, we expect to increase our R&amp;D expenses significantly for our next-generation BMP product candidates as we undergo clinical trials to demonstrate the safety and efficacy of the product in order to gain
regulatory approvals and as we fund clinical trials for other products and develop new products. These increased R&amp;D expenses on our next-generation BMP product candidates could potentially be multiples of our current R&amp;D expenses on the
next-generation BMP product candidates. We expect to incur additional R&amp;D expenses of $8.0 million over the next three years beginning in fiscal 2016 for cash milestone payments we are obligated to pay Pfizer upon the achievement of certain
milestones related to our next-generation BMP product candidates. We cannot determine with certainty the timing of initiation, duration or completion costs of future clinical trials of our next-generation BMP product candidates. See
&#147;Management&#146;s discussion and analysis of financial condition and results of operations &#151;Strategic Transactions &#151; BMP portfolio.&#148; At this time, due to the inherently unpredictable nature of preclinical and clinical
development, we are unable to estimate with any certainty the costs we will incur or the timelines </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">98 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
we will require in the continued development of our next-generation BMP product candidates and any other product candidate that we may develop. Clinical and preclinical development timelines, the
probability of success and development costs can differ materially from expectations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Restructuring costs </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Restructuring costs primarily consist of inventory write downs and employee severance and related expenses associated with the exit from a distribution agreement
with Esaote North America, Inc. for the sale of diagnostic ultrasound machines in the United States. Key assumptions in determining the restructuring costs include the net realizable value of inventory, headcount reductions, as well as terms and
payments that may be negotiated to terminate certain contractual obligations. We do not expect to incur further restructuring costs related to this Esaote agreement. Restructuring costs also include the restructuring and relocation of certain U.S.
finance functions and headcount reductions in our international business to improve operating efficiency. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Depreciation and amortization
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization expense primarily consists of amortization expense related to intellectual property, customer relationships and
other intangible assets acquired. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Interest expense </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Interest expense primarily consists of interest on our first and second lien credit facilities, which we entered into in October 2014. Prior to October 2014, interest expense primarily consisted of interest on a
related party note payable, which was repaid in full from the proceeds of our senior secured credit facilities. We expect to use net proceeds from this offering to repay our second lien term loan facility in full. We have entered into interest rate
swaps in an effort to limit our exposure to changes in the variable interest rate on our first lien term loan. Interest expense includes any fair value losses on these derivatives. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Other (income) expense </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Other (income) expense primarily consists of foreign currency transaction and
remeasurement gains and losses on transactions denominated in currencies other than our functional currency. Our foreign currency transaction and remeasurement gains and losses primarily relate to foreign currency denominated cash, liabilities and
intercompany receivables and payables. In 2014, we entered into a foreign exchange forward contract to hedge against the effect of foreign currency fluctuations on amounts owed in Euros related to the acquisition of certain Durolane assets. This
contract matured in November 2015 and fair value losses are recorded in other (income) expense. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Income tax expense </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Bioventus LLC is treated as a partnership for U.S. federal tax purposes. Accordingly, the profits and losses are passed through to the members and included in their
income tax returns. Certain wholly-owned subsidiaries of Bioventus LLC are taxable entities for United States or foreign tax purposes and file tax returns in their local jurisdictions. Income tax expense includes U.S. federal, state and
international income taxes. Certain items of income and expense are not reported in income tax returns and financial statements in the same year. The income tax effects of these differences are reported as deferred income taxes. Valuation allowances
are provided to reduce the related deferred tax assets to an amount which will, more likely than not, be realized. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">After consummation of this offering, we will become subject to U.S. federal, state and local income taxes with respect to our allocable share of any taxable income
of Bioventus LLC and will be taxed at the prevailing </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">99 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
corporate tax rates. In addition to tax expenses, we will be obligated to make payments under the Tax Receivable Agreement, which could be significant. Under the Tax Receivable Agreement, we will
be obligated to pay to the Continuing LLC Owners 85% of the amount of tax benefits, if any, that we actually realize (or in some circumstances are deemed to realize) as a result of (i) increases in the tax basis of assets of Bioventus LLC obtained
in the future when a Continuing LLC Owner receives shares of our Class&nbsp;A common stock or, if we and such Continuing LLC Owner agree, cash in connection with an exercise of such Continuing LLC Owner&#146;s right to have common units in Bioventus
LLC held by such Continuing LLC Owner redeemed by Bioventus LLC or, at the election of Bioventus, Inc., directly exchanged and (ii) certain other tax benefits related to our making payments under the Tax Receivable Agreement. For more information,
see &#147;Certain relationships and related party transactions&#151;Tax Receivable Agreement.&#148; We intend to cause Bioventus LLC to make distributions in an amount sufficient to allow us to pay our tax obligations, including distributions to
fund any ordinary course payments due under the Tax Receivable Agreement. See &#147;Certain relationships and related party transactions&#151;Bioventus&nbsp;LLC Agreement&#151;Distributions.&#148; </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Adjusted EBITDA </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We use Adjusted EBITDA, a non-GAAP
financial measure, because we believe it is a useful indicator of our operating performance. Our management uses Adjusted EBITDA principally as a measure of our operating performance and believes that Adjusted EBITDA is useful to our investors
because it is frequently used by securities analysts, investors and other interested parties in their evaluation of the operating performance of companies in industries similar to ours. Our management also uses Adjusted EBITDA for planning purposes,
including the preparation of our annual operating budget and financial projections. Adjusted EBITDA is defined as net income before depreciation and amortization, interest expense and provision for income taxes, adjusted for the impact of certain
cash and non-cash and other items that we do not consider in our evaluation of ongoing operating performance. These items include non-cash equity compensation, restructuring costs, contingent consideration, transition costs, severance, purchased
in-process R&amp;D, and OsteoAMP inventory step-up. We have incurred development costs related to our BMP product candidates in each of the past three years, and we expect to incur significant costs related to our BMP product candidates in future
periods. Such costs are not added back in the calculation of our Adjusted EBITDA. Adjusted EBITDA by segment is comprised of net sales and costs directly attributable to a segment, as well as an allocation of corporate overhead costs. The allocation
of corporate overhead costs is determined based on various methods, but was primarily based on a ratio of net sales by segment to total consolidated net sales. For more information regarding our calculation of Adjusted EBITDA, including information
about its limitations as a tool for analysis, please see footnote 2 to the table under &#147;Prospectus summary&#151;Summary historical and pro forma financial data.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">100 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Results of operations </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following table sets forth the components of our consolidated statements of operations in dollars and as a percentage of net sales for the periods presented: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Three months ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands, except for percentages)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March 28, 2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April 2, 2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53,362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">65,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cost of sales (including depreciation and amortization of $5,741 and $6,300, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">16,807</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">31.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">29.4%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Gross profit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">36,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">68.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">46,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">70.6%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Selling, general and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">37,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">69.8%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">40,184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">61.4%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,966</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.6%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in fair value of contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">16.8%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Restructuring costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.3%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.8%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.3%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(16,299</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(30.5)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,038</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3.1)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.4%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other (income) expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">496</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.2)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other expense, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,408</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(20,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(38.7)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8.3)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">603</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(39.4)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(9.3)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table presents a reconciliation of net loss to EBITDA and Adjusted EBITDA for the periods presented: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Three months ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands, except per share and share amounts)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,&nbsp;2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">603</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization(a)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,394</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>EBITDA</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>(8,401</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>7,246</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Non-cash equity compensation(b)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Restructuring costs(c)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Contingent consideration(d)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other corporate expenses(e)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Inventory step-up(f)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">164</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Adjusted EBITDA(g)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2,339</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>10,677</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes depreciation and amortization recorded in cost of sales of $5,741 and $6,300 for the three months ended March 28, 2015 and April&nbsp;2, 2016, respectively, and
depreciation and amortization recorded in R&amp;D expenses of $82 and $7 for the three months ended March 28, 2015 and April&nbsp;2, 2016, respectively, in addition to depreciation and amortization shown on the consolidated statements of operations
and comprehensive loss of $2,571 and $2,830 for the three months ended March 28, 2015 and April 2, 2016, respectively. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents non-cash equity compensation resulting from two equity-based compensation plans, the MIP and the Phantom Plan. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(c)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents restructuring expenses associated with a plan to no longer sell a diagnostic ultrasound product, including employee severance. Also includes the restructuring and
relocation of certain U.S. finance functions and headcount reductions in our international business to improve operating efficiency. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">101 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(d)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents changes in the fair value of contingent consideration related to OsteoAMP acquisition. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(e)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents expenses associated with Bioventus LLC preparing to become a public company, primarily accounting and legal fees. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(f)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents non-cash expense recorded in cost of sales for OsteoAMP and BioStructures inventory subject to valuation step-up as a result of purchase accounting.
</FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(g)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Adjusted EBITDA is burdened by BMP program costs of $2,491 and $2,535 for the three months ended March 28, 2015 and April 2, 2016, respectively. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Results of operations for the three months ended April 2, 2016 compared to the three months ended March 28, 2015 </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Consolidated results of operations </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Net sales
</I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net sales increased $12.0 million, or 22.6%, to $65.4 million during the three months ended April 2, 2016, compared to $53.4 million during the
three months ended March 28, 2015. The increase was due to an increase in net sales of $6.2 million from our Surgical segment, which was formed by the acquisition of OsteoAMP in October 2014 and BioStructures in November 2015, and increases in net
sales of $4.9 million and $0.9 million in our Active Healing Therapies &#151; U.S. and International segments, respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Cost of sales and
gross margin </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Cost of sales increased $2.4 million, or 14.3%, to $19.2 million during the three months ended April 2, 2016, compared to $16.8
million during three months ended March 28, 2015. The increase was primarily due to higher net sales in the three months ended April 2, 2016 and higher intellectual property amortization which increased $0.6 million, or 10.5%, to $6.3&nbsp;million
in the three months ended April 2, 2016, compared to $5.7 million in the three months ended March&nbsp;28, 2015, primarily as a result of the acquisition of BioStructures in November 2015.&nbsp;Gross margin for the three months ended April 2, 2016
increased to 70.6%, compared to 68.5% for the three months ended March 28, 2015. The increase in gross margin was primarily attributable to the increase in the proportion of net sales derived from our Surgical segment. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Selling, general and administrative expenses </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">SG&amp;A
expenses increased $2.9 million, or 7.8%, to $40.2 million during the three months ended April 2, 2016, compared to $37.3 million during the three months ended March 28, 2015. The increase was primarily attributable to increased sales commissions as
a result of higher net sales for the three months ended April 2, 2016 as compared to the three months ended March 28, 2015.&nbsp;This increase was partially offset by lower SG&amp;A expenses for employee healthcare plan costs in the three months
ended April 2, 2016 as compared to the three months ended March 28, 2015. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Research and development expenses </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">R&amp;D expenses increased $0.8 million, or 26.7%, to $3.7 million during the three months ended April 2, 2016, compared to $3.0 million during the three months
ended March 28, 2015. The increase was primarily attributable to increased R&amp;D expenses due to the timing of various studies related to products in our Surgical segment during the three months ended April 2, 2016 as compared to the three months
ended March 28, 2015. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Change in fair value of contingent consideration </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Change in fair value of contingent consideration was $1.3 million during the three months ended April 2, 2016, compared to $9.0 million during the three months ended March 28, 2015. The change in fair value of
contingent consideration during the three months ended March 28, 2015 was attributable to an increase in expected </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">102 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
OsteoAMP net sales and our estimate of future cash earn-out payments payable to Advanced Biologics over the term of the supply agreement, as compared to the amounts that we forecasted at the time
we completed the OsteoAMP acquisition. During the three months ended April 2, 2016, the change in fair value of contingent consideration related to interest accretion for liabilities recorded at fair value. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Restructuring costs </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Restructuring costs decreased
$0.9 million, or 82.0%, to $0.2&nbsp;million, during the three months ended April 2, 2016, compared to $1.1 million during the three months ended March 28, 2015. Restructuring costs in the three months ended March 28, 2015 were primarily
attributable to our decision in January 2015 to discontinue sales of a diagnostic ultrasound product and related sales force reorganization, as well as the restructuring and relocation of certain U.S. finance functions from Memphis, Tennessee to
Durham, North Carolina. Restructuring costs in the three months ended April 2, 2016 were primarily attributable to a plan to improve operating performance in the international business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Depreciation and amortization </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization expense increased $0.3 million, or 11.5%,
to $2.8 million during the three months ended April 2, 2016, compared to $2.6 million during the three months ended March 28, 2015. The increase was primarily attributable to amortization of intangible assets associated with the BioStructures
acquisition in November 2015. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Interest expense </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Interest expense decreased $0.3 million, or 7.7%, to $3.6 million during the three months ended April 2, 2016, compared to $3.9 million during the three months ended March 28, 2015. The decrease was primarily due
to lower non-cash interest related to the amortization of the original issue discount calculated using the effective interest method, partially offset by higher cash interest due to an increase in the LIBOR rate and an increase in the number of
calendar days used to calculate interest in 2016 compared to 2015.</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Other (income) expense </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Other (income) expense improved $0.6 million to an income of $0.1&nbsp;million during the three months ended April&nbsp;2, 2016, compared to an expense of $0.5
million during the three months ended March 28, 2015. The increase was attributable to foreign currency fluctuations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Income tax expense
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense increased $0.2 million to $0.6 million during the three months ended April 2, 2016, compared to $0.4 million during the three
months ended March 28, 2015. The increase was primarily due to an increase in taxable income of the taxable subsidiaries during the three months ended April 2, 2016 as compared to the three months ended March 28, 2015. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Segment results </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table sets forth for
the periods indicated our net sales by operating segment, with changes in net sales between the specific periods expressed in dollar amounts and as a percentage. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Three months ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Change</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April 2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Active Healing Therapies &#151; U.S.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">40,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">45,496</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,924</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Active Healing Therapies &#151; International</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,794</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11.8%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Surgical</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,926</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,186</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">125.6%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">103 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Active Healing Therapies &#151; U.S. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Net sales for our Active Healing Therapies &#151; U.S. segment increased by $4.9 million, or 12.1%, to $45.5 million during the three months ended April 2, 2016, compared to $40.6 million during the three months
ended March&nbsp;28, 2015. The increase was primarily due to four additional selling days in the three months ended April 2, 2016 compared to the three months ended March 28, 2015, as well as organic growth of both Exogen and Supartz, primarily due
to increased volume. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Active Healing Therapies &#151; International </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Net sales for our Active Healing Therapies &#151; International segment increased by $0.9 million, or 11.8%, to $8.8&nbsp;million during the three months ended April 2, 2016, compared to $7.9 million during the
three months ended March 28, 2015. The increase was primarily due to four additional selling days in the three months ended April 2, 2016 compared to the three months ended March 28, 2015. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Surgical </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net sales for our Surgical segment increased by $6.2 million, or 125.6%, to $11.1 million
during the three months ended April 2, 2016, compared to $4.9 million during the three months ended March 28, 2015. The increase was primarily due to organic growth of the OsteoAMP product line of $1.9 million attributable to increased volume and
the inclusion of the BioStructures product line sales of $4.3 million for the three months ended April 2, 2016 compared to $0 for the three months ended March 28, 2015. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Adjusted EBITDA for each of our reportable segments was as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Three months ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Change</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April 2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Active Healing Therapies &#151; U.S.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,006</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">314.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Active Healing Therapies &#151; International</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,660</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">689</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">71.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Surgical</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,686</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,546</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">860</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">51.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">BMP expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,491</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,535</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.8%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Active Healing Therapies &#151; U.S. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Adjusted EBITDA for our Active Healing Therapies &#151; U.S. segment increased by $6.8&nbsp;million, or 314.5%, to $9.0&nbsp;million during the three months ended April 2, 2016, compared to $2.2 million during the
three months ended March 28, 2015. This increase was primarily due to higher net sales, lower employee healthcare plan costs and lower marketing costs. These increases were partially offset by higher costs of goods sold and higher sales commissions.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Active Healing Therapies &#151; International </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Adjusted EBITDA for our Active Healing Therapies &#151; International segment increased $0.7&nbsp;million, or 71.0%, to $1.7 million during the three months ended April 2, 2016, compared to $1.0&nbsp;million during
the three months ended March 28, 2015. This increase was primarily due to higher net sales, which was partially offset by higher costs of goods sold and higher sales commissions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Surgical </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Adjusted EBITDA for our Surgical segment increased $0.9&nbsp;million, or 51.0%, to
$2.5&nbsp;million during the three months ended April 2, 2016, compared to $1.7 million during the three months ended March 28, 2015. We acquired the BioStructures product line in November 2015. The three months ended April 2, 2016 was the first
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">104 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
full three months that our Surgical segment was included in operating results for both OsteoAMP and BioStructures.&nbsp;The three months ended March 28, 2015 included operating results from
OsteoAMP only.&nbsp;&nbsp;&nbsp;&nbsp; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>BMP </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">BMP expense was flat&nbsp;at&nbsp;$2.5 million during the three months ended April 2, 2016, compared to $2.5 million during the three months ended March 28, 2015.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table sets forth the components of our consolidated statements of operations in dollars and as a percentage of net sales for the periods
presented: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>(in thousands, except for percentages)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">232,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">242,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">253,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cost of sales (including depreciation and amortization of $16,693, $19,622 and $22,474, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">71,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">30.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">75,792</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">31.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">74,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">29.4%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Gross profit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">161,003</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">69.3%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">167,101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">68.8%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">179,106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">70.6%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Selling, general and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">150,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">64.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">147,058</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">60.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">148,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">58.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,936</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,465</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,747</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.8%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in fair value of contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Restructuring costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,765</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.3%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,968</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,068</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3.5)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(16,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6.5)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,969</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.6%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other (income) expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.3%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(596</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.2)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,154</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other expense, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12,172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15,383</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(20,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8.7)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,353</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4.7)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(31,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12.6)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.6%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.8%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(22,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(9.6)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5.3)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(34,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(13.4)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="20" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table presents a reconciliation of net loss to EBITDA and Adjusted EBITDA for the periods presented: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands, except per share and share amounts)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(22,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(34,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest expense, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,969</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization(a)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">24,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28,820</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">33,078</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>EBITDA</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>15,677</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>29,436</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>15,336</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Non-cash equity compensation(b)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">576</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,325</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Restructuring costs(c)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Contingent consideration(d)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Transition costs(e)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,690</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other corporate expense(f)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Severance(g)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,542</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Inventory step-up(h)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,629</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">280</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Purchased in-process R&amp;D-BMP(i)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Adjusted EBITDA(j)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>32,485</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>36,193</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>42,186</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">Includes depreciation and amortization recorded in cost of sales of $16,693, $19,622 and $22,474 for the years ended December&nbsp;31, 2013, 2014, and 2015,
respectively, and depreciation and amortization recorded in R&amp;D expenses of $0, $230 and $34 for the years ended December 31, </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">105 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="1">
2013, 2014 and 2015, respectively, in addition to depreciation and amortization shown on the consolidated statements of operations and comprehensive loss of $7,765, $8,968 and $10,570 for the
years ended December 31, 2013, 2014 and 2015, respectively. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents non-cash equity compensation resulting from two equity-based compensation plans, the MIP and the Phantom Plan. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(c)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents restructuring expenses associated with a plan to no longer sell a diagnostic ultrasound product, including employee severance. Additionally this includes a provision
for inventory of $1,183 and $202 in 2014 and 2015, respectively, which is included in cost of sales. Also includes the restructuring and relocation of certain U.S. finance functions and headcount reductions in our international business to improve
operating efficiency. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(d)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents expense related to changes in the fair value of contingent consideration related to the OsteoAMP acquisition. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(e)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents expenses related to the transition of Bioventus LLC to become a separate entity as a result of the divestiture from Smith &amp; Nephew, such as product rebranding,
legal fees and consulting expenses. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(f)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents expenses associated with Bioventus LLC preparing to become a public company, primarily accounting and legal fees. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(g)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents 2013 severance costs related to headcount reductions as a result of the divestiture from Smith &amp; Nephew. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(h)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents non-cash expense recorded in cost of sales for OsteoAMP and BioStructures inventory subject to valuation step-up as a result of purchase accounting.
</FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(i)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents initial expense paid to Pfizer to acquire certain rights related to our next-generation BMP product candidates. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(j)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Adjusted EBITDA is burdened by BMP program costs of $650, $6,682, and $11,309 for the years ended December 31, 2013, 2014, and 2015, respectively. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">106 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Results of operations for the year ended December 31, 2015 compared to the year ended December 31, 2014
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Consolidated results of operations </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Net sales </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net sales increased $10.8 million, or 4.5%, to
$253.7 million during the fiscal year ended December 31, 2015, compared to $242.9 million during the fiscal year ended December&nbsp;31, 2014. The increase was due to an increase in net sales from our Surgical segment of $21.6 million which was
formed by the acquisition of OsteoAMP in October 2014, partially offset by a decrease in net sales of $8.3 million and $2.6 million in our Active Healing Therapies &#151; International and U.S. segments, respectively. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Cost of sales and gross margin </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Cost of sales
decreased $1.3 million, or 1.7%, to $74.5 million during the fiscal year ended December 31, 2015, compared to $75.8 million during fiscal year ended December 31, 2014. The decrease was primarily due to higher cost of sales in 2014 resulting from
inventory subject to valuation step-up as required by purchase accounting related to the OsteoAMP acquisition, a $1.2 million inventory reserve associated with a plan to no longer sell a diagnostic ultrasound product and lower cost of sales in 2015
resulting from lower costs of Durolane. These decreases were partially offset by higher product intellectual property amortization which increased $2.9 million, or 14.8%, to $22.5 million in the fiscal year ended December 31, 2015, compared to
$19.6&nbsp;million in the fiscal year ended December 31, 2014, primarily as a result of the acquisition of OsteoAMP in October 2014. Gross margin for the fiscal year ended December 31, 2015 increased to 70.7%, compared to 69.3% for the fiscal year
ended December 31, 2014. The increase in gross margin was primarily attributable to the increase in the proportion of net sales derived from our Surgical segment. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Selling, general and administrative expenses </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">SG&amp;A expenses increased $1.4 million, or 0.9%, to
$148.4 million during the fiscal year ended December&nbsp;31, 2015, compared to $147.1 million during the fiscal year ended December 31, 2014. The increase was attributable to $12.7 million of increased SG&amp;A expenses, including sales
commissions, related to the inclusion of OsteoAMP for a full year and BioStructures for one month in our consolidated results of operations for 2015. This increase was partially offset by an $7.1 million decrease in SG&amp;A expenses in the Active
Healing Therapies &#151; U.S. segment due to lower sales commissions as a result of lower sales compared to the year ended December&nbsp;31, 2014, a one-time legal settlement and related fees recorded in 2014 pertaining to a pre-acquisition legal
matter shared equally with Smith &amp; Nephew, and other cost savings initiatives in 2015. In addition, the Active Healing Therapies &#151; International segment experienced a $4.4 million decrease in SG&amp;A expenses due to cost savings
initiatives in 2015 and lower sales commissions as a result of lower sales compared to the year ended December&nbsp;31, 2014. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Research and
development expenses </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">R&amp;D expenses increased $5.3 million, or 55.8%, to $14.7 million during the fiscal year ended December 31, 2015,
compared to $9.5 million during the fiscal year ended December 31, 2014. The increase was primarily attributable to increased preclinical costs of $4.6 million associated with our next-generation BMP product candidates plus other increased R&amp;D
expenses of $0.7 million. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Change in fair value of contingent consideration </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Change in fair value of contingent consideration was $19.5 million during the fiscal year ended December 31, 2015, compared to $1.6 million during the fiscal year ended December 31, 2014. The change in fair value
of contingent consideration during the fiscal year ended December 31, 2015 is attributable to an increase in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">107 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
expected OsteoAMP net sales and our estimate of future cash earn-out payments payable to Advanced Biologics over the term of the supply agreement, as compared to the amounts that we forecasted at
the time we completed the OsteoAMP acquisition. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Restructuring costs </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Restructuring costs were $2.4&nbsp;million, during the fiscal year ended December&nbsp;31, 2015. Restructuring costs in 2015 were primarily attributable to our decision in January 2015 to discontinue sales of a
diagnostic ultrasound product and related sales force reorganization. 2015 restructuring costs also include restructuring and relocation of certain U.S. finance functions and headcount reductions in our international business to improve operating
efficiency. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Depreciation and amortization </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization expense increased $1.6 million, or 17.9%, to $10.6 million during the fiscal year ended December 31, 2015, compared to $9.0 million
during the fiscal year ended December 31, 2014. The increase was primarily attributable to amortization of intangible assets associated with the OsteoAMP acquisition in October 2014. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Interest expense </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Interest expense increased $2.3 million, or 18.9%, to $14.2 million during the fiscal
year ended December 31, 2015, compared to $12.0 million during the fiscal year ended December 31, 2014. Interest expense in 2014 was lower primarily due to the refinancing of the Smith &amp; Nephew debt in October 2014, which resulted in the
elimination of the unamortized loan premium. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Other (income) expense </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Other (income) expense increased $1.8 million to an expense of $1.2&nbsp;million during the fiscal year ended December 31, 2015, compared to an income of $(0.6) million during the fiscal year ended December 31,
2014. The increase was attributable to foreign currency fluctuations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Income tax expense </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense increased $0.6 million to $2.1 million during the fiscal year ended December 31, 2015, compared to $1.5 million during the fiscal year ended
December 31, 2014. Income tax expense in 2014 was lower than 2015 primarily due to a $0.9 million state tax refund received in 2014 related to the move of our headquarters from Tennessee to North Carolina in 2012. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Segment results </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table sets forth for
the periods indicated our net sales by operating segment, with changes in net sales between the specific periods expressed in dollar amounts and as a percentage. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Change</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Active Healing Therapies &#151; U.S.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">194,568</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">192,014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,554</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.2)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Active Healing Therapies &#151; International</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">44,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35,847</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18.9)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Surgical</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25,789</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">21,639</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">521.4%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Active Healing Therapies &#151; U.S. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net sales for our Active Healing Therapies &#151; U.S. segment decreased by $2.6 million, or 1.2%, to $192.0 million during the fiscal year ended December 31, 2015,
compared to $194.6 million during the fiscal year ended </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">108 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
December 31, 2014. The decrease was primarily due to the decision in January 2015 to discontinue sales of a diagnostic ultrasound product which accounted for $3.9 million in net sales in 2014 and
$0 in 2015. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Active Healing Therapies &#151; International </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Net sales for our Active Healing Therapies &#151; International segment decreased by $8.3 million, or 18.9%, to $35.8 million during the fiscal year ended December 31, 2015, compared to $44.2 million during the
fiscal year ended December 31, 2014. The decrease was due to unfavorable foreign currency translation adjustments of $5.7 million, $1.1 million related to the termination of our Russian distributor relationship and $1.5 million due to increased
competition for our Exogen system and Durolane and increased pressure from third-party payers on coverage limits. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Surgical </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net sales for our Surgical segment increased by $21.6 million, or 521.4%, to $25.8 million during the fiscal year ended December 31, 2015, compared to $4.2 million
during the fiscal year ended December 31, 2014. We acquired OsteoAMP in October 2014, therefore the fiscal year ended December 31, 2015 was the first full year of operating results for our Surgical segment compared to three months in fiscal 2014.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Adjusted EBITDA for each of our reportable segments was as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Change</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Active Healing Therapies &#151; U.S.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">33,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">40,161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,695</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">20.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Active Healing Therapies &#151; International</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,035</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(13.3)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Surgical</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,631</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,591</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,960</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">304.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">BMP expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,682</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,627</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(69.2)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Active Healing Therapies &#151; U.S. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Adjusted EBITDA for our Active Healing Therapies &#151; U.S. segment increased by $6.7&nbsp;million, or 20.0%, to $40.2&nbsp;million during the fiscal year ended December 31, 2015, compared to $33.5 million during
the fiscal year ended December 31, 2014. The net sales decrease of $2.6 million from the prior year was offset by lower costs of goods sold, lower sales commissions, SG&amp;A cost savings initiatives and lower legal and professional costs during the
fiscal year ended December 31, 2014 relating to the settlement of a pre-acquisition legal matter shared equally with Smith &amp; Nephew. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Active
Healing Therapies &#151; International </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Adjusted EBITDA for our Active Healing Therapies &#151; International segment decreased
$1.0&nbsp;million, or 13.3%, to $6.7 million during the fiscal year ended December 31, 2015, compared to $7.8&nbsp;million during the fiscal year ended December 31, 2014. The net sales decrease of $8.3 million from the prior year was partially
offset by lower cost of goods sold, lower sales commissions and SG&amp;A savings initiatives. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Surgical </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Adjusted EBITDA for our Surgical segment increased $5.0&nbsp;million, or 304.1%, to $6.6&nbsp;million during the fiscal year ended December 31, 2015, compared to
$1.6 million during the fiscal year ended December 31, 2014. We acquired the OsteoAMP product line in October 2014, therefore the fiscal year ended December 31, 2015 was the first full year of operating results for our Surgical segment compared to
three months in fiscal 2014. Additionally, Adjusted EBITDA for fiscal 2015 included one month of operating results from our BioStructures acquisition. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">109 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>BMP </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">BMP
expense increased $4.6 million to $11.3 million during the fiscal year ended December 31, 2015, compared to $6.7 million during the fiscal year ended December 31, 2014. During 2015, we significantly advanced the program through the design and
development of a new protein molecule and advanced related carrier technology that enables a more targeted, controlled release of BMP. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Results of
operations for the year ended December&nbsp;31, 2014 compared to the year ended December&nbsp;31, 2013 </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Consolidated results of operations
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Net sales </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net sales increased $10.5
million, or 4.5%, to $242.9 million during the fiscal year ended December&nbsp;31, 2014, compared to $232.4 million during the fiscal year ended December&nbsp;31, 2013. The increase was attributable to an increase of $8.9 million from our Active
Healing Therapies &#151; International segment, partially offset by a decrease of $2.6&nbsp;million from our Active Healing Therapies &#151; U.S. segment. An increase of $4.2 million was attributable to our Surgical segment that was formed with the
acquisition of the OsteoAMP product line in October 2014. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Cost of sales and gross margin </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Cost of sales increased $4.4 million, or 6.2%, to $75.8 million during the fiscal year ended December&nbsp;31, 2014, compared to $71.4 million during the fiscal
year ended December&nbsp;31, 2013. The increase was primarily attributable to an increase of $2.9 million in amortization expense in 2014 and the inclusion of cost of sales from OsteoAMP, which we acquired in October 2014, and a $1.2 million
inventory reserve associated with a plan to no longer sell a diagnostic ultrasound product. These increases were partially offset by a reduction in cost of sales for Durolane as a result of the acquisition of certain Durolane assets outside the
United States in 2013. Gross margin for the fiscal years ended December&nbsp;31, 2014 and December&nbsp;31, 2013 were 69.3% and 68.8%, respectively. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Selling, general and administrative expenses </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">SG&amp;A
expenses decreased $3.3 million, or 2.2%, to $147.1 million during the fiscal year ended December 31, 2014, compared to $150.4 million during the fiscal year ended December 31, 2013. The decrease was primarily attributable to lower transition costs
of $4.6 million and lower severance costs of $4.5 million. These decreases were partially offset by higher SG&amp;A expenses in 2014, including $1.8 million relating to the OsteoAMP acquisition in October 2014, $1.0 million for a legal settlement
and related fees pertaining to a pre-acquisition legal matter shared equally with Smith &amp; Nephew, and higher sales commissions as a result of increased sales in our Active Healing Therapies &#151; International segment. In addition, SG&amp;A
expenses were higher in 2014 due to the transition to a company-operated sales force arrangement in the International segment from the distribution arrangement with Smith &amp; Nephew established with the spin-out from Smith &amp; Nephew in May
2012. Under the distribution arrangement, Smith &amp; Nephew marketed and sold products outside the United States on our behalf until the completion of the transition to our sales force in 2014. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Research and development expenses </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">R&amp;D expenses
decreased $1.5&nbsp;million, or 13.5%, to $9.5 million during the fiscal year ended December&nbsp;31, 2014, compared to $10.9 million during the fiscal year ended December&nbsp;31, 2013. In 2013, we paid Pfizer an initial upfront cash payment for an
exclusive, worldwide license subject to certain field of use and other restrictions to certain parts of Pfizer&#146;s BMP portfolio, which was recorded as in-process R&amp;D expenses in 2013. Excluding this expense of $7.0&nbsp;million in 2013,
R&amp;D expenses increased by $5.6&nbsp;million during the fiscal year ended December&nbsp;31, 2014. This increase was primarily attributable to a $6.0&nbsp;million increase in R&amp;D expenses related to the development of our BMP product
candidates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">110 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Change in fair value of contingent consideration </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Change in fair value of contingent consideration was $1.6 million during the fiscal year ended December&nbsp;31, 2014, compared to $0 during the fiscal year ended
December&nbsp;31, 2013. The change in fair value of contingent consideration during the fiscal year ended December&nbsp;31, 2014, is attributable to an increase in expected OsteoAMP net sales and our estimate of future cash earn-out payments payable
to Advanced Biologics over the term of the supply agreement, as compared to the amounts that we forecasted at the time we completed the OsteoAMP acquisition. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Depreciation and amortization </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization increased $1.2 million, or 15.5%, to $9.0
million during the fiscal year ended December&nbsp;31, 2014, compared to $7.8 million during the fiscal year ended December&nbsp;31, 2013. The increase was primarily attributable to depreciation of fixed assets brought into service in 2014 and
amortization of intangible assets associated with the OsteoAMP acquisition in October 2014. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Interest expense </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Interest expense increased $0.5 million, or 4.5%, to $12.0 million during the fiscal year ended December&nbsp;31, 2014, compared to $11.5 million during the fiscal
year ended December&nbsp;31, 2013 primarily due to fluctuations in the amount of our outstanding indebtedness and changes in the applicable interest rate. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Other (income) expense </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Other (income) expense
improved by $1.3 million, or 184%, to income of $0.6 million during the fiscal year ended December&nbsp;31, 2014, compared to an expense of $0.7 million during the fiscal year ended December&nbsp;31, 2013. The improvement was attributable to foreign
currency fluctuations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Income tax expense </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense decreased $0.6 million, or 27.2%, to $1.5 million during the fiscal year ended December&nbsp;31, 2014, compared to $2.1 million during the fiscal
year ended December&nbsp;31, 2013. The decrease was primarily due to a $0.9 million state tax refund received in 2014 related to the move of our headquarters from Tennessee to North Carolina in 2012. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Segment results </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table sets forth for
the periods indicated our net sales by operating segment, with changes in net sales between the specific periods expressed in dollar amounts and as a percentage. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year
ended</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Change</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Active Healing Therapies &#151; U.S.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">197,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">194,568</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.3)%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Active Healing Therapies &#151; International</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35,257</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">44,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,918</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25.3%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Surgical</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">NM</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Active Healing Therapies &#151; U.S. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Net sales for our Active Healing Therapies &#151; U.S. segment decreased by $2.6 million, or 1.3%, to $194.6 million during the fiscal year ended December 31, 2014, compared to $197.1 million during the fiscal year
ended December 31, 2013. The decrease was primarily due to declining sales of the diagnostic ultrasound product to $3.9 million in 2014 from $5.1 million in 2013. Sales of diagnostic ultrasound were discontinued in January 2015. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">111 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Active Healing Therapies &#151; International </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Net sales for our Active Healing Therapies &#151; International segment increased by $8.9 million, or 25.3%, to $44.2 million during the fiscal year ended December 31, 2014, compared to $35.3 million during the
fiscal year ended December 31, 2013. The increase was primarily attributable to the completion of the transition of all of the international assets from Smith &amp; Nephew during 2014. A distribution arrangement with Smith &amp; Nephew was
established with the spin-out from Smith &amp; Nephew in May 2012. Under the distribution arrangement, Smith &amp; Nephew marketed and sold products outside the United States on our behalf until the completion of the transition to our sales force in
2014. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Surgical </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net sales for our Surgical
segment increased by $4.2 million during the fiscal year ended December 31, 2014, compared to $0 million during the fiscal year ended December 31, 2013 due to the acquisition of OsteoAMP in October 2014, which formed our Surgical business.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Adjusted EBITDA for each of our reportable segments was as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Change</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Active Healing Therapies &#151; U.S.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32,557</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">33,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">909</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.8%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Active Healing Therapies &#151; International</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">578</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,245.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Surgical</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,631</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,631</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">NM</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">BMP expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(7,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,682</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">968</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12.6%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Active Healing Therapies &#151; U.S. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Adjusted EBITDA for our Active Healing Therapies &#151; U.S. segment increased by $0.9 million, or 2.8%, to $33.5&nbsp;million during the fiscal year ended December&nbsp;31, 2014, compared to $32.6 million during
the fiscal year ended December&nbsp;31, 2013. The sales decrease of $2.5 million from the prior year was offset by lower costs of goods sold, lower sales commissions, SG&amp;A cost savings initiatives and lower R&amp;D expenses. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Active Healing Therapies &#151; International </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Adjusted EBITDA for our Active Healing Therapies &#151; International segment of $7.8 million during the fiscal year ended December 31, 2014, increased by $7.2
million, when compared to $0.6 million during the fiscal year ended December 31, 2013. The increase was primarily attributable to increased sales and earnings related to the transition of all of the intangible assets from Smith &amp; Nephew and the
completion of the transition in 2014 from the distribution arrangement with Smith &amp; Nephew to a company-operated sales force arrangement in our International segment. The distribution arrangement with Smith &amp; Nephew was initially established
with the spin-out from Smith &amp; Nephew in May 2012. Under the distribution arrangement, Smith &amp; Nephew marketed and sold products outside the United States on our behalf until the completion of the transition to our sales force in 2014. In
addition, the acquisition of certain Durolane assets outside the United States resulted in lower cost of goods sold for Durolane in 2014. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Surgical
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Adjusted EBITDA for our Surgical segment was $1.6 million during the fiscal year ended December&nbsp;31, 2014, compared to $0 during the fiscal
year ended December&nbsp;31, 2013. We acquired the OsteoAMP product line in October 2014, therefore there were no Surgical operating results or Adjusted EBITDA during the fiscal year ended December&nbsp;31, 2013. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">112 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>BMP </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">BMP
expense decreased $1.0 million, or 12.6%, to $6.7 million during the fiscal year ended December&nbsp;31, 2014, compared to $7.7 million during the fiscal year ended December 31, 2013. During 2013, we paid Pfizer an upfront cash payment for an
exclusive, worldwide license subject to certain field of use and other restrictions to certain parts of Pfizer&#146;s BMP portfolio. Excluding the initial upfront payment, BMP activity increased significantly during 2014, resulting in additional
R&amp;D costs of $6.0 million when compared to the fiscal year ended December&nbsp;31, 2013. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Seasonality and quarterly results of operations data
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our business is seasonal in nature primarily due to the variability of the U.S. healthcare insurance industry. The majority of U.S. healthcare
insurance plans renew annually at the beginning of January. As a result of individuals changing insurance companies and the reset of insurance plan deductibles, our quarterly net sales are typically lower in the first quarter of the year and highest
in the fourth quarter. Additionally, our results from quarter to quarter may be influenced by a number of factors, including, but not limited to: the number of available selling days, which can be impacted by holidays; the mix of products sold; the
geographic mix of where products are sold; the demand for our products and the products of our competitors; the timing of or failure to obtain regulatory approvals or clearances for products; increased competition; the timing of customer orders;
inventory write-offs and write-downs; costs, benefits and timing of new product introductions; the availability and cost of components and supplies and fluctuations in foreign currency exchange rates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">113 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table sets forth our unaudited quarterly consolidated statements of operations data and other data for
each of the nine most recent quarters in the period ended April 2, 2016. We have prepared the quarterly consolidated results of operations data on a consistent basis with the audited consolidated financial statements included elsewhere in this
prospectus. In the opinion of management, the quarterly results of operations data reflects all necessary adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of this data. The consolidated statements of
operations data should be read in conjunction with the consolidated financial statements and related notes included elsewhere in this prospectus. The results of historical periods are not necessarily indicative of results for a full year or for any
future period. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="34" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Three months ended </B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands, except<BR>percentages)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;29,<BR>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>June&nbsp;28,<BR>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>September<BR>27,<BR>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December<BR>31,<BR>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>June&nbsp;27,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>September<BR>26,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>December<BR>31,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50,820</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">61,549</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">60,899</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">69,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53,362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">65,794</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">63,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">71,161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">65,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cost of sales (including depreciation and amortization)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15,164</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,536</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23,269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">16,807</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,413</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">20,185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Gross profit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35,656</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">42,725</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">42,363</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">46,356</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">36,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">46,381</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">45,194</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50,976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">46,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Selling, general and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34,609</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35,211</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">36,927</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">40,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">37,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">36,909</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35,272</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">38,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">40,184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">R&amp;D expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,378</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,984</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,782</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,321</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,966</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,099</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,895</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,528</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Restructuring costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">408</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">128</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">831</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,094</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,130</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,566</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,720</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating<BR>income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,386</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">524</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(16,299</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">477</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,832</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,038</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,392</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,943</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,258</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,711</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other (income) expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">257</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">496</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">523</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other expense, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,129</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,551</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,738</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,408</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,554</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,027</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(20,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,304</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,672</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,346</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense (benefit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">663</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(153</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">258</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">603</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(770</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,341</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,085</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,078</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Liquidity and capital resources </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Overview </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our principal liquidity needs have historically been for acquisitions, working capital,
R&amp;D, clinical trials, and capital expenditures. We expect these needs to continue as we develop and commercialize new products, hire additional direct sales representatives and further our expansion into international markets. Over the next
several years, we expect to increase our R&amp;D expenses for our next-generation BMP product candidates as we undergo clinical trials to demonstrate the safety and efficacy of the product. To date, we have funded our operations primarily with cash
flow from operations and borrowings under our revolving credit facility. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of April 2, 2016, we had $6.2 million in cash and cash equivalents and $6.7
million of working capital, compared to $5.0&nbsp;million and $11.3 million, respectively at December 31, 2015 and compared to $15.8 million and $27.3 million, respectively, on December&nbsp;31, 2014. As of April 2, 2016, we had outstanding
indebtedness of $19.5 million under our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">114 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
revolving credit facility (leaving availability of $20.5&nbsp;million) and $163.5&nbsp;million under our term loan facilities. Accessing availability under our revolving credit facility is
subject to compliance with the financial covenants and other customary conditions precedent. Pursuant to the terms of the first lien term loan facilities, we are required to make quarterly payments of between $1.4 million and $5.8&nbsp;million up to
September 2019, with the remaining balance of $40.3 million due on October&nbsp;10, 2019, the maturity date of the first lien term loan facilities. The aggregate principal amount of $60.0&nbsp;million under our second lien term facility is due in
full on April&nbsp;10, 2020. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that our existing cash and cash equivalents, borrowing capacity under our revolving credit facility, cash flow
from operations and net proceeds from this offering will be sufficient in the aggregate to meet our anticipated cash requirements for at least the next twelve months. We may, however, require additional liquidity as we continue to execute our
business strategy. Our liquidity may be negatively impacted as a result of a decline in sales of our products, including declines due to changes in our customers&#146; ability to obtain third-party coverage and reimbursement for procedures that use
our products, increased pricing pressures resulting from intensifying competition and cost increases, in addition to general economic and industry factors. We anticipate that to the extent that we require additional liquidity, it will be funded
through the incurrence of other indebtedness, additional equity financings or a combination of these potential sources of liquidity. In addition, we may raise additional funds to finance future cash needs through receivables or royalty financings or
corporate collaboration and licensing arrangements. If we raise additional funds by issuing equity securities or convertible debt, our stockholders will experience dilution. Debt financing, if available, would result in increased fixed payment
obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through
collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our products, future revenue streams or product candidates or to grant licenses on terms that may not be favorable to us. The covenants
under our credit facilities limit our ability to obtain additional debt financing. We cannot be certain that additional funding will be available on acceptable terms, or at all. Any failure to raise capital in the future could have a negative impact
on our financial condition and our ability to pursue our business strategies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Cash flows &#151; three months ended </I></B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Three months ended</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash (used in) provided by:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,162</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(306</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,495</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Effect of exchange rate changes on cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net increase (decrease) in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(745</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,216</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Net cash provided by operating activities </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Net cash provided by operating activities consists primarily of net loss adjusted for certain non-cash items (including depreciation and amortization, change in fair value of contingent consideration, in-kind
interest expense, profits interest compensation, foreign currency adjustments, provisions for doubtful accounts and amortization of debt premium and capitalized loan fees), and the effect of changes in working capital and other activities.
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">115 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash provided by operating activities increased $6.0 million, or 156.6%, to $2.2 million during the three months
ended April&nbsp;2, 2016 compared to net cash used by operating activities of $3.8 million during the three months ended March&nbsp;28, 2015. For the first three months of 2016, the net loss of $6.0 million as adjusted for aggregate non-cash items
of $11.7 million was $5.7 million. This was an improvement of $6.8 million when compared to $(1.1) million in the first three months of 2015, which is comprised of the net loss of $21.0&nbsp;million as adjusted for aggregate non-cash items of $19.9
million. This improvement was primarily due to improved earnings in the Active Healing Therapies &#151; U.S., Active Healing Therapies &#150; International and Surgical segments. Other elements of net cash provided by operating activities decreased
by $0.8 million during the three months ended April 2, 2016 compared to the same period in the prior year due to the timing of cash receipts and cash payments. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Net cash (used in) investing activities </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash (used in) investing activities primarily consists of
acquisitions and capital expenditures. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in investing activities increased $6.3 million to $6.6 million during the three months ended
April&nbsp;2, 2016 compared to $0.3 million during the three months ended March&nbsp;28, 2015. The increase in net cash used in investing activities was primarily attributable to the acquisition of the exclusive U.S. distribution rights for GelSyn-3
for $6.0 million in February 2016. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Net cash (used in) provided by financing activities </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash (used in) provided by financing activities primarily consists of capital raising activities through equity or debt financing. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash provided by financing activities increased $1.6 million to $5.5 million during the three months ended April&nbsp;2, 2016, compared to $3.9 million during
the three months ended March 28, 2015. The increase in cash provided by financing activities was primarily attributable to a $5.9 million decrease in payments of contingent consideration with respect to our OsteoAMP acquisition, partially offset by
increases in principal payments on our senior secured credit facilities and lower net borrowings on our revolving credit facility. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Cash flows
&#151; annual </I></B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Years ended </B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,<BR>2015</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash (used in) provided by:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(10,999</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(31,376</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(60,185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,801</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">31,246</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Effect of exchange rate changes on cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(805</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net decrease in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,963</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(10,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Net cash provided by operating activities </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Net cash provided by operating activities consists primarily of net loss adjusted for certain non-cash items (including depreciation and amortization, change in fair value of contingent consideration, in-kind
interest expense, profits interest compensation, foreign currency adjustments, provisions for doubtful accounts and amortization of debt premium and capitalized loan fees), and the effect of changes in working capital and other activities.
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">116 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash provided by operating activities increased $3.8 million, or 25.2%, to $18.9 million during the year ended
December&nbsp;31, 2015 compared to $15.1 million during the year ended December&nbsp;31, 2014. For 2015, the net loss of $34.1 million as adjusted for aggregate non-cash items of $63.7 million was $29.6 million. This was an improvement of $2.5
million when compared to $27.1 million in 2014, which is comprised of the net loss of $12.9&nbsp;million as adjusted for aggregate non-cash items of $40.0 million. This improvement was primarily due to improved earnings in the Active Healing
Therapies &#151; U.S. and Surgical segments partially offset by lower earnings in Active Healing Therapies &#151; International and increased BMP spending. Other elements of net cash provided by operating activities improved by $1.4 million during
the fiscal year ended December 31, 2015, compared to the prior year. This improvement was primarily due to a reduction in a liability for paid in-kind interest in 2014 related to debt refinancing. The improvement was partially offset by an increase
in accounts receivable and inventories primarily resulting from increased post-acquisition OsteoAMP sales. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash provided by operating activities
increased $12.4 million, or 449.6% to $15.1 million during the fiscal year ended December&nbsp;31, 2014 compared to $2.7 million during the fiscal year ended December&nbsp;31, 2013. For 2014, the net loss of $12.9 million, as adjusted for aggregate
non-cash items of $40.0 million was $27.1 million. This was an improvement of $8.0 million when compared to $19.2&nbsp;million in 2013, which is comprised of the net loss of $22.4 million as adjusted for aggregate non-cash items of $41.5 million.
This improvement was primarily due to the earnings resulting from the OsteoAMP acquisition and increased sales and earnings related to the completion of the transition in 2014 from a distribution arrangement with Smith &amp; Nephew to a
company-operated sales force arrangement in our Active Healing Therapies &#151; International segment. The distribution arrangement with Smith &amp; Nephew was initially established with the spin-out from Smith &amp; Nephew in May 2012. Under the
distribution arrangement, Smith &amp; Nephew marketed and sold products outside the United States on our behalf until the completion of the transition of our sales force in 2014. Other elements of net cash provided by operating activities improved
by $4.4 million during the fiscal year ended December 31, 2015, compared to the prior year. This improvement was primarily due to a reduction in inventories due to working capital initiatives. The improvement was partially offset by the payment of a
liability in 2014 related to in-kind interest as a result of debt refinancing. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Net cash (used in) investing activities </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash (used in) investing activities primarily consists of acquisitions and capital expenditures. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Net cash used in investing activities increased $28.8 million, or 91.8%, to $60.2 million during the year ended December&nbsp;31, 2015 compared to $31.4 million during the year ended December&nbsp;31, 2014. The
increase in net cash used in investing activities was primarily attributable to a total of $56.8 million paid in 2015 with respect to our BioStructures acquisition and acquisition of certain Durolane assets, compared to a total of $30.2 million paid
in 2014 with respect to our OsteoAMP acquisition and acquisition of certain Durolane assets. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in investing activities increased $20.4
million, or 185.5%, to $31.4 million for the fiscal year ended December&nbsp;31, 2014 compared to $11.0 million for the fiscal year ended December&nbsp;31, 2013. The increase in net cash used in investing activities was primarily attributable to our
acquisition of OsteoAMP and certain Durolane assets in fiscal 2014, partially offset by a decrease of $5.4 million in cash used for the purchase of property and equipment. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Net cash (used in) provided by financing activities </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash (used in) provided by financing activities
primarily consists of capital raising activities through equity or debt financing. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash provided by financing activities increased $37.9 million to
$31.2 million during the year ended December&nbsp;31, 2015, compared to $6.6 million used in financing activities during the year ended December&nbsp;31, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">117 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
2014. The increase in cash provided by financing activities was primarily attributable to a $50.0 million capital contribution in connection with the BioStructures acquisition and $8.0 million of
net borrowings on our revolving credit facility, partially offset by a $14.6 million increase in payments of contingent consideration with respect to our OsteoAMP acquisition and $5.8 million increase in principal repayments on our senior secured
credit facilities. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in financing activities increased $13.4 million, or 197.7%, to $6.6 million during the fiscal year ended
December&nbsp;31, 2014, compared to net cash provided by financing activities of $6.8 million in 2013. The change was primarily attributable to payments of $160.0 million on a related party note payable and net repayments of $21.1 million on our
revolving credit facility, partially offset by the net proceeds from a borrowing of $170.5 million of cash under our senior secured credit facilities. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Indebtedness </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Credit facilities </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On October&nbsp;10, 2014, we entered into senior secured credit facilities with JPMorgan Chase Bank, N.A., as administrative agent, and a syndicate of other banks,
financial institutions and other entities as lenders. Our senior secured credit facilities are comprised of a $115.0 million first lien term loan facility, a $60.0 million second lien term loan facility and a $40.0 million first lien revolving
credit facility. All obligations under our senior secured credit facilities are guaranteed by certain of our direct and indirect wholly-owned domestic subsidiaries, and secured by substantially all of our and the guarantors&#146; assets. The first
lien term loan and revolving credit facilities mature on October&nbsp;10, 2019 and the second lien term loan facility matures on April&nbsp;10, 2020. The agreements governing our senior secured credit facilities contains various restrictive
covenants, including a covenant not to exceed a consolidated leverage ratio of 5.00 to 1.00 as of December 31, 2014, 4.75 to 1.00 as of December 31, 2015, 4.50 to 1.00 as of December 31, 2016, 4.00 to 1.00 as of December 31, 2017, and 3.65 to 1.00
as of December 31, 2018 and a covenant to maintain a fixed charge coverage ratio of at least 1.25 to 1.00. The leverage ratio and the fixed charge coverage ratio in our senior secured credit facilities are based on Consolidated EBITDA as defined in
the credit agreements, which includes several differences from Adjusted EBITDA as calculated in this prospectus. Consolidated EBITDA defined in the credit agreements permits, among other things, the exclusion of (1) non-recurring cash expenses up to
a limit of 15% of EBITDA, (2) foreign currency gains/losses recognized in the statement of operations and (3) franchise and excise taxes recognized in the statement of operations. Also, the definition of the fixed charge coverage ratio in the credit
agreements permits the exclusion of a defined amount of BMP expenses up to a limit of $10.0 million for 2016. The restrictive covenants also include limitations on our ability to repurchase shares, to pay cash dividends or to enter into a sale
transaction. As of April 2, 2016, we were in compliance with all covenants under our senior secured credit facilities and there were $163.5 million outstanding borrowings under these facilities. As of April&nbsp;2, 2016 there was $19.5 million
outstanding under our revolving credit facility. We intend to use a portion of the net proceeds from this offering to repay all of the outstanding borrowings under our revolving credit facility. See &#147;Use of Proceeds.&#148; </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On November&nbsp;20, 2015 we amended our senior secured credit facilities to enable certain sales and costs related to acquisitions to be included and certain BMP
development expenses to be excluded from future covenant calculations, as well as amending certain covenant calculations. We have entered into an amendment to the agreement governing the first lien term loan facility and the first lien revolving
credit facility, which will become operative upon the completion of this offering and will permit the consummation of the Transactions. This amendment also provides for a covenant not to exceed a consolidated leverage ratio of 3.50 to 1.00 with the
ability for us to request an increase to 4.00 to 1.00 for a period of four consecutive fiscal quarters in connection with certain permitted acquisitions (but no more than two times over the term of the facilities). We intend to use a portion of the
net proceeds from this offering to repay our second lien term loan facility in full. See &#147;Use of Proceeds.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">118 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Off-balance sheet arrangements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We do not have any off-balance sheet arrangements. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Contractual obligations </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table sets out, as of December&nbsp;31, 2015, our contractual obligations due by period. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Payments due by period</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Less&nbsp;than&nbsp;1<BR>year</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>1-3</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Years</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>3-5</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Years</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>More&nbsp;than<BR>5&nbsp;years</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Long-term debt obligations(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">125,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">174,376</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest on long-term debt obligations(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,628</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,901</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">39,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Capital lease obligations(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,354</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating lease obligations(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Purchase obligations(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">37,609</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred purchase price(6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">30,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">30,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Royalties(7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">201</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">603</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,608</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Consulting agreements(8)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,556</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,556</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">91,809</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">67,081</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">137,706</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">603</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">297,199</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Our long term debt obligations include principal amounts due on our first lien term loan, second lien term loan and revolving loan balances. We intend to use $60.0 million of the
net proceeds from this offering to reduce all of the outstanding amounts under our second lien term loan facility, together with a prepayment premium and accrued and unpaid interest thereon. We also intend to repay our outstanding revolving loan
balance with a portion of the proceeds from this offering. We have $8.0 million outstanding on our long-term revolving credit facility as of December 31, 2015, which is due at maturity on October&nbsp;10, 2019. The amounts shown in the table above
exclude unamortized original issue discount of $1.5 million and deferred financing costs of $2.3&nbsp;million. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes interest due on our first lien term loan, second lien term loan and revolving loan balances. We have entered into derivative instruments to fix the interest rate on
$70.0 million of our first lien term loans, which results in interest payments of $2.8 million annually and is included in the table above. The derivative instruments expire on November 30, 2017. The interest rates for the remaining portion of the
loans is subject to a variable rate and assumes the continuation of the interest rate in effect as of December 31, 2015. Interest on the long-term revolver balance of $8.0 million will be $0.3 million annually. Interest on long-term debt obligations
includes $6.6&nbsp;million of annual interest expense and $28.2&nbsp;million of total interest expense on our second lien term loan facility, which we intend to repay with a portion of the net proceeds with this offering. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Our capital lease obligations relate to software and computer equipment. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Our operating lease obligations relate to office facilities and other property and equipment. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Our purchase obligations include only those minimum supply agreement commitments which are non-cancelable in nature or required by a contract. Some of our products are
manufactured exclusively by single-source third party manufacturers with which we have multi-year supply agreements. The commitments under these supply agreements have been excluded from the table above except for those amounts that are
contractually committed as of December 31, 2015. The Durolane supply agreement is contracted based on a three-month forecast and the supply agreement extends through December 31, 2028. The Supartz supply agreement includes a contractual annual
minimum of up to 70% of the annual supply plan, which is $15.8 million for 2016 and $5.5 million for 2017. This supply agreement expires on May 4, 2017. Our OsteoAMP supply agreement does not state any contractual minimums, however firm purchase
commitments are agreed approximately four to six months prior to purchase. Based on management assumptions for market rates and future contract revenues, the estimated fair market value of the contingent cash consideration payable under the OsteoAMP
supply agreement is $20.8 million as of December 31, 2015. This supply agreement extends through October 2018. The table above does not include annual minimum purchase orders under the GelSyn-3 supply agreement, which was entered into in February
2016. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">We are required to pay a total of $23.5 million note payable and a $5.0 million deferred payment in November 2016 related to the BioStructures acquisition. This amount is not
contingent. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(7)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents the minimum royalties due under the license agreement between BioStructures and a third party for licensed products containing bioactive bone graft putty. We are
obligated to pay the greater of the minimum royalty or gross sales times 1.50% for 2016-2017 or 2.00% for 2018-2023. In addition, we are also party to a royalty agreement for the use of bioactive glass in certain of its products; this agreement does
not require minimum royalties and therefore has not been reflected in the table above. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(8)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">We agreed to pay $1.2 million to the former owners of BioStructures for consulting services and $0.4 million in other annually renewable consulting agreements.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The table above does not include certain contingent obligations as follows: </FONT></P>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)&nbsp;&nbsp;&nbsp;&nbsp;We may owe contingent payments to Advanced Biologics in connection with our acquisition of OsteoAMP. These payments are contingent on
achieving certain net sales targets through December 31, </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">119 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
2023 and based on expected purchases within our four-year supply agreement with Advanced Biologics. The present value of contingent consideration expected to be paid to Advanced Biologics is
approximately $20.8 million under the terms of the supply agreement and $14.7 million upon achieving certain sales targets through 2023. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">(b)&nbsp;&nbsp;&nbsp;&nbsp;We may owe a contingent payment to the former owners of BioStructures in connection with the acquisition. This payment is contingent upon the
achievement of certain research and development milestones through November 24, 2017. The present value of contingent consideration expected to be paid is $4.5 million as of December 31, 2015. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">(c)&nbsp;&nbsp;&nbsp;&nbsp;We may owe contingent payments to Pfizer upon the achievement of certain milestones, as well as royalty payments to Pfizer on sales upon
commercialization of any product covered by the license. See &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#151;Strategic Transactions&#151;BMP portfolio.&#148; </FONT></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Quantitative and qualitative disclosures about market risk </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are exposed to various market risks, which may result in potential losses arising from adverse changes in market rates, such as interest rates and foreign
exchange rates. We do not enter into derivatives or other financial instruments for trading or speculative purposes. We use derivative instruments to manage exposures to interest rates and foreign currencies. Derivatives are recorded on the balance
sheet at fair value at each balance sheet date. We have elected the fair value method of accounting and do not designate whether the derivative instrument is an effective hedge of an asset, liability or firm commitment. Changes in the fair values of
derivative instruments are recognized in the consolidated statements of operations and comprehensive loss. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Interest rate risk </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our cash and cash equivalents balance as of April 2, 2016 consisted of demand deposits and institutional money market funds held in U.S. and foreign banks. Cash
equivalents consist of highly liquid investment securities with original maturities on the date of purchase of three months or less and can be exchanged for a known amount of cash. We are exposed to the market risk related to fluctuations in
interest rates and market prices. We are exposed to interest rate risk in connection with borrowings under our senior secured credit facilities, which bear interest at a floating rate based on one-month LIBOR plus an applicable borrowing margin. As
of April&nbsp;2, 2016, 1% increase in interest rate would result in a $4.0 million increase in total interest payable over the remaining life of the credit facilities in the event we were to draw down the entire capacity of our revolving credit
facility. For variable rate debt, interest rate changes generally do not affect the fair value of the debt instrument, but do impact future earnings and cash flows, assuming other factors are held constant. In the ordinary course of business, we may
enter into contractual arrangements to reduce our exposure to interest rate risks. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November 2014, we entered into three interest rate swaps effective
November&nbsp;28, 2014 and expiring November&nbsp;30, 2017 in an effort to limit our exposure to changes in the variable interest rate on its first lien term loans. The derivative instruments have not been designated as hedges. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Foreign exchange risk management </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We operate in
countries other than the United States, and, therefore, we are exposed to foreign currency risks. We bill most direct sales outside of the United States in local currencies. We expect that the percentage of our sales denominated in foreign
currencies will increase in the foreseeable future as we continue to expand into international markets. When sales or expenses are not denominated in U.S. dollars, a fluctuation in exchange rates could affect our net income. We believe that the risk
of a significant impact on our operating income from foreign currency fluctuations is minimal. Although we do not currently have any foreign currency hedge, we </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">120 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
have used foreign exchange forward contracts in the past to protect the effect of foreign currency fluctuations and may use forward contracts, derivatives or other hedges for foreign exchange
risk management purposes in the future. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Effects of inflation </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We do not believe that inflation has had a material effect on our results of operations during the periods presented herein. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Related parties </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:arial" SIZE="2">For a description of our related party transactions, see
&#147;Certain relationships and related party transactions.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Recently issued accounting standards </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In May 2014, the U.S. Financial Accounting Standards Board, or FASB, issued guidance that provides a comprehensive new revenue recognition model that requires a
company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. The guidance also requires additional disclosure about
the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. This guidance is effective for annual and interim periods beginning after December&nbsp;15, 2017. Early adoption is permitted for annual reporting
periods beginning after December 15, 2016. We are currently evaluating the impact of this new standard on our consolidated financial statements, the date of adoption, and the transition approach to implement the new guidance. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In February 2015, the FASB issued guidance which changes the analysis in determining whether an entity is considered a variable interest entity, or VIE, and the
identification of the primary beneficiary of the VIE to determine whether the VIE should be included in an entity&#146;s consolidated financial statements. We will adopt the new accounting guidance on January 1, 2016, as required. We do not expect
this guidance to have a material effect on our consolidated financial statements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In April 2015, the FASB issued guidance that requires debt issuance
costs related to a recognized debt liability to be presented in the consolidated balance sheet as a direct deduction from the debt liability rather than as an asset. In August 2015, the FASB updated guidance issued in April 2015 related to debt
issuance costs to include SEC guidance regarding line-of-credit arrangements. The SEC staff would not object to deferring and presenting debt issuance costs as an asset for line of credit arrangement regardless of whether there is an outstanding
balance. We adopted the new accounting guidance early on December 31, 2015 resulting in a reclassification of $2.2 million and $1.8 million in other assets to a reduction of the long-term debt balance at December 31, 2014 and 2015, respectively.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In September 2015, the FASB issued guidance that eliminated the requirement that an acquirer in a business combination account for the
measurement-period adjustments retrospectively. The acquirer will recognize the measurement-period adjustment during the period in which the adjustment is determined. We adopted this guidance as of January 1, 2015, with no material effect on our
consolidated financial statements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November 2015, the FASB issued guidance that requires companies to classify all deferred tax assets and
liabilities as noncurrent on the consolidated balance sheet. We adopted the new accounting guidance early on December&nbsp;31, 2015 resulting in a reclassification of $0.3 million and $0.3 million in current deferred tax liabilities to long term at
December&nbsp;31, 2014 and 2015, respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In February 2016, the FASB issued guidance that requires lessees to put most leases on their balance
sheets but recognize expenses on their income statements. It also modifies the classification criteria and the accounting for sales-type and direct financing leases for the lessor. This guidance is effective for annual and interim
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">121 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
periods beginning after December 15, 2018. Early adoption is permitted and must be adopted using a modified retrospective transition. We are currently evaluating the impact of this new standard
on our consolidated financial statements, the date of adoption, and the transition approach to implement the new guidance. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In March 2016, the FASB
issued new accounting guidance which simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, statutory tax withholding requirements and the classification of
excess tax benefits on the statement of cash flows. The new accounting guidance will be effective for annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the impact of this new
accounting guidance on its consolidated financial statements and the date of adoption to implement the new guidance. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Internal control over financial
reporting </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements in accordance with GAAP. Prior to this offering, we were a private company and we are currently in the process of reviewing, documenting and testing our internal control over financial reporting.
In connection with the audit of our consolidated financial statements as of and for the years ended December&nbsp;31, 2015, 2014 and 2013, we identified material weaknesses in our internal control over financial reporting. See &#147;Risk
factors&#151;We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses, or if we experience additional material weaknesses in the future or otherwise fail to
maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, or comply with the accounting and reporting requirements applicable to public companies, which may
adversely affect investor confidence in us and, as a result, the value of our common stock.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have not performed an evaluation of our internal
control over financial reporting, such as required by Section&nbsp;404 of the Sarbanes-Oxley Act, nor have we engaged an independent registered accounting firm to perform an audit of our internal control over financial reporting as of any balance
sheet date or for any period reported in our financial statements. Presently, we are not an accelerated filer, as such term is defined by Rule&nbsp;12b-2 of the Exchange Act, and therefore, our management is not presently required to perform an
annual assessment of the effectiveness of our internal control over financial reporting. This requirement will first apply to our second Annual Report on Form 10-K. Our independent public registered accounting firm will first be required to attest
to the effectiveness of our internal control over financial reporting for our Annual Report on Form 10-K for the first year we are no longer an &#147;emerging growth company&#148;. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Critical accounting policies and estimates </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The preparation of the consolidated financial statements requires
us to make assumptions, estimates and judgments that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities as of the date of the consolidated financial statements, and the reported amounts of
sales and expenses during the reporting periods. Certain of our more critical accounting policies require the application of significant judgment by management in selecting the appropriate assumptions for calculating financial estimates. By their
nature, these judgments are subject to an inherent degree of uncertainty. On an ongoing basis, we evaluate our judgments, including those related to inventories, recoverability of long-lived assets and the fair value of our common stock. We use
historical experience and other assumptions as the basis for our judgments and making these estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any
changes in those estimates will be reflected in our consolidated financial statements as they occur. While our significant accounting policies are more fully described in Note 1 to our consolidated financial statements included elsewhere in this
prospectus, we believe that the following accounting policies and estimates are most critical to a full understanding and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">122 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
evaluation of our reported financial results. The critical accounting policies addressed below reflect our most significant judgments and estimates used in the preparation of our consolidated
financial statements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Revenue recognition </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Sale of products </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Product sales directly to the customer are
primarily generated through the sale of external bone growth stimulators, HA viscosupplementation therapies and bone graft substitutes. We present revenue on a net basis, excluding taxes collected from customers and remitted to governmental
authorities, as well as discounts, rebates, certain distribution fees and contractual allowances when recording revenue. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We sell products directly to
healthcare institutions, patients, distributors and dealers. Direct sales account for the majority of net sales. Revenue is recognized when title and risk of loss of the product passes to the purchaser, once all of the following conditions are
satisfied: (1)&nbsp;there is persuasive evidence of an arrangement; (2)&nbsp;the collection of the fees is reasonably assured and (3)&nbsp;the arrangement consideration is fixed or determinable. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Product sales to third-party payors are recognized in accordance with specific healthcare accounting guidance. Revenue is reported on a net basis, in consideration
of adjustments to the expected cash received. The adjustments include estimates for coverage and insurance adjustments which are based on historical knowledge and are recorded as a reduction to revenue. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For certain products, we offer chargeback rebates to wholesalers who supply their customers with our products. We have preexisting contracts with established rates
with many of the wholesalers&#146; customers who require the wholesalers to sell our product at their established rate. Accordingly we record an adjustment to revenue at the time of sale to estimate the future chargeback, based on volume of
purchases, inventory holdings, and historical data of rebates requested for each wholesaler. All liabilities associated with charge-back rebates are reviewed regularly taking into consideration known market events and trends as well as internal and
external historical data for the industry and customer. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Revenue recognition for bone growth stimulators </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Revenue from third-party payors, such as insurance companies or managed care providers is recognized when a prescription is received, patient benefits have been
verified, the product is provided and the required paperwork is executed. Such revenue is recorded at the contracted rate at the time of sale, or an estimated price based on the information available and historical results </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Revenue from a patient is negotiated with each individual and recognized when a prescription is received, the product is provided and the required paperwork is
executed. On occasion, product is provided to the patient at no cost through our Patient Assistance Program and no revenue is recognized. The full selling price is expected to be collected unless the customer defaults on payment. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Revenue recognition for HA viscosupplementation therapies </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Revenue from customers such as a healthcare provider, distribution center or specialty pharmacy is recognized when an order is received and the product is shipped
or delivered to the customer location. Revenue is recognized at the contracted price. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We offer retrospective discounts that are linked to the volume of
purchases and may increase at negotiated thresholds within a contract buying period. We record an estimated discount and returns allowance based on historical, forecasted or negotiated results, the type of customer, and the specifics of each
arrangement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">123 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Revenue recognition for bone graft substitutes </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Revenue from customers such as a healthcare provider is recognized when we are notified that a surgery was performed and the consigned inventory was consumed. Revenue is recognized at the contracted price.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Use of Estimates </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The preparation of the
consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses during the period, as well as disclosures of contingent
assets and liabilities at the date of the financial statements. Actual results may differ from these estimates under different assumptions or conditions. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Fair value </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We record certain assets and liabilities
at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable
inputs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The three levels of inputs used to measure fair value are as follows: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Level 1&#151;Quoted prices in active markets for identical assets or liabilities; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Level 2&#151;Observable inputs
other than quoted prices included within Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are
observable or can be corroborated by observable market data; and </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Level 3&#151;Unobservable inputs that are supported by little or no market data. This
includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Accounts
receivable and allowances </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Accounts receivable are amounts due from customers and payors that are recorded at net realizable value for product
sold in the ordinary course of business. We maintain a contractual allowance and an allowance for doubtful accounts. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The allowance is offset against
revenue for each sale to a contracted and non-contracted payor so that net sales and the resulting accounts receivable are recorded at the estimated determinable price at the time of the sale. When evaluating the adequacy of the contractual
allowance, we analyze pricing available for certain products as well as historical results. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The allowance for doubtful accounts is based on the
assessment of the collectability of specific customer accounts and the aging of the accounts receivable. When evaluating the adequacy of this allowance, we analyze accounts receivable, historical bad debts, customer concentrations, customer
solvency, current economic and geographic trends, and changes in customer payment terms and practices. Changes to the allowance for doubtful accounts are recorded in selling, general and administrative expense in the consolidated statements of
operations and comprehensive loss. Our reserve levels have generally been sufficient to cover credit losses. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Inventory </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We value our inventory at the lower of cost or market and adjust for the value of inventory that is estimated to be excess, obsolete or otherwise unmarketable. Cost
is determined using the first-in, first-out, or FIFO, method. We record allowances for excess and obsolete inventory based on historical and estimated future demand and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">124 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
market conditions. We plan for the production of our products based on expected market demand and expected product launches. A significant decrease in demand or change in new product launch
timing could result in an increase in the amount of excess inventory quantities on hand. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Business combinations </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquiree resulting from a business combination are recorded at their
estimated fair values on the date of the acquisition. Third-party valuations are generally completed for intangible assets in a business combination using a discounted cash flow analysis, incorporating various assumptions. Goodwill represents the
excess of the purchase price over the estimated fair value of the net assets acquired, including the amount assigned to identifiable intangible assets. The most significant estimates and assumptions inherent in a discounted cash flow analysis
include the amount and timing of projected future cash flows, the discount rate used to measure the risks inherent in the future cash flows, the assessment of the asset&#146;s life cycle, and the competitive and other trends impacting the asset,
including consideration of technical, legal, regulatory, economic and other factors. Each of these factors and assumptions can significantly affect the value of the intangible asset. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Acquired in-process research and development, or IPR&amp;D, is the fair value of projects for which the related products have not received regulatory approval and have no alternative future use and is capitalized
as an indefinite-lived intangible asset. Due to inherent uncertainty related to R&amp;D, there is no assurance that actual results will not differ materially from the assumptions used in the discounted cash flow model. Additionally, there are risks
including, but not limited to, delay or failure to receive regulatory requirements to conduct clinical trials, required market clearances, or patent issuance, and that the R&amp;D project does not result in a successful commercial product.
Development costs incurred after the acquisition are expensed as incurred. Upon receipt of regulatory approval of the related technology or product, the indefinite-lived intangible asset is then accounted for as a finite-lived intangible asset and
amortized on a straight-line basis over its estimated useful life. If the R&amp;D project is abandoned, the indefinite-lived asset is charged to expense. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We recognize contingent consideration liabilities resulting from business combinations at estimated fair value on the acquisition date. The contingent consideration
liabilities are revalued subsequent to the acquisition date with changes in fair value recognized in earnings. Contingent payments related to acquisitions consist of development, regulatory and commercial milestone payments, and are valued using
discounted cash flow techniques. Significant estimates and assumptions required for these valuations include the probability of achieving regulatory approval under specified time frames, product sales projections under various scenarios and discount
rates used to calculate the present value of the estimated payments. Changes in the fair value of contingent consideration liabilities result from changes in these estimates and assumptions. Significant judgment is employed in determining the
appropriateness of the estimates and assumptions as of the acquisition date and in post-acquisition periods. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Impairment </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We evaluate goodwill and other indefinite-lived intangible assets for impairment annually during the fourth quarter, or more frequently if events or changes in
circumstances indicate that the asset might be impaired. We have identified Advance Healing Therapies&#151;U.S., Advance Healing Therapies&#151;International and Surgical as our three reporting units and analyze each reporting unit separately in our
goodwill impairment evaluation. We used independent third-party valuation specialists in 2013, 2014 and 2015 to assist management in the performance of the two step goodwill impairment test for each reporting unit on an annual basis. The third
parties assist management in the determination of fair value of reporting units based upon inputs and assumptions provided by management, which management uses for its impairment assessment. All other indefinite-lived intangible assets are analyzed
qualitatively by management to determine if it is more likely than not for an impairment to exist. If that criteria is met, a quantitative analysis is performed to determine if an impairment exists. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">125 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Goodwill </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During the first step of our goodwill impairment testing, the estimated fair value of goodwill is compared to the carrying value at the reporting unit level. Fair
values of the reporting units are estimated using acceptable valuation methods including the income approach, which incorporates the use of a discounted free cash flow analysis, and the market approach, which incorporates the use of revenue and
earnings multiples based on market data. The discounted free cash flow analyses are based on significant judgments, including the current operating budgets, estimated long-term growth projections and future forecasts for each reporting unit. Future
cash flows are discounted based on a market comparable weighted average cost of capital rate for each reporting unit. The discount rates used in the discounted free cash flow analyses reflect the risks inherent in the expected future cash flows
generated by the respective intangible assets. Risks impacting the discount rate include market risk, industry risk and a small company premium. Bioventus LLC has never triggered step two of the goodwill impairment test since the initial acquisition
of goodwill in 2012. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the fair value of any of the reporting units is less than the carrying value, a second step is performed which compares the
implied fair value of the reporting unit&#146;s goodwill to the carrying value. The fair value of the goodwill is determined based on the difference between the fair value of the reporting unit and the net fair value of the identifiable assets and
liabilities of the reporting unit or carrying value of the indefinite-lived intangible asset. If the implied fair value of the goodwill or indefinite-lived intangible assets is less than the carrying value, the difference is recognized as an
impairment charge. Significant judgments inherent in this analysis include estimating the amount and timing of future cash flows and the selection of appropriate discount rates, royalty rate and long-term growth rate assumptions. Changes in these
estimates and assumptions could materially affect the determination of fair value for each reporting unit and for some of the reporting units and could result in an impairment charge, which could be material to our financial position and results of
operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Other indefinite-lived intangible assets </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">During the fourth quarter of 2015, in connection with the acquisition of BioStructures, we acquired IPR&amp;D with a preliminary estimated fair value of $23.0 million as of the acquisition date. We will continue to
evaluate the acquired IPR&amp;D for impairment on an annual basis and whenever events or circumstances change that would indicate that the carrying amount was impaired. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Equity compensation </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We account for equity compensation, which requires the measurement and recognition
of compensation expense for all equity-based awards made to employees and directors based on estimated fair values on the grant date. Bioventus LLC has issued profit interest units that share in any future profit for the company without any
additional voting rights. Bioventus LLC issued profit interest units through its MIP and phantom profits interest units through its Phantom Plan. The MIP units contain a put option that allow the employee to exercise that option at an amount other
than fair value (EBITDA times a fixed multiple). Therefore these units are classified as a liability until the put option expires. The Phantom Plan was amended in May 2015. Units issued prior to the amendment do not contain a put option or other
features and are equity classified. Units issued subsequent to the amendment contain a put option and are classified as a liability. Liability awards under the MIP and Phantom Plan are marked to fair value at each reporting period.</FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We estimate the fair value of profit interests granted using the Monte Carlo option pricing model. We estimate when and if performance-based awards will be earned.
If an award is not considered probable of being earned, no amount of equity-based compensation expense is recognized. If the award is deemed probable of being earned, related equity-based compensation expense is recorded. The fair value of an award
ultimately expected to vest is recognized as an expense, net of forfeitures, over the requisite service periods in our consolidated statements of operations, which is generally the vesting period of the award. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">126 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Monte Carlo option pricing model requires the input of certain subjective assumptions and the application of
judgment in determining the fair value of the awards. The most significant assumptions and judgments include the expected volatility, risk-free interest rate, the expected dividend yield, and the expected term of the awards. In addition, the
recognition of equity-based compensation expense is impacted by our estimated forfeiture rates, which is based on an analysis of historical forfeitures. We will continue to evaluate our forfeiture rate, considering our actual forfeiture experience,
analysis of employee turnover and other factors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The assumptions used in our option pricing model represent management&#146;s best estimates. If factors
change and different assumptions are used, our equity-based compensation expense could be materially different in the future. The key assumptions included in the model are as follows: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Expected volatility&#151;We determine the expected price volatility based on the historical volatilities of our peer group as we do not have a sufficient trading
history for our units. Industry peers consist of several public companies in the medical technology industry similar to us in size, stage of life cycle and financial leverage. We intend to continue to consistently apply this process using the same
or similar public companies until a sufficient amount of historical information regarding the volatility of our own stock price becomes available, or unless circumstances change such that the identified companies are no longer similar to us, in
which case, more suitable companies whose share prices are publicly available would be utilized in the calculation. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Risk-free interest rate&#151;We base the risk-free interest rate on the yield curve of a zero-coupon U.S. Treasury bond with a maturity equal to the expected
term of the option on the grant date. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Expected dividend yield&#151;We have not previously issued dividends and do not anticipate paying dividends in the foreseeable future. Therefore, we used a
dividend rate of zero based on our expectation of additional dividends. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Expected term&#151;The amount of time that the equity-based awards are expected to be outstanding. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The assumptions utilized to determine the fair value of the awards for the years ended December 31 and the three months ended March 28, 2015 and April 2, 2016 are
indicated in the following table: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year&nbsp;ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Three&nbsp;months&nbsp;ended&shy;-</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,&nbsp;2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Expected volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">42.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">40.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Risk-free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.3%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.3%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.4%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.4%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.4%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Expected dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Expected term</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, the calculation requires an estimate of fair value of the units underlying our equity-based awards to perform our
Monte Carlo calculation. Prior to our initial public offering, in the absence of a public trading market, our Board of Directors determined a reasonable estimate of the then-current fair value of our equity awards for purposes of granting
equity-based compensation based on input from management and valuation reports prepared by an independent third-party valuation specialist. We determined the fair value of our equity utilizing methodologies, approaches and assumptions consistent
with the American Institute of Certified Public Accountants Practice Aid, &#147;Valuation of Privately-Held-Company Equity Securities Issued as Compensation,&#148; which we refer to as the AICPA Practice Aid. In addition, we exercised judgment in
evaluating and assessing the foregoing based on several factors including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the nature and history of our business; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our historical operating and financial results; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the market value of companies that are engaged in a similar business to ours; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">127 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the lack of marketability of our common stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the price at which shares of our equity instruments have been sold; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the overall inherent risks associated with our business at the time stock option grants or warrants were approved; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the overall equity market conditions and general economic trends. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We will continue to accumulate additional data and use judgment in evaluating each assumption on a prospective basis. As of April 2, 2016, we had $3.3&nbsp;million of unrecognized equity-based compensation expense,
net of estimated forfeitures, related to profit interest units and phantom profit interest units and that is expected to be recognized over a weighted-average period of four and five years for the MIP and Phantom Plan, respectively. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Income taxes </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Bioventus LLC is currently a partnership
for U.S. federal income tax purposes. As a partnership, taxable income or loss is includable in the income tax returns of its members. The Company also has a subsidiary that operates as a C corporation that is subject to income tax requirements and
international operations that are subject to foreign income tax requirements. Additionally, Bioventus LLC is liable for various other state and local taxes. After consummation of this offering, we will become subject to U.S. federal, state and local
income taxes with respect to our allocable share of any taxable income of Bioventus LLC and will be taxed at the prevailing corporate tax rates. We recognize the effect of income tax positions only if these positions are more likely than not to be
sustained. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The pro forma consolidated financial statements included in this prospectus do not include a provision for federal income taxes
since each of our pro forma statements of operations have a pro forma net loss. In the future, if redemption or exchange of Bioventus LLC Units for shares of our Class&nbsp;A common stock or cash occurs and if we determine that such tax benefits are
likely to be realized by us, we will record (i)&nbsp;a deferred tax asset based on the step-up in basis resulting from the exchange and the then effective income tax rate, (ii) a payable to related party in respect of the corresponding 85% payment
under the Tax Receivable Agreement and (iii)&nbsp;a tax benefit based on the net difference between (i)&nbsp;and (ii). As cash tax savings are realized by us, the deferred tax asset will be reduced, and the payments made under the Tax Receivable
Agreement will reduce the payable to related party. Further, we will evaluate the likelihood that we will realize the benefit represented by the deferred tax asset and, to the extent that we estimate that it is more likely than not that we will not
realize the benefit, we will reduce the carrying amount of the deferred tax asset with a valuation allowance. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Long-lived assets
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment are stated at cost and are depreciated using the straight-line method over the shorter of the asset&#146;s estimated
useful life, or the lease term if related to leased property, as follows in years: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Computer software and hardware</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3 &#150; 5</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.5&nbsp;&#150;&nbsp;7.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Machinery and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5 &#150;7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Furniture and fixtures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4 &#150;7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">128 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Finite-lived identifiable intangible assets are amortized using the straight-line method over their estimated
remaining weighted average useful lives as follows in years: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intellectual property</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17.2</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Distribution rights</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Customer relationships</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Developed technology</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Non-compete agreements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We capitalize costs incurred from third-party vendors for software design, configuration, coding and testing and amortizes these
costs on a straight-line basis over the estimated useful life of the product, not to exceed three years. We do not capitalize costs that are incurred internally for labor or that are precluded from capitalization in authoritative guidance, such as
preliminary project phase costs, planning, oversight, process re-engineering costs, training costs or data conversion costs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The carrying values of
property, equipment, intangible and other long-lived assets are reviewed for recoverability if the facts and circumstances suggest that a potential impairment may have occurred. If this review indicates that carrying values may not be recoverable,
as determined based on undiscounted cash flow projections, we will perform an assessment to determine if an impairment charge is required to reduce carrying values to estimated fair value. There were no events, facts or circumstances for the years
ended December&nbsp;31, 2014 and 2013 that resulted in any impairment charges to our property, equipment, intangible or other long-lived assets. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>JOBS Act </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We qualify as an &#147;emerging growth
company&#148; pursuant to the provisions of the JOBS Act. For as long as we are an &#147;emerging growth company,&#148; we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies
that are not &#147;emerging growth companies,&#148; including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding
executive compensation in our periodic reports and proxy statements, reduced disclosure obligations relating to the presentation of financial statements in Management&#146;s discussion and analysis of financial condition and results of operations
and exemptions from the requirements of holding advisory &#147;say-on-pay&#148; votes on executive compensation and shareholder advisory votes on golden parachute compensation. We have availed ourselves of the reduced reporting obligations and
executive compensation disclosure in this prospectus, and expect to continue to avail ourselves of the reduced reporting obligations available to emerging growth companies in future filings. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, an emerging growth company can delay its adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we are choosing to &#147;opt out&#148; of
such extended transition period, and as a result, we plan to comply with any new or revised accounting standards on the relevant dates on which non-emerging growth companies must adopt such standards. Section&nbsp;107 of the JOBS Act provides that
our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We will continue to
qualify as an emerging growth company until the earliest of: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The last day of our fiscal year following the fifth anniversary of the date of our IPO; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The last day of our fiscal year in which have annual gross revenues of $1.0 billion or more; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">129 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The date on which we are deemed to be a &#147;large accelerated filer&#148;, which will occur at such time as we (1) have an aggregate worldwide market value of
common equity securities held by non-affiliates of $700 million or more as of the last business day of our most recently completed second quarter, (2) have been required to file annual and quarterly reports under the Exchange Act for a period of at
least 12 months and (3) have filed at least one annual report pursuant to the Exchange Act. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">130 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_12"></A>Industry </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Orthobiologics are used to accelerate the healing of, or reduce pain experienced in, bones, joints or damaged musculoskeletal tissue by harnessing the body&#146;s natural healing processes. We believe the current
U.S. annual total market opportunity for orthobiologic products is approximately $3.0 billion and will grow at approximately 4&#150;5% annually for the next five to seven years. There is additional opportunity outside the United States, particularly
in HA viscosupplementation. These estimates for the U.S. market include non-surgical products, such as long bone growth stimulation and HA viscosupplementation therapies; surgical bone graft substitute products, such as allografts, DBMs, synthetics,
stem cells, BMPs/growth factors; spinal stimulation; cell therapies and orthopedic cartilage repair products. Market growth is being driven by improving technologies and unaddressed market needs, an aging population, increased incidence of spinal
disorders driving the need for spinal fusion surgery and increased incidence of osteoarthritis leading to the need for HA viscosupplementation therapy or surgery. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The chart below summarizes the U.S. orthobiologics market, key product categories and our products in each of those categories: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>U.S&nbsp;current<BR>market&nbsp;size<BR>(in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014&#150;2021<BR>Market<BR>CAGR</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Primary applications</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Bioventus&nbsp;product<BR>offerings&nbsp;(1)</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><U><B>Non-surgical</B></U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Long bone stimulation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">300</FONT> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><I>&nbsp;</I></FONT> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><I>1.9%</I></FONT> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:1px" align="left"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><I>&nbsp;&nbsp;</I></FONT> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Fracture&nbsp;repair</FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Exogen</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:1px"><FONT
SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">HA viscosupplementation&nbsp;(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">873</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><I>6.1%</I></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Alleviation&nbsp;of&nbsp;osteoarthritis pain through single, three or five injection regimens</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Supartz&nbsp;FX, <FONT STYLE="white-space:nowrap">Durolane&#043;,&nbsp;GelSyn-3*</FONT></FONT></P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="10" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Subtotal</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>1,173</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="10" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" COLSPAN="4"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B><U>Surgical&#151;Bone graft substitutes</U></B></FONT></P></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Allografts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">132</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><I>(0.9)%</I></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Spinal fusion, trauma and other bone repair applications</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Purebone</FONT></P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">DBMs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">365</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><I>2.3%</I></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Spinal fusion, trauma and other bone repair applications</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Exponent</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Synthetics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">361</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><I>5.7%</I></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Spinal fusion, trauma and other bone repair applications</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Signafuse, Interface, Osteoplus</FONT></P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Stem cells</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">178</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><I>16.9%</I></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Spinal fusion, trauma and other bone repair applications</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;No offerings</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">BMPs/growth factors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">372</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><I>0.6%</I></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Spinal fusion, trauma and other bone repair applications</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;OsteoAMP</FONT></P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="10" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Subtotal</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>1,408</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>5.2%</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="10" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B><U>Other markets</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Spinal stimulation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Spinal&nbsp;fusion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;No offerings</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Cell therapy</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">143</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><I>4.0%</I></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Injectable platelet-rich plasma used for soft tissue repair</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;No offerings</FONT></P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Orthopedic cartilage repair</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">92</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><I>3.8%</I></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;Autograft-, allograft-&nbsp;and microfracture-based cartilage repair</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">&#149;&nbsp;&nbsp;No offerings</FONT></P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="10" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Subtotal</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>485</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="10" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Total</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>3,066</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="13" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">Source:</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">iData 2015 U.S. Market for Orthopedic Biomaterials, except spinal stimulation data. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">See &#147;Business&#148; for additional information regarding our products. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The HA viscosupplementation market is comprised of single injection ($279 million market), three injection ($431 million market) and five injection ($163 million market)
products. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">&#043;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">We do not market this product in the United States. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">We expect to launch GelSyn-3 in the United States in the second half of 2016. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">131 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Orthobiologic treatment of musculoskeletal conditions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Long bone stimulation for bone fractures </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Fractures, also known as broken bones, occur when there is a
high force or impact put on a bone, most commonly from trauma resulting from sports injuries, car accidents, falls or from osteoporosis, which is bone weakening due to aging. Immediately following a fracture, patients are treated to realign the
fractured bone ends. If possible or required, the affected limb is immobilized using plaster or a splint. In some cases, fractures require surgical fixation with devices like screws, plates, rods and frames. X-rays, CT and MRI imaging are utilized
to verify alignment of the bone and to assess progress towards healing. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A fracture is considered a fresh fracture during the first seven days after the
fracture occurs. After a fracture is treated, new bone tissue begins to form and connect the broken pieces. With modern treatment methods, most fractures heal spontaneously over the course of several months following injury. However, some fractures
fail to heal even when they receive the best surgical or non-surgical treatments. In clinical literature, it is estimated that five to ten percent of all fractures fail to heal, often in patients that have compromised health from old age, obesity,
diabetes or smoking. An unhealed fracture can result in continued patient morbidity and require additional treatment. A nonunion is considered to be established when the fracture site shows no visibly progressive signs of healing. Long bone
fractures, or fractures in the humerus, ulna, radius, femur, tibia and fibula, can be prone to nonunion, with tibial fractures accounting for the most common long bone nonunions. Mechanical instability due to inadequate immobilization, loss or
reduction of adequate blood supply to the fracture site and gaps in bone-to-bone contact are the most important factors leading to a nonunion. Symptoms of nonunion are swelling, pain, tenderness, deformity and difficulty bearing weight. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Patients with nonunions do not usually require surgery unless they have particular indications, such as an unstable or misaligned fracture, or a larger
inter-fragment gap. Some nonunions and fresh fractures of the tibia and radius can be treated non-surgically using a bone stimulation device that delivers low-intensity pulsed ultrasound or pulsed electromagnetic waves to the fracture site to
stimulate healing. The patient places the stimulator on the skin over the nonunion for 20 minutes to several hours daily, depending on the technology, for a period typically of up to six months for the most difficult fractures. Daily treatment is
recommended for peak effectiveness. We estimate the total long bone stimulation market to be approximately $300 million and to grow by 1.9% annually with approximately 90,000 fractures treated with long bone stimulation devices per year. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>HA viscosupplementation </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">HA is a major component of
the extracellular matrix in almost all living tissue which is produced naturally by the human body and is concentrated in the joints, cartilage and skin. HA is a natural lubricant and a major component of synovial fluid and articular cartilage and
has an important anti-inflammatory role, causing inhibition of tissue destruction and facilitating tissue healing. Viscosupplementation is a procedure in which HA is injected into the body. In the United States, the FDA has approved the use of HA
injections for treatment of pain caused by knee osteoarthritis, as well as other non-orthopedic applications. Outside of the United States, HA is used for other orthopedic indications in addition to the knee, such as the hip and shoulder, as well as
other non-orthopedic applications. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Knee osteoarthritis is a degenerative condition that is chronic in nature and caused by gradual breakdown and
destruction of the cartilage in the knee. This condition develops over years and is often found in patients who have had an infection or injury, or those who are overweight. The disease causes joint inflammation and results in symptoms that include
redness, warmth, swelling, stiffness, tenderness, limited range of motion and pain. As the condition advances, the knee joint gradually loses its ability to regenerate cartilage tissue and the cartilage
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">132 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
layer attached to the bone deteriorates to the point where eventually the bone becomes exposed. Knee osteoarthritis is one of the leading causes of disability in people 65 years of age or older,
resulting in a major impact on healthcare costs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Although there is no cure for knee osteoarthritis, several options for conservative treatment exist.
These include weight reduction, physiotherapy, physical exercise and braces for functional assistance. Pharmacological therapy is prescribed for pain relief. Among these therapies are ordinary oral analgesics, such as acetaminophen and nonsteroidal
anti-inflammatory drugs, topical nonsteroidal anti-inflammatory drugs, and intra-articular corticosteroid injection. However, patients with knee osteoarthritis often have comorbidities such as obesity and hypertension, which precludes the use of
such analgesics in these patients. Oral nonsteroidal anti-inflammatory drugs have well-known toxicities and the effects of acetaminophen on knee osteoarthritis symptoms are modest at best. Although intra-articular corticosteroid injection is
generally considered to have a positive safety profile, it has been shown to cause a transient increase in blood glucose, which may be a concern for diabetic patients. These injections often provide a relatively short period of effective relief.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The treatment regimen for HA viscosupplementation therapies usually involves a series of injections in the knee, with the number of injections depending
on the labelling of the product used and the patient. Pain relief is usually obtained by four to twelve weeks and the effect has been shown to last for up to several months. Injection schedules vary from one to five injections and patients are
generally advised to repeat the injection schedule if they are satisfied with the previous injection course. A recent study in <I>PLoS ONE</I> has shown that HA injection is associated with a significant delay in total knee replacement. For example,
patients who received no HA viscosupplementation therapy had a median time-to-total knee replacement of approximately 0.3 years. With one course of HA viscosupplementation therapy, the median time to total knee replacement increased to more than one
year and with more than five courses this number increased to 3.6 years. Thus, the dose-response relationship between the number of HA courses and time-to-total knee replacement suggests there is a significant clinical benefit from HA injections.
Potential side effects of knee osteoarthritis injections include joint swelling and pain. Among the co-authors of this study was an employee who received a salary from us as well as an employee of one of our major suppliers, Seikagaku Corporation,
which also sponsored the research. However, neither we nor Seikagaku Corporation has had any additional role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Knee osteoarthritis is one of five leading causes of disability among U.S. adults and costs due to hospitalizations for total knee replacements in patients with
severe knee osteoarthritis are estimated to be over $30 billion annually. We estimate that over 21&nbsp;million adults age 60 or over suffer from knee osteoarthritis. The Centers for Disease Control and Prevention, or CDC, estimates that one-third
of the U.S. population is considered obese and studies have shown that nearly two in three people who are obese will likely develop symptomatic knee osteoarthritis in their lifetime. Further, a study in the <I>American Journal of Epidemiology</I>
has shown that obese patients were found to have approximately a four to five times greater chance of developing knee osteoarthritis than non-obese patients. Neither we, our employees or our major suppliers were involved in this study. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In 2014, there were approximately 1.6&nbsp;million HA viscosupplementation treatments performed in the United States, with that number expected to grow to
approximately 2.2&nbsp;million treatments in 2020. The market has historically grown as each new entrant brings new sales representatives to further expand an underpenetrated total addressable market. The HA viscosupplementation therapy market is
currently approximately $850&#150;900 million in the United States. The market opportunity for the three injection segment has steadily grown by 3&#150;5% from 2009 and is projected to grow at this rate through 2021. We intend to launch a three
injection therapy, GelSyn-3, in the second half of 2016. The single injection market is growing at 11&#150;15%&nbsp;per year, but the five injection market is slowly declining. Despite the decline for the five injection market, we continue to
consider it a viable market as we believe there is a pool of physicians that continue to believe in multi-injection treatment </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">133 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
protocols, as well as those patients that simply do not respond to single or three injection treatment courses. The overall HA injection market in the United States is projected to grow by 6.1%
over the period from 2014&#151;2021. The European market, valued at <FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>265.6&nbsp;million, is expected to be approximately flat over the
period from 2014&#151;2021. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Bone graft substitutes in spinal fusion and other procedures </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Bone grafting is a surgical procedure used to fuse spinal bones, replace missing bone, fix bones that are damaged from trauma or problem joints, or to facilitate
growing bone around an implanted device, such as a total knee replacement. The bone used in a bone graft can come from a particular patient&#146;s own body which is referred to as autograft, or from a donor which is referred to as allograft, or can
be entirely man-made. Most bone grafts are expected to be reabsorbed and replaced as the natural bone heals over a few months. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In some spinal fusion
procedures, parts of the spinal bones are removed to facilitate the procedure. The removed bone can be saved and used as the graft, known as local autograft. The advantages are that it is the patient&#146;s own bone and thus will not be rejected and
it avoids the need to harvest bone from elsewhere in the body. The disadvantage is that there is a limited amount of bone that can be harvested from the small spinal bones, especially as patients get older and their bones tend to thin and weaken.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">An autograft can also be harvested from other parts of the patient&#146;s body such as the hip, rib or other areas of the spine. Iliac crest bone taken
from a patient&#146;s hip has been considered the preferred bone graft material to promote successful fusion because of its graft characteristics and because it does not carry the risk of rejection or disease transmission. Serious complications
include increased risk of subsequent pelvic fracture, peripheral nerve dysfunction causing numbness or weakness and infection. Additional difficulties with the procedure include increased operative time and blood loss and limited supply of bone
graft and increased postoperative pain. However, despite these potential adverse events, autograft procedures are still performed regularly with approximately 190,000 performed in the United States in 2014 according to the American Academy of
Orthopeadic Surgeons. The major drawback to the use of an autograft is graft-site morbidity and its major complications such as deep infection, iliac fracture, chronic pain and arterial injury, among others. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To avoid the morbidity of harvesting autograft, significant time and expense has been dedicated to the development and commercialization of bone graft substitutes
for orthopedic applications. There are several bone graft substitutes that have been developed and commercialized, including BMPs/growth factors, stem cells, synthetics, DMBs and allografts. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Different bone graft substitutes are often combined in a procedure to achieve the key elements of successful bone regeneration, which are: osteoinduction, osteoconduction and osteogenesis. Osteoinduction refers to
the ability of an implant to stimulate bone formation based primarily on soluble growth factor signals. Osteoconduction refers to the ability of an implant to promote bone formation based primarily on a physical matrix or scaffold, when placed
adjacent to viable bone tissue. Osteogenesis refers to the ability to promote new bone formation based primarily on the viable stem cells contained within the bone graft. Bone graft substitutes, depending on their design, can be used entirely in
place of autograft or by extending the volume of autograft by combining it with the bone graft substitute. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Surgeons utilize bone graft substitutes in
spinal fusion, orthopedic trauma, foot and ankle, hand and wrist, hip and knee and craniomaxillofacial surgeries. Our Surgical products are primarily used in spinal fusion and orthopedic trauma surgeries. Below is a brief description of these
applications: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Spinal fusion surgery.</I>&nbsp;&nbsp;&nbsp;&nbsp;Spinal fusion surgery is indicated for several conditions, including spine trauma, tumors and degenerative
disease in the cervical, thoracic and lumbar sections of the spine. The objective of spinal fusion is to create an environment that will allow bone to form a solid bony bridge across the involved
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">134 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
spinal segments. In 2014, bone graft substitutes were used in approximately 479,000 out of 575,000 spinal fusion procedures and the number of procedures using bone graft substitutes is expected
to grow at a five year CAGR of approximately 7.8%. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Trauma.</I>&nbsp;&nbsp;&nbsp;&nbsp;Most uses of bone graft substitutes in trauma are for fresh fracture cases, rather than nonunion, due to the nature of
these injuries. A significant amount of bone graft substitute is required for a trauma procedure and thus this indication represents a large market of approximately $175 million in 2014 with approximately 77,000 procedures performed. The number of
trauma bone graft substitute procedures performed is expected to grow at a five year CAGR of approximately 5.5%. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Other.</I>&nbsp;&nbsp;&nbsp;&nbsp;Bone graft substitutes are used in foot and ankle surgeries, as well as hand and wrist procedures to fill defects, span bone
voids and correct alignment; in hip and knee procedures when there is bone lost to disease, infection or injury, or if the bone needs assistance integrating surgically implanted devices; and in craniomaxillofacial surgeries to reduce fusion times
and in conjunction with the use of metal plates. In total, there were approximately 250,000 of these procedures performed in 2014 and the number of procedures is expected to grow at a five year CAGR of 7.1%. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Allografts.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Allograft bone is harvested from cadaveric femora or iliac crests. Depending on the preparation process, allograft
exhibits osteoconductive and sometimes osteoinductive properties. The preparation process can leave allograft devoid of many of the growth factors that foster osteoinduction. Allograft lacks osteogenic properties because of the absence of viable
stem cells. It comes in a variety of forms including freeze-dried, fresh-frozen, morselized and cancellous chips. There were approximately 230,000 procedures utilizing allograft performed in 2014. Compared to other bone graft substitutes, allograft
is less expensive and more readily available. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Demineralized bone matrix</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;DBM is an allograft material obtained from
cadaveric bone that is frozen, freeze-dried and devoid of mineral content as a result of an acid extraction process that isolates type-1 collagen proteins and growth factors, including BMP. The resulting matrix is combined with a variety of carrier
materials to produce the ultimate commercial formulation. Though DBM lacks structural strength, it provides osteoconductive and osteoinductive properties, which can make it an effective bone graft substitute for spinal fusion and other orthopedic
procedures. The structural matrix consisting of type-1 collagen provides osteoconductive activity. Varying degrees of osteoinductive activity results from the significant variation in relatively small concentrations of growth factors and the carrier
materials chosen. DBM has excellent handling characteristics and is available in multiple forms, including putty, gel, powder, fiber, flexible sheets or mixed with cortical chips. The main disadvantage of DBM is the inherently variable
osteoinductive properties between products that are present due to the differences in demineralization process, storage, washing procedure, sterilization method and source of the bone among manufacturers. In comparison to standard allograft chips,
DBM is more expensive to produce because of demineralization processing, thus commanding a higher average selling price, which is nearly double that of allograft. There were approximately 320,000 procedures involving DBMs in 2014. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Synthetics.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Synthetics are produced from ceramics such as hydroxyapatite, beta-tricalcium phosphate and bioactive glass.
Synthetics are osteoconductive, biodegradable and non-immunogenic, contain no risk of disease transmission, are readily available in large quantities and are inexpensive to manufacture. Synthetics are neither osteogenic nor osteoinductive. They are
designed to have porosity and pore size optimized for bony ingrowth. The rate of resorption is important when considering these products for spinal fusion procedures. Beta-tricalcium phosphate is absorbed over several months and hydroxyapatite is
absorbed over the course of years. Bioactive glass is a group of synthetic silicate-based materials, characterized by their bioactivity and their unique bone-bonding properties. Bioactive glass is composed mainly of silica, sodium oxide, calcium
oxide and phosphates. The bone-bonding reaction results from a sequence of reactions in the glass and its surface. After long-term implantation, this biological mineral layer is partially replaced with bone. The porosity of
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">135 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
bioactive glass provides a scaffold on which newly-formed bone can be deposited. Synthetics can be fashioned to many different sizes and shapes. A disadvantage of synthetics is that they possess
limited shear and compressive strength. There were approximately 275,000 procedures involving synthetics in 2014. The average selling price of synthetics is slightly more than DBM and more than twice the price of an allograft. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Stem cells</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>Current commercial stem cell bone graft substitutes are obtained from cadaveric cancellous bone, in which
selective cell preservation is achieved by tissue processing and washing, with the addition of DBM. The resulting bone graft substitute contains viable multipotent adult stem cells, known as mesenchymal stem cells. Stem cell therapies are usually
costly, with the average selling price over six to seven times that of allograft. Despite the increased interest in this space by the academic community and some surgeons, doubts still remain as to whether or not stem cells will emerge as a viable
bone graft substitute. We believe there is currently limited clinical data to support their use. There were approximately 75,000 stem cell procedures done in 2014. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>BMPs/growth factors.</I>&nbsp;&nbsp;&nbsp;&nbsp;In 1965, Dr.&nbsp;Marshal Urist published his landmark discovery that trace amounts of a discrete protein found in DBM was responsible for the formation of new
bone tissue in places it would normally not form. A few years later, Dr.&nbsp;Urist and his fellows termed their discovery as BMP. This protein exhibits osteoinductive activity by influencing mesenchymal stem cells through a complex signaling
pathway to stimulate osteoblasts, or the cells that secrete the matrix for bone formation, to produce bone. In order to extract BMP from cadaveric bone, the bone matrix must first undergo demineralization, a process whereby the mineral content has
been removed. Processing and sterilization methods applied to allograft tissue vary and can lead to constrained yield amounts of BMP and other growth factors found within the actual collagen matrix. Advances in biochemical techniques and the advent
of biotechnology eventually allowed for the ability to produce BMP in greater yields. It was the discovery in 1988 by a team headed by Dr.&nbsp;John Wozney at Genetics Institute, a Cambridge, Massachusetts based biotechnology company, that the human
gene BMP-2 protein could be cloned using a recombinant DNA biotechnology process that led to the creation of a commercial BMP product. The recombinant manufacturing process allows for easy reproducibility and consistent purity of large amounts of
BMP-2. In 1995, Genetics Institute entered into a partnership with Sofamor Danek Group, Inc., later acquired by Medtronic plc, or Medtronic, for the development and commercialization of recombinant human BMP-2, or rhBMP-2. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In July 2002, the FDA approved rhBMP-2, marketed as Infuse, as a bone graft substitute in conjunction with a device implant for single-level anterior lumbar
interbody fusion. In 2003, the FDA approved the use of Infuse with another implant for the same indication. Infuse remains the only FDA approved recombinant BMP on the market. The initial success of Infuse with interbody fusion soon led to
significant off-label use. By October 2004, Infuse had annualized sales over $300 million. Although the off-label use of BMP in spinal fusion has been met with radiographic and clinical success, some physicians have raised safety concerns due to
reports of rare, but significant complications with its use. Several adverse events from the use of Infuse have been reported in observational clinical studies, including retrograde ejaculation; severe dysphagia, or difficulty in swallowing; ectopic
bone formation, or unwanted bone formation occurring in the spinal canal; and potentially, cancer. In 2008, the FDA issued a Public Health Notification to alert clinicians to at least 38 reports received by the agency during the previous four years
of serious life-threatening complications associated with the off-label use of Infuse in cervical spine fusion, including swelling of the neck and throat resulting in compression of the airway and other structures. A review of publicly available
data suggesting that the risk for adverse events is 10 to 50 times higher than reported in the trial publications raised concerns about the safety of Infuse. These reports have led some clinicians to question the clinical benefits of Infuse relative
to patient safety. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In an effort to address this controversy, the Yale University Open Data Access project team invited Medtronic to provide full data
from all of its clinical trials of Infuse to allow independent analysis and interpretation. In June 2013, the first two systematic reviews and meta-analyses from this collaboration were reported in the <I>Annals of</I>
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">136 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
<I>Internal Medicine</I>. The reports had four important findings. First, in aggregate, the data showed that fusion rates with Infuse were similar to those compared to autograft iliac crest bone
graft. Second, both Infuse and iliac crest bone graft were associated with similar rates of retrograde ejaculation and neurological complications when used in anterior interbody lumbar fusion or posterolateral lumbar fusion, leading to the
conclusion that these complications were not associated with the graft material used. Third, there was clear evidence that Infuse usage leads to high rates of complication in anterior cervical procedures and high rates of ectopic bone formation in
posterior lumbar interbody procedures. Fourth, although a statistically significant higher&nbsp;risk of cancer distant from the site of implant of Infuse was observed with the use of Infuse after 24 months, more research was needed to provide more
reliable estimates of risk of cancer. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Many of the complications related to the off label use of Infuse can be explained by the uncontrolled release of
high doses of the BMP protein at the site of implantation. The average length of time during which BMPs reside at the repair site in solution is extremely short. For this reason, a carrier molecule is required to localize the protein at the site of
the repair for the appropriate amount of time. The Infuse formulation delivers BMP-2 in an absorbable collagen sponge placed in an interbody cage for lumbar interbody spine fusions and with the absorbable collagen sponge alone for open tibia
fracture repair. Although an absorbable collagen sponge meets many of the requirements for a carrier, release of BMP from the sponge is rapid, particularly in the first 24 hours, as opposed to the more ideal two to three week timeframe required for
bone repair in humans. The consequences of rapid and uncontrolled BMP release are associated to some degree with the observations of ectopic bone formation, postoperative soft tissue swelling, transient fluid formation, and transient bone resorption
observed with the use of Infuse. Rapid release of higher doses of BMP from non-optimized carriers also results in the potential for higher acute systemic exposure of BMP following implantation, and has been linked to the association of BMPs with a
potential increase in cancer risk at distant sites. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Despite safety concerns and an average selling price of eight to ten times that of allograft, Infuse
generated sales of approximately $372 million in 2014, significantly more than any other bone graft substitute on the market. In December 2015, Medtronic received FDA PMA supplement approval for three new spinal indications, allowing the marketing
of Infuse for use with certain spine implants made of polyetheretherketone in oblique lateral interbody fusion and anterior lumbar interbody fusion procedures. Given the commercial success of Infuse and the willingness of the FDA to expand the
product&#146;s on-label indications despite the various published safety concerns, we believe there is significant commercial potential for a new BMP product that addresses the safety concerns surrounding
<FONT STYLE="white-space:nowrap">rhBMP-2,</FONT> while maintaining its clinical efficacy in bone formation. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Allogeneic growth
factors.&nbsp;&nbsp;&nbsp;&nbsp;</I>Due to reported adverse events, high cost and complications related to the use of rhBMP-2, surgeons are increasingly looking for a viable alternative. Allogeneic growth factors are allogeneic morphogenic proteins
that undergo a novel tissue processing technique, utilizing angiogenic, mitogenic and osteoinductive growth factors within marrow cells to naturally bind them to the bone graft being used. In 2009, our allogenic growth factor, OsteoAMP, was made
commercially available by Advanced Biologics. This new allogeneic tissue processing technique has provided a way to access BMPs and other growth factors that are naturally found within bone marrow cells. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Unmet needs / opportunities.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;We believe the success of stem cells despite limited clinical data, the continued use of autograft
despite the morbidity associated with a second procedure and the success of Infuse despite safety issues demonstrate the significant unmet need for highly efficacious products in certain types of surgeries. Therefore, we believe that the addressable
market opportunity for bone graft substitutes is potentially significantly larger than the current $1.4 billion market, as highly efficacious and safe products have the potential to convert a number of procedures away from autografts or lower-cost
bone substitutes towards higher upfront cost, but more clinically effective alternatives. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">137 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Key dynamics in orthobiologics market </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We believe the orthobiologics market is characterized by specific product development, regulatory, sales and marketing and purchasing dynamics that include the following: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Lack of focus resulting in limited allocation of resources by existing orthobiologics competitors.</I>&nbsp;&nbsp;&nbsp;&nbsp;The majority of surgical
orthobiologics competitors are focused primarily on spinal fusion or orthopedic hardware including pedicle screws, plates, interbody devices or knee implants. These companies often view surgical orthobiologics as an accessory pull-through product to
their larger hardware businesses. In addition, many companies that offer HA viscosupplementation therapies derive a large portion of their sales from other pharmaceutical or surgical products instead. We believe this lack of focus among our
competitors leads to limited R&amp;D and sales and marketing activities for their orthobiologics businesses. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Increasing regulatory complexity and scrutiny.</I>&nbsp;&nbsp;&nbsp;&nbsp;Orthobiologics products can be regulated as a drug, a biologic, a medical device, or
human tissue, depending on the product and its classification by the FDA. This results in a number of potential regulatory pathways for approval or clearance in order to market these products, including New Drug Application, PMA, Section&nbsp;361
HCT/P, Biologics License Application, or 510(k). We believe the FDA is increasingly scrutinizing both the regulatory pathway that potential entrants utilize to seek market approval or clearance as well as off-label use of these products.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Historical lack of investment in clinical data and clinical education.</I>&nbsp;&nbsp;&nbsp;&nbsp;Historically, many of the orthobiologic products that have
been commercialized have only required 510(k) clearance for products such as synthetics, or regulation as Section&nbsp;361 HCT/Ps for products such as allografts. These products do not generally require human clinical trials as part of their
regulatory pathway to market. Additionally, many competitors have not invested in significant clinical trials to prove the efficacy of their orthobiologics once in market because orthobiologics are often viewed as pull-through products to their core
hardware products. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Hospitals increasingly favoring end-to-end orthobiologics providers.</I>&nbsp;&nbsp;&nbsp;&nbsp;Across the medical device industry, hospitals are increasingly
consolidating the range of products their physicians utilize in an attempt to control hospital costs. We believe this is especially true within the orthobiologics industry due to the diverse range of available products. We believe that surgeons
often lack loyalty to specific orthobiologics products due to the general lack of clinical data and education provided by the companies who market these products and hospitals will increasingly limit the products surgeons have at their disposal in
favor of larger end-to-end orthobiologics providers. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a result of these factors, we believe there is an opportunity for a company to
achieve leadership in the global orthobiologics market by focusing on developing and commercializing a portfolio of clinically validated, cost-effective products for use both in and out of the surgical suite. Additionally, we believe there is room
to grow the worldwide orthobiologics market opportunity beyond its current size of approximately $4.5&nbsp;billion, by developing therapies that are superior to, or have a broader label than, existing bone graft substitutes or HA
viscosupplementation therapies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">138 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_13"></A>Business </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Overview </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are a global medical technology company focused on developing and commercializing innovative and
proprietary orthobiologic products for the treatment of patients suffering from a broad array of musculoskeletal conditions. Our products address the growing need for clinically effective, cost efficient and minimally invasive solutions that enhance
the body&#146;s natural healing processes. For the year ended December&nbsp;31, 2015 and the three months ended April 2, 2016, we generated $253.7 million and $65.4 million of net sales, respectively. We operate our business through four reportable
segments: Active Healing Therapies&#151;U.S., Active Healing Therapies&#151;International, Surgical and BMP. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Active Healing Therapies</I>&#151;<I>U.S. and International</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our Active Healing Therapies segments offer two types of non-surgical
products: our market-leading, non-invasive Exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. Our Exogen system is a U.S. Food and Drug
Administration premarket approved, or PMA, product that offers significant advantages over competitors&#146; long bone stimulation systems, including shorter treatment times, superior nonunion heal rates based on a comparison of available PMA
clinical data and a broader label that is the only label for a long bone growth stimulator for certain fresh fractures. Our two PMA approved HA viscosupplementation therapies are: Supartz FX, a five injection therapy, which we market in the United
States, and GelSyn-3, a three injection therapy, which we expect to launch in the United States in the second half of 2016. We also market Durolane, a single injection therapy, outside the United States and own certain related assets.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Surgical.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our Surgical segment offers a portfolio of advanced bone graft substitutes with 510(k) clearance or regulated as HCT/Ps
in the United States that are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries. These products include our OsteoAMP allogeneic growth factor, a range of bioactive synthetics, a collagen ceramic matrix, a
demineralized bone matrix, or DBM, and allograft comprising demineralized cancellous bone in different preparations. Our development pipeline includes additional bone graft substitutes. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>BMP.&nbsp;&nbsp;&nbsp;&nbsp; </I>Our BMP segment is comprised of proprietary next-generation BMP<I>.</I> Our next-generation BMP product candidates are
designed to offer at least equivalent efficacy at a lower dose administration and provide a better-controlled release to address the safety concerns associated with Infuse, the current market-leading bone graft. Our pre-clinical data are based on
animal models, including non-human primate studies, which may not be indicative of results that we will experience in clinical trials with human subjects. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We were founded in May 2012, when a group led by Essex Woodlands Health Ventures Inc. acquired a majority stake in the biologics business of Smith&nbsp;&amp; Nephew plc, which included Exogen, exclusive U.S.
distribution rights to Supartz and exclusive distribution rights to Durolane outside the United States. Our investors believed that as an independent organization, the biologics business would provide a platform from which to build a global leader
in the rapidly evolving orthobiologics market. Since our founding, we have assembled an experienced senior executive team to execute this vision. This team has successfully accomplished the following: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Established our surgical business through the acquisition and integration of the OsteoAMP product line in 2014 and the BioStructures business in
2015.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our OsteoAMP product is an allogeneic growth factor that through our proprietary processing retains higher levels of naturally occurring growth factors, leading to better bone remodeling than Infuse. Our line of
products from the recent BioStructures acquisition includes SignaFuse and Interface, bioactive synthetic products in various preparations, as well as complementary DBM and allografts. We believe these acquisitions provide us with one of the broadest
and most differentiated portfolios of advanced bone graft substitutes. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">139 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Accelerated the research and development of our next-generation BMP product candidates by obtaining an exclusive worldwide license to an intellectual property
portfolio.</I>&nbsp;&nbsp;&nbsp;&nbsp;Since obtaining an exclusive, worldwide license, subject to certain field of use and other restrictions, to certain parts of Pfizer&#146;s BMP portfolio in 2013, we have designed and developed a protein molecule
and carrier technology in order to optimize BMP release and reduce excess bone formation. In studies involving more than 80 non-human primates, our next-generation BMP product candidates have demonstrated at least equivalent efficacy to Infuse,
while requiring only one-tenth the dosage. However, non-human primate studies may not be indicative of results that we will experience in clinical trials with human subjects. Clinical testing is expensive, is difficult to design and implement, can
take many years to complete and is inherently uncertain as to outcome. We intend to pursue three different indications for our next-generation BMP which are transforaminal lumbar interbody fusion, or TLIF, posterior lumbar interbody fusion, or PLIF,
and open tibia fractures. We plan to initiate a Phase 1 clinical trial within 18 months. However, we cannot determine with certainty the timing of initiation, the duration or the completion of current or future preclinical studies and clinical
trials of our BMP product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Enhanced our Active Healing Therapies business by securing distribution rights to commercialize a broader set of HA viscosupplementation
therapies.</I>&nbsp;&nbsp;&nbsp;&nbsp;In February 2016, we acquired the exclusive U.S. distribution rights for GelSyn-3, a PMA three injection HA viscosupplementation therapy from Institut Biochimique SA, or IBSA. We expect to launch the product in
the United States in the second half of 2016. In 2015, we began distribution of Supartz FX, which has an expanded label for repeat injection cycles, to broaden our offering of HA&nbsp;viscosupplementation therapies. In addition, we acquired certain
assets outside the United States to Durolane, a single injection HA viscosupplementation therapy, to which we previously only had the exclusive distribution rights from Galderma S.A. and Q-Med AB. This acquisition allows us to expand to new
geographic markets and increase our profitability for this product. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We currently market and sell our products in the United States and
29 other countries. Our Exogen system and Supartz FX, which accounted for the majority of our revenue for the year ended December 31, 2015, have regulatory approvals to be marketed and sold in the United States. In addition, we also have regulatory
approval to market and sell our Exogen system in key international markets, such as the European Union and Canada. As of April 2, 2016, our sales organization consisted of approximately 232 direct sales representatives and 124 independent
distributors in the United States and approximately 57&nbsp;direct sales representatives and 12 independent distributors internationally. In the United States, our Active Healing Therapies sales organization markets our products to orthopedists,
musculoskeletal and sports medicine physicians and podiatrists. Our Surgical sales organization is composed of a sales management team that markets our surgical products primarily to neurosurgeons and orthopedic spine surgeons. In international
markets, we market and sell our Active Healing Therapies through direct sales representatives in twelve countries and through independent distributors in an additional 17&nbsp;countries. Our products are typically covered and reimbursed by
third-party payors, including government authorities, such as Medicare and Medicaid, managed care providers and private health insurers. We do not sell our products through or participate in physician-owned distributorships. We have grown our total
net sales from $232.4 million for the year ended December&nbsp;31, 2013 to $242.9 million for the year ended December 31, 2014 and to $253.7 million for the year ended December&nbsp;31, 2015, at a compound annual growth rate , or CAGR, of 4.5%. We
have grown our total net sales from $53.4&nbsp;million for the three months ended March 28, 2015, to $65.4 million for the three months ended April 2, 2016, at an annual growth rate of 22.5%. For the years ended December 31, 2013, 2014 and 2015 and
the three months ended March 28, 2015 and April 2, 2016, we had net losses of $22.4&nbsp;million, $12.9 million, $34.1 million, $21.0 million and $6.0 million, respectively. We have grown our Adjusted EBITDA from $32.5 million for the year ended
December&nbsp;31, 2013 to $36.2 million for the year ended December 31, 2014 and to $42.2 million for the year ended December&nbsp;31, 2015, at a CAGR of 14.0%. Also, we have grown our Adjusted EBITDA from $2.3 million for the three months ended
March 28, 2015, to $10.7 million for the three months ended April 2, 2016 at an annual growth rate of 365.2%. Adjusted EBITDA is burdened by BMP program costs of $0.7 million, $6.7 million and $11.3 million, for the years ended December&nbsp;31,
2013, 2014, and 2015, respectively and $2.5 million and $2.5&nbsp;million for the three months ended March&nbsp;28, 2015 and April&nbsp;2, 2016, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">140 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
respectively. For a reconciliation of net loss to Adjusted EBITDA, see Note 3 to the information contained in &#147;Prospectus summary&#151;Summary historical and pro forma financial
information.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, we support our orthobiologics through global surgeon education on topics like approved patient indications,
contra-indications and overviews of the features and clinical benefits of our products. For example, we support local, regional and national educational courses to allow surgeons to learn and experience new orthobiologics. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our competitive strengths </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe we have the following
competitive strengths: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Sufficient scale combined with an exclusive focus on orthobiologics.</I>&nbsp;&nbsp;&nbsp;&nbsp;We believe we are the only company exclusively focused on the
orthobiologics market with annual net sales over $100 million. We are focused on identifying unmet orthobiologic market needs, developing products that stimulate healing in the body and successfully commercializing these products. Our team has
extensive experience working closely with regulatory agencies on achieving the appropriate path to market, designing clinical trials, gaining managed care or purchasing committee contracts, and effectively managing our direct or distributor sales
organizations. We believe we have sufficient scale and resources to be competitive and relevant in the marketplace, but are small enough to respond quickly to internal and external opportunities. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Leadership and strong competitive positions in Active Healing Therapies.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our Active Healing Therapies segments generated all of
their $227.9 million in net sales in 2015 from PMA approved products. Our Exogen system is the market leader in the long bone stimulation market, which we believe is the result of its shorter treatment times, superior nonunion heal rates based on a
comparison of available PMA clinical data and its broader label which is the only label for a long bone growth stimulator that includes certain fresh fractures. We also have a strong position in the HA viscosupplementation market with Supartz FX and
Durolane, and we expect to launch a three injection HA viscosupplementation therapy, GelSyn-3, in the United States in the second half of 2016. We believe our direct salesforce of approximately 234 representatives is among the largest sales forces
in our industry. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Portfolio of advanced orthobiologics that address a variety of surgeon needs.</I>&nbsp;&nbsp;&nbsp;&nbsp;We offer a portfolio of advanced orthobiologics
products that enables us to fulfill a greater portion of the orthobiologics needs of neurosurgeons and orthopedic spine surgeons than many of our competitors. Our product portfolio includes allogenic growth factors supported by clinical and
preclinical data, superior handling bioactive synthetics, DBMs with superior handling properties and allografts in a variety of formats such as granules, putties, sponges and strips. We believe our current product portfolio, combined with our
pipeline of next-generation products and additional indications, positions us to be a portfolio provider of surgical orthobiologic solutions. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Next-generation BMP product candidates in development.</I>&nbsp;&nbsp;&nbsp;&nbsp;Infuse revolutionized certain types of spinal fusion by enabling faster
recovery time and improved bone healing, but safety concerns have limited its ability to be used across a broader range of procedures. Our team has designed and developed a new protein molecule and carrier technology for our next-generation BMP
product candidates that enables more targeted, controlled release of BMP. In more than 80 non-human primate studies, our BMP product candidates have demonstrated at least equivalent efficacy to Infuse at one-tenth the dosage. However, non-human
primate studies may not be indicative of results that we will experience in clinical trials with human subjects. Clinical testing is expensive, is difficult to design and implement, can take many years to complete and is inherently uncertain as to
outcome. As a result, we believe our next-generation BMP&nbsp;product candidates have the potential to address market opportunities more safely and effectively than Infuse. Additionally, we have significant opportunities in the near- and medium-term
to demonstrate clinical data for our product candidates and advance them through clinical trials, including through our Phase&nbsp;1 clinical trial that we expect to commence
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">141 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
within 18 months. However, we cannot determine with certainty the timing of initiation, duration or completion of future clinical trials of our BMP product candidates.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Seasoned management focused on profitable growth.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our senior leadership team has been involved in growing large businesses or
business lines, major acquisitions and integrations, public company sale transactions, as well as the development, approval and launch of transformative medical devices and orthobiologics. We have completed five acquisitions, license and
distribution agreements to establish our Surgical business, accelerate growth in our Active Healing Therapies business and invest in our pipeline. We have completed four of these transactions without external financing and through December 31, 2015
have invested approximately $25.6&nbsp;million into our next-generation BMP product candidates, since licensing the technology from Pfizer, while growing Adjusted EBITDA. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Our strategy </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Grow our Surgical business by investing in our portfolio and expanding our distribution network.</I>&nbsp;&nbsp;&nbsp;&nbsp;Through the acquisition of
BioStructures, we expanded our existing distribution network and broadened our product portfolio. We intend to sell both OsteoAMP and BioStructures products through this expanded distribution network of approximately 135 distributors. Additionally,
we are continuing to invest in product development and clinical studies. Over the long term, we believe we can be a portfolio provider of orthobiologics to hospitals by offering bone graft substitutes backed by clinical and economic data.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Advance our next-generation BMP product candidates.</I>&nbsp;&nbsp;&nbsp;&nbsp;We are investing significant resources into our next-generation BMP product
candidates. We intend to enter clinical trials for transforaminal lumbar interbody fusion, or TLIF, posterior lumbar interbody fusion, or PLIF, and open tibial fractures, which we believe represents an approximately $240 million market for BMP-2
products in the United States, in the aggregate. We intend to enter a Phase 1 clinical trial within 18 months and expect to demonstrate advancement of our product candidates through a number of milestones over the next two years. However, we cannot
determine with certainty the timing of initiation, duration or completion of future clinical trials of our BMP product candidates. Upon the first commercial sale of a product candidate, Pfizer will assign us certain intellectual property rights
covered by our license agreement. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Grow our Active Healing Therapies business through new product introductions and selling strategies.</I>&nbsp;&nbsp;&nbsp;&nbsp;We intend to grow our HA
viscosupplementation therapies business by commercializing GelSyn-3, a three injection therapy, to which we recently obtained the U.S. distribution rights from Institut Biochimique SA, IBSA. We believe this will enable us to contract with a broader
set of payors as many payors provide reimbursement for three injection therapies, but not five injection therapies. In addition, we intend to continue to grow sales of our Exogen system by introducing new technology-based decision-making tools that
assist physicians in deciding when to prescribe bone growth stimulators, as well as highlighting our Exogen system&#146;s shorter treatment times, superior nonunion heal rates based on a comparison of available PMA clinical data and its broader
label which is the only label for a long bone growth stimulator that includes certain fresh fractures. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Selectively pursue business development opportunities.</I>&nbsp;&nbsp;&nbsp;&nbsp;We have completed five acquisitions, licensing and distribution agreements
since our founding in 2012. We intend to continue to selectively pursue business development opportunities that add to our Surgical business as well as broaden our Active Healing Therapies business. We will continue to be disciplined when evaluating
opportunities and look for products that have clinical differentiation and cost-effectiveness. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Focus on continued Adjusted EBITDA growth.</I>&nbsp;&nbsp;&nbsp;&nbsp;We have increased our Adjusted EBITDA, while making significant investments in our
development pipeline. Additionally, we are focused on continuing to increase our Adjusted EBITDA over time by leveraging the investments we have made to date, as well as maintaining our cost focus. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">142 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our products </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We offer a portfolio of orthobiologic products to meet the needs of our orthopedist, musculoskeletal and sports medicine physician, podiatrist, neurosurgeon and
orthopedic spine surgeon customers and their patients. Our current products are organized into two product categories: Active Healing Therapies, for both U.S. and International, and Surgical. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Active Healing Therapies </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our Active Healing Therapies business is comprised of two types of
non-surgical products: a non-invasive bone stimulation device and HA viscosupplementation therapies. The HA viscosupplementation therapies that we distribute, own or will launch include Supartz FX, Durolane and GelSyn-3. Our Active Healing Therapies
products are presented in the summary table below: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Product</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Description</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Regulatory<BR>pathway</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Region where marketed</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year first introduced</B></FONT></TD></TR>


<TR BGCOLOR="#cccccc">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><B>Exogen</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Ultrasound&nbsp;bone healing system for fresh fractures and nonunion fractures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;PMA</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Health Canada</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;CE Mark</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;United&nbsp;States</FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Canada</FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:13px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Outside&nbsp;the&nbsp;United&nbsp;States</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;1994 in the United&nbsp;States</FONT></P>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;1999 in Canada</FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;1996&nbsp;in&nbsp;Europe</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><B>Supartz FX</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Five injection HA viscosupplementation therapy for repeat injection cycles</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;PMA</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;United&nbsp;States</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;2015 (Supartz FX)</FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;2001 (Supartz)</FONT></P>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#cccccc">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cccccc">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><B>Durolane</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Single injection HA viscosupplementation therapy</FONT></P>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Health Canada</FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;CE Mark</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Canada</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Outside the United States</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;2003 in Canada</FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;2001</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><B>GelSyn-3</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Three injection highly-purified HA viscosupplementation therapy</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;PMA</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;United States</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Expected second half of&nbsp;2016</FONT></P></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="9" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Exogen </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We offer our
Exogen system for the non-invasive treatment of established nonunion fractures and fresh fractures. This therapy provides an effective, safe and cost-effective treatment alternative to surgical intervention for nonunions. Nonunions may occur when
the fracture moves too much, has poor blood supply or succumbs to infection. Bone grafts typically provide no inherent stability to the fracture site. Our Exogen system is the only device on the market with PMA approval for the accelerated healing
of fresh fractures of the tibia and radius. Bone stimulation devices promote bone healing in difficult to heal fractures or fusions by applying electrical or ultrasonic current to the fracture or fusion site. Electrical stimulation devices can be
applied either non-invasively or invasively, while ultrasound bone stimulation devices are only applied non-invasively. Electrical bone growth stimulators utilize treatment coils situated around the fracture or fusion site powered by an external
power supply. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our Exogen system is approved for use by patients aged 18 years or older who are skeletally mature. Our Exogen system utilizes
low-intensity pulsed ultrasound technology to stimulate the body&#146;s natural bone healing process. The ultrasound output intensity of the device is comparable to diagnostic ultrasound intensity levels used in obstetrical
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">143 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
sonogram procedures for fetal monitoring and is typically only one to five percent of the output intensity of conventional therapeutic ultrasound devices used for physical therapy. Some patients
report experiencing a tingling sensation at the treatment site. The depth and breadth of our Exogen ultrasound signal enables it to treat superficial and deep indicated fractures. Exogen ultrasound is osteoinductive, which means it stimulates cells
to differentiate into osteoblasts, or cells that make new bone. The growth of this new bone helps bridge the gap at the fracture site. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Patients use our
Exogen system to administer treatment at home or at work, once daily, for 20 minutes, or as prescribed by their physician, for accelerating bone healing. The system consists of the portable device, a charger, a gel bottle and strap. The device
features a transducer at the end of a coiled cord, a color screen, a power button and a mini-USB charging port to allow for recharging the battery. The transducer sends specifically-programmed low-intensity pulsed ultrasound to the fracture site
through the skin and soft tissue, with little or no sensation felt by the patient during the treatment. The gel lets the ultrasound signal reach the fracture site through the patient&#146;s skin. Some patients may be sensitive to the ultrasound gel.
The strap is adjustable to fit most fracture locations and utilizes a port and cap that holds the transducer down on the treatment site. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our Exogen
system provides an easy to use interface. To begin treatment, a patient holds the device in hand or on a nearby flat surface and presses the button on the device. Following a beep and the appearance of the start-up screen and calendar showing the
current month and treatment summary, a 20-minute countdown timer appears on the screen. The device begins the ultrasound treatment. When the countdown timer reaches zero, the device beeps and shows the treatment complete screen, followed by an
additional beep at which time the device turns itself off. The device features a built-in treatment-tracking calendar that records completed and missed treatments and displays the patient&#146;s compliance rate to-date. These features, combined with
the 20 minute cycle, make treatment compliance convenient for the patient and verifiable for the physician. The device stores and displays treatment history for a period of up to twelve months. Our Exogen system has demonstrated 91% treatment
compliance in a clinical study. An additional support tool for the patient is Exogen Connects, a free smartphone app that provides daily automated treatment reminders and helpful healing information. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Clinical </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our Exogen system has demonstrated clinical
effectiveness in multiple clinical trials and in case series. However, safety and effectiveness have not been established for individuals lacking skeletal maturity, pregnant or nursing women, patients with cardiac pacemakers, fractures due to bone
cancer or patients with poor blood circulation or clotting problems. In a prospective, multicenter, randomized, double-blind, placebo-controlled trial, involving 67 tibial fresh fractures at 16 centers in the United States and Israel, fractures
treated with our Exogen system experienced a statistically significant decrease in the time to overall clinical and radiographic healing. Patients treated with our Exogen system experienced healing in 96&#043;-4.9 days, compared with 154&#043;-13.7
days for patients in the control group with a P-Value of 0.001, representing a 38% increase in accelerated healing, a difference of more than eight weeks. In a separate prospective, multicenter, randomized, double-blind, placebo-controlled trial,
involving 61&nbsp;distal radial fresh fractures at 10 centers in the United States and Israel, fractures treated with our Exogen system experienced a statistically significant decrease in the time to fracture union.
<FONT STYLE="white-space:nowrap">P-value</FONT> is a conventional statistical method for measuring the statistical significance of clinical results. A p-value of less than 0.050 is generally considered to represent statistical significance, meaning
that there is a less than five percent likelihood that the observed results occurred by chance. Patients treated with our Exogen system experienced healing in 61&#043;-3 days, compared with 98&#043;-5 days for patients in the control group
(p&lt;0.0001), representing a 39% increase in accelerated healing, a difference of more than five weeks. Patients in the treatment group also experienced a 53% mean increase in fracture alignment compared with the control group (p&lt;0.01). In a
study of challenging, established nonunions, 86% of cases using our Exogen system healed in an average treatment time of 22&nbsp;weeks. On average, the postfracture period before the start of ultrasound treatment was 61 weeks. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">144 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our Exogen system has been shown to provide significant cost savings over surgery. A published cost effectiveness
study analyzed the total costs of treating a pool of 1,000 patients with tibial shaft fractures from initial trauma to union. Cost assumptions included the costs of surgery and recovery, outpatient, workers&#146; compensation, emergency room,
disability costs and the cost of purchasing the Exogen system. The study compared the costs of standard conservative treatment and use of our Exogen system to promote early fracture healing to standard conservative treatment or operative treatment
with no use of our Exogen system. The use of our Exogen system resulted in a cost savings of over $15,000 per case, or 40%, due to dramatically lowering the need for secondary procedures and workers&#146; compensation costs. The conclusion of the
analysis was that reduced healing time attributable to the use of our Exogen system could yield substantial costs savings for third-party payors, employers and government agencies, which could realize the savings if patients used our Exogen system.
Our Exogen system is effective across a wide range of patients and is the less costly bone stimulation device for conservative treatment of nonunions compared to our competitor&#146;s devices due to its greater probability of treatment success.
According to a study by the National Institute for Health and Care Excellence in the United Kingdom, treating nonunion fractures using Exogen demonstrated high rates of fracture healing with an estimated saving of over &pound;1,164&nbsp;per patient
compared to current treatment. Surgical treatment options of nonunions include the use of bone grafts, internal fixation, painful external fixation, or a combination of these options. In most cases, multiple surgeries are required to fully heal a
nonunion, which increase the burden to the patient and the healthcare system. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Although we have not conducted direct comparative studies against other
bone stimulation device, based on available published data regarding other bone stimulation devices, our Exogen system produces greater rates of bone union and accelerates fresh fractures by 38% in shorter daily treatment periods. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Comparison of U.S. long bone stimulation devices </I></B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Product</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B></B><B><I>Manufacturer</I></B><B></B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Daily<BR>treatment<BR>times</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Technology</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Indications</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>PMA heal rates</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Fresh<BR>fractures*</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Nonunions</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" BGCOLOR="#cccccc"></TD>
<TD HEIGHT="8" COLSPAN="2" BGCOLOR="#cccccc"></TD>
<TD HEIGHT="8" COLSPAN="2" BGCOLOR="#cccccc"></TD>
<TD HEIGHT="8" COLSPAN="2" BGCOLOR="#cccccc"></TD>
<TD HEIGHT="8" COLSPAN="2" BGCOLOR="#cccccc"></TD>
<TD HEIGHT="8" COLSPAN="2" BGCOLOR="#cccccc"></TD></TR>
<TR>
<TD VALIGN="top" BGCOLOR="#cccccc"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Exogen</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><I>Bioventus</I></FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" BGCOLOR="#cccccc"><FONT STYLE="font-family:arial" SIZE="2">20&nbsp;minutes</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" BGCOLOR="#cccccc"><FONT STYLE="font-family:arial" SIZE="2">Low-intensity<BR>pulsed<BR>ultrasound</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" BGCOLOR="#cccccc"><FONT STYLE="font-family:arial" SIZE="2">Fresh&nbsp;fractures<BR>and nonunions</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" BGCOLOR="#cccccc"><FONT STYLE="font-family:arial" SIZE="2">38%<BR>acceleration</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" BGCOLOR="#cccccc"><FONT STYLE="font-family:arial" SIZE="2">86%</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>EBI Bone Healing System</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><I>Zimmer Biomet
Holdings, Inc.</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10 hours</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Pulsed<BR>electromagnetic<BR>field</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Nonunions</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Not&nbsp;approved</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">63.5%</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" BGCOLOR="#cccccc"></TD>
<TD HEIGHT="8" COLSPAN="2" BGCOLOR="#cccccc"></TD>
<TD HEIGHT="8" COLSPAN="2" BGCOLOR="#cccccc"></TD>
<TD HEIGHT="8" COLSPAN="2" BGCOLOR="#cccccc"></TD>
<TD HEIGHT="8" COLSPAN="2" BGCOLOR="#cccccc"></TD>
<TD HEIGHT="8" COLSPAN="2" BGCOLOR="#cccccc"></TD></TR>
<TR>
<TD VALIGN="top" BGCOLOR="#cccccc"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>OsteoGen</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><I>Zimmer Biomet
Holdings, Inc.</I></FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" BGCOLOR="#cccccc"><FONT STYLE="font-family:arial" SIZE="2">24 hours</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" BGCOLOR="#cccccc"><FONT STYLE="font-family:arial" SIZE="2">Direct electrical<BR>current<BR>(implanted)</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" BGCOLOR="#cccccc"><FONT STYLE="font-family:arial" SIZE="2">Nonunions</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" BGCOLOR="#cccccc"><FONT STYLE="font-family:arial" SIZE="2">Not approved</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" BGCOLOR="#cccccc"><FONT STYLE="font-family:arial" SIZE="2">38.8&#150;66.7%</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Physio-Stim</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><I>Orthofix International
B.V.</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">3&nbsp;hours</FONT><BR></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Pulsed<BR>electromagnetic<BR>field</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Nonunions</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Not approved</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">35.7&#150;80.0%</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" BGCOLOR="#cccccc"></TD>
<TD HEIGHT="8" COLSPAN="2" BGCOLOR="#cccccc"></TD>
<TD HEIGHT="8" COLSPAN="2" BGCOLOR="#cccccc"></TD>
<TD HEIGHT="8" COLSPAN="2" BGCOLOR="#cccccc"></TD>
<TD HEIGHT="8" COLSPAN="2" BGCOLOR="#cccccc"></TD>
<TD HEIGHT="8" COLSPAN="2" BGCOLOR="#cccccc"></TD></TR>
<TR>
<TD VALIGN="top" BGCOLOR="#cccccc"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>DonJoy OL1000</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><I>dj
Orthopedics LLC</I></FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" BGCOLOR="#cccccc"><FONT STYLE="font-family:arial" SIZE="2">30&nbsp;minutes</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" BGCOLOR="#cccccc"><FONT STYLE="font-family:arial" SIZE="2">Combined<BR>magnetic field</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" BGCOLOR="#cccccc"><FONT STYLE="font-family:arial" SIZE="2">Nonunions</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" BGCOLOR="#cccccc"><FONT STYLE="font-family:arial" SIZE="2">Not approved</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" BGCOLOR="#cccccc"><FONT STYLE="font-family:arial" SIZE="2">80%</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Orthopak 2 Bone Growth Stimulator</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><I>Zimmer
Biomet Holdings, Inc.</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">24 hours</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Capacitive<BR>coupling</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Nonunions</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Not approved</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">72.5%</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="11" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Heal rates for fresh fracture as compared to placebo. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">145 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>HA viscosupplementation offerings </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>GelSyn-3 </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">GelSyn-3 is a highly purified three injection HA therapy that is FDA premarket approved and
indicated for the treatment of pain due to knee osteoarthritis in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. The solution treats knee osteoarthritis by providing temporary
replacement for the diseased synovial fluid and restoring lubricity of bearing joint surfaces. Physicians administer GelSyn-3 to the affected knee joint once a week for three consecutive weeks. GelSyn-3 is derived from biofermentation through a
highly purified process, which does not involve the use of animal products, thereby reducing the potential risk of an immune response following injection. This process ensures a final low-to-mid molecular weight HA product that consists of
non-chemically modified long unbranched chains of natural hyaluronan. We obtained the U.S. distribution rights to GelSyn-3 from IBSA in February 2016 and expect to launch the product in the United States in the second half of 2016. Based on market
size estimates from iData, the combined market size for three injection products, such as GelSyn-3, and five injection products, such as Supartz FX, is approximately four times the market size than for Supartz FX alone. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Clinical </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The safety and efficacy of GelSyn-3 was assessed in
a prospective, multicenter, randomized, controlled, doubleblind, non-inferiority pivotal study that enrolled 381 adult patients with knee osteoarthritis at 23 centers in Europe between November 2007 and July 2009. The safety and efficacy of Gelsyn-3
has not been established in pregnant women, nursing mothers and children. Patients were randomized to receive 2 mL intra-articular injections of GelSyn-3 (also known as Synovial outside the United States) or Synvisc, which is manufactured by Sanofi
S.A., once a week for three consecutive weeks, with follow-up visits scheduled for weeks four, twelve and 26. The primary efficacy variable for the study was the Western Ontario McMaster Universities Index, or WOMAC Index, pain subscore at week 26,
which was required to meet a delta of 8 mm protocol defined non-inferiority margin from baseline on the 100-mm visual analogue scale format. The WOMAC Index is a standardized and validated methodology consisting of 24 questions to assess pain,
stiffness and physical function in patients with knee osteoarthritis. The WOMAC Index is routinely used as a primary endpoint in clinical trials studying the effect of drugs and devices on knee osteoarthritis. Higher scores on the WOMAC Index
indicate worse pain, stiffness and functional limitations. A WOMAC Index improvement of 10&#150;20 mm represents the minimum clinically important improvement. Safety variables included adverse events, pain and local tolerability at the injection
site and global tolerability as assessed by both patient and investigator. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A total of 380 patients, the intent-to-treat, or ITT, patient population,
received at least one intra-articular injection of either GelSyn-3 or Synvisc. At 26 weeks, the 100 mm WOMAC Index pain subscore for ITT patients was 32.9&#043;1.6 for the GelSyn-3 treatment group, compared to 32.2&#043;1.7 for the Synvisc treatment
group, corresponding to a between-group mean difference in change from baseline at 26 weeks of 0.7&#043;1.7. The WOMAC Index pain subscore results met the prespecified criteria for non-inferiority. The safety data generated in the study demonstrated
that GelSyn-3 injections were well-tolerated and patient/investigator scoring for global tolerability indicated widespread procedural acceptability. One or more adverse events were recorded for some patients, including back pain, joint pain
inflammation and headache. There was no statistically significant intergroup difference in the overall incidence of adverse events or in severe, serious or suspected treatment-related adverse events. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Supartz FX </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Supartz FX, which we market in the United
States, is a sterile and viscoelastic injectable solution that is PMA approved for the treatment of pain in patients with knee osteoarthritis who failed to adequately respond to conservative nonpharmacological therapy and simple analgesics. The
solution treats knee osteoarthritis by </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">146 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
providing temporary replacement for the diseased synovial fluid and restoring the lubricity of the bearing joint surfaces. Supartz FX may also delay the need for total knee replacement. Unlike
oral analgesics or non-steroidal anti-inflammatory drugs, which affect all parts of the body, Supartz FX specifically targets knee osteoarthritis. The product is made from HA extracted from certified and veterinary inspected chicken combs. Risks can
include general knee pain, warmth and redness or pain at the injection site. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Physicians administer Supartz FX solution to affected joints typically once
a week in a flexible dosage based on the medical condition of the patient and response to treatment. A local anesthetic is applied to the knee and synovial fluid in the knee joint is removed using a syringe through a process called arthrocentesis.
Supartz FX is then injected into the knee space. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The treatment is approved for five weekly injections, which has been shown in a clinical study to
relieve pain for up to six months. Some patients may experience benefit with three injections given at weekly intervals. This has been noted in a study in which patients treated with three injections were followed for 90 days. Most patients
experience little or no discomfort during the injection. To date, over 300&nbsp;million injections of the Supartz HA formulation have been safely administered globally. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Clinical</I> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Supartz FX has demonstrated clinical effectiveness in multiple clinical trials to relieve pain,
improve mobility and improve patient quality of life. The safety and effectiveness of Supartz FX have not been established in pregnant women, nursing mothers and children. Supartz FX can allow patients to delay costly knee replacement surgery, while
controlling pain, potentially allowing patients to maintain active lifestyles. Based on a meta-analysis of available published clinical data of comparisons of common osteoarthritis treatments in the <I>Annals of Internal Medicine</I>, treatment with
HA viscosupplementation therapies, such as Supartz FX, have had the greatest effect size for both pain reduction and function and improvement of the knee compared to treatment without HA viscosupplementation therapies, such as acetaminophen,
diclofenac, ibuprofen, naproxen, celecoxib, intra-articular corticosteroids, oral placebo and intra-articular placebo. The most common adverse event occurring in patients treated with Supartz FX is joint pain with no evidence of inflammation.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In clinical studies, adverse events were no more common following treatment with Supartz FX than comparable treatment with saline placebo. In a double
blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intra-articular HA viscosupplementation therapies in knee osteoarthritis, Supartz FX reduced knee pain in patients by 50% from the baseline. Of 240 patients
randomized for inclusion in the study, 223 patients were evaluable for the modified intention to treat analysis and the statistically significant difference from the control was apparent after the series of injections was complete. Intra-articular
HA viscosupplementation therapies were significantly more effective than saline in mild to moderate knee osteoarthritis for the 13 week post injection period of the study. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In a separate retrospective analysis of 30,978 patients aged 18 to 64 years old undergoing total knee replacement, the median time-to- total knee replacement surgery was 326 days for 22,555 patients that did not
undergo HA injections and 908&nbsp;days for the cohort of 8,423 patients that underwent HA viscosupplementation therapies. Time-to-total knee replacement was defined as the total days from the date of diagnosis of knee osteoarthritis on the
patient&#146;s first visit to an orthopedic surgeon to the date of total knee replacement surgery. Those receiving HA viscosupplementation therapies had a median 1.6 years longer time-to-total knee replacement versus those who did not receive HA
viscosupplementation therapies, thereby demonstrating positive clinical and economic implications. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">147 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Comparison of U.S.-approved multi-injection HA viscosupplementation therapies </I></B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Product</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:arial" SIZE="2"><B></B><I>Manufacturer or distributor</I><B></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Source and process</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Active ingredient /<BR>treatment dosage</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number of injections<BR>per&nbsp;course</B></FONT></TD></TR>


<TR BGCOLOR="#cccccc">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>GelSyn-3</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>Bioventus</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Fermented, bacterial derived HA</FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">0.8% sodium<BR>hyaluronate (17mg)</FONT> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Three</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Supartz FX</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>Bioventus</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Naturally derived, purified HA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">1.0% sodium<BR>hyaluronate (75mg/<BR>125mg)</FONT> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Five</FONT></TD></TR>
<TR BGCOLOR="#cccccc">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Hyalgan</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>Interpace BioPharma LLC</I></FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#cccccc"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" BGCOLOR="#cccccc"><FONT STYLE="font-family:arial" SIZE="2">Naturally derived, purified HA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">1.0% sodium<BR>hyaluronate (60mg/<BR>100mg)</FONT> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Three to Five</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Synvisc</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>Sanofi S.A.</I></FONT></P>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Hylan polymers, purified HA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Hylan G-F 20</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:arial" SIZE="2">(48mg)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Three</FONT></TD></TR>
<TR BGCOLOR="#cccccc">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Orthovisc</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>DePuy Orthopaedics, Inc</I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>(Johnson &amp; Johnson</I>)</FONT></P>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Naturally derived, purified HA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">1.0% sodium<BR>hyaluronate (90mg/<BR>120mg)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Three to Four</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Euflexxa</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>Ferring Pharmaceuticals Inc.</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Fermented, bacterial derived HA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">1.0% sodium<BR>hyaluronate (60mg)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Three</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="7" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Durolane </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Durolane,
which we market outside the United States and own certain related assets, is a transparent gel which contains high levels of HA injected directly into joints affected by osteoarthritis to relieve pain, restores lubrication and cushioning which
improves joint function and restores quality of life, and helps to potentially avoid or delay hip or knee replacement surgery. Durolane is the only one-time injectable solution indicated for treatment of osteoarthritis in both the knee and hip, as
well as for treatment of other orthopedic joints. We believe that Durolane&#146;s injection schedule results in economic advantages and greater patient convenience and compliance compared to other HA viscosupplementation therapies, which require
weekly injections over a period of three to five weeks. Durolane is highly purified and based upon a natural, safe and proven, and patented non animal stabilized hyaluronic acid which ensures a reduced risk of impurities and expands use to patients
who are allergic to animal derived solutions. Durolane also contains high levels of concentrated HA that extends the half-life of Durolane considerably, whereas the HA in certain other HA viscosupplementation therapies disappears within a few days
after the injection. Durolane has not been tested in pregnant or lactating women, or children. Risks associated with Durolane include transient pain, swelling and/or stiffness at the injection site. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Clinical</I> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In a study of 103 patients who received Durolane
single injection therapy, the solution demonstrated statistically significant (p&lt;0.001) reductions in pain at three months as compared to the baseline. Furthermore, 80% of these patients reported positive satisfaction with the treatment with
minimal adverse events that did not require more than mild analgesics. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A 26-week randomized, double-blind, multicenter study of a single intra-articular
knee injection compared the efficacy of Durolane with saline (placebo) in patients with knee osteoarthritis. A total of 346 patients were treated and a favorable reduction in pain with Durolane was observed that generally began by week two and
persisted throughout the 26-week protocol. While similar results were observed in the saline group, in the group of patients with localized knee osteoarthritis, there was a significantly greater response rate following treatment with Durolane,
starting at six weeks, as compared to patients in the saline group. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">148 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In a separate prospective, multi-center, randomized, active-controlled, double-blind, non-inferiority clinical trial
with 442 enrolled patients, it was demonstrated that single injection Durolane was well tolerated and non-inferior to the corticosteroid methylprednisolone acetate, or MPA, at twelve weeks. MPA is used to treat pain and swelling that occurs with
osteoarthritis and other joint disorders. The effect size for pain, physical function and stiffness scores favored Durolane over MPA from twelve to 26 weeks. The benefit of Durolane was maintained to 26 weeks while that of MPA declined. An injection
of Durolane at 26 weeks conferred long-term improvements without increased sensitivity or risk of complications. One subset of 28 patients received an injection of Durolane at the beginning of the study, but chose not to receive a second injection
at 26 weeks. Continuing improvement from baseline was observed among these patients, reflecting the fact that they did not feel the need for a second injection. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In a prospective, open-label, three-month pilot study of a single intra-articular injection of Durolane in 31&nbsp;patients, the response rate in treating osteoarthritis of the hip was 50% at two weeks and 54% at
three months. In the extension population of patients returning for re-assessment six to eleven months post-treatment, response rates were 69% and 44% at month three and the extension visit, respectively. The proportion of patients rating their
status as good or very good increased from 0% at baseline to 46% at three months. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Comparison of major single injection HA viscosupplementation
therapies </I></B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Product</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:arial" SIZE="2"><B></B><I>Manufacturer&nbsp;or&nbsp;distributor</I><B></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Indication</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Source and process</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Active ingredient /<BR>treatment dosage</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Duration</B></FONT></TD></TR>


<TR STYLE="font-size:1pt" BGCOLOR="#cccccc">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cccccc">
<TD VALIGN="middle"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Durolane</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>Bioventus</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">Osteoarthritis&nbsp;of the knee, hip, ankle and toes </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Non-animal,&nbsp;bacteria</FONT> fermentation&nbsp;sourced, stabilized HA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">NASHA&nbsp;/&nbsp;(60&nbsp;mg)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Six&nbsp;months</FONT></TD></TR>
<TR>
<TD VALIGN="middle"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Synvisc-One</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>Sanofi S.A.</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Osteoarthritis of the knee</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Animal sourced Hylan A and Hylan B polymers</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Hylan G-F 20 /</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">(48 mg)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Six months</FONT></TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#cccccc">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cccccc">
<TD VALIGN="middle"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Monovisc</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>DePuy Orthopaedics, Inc.</I> <I>(Johnson &amp; Johnson) </I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Osteoarthritis of the knee</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Non-animal cross-linked sourced HA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">2.2% sodium hyaluronate / (88mg)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Six months</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="middle"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Gel-One</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>Zimmer Biomet Holdings, Inc.</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Knee Osteoarthritis</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Animal sourced HA</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">1.0% sodium hyaluronate /(30mg)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Three months<I></I></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="9" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Surgical </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our Surgical
business offers a portfolio of advanced bone graft substitutes designed to improve bone fusion rates following spinal and other orthopedic surgeries, including trauma and reconstructive foot and ankle procedures. These products include allogeneic
growth factors (OsteoAMP), a range of bioactive synthetics (Signafuse and Interface), a collagen ceramic matrix (Signafuse), a biphasic calcium phosphate synthetic (OsteoPlus), a demineralized bone matrix (Exponent) and allograft demineralized
cancellous bone in different preparations (PureBone). </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>OsteoAMP </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">OsteoAMP is an allogeneic bone graft designed to provide substantially higher levels of BMP-2 than other human tissue derived bone graft substitutes on the market and with fewer complications than Infuse. We
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">149 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
process OsteoAMP utilizing a novel tissue processing technique in which allograft and its native bone marrow are processed to preserve naturally occurring growth factors that are beneficial to
bone growth and remodeling. These important growth factors include: BMP-2; BMP-7; transforming growth factor beta 1, or
<FONT STYLE="white-space:nowrap">TGF-</FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>1; acidic fibroblast growth factor, or aFGF; vascular
endothelial growth factor, or VEGF; and angiopoietin 1, or ANG1. OsteoAMP is processed so that bone marrow cells containing these growth factors are naturally bound to the cadaver bone in order to make them bioavailable. Surgical preparation of
OsteoAMP is similar to other bone graft substitutes in that it is often reconstituted with blood or bone marrow aspirate. OsteoAMP is offered in compressible sponge, putty and granule preparations to meet the varying needs and preferences of our
surgeon customers. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Clinical </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">OsteoAMP
demonstrated higher fusion rates in lumbar fusion procedures, fewer adverse events and proved more cost effective as compared to Infuse in a radiographic and economic analysis. In a study comparing 321 patients with Infuse, a dual-arm radiographic
analysis was conducted at three clinical sites to evaluate the fusion success rate of OsteoAMP and Infuse in lumbar spine procedures that underwent a TLIF or lateral lumbar interbody fusion intervention. An independent radiologist was blinded to the
intervention, product and surgeon information. Patients underwent X-ray and/or computed tomography at standard postoperative follow-up intervals of approximately one, three, six, twelve and 18 months. OsteoAMP produced higher rates of fusion at all
time points compared to Infuse (<I>p</I><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>0.01). Total time for fusion for OsteoAMP was
approximately 38% shorter than that of Infuse (207.9 and 333.9 days, respectively). Radiologic evidence of ectopic bone formation in soft tissues was found in 24.2% of the Infuse cases compared to 5.3% in patients receiving OsteoAMP
(<I>p</I>&lt;0.01). The study also analyzed orthobiologic surgical supply costs to ascertain cost differences between OsteoAMP and Infuse. The OsteoAMP arm was 80.5% less expensive per patient and 73.7% less expensive per level than the Infuse arm.
There were several potential limitations to the study, including the use of different instrumentation and fixation devices at each surgical center. In addition, the study did not evaluate the clinical outcomes as follow-up computed tomography scans
as well as x-rays were used to assess fusion over each time point, and each surgeon&#146;s unique surgical techniques that may have contributed to some differences in the results. The study was conducted by Advanced Biologics, our supplier of
OsteoAMP. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The chart below on the left shows the fusion success rate of Infuse compared to OsteoAMP at various timepoints, while the chart below on the
right shows the complication rates of Infuse compared to OsteoAMP as it relates to ectopic bone formation: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>Fusion success rate at points in time</B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:1px" align="left"><FONT
SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>Complication rates</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center">


<IMG SRC="g22578g60n31.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g22578g16j40.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are sponsoring a prospective, nonradomized, noncontrolled, multicenter study of OsteoAMP in instrumented PLIF, that will enroll
approximately 120 patients at up to ten centers in the United States. The objective of this clinical study is to evaluate the long-term efficacy of OsteoAMP in patients undergoing an </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">150 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
instrumented PLIF procedure of one or two adjacent motion segments between L1 to S1 in patients suffering from lower back and leg pain. The study will evaluate OsteoAMP in spinal fusion
procedures based on fusion results, adverse event rates, and pain and health scores. Enrollment in this study has begun and we expect to complete a 24 month follow-up of all patients in 2019. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Bioactive synthetics </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our bioactive synthetics products offer a portfolio of bone graft substitutes
designed to improve bone fusion rates with bioactive and resorbable composites which enhance the body&#146;s bone tissue production to regenerate diseased and missing tissue. When implanted in living tissue, the materials undergo a <FONT
STYLE="white-space:nowrap">time-dependent</FONT> surface modification that results in the formation of a calcium phosphate layer equivalent to bone material to provide an osteoconductive scaffold for the generation of new osseous, or bone, tissue.
New bone infiltrates around the composites to allow repair of the defect to be absorbed. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our bioactive synthetics leverage the science of bioactive
glasses, or bioglass, discovered in 1969 which for the first time provided an alternative to inert implant materials to form rapid and stable bonds with host tissues to stimulate osteogenesis with little resistance or rejection in the human body.
Many advances have since been made in understanding the mechanisms of bonding to both bone and soft connective tissues. The clinical success of bioinert, bioactive and resorbable implants has been a vital response to the medical needs of the rapidly
aging population. The limited mechanical strength of bioglass has resulted in combinations of bioglass with metals or polymers to optimize its characteristics to elicit specific interactions to direct cell proliferation, differentiation and matrix
production. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Most recently, since it has been discovered that bioglass behaves like a growth factor to stimulate bone growth, focus has turned to
bioglass&#146; ability to repair the patient&#146;s own bone in a process known as osteostimulation. The bioactive substrates released from bioglass positively affect osteoblasts and stimulate more bone tissue development earlier than other
synthetic biomaterials. Numerous clinical studies have demonstrated the stimulation of osteogenic cells by inorganic bioglass to promote bone cell growth. In a retrospective, 88-patient comparative study, bioglass was shown to be as effective as
iliac crest grafts, the preferred material for spinal fusion, in achieving fusion in patients with adolescent idiopathic scoliosis. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Signafuse
Bioactive Bone Graft Putty </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Signafuse is an FDA cleared bioactive synthetic bone graft substitute comprised of a mixture of calcium phosphate
granules and bioglass granules suspended in a resorbable polymer carrier that facilitates handling and delivery of the granule components to fill spaces of missing bone. The product is indicated as a bone void filler for standalone use in
posterolateral spine fusion procedures without the aid of autologous extenders or enhancers to meet the needs of the surgeon and effectively facilitate structural fusion of the spine. The ratio of certain components in Signafuse&#146;s composition
is similar to ratios found to promote attachment and bone formation to produce a stable scaffold that allows sustained bioactivity and osteoconductivity during the healing process. The patented bioactive component is designed for a faster rate of
bone fill than bioglass particles with a broader size range. In vitro studies have demonstrated the product&#146;s effective phosphate layer formation on the surface of the implant as early as seven days after application. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Signafuse is preloaded in a syringe applicator and can be combined with autologous bone while maintaining graft integrity. The putty is moldable, which offers
superior handling characteristics. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Interface Bioactive Bone Graft </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Interface is an FDA cleared bioactive synthetic bone graft in the form of irregular granules of bioglass to repair bone defects. The product is indicated for bony voids or gaps that are not intrinsic to the
stability of bone </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">151 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
structures created from traumatic injury to the bone. The product is a bone void filler that resorbs and is replaced with bone during the body&#146;s natural healing process. When implanted in
living tissue, the material undergoes a time dependent surface modification resulting in the formation of a calcium phosphate layer, providing an osteoconductive scaffold for the generation of new bone tissue equivalent in composition and structure
to the hydroxyapatite found in bone material. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Interface is supplied as irregular synthetic bioglass granules sized from 200&#150;420 microns designed
for enhanced performance benefits and faster bone fill compared to glass particles with a broader size distribution. The device is supplied in a single-use vial. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Product</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Indications</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Regulatory pathway / year cleared</B></FONT></TD></TR>


<TR BGCOLOR="#cccccc">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><B>Signafuse Bioactive Bone Graft Putty</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Standalone posterolateral spine, extremities and pelvis, as well as a bone graft extender in the posterolateral
spine</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;510(k) / 2014</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Interface Bioactive Bone Graft</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Posterolateral spine when mixed with autograft, extremities and
pelvis</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;510(k) / 2011 (posterolateral spine)</FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;510(k) / 2010 (extremities and
pelvis)</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Signafuse Mineralized Collagen Matrix </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Signafuse is an FDA cleared next-generation mineralized two-phase calcium phosphate bone void filler comprised of a collagen scaffold designed for optimized intra-operative handling and biologic responsiveness at
the defect site. The product comprises a clinically proven mineral component suspended within a woven network of collagen fibers.&nbsp;The 90% porous matrix provides an interconnected structure optimized for the delivery of autogenic bone marrow
aspirate and subsequent population of biologic factors essential to the healing process.</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Signafuse&#146;s unique composition and structural properties
deliver a bone graft that is tailored to support bone bonding and sustained remodeling as the healing process occurs. The product provides superior handling characteristics in both strip and putty forms and is designed to be hydrated with bone
marrow aspirate prior to implantation. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Product</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Indications</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Regulatory pathway / year cleared</B></FONT></TD></TR>


<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Signafuse Mineralized Collagen </B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Extremities and pelvis</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;510(k)&nbsp;/&nbsp;2015</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Other products </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We
also distribute other products, such as OsteoPlus Synthetic Bone Graft Composite, Exponent Demineralized Bone Matrix and PureBone Demineralized Tissue. OsteoPlus Synthetic Bone Graft Composite is a biphasic calcium phosphate synthetic bone graft
substitute that mimics the structure of natural cancellous and cortical bone for providing an osteoconductive scaffold with well-defined interconnected porosity for use in spine, extremities and pelvis procedures. Exponent Demineralized Bone Matrix
is derived from human allograft bone tissue and is combined with a migration-resistant resorbable carrier and formulated into a putty for providing an osteoconductive scaffold in posterolateral spine procedures. PureBone Demineralized Tissue is
derived from trabecular bone with compressible, elastic and sponge-like attributes and is offered in filler, block and strip options to provide an osteoconductive scaffold. We also sell a premium bone marrow aspiration system designed to increase
concentrations of stem cells and progenitor cells in marrow aspiration compared to traditional needles. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">152 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Development pipeline </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Next-generation BMP product candidates in development </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We licensed certain next-generation BMP assets
from Pfizer in 2013 because we believed there was significant market opportunity for BMP that could be realized. Our development team includes Dr.&nbsp;John Wozney, the scientist who first enabled the cloning of BMP, and Dr. Howard Seeherman, a
distinguished BMP scientist, who together, led the development of Infuse. Our team has focused on the development of novel, highly potent BMP proteins and a carefully designed composite matrix carrier with the objective of promoting robust rapid
bone formation in the absence of the challenges associated with Infuse. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To date, we have evaluated our BMP product candidates in a number of
non-clinical surgical models in multiple species, including non-human primates. In these studies, we found that our BMP product candidates resulted in fusion when used for fibular segmental defect repair, posterolateal spine fusion and interbody
spine fusion at a concentration of one-tenth or less of that used with Infuse. As part of the pre-clinical testing to develop our carriers, more than 80 non-human primates were exposed to our BMP protein in trauma and spine implantations. Results in
this model, which we believe are highly predictive of clinical performance, demonstrated the localized potency of our BMP protein in promoting rapid, robust bone formation at a significantly lower dose than Infuse. Further confirmatory work in this
model is planned for 2016, which we expect will include at least 24 additional non-human primates. However, non-human primate studies may not be indicative of results that we will experience in clinical trials with human subjects. Clinical testing
is expensive, is difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our newly developed
composite matrix carrier is designed to enable targeted delivery through the use of fenestrations to provide fluid drainage and tissue ingrowth and a biomimetic, highly porous scaffold intended to facilitate tissue ingrowth. The granule surface is
engineered to enhance binding with the protein. We developed our carrier technology to circumvent the key carrier challenges faced by other BMP products, including excessive swelling caused by product overdosing in cervical fusion, subsidence,
heterotopic bone formation and painful cysts. As a result, we believe our next-generation BMP product candidates have the potential to address a large number of market opportunities more safely and at least as effectively as Infuse. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Initial clinical testing of one of our product candidates will be conducted in a Phase 1/2, adaptive trial of subjects with symptomatic lumbar or lumbosacral
degenerative spinal disorder requiring PLIF, a condition for which clinical efficacy of Infuse has previously been established. Trials of single or multi-level primary instrumented PLIF with Infuse have consistently demonstrated radiographic and
clinical outcomes at least comparable to that of autograft bone graft, the ideal for spinal fusion procedures. However, the relatively high dose of Infuse generally required to achieve these results has limited the widespread adoption and product
commercialization in this indication, largely due to concerns about systemic safety. As a first-in-human trial, our study will be designed conservatively, with an initial lead-in phase in which a limited number of subjects will be enrolled and
treated with one or more doses of one of our next-generation BMP product candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We expect to commence a Phase 1 clinical trial within 18 months. If
we are able to recruit the necessary number of patients for our Phase 1/2 PLIF clinical trial and perform the planned CT within six months of surgery, we should expect a preliminary read out of the performance of our product in 2019 through the
assessment of the Data Safety Monitoring Board. We believe Phase 2 confirmatory data could follow within twelve months of the availability of data for the Phase 1/2 PLIF clinical trial. However, we cannot determine with certainty the timing of
initiation, duration or completion of future clinical trials of our BMP product candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">After any necessary dose adjustments, the trial will then
expand to a larger number of subjects, with the intention of identifying an optimal dose for further study in a definitive, Phase 3 efficacy trial in the same </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">153 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
indication. Further to a similar lead-in phase designed to confirm dosing, we plan to pursue pivotal trials for efficacy confirmation in TLIF and open tibial fractures. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We estimate the addressable market opportunity for our next-generation BMP product candidates is approximately $1.2&nbsp;billion, which consists of approximately
300,000 procedures annually for PLIF, TLIF and open tibia fractures in the United States and spine procedures in Europe. This market is projected to grow to $1.4 billion by 2019 and the number of procedures is expected to rise to 360,000
representing CAGRs of 3.5% and 4.0%, respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following chart shows the forecasted total addressable procedures by end market for 2014 to 2019:
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Forecasted total addressable procedures by end market </I></B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px"><B><I>


<IMG SRC="g22578g59w39.jpg" ALT="LOGO">
 </I></B></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Research and clinical operations </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are committed to ongoing R&amp;D in both our Surgical and Active Healing Therapies business. As of December&nbsp;31, 2015, our R&amp;D and clinical operations staff included approximately 30 engineers,
scientists and project managers. Our R&amp;D expenses, including spending on our clinical evidence development efforts, totaled $9.5 million and $14.7 million for the years ended December&nbsp;31, 2014 and 2015, respectively and $3.0 million and
$3.7 million for the three month periods ended March 28, 2015 and April 2, 2016, respectively. Within our Active Healing Therapies business, our current R&amp;D efforts are focused primarily on improving design for ease of use and compliance. Within
our Surgical business, our efforts are primarily focused on clinical and preclinical trials for our BMP product candidates, additional clinical and preclinical studies to support our currently marketed portfolio of bone graft substitutes, and
development of new formulations of bone graft substitutes. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Competition </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The medical technology industry is highly competitive, subject to change and significantly affected by activities of industry participants. Our Exogen system competes with products marked by Orthofix International
N.V., Zimmer Biomet Holdings, Inc. and DJO Global Inc. The multi-injection HA viscosupplementation therapies that we own or distribute compete against Ferring Pharmaceutical Inc.&#146;s Euflexxa, Interpace BioPharma LLC&#146;s Hyalgan, DePuy
Orthopaedics, Inc. (Johnson &amp; Johnson)&#146;s Orthovisc and Sanofi S.A.&#146;s Synvisc. These products </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">154 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
have faced significant competition from single injection therapies, such as Sanofi S.A.&#146;s Synvisc-One, Zimmer Biomet Holdings, Inc.&#146;s Gel-One and DePuy Orthopaedics, Inc. (Johnson &amp;
Johnson)&#146;s Monovisc. See &#147;Risk factors&#150;Risks related to our business&#150;Our commercial success depends on our ability to differentiate the HA viscosupplementation therapies that we own or distribute from alternative therapies for
the treatment of osteoarthritis.&#148; Our Surgical business competes with products from Medtronic, DePuy Orthopaedics, Inc. (Johnson &amp; Johnson), Stryker Corporation, NuVasive, Inc., SeaSpine, Inc., Alphatec Holdings Inc., Orthofix International
N.V., Zimmer Biomet Holdings, Inc., LDR Holding Corporation and K2M, Inc. At any time, these or other market participants may develop alternative treatments, products or procedures that compete directly or indirectly with our products. They may also
develop and patent processes or products earlier than we can or obtain regulatory clearance or approvals for competing products more rapidly than we can. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">See &#147;Risk factors&#151;Risks related to our business&#151;We compete and may compete in the future against other companies, some of which have longer operating
histories, more established products or greater resources than we do, which may prevent us from achieving increased market penetration or improved operating results.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Intellectual property </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We strive to protect and enhance the proprietary technologies, inventions and
improvements that we believe are important to our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among
other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions and improvements that are important to the development and
implementation of our business. We also rely on trademarks, trade secrets and careful monitoring of and contractual obligations with respect to our proprietary information to protect aspects of our business that are not amenable to, or that we do
not consider appropriate for, patent protection. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our success will depend on our ability to obtain and maintain patent and other proprietary protection
for commercially important technology, inventions and know-how related to our business, defend and enforce our patents, maintain our licenses to use intellectual property owned by third parties and operate without infringing the valid and
enforceable patents and other proprietary rights of third parties. For important factors related to our proprietary technology, inventions and improvements, please see the section entitled &#147;Risk factors&#151;Risks related to intellectual
property.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Patents </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We own numerous
patents and/or patent applications which relate to our products, including patents for our Exogen system and patent applications for OsteoAMP. However, we do not consider them material to the operation of our business. We also license patents
related to our BMP product candidates. Corresponding patents and patent applications which relate to our products have also been granted or are otherwise pending in Europe, Asia, Canada, Mexico and Australia. As of April 2, 2016, we owned
approximately 24 issued U.S. patents and had applications pending for approximately 6 U.S. patents, and we owned approximately 40 issued foreign patents and had applications pending for approximately 7 foreign patents. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Trademarks </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We own registered trademarks for
Bioventus, Exogen, Exponent, OsteoAMP, OsteoPlus, PureBone and Signafuse in the United States. We own registered trademarks for certain of our products, such as Durolane, outside the United States. We also have several pending U.S. and foreign
trademark applications, including for Exogen, OsteoAMP and Durolane. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">155 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Trade secrets </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We may rely on trade secret law to protect some of our technology, including the processing of tissue for OsteoAMP. Trade secrets, however, can be difficult to protect. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We seek to protect our proprietary technology and manufacturing process, in part, by confidentiality and invention assignment agreements with employees, under which
they are bound to assign to us inventions that are made during the term of their employment and relate to our business, unless otherwise excepted. These agreements further prohibit our employees from using, disclosing, or bringing onto the premises
any proprietary information belonging to a third-party. In addition, our consultants, scientific advisors and contractors are required to sign agreements under which they must assign to us any inventions that relate to our business. These agreements
also prohibit these third-parties from incorporating into any inventions the proprietary rights of third-parties without informing us. It is our policy to require all employees to document potential inventions and other intellectual property in
laboratory notebooks and to disclose inventions to patent counsel. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We also seek to preserve the integrity and confidentiality of our data and trade
secrets by taking commercially reasonable efforts to maintain the physical security of our premises and physical and electronic security of our information technology systems. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached (or not obtained in the first place) and we may not have adequate remedies for any breach.
In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may
arise as to the rights in related or resulting know-how and inventions. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>License agreement with Pfizer </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In June 2013, we entered into an agreement with Pfizer for an exclusive, worldwide license to certain parts of Pfizer&#146;s BMP portfolio, subject to certain field
of use and other restrictions. The portfolio includes rights to develop, commercialize, make, use and sell products containing next-generation BMP and products containing BMP-2, in each case, for the prevention, treatment, or amelioration of disease
in humans and animals. Under the license agreement, we also acquired an option to acquire an exclusive license for BMP-12 products. Pursuant to the license agreement, Pfizer transferred to us certain existing development work for their BMP assets
and agreed to undertake certain early-development activities relating to the next-generation BMP product candidates. Pfizer also manufactures BMP-2 and has agreed to supply it to us pursuant to a separate supply agreement effective June 2013.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During the term of the license agreement, we are obligated to use commercially reasonable efforts to develop and commercialize (i)&nbsp;products
containing next-generation BMP and (ii)&nbsp;products containing BMP-2. Upon the first commercial sale of a product containing next-generation BMP, Pfizer will assign to us certain IP rights relating to next-generation BMP, though we will continue
to license certain material background IP from Pfizer under the agreement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with this agreement, we paid Pfizer a one-time, non-creditable,
non-refundable license fee. We also agreed to pay Pfizer royalties of a mid-single digit percentage of net sales for BMP-2 and BMP-12 and a low-double digit percentage of net sales for next-generation BMP, subject to specified adjustments.
Additionally, we are required to pay Pfizer certain milestone payments with respect to the licensed products upon achievement of certain development and commercialization milestones. See &#147;Management&#146;s discussion and analysis of financial
condition and results of operations&#151;Strategic Transactions&#151;BMP portfolio.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The term of the agreement will expire on a country-by-country
and product-by-product basis upon the later of (i)&nbsp;the last to expire patent claim covering such product in such country, and (ii)&nbsp;ten years after the first </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">156 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
commercial sale of such product in such country . Either party can terminate the agreement upon material breach or in case of bankruptcy of the other party. We can terminate the agreement for any
reason (i)&nbsp;with respect to the next-generation BMP product candidates at any time after approximately July 2018, (ii)&nbsp;with respect to BMP-2 at any time after approximately July 2016, and (iii)&nbsp;with respect to BMP-12, if the option is
exercised, any time after the three year anniversary of the date we exercise such option, in each case, subject to certain notice obligations. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Distribution agreement for Supartz FX </I></B></FONT></P>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In June
2016, we renewed an agreement with Seikagaku Corporation, or SKK, whereby we obtained promotion and distribution rights, with the right to engage sub-distributors, for Supartz FX in the United States. Under the agreement, SKK supplies to us Supartz
FX on a purchase order basis, based on the amounts of Supartz FX we require as set forth in rolling forecasts, and in exchange we pay to SKK a percentage of the average selling price per unit of Supartz FX, subject to certain adjustments. We are
subject to certain annual minimum purchase requirements based on a percentage of our Supartz FX annual forecast, and are obligated to commercialize Supartz FX in the United States. </FONT></P>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The term of the SKK agreement continues on an exclusive basis until May 2017, subject to the next sentence, and remains in effect on a non-exclusive basis until May 2019. If we fail to order a minimum quantity of
Supartz FX from SKK in any year during the exclusive period of the agreement, SKK shall have the right to make our promotion and distribution right non-exclusive, unless we make a payment to SKK equal to the lesser of the purchase price for the
shortfall amount or one million dollars. </FONT></P>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Either party may terminate the agreement on written notice for the other party&#146;s material breach that
remains uncured for sixty days after receipt of prior written notice thereof. SKK may terminate the agreement immediately if we fail to pay undisputed amounts due under the agreement within a certain time of receiving written notice of our
nonpayment. Either party may terminate the agreement for the other party&#146;s bankruptcy or insolvency-related events. We may terminate the agreement upon fifteen days written notice if we are enjoined from selling Supartz FX in any part of the
United States for at least six months due to patent infringement. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Exclusive distribution agreement for GelSyn-3 </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In February 2016, we entered into an agreement with IBSA where we obtained the exclusive distribution rights for GelSyn-3 in the United States, as well as an
assignment of the related GelSyn-3 trademark. IBSA will maintain the ownership of all regulatory, technical and clinical data, among other information and documentation, concerning GelSyn-3. Under the agreement, IBSA will supply GelSyn-3 on a
purchase order basis, based on the amounts of GelSyn-3 that we require as set forth in rolling forecasts. We will be subject to certain annual minimum purchase requirements. We are obligated to use commercially reasonable efforts to launch GelSyn-3,
and we are obligated to diligently market GelSyn-3 in the United States. Additionally, during the term of the agreement, IBSA may not actively promote certain competing products in the United States. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The term of the IBSA agreement continues in effect for ten years until February 2026. Thereafter, the agreement will be automatically renewed for consecutive five
year terms, unless either we or IBSA gives notice of termination at least six months prior to the expiration of the initial term or any renewal term. If we fail to meet at least 50% of the annual minimum purchase requirement in any year during the
term of the agreement, IBSA will have the right to either demand payment for a percentage of the purchase price for the shortfall amount or terminate this agreement upon 30 days prior notice to us. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Either party may terminate the agreement on written notice for the other party&#146;s material breach that remains uncured for thirty days after receipt of prior
written notice. Either party may terminate the agreement upon </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">157 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
written notice for the other party&#146;s bankruptcy or insolvency-related events. IBSA may terminate this agreement upon 30 days prior notice to us if we fail to meet at least 50% of the annual
minimum purchase requirement in any year during the term of the agreement, but not if we cure by issuing purchase orders for certain amount within the 30 day period. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Manufacturing and supply </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We assemble, inspect, test and package our Exogen system at our facility in Cordova,
Tennessee with components supplied by third-party suppliers. Our Exogen system includes a transducer which is a key component that is supplied by a single-source supplier. We perform inspections of these components before use in our manufacturing
operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our HA viscosupplementation therapies and certain of our Surgical products, including OsteoAMP, are manufactured exclusively by
single-source third-party manufacturers, pursuant to multi-year supply agreements. We work closely with each of our manufacturing partners and provide them with a forecast, which enables them to better capacity plan and sequence their production
efficiently. For Supartz FX, we are subject to certain annual minimum purchase requirements based on a percentage of our Supartz FX annual forecast For Durolane, we are subject to minimum order volumes for each order and purchase amounts are also
based in part on forecasts. For GelSyn-3, we will be subject to certain annual minimum purchase requirements and purchase amounts will be based on rolling forecasts. We do not have guaranteed minimum orders for OsteoAMP, which are purchased pursuant
to purchase orders. We are also subject to a supply agreement with Advanced Biologics to purchase OsteoAMP until October 2018. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe our
manufacturing operations are in compliance with regulations mandated by the FDA. We are an FDA-registered medical device manufacturer. Our manufacturing facilities and processes are subject to periodic inspections and audits by various federal,
state and foreign regulatory agencies. Our facility was last inspected in April 2015 by the FDA and August 2015 by the British Standards Institute, or BSI Group, our Notified Body, and no major nonconformance reports were issued as a result of those
inspection. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We intend to maintain sufficient supplies of the products and components from these single-source suppliers in the event that one or more of
these suppliers were to encounter certain interruptions in supply. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Government regulation </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Government regulation of medical devices </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our medical
devices are subject to regulation by numerous government agencies, including the FDA and comparable foreign agencies. The FDA and other U.S. and foreign governmental agencies regulate, among other things, with respect to medical devices: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">design, development and manufacturing; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">testing, labeling, content and language of instructions for use and storage; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">product safety; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">marketing, sales and distribution; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">premarket clearance and approval; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">158 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">record keeping procedures; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">advertising and promotion; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">recalls and field safety corrective actions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">postmarket surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">postmarket approval studies; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">product import and export. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The regulations to
which we are subject are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>FDA premarket clearance and approval requirements</I> <I></I> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Each medical device we seek to commercially distribute in the United States must first receive 510(k) clearance or PMA from FDA, unless specifically exempted by the agency. The FDA classifies all medical devices
into one of three classes. Devices deemed to pose lower risk are categorized as either Class I or Class II, which requires the manufacturer to submit to the FDA a 510(k) pre-market notification requesting clearance of the device for commercial
distribution in the United States. Some low risk devices are exempted from this requirement. Devices deemed by the FDA to pose the greatest risk, such as life sustaining, life-supporting or implantable devices, or devices deemed not substantially
equivalent to a previously 510(k) cleared device are categorized as Class III, generally requiring PMA. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>510(k) clearance process</I> </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To obtain 510(k) clearance, we must submit a premarket notification to the FDA demonstrating the proposed device to be substantially equivalent to a previously
cleared 510(k) device, a device that was in commercial distribution before May&nbsp;28, 1976 for which the FDA has not yet called for the submission of PMA applications, or is a device that has been reclassified from Class III to either Class II or
I. In rare cases, Class III devices may be cleared through the 510(k) process as described in the prior paragraph. The FDA&#146;s 510(k) clearance process usually takes from three to twelve months from the date the application is submitted and filed
with the FDA, but may take significantly longer and clearance is never assured. Although many 510(k) premarket notifications are cleared without clinical data, in some cases, the FDA requires significant clinical data to support substantial
equivalence. In reviewing a premarket notification, the FDA may request additional information, including clinical data, which may significantly prolong the review process. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">After a device receives 510(k) clearance, any subsequent modification of the device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, will
require a new 510(k) clearance or could require PMA. The FDA requires each manufacturer to make this determination initially, but the FDA may review any such decision and may disagree with a manufacturer&#146;s determination. If the FDA disagrees
with a manufacturer&#146;s determination, the FDA may require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or PMA is obtained. We have modified aspects of some of our devices since receiving regulatory
clearance. We concluded that some of those modifications could not significantly affect the safety or efficacy of the device, and therefore, that new 510(k) clearances or PMAs were not required. We have also obtained new 510(k) clearances from the
FDA for other modifications to our devices. In the future, we may make additional modifications to our products after they </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">159 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
have received FDA clearance or approval, and in appropriate circumstances, determine that new clearance or approval is unnecessary. However, the FDA may disagree with our determination and if the
FDA requires us to seek 510(k) clearance or PMA for any modifications to a previously cleared product, we may be required to cease marketing or recall the modified device until we obtain the required clearance or approval. Under these circumstances,
we may also be subject to significant regulatory fines or other penalties. In addition, the FDA is currently evaluating the 510(k) process and may make substantial changes to industry requirements, including which devices are eligible for 510(k)
clearance, the ability to rescind previously granted 510(k)s and additional requirements that may significantly impact the process. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have obtained
510(k) premarket clearance from the FDA for Signafuse Bioactive Bone Graft Putty, Interface Bioactive Bone Graft and Signafuse Mineralized Collagen Scaffold. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Premarket approval process</I> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A PMA application must be submitted if the medical device is in Class III (although
the FDA has the discretion to continue to allow certain pre-amendment Class III devices to use the 510(k) process) or cannot be cleared through the 510(k) process. A PMA application must be supported by, among other things, extensive technical,
preclinical, clinical trials, manufacturing and labeling data to demonstrate to the FDA&#146;s satisfaction the safety and effectiveness of the device. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">After a PMA application is submitted and filed, the FDA begins an in-depth review of the submitted information, which typically takes between one and three years,
but may take significantly longer. During this review period, the FDA may request additional information or clarification of information already provided. Also during the review period, an advisory panel of experts from outside the FDA will usually
be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. In addition, the FDA will conduct a pre-approval inspection of the manufacturing facility to ensure compliance with
Quality System Regulation, or QSR, which impose elaborate design development, testing, control, documentation and other quality assurance procedures in the design and manufacturing process. The FDA may approve a PMA with post-approval conditions
intended to ensure the safety and effectiveness of the device including, among other things, restrictions on labeling, promotion, sale and distribution and collection of long-term follow-up data from patients in the clinical study that supported
approval. Failure to comply with the conditions of approval can result in materially adverse enforcement action, including the loss or withdrawal of the approval. New PMAs or PMA supplements are required for significant modifications to the
manufacturing process, labeling of the product and design of a device that is approved through the PMA process. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information
needed to support any changes from the device covered by the original PMA, and may not require as extensive clinical data or the convening of an advisory panel. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our Exogen system, Supartz FX and GelSyn-3, have obtained PMA approval. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Clinical trials</I><B> </B><I></I>
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A clinical trial is typically required to support a PMA and is sometimes required for a 510(k) premarket notification. In the United States, clinical
trials generally require submission of an application for an Investigational Device Exemption, or IDE, to the FDA. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to
test the device in humans and that the investigational protocol is scientifically sound. The IDE application must be approved in advance by the FDA for a specified number of patients, unless the product is deemed a non-significant risk device and
eligible for more abbreviated IDE requirements. Clinical trials for a significant risk device may begin once the IDE </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">160 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
application is approved by the FDA as well as the appropriate institutional review boards, or IRBs, at the clinical trial sites, and the informed consent of the patients participating in the
clinical trial is obtained. After a trial begins, the FDA may place it on hold or terminate it if, among other reasons, it concludes that the clinical subjects are exposed to an unacceptable health risk. Any trials we conduct must be conducted in
accordance with FDA regulations as well as other federal regulations and state laws concerning human subject protection and privacy. Moreover, the results of a clinical trial may not be sufficient to obtain clearance or approval of the product.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Pervasive and continuing FDA regulation</I> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">After a
medical device is placed on the market, numerous FDA regulatory requirements apply, including, but not limited to the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Quality System Regulation, which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures during the
manufacturing process; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Establishment Registration, which requires establishments involved in the production and distribution of medical devices, intended for commercial distribution in
the United States, to register with the FDA; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Medical Device Listing, which requires manufacturers to list the devices they have in commercial distribution with the FDA; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Labeling regulations, which prohibit &#147;misbranded&#148; devices from entering the market, as well as prohibit the promotion of products for unapproved or
&#147;off-label&#148; uses and impose other restrictions on labeling; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Postmarket surveillance including Medical Device Reporting, which requires manufacturers to report to the FDA if their device may have caused or contributed to a
death or serious injury, or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Corrections and Removal Reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken
to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The FDA
enforces these requirements by inspection and market surveillance. Failure to comply with applicable regulatory requirements may result in enforcement action by the FDA, which may include one or more of the following sanctions: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">untitled letters or warning letters; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">fines, injunctions and civil penalties; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">mandatory recall or seizure of our products; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">administrative detention or banning of our products; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">operating restrictions, partial suspension or total shutdown of production; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">refusing our request for 510(k) clearance or PMA for new product versions; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">revocation of 510(k) clearance or PMAs previously granted; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">criminal prosecution and penalties. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>International regulation of medical devices </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Sales of
medical devices outside the United States are subject to foreign government regulations, which vary substantially from country to country. In order to market our products in other countries, we must obtain
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">161 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
regulatory approvals and comply with extensive safety and quality regulations in other countries. The time required to obtain approval by a foreign country may be longer or shorter than that
required for FDA approval, and the requirements may differ significantly. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>&nbsp;&nbsp;&nbsp;&nbsp;European Union&#146;s regulation of medical
devices </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The European Union, or EU, has adopted legislation, in the form of directives to be implemented in each Member State, concerning the
regulation of medical devices within the European Union. The directives include, among others, the Medical Device Directive (Council Directive 93/42/EEC) that establishes certain requirements, i.e. the essential requirements, with which medical
devices must comply before they can be commercialized in the EEA (which is comprised of the Member States of the EU plus Norway, Liechtenstein and Iceland). Under the EU Medical Device Directive, medical devices are classified into four Classes, I,
IIa, IIb, and III, with Class I being the lowest risk and Class III being the highest risk. Under the Medical Device Directive, a competent authority is nominated by the government of each Member State to monitor and ensure compliance with the
Directive. To demonstrate compliance of their medical devices with the essential requirements, manufacturers must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. Except for
certain types of low risk medical devices (Class I <FONT STYLE="white-space:nowrap">non-sterile,</FONT> <FONT STYLE="white-space:nowrap">non-measuring</FONT> devices), where the manufacturer can issue an EC Declaration of Conformity based on a
self-assessment of the conformity of its products with the essential requirements of the Medical Devices Directive, a conformity assessment procedure requires the intervention of an organization accredited by a Member State of the EEA to conduct
conformity assessments, a so-called Notified Body. The Notified Body would typically audit and examine the quality system for the manufacture, design and final inspection of the medical devices before issuing a certification demonstrating compliance
with the essential requirements. Medical devices that comply with the essential requirements are entitled to bear the CE mark, which is an abbreviation for Conformit&eacute; Europ&eacute;ene or European Conformity. Medical devices properly bearing
the CE mark may be commercially distributed throughout the EEA. We have received CE certification from the British Standards Institute, a United&nbsp;Kingdom Notified Body, for conformity with the EU Medical Device Directive allowing us to place the
CE mark on our Durolane and Exogen products. Additional premarket approvals in individual EEA countries are sometimes required prior to marketing of a product. Failure to maintain the CE mark would preclude us from selling our products in the EEA,
as could failure to comply with the specific requirements of the Member States. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In September 2012, the European Commission published proposals for the
revision of the EU regulatory framework for medical devices. The proposal would replace the Medical Devices Directive with a new regulation, or the Medical Devices Regulation. Unlike the Directives that must be implemented into national laws, the
Medical Devices Regulation would be directly applicable in all EEA Member States and so is intended to eliminate current national differences in regulation of medical devices.&nbsp;In October 2013, the European Parliament approved a package of
reforms to the European Commission&#146;s proposals. Under the revised proposals, only designated &#147;special notified bodies&#148; would be entitled to conduct conformity assessments of high-risk devices. These special notified bodies will need
to notify the European Commission when they receive an application for a conformity assessment for a new high-risk device. The European Commission will then forward the notification and the accompanying documents on the device to the Medical Devices
Coordination Group, or MDCG, (a new, yet to be created, body chaired by the European Commission, and representatives of Member States) for an opinion. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If finally adopted, the Medical Devices Regulation is expected to enter into force in 2016 and become applicable three years thereafter. The adoption of the Medical
Devices Regulation may, however, be materially delayed. In its current form it would, among other things, also impose additional reporting requirements on manufacturers of high risk medical devices, impose an obligation on manufacturers to appoint a
&#147;qualified person&#148; responsible for regulatory compliance, and provide for more strict clinical evidence requirements. These new rules and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">162 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
procedures may result in increased regulatory oversight of certain devices and this may, in turn, increase the costs, time and requirements that need to meet in order to maintain or place such
devices on the EEA market. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Further, the advertising and promotion of our products in the EEA is subject to the laws of individual EEA Member States
implementing the EU Medical Devices Directive, Directive 2006/114/EC concerning misleading and comparative advertising, and Directive 2005/29/EC on unfair commercial practices, as well as other EEA Member State laws governing the advertising and
promotion of medical devices. These laws may limit or restrict the advertising and promotion of our products to the general public and may impose limitations on our promotional activities with healthcare professionals. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our Exogen system and Durolane, bear the CE mark. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>&nbsp;&nbsp;&nbsp;&nbsp;Other countries&#146; regulation of medical devices </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Many other countries have specific requirements for classification, registration and postmarketing surveillance that are independent of the countries already listed. We obtain what we believe are the appropriate
clearances for our Exogen system and Durolane and conduct our business in accordance with the applicable laws of each country. This landscape is constantly changing and we could be found in violation if we interpret the laws incorrectly or fail to
keep pace with changes. In the event of either of these occurrences, we could be instructed to recall products, cease distribution and/or be subject to civil or criminal penalties. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Government regulation of HCT/Ps </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our products, including OsteoAMP and PureBone, are regulated as human
cells, tissues and cellular and tissue-based products, or HCT/Ps. Section&nbsp;361 of the Public Health Service Act, or PHSA, authorizes the FDA to issue regulations to prevent the introduction, transmission or spread of communicable disease. HCT/Ps
regulated as &#147;361&#148; HCT/Ps are subject to requirements relating to registering facilities and listing products with the FDA, screening and testing for tissue donor eligibility, Good Tissue Practice when processing, storing, labeling, and
distributing HCT/Ps, including required labeling information, stringent record keeping, and adverse event reporting, among other applicable requirements and laws. Section 361 HCT/Ps do not require 510(k) clearance, PMA approval, BLAs, or other
premarket authorization from the FDA before marketing. We believe our OsteoAMP product is regulated as a Section 361 HCT/P, and therefore have not sought or obtained 510(k) clearance, PMA approval, or licensure through a BLA. However, the FDA&#146;s
CDRH issued us a letter in March 2016 in which it asserted that OsteoAMP meets the definition of a medical device, and requested that we provide CDRH with information in support of our position that OsteoAMP does not require 510(k) clearance or PMA
approval. We provided CDRH with the requested information in support of this position in May 2016 and we have received no further inquiries to date. We believe that CDRH&#146;s assertion is unfounded and inconsistent with a 2011 letter from the FDA
concluding that OsteoAMP meets the criteria for regulation solely as a Section 361 HCT/P. However, if the FDA were to disagree, and if we are otherwise unsuccessful in asserting our position, the FDA may then require that we obtain 510(k) clearance
or PMA approval and that we cease marketing OsteoAMP and/or recall OsteoAMP unless and until we receive clearance or approval. We estimate that if we were to cease marketing OsteoAmp and/or recall OsteoAmp that our net sales would decrease, which
would adversely affect our results of operations. See &#147;Risk factors &#150; Our HCT/P products are subject to extensive government regulation and our failure to comply with these requirements could cause our business to suffer.&#148; </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Government regulation of combination products </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We
expect that certain of our products under development will be regulated as combination products, which means that they are comprised of two or more different components that, if marketed individually, would be
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">163 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
subject to different regulatory pathways and would require approval of independent marketing applications by the FDA. A combination product, however, is assigned to a Center within the FDA that
will have primary jurisdiction over its regulation based on a determination of the combination product&#146;s primary mode of action, which is the single mode of action that provides the most important therapeutic action. In that case, the
combination product would be regulated as a drug and subject to the review of the FDA&#146;s Center for Drug Evaluation and Research, or CDER, who will have primary jurisdiction over premarket development. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Government regulation of drugs </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The process required
by the FDA before a drug may be marketed in the United States generally involves the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#146;s good laboratory practice, or GLP,
regulations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials may begin;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">approval by an independent IRB at each clinical site before each trial may be initiated; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and
efficacy of the proposed drug product for each indication; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">submission to the FDA of a new drug application, or NDA; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">satisfactory completion of an FDA advisory committee review, if applicable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good
manufacturing practice, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and purity; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">FDA review and approval of the NDA. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Preclinical studies </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Preclinical studies include laboratory
evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data
and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless
before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the
clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Clinical trials
</I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in
accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">164 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A
protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical
trial before it commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov website.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Phase 1:</I>&nbsp;&nbsp;&nbsp;&nbsp;The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested
for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Phase 2:</I>&nbsp;&nbsp;&nbsp;&nbsp;The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to
preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Phase 3:</I>&nbsp;&nbsp;&nbsp;&nbsp;The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in
well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling
of the product. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more
frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any
time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being
conducted in accordance with the IRB&#146;s requirements or if the drug has been associated with unexpected serious harm to patients. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Marketing
approval </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with
detailed information relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most
cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#147;filing&#148; of a
standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#147;filing&#148; decision.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, plan to ensure that the benefits of the drug outweigh its
risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are
sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is
also subject to review before the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">165 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is
safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#146;s continued safety, quality and purity. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and
provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an
application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an
NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">After evaluating the NDA and all related
information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A
complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for FDA to reconsider the application.
Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#146;s satisfaction, the FDA will
typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that
post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#146;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions,
including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the
results of postmarketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing
requirements and FDA review and approval. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Post-approval requirements </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting,
product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior
FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical
data. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require postmarketing
testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">166 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are
required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are
strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor
and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after
the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in mandatory revisions to the approved labeling to add new safety information; imposition of postmarket studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other
potential consequences include, among other things: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">fines, warning letters or holds on post-approval clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">product seizure or detention, or refusal to permit the import or export of products; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">injunctions or the imposition of civil or criminal penalties. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of
the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, to the extent we seek approval for our products in development in other countries, we would need to comply with numerous and varying
regulatory requirements of such other countries and jurisdictions regarding quality, safety, and efficacy that govern, among other things, clinical trials, manufacturing, marketing authorization, commercial sales, and distribution of our products,
regardless of whether or not we have obtained FDA approval for such product. Although many of the issues discussed above with respect to the United States apply similarly in the context of other countries in which we may seek approval, the approval
process varies among countries and jurisdictions and can involve different amounts of product testing and additional administrative review periods. For example, in Europe, a sponsor must submit a clinical trial application, or CTA, much like an IND
prior to the commencement of human clinical trials. A CTA must be submitted to each national health authority and an independent ethics committee. It is our intent to complete the requisite clinical studies and obtain coverage and reimbursement
approval in countries where it makes economic sense to do so. The time required to obtain approval in other countries and jurisdictions might differ from or be longer than that required to obtain FDA approval. Regulatory approval in one country or
jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively affect the regulatory approval process in other countries. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">167 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Anti-kickback, false claims and other healthcare laws </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to FDA restrictions on the marketing of pharmaceutical, biological and medical device products, we are also subject to healthcare regulation and
enforcement by the federal government and the states and foreign governments and authorities in the locations in which we conduct our business. These other agencies include, without limitation, the Centers for Medicare and Medicaid Services, or CMS,
other divisions of the U.S. Department of Health and Human Services, the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, as well as state and local governments. Such agencies enforce a variety of
laws which include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, data privacy and security, and physician payment transparency laws and regulations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The federal Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or
rebate), directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any good, facility, item or service reimbursable, in whole or in part, by
Medicare, Medicaid or other federal healthcare programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value, including cash, improper discounts, and free or reduced price items and services. Among other
things, the Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical, biotechnology and medical device manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there
are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce
prescribing, purchases or recommendations may be subject to scrutiny if they do not meet the requirements of a statutory or regulatory exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception
or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and
circumstances. Several courts have interpreted the statute&#146;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Anti-Kickback Statute
has been violated. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, a claim including items or services resulting from a violation
of the federal Anti-Kickback Statute also constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The federal false
claims and civil monetary penalties laws, including the civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to or approval by the
federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#147;any request or demand&#148; for money or property
presented to the U.S. government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the U.S. government. Violations of the False Claims Act can result in very
significant monetary penalties and treble damages. The federal government is using the False Claims Act, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical, biotechnology and medical device
companies throughout the country, for example, in connection with the promotion of products for unapproved uses and other sales and marketing practices. The government has obtained multi-million and multi-billion dollar settlements under the False
Claims Act in addition to individual criminal convictions under applicable criminal statutes. In addition, the federal civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have
presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">168 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
provided as claimed or is false or fraudulent. Given the significant size of actual and potential settlements, it is expected that governmental authorities will continue to devote substantial
resources to investigating healthcare providers&#146; and manufacturers&#146; compliance with applicable fraud and abuse laws. For drugs that are covered under Medicare Part B, the manufacturer must report average sales price, or ASP, to CMS on a
quarterly basis. Failure to report this information in a timely and accurate manner can lead to substantial civil and criminal penalties and to liability under the False Claims Act. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">HIPAA created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including
private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a
material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need
to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Also, many states have similar
fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, a person who offers or transfers to a Medicare or Medicaid beneficiary any remuneration, including waivers of co-payments and deductible amounts (or any part thereof), that the person knows or should
know is likely to influence the beneficiary&#146;s selection of a particular provider, practitioner or supplier of Medicare or Medicaid payable items or services may be liable for civil monetary penalties of up to $10,000 for each wrongful act.
Moreover, in certain cases, providers who routinely waive copayments and deductibles for Medicare and Medicaid beneficiaries can also be held liable under the Anti-Kickback Statute and civil False Claims Act, which can impose additional penalties
associated with the wrongful act. One of the statutory exceptions to the prohibition is non-routine, unadvertised waivers of copayments or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable
collection efforts. The Office of Inspector General of the Department of Health and Human Services emphasizes, however, that this exception should only be used occasionally to address special financial needs of a particular patient. Although this
prohibition applies only to federal healthcare program beneficiaries, the routine waivers of copayments and deductibles offered to patients covered by commercial payers may implicate applicable state laws related to, among other things, unlawful
schemes to defraud, excessive fees for services, tortious interference with patient contracts and statutory or common law fraud. To the extent our patient assistance programs are found to be inconsistent with applicable laws, we may be required to
restructure or discontinue such programs, or be subject to other significant penalties. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, there has been a recent trend of increased federal
and state regulation of payments made to physicians and certain other healthcare providers. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education and Reconciliation Act, or collectively, the Affordable Care Act,
imposed, among other things, new annual reporting requirements through the Physician Payments Sunshine Act for covered manufacturers for certain payments and &#147;transfers of value&#148; provided to physicians and teaching hospitals, as well as
ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests may
result in civil monetary penalties of up to an aggregate of $150,000 per year and up to an aggregate of $1 million per year for &#147;knowing failures.&#148; Covered manufacturers must submit reports by the 90th day of each calendar year. In
addition, certain states require implementation of compliance programs and compliance with the industry&#146;s voluntary compliance guidelines </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">169 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices, and/or require tracking and reporting of gifts, compensation and other
remuneration or items of value provided to physicians and other healthcare professionals and entities. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These laws impact the kinds of financial
arrangements we may have with hospitals, physicians or other potential purchasers of our products. They particularly impact how we structure our sales offerings, including discount practices, customer support, education and training programs,
physician consulting, research grants and other arrangements. If our operations are found to be in violation of any of the health regulatory laws described above or any other laws or regulations that apply to us, we may be subject to penalties,
including, without limitation, potentially significant criminal, civil and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs, imprisonment, contractual damages, reputational
harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a result of our sale or
distribution of products in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable postmarketing requirements, including safety surveillance, anti-fraud and abuse laws, and
implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We participate in
state government-managed Medicaid programs as well as certain other qualifying federal and state government programs where discounts and mandatory rebates are provided to participating state and local government entities. In connection with several
of these government programs, we are required to report prices to various government agencies. Pricing calculations vary among programs. The calculations are complex and are often subject to interpretation by the reporting entities, government
agencies and the courts. Our methodologies for calculating these prices could be challenged under false claims laws or other laws. We could make a mistake in calculating reported prices and required discounts, which could result in retroactive
liability to government agencies. Government agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. If we make these
mistakes or if governmental agencies make these changes, we could face, in addition to prosecution under federal and state false claims laws, substantial liability and civil monetary penalties, exclusion of our products from reimbursement under
government programs, criminal fines or imprisonment, or prosecutors may impose a Corporate Integrity Agreement, Deferred Prosecution Agreement, or similar arrangement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, requires that manufacturers report data to CMS on pricing of covered drugs reimbursed under Medicare Part&nbsp;B. These are
generally drugs, such as injectable products, that are administered &#147;incident to&#148; a physician service, and in general are not self-administered. Effective January&nbsp;1, 2005, ASP became the basis for reimbursement to physicians and
suppliers for drugs and biologicals covered under Medicare Part&nbsp;B, replacing the average wholesale price, or AWP, provided and published by pricing services. In general, we must comply with all reporting requirements for any drug that is
separately reimbursable under Medicare. The Supartz FX product is reimbursed under Medicare Part&nbsp;B and, as a result, we provide ASP data on this product to CMS on a quarterly basis. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Manufacturing requirements </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Manufacturers of medical devices are required to comply with FDA
manufacturing requirements contained in the FDA&#146;s cGMP set forth in the quality system regulations promulgated under section 520 of the FDCA. cGMP regulations require, among other things, quality control and quality assurance as well as the
corresponding </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">170 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
maintenance of records and documentation. Failure to comply with statutory and regulatory requirements subjects a manufacturer to possible legal or regulatory action, including the seizure or
recall of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations, and civil and criminal penalties. Adverse experiences with the product must be reported to the FDA and could result in the
imposition of marketing restrictions through labeling changes or in product withdrawal. Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product occur
following the approval. We expect to use third-party manufacturers to manufacture our products (other than our Exogen system) for the foreseeable future. We will therefore be dependent on their compliance with these requirements to market our
products. We work closely with our third-party manufacturers to assure that our products are in compliance with these regulations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the EU, the
manufacture of medical devices is subject to good manufacturing practice, or GMP, as set forth in the relevant laws and guidelines of the EU and its Member States. Compliance with GMP is generally assessed by the competent regulatory authorities.
Typically, quality system evaluation is performed by a Notified Body, which also recommends to the relevant competent authority for the European Community CE Marking of a device. The competent authority may conduct inspections of relevant
facilities, and review manufacturing procedures, operating systems and personnel qualifications. In addition to obtaining approval for each product, in many cases each device manufacturing facility must be audited on a periodic basis by the Notified
Body. Further inspections may occur over the life of the product. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Privacy and data protection laws in the United States </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Health Insurance Portability and Accountability Act of 1996, and its implementing regulations, as amended by the regulations promulgated pursuant to Health
Information Technology for Economic and Clinical Health Act, or HITECH Act, which we collectively refer to as HIPAA, contain substantial restrictions and requirements with respect to the use and disclosure of certain individually identifiable health
information (referred to as Protected Health Information, or PHI). These restrictions and requirements are set forth in the HIPAA Privacy, Security and Breach Notification Rules. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In some of our operations, such those involving the acceptance of payments, we are a &#147;covered entity&#148; under HIPAA and therefore required to comply with the Privacy, Security and Breach Notification Rules,
and are subject to significant civil and criminal penalties for failure to do so. We also provide services to customers that are covered entities themselves, and we are required to provide satisfactory written assurances to these customers through
written &#147;business associate&#148; agreements that we will provide our services in accordance with HIPAA. Failure to comply with these contractual agreements could lead to loss of customers, contractual liability to our customers, and direct
action by the federal government, including penalties. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Final Rule published by the Office for Civil Rights, or OCR, of the Department of Health and
Human Services in January 2013, modified the HIPAA Privacy, Security, Breach Notification and Enforcement Rules, including revisions/additions made by the HITECH Act. The rule expanded the privacy and security requirements for business associates
that create, receive, maintain or transmit protected health information for or on behalf of covered entities, increased penalties for noncompliance, and strengthened requirements for reporting of breaches of unsecured protected health information,
among other changes. The rule also made business associates and their subcontractors directly liable for civil monetary penalties for impermissible uses and disclosures of protected health information. The rule became effective on March&nbsp;23,
2013, and, with limited exception, covered entities and business associates covered by the rule were required to comply with most of the applicable requirements by September&nbsp;23, 2013. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition to HIPAA, we must adhere to state patient confidentiality laws that are not preempted by HIPAA, including those that are more stringent than HIPAA requirements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">171 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Numerous other state, federal and foreign laws, including consumer protection laws and regulations, govern the
collection, dissemination, use, access to, confidentiality and security of patient health information. In addition, Congress and some states are considering new laws and regulations that further protect the privacy and security of medical records or
medical information. With the recent increase in publicity regarding data breaches resulting in improper dissemination of consumer information, many states have passed laws regulating the actions that a business must take if it experiences a data
breach, such as prompt disclosure to affected customers. Generally, these laws are limited to electronic data and make some exemptions for smaller breaches. Congress has also been considering similar federal legislation relating to data breaches.
The FTC and states&#146; Attorneys General have also brought enforcement actions and prosecuted some data breach cases as unfair and/or deceptive acts or practices under the FTC Act. In addition to data breach notification laws, some states have
enacted statutes and rules requiring businesses to reasonably protect certain types of personal information they hold or to otherwise comply with certain specified data security requirements for personal information. As with HIPAA, these laws may
apply directly to our business or indirectly by contract when we provide services to other companies. We intend to continue to comprehensively protect all consumer data and to comply with all applicable laws regarding the protection of this data.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Privacy and data protection laws in other jurisdictions </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In the EU, we are subject to laws relating to our collection, control, processing and other use of personal data (i.e. data relating to an identifiable living individual). We process personal data in relation to
our operations. We process data of both our employees and our customers, including health and medical information. The data privacy regime in the EU includes the EU Data Protection Directive (95/46/EC)&nbsp;regarding the processing of personal data
and the free movement of such data, the E-Privacy Directive 2002/58/EC and national laws implementing each of them. As each Member State of the EU has transposed the requirements laid down by this Privacy and Data Protection Directive into its own
national data privacy regime, the laws therefore differ significantly by jurisdiction. In addition, on December&nbsp;15, 2015, the European Commission, European Parliament and Council of the EU reached agreement on new data protection rules which
will implement significant changes to the current EU data protection regime. Unlike the Privacy and Data Protection Directive, the Regulation has direct effect in each Member State, without the need for further enactment. The Regulation has a
two-year implementation period. When implemented, the Regulation will likely strengthen individuals&#146; rights and impose stricter requirements on companies processing personal data. Prior to its full implementation, we may not be able to
accurately assess its full impact on our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The requirements include that personal data may only be collected for specified, explicit and
legitimate purposes based on legal grounds set out in the local laws, and may only be processed in a manner consistent with those purposes. Personal data must also be adequate, relevant, not excessive in relation to the purposes for which it is
collected, be secure, not be transferred outside of the EEA unless certain steps are taken to ensure an adequate level of protection and must not be kept for longer than necessary for the purposes of collection. To the extent that we process,
control or otherwise use sensitive data relating to living individuals (for example, patients&#146; health or medical information), more stringent rules apply, limiting the circumstances and the manner in which we are legally permitted to process
that data and transfer that data outside of the EEA. In particular, in order to process such data, explicit consent to the processing (including any transfer) is usually required from the data subject (being the person to whom the personal data
relates). The European Court of Justice has ruled that the U.S.-E.U. Safe Harbor framework, one compliance method by which companies could transfer personal data regarding citizens of the European Union to the United States, could no longer be
relied upon. The potential impact of this ruling is subject to further determination and additional developments, including the recently released legal texts that will form the basis of the EU-US Privacy Shield Framework, a new form of Safe Harbor
framework. These changes may require us to find alternative bases for the compliant transfer of personal data from the E.U. to the U.S. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">172 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are subject to the supervision of local data protection authorities in those jurisdictions where we are established
or otherwise subject to applicable law. We depend on a number of third parties in relation to our provision of our services, a number of which process personal data on our behalf. With each such provider we enter into contractual arrangements to
ensure that they only process personal data according to our instructions, and that they have sufficient technical and organizational security measures in place. Where we transfer personal data outside the EEA, we do so in compliance with the
relevant data export requirements. We take our data protection obligations seriously, as any improper disclosure, particularly with regard to our customers&#146; sensitive personal data, could negatively impact our business and/or our reputation.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There are costs and administrative burdens associated with ongoing compliance with HIPAA and similar state, federal and foreign law requirements. Any
failure or perceived failure to comply carries with it the risk of significant penalties and sanctions. These laws at a state, federal or foreign level, or new interpretations of these laws, could create liability for us, could impose additional
operational requirements on our business, could affect the manner in which we use and transmit patient information and could increase our cost of doing business. Claims of violations of privacy rights or contractual breaches, even if we are not
found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Coverage and
reimbursement </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical, biological or medical device
product. In the United States and markets in other countries, patients who are prescribed treatments or undergo procedures for their conditions and the providers performing the services generally rely on
<FONT STYLE="white-space:nowrap">third-party</FONT> payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant
portion of the cost of our products or related procedures. Sales of any products will therefore depend, in part, on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include government authorities,
managed care providers, private health insurers and other organizations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The process for determining whether a third-party payor will provide coverage
for a product typically is separate from the process for setting the price of such product or for establishing the reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to
specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication, or place products at certain formulary levels that result in lower reimbursement levels and
higher cost-sharing obligation imposed on patients. A decision by a third-party payor not to cover any of our product candidates could reduce physician utilization of our products once approved and have a material adverse effect on our sales,
results of operations and financial condition. Moreover, a third-party payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be
available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Additionally, coverage and reimbursement for products can differ significantly from payor to payor. One third-party
payor&#146;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement rate. As a result, the
coverage determination process will often require us to provide scientific and clinical support for the use of our products to each payor separately and can be a time-consuming process. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain
and maintain coverage and reimbursement for any product, we may need to conduct expensive clinical trials in order to demonstrate the medical necessity and cost-effectiveness of such product, in addition to the costs
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">173 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
required to obtain regulatory approvals. Our products may not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to
other available therapies, they may not cover the product as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. Any changes in coverage and reimbursement that
further restricts coverage of our products or lowers reimbursement for procedures using our devices could materially affect our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Outside of the
United States, the pricing of medical devices and prescription pharmaceuticals is subject to governmental control in many countries. For example, in the EU, pricing and reimbursement schemes vary widely from country to country. Some countries
provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular therapy to currently available therapies or
so called health technology assessments, in order to obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to
limit prescriptions. Efforts to control prices and utilization of medical devices and pharmaceutical products could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced
by many countries in the EU. There can be no assurance that any country that has price controls or reimbursement limitations for medical devices or pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our
products, if approved in those countries. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Exogen reimbursement and order fulfillment </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our Exogen system is classified as durable medical equipment, meaning the product is used by the patient in the home and that the patient and/or insurance company,
rather than the physician, is billed for the product. We bill third-party payors, such as private insurance or Medicare, on behalf of our patients and bill the patient for their co-payment obligations and deductibles. We bill and process orders for
our Exogen system through a team of approximately 40 employees trained in verifying case-by-case benefits, obtaining prior authorization, and billing and collecting payments from payors. We also have a separate dedicated team of employees that
provides customer support services for our Exogen system. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have strong and established payor relationships, including the largest private payors in
the United&nbsp;States. Based on our estimates, we are contracted or enrolled as an in-network provider with payors covering over 100 million lives. These contracts allow us to be an in-network provider for patients, enabling them to access our
Exogen system at a competitive rate and copay comparable to other suppliers, and easing our administrative burden in processing at both authorization and when billing. Our Exogen system is reimbursed under HCPCS code E0760. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Healthcare reform </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A primary trend in the U.S.
healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services. In recent
years, Congress has enacted a number of laws that affect Medicare reimbursement for and coverage of durable medical equipment and durable medical equipment, prosthetics, orthotics and supplies, such as our Exogen system. These laws have included
temporary freezes or reductions in Medicare fee schedule updates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For example, the Affordable Care Act substantially changed healthcare financing and
delivery by both governmental and private insurers, and significantly impacted the pharmaceutical and medical device </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">174 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
industries. The Affordable Care Act, among other things, subjects biologic products to potential competition by lower-cost biosimilars; addresses a new methodology by which rebates owed by
manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and
extends the rebate program to individuals enrolled in Medicaid managed care organizations; establishes a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices
of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs coverage under Medicare Part D; subjects drug manufacturers to new annual fees based on pharmaceutical
companies&#146; share of sales to federal healthcare programs; imposes a new federal excise tax on the sale of certain medical devices; created a new Patient Centered Outcomes Research Institute to oversee, identify priorities in, and conduct
comparative effectiveness research, along with funding for such research; implements payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination,
quality and efficiency of certain healthcare services through bundled payment models; and creates an independent payment advisory board that will submit recommendations to reduce Medicare spending if projected Medicare spending exceeds a specified
growth rate. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. On
August&nbsp;2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not
achieve a targeted deficit reduction of at least $1.2&nbsp;trillion for the years 2013 through 2021, triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to
providers of up to 2%&nbsp;per fiscal year, which went into effect on April&nbsp;1, 2013 and, due to the Bipartisan Budget Act of 2015, will stay in effect through 2025 unless additional Congressional action is taken. On January&nbsp;2, 2013, the
American Taxpayer Relief Act of 2012, was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations
period for the government to recover overpayments to providers from three to five years. President Obama signed the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, on April&nbsp;16, 2015, which repealed and replaced the Sustainable
Growth Rate, or SGR, formula for Medicare payment adjustments to physicians. MACRA provides a solution to the annual interim legislative updates that had previously been necessary to delay or prevent significant reductions to payments under the
Physician Fee Schedule. MACRA extended existing payment rates under Protecting Access to Medicare Act of 2014, or PAMA, through June&nbsp;30, 2015, with a 0.5% update for July&nbsp;1, 2015, through December&nbsp;31, 2015 and for each calendar year
through 2019, after which there will be a 0% annual update each year through 2025. MACRA also requires CMS, beginning in 2019, to provide incentive payments for physicians and other eligible professionals that participate in alternative payment
models, such as accountable care organizations, that emphasize quality and value over the traditional volume-based fee-for-service model. MACRA is still new and the manner in which it will be implemented is not certain. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We expect that additional foreign, state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and
state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressure. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Employees </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of April 2, 2016, we had approximately 650
employees, none of which were covered by collective bargaining agreements. Most of these employees are located in the United States with approximately 130&nbsp;located outside the United States. We believe that our relations with our employees are
generally good. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">175 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Facilities </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our
principal executive offices occupy approximately 45,853 square feet of leased office space located in Durham, North Carolina. We also occupy approximately 39,800 square feet of leased office and manufacturing space in Cordova, Tennessee. As a result
of our acquisition of BioStructures, we also occupy leased space in Newport Beach, California. In addition, our international operations are located in Hoofddorp, Netherlands where we occupy approximately 7,190 square feet of leased office space. We
also occupy leased R&amp;D facilities in Boston, Massachusetts. We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed on acceptable terms. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Legal proceedings </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are not currently a party to any
material legal proceedings. We may at times be involved in litigation and other legal claims in the ordinary course of business. When appropriate in our estimation, we may record reserves in our financial statements for pending litigation and other
claims. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">176 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_14"></A>Management </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Executive officers, key employees and directors </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table sets forth information regarding the
individuals who have agreed to become our executive officers, key employees and directors upon the completion of this offering, as of July&nbsp;19, 2016: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="63%"></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Age</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Position(s)</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Executive&nbsp;Officers</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Anthony P. Bihl III</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">59</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Chief Executive Officer and Director</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">David J. Price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Senior Vice President and Chief Financial Officer</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Gregory O. Anglum</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">46</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Chief Accounting Officer</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Jeanne M. Forneris</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">63</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Senior Vice President, Strategy and General Counsel</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Henry C. Tung, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Senior Vice President, Bioventus and President, Bioventus Surgical</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-Employee&nbsp;Directors</FONT></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Philip G. Cowdy</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">William A. Hawkins</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">62</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Michael R. Minogue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Guido J. Neels</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">67</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Guy P. Nohra</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">56</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">David J. Parker</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cyrille Y. N. Petit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">46</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Martin P. Sutter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">61</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following are biographical summaries and a description of the business experience of those individuals who serve as officers of
Bioventus LLC. Upon the consummation of this offering, such individuals will serve in the same capacities at Bioventus Inc. The following also contains biographical summaries and a description of the business experience of those individuals who will
serve as directors of Bioventus Inc. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Executive officers and directors </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Anthony P. Bihl III</I> has served as Chief Executive Officer, and as a manager of Bioventus LLC, since December 2013. From June 2011 through June 2012, Mr.&nbsp;Bihl was Group President of American Medical
Systems Holdings, a subsidiary of Endo Pharmaceuticals. From April 2008 until Endo Pharmaceuticals acquired American Medical Systems Holdings in June 2011, he was Chief Executive Officer and a director of American Medical Systems Holdings, a company
engaged in developing and delivering medical technology solutions to physicians treating men&#146;s and women&#146;s pelvic health conditions. From January 2007 to November 2007, Mr.&nbsp;Bihl served as Chief Executive Officer of Siemens Medical
Solutions&#146; Diagnostics Division. From 2004 through 2006, he served as President of the Diagnostics Division of Bayer HealthCare<B>. </B>Prior to that, he served in a number of operations and finance roles at Bayer Healthcare and E.I. DuPont.
Mr.&nbsp;Bihl also is chairman of the board of directors of Spectral Diagnostics, Inc., a company that develops products for the diagnosis and treatment of severe sepsis and septic shock, and a director of Nuvectra Inc. Mr.&nbsp;Bihl received his
B.S. in Business Administration from Pennsylvania State University. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">177 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe Mr.&nbsp;Bihl&#146;s experience in the industry, his role as our Chief Executive Officer and his knowledge
of the Company enable him to make valuable contributions to our board of directors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>David J. Price</I> has served as the Vice President and Chief
Financial Officer at Bioventus LLC since October 2012 and was made Senior Vice President and Chief Financial Officer in February 2016. From July 2010 to August 2012 and May 2011 to August 2012, Mr.&nbsp;Price served as the Chief Financial Officer
and Chief Operating Officer of EDGAR Online Inc., respectively. From September 2008 to July 2010, Mr.&nbsp;Price served various roles at Cornerstone Therapeutics Inc., including Chief Financial Officer and Executive Vice President of Finance. Prior
to that, he served as a Managing Director in the healthcare sector at both Jefferies and Bear Stearns. Mr.&nbsp;Price is a member of the Institute of Chartered Accountants in England and Wales. Mr.&nbsp;Price holds a Bachelor&#146;s of Science
Honours Degree in Accounting and Financial Management from Lancaster University (United Kingdom). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Gregory O. Anglum</I> has served as our Chief
Accounting Officer at Bioventus LLC since April 2016. From September&nbsp;2014 to April 2016, Mr. Anglum was Chief Financial Officer of Overture Networks, Inc., a leading global provider of network functions virtualization, software-defined
networking and carrier ethernet solutions for communications networks. From December 2013 to August 2014, he was Chief Financial Officer at StrikeIron, Inc., a Data-as-a-Service software company. From August 2004 to July 2013, Mr. Anglum was an
audit partner at Grant Thornton LLP where he also served as leader for the Raleigh local office from August 2009 through July 2013 and was on the firm-wide leadership team for the technology industry group. Mr. Anglum helped open the Grant Thornton
office in Raleigh in July 2002 as a senior manager when he joined that firm after starting his career as a staff auditor at Arthur Andersen LLP in July 1993 and progressing to the role of manager. He is a Certified Public Accountant. Mr. Anglum
holds an Masters of Business Administration with a concentration in Accounting from Vanderbilt University&#146;s Owen Graduate School of Management and a Bachelors of Arts in Economics from Vanderbilt University. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Jeanne M. Forneris</I> has served as Vice President, Strategy and General Counsel at Bioventus LLC since May 2012 and was made Senior Vice President, Strategy
and General Counsel in February 2016. From February 2010 to November 2011, Ms.&nbsp;Forneris served as Senior Vice President and General Counsel at American Medical Systems Holdings Inc. From January 2007 to February 2010, she served as Vice
President of Strategic Investments for the Cardiac Rhythm Disease Management Division of Medtronic. From July 2000 to December 2006, Ms.&nbsp;Forneris served as Vice President and Senior Counsel for the Cardiac Rhythm Disease Management Division of
Medtronic. Ms.&nbsp;Forneris holds a Bachelor of Arts in Political Science and History from Macalester College and a Juris Doctorate from the University of Minnesota. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Henry C. Tung, M.D. </I>has served as Vice President, Bioventus and General Manager, Bioventus Surgical at Bioventus LLC since October 2014 and was made Senior Vice President, Bioventus and President, Bioventus
Surgical in February 2016. Dr.&nbsp;Tung previously served as Vice President and Managing Director of the International Headquarters of Bioventus. From 2009 to May 2012, he led strategic planning and business development for the Biologics Division
of S&amp;N. From February 2005 to 2008, he served as Corporate Vice President Global Surgical and President of North America Surgical for Bausch&nbsp;&amp; Lomb, where he managed its medical device business. From 2000 to February 2005, he served as
Vice President, New Business Development at Boston Scientific Corporation. Dr.&nbsp;Tung received his Master of Business Administration from Northwestern University&#146;s Kellogg Graduate School of Management, his medical degree from the University
of California School of Medicine, and his bachelor&#146;s degree from Stanford University. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Non-employee directors </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Philip G. Cowdy</I> has served as a manager of the board of managers of Bioventus LLC since January 2012 and is a member of the audit committee of Bioventus
LLC.&nbsp;Mr. Cowdy is the Head of Corporate Affairs and Strategic Planning for Smith &amp; Nephew, a global medical technology business.&nbsp;Since joining Smith &amp; Nephew in 2008, he </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">178 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
has also served as Group Director of Corporate Affairs and Director of Investor Relations. Prior to joining Smith &amp; Nephew, Mr. Cowdy served as a Senior Director at Deutsche Bank for 13
years, providing corporate finance and equity capital markets advice to a variety of UK-based companies. Mr. Cowdy received his Bachelor of Science in Natural Sciences at Durham University (UK). </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe Mr.&nbsp;Cowdy&#146;s experience in the industry and his knowledge of&nbsp;Bioventus will enable him to make valuable contributions to our board of
directors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>William A. Hawkins</I> has served as a manager of the board of managers of Bioventus LLC since January 2016.&nbsp;From October 2011 to
July 2015, Mr. Hawkins served as President and CEO of Immucor, a leading provider of transfusion and transplantation diagnostic products worldwide. From August 2007 to April 2011, Mr. Hawkins served as Chairman and CEO of Medtronic, Inc., a
prominent global company in medical technology and services, which he joined in January 2002. Previously, he served as President and CEO of Novoste Corp. Mr.&nbsp;Hawkins has also held senior leadership positions at American Home Products, Johnson
&amp; Johnson, Guidant Corp. and Eli Lilly and Company. Mr. Hawkins currently serves on the board of directors of Halyard Health, Inc., a public medical technology company, and Immucor, Inc., a private medical diagnostics company. Mr. Hawkins
received a Bachelor of Science in electrical and biomedical engineering from Duke University and a Masters of Business Administration from the Darden School of Business, University of Virginia. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe Mr.&nbsp;Hawkins&#146; experience in and knowledge of the life science industry will enable him to make valuable contributions to our board of directors.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Michael R. Minogue</I>&nbsp;has served as a manager of the board of managers of Bioventus LLC since June 2016.&nbsp;From 2004 to the present, Mr.
Minogue has served as Chief Executive Officer, President and Chairman of Abiomed Inc., a public company that manufactures cardiac support, recovery, and replacement devices.&nbsp;Previously, Mr. Minogue spent eleven years at GE Healthcare, a
subsidiary of General Electric, where he holds three patents and developed expertise in sales, marketing, product development and software/service operations around diagnostic imaging and treatment of cancer and cardiovascular disease. Mr. Minogue
also currently serves on the board of directors for the Advanced Medical Technology Association, a medical device trade association, and as Chairman of the Medical Device Industry Consortium, a public private partnership with the industry,
government and non-profits.&nbsp;Mr. Minogue is also one of the co-founders and Chairman of the MedTech and BioTech Veterans Program, a non-profit organization that helps military veterans network with industry mentors to discover career
opportunities in the life sciences industries. Mr. Minogue received his Bachelor of Science degree in Engineering Management from the United States Military Academy at West Point and his Master of Business Administration from the University of
Chicago. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe Mr. Minogue&#146;s experience working in the industry and his knowledge of the medical device industry will enable him to make
valuable contributions to our board of directors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Guido J. Neels</I> has served as a manager of the board of managers of Bioventus LLC since May
2012. Mr.&nbsp;Neels has been with Essex Woodlands since 2006, where he is now a Venture Partner. Prior to joining Essex Woodlands, Mr.&nbsp;Neels served in a variety of management positions at Guidant, a developer of cardiovascular medical
products. From July 2004 until retiring in November 2005, Mr.&nbsp;Neels served as Guidant&#146;s Chief Operating Officer, where he was responsible for the global operations of Guidant&#146;s four operating units: Cardiac Rhythm Management, Vascular
Intervention, Cardiac Surgery and Endovascular Solutions. From December 2002 to July 2004, Mr.&nbsp;Neels served as Guidant&#146;s Group Chairman, Office of the President, responsible for worldwide sales operations, corporate communications,
corporate marketing, investor relations and government relations. In January 2000, Mr.&nbsp;Neels was named Guidant&#146;s President, Europe, Middle East, Africa and Canada. In addition, Mr.&nbsp;Neels served as Guidant&#146;s Vice President, Global
Marketing, Vascular Intervention, from 1996 to 2000 and as Guidant&#146;s General Manager, Germany and Central Europe, from 1994 to 1996. Mr.&nbsp;Neels currently serves on the board of directors of 480 Biomedical, Inc., Oraya Therapeutics, Inc.,
Arsenal </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">179 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Medical, Inc., EndGenitor Technologies, Inc. and White Pine Medical LLC, all privately held medical device companies, and Christel House International, a not-for-profit organization. He also
serves on the board of Endologix, where he serves on the board&#146;s compensation and nominating and governance committees. Mr.&nbsp;Neels has a business engineering degree from the University of Leuven in Belgium and a Masters in Business
Administration from the Stanford University Graduate School of Business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that Mr.&nbsp;Neels&#146; experience in the industry, familiarity
with serving on the boards of public companies and his knowledge of Bioventus will enable him to make valuable contributions to our board of directors. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Guy P. Nohra </I>has served as a manager of the board of managers of Bioventus LLC since May 2012 and serves as the Chair of the Compensation Committee of
Bioventus LLC. In March 1996, Mr. Nohra co-founded Alta Partners, a life sciences venture capital firm, and he has since been involved in the funding and development of numerous medical technology and life sciences companies. Mr. Nohra currently
serves as a member of the boards of directors of several life sciences companies, including<I> </I>Carbylan Biosurgery, USGI Medical, Vertiflex, and ZS Pharma, and is the Chairman of the Board of USGI Medical and ZS Pharma. He also served on the
board of directors of the Medical Device Manufacturing Association (MDMA) from 2003 to 2013<I>. </I>Mr. Nohra received a Bachelor of Arts in History from Stanford University and a Masters in Business Administration from the University of Chicago.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe Mr. Nohra is qualified to serve on our board because of his extensive experience in the life sciences industry, his investment and
development experience, and his service as a director of other life sciences companies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>David J. Parker</I> has served as a manager of the board of
managers of Bioventus LLC since May 2012 and serves as the Chair of the Audit, Quality and Compliance Committee. Since 2010, Mr.&nbsp;Parker has been Partner and General Partner at Ampersand Capital Partners after joining Ampersand Capital Partners
in 1994.&nbsp;From November 2007 to October 2010, Mr. Parker served as the Chief Financial Officer and Executive Vice President of Victory Pharma, Inc. From January 1997 to December 1997, he served as a Vice President of Corporate Development at
Novel Experimental Technology. Mr. Parker has served as a director of Accuratus Lab Services, Inc., BPA Holding Corporation, CutisPharma, Inc., Eaton Veterinary Pharmaceutical, Inc., Gyros Holding AB and Protein Technologies, Inc.<I>&nbsp;</I>Mr.
Parker holds a Masters in Business Administration in Finance from Wharton School of the University of Pennsylvania and a Bachelor of Arts in Government and Economics from Dartmouth College. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We believe Mr. Parker is qualified to serve on our board because of his extensive experience in the life sciences industry, his finance and investment experience, and his service as a director of other life
sciences companies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Cyrille Y. N. Petit</I> has served as a manager of the board of managers of Bioventus LLC since November 2012. From May 2012, Mr.
Petit has served as Chief Corporate Development Officer and President of Global Business Services of Smith &amp; Nephew PLC. Prior to that,<I> </I>Mr. Petit spent the previous 15 years of his career with General Electric Company, where he held
progressively senior positions beginning with GE Capital, GE Healthcare and ultimately as the General Manager of Global Business Development of the Transportation Division. Mr. Petit&#146;s career began in investment banking at BNP Paribas and
Goldman Sachs. Mr. Petit holds a Master of Arts in Finance from the HEC School of Management in Paris, France. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe Mr. Petit&#146;s experience in
the life sciences industry and his business development expertise led to the conclusion that he should serve as a director of our board of directors. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Martin P. Sutter </I>has served as a manager of the board of managers of Bioventus LLC since May 2012. Mr. Sutter is one of the two founding managing directors
of Essex Woodlands, one of the oldest and largest life sciences/healthcare focused venture capital firms, with nearly $3 billion under management. Mr. Sutter was a founder of Essex Woodlands Health Ventures In 1994. Mr. Sutter has more than 30 years
of management experience in operations, marketing, finance and venture capital. Mr.&nbsp;Sutter currently serves on the board of directors of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">180 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
QSpex Technologies, Inc. and Abiomed, Inc., a public company. Mr. Sutter holds a Bachelor of Science from Louisiana State University and a Masters in Business Administration from the University
of Houston. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe Mr. Sutter is qualified to serve on our board because of his extensive experience in the life sciences industry, his investment
experience, and his service as a director of other life sciences companies. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Corporate governance </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Composition of our board of directors </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Upon the
consummation of this offering, the number of directors will be increased to nine. Further, our amended and restated certificate of incorporation and bylaws will provide for the division of our board of directors into three classes, as nearly equal
in number as possible, with the directors in each class serving for a <FONT STYLE="white-space:nowrap">three-year</FONT> term, and one class being elected each year by our stockholders. Prior to the consummation of this offering, David J. Price will
resign as a director and each of Philip G. Cowdy, William A. Hawkins, Michael R. Minogue, Guido J. Neels, Guy P. Nohra, David J. Parker, Cyrille Y. N. Petit and Martin P. Sutter, will join our board of directors. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">When considering whether directors and nominees have the experience, qualifications, attributes or skills, taken as a whole, to enable our board of directors to
satisfy its oversight responsibilities effectively in light of our business and structure, the board of directors focuses primarily on each person&#146;s background and experience as reflected in the information discussed in each of the
directors&#146; individual biographies set forth above. We believe that our directors provide an appropriate mix of experience and skills relevant to the size and nature of our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In accordance with our amended and restated certificate of incorporation and the Stockholders Agreement, each of which will be in effect upon the closing of this offering, our board of directors will be divided
into three classes with staggered three year terms. At each annual meeting of stockholders after the initial classification, the successors to the directors whose terms will then expire will be elected to serve from the time of election and
qualification until the third annual meeting following their election. Our directors will be divided among the three classes as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Class I directors will be Messrs. Neels, Nohra and Parker, and their terms will expire at the annual meeting of stockholders to be held in 2017;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Class II directors will be Messrs. Hawkins, Minogue and Petit, and their terms will expire at the annual meeting of stockholders to be held in 2018; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Class III directors will be Messrs. Bihl, Cowdy and Sutter and their terms will expire at the annual meeting of stockholders to be held in 2019.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any increase or decrease in the number of directors will be distributed among the three classes so that, as nearly as possible, each
class will consist of one-third of the directors. This classification of our board of directors may have the effect of delaying or preventing changes in control of our Company. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Director independence </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Prior to the consummation of this offering, our board of directors undertook a
review of the independence of our directors and considered whether any director has a material relationship with us that could compromise that director&#146;s ability to exercise independent judgment in carrying out that director&#146;s
responsibilities. Our board of directors has determined that, except as described below with respect to Anthony P. Bihl III, all of the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">181 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
members of each of the board&#146;s three standing committees are independent as defined under the rules of The NASDAQ Global Market, including, in the case of all members of the audit committee,
except Philip G. Cowdy, the independence requirements contemplated by <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> under the Exchange Act. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Board committees </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our board has established three
standing committees&#151;audit, compensation, and nominating and corporate governance&#151;each of which operates under a charter that has been approved by our board of directors. Current copies of each committee&#146;s charter are posted on our
website, <I>www.bioventusglobal.com</I>. The information on any of our websites is deemed not to be incorporated in this prospectus or to be part of this prospectus. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Following this offering, the Voting Group, which will hold Class&nbsp;A common stock and Class&nbsp;B common stock collectively representing a majority of the combined voting power of our total common stock
outstanding, intends to enter into the Stockholders Agreement to elect the nominees of certain members of the Voting Group to our board of directors. See &#147;Description of capital stock&#151;Stockholders Agreement.&#148; As a result, we will be a
&#147;controlled company&#148; under The NASDAQ Global Market governance standards. As a controlled company, exemptions under the standards will mean that we are not required to comply with certain corporate governance requirements, including the
following requirements: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">that a majority of our board of directors consists of &#147;independent directors,&#148; as defined under the NASDAQ rules; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">that we have a nominating and corporate governance committee that is composed entirely of independent directors with a written charter addressing the
committee&#146;s purpose and responsibilities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">that we have a compensation committee that is composed entirely of independent directors with a written charter addressing the committee&#146;s purpose and
responsibilities; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">for an annual performance evaluation of the nominating and governance committee and compensation committee. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These exemptions do not modify the independence requirements for our audit committee, and we intend to comply with the applicable requirements of the <FONT
STYLE="white-space:nowrap">Sarbanes-Oxley</FONT> Act and rules with respect to our audit committee within the applicable time frame. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Audit
committee </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The audit committee will be responsible for, among other matters: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">appointing, compensating, retaining, evaluating, terminating and overseeing our independent registered public accounting firm; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">discussing with our independent registered public accounting firm their independence from management; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reviewing with our independent registered public accounting firm the scope and results of their audit; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">approving all audit and permissible <FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our independent registered public accounting
firm; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">overseeing the financial reporting process and discussing with management and our independent registered public accounting firm the interim and annual financial
statements that we file with the SEC; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reviewing and monitoring our accounting principles, accounting policies, financial and accounting controls and compliance with legal and regulatory requirements;
and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">establishing procedures for the confidential anonymous submission of concerns regarding questionable accounting, internal controls or auditing matters.
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">182 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Upon the closing of this offering, our audit committee will consist of Philip&nbsp;G. Cowdy, David&nbsp;J. Parker and
Michael&nbsp;R. Minogue, with David&nbsp;J. Parker serving as chair. <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> of the Exchange Act and NASDAQ rules require us to have one independent audit committee member upon the listing of our
common stock, a majority of independent directors on our audit committee within 90&nbsp;days of the date of this prospectus and an audit committee composed entirely of independent directors within one year of the date of this prospectus. Our board
of directors has affirmatively determined that David&nbsp;J. Parker and Michael&nbsp;R. Minogue meet the definition of &#147;independent director&#148; for purposes of serving on an audit committee under
<FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> and NASDAQ rules, and we intend to comply with the other independence requirements within the time periods specified. In addition, our board of directors has determined that David&nbsp;J.
Parker will qualify as an &#147;audit committee financial expert,&#148; as such term is defined in Item&nbsp;407(d)(5) of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT> </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Compensation committee </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The compensation committee&#146;s responsibilities include: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reviewing and approving the compensation of our directors, Chief Executive Officer and other executive officers; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">appointing and overseeing any compensation consultants. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Upon the closing of this offering, our compensation committee will consist of Guy&nbsp;P. Nohra, Guido&nbsp;J. Neels and Cyrille&nbsp;Y. N. Petit, with Guy&nbsp;P. Nohra serving as chair. As a controlled company,
we will rely upon the exemption from the requirement that we have a compensation committee composed entirely of independent directors. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Nominating
and corporate governance committee </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The nominating and corporate governance committee&#146;s responsibilities include: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">identifying individuals qualified to become members of our board of directors, consistent with criteria approved by our board of directors; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">developing and recommending to our board of directors a set of corporate governance guidelines and principles. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The members of our nominating and corporate governance committee are Martin&nbsp;P. Sutter, Guy&nbsp;P. Nohra and Cyrille&nbsp;Y.&nbsp;N. Petit, with Martin P.
Sutter serving as chair. As a controlled company, we will rely upon the exemption from the requirement that we have a nominating and corporate governance committee composed entirely of independent directors. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risk oversight </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our board of directors is responsible for
overseeing our risk management process. Our board of directors focuses on our general risk management strategy, the most significant risks facing us, and oversees the implementation of risk mitigation strategies by management. Our board of directors
is also apprised of particular risk management matters in connection with its general oversight and approval of corporate matters and significant transactions. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Risk considerations in our compensation program </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We conducted an assessment of our compensation policies and
practices for our employees and concluded that these policies and practices are not reasonably likely to have a material adverse effect on us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">183 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Director compensation </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">None of our directors received compensation as a director during fiscal 2015. We intend to approve and implement a compensation policy that, effective upon the closing of this offering, will be applicable to all of
our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Compensation committee interlocks and insider participation </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During fiscal 2015, the members of Bioventus LLC&#146;s compensation committee were Guy P. Nohra, Guido J. Neels and Cyrille&nbsp;Y. N. Petit. No member of our
compensation committee is or has been a current or former officer or employee of Bioventus or had any related person transaction involving Bioventus. None of our executive officers served as a director or a member of a compensation committee (or
other committee serving an equivalent function) of any other entity, one of whose executive officers served as a director or member of Bioventus LLC&#146;s compensation committee during fiscal 2015. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Code of ethics and code of conduct </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have adopted a
written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar
functions. We have posted a current copy of the code on our website, <I>www.bioventusglobal.com</I>. In addition, we intend to post on our website all disclosures that are required by law or NASDAQ listing standards concerning any amendments to, or
waivers from, any provision of the code. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">184 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_15"></A>Executive compensation </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">This section discusses the material components of the executive compensation program for our executive officers who are named in the &#147;2015 Summary compensation table&#148; below. In 2015, our &#147;named
executive officers&#148; and their positions were as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Anthony P. Bihl III, Chief Executive Officer; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">David J. Price, Chief Financial Officer; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Henry C. Tung, M.D., Vice President, Bioventus and General Manager,&nbsp;Bioventus Surgical. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future
compensation programs. Actual compensation programs that we adopt following the completion of this offering may differ materially from the currently planned programs summarized in this discussion. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>2015 Summary compensation table </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table sets
forth information concerning the compensation of our named executive officers for the year ended December&nbsp;31, 2015. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Name and&nbsp;principal</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:arial" SIZE="2"><B>position</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Salary<BR>($)(1)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Equity&nbsp;awards<BR>($)(2)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Non-equity&nbsp;incentive<BR>plan&nbsp;compensation</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:arial" SIZE="2"><B>($)(3)</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>All Other<BR>Compensation</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>($)(4)</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>($)</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Anthony&nbsp;P.&nbsp;Bihl&nbsp;III</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">602,308</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">670,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,292,383</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>Chief&nbsp;Executive&nbsp;Officer</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">David J. Price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">356,760</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">65,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">198,460</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">22,055</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">642,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>Chief&nbsp;Financial&nbsp;Officer</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Henry&nbsp;C.&nbsp;Tung,&nbsp;M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">361,278</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">65,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">287,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">21,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">735,482</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><I>General Manager, Bioventus Surgical</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="24" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Amounts reflect annual base salary paid during 2015, including an additional pay period during the fiscal year. Amounts for each of Mr.&nbsp;Price and Dr.&nbsp;Tung reflect
annual merit increases to base salaries, effective as of March&nbsp;30, 2015. </FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Amounts reflect the grant date fair value of the phantom profits interest unit awards granted to Mr.&nbsp;Price and Dr.&nbsp;Tung during 2015 computed in accordance with
Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation&#151;Stock Compensation, or FASB ASC Topic 718, rather than the amounts paid to or realized by the named executive officers. We provide information
regarding the assumptions used to determine the value of all phantom profits interest unit awards made to named executive officers in the section entitled &#147;Management&#146;s discussion and analysis of financial condition and results of
operations&#151;Critical accounting policies and estimates&#151;Equity compensation&#148; above. </FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The annual performance-based cash incentives earned by our named executive officers in 2015 were determined in accordance with the achievement of corporate and personal
performance objectives as set forth in the 2015 Executive Annual Incentive Plan&#151;Non-Commercial and the 2015 Executive/Director Annual Incentive Plan&#151;Bioventus Surgical, as applicable. For a discussion of the determination of these amounts,
please review the section entitled &#147;&#151;Narrative disclosure to summary compensation table&#151;2015 Bonus incentives&#148; below. </FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Amounts reflect (a)&nbsp;a $7,950 matching 401(k) contribution made by Bioventus LLC to each of the named executive officer&#146;s 401(k) accounts in 2015, (b)&nbsp;an additional
fixed non-elective contribution of $11,925 made by Bioventus LLC to the 401(k) accounts of each of Messrs. Bihl and Price and Dr.&nbsp;Tung and (c)&nbsp;reimbursement of cellular telephone expenses to each of Mr. Price and Dr. Tung equal to $2,180
and $1,584, respectively. </FONT></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Narrative to summary compensation table </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Employment agreements </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Bioventus LLC offered employment to each of Messrs. Bihl and Price and
Dr.&nbsp;Tung pursuant to employment letters dated November&nbsp;4, 2013,&nbsp;September&nbsp;27, 2012 and April&nbsp;20, 2012, respectively. Pursuant to their respective employment letters, Mr.&nbsp;Bihl was hired to serve as the Chief Executive
Officer, Mr.&nbsp;Price was hired to serve as the Chief Financial Officer and Dr.&nbsp;Tung was hired to serve as the Vice President &#150; Strategic Planning&nbsp;&amp; Business Development and was later promoted to Vice President&nbsp;&amp;
General Manager, Surgical in October 2014. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">185 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Mr.&nbsp;Bihl also serves as a member of the Bioventus LLC board of managers. In connection with this offering, we intend to enter into new employment agreements with each of our named executive
officers, as described below under &#147;New incentive arrangements&#151;New employment agreements.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>2015 Salaries </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The named executive officers receive a base salary to compensate them for services rendered to Bioventus LLC. The base salary payable to each named executive
officer is intended to provide a fixed component of compensation reflecting the named executive officer&#146;s skill set, experience, role and responsibilities. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Pursuant to the terms of their respective existing employment letters, the annual base salary payable to each of Messrs. Bihl and Price and Dr.&nbsp;Tung was set at $600,000, $325,000 and $309,001, respectively.
Since their date of hire, each of Mr.&nbsp;Price and Dr.&nbsp;Tung has received annual merit increases to base salary based on performance. On March&nbsp;30, 2015, each of Mr.&nbsp;Price and Dr.&nbsp;Tung received an additional merit increase to
place their salary at $358,670 and $362,401, respectively. As of December&nbsp;31, 2015, Mr.&nbsp;Bihl&#146;s annual base salary remained unchanged, however we expect that base salaries for each of our named executive officers will increase pursuant
to their expected new employment agreements, as described below under &#147;New incentive arrangements&#151;New employment agreements.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>2015
Bonus incentives </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In 2015, each of our named executive officers was eligible to earn an annual performance-based cash bonus from the Company
pursuant to either the 2015 Executive Annual Incentive Plan&#151;Non-Commercial (the Non-Commercial AIP) or the 2015 Executive/Director Annual Incentive Plan &#150; Bioventus Surgical (the Surgical AIP). Bonuses earned by our named executive
officers under each of these incentive plans in 2015 were based upon threshold, target and maximum achievement of the following objective business measures: sales, Adjusted EBITDA, excluding BMP program costs, certain non-financial objectives
(portfolio development including business development and progress of the development of the BMP product candidates) and Exogen growth for the Non-Commercial AIP and business development and market access for the Surgical AIP, as well as the
threshold, target and maximum achievement of personal performance standards based on whether the named executive officer inconsistently met, consistently met or consistently exceeded obligations and the method of achieving such obligations. Upon
achievement of the target Non-Commercial AIP and personal performance objectives, each of Messrs. Bihl and Price was eligible, pursuant to his respective offer letter, to receive a target incentive under the Non-Commercial AIP in the amount of 100%
and 50% of his respective annual base salary and Dr.&nbsp;Tung was eligible to receive a target incentive under the Surgical AIP in the amount of 50% of his annual base salary. Payouts for the objective business measures under the Non-Commercial AIP
and the Surgical AIP may be reduced to 50%, or increased to 200%, of the applicable objective business measure target for achievement of minimum or maximum performance results, respectively. We expect the target incentives for each of our named
executives officers to remain the same pursuant to their expected new employment agreements, as described below under &#147;New incentive arrangements&#151;New employment agreements.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Of the targeted objective business measures for the Non-Commercial AIP, we achieved 104% of sales, 82% of Adjusted EBITDA, 200% of business development, 100% of the targeted development of the BMP product
candidates and 0% of Exogen growth. In addition to our business performance, each of Messrs. Bihl and Price achieved 200% of their targeted individual performance, resulting in overall payments of 111.7% of his respective target incentive. Of the
targeted objective business measures for the Surgical AIP, we achieved 181% of sales, 82% of Adjusted EBITDA, excluding BMP program costs, 200% of business development and 100% of increased market access. In addition to our business performance, Dr.
Tung achieved 200% of his targeted </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">186 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
individual performance, resulting in an overall payment to Dr. Tung of 159.7% of his target incentive. The actual amount of the performance-based cash incentives earned by each named executive
officer, paid in 2016, with respect to 2015 performance is set forth above in the Summary Compensation Table in the column entitled &#147;Non-equity incentive plan compensation.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Equity-based compensation </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each of our named executive officers hold equity-based compensation in
Bioventus LLC as set forth below. The grant date fair value of the equity-based awards granted to the named executives officers in 2015 is set forth above in the Summary Compensation Table in the column entitled &#147;Equity Awards&#148; and the
critical accounting policies and estimates with respect to these equity-based awards are described above in the section entitled &#147;Management&#146;s discussion and analysis of financial condition and results of operations &#151; Critical
accounting policies and estimates &#151; Equity compensation.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Profits interest units </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Bioventus LLC currently maintains a profits interest plan, which we call the Bioventus LLC Management Incentive Plan, or the &#147;MIP&#148;. Profits interest units
awarded under the MIP generally vest twenty-five percent (25%)&nbsp;on the first anniversary of the date of grant, and then continue to vest 6.25% on each quarter thereafter. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">On December&nbsp;2, 2013, Mr.&nbsp;Bihl was granted 333,330 profits interest units pursuant to the terms of the MIP and an individual profits interest award agreement thereunder. Neither Mr.&nbsp;Price nor
Dr.&nbsp;Tung hold any profits interest units. In connection with the offering, each profits interest unit awarded under the MIP will be exchanged for LLC Interests which may then be exchanged for shares of Class A common stock (upon redemption or
cancellation of the same number of their shares of our Class B common stock) or a cash payment (if mutually agreed). To the extent exchanged profits interest units are subject to vesting, the corresponding LLC Interests will also be subject to
vesting and shall continue to vest in accordance with the vesting terms of the exchanged profits interest units; provided, however, any portion of the LLC Interests that remains unvested as of the 12-month anniversary following the termination of
the Phantom Profits Interest Plan (as described further below), will accelerate and vest on such 12-month anniversary date. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Phantom profits interest
units </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Bioventus LLC currently maintains a phantom equity plan, which we call the &#147;Phantom Profits Interest Plan&#148; or &#147;Phantom
Plan.&#148; Participants in the Phantom Plan are eligible to receive cash payments upon separation from service or a change of control in an amount determined with reference to the value of our profits interests. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with their hire, Mr.&nbsp;Price and Dr.&nbsp;Tung were granted 111,110 and 55,555 phantom profits interest units, respectively, under the Phantom
Plan. The applicable award agreements for each of Mr.&nbsp;Price and Dr.&nbsp;Tung provide for vesting of twenty percent (20%)&nbsp;of the phantom profits interest units subject to the award on the first anniversary of the date of grant, with the
remainder vesting five percent (5%)&nbsp;on each quarter thereafter. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, on June&nbsp;1, 2015, each of Mr.&nbsp;Price and Dr.&nbsp;Tung were
granted 20,000 phantom profits interest units under the Phantom Plan, with each award scheduled to cliff vest 50% after three years if the 2017 enterprise valuation exceeds $690 million and cliff vest 100% after three years if the 2017 enterprise
valuation exceeds $740 million. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with this offering, we intend to terminate the Phantom Plan and settle all awards thereunder 12 months
following termination. We expect that, in connection with the Phantom Plan termination, Bioventus Inc. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">187 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
will assume obligations of Bioventus LLC and that Phantom Plan awards will be paid in the form of shares of Class A common stock. The number of shares of Class A common stock received by each
participant, including our named executive officers, will be determined by dividing the participant&#146;s account balance as of the date of plan termination by the initial public offering price of Class A common stock. To the extent that a Phantom
Plan award is not otherwise vested as of the date the Phantom Plan is terminated, payment will be subject to the participant&#146;s continued employment with us through the applicable vesting date or the twelve month anniversary of plan termination,
if earlier. Certain awards made under the Phantom Plan have been amended to adjust the benchmark amount in connection with the offering. On and following the date of this offering, no further awards will be made under the Phantom Plan. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>New equity-based compensation </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with the
offering, we intend to adopt a 2016 Incentive Award Plan in order to facilitate the grant of cash and equity incentives to our non-employee directors, employees (including our named executive officers) and consultants and employees and consultants
of our subsidiaries and to enable our Company and our subsidiaries to obtain and retain services of these individuals, which is essential to our long-term success. We expect that the 2016 Incentive Award Plan will be effective prior to this
offering, subject to approval of such plan by our stockholders. In connection with this offering, we intend to grant awards with respect to shares of Class A common stock under the 2016 Incentive Award Plan to certain of our employees, including our
named executive officers. For additional information about the 2016 Incentive Award Plan and the intended grants to be made under this plan in connection with this offering, please see the section titled &#147;New incentive arrangements&#151;2016
Incentive award plan&#148; below. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Severance </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The existing employment letters for each of Mr.&nbsp;Bihl and Dr.&nbsp;Tung provide for severance payments upon termination of employment at any time without cause (other than as a result of death or disability) or
a termination for good reason (as defined below) during the two year period following the date of a change in control (as defined in the respective employment agreement). The employment letter for Mr.&nbsp;Price provides for severance payments upon
termination of employment without cause (other than as a result of death or disability) or a termination for good reason (as defined below) at any time prior to a change in control (as defined in the employment agreement) or during the two year
period following the date of a change in control. In the event of a termination without cause or for good reason, as described above, each of Mr.&nbsp;Price and Dr.&nbsp;Tung would be entitled to receive (i)&nbsp;twelve months base salary, payable
over a twelve-month period, (ii)&nbsp;100% of their respective target annual cash incentive, paid on or about 60 days following termination of employment and (iii)&nbsp;payment of COBRA premiums for the first twelve months of coverage following
termination of employment. In the event of a termination without cause or for good reason, as described above, Mr.&nbsp;Bihl would be entitled to receive the same severance payments as those outlined above for Mr.&nbsp;Price and Dr.&nbsp;Tung, with
the exception that (i)&nbsp;Mr.&nbsp;Bihl is entitled to a lump sum payment of twelve months base salary on or about 60 days following termination and (ii) if he terminates employment for good reason during the two-year period following a change in
control (as defined in the employment agreement), Mr.&nbsp;Bihl is entitled to enhanced severance equal to twenty-four months of base salary and his target annual cash incentive, payable in a lump sum on or about 60 days following termination of
employment. The severance payments for Messrs. Bihl and Price and Dr.&nbsp;Tung are conditioned upon execution and delivery of a release and compliance with confidentiality and restrictive covenant obligations as set forth in a separate proprietary
information agreement. In connection with this offering, we expect to enter into new employment agreements with each of our named executive officers that will modify their existing severance arrangements, as described below under &#147;New incentive
arrangements&#151;New employment agreements.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">188 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For purposes of the existing employment letters, &#147;cause&#148; is defined generally as the occurrence of any one
of the following events by a named executive officer, and with respect to Messrs. Bihl and Price, without full cure of such event by such named executive officer within 30 days of written notice provided by the board of managers of Bioventus LLC:
(a)&nbsp;conviction (including a guilty plea or plea of nolo contendere) of any felony or any other crime involving fraud or violence (or with respect to Mr.&nbsp;Bihl or Dr.&nbsp;Tung, dishonesty), (b)&nbsp;commission of or participation in a fraud
or act of dishonesty or misrepresentation against Bioventus LLC, (c)&nbsp;violation of any written and fully executed contract or agreement between the named executive officer and Bioventus LLC, including without limitation, breach of the
restrictive covenants agreement, (d)&nbsp;gross negligence or willful misconduct, (e)&nbsp;continued and substantial failure to perform applicable duties or (f)&nbsp;violation of any material policies, practices or procedures of Bioventus LLC; and
&#147;good reason&#148; is defined generally as the occurrence of any one of the following events without either express prior written consent or full cure within 30 days of written notice provided to Bioventus LLC: (i)&nbsp;a material diminution of
duties or responsibilities, (ii)&nbsp;a material reduction in salary, other than for across-the-board reductions similarly affecting all senior executive officers, (iii)&nbsp;the relocation of principal office, or principal place of employment, to a
location more than 50&nbsp;miles from the location of the principal office or place of business as of the effective date of the employment letter, or (iv)&nbsp;a failure to pay earned compensation. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Restrictive covenants </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our named executive officers
are subject to certain post-employment restrictive covenants, including twelve-month non-competition and non-solicitation obligations, as set forth in proprietary information agreements entered into with each named executive officer. Further, the
employment letters for each of our named executive officers provide for mutual non-disparagement obligations. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Retirement plans
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Bioventus LLC currently maintains a 401(k) retirement savings plan, or the 401(k) plan, in which all Bioventus LLC employees, including our
named executive officers, who satisfy certain eligibility requirements may participate. The Internal Revenue Code allows eligible employees to defer a portion of their compensation, within prescribed limits, on a pre-tax basis through contributions
to the 401(k) plan. Under the terms of the 401(k) plan, we currently make (a)&nbsp;non-discretionary matching contributions equal to 50% of the employee&#146;s contributions, up to a maximum of 6% of the employee&#146;s eligible compensation and
(b)&nbsp;a non-elective contribution equal to 4.5% of the employee&#146;s compensation for the plan year, subject to continued employment through the end of the plan year. Further, our board of managers has discretion under the 401(k) plan to
provide for (i)&nbsp;annual discretionary matching contributions based on eligible compensation contributed by each employee and (ii)&nbsp;discretionary nonelective contributions in an amount determined by the board at year end, subject to continued
employment through year end. We believe that providing a vehicle for tax-deferred retirement savings though the 401(k) plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our
named executive officers, in accordance with our compensation policies. Following the consummation of this offering, we anticipate that our employees will continue to be eligible to participate in a 401(k) plan maintained by us. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Employee benefits </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Health and Welfare Plans. All of
our full-time employees, including our named executive officers, are eligible to participate in health and welfare plans maintained by Bioventus LLC, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">medical, dental and vision benefits; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">medical and dependent care flexible spending accounts; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">short-term and long-term disability insurance. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">189 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our named executive officers participate in these plans on the same basis as other eligible employees. We do not
maintain any supplemental health and welfare plans for our named executive officers. We reimburse our named executive officers for the full cost of their personal cellular phones. We believe the benefits described above are necessary and appropriate
to provide a competitive compensation package to our named executive officers. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>No tax gross-ups </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We do not make gross-up payments to cover our named executive officers&#146; personal income taxes that may pertain to any of the compensation or perquisites paid
or provided by our Company. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Outstanding equity awards at fiscal year-end </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following table summarizes the number of profits interest units and phantom profits interest units underlying outstanding equity incentive plan awards for our named executive officers as of December&nbsp;31,
2015. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Profits interest units</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Phantom&nbsp;profits&nbsp;interests</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Number&nbsp;of&nbsp;profits<BR>interest&nbsp;units&nbsp;that<BR>have&nbsp;not&nbsp;vested&nbsp;(#)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Market&nbsp;value&nbsp;of&nbsp;profits<BR>interest&nbsp;units&nbsp;that&nbsp;have<BR>not vested ($)(4)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Number&nbsp;of&nbsp;profits<BR>interest&nbsp;units<BR>underlying&nbsp;phantom<BR>profits interests
(#)<BR>vested</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Number&nbsp;of&nbsp;profits&nbsp;interest<BR>units&nbsp;underlying&nbsp;phantom<BR>profits&nbsp;interests&nbsp;(#)&nbsp;
unvested</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>Number&nbsp;of&nbsp;profits<BR>interest units<BR>underlying<BR>unearned&nbsp;phantom<BR>profits interests<BR>unvested
(#)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Anthony P. Bihl III</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">166,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(1)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,216,651</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">David J. Price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">66,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(2)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">44,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(2)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">0</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">20,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">(2)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Henry&nbsp;C.&nbsp;Tung,&nbsp;M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">38,889</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(3)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">16,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">(3)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">0</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">20,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">(3)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="20" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Mr.&nbsp;Bihl was granted 333,330 profits interest units on December&nbsp;2, 2013. As of December&nbsp;31, 2015, 166,665 of Mr.&nbsp;Bihl&#146;s profits interest units were
vested. Twenty-five percent (25%)&nbsp;of the profits interest units granted to Mr.&nbsp;Bihl vested, or will vest, on the first anniversary of the grant date and 6.25% of the profits interest units granted to Mr.&nbsp;Bihl vested, or will vest, on
a quarterly basis thereafter. </FONT></TD></TR></TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Mr.&nbsp;Price was granted 111,110 phantom profits interest units on October&nbsp;22, 2012 and 20,000 phantom profits interest units on June&nbsp;1, 2015. As of December&nbsp;31,
2015, 66,666 of Mr.&nbsp;Price&#146;s phantom profits interest units were vested. The October&nbsp;22, 2012 grant vests twenty percent (20%)&nbsp;on the first anniversary of the grant date and five percent (5%)&nbsp;on a quarterly basis thereafter.
The June&nbsp;1, 2015 grant cliff vests as described above in &#147;Narrative to summary compensation table&#151;Equity-based compensation&#151;Phantom profits interests units.&#148; </FONT></TD></TR></TABLE>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Dr.&nbsp;Tung was granted 55,555 phantom profits interest units on May&nbsp;4, 2012 and 20,000 phantom profits interest units on June&nbsp;1, 2015. As of December&nbsp;31, 2015,
38,889 of Dr.&nbsp;Tung&#146;s phantom profits interest units were vested. The May&nbsp;4, 2012 grant vests twenty percent (20%)&nbsp;on the first anniversary of the grant date and five percent (5%)&nbsp;on a quarterly basis thereafter. The
June&nbsp;1, 2015 grant cliff vests as described above in &#147;Narrative to summary compensation table&#151;Equity-based compensation&#151;Phantom profits interests units.&#148; </FONT></TD></TR></TABLE>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">There is no public market for the profits interest units. We valued the profits interest units based on a board determination of valuation with reference to a third party
valuation for purposes of this disclosure. The amount reported above under the heading &#147;Market value of profits interest units that have not vested&#148; reflects the intrinsic value of the profits interest units as of December&nbsp;31, 2015.
In connection with the offering, each profits interest unit will be exchanged for LLC Interests. </FONT></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Director compensation </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Members of the Bioventus LLC board of managers have not historically received compensation for their services as board members. In connection with this offering, we
have adopted a compensation policy that, effective upon the closing of this offering, will be applicable to all of our non-employee directors. Pursuant to this policy, each eligible non-employee director will receive an annual cash retainer of
$40,000. The chairperson of the board will receive an additional annual retainer of $50,000 for such service. Each member of the audit, compensation and nominating and corporate governance committees, other than the committee chairperson, will
receive an additional annual cash retainer of $20,000, $15,000 and $10,000, respectively, and the committee chairperson for each committee will receive an additional annual cash retainer of $10,000, $7,500 and $5,000, respectively. Each annual
retainer will be paid quarterly in arrears. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">190 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Also, pursuant to this director compensation policy, each non-employee director who, as of the date of this offering,
is serving on our board of directors and is expected to continue his or her service following this offering will be granted an award of stock options with an aggregate grant date fair value equal to $187,500, provided that certain investor directors
may elect to receive such award in the form of cash-settled restricted stock units in lieu of stock options. In addition, we will grant each eligible non-employee director who is initially elected or appointed to the board following the pricing of
the offering an initial stock option award upon such initial election or appointment with an aggregate grant date fair value equal to $187,500. Finally, commencing with fiscal year 2017, each non-employee director will be entitled to receive, on the
date of our annual meeting, an annual award of stock options with an aggregate grant date fair value equal to $125,000. The terms of each such award will be set forth in a written award agreement between each non-employee director and us.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to the non-employee director compensation policy, we have adopted a director stock ownership policy encouraging non-employee directors to
hold shares of our Class A Common Stock and/or LLC Interests with a value equal to at least three times the value of the director&#146;s annual base retainer fee. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In connection with our December 11, 2015 offer to Mr.&nbsp;William&nbsp;A. Hawkins to join the Bioventus LLC board of managers as its chairman, we agreed, pursuant to an offer letter, effective January&nbsp;1,
2016, to (1)&nbsp;pay Mr.&nbsp;Hawkins an annual retainer fee of $40,000 for his service as a member of the board and $50,000 for his service as chairman of the board, payable in quarterly installments in arrears and pro-rated for any partial period
of service and (2)&nbsp;award Mr.&nbsp;Hawkins a one-time grant of 50,000 phantom profits interest units under the Phantom Plan. Mr. Hawkins will be eligible to receive annual awards in accordance with the non-employee director compensation policy.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>New incentive arrangements </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>2016
Incentive award plan </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with the offering, we intend to adopt the 2016 Incentive Award Plan, or the Plan, subject to approval by our
stockholders, under which we may grant cash and equity incentive awards to eligible service providers in order to attract, motivate and retain the talent for which we compete. The material terms of the Plan, as it is currently contemplated, are
summarized below. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Eligibility and administration.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Our employees, consultants and non-employee directors, and
employees and consultants of our subsidiaries will be eligible to receive awards under the Plan. Following the offering, the Plan will be administered by our board of directors with respect to awards to non-employee directors and by our compensation
committee with respect to other participants, each of which may delegate its duties and responsibilities to committees of our directors and/or officers (referred to collectively as the plan administrator below), subject to certain limitations that
may be imposed under Section&nbsp;162(m) of the Code, Section&nbsp;16 of the Exchange Act, and/or stock exchange rules, as applicable. The plan administrator will have the authority to make all determinations and interpretations under, prescribe all
forms for use with, and adopt rules for the administration of, the Plan, subject to its express terms and conditions. The plan administrator will also set the terms and conditions of all awards under the Plan, including any vesting and vesting
acceleration conditions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Limitation on awards and shares available.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;An aggregate of 2,981,436 shares of our Class A
common stock will be available for issuance under awards granted pursuant to the Plan, which shares may be authorized but unissued shares, treasury common stock, or shares purchased in the open market. In addition, the number of shares available for
issuance under the 2016 Incentive Award Plan will be annually increased each calendar year beginning in 2017 and ending in 2026, by an amount equal to the least of (a)&nbsp;1,494,464 shares, (b)&nbsp;4% of the Company&#146;s shares outstanding on
the final day of the immediately preceding calendar year and (c) such </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">191 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
lesser number of shares as is determined by our board of directors. If an award under the Plan is forfeited, expires, converted or is settled for cash, any shares subject to such award may, to
the extent of such forfeiture, expiration, conversion or cash settlement, be used again for new grants under the Plan. However, the following shares may not be used again for grants under the Plan: (1)&nbsp;shares tendered or withheld to satisfy
grant or exercise price or tax withholding obligations associated with an option or stock appreciation right, or &#147;SAR&#148;; (2)&nbsp;shares subject to a SAR that are not issued in connection with the stock settlement of the SAR on its
exercise; and (3)&nbsp;shares purchased on the open market with the cash proceeds from the exercise of options. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Awards granted under the Plan upon the
assumption of, or in substitution for, awards authorized or outstanding under a qualifying equity plan maintained by an entity with which we enter into a merger or similar corporate transaction will not reduce the shares available for grant under
the Plan. The maximum number of shares of our Class&nbsp;A common stock that may be subject to one or more awards granted to any person pursuant to the Plan during any calendar year will be 1,494,464 and the maximum amount that may be paid in cash
under an award pursuant to the Plan to any one participant during any calendar year period will be $2,000,000. Further, the maximum aggregate grant date fair value of awards granted to any non-employee director during any calendar year will be
$500,000. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Awards.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The Plan provides for the grant of stock options, including incentive stock options, or
&#147;ISOs,&#148; and nonqualified stock options, or &#147;NSOs,&#148; stock appreciation rights, or &#147;SARs,&#148; restricted stock, restricted stock units, or &#147;RSUs,&#148; and other stock or cash-based awards. No determination has been
made as to the types or amounts of awards that will be granted to specific individuals pursuant to the Plan. Certain awards under the Plan may constitute or provide for a deferral of compensation, subject to Section&nbsp;409A of the Code, which may
impose additional requirements on the terms and conditions of such awards. All awards under the Plan will be set forth in award agreements, which will detail all terms and conditions of the awards, including any applicable vesting and payment terms
and post-termination exercise limitations. Awards generally will be settled in shares of our Class&nbsp;A common stock, but the plan administrator may provide for cash settlement of any award. A brief description of each award type follows.
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Stock options.</I>&nbsp;&nbsp;&nbsp;&nbsp;Stock options provide for the right to purchase shares of our Class&nbsp;A common stock in the future at an exercise
price set on the grant date. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Code are satisfied. The exercise
price of a stock option may not be less than 100% of the fair market value of the underlying share on the date of grant (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to certain substitute options
granted in connection with a corporate transaction. The term of a stock option may not be longer than ten years (or five years in the case of ISOs granted to certain significant stockholders). Vesting conditions determined by the plan administrator
may apply to stock options and may include continued service, performance and/or other conditions. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I></I><I>SARs.</I>&nbsp;&nbsp;&nbsp;&nbsp;SARs entitle their holder, upon exercise, to receive from us an amount equal to the appreciation of the shares subject
to the award between the grant date and the exercise date. The exercise price of a SAR may not be less than 100% of the fair market value of the underlying share on the date of grant (except with respect to certain substitute SARs granted in
connection with a corporate transaction) and the term of a SAR may not be longer than ten years. Vesting conditions determined by the plan administrator may apply to SARs and may include continued service, performance and/or other conditions.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Restricted stock and RSUs.</I>&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock is an award of nontransferable shares of our Class&nbsp;A common stock that remain
forfeitable unless and until specified conditions are met, and which may be subject to a purchase price. RSUs are contractual promises to deliver shares of our Class&nbsp;A common stock in the future, which may also remain forfeitable unless and
until specified conditions are met. Delivery of the shares underlying RSUs may be deferred under the terms of the award or at the election of the participant, if the </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">192 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
plan administrator permits such a deferral. Conditions applicable to restricted stock and RSUs may be based on continuing service, the attainment of performance goals and/or such other conditions
as the plan administrator may determine. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Other Stock or Cash-Based Awards.&nbsp;&nbsp;&nbsp;&nbsp;</I>Other stock or cash-based awards are cash payments, cash-bonus awards, stock payments, stock
bonus awards, performance awards or incentive awards paid in cash, shares of our Class A common stock or a combination of both, and include deferred stock, deferred stock units, retainers, committee fees and meeting-based fees.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Dividend Equivalents.</I>&nbsp;&nbsp;&nbsp;&nbsp;Dividend equivalents represent the right to receive the equivalent value of dividends paid on shares of our
Class A common stock and may be granted alone or in tandem with awards other than stock options or SARs. Dividend equivalents are credited as of dividend record dates occurring during the period between the date an award is granted and the date such
award vests, is exercised, is distributed or expires, as determined by the plan administrator. Dividend equivalents may not be paid on awards granted under the Plan subject to performance based vesting unless and until such awards have vested.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Section&nbsp;162(m).</I>&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;162(m) of the Code imposes a $1,000,000 cap on the compensation
deduction that a public company may take in respect of compensation paid to our &#147;covered employees&#148; (which includes our Chief Executive Officer and our next three most highly compensated employees other than our Chief Financial Officer),
but excludes from the calculation of amounts subject to this limitation any amounts that constitute &#147;qualified performance-based compensation,&#148; or &#147;QPBC,&#148; within the meaning of Section&nbsp;162(m) of the Code. Under current tax
law, we do not expect Section&nbsp;162(m) of the Code to apply to certain awards under the Plan until the earliest to occur of (1)&nbsp;our annual stockholders&#146; meeting at which members of our board of directors are to be elected that occurs
after the close of the third calendar year following the calendar year in which occurred the first registration of our equity securities under Section&nbsp;12 of the Exchange Act; (2)&nbsp;a material modification of the Plan; (3)&nbsp;an exhaustion
of the share supply under the Plan; or (4)&nbsp;the expiration of the Plan. However, QPBC performance criteria may be used with respect to awards that are not intended to constitute QPBC. In addition, the company may issue awards that are not
intended to constitute QPBC even if such awards might be non-deductible as a result of Section&nbsp;162(m) of the Code. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In order to constitute QPBC
under Section&nbsp;162(m) of the Code, in addition to certain other requirements, the relevant amounts must be payable only upon the attainment of pre-established, objective performance goals set by our compensation committee and linked to
stockholder-approved performance criteria. For purposes of the Plan, one or more of the following performance criteria will be used in setting performance goals applicable to QPBC, and may be used in setting performance goals applicable to other
awards: (i) net earnings or losses (either before or after one or more of the following: (A)&nbsp;interest, (B)&nbsp;taxes, (C)&nbsp;depreciation, (D)&nbsp;amortization, (E) non-cash equity-based compensation expense and (F) other non-cash, one-time
or non-recurring items); (ii)&nbsp;gross or net sales or revenue or sales or revenue growth; (iii)&nbsp;net income (either before or after taxes); (iv)&nbsp;adjusted net income; (v)&nbsp;operating earnings or profit (either before or after taxes);
(vi)&nbsp;cash flow (including, but not limited to, operating cash flow and free cash flow); (vii)&nbsp;return on assets or net assets; (viii)&nbsp;return on capital (or invested capital) and cost of capital; (ix)&nbsp;return on stockholders&#146;
equity; (x)&nbsp;total stockholder return; (xi)&nbsp;return on sales; (xii)&nbsp;gross or net profit or operating margin; (xiii)&nbsp;costs, reductions in costs and cost control measures; (xiv)&nbsp;funds from operations or funds available for
distributions; (xv)&nbsp;expenses; (xvi)&nbsp;working capital; (xvii)&nbsp;earnings or loss per share; (xviii)&nbsp;adjusted earnings or loss per share; (xix)&nbsp;price per share or dividends with respect to common stock or appreciation in and/or
maintenance of such price or dividends; (xx)&nbsp;economic value added models or similar metrics; (xxi)&nbsp;regulatory achievements or compliance (including, without limitation, regulatory body approval for commercialization of a product);
(xxii)&nbsp;implementation, completion or attainment of critical projects, processes or objectives relating to research, development, regulatory, commercial or strategic milestones or developments; (xxiii)&nbsp;sales, unit volume or market share;
(xxiv)&nbsp;licensing </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">193 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
revenue; (xxv)&nbsp;brand recognition/acceptance; (xxvi)&nbsp;inventory turns or cycle time (xxvii)&nbsp;strategic initiatives (including, without limitation, with respect to market penetration
and spending efficiency, geographic business expansion, manufacturing, commercialization, production and productivity, customer satisfaction and growth, employee satisfaction, recruitment and maintenance of personnel, human resources management,
supervision of litigation and other legal matters, information technology, strategic partnerships and transactions (including acquisitions, dispositions, joint ventures, in-licensing and out-licensing of intellectual property), establishment of or
growth in relationships with dealers or other commercial entities with respect to the marketing, distribution and sale of Company products, factoring transactions, R&amp;D and related activity, financial or other capital raising transactions,
operating efficiency and asset quality); (xxviii)&nbsp;financial ratios (including, without limitation, those measuring liquidity, activity, profitability or leverage); (xxix) compound annual growth rate; (xxx) debt levels or reduction; (xxxi)
sales-related goals; (xxxii) comparisons with other stock market indices; (xxxiii) quality control or quality performance; (xxxiv) rate of new product introduction; (xxxv) product launches; and (xxxvi) business development transactions, any of which
may be measured either in absolute terms or as compared to any incremental increase or decrease or as compared to results of a peer group or to market performance indicators or indices. The Plan also permits the plan administrator to provide for
objectively determinable adjustments to the applicable performance criteria in setting performance goals for QPBC awards. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Certain
transactions.</I>&nbsp;&nbsp;&nbsp;&nbsp;The plan administrator has broad discretion to take action under the Plan, as well as make adjustments to the terms and conditions of existing and future awards to prevent the dilution or enlargement of
intended benefits and facilitate necessary or desirable changes in the event of certain transactions and events affecting our common stock, such as stock dividends, stock splits, mergers, acquisitions, consolidations and other corporate
transactions. In addition, in the event of certain non-reciprocal transactions with our stockholders known as &#147;equity restructurings,&#148; the plan administrator will make equitable adjustments to the Plan and outstanding awards. In the event
of a change in control of our company (as defined in the Plan), to the extent that the surviving entity declines to assume or substitute outstanding awards, then the administrator may cause any or all of such awards to become fully vested and
exercisable in connection with the transaction. Individual award agreements may provide for additional accelerated vesting and payment provisions. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Foreign participants, claw-back provisions, transferability, and participant payments.</I>&nbsp;&nbsp;&nbsp;&nbsp;The plan administrator may modify award terms,
establish subplans and/or adjust other terms and conditions of awards, subject to the share limits described above, in order to facilitate grants of awards subject to the laws and/or stock exchange rules of countries outside of the United States.
All awards will be subject to the provisions of any claw-back policy implemented by our company to the extent set forth in such claw-back policy and/or in the applicable award agreement. With limited exceptions for estate planning, domestic
relations orders, certain beneficiary designations and the laws of descent and distribution, awards under the Plan are generally non-transferable prior to vesting, and are exercisable only by the participant. With regard to tax withholding, exercise
price and purchase price obligations arising in connection with awards under the Plan, the plan administrator may, in its discretion, accept cash or check, shares of our Class&nbsp;A common stock that meet specified conditions, a &#147;market sell
order&#148; or such other consideration as it deems suitable. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Plan amendment and termination.&nbsp;&nbsp;&nbsp;&nbsp;</I>Our board of directors may
amend or terminate the Plan at any time; however, except in connection with certain changes in our capital structure, stockholder approval will be required for any amendment that increases the number of shares available under the Plan, reduces the
price per share of any outstanding stock option or SAR, or cancels any stock option or SAR in exchange for cash or another award when the option or SAR price per share exceeds the fair market value of the underlying shares. No award may be granted
pursuant to the Plan after the tenth anniversary of the date on which our board of directors adopts the Plan. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">194 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>New Equity Awards </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In connection with this offering, we intend to grant stock options with respect to 2,514,265 shares of Class A common stock under the Plan to certain of our employees, including our named executive officers (the
&#147;offering grants&#148;). The offering grants are expected to vest over time, subject to continued employment. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>2016 Senior executive bonus
plan </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with the offering, we intend to adopt the 2016 Senior Executive Incentive Bonus Plan, or the Executive Bonus Plan, to be
effective as of the day immediately prior to this offering. The Executive Bonus Plan is intended to provide an incentive for superior work and to motivate covered key executives toward even greater achievement and business results, to tie their
goals and interests to those of us and our stockholders and to enable us to attract and retain highly qualified executives. The principal features of the Executive Bonus Plan are summarized below. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Executive Bonus Plan is an incentive bonus plan under which certain key executives, including our named executive officers, will be eligible to receive bonus
payments. Bonuses will generally be payable under the Executive Bonus Plan upon the attainment of pre-established performance goals. Notwithstanding the foregoing, we may pay bonuses (including, without limitation, discretionary bonuses) to
participants under the Executive Bonus Plan based upon such other terms and conditions as our compensation committee may in its sole discretion determine. The payment of a bonus under the Executive Bonus Plan to a participant with respect to a
performance period will generally be conditioned on such participant&#146;s continued employment on the last day of such performance period, provided that our compensation committee may make exceptions to this requirement in its sole discretion.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The performance goals under the Executive Bonus Plan will relate to one or more financial, operational or other metrics with respect to individual or
company performance with respect to us or any of our affiliates, including but not limited to the following possible performance goals: (i) net earnings or losses (either before or after one or more of the following: (A)&nbsp;interest,
(B)&nbsp;taxes, (C)&nbsp;depreciation, (D)&nbsp;amortization, (E) non-cash equity-based compensation expense and (F) other non-cash, one-time or non-recurring items); (ii)&nbsp;gross or net sales or revenue or sales or revenue growth; (iii)&nbsp;net
income (either before or after taxes); (iv)&nbsp;adjusted net income; (v)&nbsp;operating earnings or profit (either before or after taxes); (vi)&nbsp;cash flow (including, but not limited to, operating cash flow and free cash flow);
(vii)&nbsp;return on assets or net assets; (viii)&nbsp;return on capital (or invested capital) and cost of capital; (ix)&nbsp;return on stockholders&#146; equity; (x)&nbsp;total stockholder return; (xi)&nbsp;return on sales; (xii)&nbsp;gross or net
profit or operating margin; (xiii)&nbsp;costs, reductions in costs and cost control measures; (xiv)&nbsp;funds from operations or funds available for distributions; (xv)&nbsp;expenses; (xvi)&nbsp;working capital; (xvii)&nbsp;earnings or loss per
share; (xviii)&nbsp;adjusted earnings or loss per share; (xix)&nbsp;price per share or dividends with respect to common stock of the Company or appreciation in and/or maintenance of such price or dividends; (xx)&nbsp;economic value added models or
similar metrics; (xxi)&nbsp;regulatory achievements or compliance (including, without limitation, regulatory body approval for commercialization of a product); (xxii)&nbsp;implementation, completion or attainment of critical projects, processes or
objectives relating to research, development, regulatory, commercial or strategic milestones or developments; (xxiii)&nbsp;sales, unit volume or market share; (xxiv)&nbsp;licensing revenue; (xxv)&nbsp;brand recognition/acceptance;
(xxvi)&nbsp;inventory turns or cycle time; (xxvii)&nbsp;strategic initiatives (including, without limitation, with respect to market penetration and spending efficiency, geographic business expansion, manufacturing, commercialization, production and
productivity, customer satisfaction and growth, employee satisfaction, recruitment and maintenance of personnel, human resources management, supervision of litigation and other legal matters, information technology, strategic partnerships and
transactions (including acquisitions, dispositions, joint ventures, in-licensing and out-licensing of intellectual property), and establishment of or growth in relationships with dealers or other commercial entities with respect to the marketing,
distribution and sale of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">195 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Company products, factoring transactions, R&amp;D and related activity, and financial or other capital raising transactions, operating efficiency and asset quality); (xxviii)&nbsp;financial
ratios (including, without limitation, those measuring liquidity, activity, profitability or leverage); (xxix) compound annual growth rate; (xxx) debt levels or reduction; (xxxi) sales-related goals; (xxxii) comparisons with other stock market
indices; (xxxiii) quality control or quality performance; and (xxxiv) rate of new product introduction, (xxv) product launches; and (xxxvi) business development transactions, any of which may be measured either in absolute terms or as compared to
any incremental increase or decrease or as compared to results of a peer group or to market performance indicators or indices. The Plan also permits the plan administrator to provide for objectively determinable adjustments to the applicable
performance criteria in setting performance goals for Executive Bonus Plan awards. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Executive Bonus Plan is administered by our compensation
committee. Our compensation committee will select the participants in the Executive Bonus Plan and any performance goals to be utilized with respect to the participants, establish the bonus formulas for each participant&#146;s annual bonus, and
certify whether any applicable performance goals have been met with respect to a given performance period. The Executive Bonus Plan provides that we may amend or terminate the Executive Bonus Plan at any time in our sole discretion. Any amendments
to the Executive Bonus Plan will require stockholder approval only to the extent required by applicable law, rule or regulation. The Executive Bonus Plan will expire on the earliest of: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The first material modification of the Executive Bonus Plan; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The first stockholders meeting at which members of our board of directors are elected during 2020; or </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Such other date required by Section&nbsp;162(m) of the Code. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>2016 Employee Stock Purchase Plan </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with this offering, we intend to adopt the 2016 Employee Stock
Purchase Plan, or the ESPP. The material terms of the ESPP, as it is currently contemplated, are summarized below. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Shares Available;
Administration</I>. A total of 373,616 shares of our Class A common stock will initially be reserved for issuance under our ESPP. In addition, the number of shares available for issuance under the ESPP will be annually increased each calendar year
beginning in 2017 and ending in 2026, by an amount equal to the least of: (a) 186,808 shares, (b) 0.5% of the Company&#146;s shares outstanding on the final day of the immediately preceding calendar year and (c) such lesser number of shares as is
determined by our board of directors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our board of directors or the compensation committee will have authority to interpret the terms of the ESPP and
determine eligibility of participants. We expect that the compensation committee of our board of directors will be the initial administrator of the ESPP. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Eligibility</I>. We expect that our employees, other than employees that, immediately after the grant of a right to purchase Class A common stock under the ESPP,
would own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of our common or other class of stock, will be eligible to participate in the ESPP. However, consistent with Section
423 of the Code the plan administrator may provide that other groups of employees, including without limitation those customarily employed by us for fewer than 20 hours per week or less than five months in any calendar year, will not be eligible to
participate in the ESPP. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Grant of Rights</I>. The ESPP will be intended to qualify under Section 423 of the Code and shares of our Class A common
stock will be offered under the ESPP during offering periods. The length of the offering periods under the ESPP will be determined by the plan administrator and may be up to 27 months long. Employee payroll deductions will be used to purchase shares
on each purchase date during an offering period. The purchase dates for each offering period will be the final trading day in each purchase period. Offering periods under the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">196 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
ESPP will commence when determined by the plan administrator. The plan administrator may, in its discretion, modify the terms of future offering periods. We do not expect that any offering
periods will commence under the ESPP at the time of this offering. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The ESPP will permit participants to purchase Class A common stock through payroll
deductions of up to a fixed dollar amount or percentage of their eligible compensation, which includes a participant&#146;s gross base compensation for services to us. The plan administrator will establish a maximum number of shares that may be
purchased by a participant during any offering period, which, in the absence of a contrary designation, will be 25,000 shares. In addition, no employee will be permitted to accrue the right to purchase stock under the ESPP at a rate in excess of
$25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market value per share of our Class A common stock as of the first day of the offering period). </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On the first trading day of each offering period, each participant will automatically be granted an option to purchase shares of our Class A common stock. The
option will expire at the end of the applicable offering period, and will be exercised on each purchase date during such offering period to the extent of the payroll deductions accumulated during the offering period. Unless the plan administrator
otherwise determines, the purchase price of the shares will be 85% of the lower of the fair market value of our Class A common stock on the first trading day of the offering period or on the purchase date, which will be the final trading day of the
purchase period. Participants may voluntarily end their participation in the ESPP prior to the end of the applicable offering period, and will be paid their accrued payroll deductions that have not yet been used to purchase shares of Class A common
stock. Participation will end automatically upon a participant&#146;s termination of employment. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A participant will not be permitted to transfer rights
granted under the ESPP other than by will, the laws of descent and distribution or as otherwise provided under the ESPP. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Certain Transactions</I>. In
the event of certain transactions or events affecting our Class A common stock, such as any stock dividend or other distribution, change in control, reorganization, merger, consolidation or other corporate transaction, the plan administrator will
make equitable adjustments to the ESPP and outstanding rights. In addition, in the event of the foregoing transactions or events or certain significant transactions, including a change in control, the plan administrator may provide for (1) either
the replacement of outstanding rights with other rights or property or termination of outstanding rights in exchange for cash, (2) the assumption or substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary
thereof, if any, (3) the adjustment in the number and type of shares of stock subject to outstanding rights, (4) the use of participants&#146; accumulated payroll deductions to purchase stock on a new purchase date prior to the next scheduled
purchase date and termination of any rights under ongoing offering periods or (5) the termination of all outstanding rights. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Plan Amendment</I>. The
plan administrator may amend, suspend or terminate the ESPP at any time. However, stockholder approval of any amendment to the ESPP will be obtained for any amendment which increases the aggregate number or changes the type of shares that may be
sold pursuant to rights under the ESPP, changes the corporations or classes of corporations whose employees are eligible to participate in the ESPP or changes the ESPP in any manner that would cause the ESPP to no longer be an employee stock
purchase plan within the meaning of Section 423(b) of the Code. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I></I></B><I>New employment agreements</I><B><I> </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We entered into new employment agreements with each of our named executive officers to be effective upon the consummation of this offering. Base salaries for each
of Messrs. Bihl and Price and Dr. Tung will increase pursuant to their new employment agreements to $624,000, $382,340 and $380,520, respectively. The target </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">197 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
incentives for each of our named executive officers remain the same as that provided in their existing employment agreements, as described above in &#147;2015 Bonus incentives.&#148; </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The new employment agreements for our named executive officers will each continue to provide for severance payments upon a termination of employment at such times
as provided in their existing employment agreements (as described above). In the event of a termination of employment of any named executive officer without cause at any time prior to a change in control or a termination of employment by Mr. Price
for good reason (other than during the two-year period following a change in control), the new employment agreements provide each named executive officer the same severance benefits as each is entitled to receive in their existing employment
agreements, with the exception that Mr. Bihl is entitled to severance equal to (i) eighteen months base salary, payable in a lump sum payment, (ii) 150% of his target annual cash incentive, paid on or about 60 days following termination of
employment and (iii) payment of COBRA premiums for the first eighteen months of coverage following termination of employment. In the event of any termination of employment of any named executive officer without cause or a termination of employment
by any named executive officer for good reason during the two-year period on or following a change in control, the new employment agreements will provide (A) Mr. Price and Dr. Tung (i) eighteen months base salary, payable over an eighteen-month
period, (ii) 150% of their respective target annual cash incentive, paid on or about 60 days following termination of employment and (iii) payment of COBRA premiums for the first eighteen months of coverage following termination of employment; and
(B) Mr. Bihl the same severance payments as those outlined above for Mr. Price and Dr. Tung, with the exception that Mr. Bihl will be entitled to (i) a lump sum payment of twenty-four months base salary, (ii) 200% of his target annual cash
incentive, paid on or about 60 days following termination of employment and (iii) payment of COBRA premiums for twenty-four months. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">198 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_16"></A>Certain relationships and related party transactions </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following is a description of transactions since our inception to which we have been a party in which the amount involved exceeds $120,000 and in which any of
our directors, executive officers or beneficial holders of more than 5% of our Class&nbsp;A common stock, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each agreement described below is filed as an exhibit to the registration statement of which this prospectus forms a part, and the following descriptions are
qualified by reference to such agreements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Compensation arrangements for our directors and named executive officers are described in this prospectus
under the section entitled &#147;Executive compensation.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Limitation of liability and indemnification </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation and our amended and restated bylaws, each of which will be effective upon the closing of this offering, will
provide that we will indemnify our directors and officers to the fullest extent permitted under Delaware law, which prohibits our amended and restated certificate of incorporation from limiting the liability of our directors for the following:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any breach of the director&#146;s duty of loyalty to us or our stockholders; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">unlawful payment of dividends or unlawful stock repurchases or redemptions; or </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any transaction from which the director derived an improper personal benefit. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation and our amended and restated bylaws will also provide that if Delaware law is amended to authorize corporate action further eliminating or limiting the personal
liability of a director, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. This limitation of liability does not apply to liabilities arising under the federal
securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated certificate
of incorporation and our amended and restated bylaws will also provide that we shall have the power to indemnify our employees and agents to the fullest extent permitted by law. Our amended and restated bylaws also permit us to secure insurance on
behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in this capacity, regardless of whether we would have the power to indemnify such person against such expense, liability or loss under the
General Corporation Law of the State of Delaware. We have obtained directors&#146; and officers&#146; liability insurance. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with this
offering, we intend to enter into separate indemnification agreements with our directors and executive officers, in addition to indemnification provided for in our amended and restated certificate of incorporation and amended and restated bylaws.
These agreements, among other things, provide for indemnification of our directors and executive officers for expenses, judgments, fines and settlement amounts incurred by this person in any action or proceeding arising out of this person&#146;s
services as a director or executive officer or at our request. We believe that these provisions in our amended and restated certificate of incorporation and amended and restated bylaws and indemnification agreements are necessary to attract and
retain qualified persons as directors and executive officers. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The above description of the indemnification provisions of our amended and restated
certificate of incorporation, our amended and restated bylaws and our indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to this registration statement to
which this prospectus forms a part. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">199 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation
and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an
action, if successful, might benefit us and our stockholders. A stockholder&#146;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.
Insofar as indemnification for liabilities under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is
against public policy as expressed in the Securities Act and is therefore unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any
pending or threatened litigation that may result in claims for indemnification by any director or officer. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Tax Receivable Agreement </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We expect to obtain an increase in our share of the tax basis of the assets of Bioventus LLC when (as described below under &#147;&#151;Bioventus LLC
Agreement&#151;LLC Interest Redemption Right&#148;) a Continuing LLC Owner receives shares of our Class&nbsp;A common stock or, if we and such Continuing LLC Owners agree, cash in connection with an exercise of such Continuing LLC Owner&#146;s right
to have LLC Interests held by such Continuing LLC Owner redeemed by Bioventus LLC or, at the election of Bioventus, Inc., directly exchanged (such basis increase, the &#145;&#145;Basis Adjustments&#146;&#146;). We intend to treat such acquisition of
LLC Interests as our direct purchase of LLC Interests from a Continuing LLC Owner for U.S. federal income and other applicable tax purposes, regardless of whether such LLC Interests are surrendered by a Continuing LLC Owner to Bioventus LLC for
redemption or sold to us upon the exercise of our election to acquire such LLC Interests directly. A Basis Adjustment may have the effect of reducing the amounts that we would otherwise pay in the future to various tax authorities. The Basis
Adjustments may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In connection with the transactions described above, we will enter into the Tax Receivable Agreement (the &#145;&#145;TRA&#146;&#146;) with the Continuing LLC Owners. The TRA will provide for our payment to such
persons of 85% of the amount of tax benefits, if any, that we actually realize, or in some circumstances are deemed to realize, as a result of any Basis Adjustments and certain other tax benefits related to our making payments under the TRA.
Bioventus LLC will have in effect an election under Section&nbsp;754 of the Code effective for each taxable year in which a redemption or exchange (including deemed exchange) of LLC Interests for shares of our Class&nbsp;A common stock or cash
occurs. These TRA payments are not conditioned upon any continued ownership interest in either Bioventus LLC or us by any Continuing LLC Owner. The rights of each Continuing LLC Owner under the TRA are assignable to transferees of its LLC Interests
(other than Bioventus as transferee pursuant to subsequent redemptions (or exchanges) of the transferred LLC Interests). We expect to benefit from the remaining 15% of tax benefits, if any, that we may actually realize. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The actual Basis Adjustments, as well as any amounts paid to the Continuing LLC Owners under the TRA, will vary depending on a number of factors, including:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>the timing of any subsequent redemptions or exchanges&#151;</I>for instance, the increase in any tax deductions will vary depending on the fair value, which
may fluctuate over time, of the depreciable or amortizable assets of Bioventus LLC at the time of each redemption or exchange; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>the price of shares of our Class A common stock at the time of redemptions or exchanges</I>&#151;<I></I>the Basis Adjustments, as well as any related increase
in any tax deductions, is directly related to the price of shares of our Class&nbsp;A common stock at the time of each redemption or exchange; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">200 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>the extent to which such redemptions or exchanges are taxable&#151;</I>if a redemption or exchange is not taxable for any reason, increased tax deductions
will not be available; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>the amount and timing of our income&#151;</I>the TRA generally will require Bioventus to pay 85% of the tax benefits as and when those benefits are treated as
realized under the terms of the TRA. Except as discussed below in cases of (i)&nbsp;a material breach of a material obligation under the TRA, (ii)&nbsp;a change of control or (iii)&nbsp;an early termination of the TRA, if Bioventus does not have
taxable income, it will generally not be required to make payments under the TRA for that taxable year because no tax benefits will have been realized. However, any tax benefits that do not result in realized tax benefits in a given taxable year
will likely generate tax attributes that may be utilized to generate tax benefits in previous or future taxable years. The utilization of any such tax attributes will result in payments under the TRA. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For purposes of the TRA, cash savings in income tax will be computed by comparing our actual income tax liability to the amount of such taxes that we would have
been required to pay had there been no Basis Adjustments and had the TRA not been entered into. The TRA will generally apply to each of our taxable years, beginning with the first taxable year ending after the consummation of the offering. There is
no maximum term for the TRA; however, the TRA may be terminated by us pursuant to an early termination procedure that requires us to pay the Continuing LLC Owners an agreed upon amount equal to the estimated present value of the remaining payments
to be made under the agreement (calculated based on certain assumptions, including regarding tax rates and utilization of the Basis Adjustments). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
payment obligations under the TRA are obligations of Bioventus and not of Bioventus LLC. Although the actual timing and amount of any payments that may be made under the TRA will vary, we expect that the payments that we may be required to make to
the Continuing LLC Owners could be significant. Any payments made by us to Continuing LLC Owners under the TRA will generally reduce the amount of overall cash flow that might have otherwise been available to us or to Bioventus LLC and, to the
extent that we are unable to make payments under the TRA for any reason, the unpaid amounts generally will be deferred and will accrue interest until paid by us. Decisions made by us in the course of running our business, such as with respect to
mergers, asset sales, other forms of business combinations or other changes in control, may influence the timing and amount of payments that are received by a Continuing LLC Owner under the TRA. For example, the earlier disposition of assets
following a transaction that results in a Basis Adjustment will generally accelerate payments under the TRA and increase the present value of such payments. We anticipate funding ordinary course payments under the TRA from distributions from
Bioventus LLC out of distributable cash, to the extent permitted by our agreements governing our indebtedness. See &#147;&#151;Bioventus&nbsp;LLC Agreement.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The TRA provides that if (i)&nbsp;we materially breach any of our material obligations under the TRA, (ii)&nbsp;certain mergers, asset sales, other forms of business combination, or other changes of control were to
occur, on or before December 31, 2017 or (iii)&nbsp;we elect an early termination of the TRA, then our obligations, or our successor&#146;s obligations, under the TRA would be based on certain assumptions, including an assumption that we would have
sufficient taxable income to fully utilize all potential future tax benefits that are subject to the TRA. The TRA also provides that in the case of certain mergers, asset sales, other forms of business combination or other changes of control
occurring on or after January 1, 2018, payments under the TRA would be based on certain assumptions, including an assumption that in each taxable year ending on or after the change of control, we would have taxable income equal to the greater of
(A)&nbsp;actual taxable income for such taxable year and (B)&nbsp;the product of (x)&nbsp;four and (y)&nbsp;the highest taxable income in any of the four fiscal quarters ended prior to the change in control (increased by 10% for each taxable year
beginning with the second taxable year following the change in control), in each case, as adjusted to take into account our actual percentage ownership in Bioventus LLC for the taxable year for which the tax benefit payment is being determined.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">201 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a result of the foregoing, (i)&nbsp;we could be required to make cash payments to the Continuing LLC Owners that
are greater than the specified percentage of the actual benefits we ultimately realize in respect of the tax benefits that are subject to the TRA, and (ii)&nbsp;if we materially breach any of our material obligations under the TRA or if we elect to
terminate the TRA early, we would be required to make an immediate cash payment equal to the present value of the anticipated future tax benefits that are the subject of the TRA, which payment may be made significantly in advance of the actual
realization, if any, of such future tax benefits. In these situations, our obligations under the TRA could have a material adverse effect on our liquidity and could have the effect of delaying, deferring or preventing certain mergers, asset sales,
other forms of business combination, or other changes of control. There can be no assurance that we will be able to finance our obligations under the TRA. We may elect to completely terminate the TRA early only with the written approval of a
majority of our directors other than any directors that have been appointed or designated by a Continuing LLC Member or any of such person&#146;s affiliates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Payments under the TRA will be based on the tax reporting positions that we determine. Pursuant to the TRA, Continuing LLC Members are required to reimburse us for cash payments previously made to any Continuing
LLC Owner pursuant to the TRA if any tax benefits initially claimed by us are subsequently challenged by a taxing authority and ultimately disallowed. In addition, but without duplication of any amounts previously reimbursed by a Continuing LLC
Member, any excess cash payments made by us to a Continuing LLC Owner will be netted against any future cash payments that we might otherwise be required to make under the terms of the TRA. However, a challenge to any tax benefits initially claimed
by us may not arise for a number of years following the initial time of such payment and we might not determine that we have effectively made an excess cash payment to the Continuing LLC Owners for a number of years following the initial time of
such payment. Moreover, there can be no assurance that any excess cash payments for which a Continuing LLC Member has a reimbursement obligation under the TRA will be repaid to us. As a result, it is possible that we could make cash payments under
the TRA that are substantially greater than our actual cash tax savings. The applicable U.S. federal income tax rules are complex and factual in nature, and we cannot assure you that the IRS or a court will not disagree with our tax reporting
positions. We will have full responsibility for, and sole discretion over, all Bioventus&#146; and Bioventus LLC&#146;s tax matters, including the filing and amendment of all tax returns and claims for refund and defense of all tax contests, subject
to certain participation and approval rights held by the Continuing LLC Owners. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Payments are generally due under the TRA within a specified period of
time following the filing of our tax return for the taxable year with respect to which the payment obligation arises, although interest on such payments will begin to accrue at a rate of LIBOR plus 100 basis points from the due date (without
extensions) of such tax return and ending on the date that such payments are required to be made under the terms of the TRA. Any late payments that may be made under the TRA will continue to accrue interest at LIBOR plus 500 basis points from the
due date of such payments under the TRA until such payments are made, including any late payments that we may subsequently make because we did not have enough available cash to satisfy our payment obligations at the time at which they originally
arose, including as a result of restrictions on payments to our equity owners in the agreements governing our indebtedness. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Bioventus LLC Agreement
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We will operate our business through Bioventus LLC and its subsidiaries. In connection with the completion of this offering, we and the Continuing
LLC Owners will enter into Bioventus LLC&#146;s second amended and restated limited liability company agreement, which we refer to as the &#147;Bioventus&nbsp;LLC Agreement.&#148; The operations of Bioventus LLC, and the rights and obligations of
the holders of&nbsp;LLC Interests, will be set forth in the Bioventus&nbsp;LLC Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">202 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Appointment as Manager</I>. Under the Bioventus LLC Agreement, we will become a member and the sole manager of
Biovtenus LLC. As the sole manager, we will be able to control all of the day-to-day business affairs and decision-making of Bioventus LLC. As such, we, through our officers and directors, will be responsible for all operational and administrative
decisions of Bioventus LLC and the <FONT STYLE="white-space:nowrap">day-to-day</FONT> management of Bioventus LLC&#146;s business. Pursuant to the terms of the Bioventus LLC Agreement, we cannot, under any circumstances, be removed as the sole
manager of Bioventus LLC except by our election. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Compensation</I>. We will not be entitled to compensation for our services as manager. We will be
entitled to reimbursement by Bioventus LLC for fees and expenses incurred on behalf of Bioventus LLC, including all expenses associated with this offering and maintaining our corporate existence. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Distributions</I>. The Bioventus LLC Agreement will require &#147;tax distributions&#148; to be made by Bioventus LLC to its members, as that term is defined in
the agreement. Tax distributions will be made as and when members are required to file tax returns, which we expect will be approximately on a quarterly basis, to each member of Bioventus LLC, including us, based on such member&#146;s allocable
share of the taxable income of Bioventus LLC and an assumed tax rate that will be determined by us. For this purpose, the taxable income of Bioventus LLC, and Bioventus Inc.&#146;s allocable share of such taxable income, shall be determined without
regard to any Basis Adjustment (as described above under &#147;&#151;Tax Receivable Agreement&#148;). The assumed tax rate that we expect to use for purposes of determining tax distributions from Bioventus LLC to its members will approximate our
reasonable estimate of the highest combined federal, state, and local tax rate that may potentially apply to any one of Bioventus LLC&#146;s members, regardless of the actual final tax liability of any such member. Tax distributions will also be
made only to the extent all distributions from Bioventus LLC for the relevant period were otherwise insufficient to enable each member to cover its tax liabilities as calculated in the manner described above. The Bioventus LLC Agreement will also
allow for distributions to be made by Bioventus LLC to its members on a pro rata basis out of &#147;distributable cash,&#148; as that term is defined in the agreement. We expect Bioventus LLC may make distributions out of distributable cash
periodically to the extent permitted by our agreements governing our indebtedness and necessary to enable us to cover our operating expenses and other obligations, including our tax liability and obligations under the Tax Receivable Agreement, as
well as to make dividend payments, if any, to the holders of our Class&nbsp;A common stock. Amounts distributable to Mr. Bihl with respect to any unvested Common Units shall be held in escrow and shall not be paid to Mr. Bihl until such unvested
Common Units become vested in accordance with the terms of Mr. Bihls&#146; profits interest award agreement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>LLC Interest Redemption Right</I>. The
Bioventus LLC Agreement provides a redemption right to the Continuing LLC Owners which entitles them to have their LLC Interests redeemed, at the election of each such person, for newly-issued shares of our Class&nbsp;A common stock on a one-for-one
basis or a cash payment equal to a volume weighted average market price of one share of Class&nbsp;A common stock for each LLC Interest redeemed (subject to customary adjustments, including for stock splits, stock dividends and reclassifications).
If the Continuing LLC Owner elects to receive a cash payment, we may elect to settle such redemption with Class A common stock in lieu of a cash payment, provided that if we elect to do so, the Continuing LLC Owner has the option to rescind its
redemption request within a specified time period. Upon the exercise of the redemption right, the redeeming member will surrender its LLC Interests to Bioventus LLC for cancellation. The Bioventus LLC Agreement requires that we contribute cash or
shares of our Class&nbsp;A common stock to Bioventus LLC in exchange for an amount of newly-issued LLC Interests in Bioventus LLC that will be issued to us equal to the number of LLC Interests redeemed from the Continuing LLC Owner. Bioventus LLC
will then distribute the cash or shares of our Class&nbsp;A common stock to such Continuing LLC Owner to complete the redemption. In the event of such a redemption election by a Continuing LLC Owner, we may effect a direct exchange of cash or our
Class&nbsp;A common stock for such LLC Interests in lieu of such a redemption. Whether by redemption or exchange, we are obligated to ensure that at all times the number of LLC Interests that we own equals the number of shares of
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">203 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Class&nbsp;A common stock issued by us (subject to certain exceptions for treasury shares and shares underlying certain convertible or exchangeable securities). </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Indemnification</I>. The Bioventus LLC Agreement provides for indemnification of the manager, members and officers of Bioventus LLC and their respective
subsidiaries or affiliates. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Stockholders Agreement </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Substantially concurrent with the closing of this offering, the Voting Group, which will hold Class&nbsp;A common stock or Class&nbsp;B common stock representing approximately 72.9% of the combined voting power of
our Class&nbsp;A and Class&nbsp;B common stock intend to enter into the Stockholders Agreement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Voting Agreement.</I>&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the terms of the Stockholders Agreement, Essex Woodlands Health Ventures, Spindletop Healthcare Capital, Pantheon Global, Ampersand Capital and Alta Partners, as members of the Voting Group (whom we refer to as the &#147;Essex Members&#148;),
collectively have the right to designate up to three individuals to be included in the slate of nominees recommended by our board of directors. Smith &amp; Nephew, as the other member of the Voting Group, will have the right to designate up to two
individuals to be included in the slate of nominees recommended by our board of directors. The number of individuals that the Essex Members and Smith &amp; Nephew may designate will decrease if they dispose of certain percentages of the shares of
our Class A common stock or Class B common stock, as applicable, that they own on the date this offering is consummated. At such time as the Essex Members or Smith &amp; Nephew own less than 10% of the shares of Class A common stock or Class B
common stock that they owned on the date this offering is consummated, the Essex Members or Smith &amp; Nephew, as the case may be, will no longer have designation rights under the Stockholders Agreement. Until such time, or if the Stockholders
Agreement is otherwise terminated in accordance with its terms, the parties to the Stockholders Agreement will agree to vote their shares of Class A common stock and Class B common stock in favor of the election of the nominees of the Essex Members
and Smith &amp; Nephew to our board of directors upon their nomination by the nominating and corporate governance committee of our board of directors. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Voting Group Approvals.</I>&nbsp;&nbsp;&nbsp;&nbsp;Under the Stockholders Agreement, any increase or decrease in the size of our board of directors or any
committee, and any amendment to our organizational documents, will in each case require the approval of the Essex Members, for so long as the Essex Members collectively owns at least 10% of the total shares of our Class A common stock owned by them
as of the date this offering is consummated, and will also require the approval of Smith &amp; Nephew, for so long as Smith &amp; Nephew owns at least 10% of the total shares of our Class B common stock owned by them as of the date this offering is
consummated. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Registration Rights Agreement </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We
intend to enter into a Registration Rights Agreement with the Original LLC Owners in connection with this offering. The Registration Rights Agreement will provide the Original LLC Owners certain registration rights whereby, at any time following our
initial public offering and the expiration of any related <FONT STYLE="white-space:nowrap">lock-up</FONT> period, the Continuing LLC Owners can require us to register under the Securities Act shares of Class&nbsp;A common stock issuable to them
upon, at our election, redemption or exchange of their&nbsp;LLC Interests and the Former LLC Owners can require us to register under the Securities Act the shares of Class&nbsp;A common stock issued to them in connection with the Transactions. The
Registration Rights Agreement will also provide for piggyback registration rights for the Original LLC Owners. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">204 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Continuation of Product Partnership Right of First Negotiation </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We intend to enter into a letter agreement that provides for the continuation of a product partnership right of first negotiation with Smith &amp; Nephew upon
consummation of this offering. Under the terms of the letter agreement, Smith &amp; Nephew will be granted a right of first negotiation with respect to any agreement or arrangement between us and a third party regarding the development, manufacture,
marketing or distribution of a new product until the earlier to occur of (i) May 4, 2019, (ii) the first anniversary of a change of control of the Company and (iii) the six month anniversary of a competitor change of control of Smith &amp; Nephew.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Policies and procedures for related party transactions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our board of directors has adopted a written related person transaction policy, to be effective upon the closing of this offering, setting forth the policies and procedures for the review and approval or
ratification of related person transactions. This policy will cover, with certain exceptions set forth in Item&nbsp;404 of Regulation S-K under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions,
arrangements or relationships, in which we were or are to be a participant, where the amount involved exceeds $120,000 in any fiscal year and a related person had, has or will have a direct or indirect material interest, including without
limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including, but not limited to,
whether the transaction is on terms comparable to those that could be obtained in an arm&#146;s length transaction and the extent of the related person&#146;s interest in the transaction. All of the transactions described in this section occurred
prior to the adoption of this policy. In connection with the review and approval or ratification of a related person transaction, management must disclose to the audit committee or disinterested directors, as applicable, the name of the related
person and the basis on which the person is a related person, the material terms of the related person transaction, including the approximate dollar value of the amount involved in the transaction, and all the material facts as to the related
person&#146;s direct or indirect interest in, or relationship to, the related person transaction. Management must advise the audit committee or disinterested directors, as applicable, as to whether the related person transaction complies with the
terms of our agreements governing our material outstanding indebtedness that limit or restrict our ability to enter into a related person transaction, and whether the related person transaction will be required to be disclosed in our applicable
filings under the Securities Act or the Exchange Act, and related rules, and, to the extent required to be disclosed, management must ensure that the related </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">person transaction is disclosed in accordance with such Acts and related rules. Management must advise the committee or disinterested directors, as applicable, as to whether the related person transaction
constitutes a &#147;personal loan&#148; for purposes of Section 402 of the Sarbanes-Oxley Act. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">205 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_17"></A>Principal stockholders </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following table presents information as to the beneficial ownership of our Class&nbsp;A common stock and Class&nbsp;B common stock, after the consummation of the Transactions, including this offering, for:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our Class&nbsp;A common stock or our Class B common stock;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">each named executive officer; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">each of our directors; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">all executive officers and directors as a group. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As described in &#147;Transactions&#148; and &#147;Certain relationships and related party transactions,&#148; each Continuing LLC Owner will be entitled to have
their&nbsp;LLC Interests redeemed for Class&nbsp;A common stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, or, if Bioventus and such person agree, cash equal to the market value of the
applicable number of our shares of Class&nbsp;A common stock. In addition, at Bioventus&#146; election, Bioventus may effect a direct exchange of such Class&nbsp;A common stock or such cash (if mutually agreed) for such&nbsp;LLC Interests in lieu of
such a redemption. In connection with this offering, we will issue to each Continuing LLC Owner one share of Class&nbsp;B common stock for each&nbsp;LLC Interest it owns. As a result, the number of shares of Class&nbsp;B common stock listed in the
table below correlates to the number of&nbsp;LLC Interests each such Continuing LLC Owner will own immediately prior to and after this offering (but after giving effect to the Transactions other than this offering). See &#147;Transactions.&#148;
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC and includes voting or investment power with
respect to securities. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power. In computing the number of shares beneficially owned by an individual or
entity and the percentage ownership of that person, shares of common stock subject to options, or other rights, including the redemption right described above, held by such person that are currently exercisable or will become exercisable within
60&nbsp;days of the date of this prospectus, are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person. Unless otherwise indicated, the address of each of
the individuals and entities named below is c/o Bioventus Inc., 4721 Emperor Boulevard, Suite 100, Durham, NC 27703. Each of the stockholders listed has sole voting and investment power with respect to the shares beneficially owned by the
stockholder unless noted otherwise, subject to community property laws where applicable. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Shares of class&nbsp;A</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>common
stock</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>beneficially owned</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Shares of class&nbsp;B</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>common
stock</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>beneficially owned</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>common</B></FONT><br><FONT
STYLE="font-family:arial" SIZE="2"><B>stock</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>beneficially</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>owned</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name of beneficial owner</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B><I>5% Stockholders</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Essex Woodlands Health Ventures(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,493,257</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">27.4%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Smith&nbsp;&amp; Nephew(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,134,022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,374,130</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">97.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34.6%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Spindletop Healthcare Capital L.P.(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,947,976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pantheon Global Co-Investment Opportunities Fund L.P.(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,406,870</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Ampersand Capital(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,623,315</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6.8%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Alta Partners VIII, L.P.(6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,298,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">206 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Shares of class&nbsp;A</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>common
stock</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>beneficially owned</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Shares of class&nbsp;B</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>common
stock</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>beneficially owned</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>common</B></FONT><br><FONT
STYLE="font-family:arial" SIZE="2"><B>stock</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>beneficially</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>owned</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name of beneficial owner</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Named Executive Officers and Directors</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Anthony P. Bihl III(7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">197,634</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">David J. Price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Henry C. Tung, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Philip G. Cowdy</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">William A. Hawkins</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Michael R. Minogue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Guido J. Neels</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Guy P. Nohra</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">David J. Parker</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cyrille Y. N. Petit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Martin P. Sutter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">All directors and named executive officers as a group (11&nbsp;persons)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">197,634</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="20" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents beneficial ownership of less than 1%. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents shares held by Essex Woodlands Health Ventures Fund VIII, L.P., Essex Woodlands Health Ventures Fund VIII-A, L.P. and Essex Woodlands Health Ventures Fund VIII-B,
L.P., which we collectively refer to as the &#147;Essex Stockholders.&#148; Essex Woodlands Health Ventures VIII, L.P., a Delaware limited partnership, is the general partner of each of the Essex Stockholders and is referred to as the
&#147;Partnership,&#148; and Essex Woodlands Health Ventures VIII, LLC, a Delaware limited liability company, is the general partner of the Partnership and is referred to as the &#147;General Partner.&#148; James L. Currie, Martin P. Sutter,
Immanuel Thangaraj, Petri Vainio, Jeff Himawan, Ron Eastman, Guido Neels and Steve Wiggins are the managers of the General Partner, and each is referred to as a &#147;Manager&#148; and collectively as the &#147;Managers.&#148; The Partnership is
deemed to have sole voting and dispositive power with respect to the shares held by each of the Essex Stockholders. The Managers are deemed to have shared voting and dispositive power with respect to the shares held by each of the Essex Stockholders
by unanimous consent and through the Partnership. Each Manager disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The address of the Essex Stockholders is 21 Water Way Avenue, Suite 225, The
Woodlands, Texas 77380. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents shares held by Smith&nbsp;&amp; Nephew, Inc. and Smith&nbsp;&amp; Nephew OUS, Inc., which we collectively refer to as the &#147;S&amp;N Stockholders.&#148; The address
of the S&amp;N Stockholders is 7135 Goodlett Farms, Cordova, Tennessee 38106. The S&amp;N Stockholders are U.S. based subsidiaries of Smith &amp; Nephew plc, which is a United Kingdom based public company listed on the London Stock Exchange with
American Depositary Receipts traded on the New York Stock Exchange. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents shares held by Spindletop Healthcare Capital L.P. Evan Melrose is the Manager of the General Partner of the General Partner of Spindletop Healthcare Capital L.P. and
may be deemed to have shared voting and dispositive power with respect to the shares held by Spindletop Healthcare Capital L.P.The address of Spindletop Healthcare Capital L.P. is 3571 Far West Blvd., PMB #108, Austin, Texas 78731.
</FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents shares held by Pantheon Global Co-Investment Opportunities Fund L.P. David Braman, Susan Long McAndrews and Lily Wong are directors of Pantheon Global Co-Investment
Opportunities GP Limited, the general partner of Pantheon Global Co-Investment Opportunities Fund, L.P. and make the investment and voting decisions with respect to shares held by of Pantheon Global Co-Investment Opportunities Fund, L.P. The address
of Pantheon Global Co-Investment Opportunities Fund L.P. is 600 Montgomery Street, 23rd Floor, San Francisco, CA 94111. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents shares held by Ampersand 2006 Limited Partnership 1 and Ampersand 2011 Limited Partnership which we collectively refer to as the &#147;Ampersand Capital
Stockholders.&#148; Richard A. Charpie and Herbert H. Hooper, the Managing Members of the General Partner of the General Partner of each of the Ampersand Capital Stockholders, may be deemed to have shared voting and dispositive power with respect to
shares held by Ampersand 2006 Limited Partnership. The address of the Ampersand Capital Stockholders is in care of Ampersand Capital Partners, 55 William Street, Suite 240, Wellesley, Massachusetts 02481, </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents shares held by Alta Partners VIII, L.P. Alta Partners Management VIII, LLC is the general partner of Alta Partners VIII, L.P. Guy Nohra, Daniel Janney and Farah
Champsi are managing directors of Alta Partners Management VIII, LLC and exercise shared voting and investment powers with respect to the shares owned by Alta Partners VIII, L.P. Each of the reporting persons disclaims beneficial ownership of such
shares, except to the extent of their proportionate pecuniary interest therein, if any. The principal business address of Alta Partners VIII, L.P. is One Embarcadero Center, 37th Floor San Francisco, CA 94111. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(7)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Of the 197,634 shares of Class B common stock and LLC Interests held by Mr.&nbsp;Bihl, 74,113 shares of Class&nbsp;B common stock and LLC Interests are unvested shares of
Class&nbsp;B common stock and are subject to vesting in accordance with the vesting terms of the exchanged profits interests units. Any portion of the unvested shares of Class&nbsp;B common stock and LLC Interests that remains unvested as of the
12-month anniversary following the termination of the Phantom Profits Interest Plan will accelerate and vest on such 12-month anniversary date. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">207 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_18"></A>Description of capital stock </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following descriptions of our capital stock and provisions of our amended and restated certificate of incorporation, and our bylaws, each of which will be in effect prior to the completion of this offering, are
summaries and are qualified by reference to the amended and restated certificate of incorporation and the bylaws, which are filed as exhibits to the registration statement of which this prospectus forms&nbsp;a part. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our current authorized capital stock consists of 100 shares of Common Stock, par value $0.001 per share. As of the consummation of this offering, our authorized
capital stock will consist of 150,000,000 shares of Class&nbsp;A common stock, par value $0.001, 15,000,000 shares of Class&nbsp;B common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Common stock </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of the consummation of this offering,
there will be 23,727,619 shares of our Class&nbsp;A common stock issued and outstanding, and 9,571,764 shares of our Class&nbsp;B common stock issued and outstanding. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Class&nbsp;A common stock </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Voting rights </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Holders of our Class&nbsp;A common stock will be entitled to cast one vote per share. Holders of our Class&nbsp;A common stock will not be entitled to cumulate their votes in the election of directors. Generally,
all matters to be voted on by stockholders must be approved by a majority (or, in the case of election of directors, by a plurality) of the votes entitled to be cast by all holders of Class&nbsp;A common stock and Class&nbsp;B common stock present
in person or represented by proxy, voting together as a single class. Except as otherwise provided by law, amendments to the amended and restated certificate of incorporation must be approved by a majority or, in some cases, a <FONT
STYLE="white-space:nowrap">super-majority</FONT> of the combined voting power of all shares of Class&nbsp;A common stock and Class&nbsp;B common stock, voting together as a single class. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Dividend rights </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Holders of Class&nbsp;A common stock will share ratably (based on the number of shares of
Class&nbsp;A common stock held) if and when any dividend is declared by the board of directors out of funds legally available therefor, subject to any statutory or contractual restrictions on the payment of dividends and to any restrictions on the
payment of dividends imposed by the terms of any outstanding preferred stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Liquidation rights </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On our liquidation, dissolution or winding up, each holder of Class&nbsp;A common stock will be entitled to a pro rata distribution of any assets available for
distribution to common stockholders. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Other matters </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">No shares of Class&nbsp;A common stock will be subject to redemption or have preemptive rights to purchase additional shares of Class&nbsp;A common stock. Holders
of shares of our Class&nbsp;A common stock do not have subscription, redemption or conversion rights. There will be no redemption or sinking fund provisions applicable to the Class&nbsp;A common stock. Upon consummation of this offering, all the
outstanding shares of Class&nbsp;A common stock will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Class&nbsp;B common stock </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Issuance of class&nbsp;B
common stock with&nbsp;LLC interests </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Shares of Class&nbsp;B common stock will only be issued in the future to the extent necessary to maintain a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> ratio between the number of&nbsp;LLC Interests held by Continuing LLC Owners and the number of shares </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">208 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
of Class&nbsp;B common stock issued to Continuing LLC Owners. Shares of Class&nbsp;B common stock are transferable only together with an equal number of&nbsp;LLC Interests. Shares of Class&nbsp;B
common stock will be cancelled on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis if we, at the election of a Continuing LLC Owner, redeem or exchange&nbsp;LLC Interests of such Continuing LLC
Owners pursuant to the terms of the Bioventus LLC Agreement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Voting rights </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Holders of Class&nbsp;B common stock will be entitled to cast one vote per share, with the number of shares of Class&nbsp;B common stock held by each Continuing LLC Owner being equivalent to the number of&nbsp;LLC
Interests held by such Continuing LLC Owner. Holders of our Class&nbsp;B common stock will not be entitled to cumulate their votes in the election of directors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Generally, all matters to be voted on by stockholders must be approved by a majority (or, in the case of election of directors, by a plurality) of the votes entitled to be cast by all Class&nbsp;A and Class&nbsp;B
stockholders present in person or represented by proxy, voting together as a single class. Except as otherwise provided by law, amendments to the amended and restated certificate of incorporation must be approved by a majority or, in some cases, a <FONT
STYLE="white-space:nowrap">super-majority</FONT> of the combined voting power of all shares of Class&nbsp;A common stock and Class&nbsp;B common stock, voting together as a single class. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Dividend rights </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Holders of our Class&nbsp;B common stock will not participate in any dividend declared by the
board of directors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Liquidation rights </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On our
liquidation, dissolution or winding up, holders of Class&nbsp;B common stock will not be entitled to receive any distribution of our assets. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Transfers </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to the Bioventus LLC Agreement, each
holder of Class&nbsp;B common stock agrees that: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the holder will not transfer any shares of Class&nbsp;B common stock to any person unless the holder transfers an equal number of&nbsp;LLC Interests to the same
person; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">in the event the holder transfers any&nbsp;LLC Interests to any person, the holder will transfer an equal number of shares of Class&nbsp;B common stock to the
same person. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Other matters </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">No
shares of Class&nbsp;B common stock will have preemptive rights to purchase additional shares of Class&nbsp;B common stock. Holders of shares of our Class&nbsp;B common stock do not have subscription, redemption or conversion rights. There will be
no redemption or sinking fund provisions applicable to the Class&nbsp;B common stock. Upon consummation of this offering, all outstanding shares of Class&nbsp;B common stock will be validly issued, fully paid and nonassessable. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Preferred stock </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of
incorporation provides that our board of directors has the authority, without action by the stockholders, to designate and issue up to 10,000,000 shares of preferred stock in one or more classes or series and to fix the powers, rights, preferences,
and privileges of each class or series of preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences and the number of shares constituting any class or series, which may be greater than
the rights of the holders of the common stock. There will be no shares of preferred stock outstanding immediately after this offering. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">209 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is
to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the
effect of making it more difficult for a third-party to acquire, or could discourage a third-party from seeking to acquire, a majority of our outstanding voting stock. Additionally, the issuance of preferred stock may adversely affect the holders of
our Class&nbsp;A common stock by restricting dividends on the Class&nbsp;A common stock, diluting the voting power of the Class&nbsp;A common stock or subordinating the liquidation rights of the Class&nbsp;A common stock. As a result of these or
other factors, the issuance of preferred stock could have an adverse impact on the market price of our Class&nbsp;A common stock. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Exclusive venue
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation, as it will be in effect upon the closing of this offering, will require, to the fullest
extent permitted by law, that (1)&nbsp;any derivative action or proceeding brought on our behalf, (2)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our
stockholders, (3)&nbsp;any action asserting a claim against us arising pursuant to any provision of the DGCL or our amended and restated certificate of incorporation or the bylaws or (4)&nbsp;any action asserting a claim against us governed by the
internal affairs doctrine will have to be brought only in the Court of Chancery in the State of Delaware. Although we believe this provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits
to which it applies, the provision may have the effect of discouraging lawsuits against our directors and officers. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B><FONT STYLE="white-space:nowrap">Anti-takeover</FONT> effects of provisions of our amended and restated certificate of incorporation, our bylaws and delaware
law </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our certificate of incorporation and bylaws, as they will be in effect upon completion of this offering, also contain provisions that may delay,
defer or discourage another party from acquiring control of us. We expect that these provisions, which are summarized below, will discourage coercive takeover practices or inadequate takeover bids. These provisions are also designed to encourage
persons seeking to acquire control of us to first negotiate with our board of directors, which we believe may result in an improvement of the terms of any such acquisition in favor of our stockholders. However, they also give our board of directors
the power to discourage acquisitions that some stockholders may favor. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Classified board of directors </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation will provide that our board of directors will be divided into three classes, with the classes as nearly equal
in number as possible and each class serving <FONT STYLE="white-space:nowrap">three-year</FONT> staggered terms. In addition, our amended and restated certificate of incorporation will provide that directors may only be removed from our board of
directors with cause. These provisions may have the effect of deferring, delaying or discouraging hostile takeovers, or changes in control of us or our management. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Authorized but unissued shares </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The authorized but unissued shares of common stock and preferred stock
are available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of The NASDAQ Global Market. These additional shares may be used for a variety of corporate finance transactions,
acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer,
merger or otherwise. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">210 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Requirements for advance notification of stockholder meetings, nominations and proposals </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation will provide that stockholders at an annual meeting may only consider proposals or nominations specified in
the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a qualified stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely
written notice in proper form to our secretary of the stockholder&#146;s intention to bring such business before the meeting. Our amended and restated certificate of incorporation will provide that, subject to applicable law, special meetings of the
stockholders may be called only by a resolution adopted by the affirmative vote of the majority of the directors then in office. Our bylaws will prohibit the conduct of any business at a special meeting other than as specified in the notice for such
meeting. In addition, any stockholder who wishes to bring business before an annual meeting or nominate directors must comply with the advance notice and duration of ownership requirements set forth in our bylaws and provide us with certain
information. These provisions may have the effect of deferring, delaying or discouraging hostile takeovers or changes in control of us or our management. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Stockholder action by written consent </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to
Section&nbsp;228 of the DGCL, any action required to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice and without a vote if a consent or consents in writing, setting forth the action
so taken, is signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of our stock entitled to vote thereon were present and
voted, unless our amended and restated certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation will provide that stockholder action by written consent will be permitted only if the action to be effected
by such written consent and the taking of such action by such written consent have been previously approved by the board of directors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Amendment
of amended and restated certificate of incorporation or bylaws </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">The Delaware General Corporation Law provides generally that
the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#146;s certificate of incorporation or bylaws, unless a corporation&#146;s certificate of incorporation or bylaws, as the case may be,
requires a greater percentage. Upon completion of this offering, our bylaws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders of at least 66-<FONT SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;2</SUP></FONT><FONT SIZE="2">/</FONT><FONT SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.1ex">3</SUB></FONT><FONT STYLE="font-family:arial" SIZE="2">% of
the votes which all our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least
66-<FONT SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;2</SUP></FONT><FONT SIZE="2">/</FONT><FONT SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.1ex">3</SUB></FONT><FONT
STYLE="font-family:arial" SIZE="2">% of the votes which all our stockholders would be entitled to cast in any election of directors will be required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our
certificate described above. </FONT></FONT></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The foregoing provisions of our amended and restated certificate of incorporation and bylaws could discourage
potential acquisition proposals and could delay or prevent a change in control. These provisions are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by our
board of directors and to discourage certain types of transactions that may involve an actual or threatened change of control. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are
intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the
market price of our shares of Class&nbsp;A common stock that could result from actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in our management or delaying or preventing a transaction that might
benefit you or other minority stockholders. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">211 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, we are subject to Section&nbsp;203 of the Delaware General Corporation Law. Subject to certain
exceptions, Section&nbsp;203 prevents a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with any &#147;interested stockholder&#148; for three years following the date that the person became an interested
stockholder, unless the interested stockholder attained such status with the approval of our board of directors or unless the business combination is approved in a prescribed manner. A &#147;business combination&#148; includes, among other things, a
merger or consolidation involving us and the &#147;interested stockholder&#148; and the sale of more than 10% of our assets. In general, an &#147;interested stockholder&#148; is any entity or person beneficially owning 15% or more of our outstanding
voting stock and any entity or person affiliated with or controlling or controlled by such entity or person. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Limitations on liability and
indemnification of officers and directors </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated certificate of incorporation and bylaws provide indemnification for our directors
and officers to the fullest extent permitted by the DGCL. Prior to the completion of this offering, we intend to enter into indemnification agreements with each of our directors that may, in some cases, be broader than the specific indemnification
provisions contained under Delaware law. In addition, as permitted by Delaware law, our amended and restated certificate of incorporation includes provisions that eliminate the personal liability of our directors for monetary damages resulting from
breaches of certain fiduciary duties as a director. The effect of this provision is to restrict our rights and the rights of our stockholders in derivative suits to recover monetary damages against a director for breach of fiduciary duties as a
director, except that a director will be personally liable for: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any breach of his duty of loyalty to us or our stockholders; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any transaction from which the director derived an improper personal benefit; or </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">improper distributions to stockholders. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These
provisions may be held not to be enforceable for violations of the federal securities laws of the United States. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Corporate opportunities
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In recognition that partners, principals, directors, officers, members, managers and/or employees of the Original LLC Owners and their affiliates
and investment funds, which we refer to as the Corporate Opportunity Entities, may serve as our directors and/or officers, and that the Corporate Opportunity Entities may engage in activities or lines of business similar to those in which we engage,
our amended and restated certificate of incorporation provides for the allocation of certain corporate opportunities between us and the Corporate Opportunity Entities. Specifically, none of the Corporate Opportunity Entities has any duty to refrain
from engaging, directly or indirectly, in the same or similar business activities or lines of business that we do. In the event that any Corporate Opportunity Entity acquires knowledge of a potential transaction or matter which may be a corporate
opportunity for itself and us, we will not have any expectancy in such corporate opportunity, and the Corporate Opportunity Entity will not have any duty to communicate or offer such corporate opportunity to us and may pursue or acquire such
corporate opportunity for itself or direct such opportunity to another person. In addition, if a director of our Company who is also a partner, principal, director, officer, member, manager or employee of any Corporate Opportunity Entity acquires
knowledge of a potential transaction or matter which may be a corporate opportunity for us and a Corporate Opportunity Entity, we will not have any expectancy in such corporate opportunity. Messrs. Philip G. Cowdy, Guido J. Neels, Guy P.&nbsp;Nohra,
David J. Parker, Cyrille&nbsp;Y.&nbsp;N. Petit and Martin P. Sutter, who will serve as directors on our Board of Directors, are or are affiliated with Original LLC Owners. In the event that any other director of ours acquires knowledge of a
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">212 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
potential transaction or matter which may be a corporate opportunity for us we will not have any expectancy in such corporate opportunity unless such potential transaction or matter was presented
to such director expressly in his or her capacity as such. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">By becoming a stockholder in our Company, you will be deemed to have notice of and consented
to these provisions of our amended and restated certificate of incorporation. Any amendment to the foregoing provisions of our amended and restated certificate of incorporation requires the affirmative vote of at least
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of the voting power of all shares of our common stock then outstanding. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Dissenters&#146; rights
of appraisal and payment </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the Delaware General Corporation Law, with certain exceptions, our stockholders will have appraisal rights in
connection with a merger or consolidation. Pursuant to the Delaware General Corporation Law, stockholders who properly request and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the
fair value of their shares as determined by the Delaware Court of Chancery. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Stockholders&#146; derivative actions </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the Delaware General Corporation Law, any of our stockholders may bring an action in our name to procure a judgment in our favor, also known as a derivative
action, provided that the stockholder bringing the action is a holder of our shares at the time of the transaction to which the action relates or such stockholder&#146;s stock thereafter devolved by operation of law and such suit is brought in the
Court of Chancery in the State of Delaware. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Listing </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our Class&nbsp;A common stock will be listed on The NASDAQ Global Market under the trading symbol &#147;BIOV&#148;. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Transfer agent and registrar </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Upon the closing of this
offering, the transfer agent and registrar for our Class&nbsp;A common stock will be American Stock Transfer &amp; Trust Company, LLC. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Stockholders
Agreement </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with this offering, we will enter into the Stockholders Agreement with the Voting Group pursuant to which the Voting Group
will have specified board representation rights, governance rights and other rights. See &#147;Certain relationships and related party transactions&#151;Stockholders Agreement.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">213 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_19"></A>Description of indebtedness </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">On October&nbsp;10, 2014, we entered into two&nbsp;credit agreements, which we refer to collectively as the 2014 Credit Agreement, with JPMorgan Chase Bank, N.A., as administrative agent, as well as a syndicate of
other banks, financial institutions and other entities, or Lenders. The 2014 Credit Agreement is comprised of a $115.0&nbsp;million first lien term loan, a $60.0 million&nbsp;second lien term loan and a $40.0 million first lien revolving facility,
or 2014 revolver. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">All obligations under the 2014 Credit Agreement are guaranteed by certain of our direct and indirect wholly-owned domestic
subsidiaries. The obligations under the 2014 Credit Agreement are collateralized by substantially all of our and the guarantors&#146; assets. The first lien term loan and 2014 revolver mature on October&nbsp;10, 2019 and the second lien term loan
matures on April&nbsp;10, 2020. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of April 2, 2016, $102.3 million&nbsp;was outstanding under the first lien term loan, net of the unamortized original
issue discount of $0.5 million and deferred financing costs of $0.7 million. We may voluntarily prepay the first lien term loan without premium or penalty upon prior notice. Scheduled quarterly principal payments under the first lien term loan as a
percentage of the aggregate initial principal borrowed are as follows, with the remaining outstanding principal due at maturity: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Quarterly<BR>payment</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">December&nbsp;31, 2014 to September&nbsp;30, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.25%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.4&nbsp;million</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">December&nbsp;31, 2015 to September&nbsp;30, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.50%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.9 million</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">December&nbsp;31, 2016 to September&nbsp;30, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.75%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.3 million</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">December&nbsp;31, 2017 to September&nbsp;30, 2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.75%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.3 million</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">December&nbsp;31, 2018 to maturity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.8 million</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of April 2, 2016, $57.6 million&nbsp;was outstanding under the second lien term loan, net of the unamortized original issue
discount of $0.9 million and deferred financing costs of $1.5 million. There are no scheduled principal payments under the second lien term loan until maturity. After October&nbsp;10, 2017, we may voluntarily prepay the second lien term loan without
premium or penalty upon prior notice. Prepayments made prior to October&nbsp;10, 2017 will be subject to the prepayment premiums below: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Payment timing</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Premium</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">In advance of October&nbsp;10, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">On October&nbsp;10, 2015 but in advance of October&nbsp;10, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">On October&nbsp;10, 2016 but in advance of October&nbsp;10, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The first and second lien term loans permit at our election either Eurodollar or Alternate Base Rate, or ABR, term loans, which are
due at maturity. ABR loans are due at maturity unless converted to a Eurodollar loan at our option. ABR term loans have interest due on the last day of each calendar quarter-end. Eurodollar loans are one, two, three or six-month loans and interest
is due on the last day of each three-month period. In advance of the last day of a Eurodollar loan, we may choose to change such loan for a new loan type so long as it does not extend beyond maturity. The outstanding first and second lien term loans
have been Eurodollar loans since inception. In addition, both first and second lien term loans have an interest due date concurrent with any repayment or prepayment. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The 2014 revolver is a five-year revolving credit facility of $40.0 million which includes revolving and swingline loans as well as letters of credit. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">214 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">2014 revolver loans may be Eurodollar or ABR loans at our election, which are not due until maturity, and interest is
payable at the same term as described in the previous paragraph for the first and second lien term loans. Swingline loans are available as ABR loans only and are due within five business days or maturity whichever is earlier. As of April 2, 2016, we
had $19.5 million of borrowings outstanding under the 2014 revolver, leaving $20.5&nbsp;million available. There were no letters of credit outstanding under the 2014 revolver as of April 2, 2016. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">The base interest rate for all ABR loans is equal to the highest of (a)&nbsp;the JP Morgan Prime Rate, (b)&nbsp;the Federal Funds Effective
Rate plus <FONT SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;1</SUP></FONT><FONT SIZE="2">/</FONT><FONT SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.1ex">2</SUB></FONT><FONT
STYLE="font-family:arial" SIZE="2">% and (c)&nbsp;the Eurodollar Rate for a USD deposit with a maturity of one month plus 1.0% (rounded upward to the next 1/16 of 1%). </FONT></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The base interest rate for all Eurodollar loans is equal to the rate determined for such day in accordance with the following formula with the second lien term loans having a floor of 1.00%: </FONT></P>
<P STYLE="font-size:16px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>LIBOR</B></FONT></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">1&#151;Eurocurrency Reserve Requirements</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to the base interest rate, all Eurodollar and ABR loans have an applicable margin for borrowings. The first lien term
loan margins are tied to a leverage ratio which is defined as the ratio of (a)&nbsp;consolidated GAAP secured debt to (b)&nbsp;Consolidated EBITDA (as defined in the 2014 Credit Agreement) for four consecutive quarters at the end of each period.
Pricing grids are used to determine the margin based on the type of loan and the leverage ratio. The second lien term loan margins are fixed at 10.00% for Eurodollar loans and 9.00% for ABR loans. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The first lien term loan margin is adjusted after the quarterly financial statements are delivered to the lenders. The table below set forth the leverage-based
pricing grid for the first lien term loan: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Leverage ratio</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Eurodollar</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>ABR</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT><FONT
STYLE="font-family:arial" SIZE="2"></FONT> 4.00 to 1.00</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT><FONT
STYLE="font-family:arial" SIZE="2"></FONT> 3.00 to 1.00 but &lt; 4.00 to 1.00</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.75%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.75%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT><FONT
STYLE="font-family:arial" SIZE="2"></FONT> 2.00 to 1.00 but &lt; 3.00 to 1.00</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.50%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.50%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&lt; 2.00 to 1.00</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.25%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.25%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Interest is calculated based on a 360-day year except for ABR loans where the base interest is the JP Morgan Prime Rate, in which
case it is calculated based on a calendar-day year. As of April 2, 2016, the first and second lien term loan interest rates including the margin were 3.18% and 11.0%, respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We may be required to make additional principal payments on the first and second lien term loans dependent upon the generation of certain cash flow events as defined in the 2014 Credit Agreement. These additional
prepayments will be applied to the scheduled installments of principal in direct order of maturity of the ABR loans first and then the Eurodollar loans. There were no additional principal payments required for the year ended December 31, 2015.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The 2014 revolver includes a commitment fee at 0.50% of the average daily amount of the available revolving commitment, excluding the amount of
swingline loans outstanding. There were no swingline loans outstanding as of April 2, 2016. The fee is payable quarterly in arrears on the last day of the calendar quarters and maturity. On and after the first adjustment date, the rate will be
determined based on the pricing grid below. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Leverage ratio</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Commitment<BR>fee rate</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT><FONT
STYLE="font-family:arial" SIZE="2"></FONT> 4.00 to 1.00</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.50%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT><FONT
STYLE="font-family:arial" SIZE="2"></FONT> 3.00 to 1.00 but &lt; 4.00 to 1.00</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.45%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT><FONT
STYLE="font-family:arial" SIZE="2"></FONT> 2.00 to 1.00 but &lt; 3.00 to 1.00</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.40%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&lt; 2.00 to 1.00</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.35%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">215 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Letters of credit are available in an amount not to exceed $5.0 million. Fees are charged on all outstanding letters
of credit at an annual rate equal to the margin in effect on Eurodollar revolving loans. A fronting fee of 0.125%&nbsp;per year on the undrawn and unexpired amount of each letter of credit is payable as well. The fees are payable quarterly in
arrears on the last day of each calendar quarter after October&nbsp;10, 2014. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The 2014 Credit Agreement requires that, on or before January&nbsp;8,
2015, we enter into, and thereafter maintain for not less than three years, agreements so that at least 25% of the first lien term loans are subject to a fixed interest rate. During November 2014, we entered into three interest rate swap agreements
totaling $70.0 million with a term of three years. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of April 2, 2016, the effective interest rate, including the applicable lending margin, on 67.63%,
or $70.0 million, of the outstanding principal amount of our first lien term loan was fixed at 3.94% through the use of the interest rate swaps. As of April 2, 2016, our effective weighted average interest rate on all outstanding debt, including the
commitment fee and interest rate swaps, was 5.48%. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The 2014 Credit Agreement contains a number of covenants, including a covenant not to exceed a
consolidated leverage ratio of 4.50 to 1.00 as of December 31, 2016, 4.00 to 1.00 as of December 31, 2017, and 3.65 to 1.00 as of December 31, 2018 and a covenant to maintain a fixed charge coverage ratio of at least 1.25 to 1.00. The leverage ratio
and the fixed charge coverage ratio in the 2014 Credit Agreement are based on Consolidated EBITDA as defined in such agreement, which includes several differences from Consolidated EBITDA as calculated in this prospectus. Consolidated EBITDA defined
in the 2014 Credit Agreements permits, among other things, the exclusion of (1) non-recurring cash expenses up to a limit of 15% of EBITDA, (2) foreign currency gains/losses recognized in the statement of operations and (3) franchise and excise
taxes recognized in the statement of operations. Also, the definition of the fixed charge coverage ratio in the 2014 Credit Agreements permits the exclusion of a defined amount of BMP expenses up to a limit of $10.0 million for 2016. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, the 2014 Credit Agreement contains covenants that restrict the ability of the borrower and its restricted subsidiaries to (subject to certain
exceptions): </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">incur additional indebtedness; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">create liens on assets; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">engage in mergers, consolidations or other fundamental changes (as defined in the 2014 Credit Agreement); </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">dispose or sell assets; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">pay dividends and make other payments in respect of capital stock; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">make any capital expenditures; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">make investments, loans or advances; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">pay and modify the terms of certain indebtedness and organizational documents; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">engage in certain transactions with affiliates; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">enter into sale and leaseback transactions and swap agreements; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">change fiscal periods; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">enter into negative pledge clauses and clauses restricting subsidiary distributions; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">enter new lines of business. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of April 2,
2016, we were in compliance with the covenants under the 2014 Credit Agreement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The 2014 Credit Agreement contains customary events of default
including, but not limited to, failure to pay principal or interest, breaches of representations and warranties, violations of affirmative or negative covenants, cross-defaults to other indebtedness, a bankruptcy or similar proceeding being
instituted by or against us, rendering of certain monetary judgments against us, impairments of loan documentation or security, changes of control, and defaults with respect to certain ERISA obligations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">216 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each Lender may provide an additional first lien, second lien and or revolving loan by executing and delivering notice
specifying the terms, subject to certain conditions. The aggregate amount of all additional borrowings may not exceed $25.0 million without the consent of the Lenders holding more than 50% of the total outstanding debt under the 2014 Credit
Agreement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On November 20, 2015 we amended our senior secured credit facilities to enable certain sales and costs related to acquisitions to be included
and certain BMP development expenses to be excluded from future covenant calculations, as well as amending certain covenant calculations. We have entered into an amendment to the agreement governing the first lien term loan facility and the first
lien revolving credit facility, which will become operative upon the completion of this offering and will permit the consummation of the Transactions. This amendment also provides for a covenant not to exceed a consolidated leverage ratio of 3.50 to
1.00 with the ability for us to request an increase to 4.00 to 1.00 for a period of four consecutive fiscal quarters in connection with certain permitted acquisitions (but no more than two times over the term of the facilities). We intend to use a
portion of the net proceeds from this offering to repay our second lien term loan facility in full, together with a prepayment premium and accrued and unpaid interest thereon and to repay all of the outstanding borrowings under the 2014 Revolver.
See &#147;Use of Proceeds.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">217 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_20"></A>Shares eligible for future sale </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Immediately prior to this offering, there was no public market for our Class&nbsp;A common stock. Future sales of substantial amounts of Class&nbsp;A common stock
in the public market (including shares of Class&nbsp;A common stock issuable upon redemption or exchange of&nbsp;LLC Interests), or the perception that such sales may occur, could adversely affect the market price of our Class&nbsp;A common stock.
Although we have applied to have our Class&nbsp;A common stock listed on The NASDAQ Global Market, we cannot assure you that there will be an active public market for our Class&nbsp;A common stock. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Upon the closing of this offering, we will have outstanding an aggregate of 23,727,619 shares of Class&nbsp;A common stock, assuming the issuance of 8,823,529
shares of Class&nbsp;A common stock offered by us in this offering and the issuance of 14,904,090 shares of Class&nbsp;A common stock to the Former LLC Owners. In addition, upon the closing of this offering, the Phantom Plan will be terminated and
Phantom Plan Participants will hold rights to receive 513,117 shares of Class&nbsp;A common stock upon settlement of their awards on the twelve month anniversary of the termination of the Phantom Plan (as more fully described above under
&#147;Executive compensation&#151;Narrative to summary compensation table&#151;Equity-based compensation&#151;Phantom profits interest units&#148;). In connection with the offering, each profits interest unit awarded under the MIP will be exchanged
for LLC Interests which may then be exchanged for shares of Class A common stock (upon redemption or cancellation of the same number of their shares of our Class B common stock) or a cash payment (if mutually agreed). Of these shares, all shares
sold in this offering will be freely tradable without restriction or further registration under the Securities Act, except for any shares purchased by our &#147;affiliates,&#148; as that term is defined in Rule&nbsp;144 under the Securities Act,
whose sales would be subject to the Rule&nbsp;144 resale restrictions described below, other than the holding period requirement. The remaining outstanding shares of our common stock will be &#147;restricted securities&#148; as that term is defined
under Rule 144 of the Securities Act. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below and the provisions of
Rules&nbsp;144 and 701 under the Securities Act, these restricted securities (including shares of Class&nbsp;A common stock issuable upon redemption or exchange of&nbsp;LLC Interests) will be available for sale in the public market as follows:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">no shares will be available for sale until 180 days after the date of this prospectus, subject to certain limited exceptions provided for in the lock-up
agreements; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">14,904,090 shares, plus any shares purchased by our affiliates in this offering, will be eligible for sale beginning more than 180 days after the date of this
prospectus, subject, in the case of shares held by our affiliates, to the volume limitations under Rule 144. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B><FONT
STYLE="white-space:nowrap">Lock-up</FONT> agreements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with this offering, our officers and directors, and certain of our stockholders,
have each entered into a lock-up agreement with the underwriters of this offering that restricts the sale of shares of our common stock by those parties for a period of 180 days after the date of this prospectus without the prior written consent of
J.P. Morgan Securities LLC. However, J.P. Morgan Securities LLC, on behalf of the underwriters, may, in its sole discretion, choose to release any or all of the shares of our common stock subject to these lock-up agreements at any time prior to the
expiration of the lock-up period without notice. For more information, see &#147;Underwriting.&#148; Upon the expiration of the lock-up period, substantially all of the shares subject to such lock-up restrictions will become eligible for sale,
subject to the limitations discussed above. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">218 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Rule&nbsp;144 </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Affiliate resales of restricted securities </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In
general, beginning 90&nbsp;days after the effective date of the registration statement of which this prospectus is a part, a person who is an affiliate of ours, or who was an affiliate at any time during the 90&nbsp;days before a sale, who has
beneficially owned shares of our Class&nbsp;A common stock for at least 180&nbsp;days would be entitled to sell in &#147;broker&#146;s transactions&#148; or certain &#147;riskless principal transactions&#148; or to market makers, a number of shares
within any <FONT STYLE="white-space:nowrap">three-month</FONT> period that does not exceed the greater of: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">1% of the number of shares of our Class&nbsp;A common stock then outstanding, which will equal approximately 237,276 shares immediately after this offering; or
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the average weekly trading volume in our Class&nbsp;A common stock on The NASDAQ Global Market during the four calendar weeks preceding the filing of a notice on
Form&nbsp;144 with respect to such sale. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Affiliate resales under Rule&nbsp;144 are also subject to the availability of current public
information about us. In addition, if the number of shares being sold under Rule&nbsp;144 by an affiliate during any <FONT STYLE="white-space:nowrap">three-month</FONT> period exceeds 5,000 shares or has an aggregate sale price in excess of $50,000,
the seller must file&nbsp;a notice on Form&nbsp;144 with the SEC and The NASDAQ Global Market concurrently with either the placing of a sale order with the broker or the execution directly with a market maker. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-affiliate</FONT> resales of restricted securities </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In general, beginning 90&nbsp;days after the effective date of the registration statement of which this prospectus is a part, a person who is not an affiliate of ours at the time of sale, and has not been an
affiliate at any time during the 90&nbsp;days preceding a sale, and who has beneficially owned shares of our Class&nbsp;A common stock for at least six months but less than a year, is entitled to sell such shares subject only to the availability of
current public information about us. If such person has held our shares for at least one year, such person can resell under Rule&nbsp;144(b)(1) without regard to any Rule&nbsp;144 restrictions, including the
<FONT STYLE="white-space:nowrap">90-day</FONT> public company requirement and the current public information requirement. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the manner of sale, volume limitation or notice filing provisions of Rule&nbsp;144.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Rule&nbsp;701 </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In general, under Rule&nbsp;701,
any of an issuer&#146;s employees, directors, officers, consultants or advisors who purchases shares from the issuer in connection with a compensatory stock or option plan or other written agreement before the effective date of a registration
statement under the Securities Act is entitled to sell such shares 90&nbsp;days after such effective date in reliance on Rule&nbsp;144. An affiliate of the issuer can resell shares in reliance on Rule&nbsp;144 without having to comply with the
holding period requirement, and <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of the issuer can resell shares in reliance on Rule&nbsp;144 without having to comply with the current public information and holding period requirements.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The SEC has indicated that Rule&nbsp;701 will apply to typical stock options granted by an issuer before it becomes subject to the reporting
requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after an issuer becomes subject to the reporting requirements of the Exchange Act. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">219 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Equity plans </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We intend to file one or more registration statements on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities Act to register all shares of
Class&nbsp;A common stock (i)&nbsp;issuable under our stock plans and (ii)&nbsp;issuable to the Phantom Plan Participants under the Phantom Plan. We expect to file the registration statement covering shares offered pursuant to our stock plans
shortly after the date of this prospectus, permitting the resale of such shares by non-affiliates in the public market without restriction under the Securities Act and the sale by affiliates in the public market subject to compliance with the resale
provisions of Rule&nbsp;144. We expect that the initial registration statement on Form S-8 will cover 3,868,169 shares. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Registration rights
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Upon the closing of this offering, the holders of 24,475,854 shares of Class&nbsp;A common stock (including the holders of&nbsp;LLC Interests
redeemable or exchangeable for shares of Class&nbsp;A common stock) or their transferees will be entitled to various rights with respect to the registration of these shares under the Securities Act. Registration of these shares under the Securities
Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration. See &#147;Certain relationships and related party transactions&#151;Registration Rights
Agreement&#148; for additional information. Shares covered by a registration statement will be eligible for sale in the public market upon the expiration or release from the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">220 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_21"></A>Material U.S. federal income tax consequences to Non-U.S. Holders </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following discussion is a summary of the material U.S. federal income tax consequences to Non-U.S. Holders (as defined below) of the purchase, ownership and
disposition of our Class&nbsp;A common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any
applicable state, local or non-U.S. tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended, or the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and
administrative pronouncements of the IRS, in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner
that could adversely affect a Non-U.S. Holder of our Class&nbsp;A common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a
contrary position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our Class&nbsp;A common stock. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This discussion is limited to Non-U.S. Holders that hold our Class&nbsp;A common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the
Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a Non-U.S. Holder&#146;s particular circumstances, including the impact of the Medicare contribution tax on net
investment income. In addition, it does not address consequences relevant to Non-U.S. Holders subject to special rules, including, without limitation: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">U.S. expatriates and former citizens or long-term residents of the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">persons subject to the alternative minimum tax; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">persons holding our Class&nbsp;A common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other
integrated investment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">banks, insurance companies, and other financial institutions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">brokers, dealers or traders in securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that accumulate earnings to avoid U.S. federal
income tax; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein);
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">tax-exempt organizations or governmental organizations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">persons deemed to sell our Class&nbsp;A common stock under the constructive sale provisions of the Code; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">persons who hold or receive our Class&nbsp;A common stock pursuant to the exercise of any employee stock option or otherwise as compensation; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">tax-qualified retirement plans. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If an entity
treated as a partnership for U.S. federal income tax purposes holds our Class&nbsp;A common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain
determinations made at the partner level. Accordingly, partnerships holding our Class&nbsp;A common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S.
FEDERAL INCOME TAX </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">221 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>
LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR CLASS A COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS
OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Definition of a Non-U.S. Holder
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For purposes of this discussion, a &#147;Non-U.S. Holder&#148; is any beneficial owner of our Class&nbsp;A common stock that is neither a &#147;U.S.
person&#148; nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">an individual who is a citizen or resident of the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a trust that (1)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more &#147;United States persons&#148; (within the meaning
of Section&nbsp;7701(a)(30) of the Code), or (2)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Distributions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As described in the section entitled &#147;Dividend policy,&#148; we do not anticipate declaring
or paying dividends to holders of our Class&nbsp;A common stock in the foreseeable future. However, if we do make distributions of cash or property on our Class&nbsp;A common stock, such distributions will constitute dividends for U.S. federal
income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of
capital and first be applied against and reduce a Non-U.S. Holder&#146;s adjusted tax basis in its Class&nbsp;A common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under
&#147;&#151;Sale or other taxable disposition.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Subject to the discussion below on effectively connected income, dividends paid to a Non-U.S.
Holder of our Class&nbsp;A common stock will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the Non-U.S. Holder furnishes a
valid IRS Form W-8BEN or W-8BEN-E (or other applicable documentation) certifying qualification for the lower treaty rate). A Non-U.S. Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may
obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. Non-U.S. Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If dividends paid to a Non-U.S. Holder are effectively connected with the Non-U.S. Holder&#146;s conduct of a trade or business within the United States
(and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such dividends are attributable), the Non-U.S. Holder will be exempt from the U.S. federal withholding tax
described above. To claim the exemption, the Non-U.S. Holder must furnish to the applicable withholding agent a valid IRS Form W-8ECI, certifying that the dividends are effectively connected with the Non-U.S. Holder&#146;s conduct of a trade or
business within the United States. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the
regular graduated rates. A Non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">222 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. Non-U.S. Holders should consult their tax
advisors regarding any applicable tax treaties that may provide for different rules. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Sale or other taxable disposition </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Subject to the discussion below under &#145;&#145;Information reporting and backup withholding&#146;&#146; and &#145;&#145;Additional withholding tax on payments
made to foreign accounts,&#146;&#146; a Non-U.S. Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our Class&nbsp;A common stock unless: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the gain is effectively connected with the Non-U.S. Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable
income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such gain is attributable); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Non-U.S. Holder is a nonresident alien individual present in the United States for 183 days or more during the taxable year of the disposition and certain
other requirements are met; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our Class&nbsp;A common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a U.S. real property holding corporation, or
USRPHC, for U.S. federal income tax purposes. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Gain described in the first bullet point above generally will be subject to U.S. federal
income tax on a net income basis at the regular graduated rates. A Non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such
effectively connected gain, as adjusted for certain items. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Gain described in the second bullet point above will be subject to U.S. federal income tax at
a rate of 30% (or such lower rate specified by an applicable income tax treaty), which may be offset by U.S. source capital losses of the Non-U.S. Holder (even though the individual is not considered a resident of the United States), provided the
Non-U.S. Holder has timely filed U.S. federal income tax returns with respect to such losses. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">With respect to the third bullet point above, we believe
we currently are not, and do not anticipate becoming, a USRPHC. Because the determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our non-U.S. real property interests
and our other business assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a Non-U.S. Holder of
our Class&nbsp;A common stock will not be subject to U.S. federal income tax if our Class&nbsp;A common stock is &#147;regularly traded,&#148; as defined by applicable Treasury Regulations, on an established securities market, and such Non-U.S.
Holder owned, actually or constructively, 5% or less of our Class&nbsp;A common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the Non-U.S. Holder&#146;s holding period.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Non-U.S. Holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Information reporting and backup withholding </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Payments of dividends on our Class&nbsp;A common stock will not be subject to backup withholding, provided the applicable withholding agent does not have actual
knowledge or reason to know the holder is a United States person and the holder either certifies its non-U.S. status, such as by furnishing a valid IRS Form W-8BEN, W-8BEN-E or W-8ECI, or otherwise establishes an exemption. However, information
returns are required to be filed with the IRS in connection with any dividends on our Class&nbsp;A common stock paid to the Non-U.S. Holder, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">223 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
regardless of whether any tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our Class&nbsp;A common stock within the United States or conducted through
certain U.S.-related brokers generally will not be subject to backup withholding or information reporting, if the applicable withholding agent receives the certification described above and does not have actual knowledge or reason to know that such
holder is a United States person, or the holder otherwise establishes an exemption. Proceeds of a disposition of our Class&nbsp;A common stock conducted through a non-U.S. office of a non-U.S. broker generally will not be subject to backup
withholding or information reporting. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Copies of information returns that are filed with the IRS may also be made available under the provisions of an
applicable treaty or agreement to the tax authorities of the country in which the Non-U.S. Holder resides or is established. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Backup withholding is not
an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a Non-U.S. Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Additional withholding tax on payments made to foreign accounts </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax Compliance Act, or FATCA) on certain types of payments made to non-U.S.
financial institutions and certain other non-U.S. entities. Specifically, a 30% withholding tax may be imposed on dividends on, or gross proceeds from the sale or other disposition of, our Class&nbsp;A common stock, in each case, paid to a
&#147;foreign financial institution&#148; or a &#147;non-financial foreign entity&#148; (each as defined in the Code), unless (1)&nbsp;the foreign financial institution undertakes certain diligence and reporting obligations (including providing
sufficient documentation evidencing its compliance (or deemed compliance) with FATCA), (2)&nbsp;the non-financial foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes
identifying information regarding each substantial United States owner, or (3)&nbsp;the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial
institution and is subject to the diligence and reporting requirements in (1)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain
&#147;specified United States persons&#148; or &#147;United States-owned foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to non-compliant foreign
financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends on our Class&nbsp;A common
stock, and will apply to payments of gross proceeds from the sale or other disposition of such stock on or after January&nbsp;1, 2019. If a dividend payment is both subject to withholding under FATCA and subject to the withholding tax discussed
above under &#145;&#145;Distributions,&#146;&#146; the withholding under FATCA may be credited against and therefore reduce such other withholding tax. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our Class&nbsp;A
common stock. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">224 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_22"></A>Underwriting </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are offering the shares of Class&nbsp;A common stock described in this prospectus through a number of underwriters. J.P. Morgan Securities LLC and Piper Jaffray&nbsp;&amp; Co. are acting as joint <FONT
STYLE="white-space:nowrap">book-running</FONT> managers of the offering and J.P. Morgan Securities LLC is acting as representative of the underwriters. We have entered into an underwriting agreement with the underwriters. Subject to the terms and
conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover page of
this prospectus, the number of shares of Class&nbsp;A common stock listed next to its name in the following table: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number&nbsp;of<BR>shares</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">J.P. Morgan Securities LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Piper Jaffray&nbsp;&amp; Co.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Leerink Partners LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,823,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters are committed to purchase all the shares of Class&nbsp;A common stock offered by us if they purchase any shares.
The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of non-defaulting underwriters may also be increased or the offering may be terminated. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The underwriters propose to offer the shares of Class&nbsp;A common stock directly to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers at that
price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. Any such dealers may resell shares to certain other brokers or dealers at a discount of up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share from the initial public offering price. After the initial public offering of the shares, the offering price and other selling terms may be changed by the underwriters. Sales of shares
made outside of the United States may be made by affiliates of the underwriters. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters have an over-allotment option to buy up to 1,323,529
additional shares of Class&nbsp;A common stock from us to cover sales of shares by the underwriters which exceed the number of shares specified in the table above. The underwriters have 30&nbsp;days from the date of this prospectus to exercise this <FONT
STYLE="white-space:nowrap">over-allotment</FONT> option. If any shares are purchased with this over-allotment option, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of
Class&nbsp;A common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being offered. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The underwriting fee is equal to the public offering price per share of Class&nbsp;A common stock less the amount paid by the underwriters to us per share of Class&nbsp;A common stock. The underwriting fee is
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the underwriters&#146; over-allotment
option to purchase additional shares. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Without<BR><FONT STYLE="white-space:nowrap">over-allotment</FONT><BR>exercise</B></FONT></TD>

<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>With
full<BR><FONT STYLE="white-space:nowrap">over-allotment</FONT><BR>exercise</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal and
accounting expenses, but excluding the underwriting discounts and commissions, will be </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">225 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
approximately $3,900,000. We have also agreed to reimburse the underwriters for certain of their expenses in an amount up to $25,000&nbsp;as set forth in the underwriting agreement. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in
the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters and
selling group members that may make Internet distributions on the same basis as other allocations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have agreed that for a period of 180 days after
the date of this prospectus we will not (i)&nbsp;offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase
or otherwise transfer or dispose of, directly or indirectly, or file with the SEC a registration statement under the Securities Act relating to, any shares of our Class&nbsp;A common stock or securities convertible into or exchangeable or
exercisable for any shares of our Class&nbsp;A common stock or any securities convertible into or exercisable or exchangeable for our Class&nbsp;A common stock, or publicly disclose the intention to make any offer, sale, pledge, disposition or
filing, or (ii)&nbsp;enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any shares of Class&nbsp;A common stock or any such other securities (regardless of whether
any of these transactions are to be settled by the delivery of shares of Class&nbsp;A common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our directors and executive officers, and certain of our significant shareholders have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with
the underwriters prior to the commencement of this offering pursuant to which each of these persons or entities, with limited exceptions, for a period of 180&nbsp;days after the date of this prospectus, may not, without the prior written consent of
J.P. Morgan Securities LLC, (1)&nbsp;offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or
otherwise transfer or dispose of, directly or indirectly, any shares of our Class&nbsp;A common stock or any securities convertible into or exercisable or exchangeable for our Class&nbsp;A common stock (including, without limitation, Class&nbsp;A
common stock or such other securities which may be deemed to be beneficially owned by such directors, executive officers, managers and members in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise
of a stock option or warrant) or (2)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Class&nbsp;A common stock or such other securities, whether any such
transaction described in clause&nbsp;(1) or&nbsp;(2) above is to be settled by delivery of Class&nbsp;A common stock or such other securities, in cash or otherwise, or (3)&nbsp;make any demand for or exercise any right with respect to the
registration of any shares of our Class&nbsp;A common stock or any security convertible into or exercisable or exchangeable for our Class&nbsp;A common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or contribute payments that the underwriters may be required to make in that respect.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We will apply to have our Class&nbsp;A common stock approved for listing on The NASDAQ Global Market under the symbol &#147;BIOV&#148;. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares of
Class&nbsp;A common stock in the open market for the purpose of preventing or retarding a decline in the market price of the Class&nbsp;A common stock while this offering is in progress. These stabilizing transactions may include making short sales
of the Class&nbsp;A common stock, which involves the sale by the underwriters of a greater number of shares of Class&nbsp;A common stock than they are required to purchase in this offering, and purchasing shares of Class&nbsp;A common stock on the
open market to cover positions created by short sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">226 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
amount not greater than the underwriters&#146; <FONT STYLE="white-space:nowrap">over-allotment</FONT> option referred to above, or may be &#147;naked&#148; shorts, which are short positions in
excess of that amount. The underwriters may close out any covered short position either by exercising their <FONT STYLE="white-space:nowrap">over-allotment</FONT> option, in whole or in part, or by purchasing shares in the open market. In making
this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the
<FONT STYLE="white-space:nowrap">over-allotment</FONT> option. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the Class&nbsp;A common stock in the open market
that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters have advised us that, pursuant to Regulation&nbsp;M of the Securities Act, they may also engage in other activities that stabilize, maintain or
otherwise affect the price of the Class&nbsp;A common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase Class&nbsp;A common stock in the open market in stabilizing transactions or to
cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discounts and commissions received by them. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">These activities may have the effect of raising or maintaining the market price of the Class&nbsp;A common stock or preventing or retarding a decline in the market price of the Class&nbsp;A common stock, and, as a
result, the price of the Class&nbsp;A common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The underwriters may carry out these
transactions on the NASDAQ, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Prior to this offering, there has been no public market for our Class&nbsp;A common stock. The initial public offering price will be determined by negotiations
between us and the representatives of the underwriters. In determining the initial public offering price, we and the representatives of the underwriters expect to consider a number of factors including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the information set forth in this prospectus and otherwise available to the representatives; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our prospects and the history and prospects for the industry in which we compete; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">an assessment of our management; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our prospects for future earnings; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the general condition of the securities markets at the time of this offering; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">other factors deemed relevant by the underwriters and us. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Neither we nor the underwriters can assure investors that an active trading market will develop for our common shares, or that the shares will trade in the public market at or above the initial public offering
price. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered
by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements
in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into
whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">227 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any
jurisdiction in which such an offer or a solicitation is unlawful. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Selling restrictions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>United Kingdom </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This document is only being distributed to and is only directed at (i)&nbsp;persons who
are outside the United Kingdom or (ii)&nbsp;to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the &#147;Order&#148;) or (iii)&nbsp;high net worth entities, and
other persons to whom it may lawfully be communicated, falling with Article 49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;). The securities are only available to, and any invitation,
offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>European economic area </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In relation to each Member
State of the European Economic Area which has implemented the Prospectus Directive (each, a &#145;&#145;Relevant Member State&#146;&#146;), from and including the date on which the EU Prospectus Directive (the &#145;&#145;EU Prospectus
Directive&#146;&#146;) was implemented in that Relevant Member State (the &#145;&#145;Relevant Implementation Date&#146;&#146;) an offer of securities described in this prospectus may not be made to the public in that Relevant Member State prior to
the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant Member State or, where appropriate, approved in another Relevant Member State and notified to the competent authority in
that Relevant Member State, all in accordance with the EU Prospectus Directive, except that, with effect from and including the Relevant Implementation Date, an offer of securities described in this prospectus may be made to the public in that
Relevant Member State at any time: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">to any legal entity which is a qualified investor as defined under the EU Prospectus Directive; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150 natural or legal persons (other
than qualified investors as defined in the EU Prospectus Directive); or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">in any other circumstances falling within Article 3(2) of the EU Prospectus Directive, provided that no such offer of securities described in this prospectus
shall result in a requirement for the publication by us of a prospectus pursuant to Article 3 of the EU Prospectus Directive. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For the
purposes of this provision, the expression an &#145;&#145;offer of securities to the public&#146;&#146; in relation to any securities in any Relevant Member State means the communication in any form and by any means of sufficient information on the
terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe for the securities, as the same may be varied in that Member State by any measure implementing the EU Prospectus Directive in that
Member State. The expression &#147;EU Prospectus Directive&#148; means Directive 2003/71/EC (and any amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State) and includes any relevant
implementing measure in each Relevant Member State, and the expression &#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">228 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Other relationships </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain commercial banking, financial advisory, investment banking
and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. In addition, from time to time, certain of the underwriters and their
affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">An affiliate of J.P. Morgan Securities LLC served as an arranger and lender under our senior secured credit facility. Such affiliate of the representative of the
underwriters receives customary fees and expenses in connection with its provision of these services. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">229 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_23"></A>Legal matters </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The validity of the issuance of our Class&nbsp;A common stock offered in this prospectus will be passed upon for us by Latham&nbsp;&amp; Watkins LLP, New York, New York. The validity of the issuance of our
Class&nbsp;A common stock offered in this prospectus will be passed upon for the underwriters in connection with this offering by Simpson Thacher&nbsp;&amp; Bartlett LLP, New York, New York. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_24"></A>Experts </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Bioventus LLC financial statements as of December 31, 2015 and 2014 and
for each of the three years in the period ended December 31, 2015 included in this prospectus have been so included in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of
said firm as experts in auditing and accounting. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The BioStructures, LLC financial statements as of December 31, 2014 and for the period ended December
31, 2014 included in this prospectus have been so included in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_25"></A>Where you can find more information </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of Class&nbsp;A common stock offered hereby. This prospectus, which constitutes a part of the
registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith, certain portions of which are omitted as permitted by the rules and regulations of the SEC. For
further information with respect to Bioventus Inc. and the shares of Class&nbsp;A common stock offered hereby, reference is made to the registration statement and the exhibits and schedules filed therewith. Statements contained in this prospectus
regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract
or other document filed as an exhibit to the registration statement. A copy of the registration statement and the exhibits and schedules filed therewith may be inspected without charge at the public reference room maintained by the SEC, located at
100 F Street N.E., Room 1580, Washington, D.C. 20549, and copies of all or any part of the registration statement may be obtained from such offices upon the payment of the fees prescribed by the SEC. Please call the SEC at 1-800- SEC-0330 for
further information about the public reference room. The SEC also maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address is
www.sec.gov. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a result of this offering, we will become subject to the information and reporting requirements of the Exchange Act and, in accordance
with this law, will file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and other information will be available for inspection and copying at the SEC&#146;s public reference room and
the website of the SEC referred to above. We also maintain a website at www.bioventusglobal.com. The reference to our website address does not constitute incorporation by reference of the information contained on our website, and you should not
consider the contents of our website in making an investment decision with respect to our common stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">You may also request a copy of these filings, at
no cost to you, by writing or telephoning us at the following address: </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Bioventus Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">4721 Emperor Boulevard, Suite 100 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Durham, NC 27703 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Attention: Chief
Financial Officer </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">(919)&nbsp;474-6700 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">230 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom22578_26"></A>Index to financial statements </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Bioventus LLC </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Years ended December&nbsp;31, 2013, 2014
and 2015 </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_4">Report of independent registered public accounting firm</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_5">Consolidated statements of operations and comprehensive loss</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_6">Consolidated balance sheets</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_7">Consolidated statements of changes in members&#146; equity</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_8">Consolidated statements of cash flows</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_9">Notes to consolidated financial statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Three months ended March 28, 2015 and April 2, 2016 (unaudited) </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_21">Consolidated statements of operations and comprehensive loss</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_22">Consolidated balance sheets</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_23">Consolidated statements of changes in members&#146; equity</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_24">Consolidated statements of cash flows</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_25">Notes to consolidated financial statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>BioStructures LLC </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Year
ended December 31, 2014 </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_10">Independent auditor&#146;s report</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_11">Statement of financial position</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_12">Statement of income and comprehensive income</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_13">Statement of changes in members&#146; equity</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_14">Statement of cash flows</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_15">Notes to financial statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Nine month periods ended September 30, 2014 and 2015 (unaudited) </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_16">Statements of financial position</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_17">Statements of income and comprehensive income</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_18">Statement of changes in members&#146; equity</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_19">Statements of cash flows</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin22578_20">Notes to financial statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="3"><B><A NAME="fin22578_4"></A>Report of independent registered public accounting firm </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">To</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Board of Managers and Members of </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Bioventus LLC: </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In our opinion, the accompanying consolidated
balance sheets and the related consolidated statements of operations and comprehensive loss, of changes in members&#146; equity and of cash flows present fairly, in all material respects, the financial position of Bioventus LLC and its subsidiaries
at December&nbsp;31, 2015 and 2014, and the results of their operations and their cash flows for each of the three years in the period ended December&nbsp;31 2015, in conformity with accounting principles generally accepted in the United States of
America. These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance
with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement.
An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis for our opinion. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">/s/ PricewaterhouseCoopers LLP </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Raleigh, North Carolina </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">April&nbsp;19, 2016, except for the effects
of the revision discussed under the caption &#145;May 2016 Revision&#146; in Note&nbsp;19 to the consolidated financial statements, as to which the date is May&nbsp;26, 2016, and except for the effects of the revision discussed under the caption
&#145;July 2016 Revision&#146; in Note&nbsp;19 to the consolidated financial statements, as to which the date is July&nbsp;19, 2016. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin22578_5"></A>Bioventus LLC </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Consolidated statements of operations and comprehensive loss </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Years ended December&nbsp;31, 2013, 2014 and
2015 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Dollars in thousands, except per unit and per share data) </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">232,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">242,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">253,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cost of sales (including depreciation and amortization of $16,693, $19,622 and $22,474, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">71,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">75,792</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">74,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Gross profit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">161,003</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">167,101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">179,106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Selling, general and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">150,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">147,058</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">148,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,936</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,465</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,747</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in fair value of contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Restructuring costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,765</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,968</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,068</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(16,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,969</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other (income) expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(596</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,154</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other expense, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12,172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15,383</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(20,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,353</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(31,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(22,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(34,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other comprehensive (loss) income, net of tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in prior service cost and unrecognized loss for defined benefit plan adjustment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in foreign currency translation adjustments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(712</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other comprehensive (loss) income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">88</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(664</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(22,418</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12,812</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(34,775</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(22,367</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12,900</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(34,111</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated and unpaid preferred distributions (as revised)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,610</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,718</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,997</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss attributable to common unit holders (as revised)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(25,977</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(16,618</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(38,108</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per unit, basic and diluted (Note 14)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5.30</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3.39</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(7.78</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted average common units outstanding, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,900</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,900</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,900</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Unaudited pro forma net loss per share (Note 18):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.45</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted average common shares, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,904,090</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:48px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin22578_6"></A>Bioventus LLC </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Consolidated balance sheets </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>December&nbsp;31, 2014 and 2015 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Dollars in thousands) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Current assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">15,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">343</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accounts receivable, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">47,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">54,511</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Inventory, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">26,674</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">35,178</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Prepaid and other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">5,708</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">95,231</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">99,427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">10,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">9,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Goodwill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">49,953</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">58,694</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Intangible assets, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">274,332</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">319,152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">298</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Deferred tax asset</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">179</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">84</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">430,421</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">487,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Liabilities and Members&#146; Equity</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Current liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">5,383</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">8,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accrued liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">25,969</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">34,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Note payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">23,546</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">7,266</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">7,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">License agreement obligation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">5,662</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">7,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">12,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Capital lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">688</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">52,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">87,690</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Long-term debt, less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">162,297</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">149,607</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Long-term revolver</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">8,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Contingent consideration, less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">24,949</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">32,635</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Capital lease obligations, less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">803</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,222</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Other long-term liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,399</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">7,080</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Deferred tax liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">9,328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">8,780</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">252,932</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">295,014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Commitments and contingencies (Note 13)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Members&#146; equity (preferred unit liquidation preference of $127,649 and $181,645 at December 31, 2014 and 2015,
respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">233,970</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">284,828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accumulated other comprehensive income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(56,495</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(91,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Total members&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">177,489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">192,338</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Total liabilities and members&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">430,421</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">487,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin22578_7"></A>Bioventus LLC </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Consolidated statements of changes in members&#146; equity </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Years ended December&nbsp;31, 2013, 2014 and
2015 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Dollars in thousands) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Members&#146;<BR>equity</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Accumulated&nbsp;Other<BR>comprehensive <BR>loss</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Accumulated</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>deficit</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total <BR>members&#146; <BR>equity</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at December&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">232,523</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(16,328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">216,172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Profits interest compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">576</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">576</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Distribution to members</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(22,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(22,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Translation adjustment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at December&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">233,099</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(41,196</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">191,829</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Profits interest compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">871</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">871</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Distribution to members</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,399</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,399</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Defined benefit plan adjustment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Translation adjustment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">233,970</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(56,495</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">177,489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Capital contribution</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Profits interest compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">858</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">858</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Distribution to members</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(34,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(34,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Defined benefit plan adjustment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Translation adjustment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(712</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(712</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">284,828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(91,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">192,338</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:160px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin22578_8"></A>Bioventus LLC </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Consolidated statements of cash flows<BR> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Years ended December&nbsp;31, 2013, 2014 and 2015 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Dollars in thousands) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Operating activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(22,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(12,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(34,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Adjustments to reconcile net loss to net cash provided by operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">24,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">28,820</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">33,078</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Change in fair value of contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">19,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Provision for doubtful accounts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">5,485</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">5,880</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,707</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">In-kind interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">11,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Profits interest compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">576</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">871</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">858</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Management incentive plan and liability-classified awards compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,467</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Change in fair value of Equity Participation Rights unit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Deferred income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(475</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(701</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(432</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Unrealized foreign currency transaction (gains) losses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(575</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Amortization of debt (premium) discount and capitalized loan fees, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(562</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">871</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Changes in operating assets and liabilities, net of acquisitions:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(11,094</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(217</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(11,266</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Inventories</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(3,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">10,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(5,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accounts payable and accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(2,928</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,043</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">5,182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Other current assets and liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,335</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(3,152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Payment of in-kind interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(22,329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net cash provided by operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">15,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">18,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Investing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Acquisition of business, net of cash acquired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(10,546</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(51,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Acquisition of intellectual property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(19,668</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(5,324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Acquisition of distributor assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(4,643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Purchase of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(6,356</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,162</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(2,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Settlement of foreign currency forward contract</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(941</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(343</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(10,999</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(31,376</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(60,185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Payment on note payable to related party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(160,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Proceeds from the issuance of long-term debt, net of issuance costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">170,505</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Payments on long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(7,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Long-term debt modification costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Payment of contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(16,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Borrowing on the revolving line of credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">12,839</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,068</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">23,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Payments on the revolving line of credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(2,071</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(14,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(15,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Principal payments toward capital lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,277</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,487</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Capital contribution</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Distribution to members</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(2,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(2,399</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net cash provided by (used in) financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">6,801</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(6,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">31,246</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Effect of exchange rate changes on cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(805</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Net change in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(1,963</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(24,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(10,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Cash and cash equivalents at the beginning of the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">42,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">40,114</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">15,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Cash and cash equivalents at the end of the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">40,114</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">15,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">4,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Supplemental disclosure of cash flow information</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Cash paid for income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,614</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Cash paid for interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">31,901</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">15,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Supplemental disclosure of noncash investing and financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Notes payable, contingent consideration and other accrued liabilities for business acquisitions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">32,343</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">33,028</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Liabilities assumed for intellectual property acquisition</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">25,738</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Capital lease obligations for purchase of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,612</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">622</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,418</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accrued member distributions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">218</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B><A NAME="fin22578_9"></A>1. Organization and basis of presentation of financial information (dollars in thousands)
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>The Company </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Bioventus LLC, or Bioventus or
the Company, is a limited liability company formed under the laws of the state of Delaware on November&nbsp;23, 2011 and operates as a partnership. Bioventus is a global medical technology company, conducting business in various countries, primarily
in North America and Europe, with nearly 650&nbsp;employees. The Company is focused on developing and commercializing innovative and proprietary orthobiologic products for the treatment of patients suffering from a broad array of musculoskeletal
conditions. The Company seeks to address the growing need for clinically effective, cost efficient and minimally invasive solutions that enhance the body&#146;s natural healing processes. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">On November&nbsp;23, 2011, Smith&nbsp;&amp; Nephew plc, or S&amp;N, filed a certificate of formation for the Company. On January&nbsp;3, 2012, a series of agreements were executed with investment vehicles sponsored
and managed by Essex Woodlands (Essex), a healthcare growth equity firm, in order to effect a spin-off of S&amp;N&#146;s biologic and clinical therapies segment (the Business) into Bioventus. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">On May&nbsp;4, 2012, S&amp;N sold certain assets related to the Business&#146; worldwide operations to Essex and the assets were subsequently contributed by Essex to Bioventus in addition to $20,000 cash in
exchange for 5,100 preferred units, representing a 51% ownership interest. S&amp;N then contributed certain other assets, primarily related to the Business&#146; remaining worldwide operations, to Bioventus for 4,900 common units, representing a 49%
ownership interest. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On May&nbsp;4, 2012, the Company commenced operations in Durham, North Carolina, USA, which is its headquarters. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Principles of consolidation </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The consolidated financial
statements have been prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP) and regulations of the United States Securities Exchange Commission (SEC). All significant intercompany accounts and
transactions have been eliminated in consolidation. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Unaudited pro forma net loss per common unit </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Unaudited pro forma basic and diluted net loss per unit reflects the conversion of all outstanding units of members&#146; capital as if the conversion had occurred
at the beginning of the period or the date of issuance, if later. The unaudited pro forma basic and diluted net loss per unit amounts do not give effect to the issuance of shares from the planned initial public offering, nor do they give effect to
potential dilutive securities where the impact would be anti-dilutive. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Segment reporting </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company identifies a business as an operating segment if: i) it engages in business activities from which it may earn revenues and incur expenses; ii) its
operating results are regularly reviewed by the Chief Operating Decision Maker, or CODM, to make decisions about resources to be allocated to the segment and assess its performance; and iii) it has available discrete financial information. The
Company&#146;s CODM is its Chief Executive Officer. The CODM reviews financial information at the operating segment level to allocate resources and to assess the operating results and financial performance for each operating segment. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company&#146;s four reportable segments include: Active Healing Therapies (AHT) U.S. business (U.S. AHT), AHT
International business (International AHT), Surgical business and bone morphogenetic protein research and development (BMP) business (discussed further in Note&nbsp;16). AHT products are primarily sold to orthopedists, musculoskeletal and sports
medicine physicians, and podiatrists, as well as to their patients. Surgical products are primarily sold to neurosurgeons and orthopedic spine surgeons. BMP is a research and development operation for future surgical bone growth products.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Use of estimates </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The preparation of the
consolidated financial statements in conformity with US&nbsp;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses during the period, as well as disclosures of
contingent assets and liabilities at the date of the financial statements. Actual results may differ from these estimates under different assumptions or conditions. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>2. Summary of significant accounting policies </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Effect of foreign currency </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The assets and liabilities of foreign subsidiaries are translated at rates of exchange in effect at the close of their month end. Equity accounts are translated at
their historical rates. Revenues and expenses are translated at the exchange rate on the transaction date. Translation gains and losses are accumulated within accumulated other comprehensive loss as a separate component of members&#146; equity.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Foreign currency transaction gains and losses are included in other expense (income) on the consolidated statements of operations and comprehensive loss
and were $713, $(777) and $213 for the years ended December&nbsp;31, 2013, 2014 and 2015, respectively. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Other comprehensive loss </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Comprehensive loss consists of two components: net loss and other comprehensive loss. Other comprehensive loss refers to gains and losses that under U.S.&nbsp;GAAP
are recorded as an element of members&#146; equity and are excluded from net loss. The Company&#146;s other comprehensive loss consists of a defined benefit plan adjustment and foreign currency translation adjustments from those subsidiaries not
using the U.S. dollar as their functional currency. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Cash, cash equivalents and restricted cash </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents consist of highly liquid investments with an original maturity of three months or less at date of purchase. At December&nbsp;31, 2014 and
2015 the Company did not have any cash equivalents. The Company&#146;s cash and cash equivalents consist principally of cash which is primarily held in financial institutions in the US and the Netherlands. The Company maintains cash balances in the
United States in excess of the federally insured limits. The Company&#146;s restricted cash primarily consisted of amounts collateralizing standby letters of credit issued in favor of lease and other commitments. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Derivatives </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company uses derivative instruments to
manage exposures to interest rates and foreign currencies. Derivatives are recorded on the balance sheet at fair value at each balance sheet date. The Company has elected the fair value method of accounting and does not designate whether the
derivative instrument is an </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
effective hedge of an asset, liability or firm commitment. Changes in the fair values of derivative instruments are recognized in the consolidated statements of operations and comprehensive loss.
The Company has entered, and may in the future enter, into derivative contracts related to its debt and forecasted foreign currency transactions. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Fair value </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company records certain assets and
liabilities at fair value (discussed further in Note 8). Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly
transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs
and minimize the use of unobservable inputs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The three levels of inputs used to measure fair value are as follows: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Level&nbsp;1&#151;Quoted prices in active markets for identical assets or liabilities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Level&nbsp;2&#151;Observable inputs other than quoted prices included within Level 1, such as quoted prices for similar assets and liabilities in active markets;
quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Level&nbsp;3&#151;Unobservable inputs that are supported by little or no market data. This includes certain pricing models, discounted cash flow methodologies
and similar techniques that use significant unobservable inputs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Revenue recognition </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Sale of products </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Product sales directly to the
customer are primarily generated through the sale of external bone growth stimulators, osteoarthritis pain treatment products and surgical bone growth products. The Company presents revenue on a net basis, excluding taxes collected from customers
and remitted to governmental authorities, as well as discounts, rebates, certain distribution fees and contractual allowances when recording revenue. The Company sells product directly to healthcare institutions, patients, distributors and dealers.
Direct sales account for the majority of net sales. Revenue is recognized when title and risk of loss of the product passes to the purchaser, once all of the following conditions are satisfied: (1)&nbsp;there is persuasive evidence of an
arrangement; (2)&nbsp;the collection of the fees is reasonably assured and (3)&nbsp;the arrangement consideration is fixed or determinable. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company
recorded revenue from contractual payors at the contractual rate, net of contractual allowances, at the time of sale. For non-contracted payors, the Company records revenue at the estimated recoverable amount based on historical results and other
available information. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For certain products, we offer chargebacks to distributors who supply their customers with our products. We have preexisting
contracts with established rates with many of the wholesalers&#146; customers who require the wholesalers to sell our product at their established rate. Accordingly we record an adjustment to revenue at the time of sale to estimate the future
chargebacks, based on volume of purchases, inventory holdings and historical data of rebates requested for each wholesaler. All liabilities associated with chargebacks are reviewed regularly taking into consideration known market events and trends,
as well as internal and external historical data for the industry and customer. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Revenue recognition for external bone growth stimulators </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Revenue from third-party payors, such as insurance companies or managed care providers is recognized when the patient has accepted the product. Such revenue is
recorded at the contracted rate at the time of sale, or an estimated price based on historical results and other available information for non-contracted payors. Revenue from a patient is negotiated with each individual and recognized when the
patient has accepted the product. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Revenue recognition for osteoarthritis pain treatment products </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Revenue from customers such as a healthcare provider, distribution center or specialty pharmacy is recognized when an order is received and the product is delivered
to the customer location. Revenue is recognized at the contracted price. The Company offers retrospective discounts that are linked to the volume of purchases and may increase at negotiated thresholds within a contract buying period. The Company
records an estimated discount and returns allowance based on historical, forecasted or negotiated results, the type of customer and the specifics of each arrangement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Revenue recognition for surgical bone growth products </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Revenue from customers such as a healthcare
provider is recognized when a surgery is performed and the consigned inventory has been consumed. Revenue is recognized at the contracted price. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>S&amp;N distribution arrangement </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During 2013 and
2014, the Company participated in a distribution arrangement with S&amp;N, whereby S&amp;N marketed and sold products outside the US on the Company&#146;s behalf. The Company recognized revenue under this distribution arrangement upon sale to
third-party customers. Sales totaled $3,176 and $556 for the years ended December&nbsp;31, 2013 and 2014, respectively. During the period from May&nbsp;4, 2012 through September 2013, the Company entered into many of these markets directly and sales
under this agreement ended December&nbsp;31, 2014. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Shipping and handling </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Company classifies amounts billed for shipping and handling as a component of net sales. The related shipping and handling fees and costs as well as other distribution costs are included in cost of sales.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Accounts receivable and allowances </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Accounts
receivables are amounts due from customers and payors that are recorded at net realizable value for product sold in the ordinary course of business. The Company maintains a contractual allowance and an allowance for doubtful accounts. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The contractual allowance is offset against revenue for each sale to a contracted and non-contracted payor so that revenue and the resulting accounts receivable are
recorded at the expected reimbursement amount at the time of the sale. When evaluating the adequacy of the contractual allowance, the Company analyzes contractual pricing with third party payors as well as historical results with contractual and
non-contractual payors. The difference between actual contract adjustments and the estimates recorded have not been material. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The allowance for doubtful
accounts is based on the assessment of the collectability of specific customer accounts and the aging of the accounts receivable. When evaluating the adequacy of this allowance, the Company analyzes accounts receivable, historical bad debts,
customer concentrations, customer solvency, current economic and geographic trends, and changes in customer payment terms and practices. Credit is </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-10 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
granted to costumers in the normal course of business, generally without collateral. Charges to the allowance for doubtful accounts are recorded in selling, general and administrative expense
(SG&amp;A) in the consolidated statements of operations and comprehensive loss. The Company&#146;s reserve levels have generally been sufficient to cover credit losses. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Inventory </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company values its inventory at the lower of cost or market and adjusts for the value of
inventory that is estimated to be excess, obsolete or otherwise unmarketable. Cost is determined using the first-in, first-out (FIFO) method. The Company records allowances for excess and obsolete inventory based on historical and estimated future
demand and market conditions. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Business combinations </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Accounting for acquisitions requires the Company to recognize separately from goodwill the assets acquired and the liabilities assumed at their acquisition date fair values. Goodwill as of the acquisition date is
measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. While best estimates and assumptions are used to accurately value assets acquired and
liabilities assumed at the acquisition date, as well as contingent consideration where applicable, estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date,
the Company may record adjustments to the assets acquired and liabilities assumed with a corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed,
whichever comes first, any subsequent adjustments are recorded to our consolidated statements of operations and comprehensive loss. Subsequent changes in the estimated fair value of contingent consideration are recognized in earnings in the period
of change. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Long-lived assets </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Property and
equipment are stated at cost and are depreciated using the straight-line method over the shorter of the asset&#146;s estimated useful life, or the lease term if related to leased property, as follows (in years): </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Computer software and hardware</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3-5</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.5-7.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Machinery and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5-7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Furniture and fixtures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4-7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Finite-lived identifiable intangible assets are amortized using the straight-line method over their estimated remaining useful lives
as follows (in years):</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Weighted</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Average</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Useful&nbsp;Life</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intellectual property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Distribution rights</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Customer relationships</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Developed technology</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Non-compete agreements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company evaluates goodwill for impairment annually or more frequently if events or changes in circumstances
indicate that goodwill might be impaired. The Company reviews goodwill for impairment by applying a quantitative impairment analysis using the two step method. Under the first step, the fair value of the reporting unit is compared with its carrying
value (including goodwill). If the fair value of the reporting unit exceeds its carrying value, goodwill is not considered impaired and no additional analysis is performed. If the fair value of the reporting unit is less than its carrying value, the
Company will recognize the amount of the impairment loss for any excess carrying amount of the reporting unit&#146;s goodwill over the implied fair value of that goodwill. The implied fair value of goodwill is determined by allocating the fair value
of the reporting unit in a manner similar to a purchase price allocation, and the residual fair value after this allocation is the implied fair value of the reporting unit goodwill. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">In the fourth quarter of 2014, as a result of the OsteoAmp acquisition, the Company changed from a geographic operating segment and reporting
unit basis to a product basis resulting in three operating segments, U.S. AHT, International AHT&nbsp;&amp; Surgical. Goodwill impairment was reassessed resulting in no impairment. The Company also performed its annual impairment&nbsp;test on
October&nbsp;31</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">. On December&nbsp;31, 2015 the Company began presenting
information in four operating segments to the CODM and an updated impairment test was performed. A portion of U.S. AHT goodwill was reassigned to the fourth reporting unit, BMP, based on relative fair value. There were no impairment charges for the
years ended December&nbsp;31, 2013, 2014 and 2015. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company capitalizes costs incurred from third-party vendors for software design, configuration,
coding and testing and amortizes these costs on a straight-line basis over the estimated useful life of the product, not to exceed three years. The Company does not capitalize costs that are precluded from capitalization in authoritative guidance,
such as preliminary project phase costs, planning, oversight, process re-engineering costs, training costs or data conversion costs. Capitalized software costs totaled $9,715 and $10,981 at December&nbsp;31, 2014 and 2015, respectively. The related
accumulated amortization totaled $3,868 and $7,068 as of December&nbsp;31, 2014 and 2015, respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The carrying values of property, equipment,
intangible as well as other long-lived and indefinite lived assets are reviewed for recoverability if the facts and circumstances suggest that a potential impairment may have occurred. If this review indicates that carrying values may not be
recoverable, as determined based on undiscounted cash flow projections, the Company will perform an assessment to determine if an impairment charge is required to reduce carrying values to estimated fair value. There were no events, facts or
circumstances for the years ended December&nbsp;31, 2013, 2014 and 2015 that resulted in any impairment charges to the Company&#146;s property, equipment, intangible or other long-lived assets. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Acquired in-process research and development </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The fair value
of acquired in-process research and development, or IPR&amp;D, projects acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets. Once the development is completed and the product is available for
sale, the asset is transferred to developed technology and amortized over its remaining estimated useful life. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The initial costs of rights to IPR&amp;D
projects obtained in an asset acquisition are expensed unless the project has an alternative future use. During June 2013, the Company entered into a license agreement for $7,000 granting the Company a research license for certain compounds as well
as related rights and options. If the Company reaches certain development milestones or exercises certain other options, the Company will be subject to cash payments upon the achievement of certain development milestones and royalties ranging from
mid-single digit to low double digit percentages of net sales. The transaction was accounted for as an asset acquisition and the 2013 payment is included in research and development expense (R&amp;D) on the consolidated statement of operations and
comprehensive loss. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-12 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Concentration of risk </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Company provides credit, in the normal course of business, to its customers. The Company does not require collateral or other securities to support customer receivables. Credit losses are provided for through
allowances and have historically been materially within management&#146;s estimates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain suppliers provide the Company with product that results in
a significant percentage of total sales for the years ended December&nbsp;31 as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Supplier A</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">37%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">33%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Supplier B</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Supplier C</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Two of the Company&#146;s products make up 89%, 87% and 83% of sales for the years ended December&nbsp;31, 2013, 2014 and 2015.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Restructuring costs </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company has
restructured portions of its operations and future restructuring activities are possible. Identifying and calculating the cost to exit these operations requires certain assumptions to be made, the most significant of which are anticipated future
liabilities. Although estimates have been reasonably accurate in the past, significant judgment is required, and these estimates and assumptions may change as additional information becomes available and facts or circumstances change. Restructuring
costs are recorded at estimated fair value. Key assumptions in determining the restructuring costs include the net realizable value of inventory as well as negotiated terms and payments to terminate certain contractual obligations. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Profits interest compensation </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company measures profits
interest compensation cost at the grant date based on the fair value of the award and recognizes this cost as compensation expense over the required or estimated service period for awards expected to vest. Certain awards are liability-classified,
which require they be remeasured at each reporting date. Compensation expense is included in SG&amp;A and R&amp;D on the consolidated statement of operations and comprehensive loss based upon the classification of the employees who were granted the
awards. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company uses the Monte Carlo option model to allocate the fair value to the granted profits interest awards and other equity instruments.
Expected stock price volatility is based on an average of several peer public companies due to the Company&#146;s limited operating history. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected
life of the award. The dividend yield percentage is zero because the Company neither currently pays dividends nor intends to do so during the expected term. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The expected term of awards represents the average time the awards are expected to be outstanding. The expected term is based on the mid-point between the vesting date and the contractual term. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Advertising costs </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Advertising costs include costs incurred
to promote the Company&#146;s business and are expensed as incurred. Advertising costs were $1,852, $1,791 and $1,543 for the years ended December&nbsp;31, 2013, 2014 and 2015, respectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-13 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Research and development </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">R&amp;D consists primarily of employee compensation and related expenses and contract research organization services. Internal R&amp;D costs are expensed as incurred. R&amp;D costs incurred by third parties are
expensed as the contracted work is performed. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Net loss per unit </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Basic loss per common unit is determined by dividing the net loss allocable to common unit holders by the weighted average number of common units outstanding during the periods presented. Diluted loss per common
unit is computed by dividing the net loss allocable to common unit holders on an &#147;if converted&#148; basis by the weighted average number of actual common units outstanding and, when dilutive, the unit equivalents that would arise from the
assumed conversion of convertible instruments. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Income taxes </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Bioventus is treated as a partnership for U.S. tax purposes. Accordingly, the profits and losses are passed through to the members and included in their income tax returns. The Company is required to make tax
distributions to its members in an amount equal to 40% of the members&#146; taxable income attributable to their ownership. The tax rate applied for purposes of this distribution may be changed only by approval of the Board of Managers. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain wholly-owned subsidiaries of Bioventus are taxable entities for U.S. or foreign tax purposes and file tax returns in their local jurisdictions. Income tax
expense includes U.S. federal, state and international income taxes. Certain items of income and expense are not reported in income tax returns and financial statements in the same year. The income tax effects of these differences are reported as
deferred income taxes. Valuation allowances are provided to reduce the related deferred tax assets to an amount which will, more likely than not, be realized. Interest and penalties related to unrecognized tax benefits are recognized as a component
of income tax expense. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company recognizes a tax benefit from any uncertain tax positions only if they are more likely than not to be sustained upon
examination based on the technical merits of the position. The amount of the accrual for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that the Company believes is more likely than
not to be realized upon ultimate settlement of the position. Components of the reserve, if relevant, are classified as a current liability in the consolidated balance sheet based on when the Company expects each of the items to be settled.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Subsequent events </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company has considered
the effects of subsequent events through April&nbsp;19, 2016, the date the Company&#146;s consolidated financial statements were issued. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Recent
accounting pronouncements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In May 2014, the U.S. Financial Accounting Standards Board (FASB) issued guidance that provides a comprehensive new
revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. The guidance
also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. This guidance is effective for annual and interim periods beginning after December&nbsp;15, 2017. Early
adoption is permitted for annual reporting periods beginning after December&nbsp;15, 2016. The Company is currently evaluating the impact of this new standard on its consolidated financial statements, the date of adoption, and the transition
approach to implement the new guidance. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-14 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In February 2015, the FASB issued guidance which changes the analysis in determining whether an entity is considered a
variable interest entity (VIE) and the identification of the primary beneficiary of the VIE to determine whether the VIE should be included in an entity&#146;s consolidated financial statements. The Company will adopt the new accounting guidance on
January&nbsp;1, 2016, as required. The Company does not expect this guidance to have a material effect on the Company&#146;s consolidated financial statements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In April 2015, the FASB issued guidance that requires debt issuance costs related to a recognized debt liability to be presented in the consolidated balance sheet as a direct deduction from the debt liability
rather than as an asset. In August 2015, the FASB issued updated guidance related to debt issuance costs to include SEC guidance regarding line-of-credit arrangements. The SEC staff would not object to deferring and presenting debt issuance costs as
an asset for line of credit arrangement regardless of whether there is an outstanding balance. This guidance is effective for annual and interim periods beginning after December&nbsp;15, 2015. The Company adopted the new accounting guidance early on
December&nbsp;31, 2015 resulting in a reclassification of $2,196 and $1,760 in other assets to a reduction of the long-term debt balance at December&nbsp;31, 2014 and 2015, respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In September 2015, the FASB issued guidance that eliminated the requirement that an acquirer in a business combination account for the measurement-period adjustments retrospectively. The acquirer will recognize the
measurement-period adjustment during the period in which the adjustment is determined. The Company adopted the new accounting guidance early on January&nbsp;1, 2015 with no material effect on the Company&#146;s consolidated financial statements.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November 2015, the FASB issued guidance that requires companies to classify all deferred tax assets and liabilities as noncurrent on the consolidated
balance sheet. The Company adopted the new accounting guidance early on December&nbsp;31, 2015 resulting in a reclassification of $276 and $251 in current deferred tax liabilities to long term at December&nbsp;31, 2014 and 2015, respectively.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In February 2016, the FASB issued guidance that requires lessees to recognize the rights and obligations resulting from leases as assets and
liabilities. It also modifies the classification criteria and the accounting for sales-type and direct financing leases for the lessor. This guidance is effective for annual and interim periods beginning after December&nbsp;15, 2018. Early adoption
is permitted and must be adopted using a modified retrospective transition. The Company is currently evaluating the impact of this new standard on its consolidated financial statements and the date of adoption to implement the new guidance.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>3. Balance sheet information </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Accounts
receivable, net </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:arial" SIZE="2">Accounts receivable, net of allowances, consisted of the following as of December&nbsp;31:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">74,366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">87,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Contractual allowances</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(19,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,114</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Allowances for doubtful accounts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,671</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">46,577</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">54,511</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Receivables from related parties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">498</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">47,075</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">54,511</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-15 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Changes in the allowances for doubtful accounts were as follows for the years ended December&nbsp;31: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance, beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,430</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,634</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,671</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Provision for losses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,485</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,880</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,707</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Write-offs, net of recoveries</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,843</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,776</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,634</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,671</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,602</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Inventory, net </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT
STYLE="font-family:arial" SIZE="2">Inventory consisted of the following as of December&nbsp;31: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Raw materials and supplies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,266</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Finished goods</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">24,006</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">27,861</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Gross</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">29,272</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">36,294</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Excess and obsolete reserves</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,598</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,116</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">26,674</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35,178</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:arial" SIZE="2">Changes in excess and obsolete reserves for inventory were as follows for the years ended
December&nbsp;31: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance, beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,088</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,598</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Provision for losses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(303</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,364</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Write-offs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,692</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,088</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,598</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,116</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Property and equipment, net </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT
STYLE="font-family:arial" SIZE="2">Property and equipment consisted of the following as of December&nbsp;31: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Computer equipment and software</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,640</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">16,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,349</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Furniture and fixtures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">925</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Machinery and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">914</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">914</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Assets not yet placed in service</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">499</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,327</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23,775</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less accumulated depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,899</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(14,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Depreciation expense was $3,541, $5,064 and $5,321 for the years ended December&nbsp;31, 2013, 2014 and 2015, respectively.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-16 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Goodwill and intangible assets, net </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:arial" SIZE="2">The following is a summary of goodwill by segment: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>US AHT</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>International<BR>AHT</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Surgical</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>BMP</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Consolidated</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at December 31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">48,339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">48,339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">OsteoAMP acquisition</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,614</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,614</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Allocation to new segment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,760</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,760</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">39,579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,760</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,614</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">49,953</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">OsteoAMP acquisition measurement period adjustment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(376</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(376</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">BioStructures acquisition</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Allocation to new segment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">30,685</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,760</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">58,694</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="20" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There were no changes to goodwill during the year ended December&nbsp;31, 2013. During 2015, goodwill was adjusted primarily for the
reduction in working capital related to inventory and prepaid assets. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Intangible assets consisted of the following as of December&nbsp;31: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intellectual property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">213,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">259,238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Distribution rights</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">60,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">42,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Customer relationships</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">57,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">IPR&amp;D</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">27,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Developed technology</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other intangibles</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">424</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">474</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total carrying amount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">334,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">389,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less accumulated amortization:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intellectual property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(23,460</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(36,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Distribution rights</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(22,072</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,598</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Customer relationships</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(13,306</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(19,887</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Developed technology</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,273</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other intangibles</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total accumulated amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(60,130</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(70,760</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intangible assets, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">274,332</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">319,152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Amortization expense related to intangible assets was $21,087, $25,152 and $28,529 for the years ended December&nbsp;31, 2013, 2014
and 2015 of which $6,505, $7,983 and $8,565 are included in ending inventory at December&nbsp;31, 2013, 2014 and 2015, respectively. Estimated amortization expense for the years ended December&nbsp;31, 2016 through 2020 is expected to be $27,597,
$27,150, $25,310, $24,022 and $23,873, respectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-17 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Accrued liabilities </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT
STYLE="font-family:arial" SIZE="2">Accrued liabilities consisted of the following at December&nbsp;31: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Bonus and commission</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Compensation and benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">BioStructure second close payment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,965</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Product costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">966</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income and other taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,313</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,656</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounting and legal fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,032</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Amounts due to managed care organizations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,698</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research, development and regulatory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,116</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,465</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25,969</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34,368</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>4. Business combination </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>OsteoAMP acquisition </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On October&nbsp;3, 2014, in
order to enter the surgical orthobiologics market, the Company purchased the OsteoAMP assets of the biologic growth factor technology business from a California biologics company (the OsteoAMP Seller). The total purchase price was $42,890. The
purchase price consisted of contingent consideration of $32,344 and cash of $10,546. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company accounted for the OsteoAMP purchase using the
acquisition method of accounting whereby the total purchase price was preliminarily allocated to tangible and intangible assets acquired and liabilities assumed based on respective fair values. The following table summarizes the preliminary and
final fair values of the assets acquired and liabilities assumed at the acquisition date: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Preliminary</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Measurement<BR>period<BR>adjustments</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Final</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fair value of consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">42,890</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">42,890</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Assets acquired:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,509</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Prepaid and other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">39,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">39,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total assets acquired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">41,909</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">376</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">42,285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Liabilities assumed:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">633</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">633</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net identifiable assets acquired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">41,276</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">376</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">41,652</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Resulting goodwill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,614</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(376</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of December&nbsp;31, 2014, the purchase price allocation for the OsteoAMP acquisition was preliminary and subject to completion.
Adjustments to the current fair value estimates in the above table occurred as the process conducted for various valuations and assessments was finalized in September 2015, including tax </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-18 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
assets, liabilities and other attributes. Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and nearly 100% represents the estimated future
economic benefits arising from other assets acquired that could not be individually identified and separately recognized. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The factors contributing to
the recognition of goodwill are based on several strategic and synergistic benefits that are expected to be realized from the OsteoAMP acquisition including the expansion into the surgical market. The goodwill is tax deductible and was allocated to
the Surgical reporting unit for purposes of the evaluation for any future goodwill impairment. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The contingent consideration consists of up to $12,000
for various cash earn-out payments upon the achievement of certain net sales targets through December&nbsp;31, 2019, a royalty on certain future net sales of OsteoAMP beginning January 1, 2019 through December 31, 2023 and a supply agreement with
the OsteoAMP Seller ending in October 2018. Under the terms of the supply agreement, the Company will purchase the OsteoAMP product from the OsteoAMP Seller at prices above the market rate. Contingent consideration payments may be up to $70,117.
There was $1,731 and $16,345 in contingent consideration payments for the year ended December&nbsp;31, 2014 and 2015, respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The intangible
assets purchased consisted of the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Fair&nbsp;value</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Useful&nbsp;life<BR>(in years)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intellectual property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">30,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Customer relationships</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">IPR&amp;D</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Non-compete agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total intangible assets acquired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">39,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The preliminary fair value of the OsteoAMP intellectual property and IPR&amp;D was determined using the income approach through an
excess earnings analysis, with projected earnings discounted at a rate of 25.0% and 27.0%, respectively. The IPR&amp;D consists of certain R&amp;D progress toward the next-generation of OsteoAMP. The preliminary fair value of the customer
relationship asset was determined using the income approach through an incremental cash flow analysis utilizing the with-and-without or lost profits method, with projected cash flow discounted at a rate of 24.0%. The determination of the useful
lives was based upon consideration of market participant assumptions and transaction specific factors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The results of OsteoAMP operations of the
business have been included in the accompanying consolidated financial statements since the October&nbsp;3, 2014 acquisition date. OsteoAMP revenue and earnings included in operations are as follows for the years ended December&nbsp;31: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">24,034</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,092</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(17,709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Revenue and earnings including the OsteoAMP operations as if it was acquired at January&nbsp;1, 2013 are as follows for the years
ended December&nbsp;31: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">241,780</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">254,579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(19,351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(9,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-19 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">OsteoAMP acquisition-related costs for the year ended December&nbsp;31, 2014 were $178 and are recorded in SG&amp;A in
the consolidated statement of operations and comprehensive loss. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>BioStructures acquisition </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On November&nbsp;24, 2015, in order to increase its presence in the surgical orthobiologics market, the Company purchased BioStructures, LLC for cash of $48,397, a
$23,528 note payable to the former BioStructures owners, contingent consideration of $4,542 and a second closing payment of $4,960. Contingent consideration is made up of future earn-out payments contingent upon the achievement of certain research
and development milestones through November&nbsp;24, 2017. BioStructures, LLC is a limited liability company formed under the laws of the state of California on August&nbsp;22, 2007 and operates as a partnership. The Company accounted for the
BioStructures purchase using the acquisition method of accounting whereby the total purchase price was preliminarily allocated to tangible and intangible assets acquired and liabilities assumed based on respective fair values. The following table
summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fair value of consideration</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;81,427</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Assets acquired:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,677</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,924</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">73,350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total assets acquired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">77,773</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Liabilities assumed:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accrued liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,386</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net identifiable assets acquired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">72,310</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Resulting goodwill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of December&nbsp;31, 2015, the purchase price allocation for the BioStructures acquisition was preliminary and subject to
completion. Adjustments to the current fair value estimates in the above table may occur as the process conducted for various valuations and assessments is finalized, including tax liabilities and other working capital accounts. Goodwill is
calculated as the excess of the consideration transferred over the net assets recognized and nearly 100% represents the estimated future economic benefits arising from other assets acquired that could not be individually identified and separately
recognized. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The factors contributing to the recognition of goodwill are based on several strategic and synergistic benefits that are expected to be
realized from the BioStructures acquisition including the expansion into the surgical market. The goodwill is tax deductible and was allocated to the Surgical reporting unit for purposes of the evaluation for any future goodwill impairment.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Contingent consideration is made up of future earn-out payments contingent upon the achievement of certain R&amp;D milestones to be achieved by the
former BioStructures owners. The contingent consideration could be lowered and is not to exceed $5,000. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-20 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:arial" SIZE="2">The intangible assets purchased consisted of the following: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Fair&nbsp;value</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Weighted<BR>average</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Useful&nbsp;life<BR>(in years)</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intellectual property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">45,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">IPR&amp;D</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Distributor relationships</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Trade name</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total intangible assets acquired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">73,350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The preliminary fair value of the BioStructures intellectual property and IPR&amp;D was determined using the income approach through
an excess earnings analysis, with projected earnings discounted at a rate of 17.0% and 18.0%, respectively. The IPR&amp;D consists of certain R&amp;D progress toward the next-generation of Silhouette and SignaFuse. The preliminary fair value of the
distributor relationship asset was determined using the income approach through an incremental cash flow analysis utilizing the with-and-without or lost profits method for consignment distributors and the cost method for stocking distributors, with
projected cash flow discounted at a rate of 17.0%. The determination of the useful lives was based upon consideration of market participant assumptions and transaction specific factors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The results of operations of the business have been included in the accompanying consolidated financial statements since the November&nbsp;24, 2015 acquisition date. BioStructures revenue and earnings included in
operations are as follows for the year ended December&nbsp;31: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">410</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Revenue and earnings including the BioStructures operations as if it was acquired at January&nbsp;1, 2014 are as follows for the
years ended December&nbsp;31: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">255,071</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">265,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(7,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(28,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">BioStructures acquisition-related costs for the year ended December&nbsp;31, 2015 were $332 and are recorded in SG&amp;A in the
consolidated statement of operations and comprehensive loss. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>5. Debt </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Related party note </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On May&nbsp;4, 2012, in conjunction with the business formation, the Company entered into
the note payable to S&amp;N (Related Party Note) at a premium of $3,188, due May&nbsp;4, 2017. Premiums of $637 and $2,126 for the years ended December&nbsp;31, 2013 and December&nbsp;31, 2014 were amortized and reduced interest expense in the
consolidated statement of operations and comprehensive loss. Interest was calculated based on a calendar day year and accrued annually in arrears on May&nbsp;4 of each year (Interest Payment Date). The interest rate was equal to LIBOR plus
5%&nbsp;per year provided however, that LIBOR was not lower than 1.75% or higher than 2.5%. As of December&nbsp;31, 2013, the interest rate on the Related Party Note was 6.75%. Until and including the Interest Payment Date occurring on May&nbsp;4,
2014, the interest was paid-in-kind and, on the applicable Interest Payment </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-21 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Date, was added to the outstanding principal amount, from which succeeding interest was calculated. The principal of $160,000, in-kind interest of $22,329 and accrued interest of $5,361 were
repaid in full in October 2014. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>2013 revolving credit agreement </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">During June 2013, the Company entered into a two-year revolving credit facility of $25,000 (2013 Revolver). The 2013 Revolver included a commitment fee of 0.375% of the average daily amount of the available
revolving commitment. The fee was payable monthly in arrears on the first day of the month. As of December&nbsp;31, 2013, the weighted average interest rate on the borrowings under the 2013 Revolver was 2.05%. In October 2014, the Company repaid and
terminated the 2013 Revolver. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>2014 credit agreement </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">On October&nbsp;10, 2014 (Closing), the Company entered into a $215,000&nbsp;credit agreement (2014 Credit Agreement) with JPMorgan Chase Bank, N.A. (JP Morgan), as well as a syndicate of other banks, financial
institutions and other entities (Lenders). The 2014 Credit Agreement is comprised of a $115,000&nbsp;first lien term loan (First Lien Term Loan), a $60,000&nbsp;second lien term loan (Second Lien Term Loan) and a $40,000&nbsp;revolving facility
(2014 Revolver). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">All obligations under the 2014 Credit Agreement are guaranteed by the Company and certain of the Company&#146;s direct and indirect
wholly-owned domestic subsidiaries. The obligations under the 2014 Credit Agreement are collateralized by substantially all of the assets of the Company. The First Lien Term Loan obligations rank higher in right of payment to the Second Lien Term
Loan. The First Lien Term Loan and 2014 Revolver mature on October&nbsp;10, 2019 and the Second Lien Term Loan matures on April&nbsp;10, 2020 (Maturity). </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of December&nbsp;31, 2014 and 2015, $112,248 and $105,085&nbsp;was outstanding on the First Lien Term Loan, net of the unamortized original issue discount of
$736 and $581 and deferred financing costs of $578 and $708, respectively. The Company may voluntarily prepay the First Lien Term Loan without premium or penalty upon prior notice. Scheduled quarterly principal payments as a percentage of the
aggregate initial principal borrowed are as follows, with the remaining outstanding principal due at Maturity: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Quarterly<BR>payment</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">December&nbsp;31, 2014 to September&nbsp;30, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.25%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">December&nbsp;31, 2015 to September&nbsp;30, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.50%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">December&nbsp;31, 2016 to September&nbsp;30, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.75%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">December&nbsp;31, 2017 to September&nbsp;30, 2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.75%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,313</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">December&nbsp;31, 2018 to Maturity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Second Lien Term Loan principal is due at Maturity and as of December&nbsp;31, 2014 and 2015, $57,225&nbsp;and $57,459&nbsp;was
outstanding, net of the unamortized original issue discount of $1,147 and $927 and deferred financing costs of $1,630 and $1,613, respectively. After October&nbsp;10, 2017, the Company may voluntarily prepay the Second Lien Term Loan without premium
or penalty upon prior notice. Prepayments made prior to October&nbsp;10, 2017 will be subject to the prepayment premiums below: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Payment timing</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Premium</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">In advance of October&nbsp;10, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">On October&nbsp;10, 2015 but in advance of October&nbsp;10, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">On October&nbsp;10, 2016 but in advance of October&nbsp;10, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-22 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The First and Second Lien Term Loans permit at the Company&#146;s election either Eurodollar or Alternate Base Rate
(ABR) term loans, which are due at Maturity. ABR term loans have interest due the last day of each calendar quarter-end. Eurodollar loans are one, two, three or six-month loans and interest is due on the last day of each three-month period or the
last day of the loan term if less than three months. In advance of the last day of the current Eurodollar Loan, the Company may select a new loan type so long as it does not extend beyond Maturity. The outstanding First and Second Lien Term Loans
have been Eurodollar Loans since inception. In addition, both First and Second Lien Term Loans have an interest due date concurrent with any scheduled principal repayment or prepayment. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The 2014 Revolver is a five-year revolving credit facility of $40,000 which includes revolving and swingline loans as well as letters of credit (LOC) and, inclusive of all, cannot exceed $40,000 at any one time.
Revolving loans may be Eurodollar or ABR loans at the Company&#146;s election which are not due until the termination date or Revolver Maturity, and interest is payable on the same terms as described in the previous paragraph for the First and
Second Lien Term Loans. Swingline loans are available as ABR loans only and are due within five business days or Revolver Maturity whichever is earlier. The Company had not borrowed on the 2014 Revolver at December&nbsp;31, 2014, leaving
$40,000&nbsp;available. As of December&nbsp;31, 2015, the 2014 Revolver balance is $8,000, leaving $32,000 available. There were no LOCs outstanding under the 2014 Revolver, as of December&nbsp;31, 2014 and 2015. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">The base interest rate for all ABR loans is equal to the highest of (a)&nbsp;the JP Morgan Prime Rate, (b)&nbsp;the Federal Funds Effective
Rate plus <FONT SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;1</SUP></FONT><FONT SIZE="2">/</FONT><FONT SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.1ex">2</SUB></FONT><FONT
STYLE="font-family:arial" SIZE="2">% and (c)&nbsp;the Eurodollar Rate for a USD deposit with a maturity of one month plus 1.0% (rounded upward to the next 1/16 of 1%). The base interest rate for all Eurodollar Loans is equal to the rate determined
for such day in accordance with the following formula with the Second Lien Term Loans having a floor of 1.00%: </FONT></FONT></P> <P STYLE="font-size:16px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">LIBOR</FONT></P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">1&#151;Eurocurrency Reserve Requirements</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to the base interest rate, all Eurodollar and ABR loans have a margin. The First Lien Term Loan margins are tied to a
leverage ratio which is the ratio of debt to Consolidated EBITDA (as defined in the 2014 Credit Agreement) for four consecutive quarters at the end of each period. Pricing grids are used to determine the margin based on the type of loan and the
leverage ratio. The Second Lien Term Loan margins are fixed at 10.00% for Eurodollar Loans and 9.00% for ABR Loans. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The First Lien Term Loan margin is
adjusted after the quarterly financial statements are delivered to the lenders. Below is the pricing grid: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Leverage ratio</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Eurodollar</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>ABR</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT><FONT
STYLE="font-family:arial" SIZE="2"></FONT> 4.00 to 1.00</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT><FONT
STYLE="font-family:arial" SIZE="2"></FONT> 3.00 to 1.00 but <FONT STYLE="font-family:Times New Roman" SIZE="2">&#060;</FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT> 4.00 to 1.00</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.75%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.75%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT><FONT
STYLE="font-family:arial" SIZE="2"></FONT> 2.00 to 1.00 but <FONT STYLE="font-family:Times New Roman" SIZE="2">&#060;</FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT> 3.00 to 1.00</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.50%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.50%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#060;</FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT> 2.00 to
1.00</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.25%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.25%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Interest is calculated based on a 360-day year except for ABR loans where the base interest is the JP Morgan Prime Rate, in which
case it is calculated based on a calendar-day year. As of December&nbsp;31, 2015, the First and Second Lien Term Loan interest rates including the margin were 3.2% and 11.0%, respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Company may be required to make additional principal payments on the First and Second Lien Term Loans dependent upon the generation of certain cash flow events or excess cash as defined in the 2014 Credit
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-23 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Agreement. These additional prepayments will be applied to the scheduled installments of principal in direct order of maturity of the ABR Loans first and then the Eurodollar Loans. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The 2014 Revolver includes a commitment fee at 0.50% of the average daily amount of the available revolving commitment, assuming any swingline loans outstanding are
$0. There were no swingline loans outstanding at December&nbsp;31, 2014 or 2015. The fee is payable quarterly in arrears on the last day of the calendar quarters and the Revolver Maturity. On and after the first adjustment date the rate will be
determined based on the pricing grid below. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Leverage ratio</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Commitment&nbsp;fee<BR>rate</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT><FONT
STYLE="font-family:arial" SIZE="2"></FONT> 4.00 to 1.00</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.50%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT><FONT
STYLE="font-family:arial" SIZE="2"></FONT> 3.00 to 1.00 but <FONT STYLE="font-family:Times New Roman" SIZE="2">&#060;</FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT> 4.00 to 1.00</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.45%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT><FONT
STYLE="font-family:arial" SIZE="2"></FONT> 2.00 to 1.00 but <FONT STYLE="font-family:Times New Roman" SIZE="2">&#060;</FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT> 3.00 to 1.00</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.40%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#060;</FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT> 2.00 to
1.00</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.35%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">LOCs are available in an amount not to exceed $5,000. Fees are charged on all outstanding LOCs at an annual rate equal to the margin
in effect on Eurodollar revolving loans. A fronting fee of 0.125%&nbsp;per year on the undrawn and unexpired amount of each LOC is payable as well. The fees are payable quarterly in arrears on the last day of the calendar quarters after Closing.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The 2014 Credit Agreement required that, on or before January&nbsp;8, 2015, the Company to enter into, and thereafter maintain for not less than three
years, agreements so that at least 25% of the First Lien Term Loans are subject to a fixed interest rate. During November 2014, the Company entered into three interest rate swap agreements totaling $70 million with a term of three years (discussed
further in Note 6). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of December&nbsp;31, 2014 and 2015, the effective interest rate, including the applicable lending margin, on 61.6% and 65.8%,
respectively, or $70.0 million, of the outstanding principal of the Company&#146;s First Lien Term Loan was fixed at 4.19% through the use of the interest rate swaps. As of December&nbsp;31, 2014 and 2015, the Company&#146;s effective weighted
average interest rate on all outstanding debt, including the commitment fee and interest rate swaps, was 6.21% and 6.38%, respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The 2014 Credit
Agreement contains certain covenants, including, but not limited to (1)&nbsp;a minimum fixed charge ratio and a maximum debt leverage ratio requirement as defined in the 2014 Credit Agreement, (2)&nbsp;restrictions on the declaration or payment of
certain distributions on or in respect of the Company&#146;s equity interests, (3)&nbsp;restrictions on acquisitions, investments and certain other payments, (4)&nbsp;limitations on the incurrence of new indebtedness, (5)&nbsp;limitations on
transfers, sales and other dispositions and (6)&nbsp;limitations on making any material change in any of the Company&#146;s business objectives that could reasonably be expected to have a material adverse effect on the repayment of the note.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each Lender may provide an additional First Lien, Second Lien and or Revolving Loan by executing and delivering notice specifying the terms, provided
that doing so would not cause certain undesired events to occur as defined in the 2014 Credit Agreement or extend repayment beyond Maturity. The aggregate amount of all additional borrowings may not exceed $25,000 without the consent of the Lenders
holding more than 50% of the total outstanding debt under the 2014 Credit Agreement. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Financing costs </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a result of entering into the 2013 Revolver, the Company incurred a total of $275 in financing costs. These costs were recorded in prepaid and other current
assets and were being amortized to interest expense on a straight-line basis over the life of the 2013 Revolver, which approximated the effective interest method. During </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-24 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
October 2014, the bank that provided the 2013 Revolver became one of the syndicate banks for the 2014 Credit Agreement. The net financing costs related to the 2013 Revolver of $97 were combined
with the 2014 Credit Agreement financing costs of $2,520 and totaled $2,617. During November 2015, the Company paid financing costs totaling $910 in order to amend future debt covenant requirements and to obtain approval for the BioStructures
acquisition. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">$192 of the 2015 finance costs were recorded directly to interest expense. The remaining $718 along with the $2,617 was capitalized to the
consolidated balance sheet. The portion related to the First and Second Lien Term Loans totaling $2,893 was recorded as a reduction to long-term debt while the portion related to the 2014 Revolver totaling $456 was recorded in other assets. The
deferred financing costs are being amortized to interest expense on a straight-line basis over each of the lives of the First Lien Term Loan, Second Lien Term Loans and 2014 Revolver, as applicable, which approximates the effective interest method.
The Company recorded $75, $226 and $510 in interest expense associated with these deferred costs for the years ended December&nbsp;31, 2013, 2014 and 2015, respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Contractual maturities of long-term debt at December&nbsp;31, 2015, were as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2016</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> 12,938</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,688</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">57,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2020 and thereafter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">60,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred finance costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,322</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Original issue discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,509</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">162,545</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">149,607</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>6. Derivatives </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company
does not use derivative financial instruments for speculative or trading purposes. The Company was not a party to derivative instruments in 2013. As of December&nbsp;31, 2014 the Company had one foreign exchange forward contract (5,000 Euro
notional) to protect against the effect of foreign currency fluctuations on a 5,000 Euro payment made in November 2015. The derivative instrument was not designated as a hedge. In November 2015 the Company paid $6,234 for the 5,000 Euro resulting in
a realized loss of $941 recorded in other (income) expense on the consolidated statement of operations and comprehensive loss. This realized loss was 100% offset by the realized gain recognized on the final license agreement payment discussed
further in Note 13. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November 2014, the Company entered into three interest rate swaps effective November&nbsp;28, 2014 and expiring November&nbsp;30,
2017 in an effort to limit its exposure to changes in the variable interest rate on its First Lien Term Loan (as discussed in Note 5). The derivative instruments have not been designated as hedges. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The fair values of the Company&#146;s derivatives recorded in accrued liabilities in the Company&#146;s consolidated balance sheets are as follows at
December&nbsp;31: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest rate swaps</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(134</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign exchange forward contract</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(321</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-25 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The effect of the Company&#146;s derivatives on the consolidated statements of operations and comprehensive loss is as
follows for the year ended December&nbsp;31 (except for 2013 where there was no derivative outstanding): </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Statement&nbsp;of&nbsp;operations&nbsp;and<BR>comprehensive</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:arial" SIZE="2"><B>loss</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest rate swaps</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Interest&nbsp;expense</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">134</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign exchange forward contract</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Other&nbsp;(income)&nbsp;expense</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">321</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>7. Members&#146; equity </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Members&#146; equity consisted of the following at December&nbsp;31: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Preferred</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">118,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">168,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Common</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">113,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">113,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Profits interest (discussed further in Note 10)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,455</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">233,970</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">284,828</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The authorized number of common and preferred units is unlimited. On May&nbsp;4, 2012, 4,900 common units and 5,100 preferred units
(2012 Preferred Units) were issued and remained outstanding as of December&nbsp;31, 2014. During November 2015, the Company obtained a $50,000 capital contribution from its existing members and 1,490 in preferred units were issued (2015 Preferred
Units). The Common and Preferred Members have stated rights and privileges which include, but are not limited to: (1)&nbsp;voting and Company governance, (2)&nbsp;the transfer of membership interests and (3)&nbsp;dissolutions and liquidation of the
Company. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each preferred unit carries a priority payout (the Liquidation Preference as defined in the agreement) upon certain events, including but not
limited to a qualified initial public offering, sale of the Company or a liquidation or dissolution of the Company (Distribution Event). The initial Liquidation Preference for the 2012 and 2015 Preferred units are $23.14 and $33.57, respectively.
Until such time as preferred units are converted to common units, the preferred units will also accrue a distribution right (the Preferred Distribution) at a rate of 3%&nbsp;per annum and as long as it is unpaid, such Preferred Distribution shall be
added annually to the Liquidation Preference. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to the common units, the Common Member owns the only Equity Participation Right (EPR) Unit.
The EPR Unit is junior to the common units and its only entitlement is 0.55% of available distributions arising from a Distribution Event. Upon the conclusion of a Distribution Event, the EPR Unit will cease to exist and all entitlements will end.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>8. Fair value measurements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Recurring fair
value measurements </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There were no material assets subject to recurring fair value measurement carried on the accompanying consolidated balance
sheet at December&nbsp;31, 2014 and 2015. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-26 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table provides information, by level, for liabilities that were measured at fair value on a recurring
basis at December&nbsp;31, 2014: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;2</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level 3</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32,215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32,215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest rate swaps</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">134</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">134</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign exchange forward contracts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Management incentive plan and liability-classified awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">EPR liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,037</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,037</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35,057</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">321</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34,736</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table provides information, by level, for liabilities that are measured at fair value on a recurring basis at
December&nbsp;31, 2015: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;2</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level 3</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">39,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">39,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest rate swaps</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Management incentive plan and liability-classified awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,924</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,924</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">EPR liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">46,504</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">46,218</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Below is a summary of the valuation techniques used in determining fair value: </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Contingent consideration</I>&#151;The Company values contingent consideration related to business combinations using a weighted probability calculation of
potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include revenue, net new business and operating
forecasts and the probability of achieving the specific targets. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Interest rate swaps</I>&#151;The Company values interest rate swaps by discounting
cash flows of the swap. Forward curves and volatility levels are used to estimate future cash flows that are not certain. These are determined using observable market inputs when available and on the basis of estimates when not available.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Foreign exchange forward contracts</I>&#151;The Company values foreign exchange forward contracts using quoted market prices for similar assets in
less active markets or using other observable inputs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Management incentive plan (MIP) and liability-classified awards</I>&#151;The Company values
these awards using the Monte Carlo option model to allocate fair value. Key assumptions used to estimate the fair value include expected stock price volatility, risk-free interest rate, dividend yield and the average time the award is expected to be
outstanding. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>EPR liability</I>&#151;The Company values the EPR Unit using a weighted probability calculation of potential payment scenarios
discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of the EPR Unit include the timing and amount available from a Distribution Event. In addition, in 2013 a key
assumption used was the date at which the percentage applied to the distributions would become fixed, which coincided with the Related Party Note repayment date. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-27 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The percentages that would be applied to distributions resulting from a Distribution Event started in 2013 and accrued
daily on a straight-line basis: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">November&nbsp;4, 2013 and before</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.00%</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">November&nbsp;4, 2013 to May&nbsp;4, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">0.00%-0.89%</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">May&nbsp;4, 2015 to May&nbsp;4, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">0.89%-1.61%</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">May&nbsp;4, 2016 to May&nbsp;4, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">1.61%-2.50%</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Management&#146;s probability assessment of the Related Party Note repayment date included the following three scenarios in 2013:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Prior to November 2014</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>90%</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Prior to June&nbsp;30, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>9%</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Prior to May&nbsp;4, 2017 (maturity)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>1%</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In October 2014, the percentage that will be applied to distributions resulting from a Distribution Event became fixed at 0.55%.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following tables summarize the changes in the Level 3 contingent consideration liabilities measured on a recurring basis for the years ended
December&nbsp;31: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Contingent<BR>consideration</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>MIP and liability-<BR>classified awards</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>EPR liability</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Beginning balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32,215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,037</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Initial estimate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32,344</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,542</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,244</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in fair value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,196</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Payment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(16,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="21" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Ending balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32,215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">39,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,924</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,037</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="24" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The contingent consideration change in fair value of $1,602 and $19,493 for the years ended December 31, 2014 and 2015,
respectively, was primarily driven by sales exceeding estimates at the OsteoAMP acquisition date as well as higher than estimated inventory on hand. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
revaluation for the EPR liability is recognized in interest expense on the consolidated statements of operations and comprehensive loss. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Non-recurring fair value measurements </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The carrying
value of the 2014 Credit Agreement and other indebtedness was not materially different from fair value at December&nbsp;31, 2014 and 2015. The fair value of these obligations was determined based on discounted cash flows using estimated incremental
borrowing rates for obligations with similar characteristics. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of December&nbsp;31, 2014 and 2015, assets carried on the consolidated balance sheet
and not remeasured to fair value on a recurring basis are comprised of long-lived assets, finite and indefinite-lived intangible assets and goodwill. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>9. Restructuring costs </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November&nbsp;2014, the Company
adopted a plan to restructure and no longer sell a diagnostic ultrasound product in order to improve margins, principally through headcount reduction which was communicated to the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-28 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
affected employees in January 2015. Costs included in the restructuring plan are employee severance and other administrative expenses. For the year ended December&nbsp;31, 2015, the Company
recorded total pre-tax charges of $490 related to severance and $221 in other administrative expenses. The plan was completed in 2015 with total costs incurred of $711. Additionally, related to this restructuring, the Company recorded inventory
provisions in cost of sales totaling $1,183 for the year ended December 31, 2014 and $202 for the year ended December 31, 2015. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In January&nbsp;2015,
the Company adopted a plan to restructure and relocate certain finance functions from Memphis, TN to headquarters in Durham, NC. The plan was completed in 2015 with charges totaling $960. For the year ended December&nbsp;31, 2015, the Company
recorded total pre-tax charges of $508 related to severance and temporary labor, $258 related to consulting and compensation for departing employees that remained through the transition and $194 in other administrative expenses. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November 2015, the Company adopted a restructuring plan to improve margins in the international business principally through headcount reduction. The plan is
expected to be completed in 2016. For the year ended December&nbsp;31, 2015, the Company recorded total pre-tax charges of $772 related to severance. The Company estimates that the one-time costs will total $952 upon completion. Final restructuring
costs of $180 are expected to be expensed in 2016 upon notifying employees of termination. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These charges are included in restructuring expenses in the
consolidated statement of operations and comprehensive loss and all relate to the Active Healing Therapies segment. There were no restructuring charges in 2013 or 2014. During the year ended December&nbsp;31, 2015 the Company made payments and
provision adjustments for all plans as presented below: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Employee<BR>severance&nbsp;and<BR>temporary<BR>labor costs</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Other<BR>charges</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Expenses incurred</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,770</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">673</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Payments made</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(998</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(673</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,671</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">772</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">772</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>10. Benefit plans </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Equity-based compensation plans </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company operates
two equity-based compensation plans, the MIP and the Phantom Profits Interest Plan (PIP). The awards granted under both plans represent a non-managing, non-voting interest in the Company designed for grantees to share in the future appreciation of
the value of the Company. The total amount of awards available for grant through May 2015 was limited to 1,111,111. In June 2015 the PIP was amended and restated increasing the awards available for distribution by 821,722 bringing the total awards
available to 1,932,833. At December&nbsp;31, 2015, 484,370 units were available for award. Profits interest compensation of $576, $2,355 and $3,325 was recognized for the years ended December&nbsp;31, 2013, 2014 and 2015, respectively. The expense
is included in SG&amp;A and R&amp;D on the consolidated statement of operations and comprehensive loss based upon the classification of the employee. As of December&nbsp;31, 2015, there was approximately $3,747 (as revised) of unrecognized
compensation expense to be recognized over a weighted-average period of 0.5 years for the MIP and 1.5 years for the PIP. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>MIP liability-classified
</I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The awards granted under MIP vest 25% upon the first anniversary of the grant date and 6.25%&nbsp;per quarter thereafter. Receipt of value will be
realized upon sale of the Company or a liquidation or dissolution of the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-29 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">
Company as defined in the LLC Agreement (MIP Distribution Event) and will be based on the grantees to vested ownership of their award in proportion to the Company&#146;s equity, including vested
interests under both the MIP and PIP plans, after all debt and equity holders have been repaid. Cumulative distributions that must be made to the members before distributions are made (Benchmark Amount) total $231,372 for MIP awards. The MIP award
allows the grantee to force a cash settlement after the 5</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"> anniversary of the
effective date of the award if the grantee retires. The proceeds received by the MIP grantee upon a forced cash settlement will be calculated on the same basis as if a MIP Distribution Event occurred. The value to be allocated to the MIP grantee
will be calculated as the greater of fair value in an arms-length transaction or 8.25 times the annualized most recent 6 month EBITDA. The MIP awards are re-measured to fair value at each reporting date and are included in other long-term
liabilities on the consolidated balance sheet (as discussed in Note 8). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>2012 PIP equity-classified </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Awards granted under the 2012 PIP generally vest over a five-year period. The majority of the awards vest 20% on each of the first five anniversaries from the grant
date. Certain awards vest 20% upon the first anniversary of the grant date and 5%&nbsp;per quarter thereafter. Receipt of value will be realized upon the closing of a sale of units representing a percentage interest of more than 66.66%, or the sale
of all or substantially all of the assets of the Company, provided such event constitutes a change of control (PIP Distribution Event) and will be based on the grantees vested ownership of their award in proportion to the Company&#146;s equity,
including vested interests under both the MIP and PIP plans, after all debt and equity holders have been repaid. Payment amount for vested awards shall be equal to an amount that would be payable with respect to the equivalent number of PIP units
with an equivalent Benchmark Amount pursuant to the LLC Agreement, which is $231,372. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>2015 PIP value creation liability-classified </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">2015 PIP Value Creation awards were granted in 2015 with a three year cliff vesting related to the 2017 enterprise value as follows: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017 enterprise value</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>&#060;$690,000</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>$690,000&nbsp;
but<BR>&#060;$740,000</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>$740,000</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Percent vested</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Receipt of value will be realized upon a PIP Distribution Event or termination that was not for cause, whichever comes first. The
payment amount for vested awards shall be an amount that would be allocated to an equivalent number of PIP units with an equivalent Benchmark Amount, or $367,264, upon a PIP Distribution Event or upon termination as if the Company were liquidated on
the termination date at fair market value. Payment will be based on the grantees vested ownership of their award in proportion to the Company&#146;s equity, including vested interests under both the MIP and PIP plans, after all debt and equity
holders have been repaid. The 2015 PIP Value Creation awards are re-measured to fair value at each reporting date and are included in other long-term liabilities on the consolidated balance sheet (as discussed in Note 8). </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>2015 PIP liability-classified </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Awards granted under the 2015
PIP generally vest over a five-year period. The majority of the awards vest 20% on each of the first five anniversaries from the grant date. Certain awards vest 20% upon the first anniversary of the grant date and 5%&nbsp;per quarter thereafter.
Receipt of value will be realized upon a PIP Distribution Event or termination that was not for cause whichever comes first. The payment amount for vested awards shall be an amount that would be allocated to an equivalent number of PIP units with an
equivalent Benchmark Amount, or $367,264, upon a PIP Distribution Event or upon termination as if the Company were liquidated on the termination date at fair market value. Payment will be based on the grantees vested ownership of their award in
proportion to the Company&#146;s equity, including vested interests under both the MIP and PIP plans, after all </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-30 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
debt and equity holders have been repaid. The 2015 PIP awards are re-measured to fair value at each reporting date and are included in other long-term liabilities on the consolidated balance
sheet (as discussed in Note 8). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The assumptions utilized to determine the fair value of the awards for the years ended December&nbsp;31 are indicated in
the following&nbsp;table: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Expected dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Expected volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">42.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">40.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Risk-free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.3%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.3%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.4%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Time to exit event (in&nbsp;years)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A summary of the award activity of the Plans is as follows (number of awards in thousands): </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>MIP and 2012 plan</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015 plan</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number<BR>of<BR>awards</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Weighted-<BR>average<BR><FONT STYLE="white-space:nowrap">grant-date</FONT><BR>fair value</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number<BR>of<BR>awards</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Weighted-<BR>average<BR><FONT STYLE="white-space:nowrap">grant-date</FONT><BR>fair value</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Outstanding at December&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">817</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.89</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(358</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Outstanding at December&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">965</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9.31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6.03</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Outstanding at December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">379</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Outstanding at December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,069</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">379</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The weighted average fair value per 2012 Plan awards granted in the years ended December&nbsp;31, 2013, 2014 and 2015 was $4.89,
$9.31 and $10.01, respectively. The weighted average fair value per 2015 Plan awards granted in the year ended December&nbsp;31, 2015 was $3.92. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>MIP and 2012 plan</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number&nbsp;of<BR>awards</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>grant-date fair<BR>value</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Nonvested at December&nbsp;31, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">817</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Vested during 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">128</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Nonvested at December&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Vested during 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6.66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Nonvested at December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">726</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7.31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Vested during 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Nonvested at December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">891</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7.58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The total fair value of 2012 Plan shares vested in the years ended December&nbsp;31, 2013, 2014 and 2015 was $655, $1,312 and
$3,001, respectively. No 2015 Plan shares have vested. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-31 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Defined contribution plans </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Company has various defined contribution plans or plans that share profit which are offered in Australia, Canada, Finland, France, Germany, Italy, the Netherlands and the United Kingdom. In some cases, these
plans are required by local laws or regulations. Contributions are primarily discretionary, except in some countries where contributions are contractually required. These plans cover substantially all eligible employees in the countries where the
plans are offered either voluntarily or statutorily. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the US, the Company provides a 401(k) defined contribution plan that covers substantially all US
employees that meet minimum age requirements, or US Plan. The Company matches 50% of the employees&#146; contribution up to 6% of the employees&#146; wages. In addition, the Company contributes 4.5% of the employees&#146; wages to the US Plan.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For the years ended December&nbsp;31, 2013, 2014 and 2015 Company contributions totaled $4,514, $4,831 and $4,562, respectively, for all global plans.
The expense is included in cost of sales, SG&amp;A and R&amp;D on the consolidated statement of operations and comprehensive loss based upon the classification of the employee. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>11. Income taxes </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The components of income (loss) from operations before income taxes for the years ended
December&nbsp;31 are as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Taxable subsidiaries:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Domestic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,804</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,985</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,211</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,516</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,236</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,735</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other domestic subsidiaries</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(22,756</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(16,589</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(38,706</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pretax loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(20,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,353</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(31,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Federal income taxes:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,728</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,335</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,770</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(476</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(476</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(476</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign income taxes:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,291</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">633</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">State income taxes:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">432</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(378</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">190</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(277</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Provision for income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-32 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The differences between the effective income tax rate and the federal statutory income tax rates for the years ended
December&nbsp;31 by taxable and other subsidiaries are as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">U.S. statutory income tax rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">LLC flow-through structure</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(38.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(49.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(41.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">State and local income taxes, net of federal benefit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign rate differential</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Provision to return adjustment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">State refund for jurisdiction change</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Effective income tax rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(10.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(13.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company&#146;s effective tax rate differs from statutory rates primarily due to Bioventus LLC&#146;s pass-through structure for
U.S. income tax purposes while being treated as taxable in certain states and various foreign jurisdictions as well as for certain subsidiaries. The 2014 taxable provision to return adjustment was driven in part by changes in items estimated in the
original provision. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Tax effects of temporary differences give rise to deferred tax assets and liabilities. The deferred taxes as of December&nbsp;31 are
as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred tax assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net operating losses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">179</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">84</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred tax liability:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(9,052</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Negotiated tax deferral</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(276</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(9,328</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,780</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net deferred tax liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(9,149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,696</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company has foreign NOL carryforwards of $527 and $227 at December 31, 2014 and 2015, respectively, for which no valuation
allowance has been established as there are no jurisdictions where the Company believes future benefit is uncertain. These NOL carryforwards do not expire. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Dutch income taxes are imposed on a negotiated percentage of sales. The Company has an agreement with the Dutch taxing authorities where the Company&#146;s Netherland subsidiary will incur but not have to pay
income taxes in years when the subsidiary is operating at a loss. As a result, based on the net sales for the year ended December&nbsp;31, 2013, the Company recorded a deferred tax liability of $276 which is still outstanding at December&nbsp;31,
2015. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Minimal interest and penalties were incurred for the years ended December&nbsp;31, 2013, 2014 and 2015. The Company is subject to audit by various
taxing jurisdictions for the years ended December&nbsp;31, 2013, 2014 and 2015. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>12. Related-party transactions </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Sales of $3,176 and $556 were made to S&amp;N for the years ended December&nbsp;31, 2013 and 2014, respectively, and as of December&nbsp;31, 2014 the related trade
receivables totaled $498. There were no such sales for the year ended December&nbsp;31, 2015 and no receivable outstanding at December&nbsp;31, 2015. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-33 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company made cash tax distributions of $2,501, $2,399 and $1,016 to its members in an amount equal to
approximately 40% of the members&#146; estimated taxable income for the years ended December&nbsp;31, 2013, 2014 and 2015, respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In conjunction
with the business formation, the Company entered into a $160,000 senior secured note with S&amp;N which was repaid in October 2014 (discussed further in Note 5). During 2013, the Company acquired from S&amp;N additional net distributor assets in
foreign markets for $4,874. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On May&nbsp;4, 2012, the Company entered into a Transition Services Agreement (TSA) with S&amp;N indicating that certain
services would be provided to the Company relating to operations, logistics and distribution, global information services, finance and human resources. In consideration for these services, the Company incurred estimated arms-length expenses of
$4,298 and $216 for the years ended December&nbsp;31, 2013 and 2014, respectively. There were no such expenses for the year ended December&nbsp;31, 2015 and there were no related payables at December&nbsp;31, 2014 and 2015. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>13. Commitments and contingencies </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Leases
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company leases its office facilities as well as other property and equipment under operating lease agreements that expire in various years
through 2020 and records rent expense related to the leases on a straight-line basis over the term of the lease. Rent expense was $3,131, $3,182 and $3,186 for the years ended December&nbsp;31, 2013, 2014 and 2015, respectively. Certain facility
leases provide for reduced rent periods. As of December&nbsp;31, 2014 and 2015, respectively, these rent concessions totaling $982 and $902 have been reflected in accrued liabilities and other long-term liabilities in the consolidated balance
sheets. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Lease payments are subject to increases as specified in the lease agreements. Future minimum lease payments, by year and in the aggregate, under
capital leases and non-cancelable operating leases as of December&nbsp;31, 2015, were as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Operating<BR>leases</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Capital<BR>leases</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,354</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,599</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,456</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2020</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">447</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2021 and thereafter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total minimum payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less amounts representing interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Present value of capital lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,422</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less current maturities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Capital lease obligations, less current maturities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,222</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">No particular lease obligation ranks senior in right of payment to any other. The gross value of assets under capital leases at
December&nbsp;31, 2014 and 2015 was approximately, $4,143 and $4,679, respectively. These assets mainly consist of software and computer equipment and are included in property and equipment. The accumulated depreciation associated with these assets
at December&nbsp;31, 2013, 2014 and 2015, was approximately $913, $2,055 and $3,412, respectively. Depreciation of capital lease assets is included in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-34 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
depreciation and amortization expense as well as cost of sales in the consolidated statements of operations and comprehensive loss. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Other matters </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On December&nbsp;31, 2013 the Company entered into an amended and restated license
agreement with a supplier (the License Agreement) that included an option to purchase certain trademarks as well as product registrations and clinical data (the IP) of a product the Company currently sells. The License Agreement grants the Company
an exclusive license to commercialize the product outside of the U.S. without competition for five years. In addition, the Company was no longer required to make royalty payments to the supplier. In accordance with the License Agreement, the Company
made payments of $19,668 in 2014 and $3,726 in 2015, including implicit interest. The Company also paid $1,597 and exercised the option to purchase the IP. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In November 2015 upon acquiring BioStructures, the Company assumed an exclusive license and supply agreement for the use of bioactive glass in certain of its products. The Company assumed a world-wide, royalty
bearing license, as well as the right to sublicense, for the use of certain developed technologies related to spine repair. The Company is required to pay a royalty of 3% on all commercial sales revenue from the licensed products. Royalty expense is
included in cost of sales. The agreement will expire in 2019 upon the expiration of the last to expire patents held by the licensor. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November 2015
upon acquiring BioStructures, the Company assumed an exclusive license agreement for bioactive bone graft putty. The Company was required to pay a royalty of 3% on all commercial sales revenue from the license products with a minimum annual royalty
payment of $201 for the period from 2015 through 2023. In March 2016 this royalty agreement was amended. Subsequent to the amendment, the royalty rate has changed to 1.5% in 2016 and 2017 and 2.0% for 2018 through 2023. Royalty expense is included
in cost of sales. The agreement will expire in 2023 upon the expiration of the patent held by the licensor. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">From time to time, the Company causes LOCs
to be issued to provide credit support for guarantees, contractual commitments and insurance policies. The fair values of the letters of credit reflect the amount of the underlying obligation and are subject to fees payable to the issuers of the
letters of credit, competitively determined in the marketplace. As of December&nbsp;31, 2014 and 2015, the Company had a letter of credit for $122 and $110, respectively, outstanding with one of the Company&#146;s banking institutions. As of
December&nbsp;31, 2015, the Company had a letter of credit for $110 outstanding and $28 outstanding with the Company&#146;s primary banking institution. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of property.
These policies provide coverage for a variety of potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice. The Company&#146;s retentions and
deductibles associated with these insurance policies range in amounts up to $1,250. The Company is self-insured for health insurance for the majority of its employees located within the US, but maintains stop-loss insurance on a &#147;claims
made&#148; basis for expenses in excess of $100 per member per year. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As part of the formation of the Company, Bioventus is liable to S&amp;N for
one-half of all costs incurred in the defense and litigation of a certain pre-acquisition legal dispute for an amount not to exceed $5,000. Legal expenses for the years ended December&nbsp;31, 2014 and 2015 totaled $274 and $131, respectively, and
are included in SG&amp;A on the consolidated statements of operations and comprehensive loss. The legal expense liability at December&nbsp;31, 2014 was $160. There was no legal expense liability outstanding at December&nbsp;31, 2015. As of
December&nbsp;31, 2014, a settlement liability totaling $688 was established for this contingency as an adverse outcome of these legal proceedings was deemed to be probable or reasonably estimable and the liability remains outstanding at
December&nbsp;31, 2015. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-35 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the normal course of business, the Company periodically becomes involved in various claims and lawsuits that are
incidental to the business. Management of the Company, after consultation with legal counsel, does not believe there are any unrecorded matters that will have a material effect upon the Company&#146;s financial statements. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>14. Net loss per unit </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table presents the
computation of basic and diluted net loss per unit for the years ended December 31, 2013, 2014 and 2015 as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(22,367</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12,900</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(34,111</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated and unpaid preferred distributions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,610</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,997</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss attributable to common unit holders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(25,977</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(16,618</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(38,108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted average units used in computing net loss per unit, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per unit, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3.39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(7.78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The computation of diluted earnings per unit for the years ended December&nbsp;31, 2013, 2014 and 2015 excludes the effect of
potential common units that would be issued upon the conversion of preferred units, profits interest units and the EPR unit. The effect of these units would be antidilutive due to the Company being in a net loss position and these units only convert
upon completion of a Distribution Event. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>15. Operations by geographic location </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Net sales to external customers are attributed to the United States and to all foreign countries based on the location from which the sale originated. Net sales to external customers and long-lived asset
information by geographic area are summarized as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>United&nbsp;States</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>The&nbsp;Netherlands</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Other</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Year ended December&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">197,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">31,753</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,504</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">232,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,201</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">455</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,656</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Year ended December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">198,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">38,261</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,914</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">242,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,006</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">422</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Year ended December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">217,803</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">30,025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,822</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">253,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">232</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-36 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>16. Segments </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The AHT business is comprised of two types of non-surgical products including external bone growth stimulation product for long bone fracture healing and
osteoarthritis pain relief products. Following are the net sales for each product type for the years ended December&nbsp;31: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">External bone growth stimulators</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">121,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">131,528</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">130,367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Diagnostic ultrasound products</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,065</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,935</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Osteoarthritis pain treatment products</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">105,977</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">103,280</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">97,494</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">232,375</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">238,743</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">227,861</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Surgical business offers a portfolio of advanced bone graft substitutes that are designed to improve bone fusion rates following
spinal fusion and other orthopedic surgeries. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table presents net sales by reportable segment for the years ended December 31 as follows:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">U.S. AHT</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">197,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">194,568</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">192,014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">International AHT</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35,257</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">44,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35,847</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Surgical</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25,789</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">232,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">242,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">253,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table presents total assets by reportable segment as of December 31 as follows: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">U.S. AHT (as revised)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">366,820</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">310,246</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">289,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">International AHT (as revised)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">76,687</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">63,187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">56,039</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Surgical</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">47,336</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">132,355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">BMP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,231</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,652</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,320</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">452,738</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">430,421</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">487,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table presents segment adjusted EBITDA and reconciliation to loss before income taxes for the years ended December 31
as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Segment adjusted EBITDA</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">U.S. AHT</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32,557</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">33,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">40,161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">International AHT</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">578</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Surgical</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,631</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,591</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">BMP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(7,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,682</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(28,820</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(33,078</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,969</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(14,229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Equity compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(576</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,325</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in fair value of contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(19,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Inventory step-up</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,629</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(280</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Restructuring costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Transition and other non-recurring</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(9,232</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(20,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,353</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(31,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-37 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>17. Subsequent events </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">On February&nbsp;9, 2016, in order to enter the three-injection Osteoarthritis pain treatment US market, the Company purchased for ten years with automatic renewal periods the exclusive distribution rights of a
three-injection, hyaluronic acid product for pain relief associated with osteoarthritis of the knee for cash of $6,000. As part of this agreement, the seller will supply the Company products subject to annual minimum purchase requirements for ten
years. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>18. Unaudited pro forma net loss per share </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pro forma basic net loss per share is calculated by dividing net loss attributable to Class A common stockholders by the number of weighted average shares of Class
A common stock after giving effect to the corporate conversion. </FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share, basic and diluted:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Numerator</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(35,426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less: Net loss attributable to non-controlling interests</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(13,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss attributable to Class A common stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Denominator</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Shares of Class A common stock held by the Former LLC Owners</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,904,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted-average shares of Class A common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,904,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.45</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Due to the pro forma net loss of Bioventus LLC for the year ended December 31, 2015, the exchange of 9,571,764 shares of
Class&nbsp;B common stock was excluded from the calculation of diluted net loss per share and no adjustment to the net loss attributable to non-controlling interests was necessary since all shares were antidilutive. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>19. Revision of Consolidated Financial Statements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>May
2016 Revision </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with the preparation of the consolidated financial statements of April 2,2016 and for the three months then ended, the
Company determined that it had errors in certain presentation matters and footnote disclosures related to the consolidated financial statements for the years ended December 31, 2013, 3014 and 2015. The Company concluded that the correction of these
errors was not material individually, or in the aggregate, to the previously issued financial statements. Accordingly, the Company has revised the consolidated statements of operations and comprehensive loss and related footnotes for the years ended
December 31, 2013, 2014 and 2015. The adjustments in these periods are all corrections to presentation and footnotes to the consolidated financial statements. The adjustments made in connection with the revisions include: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Adding the lines for accumulated and unpaid preferred distributions and the total for net loss attributable to common unit holders used in the calculation of EPS
on the face of the consolidated statements of operations and comprehensive loss for the years ended December 31, 2013, 2014 and 2015. This financial information had previously only been disclosed in Note 14. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">An $8,760 reclassification of goodwill from U.S. AHT total assets to International AHT total assets as of December 31, 2013 and 2014 in Note 16.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">A $3,012 decrease in unrecognized compensation expense to be recognized in future periods as of December&nbsp;31, 2015 in Note 10. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-38 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following schedules reconcile the amounts, as previously reported in the Notes to the consolidated financial
statements, to the corresponding revised amounts: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year End December 31, 2013</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As<BR>previously<BR>reported</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Revision<BR>adjustment</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>As </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>revised</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">U.S. AHT total assets (Note 16)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">375,580</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,760</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">366,820</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">International AHT total assets (Note 16)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">67,927</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,760</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">76,687</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year End December 31, 2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As<BR>previously<BR>reported</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Revision<BR>adjustment</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>As </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>revised</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">U.S. AHT total assets (Note 16)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">319,006</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,760</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">310,246</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">International AHT total assets (Note 16)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">54,427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,760</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">63,187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year End December 31, 2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As<BR>previously<BR>reported</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Revision<BR>adjustment</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>As </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>revised</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Unrecognized compensation expense (Note 10)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,759</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,747</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>July 2016 Revision </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
Company determined that it had incorrectly included an inventory write-down of the diagnostic ultrasound product line as a restructuring cost rather than as cost of sales in the consolidated statements of operations and comprehensive loss for the
years ended December&nbsp;31, 2014 and 2015. The Company concluded that the correction of these errors was not material to the previously issued financial statements. Accordingly, the Company has revised the consolidated statements of operations and
comprehensive loss and related footnote (Note&nbsp;9) for the years ended December&nbsp;31, 2014 and 2015. The adjustments include a $1,183 and $202 reclassification from restructuring costs to cost of sales in the consolidated statements of
operations and comprehensive loss for the years ended December&nbsp;31, 2014 and 2015, respectively. In addition, the related activity in the restructuring reserve rollforward table in Note&nbsp;9 has been corrected. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following schedule reconciles the amounts, as previously reported in the consolidated financial statements, to the corresponding revised amounts: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year End December 31, 2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Consolidated Statement of Operations and Comprehensive Loss</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As<BR>previously<BR>reported</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Revision<BR>adjustment</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>As </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>revised</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cost of Sale</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">74,609</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">75,792</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Gross Profit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">168,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">167,101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Restructuring Costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-39 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year End December 31, 2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Consolidated Statement of Operations and Comprehensive Loss </B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As<BR>previously<BR>reported</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Revision<BR>adjustment</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As revised</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cost of Sale</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">74,342</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">74,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Gross Profit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">179,308</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">179,106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Restructuring Costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year End December 31, 2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Notes to Consolidated Financial Statements</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As<BR>previously<BR>reported</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Revision<BR>adjustment</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>As </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>revised</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Expenses incurred (Note 9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Inventory reserved for (Note 9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year End December 31, 2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Notes to Consolidated Financial Statements</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As<BR>previously<BR>reported</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Revision<BR>adjustment</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As<BR>revised</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Expenses incurred (Note 9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">673</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Payments made (Note 9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(673</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-40 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin22578_21"></A>Bioventus LLC </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Consolidated statements of operations and comprehensive loss </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Three months ended March&nbsp;28, 2015 and
April&nbsp;2, 2016 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Dollars in thousands, except per unit and per share data) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B>(unaudited) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2, 2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53,362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">65,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cost of sales (including depreciation and amortization of $5,741 and $6,300, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">16,807</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Gross profit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">36,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">46,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Selling, general and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">37,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">40,184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,966</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in fair value of contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Restructuring costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(16,299</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,038</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other (income) expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">496</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other expense, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,408</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(20,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">603</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other comprehensive (loss) income, net of tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in prior service cost and unrecognized loss for defined benefit plan adjustment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in foreign currency translation adjustments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(397</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other comprehensive (loss) income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,403</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,959</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,018</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,049</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT><BR></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated and unpaid preferred distributions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(953</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,042</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss attributable to common unit holders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(7,091</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per unit, basic and diluted (Note 11)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted average common units outstanding, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Unaudited pro forma net loss per share (Note 13):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted average common shares, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,904,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:54px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these
consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-41 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin22578_22"></A>Bioventus LLC </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Consolidated balance sheets </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Dollars in thousands) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(unaudited) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,<BR>2015</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>(Note 1)</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">343</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">343</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts receivable, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">54,511</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">51,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Inventory, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35,178</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">37,119</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Prepaid and other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,445</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,248</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">99,427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">99,985</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,984</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Goodwill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">58,694</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">58,694</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intangible assets, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">319,152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">318,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">371</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred tax asset</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">84</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">89</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">487,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">486,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Liabilities and Members&#146; Equity</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accrued liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">30,534</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Note payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23,546</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Capital lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">87,690</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">86,799</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Long-term debt, less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">149,607</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">145,535</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Long-term revolver</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Contingent consideration, less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32,635</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">31,136</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Capital lease obligations, less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,222</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,030</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other long-term liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,080</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,313</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred tax liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,780</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">295,014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">299,962</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Commitments and contingencies (Note 10)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Members&#146; equity (preferred unit liquidation preference of $181,645 and $182,687 at December&nbsp;31, 2015 and April&nbsp;2, 2016,
respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">284,828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">284,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated other comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(91,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(97,975</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total members&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">192,338</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">186,302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total liabilities and members&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">487,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">486,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:10px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-42 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin22578_23"></A>Bioventus LLC </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Consolidated statements of changes in members&#146; equity </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Three months ended April&nbsp;2, 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Dollars in thousands) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(unaudited)
</B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Members&#146;<BR>equity</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Accumulated&nbsp;other<BR>comprehensive</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:arial" SIZE="2"><B>loss</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Accumulated</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>deficit</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>members&#146;</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>equity</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">284,828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(91,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">192,338</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Profits interest compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Distribution to members</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Translation adjustment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at April&nbsp;2, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">284,837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(560</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(97,975</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">186,302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:60px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:60px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:60px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:60px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:150px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying
notes are an integral part of these consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-43 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin22578_24"></A>Bioventus LLC </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Consolidated statements of cash flows </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Three months ended March&nbsp;28, 2015 and April&nbsp;2, 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Dollars in thousands) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(unaudited)
</B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Operating activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,394</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in fair value of contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Provision for doubtful accounts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,128</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,133</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Profits interest compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Management incentive plan and liability-classified awards compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">342</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">279</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in fair value of Equity Participation Rights unit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">326</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(131</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(131</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Unrealized foreign currency transaction (gains) losses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">476</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Amortization of debt discount and capitalized loan fees, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">262</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Changes in operating assets and liabilities, net of acquisitions:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,217</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Inventories</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts payable and accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other current assets and liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,969</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(841</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash (used in) provided by operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,162</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Investing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Acquisition of distribution rights</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Purchase of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(306</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(306</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Payments on long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Payment of contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,790</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,914</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Borrowing on the revolving line of credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">20,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Payments on the revolving line of credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(9,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Principal payments toward capital lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(358</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(216</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,495</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Effect of exchange rate changes on cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net change in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(745</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,216</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents at the beginning of the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents at the end of the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Supplemental disclosure of noncash investing and financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Capital lease obligations for purchase of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accrued member distributions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">194</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-44 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin22578_25"></A>Bioventus LLC </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Dollars in thousands) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(unaudited) </B></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>1. Summary of significant accounting
policies </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Unaudited interim financial information </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The accompanying unaudited consolidated financial statements of Bioventus LLC and its subsidiaries (the Company) have been prepared in accordance with generally accepted accounting principles in the United States
of America (U.S. GAAP) for interim financial information. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Accordingly, they do not include all of the information and notes required by U.S.&nbsp;GAAP
for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company&#146;s financial condition and results of operations have been
included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the full year. As such, the information included in this report should be read in conjunction with the Company&#146;s
audited consolidated financial statements for the year ended December&nbsp;31, 2015. The balance sheet at December&nbsp;31, 2015 has been derived from the audited consolidated financial statements of the Company but does not include all the
disclosures required by U.S. GAAP. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Fair value </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company records certain assets and liabilities at fair value (discussed further in Note 6). Fair value is defined as the price that would be received to sell an
asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the
inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The three levels of inputs used to measure fair value are as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Level&nbsp;1&#151;Quoted prices in active markets for identical assets or liabilities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Level&nbsp;2&#151;Observable inputs other than quoted prices included within Level 1, such as quoted prices for similar assets and liabilities in active markets;
quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Level&nbsp;3&#151;Unobservable inputs that are supported by little or no market data. This includes certain pricing models, discounted cash flow methodologies
and similar techniques that use significant unobservable inputs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Concentration of risk </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company provides credit, in the normal course of business, to its customers. The Company does not require collateral or other securities to support customer
receivables. Credit losses are provided for through allowances and have historically been materially within management&#146;s estimates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-45 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain suppliers provide the Company with product that results in a significant percentage of total sales for the
three months ended as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,<BR>2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Supplier A</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">33%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Supplier B</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Two of the Company&#146;s products make up 85% and 77% of sales for the three months ended March&nbsp;28, 2015 and April&nbsp;2,
2016, respectively. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Recent accounting pronouncements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In May 2014, the U.S. Financial Accounting Standards Board (FASB) issued guidance that provides a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of
goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue
and cash flows arising from customer contracts. This guidance is effective for annual and interim periods beginning after December&nbsp;15, 2017. Early adoption is permitted for annual reporting periods beginning after December&nbsp;15, 2016. The
Company is currently evaluating the impact of this new standard on its consolidated financial statements, the date of adoption and the transition approach to implement the new guidance. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In February 2016, the FASB issued guidance that requires lessees to recognize the rights and obligations resulting from leases as assets and liabilities. It also modifies the classification criteria and the
accounting for sales-type and direct financing leases for the lessor. This guidance is effective for annual and interim periods beginning after December&nbsp;15, 2018. Early adoption is permitted and must be adopted using a modified retrospective
transition. The Company is currently evaluating the impact of this new standard on its consolidated financial statements and the date of adoption to implement the new guidance. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In March 2016, the FASB issued new accounting guidance which simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures,
statutory tax withholding requirements and the classification of excess tax benefits on the statement of cash flows. The new accounting guidance will be effective for annual reporting periods beginning after December&nbsp;15, 2016. Early adoption is
permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements and the date of adoption to implement the new guidance. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>2. Balance sheet information </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Accounts receivable, net </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Accounts receivable, net of allowances, consisted of the following as of: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">87,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">83,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Contractual allowances</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,114</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,204</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Allowances for doubtful accounts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,644</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">54,511</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">51,109</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-46 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Changes in the allowances for doubtful accounts were as follows for the three months ended: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance, beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,671</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Provision for losses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,128</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,133</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Write-offs, net of recoveries</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,239</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,091</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,560</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,644</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Inventory, net </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Inventory
consisted of the following as of: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Raw materials and supplies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Finished goods</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">27,861</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">29,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Gross</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">36,294</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">38,605</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Excess and obsolete reserves</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,116</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,486</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35,178</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">37,119</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:arial" SIZE="2">Changes in excess and obsolete reserves for inventory were as follows for the three months ended:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance, beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,598</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,116</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Provision for losses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(143</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Write-offs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">232</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">480</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,509</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,486</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Property and equipment, net </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment consisted of the following as of: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Computer equipment and software</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">16,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">16,268</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,593</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Furniture and fixtures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,183</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Machinery and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">914</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,040</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Assets not yet placed in service</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23,775</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">22,484</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less accumulated depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(14,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(13,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,602</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,984</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Depreciation expense was $1,311 and $1,485 for the three months ended March&nbsp;28, 2015 and April&nbsp;2, 2016, respectively.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-47 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Goodwill and intangible assets, net </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">There were no changes to goodwill during the three months ended April&nbsp;2, 2016. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Intangible assets consisted of
the following as of: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intellectual property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">259,238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">259,238</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Distribution rights</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">42,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">48,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Customer relationships</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">57,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">57,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">IPR&amp;D</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">27,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">27,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Developed technology</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other intangibles</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">474</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">474</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total carrying amount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">389,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">395,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less accumulated amortization:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intellectual property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(36,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(40,434</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Distribution rights</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,598</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12,488</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Customer relationships</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(19,887</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Developed technology</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other intangibles</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(129</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total accumulated amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(70,760</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(77,771</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intangible assets, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">319,152</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">318,141</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">On February&nbsp;9, 2016, in order to enter the three-injection osteoarthritis pain treatment in the U.S.
market, the Company purchased a license for the exclusive U.S. distribution rights of a three-injection, hyaluronic acid product for pain relief associated with osteoarthritis of the knee for cash of $6,000. This purchase was accounted for as an
asset acquisition as the product is fully developed and available for commercialization. The Company expects to begin selling this product in the second half of 2016. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Amortization expense related to intangible assets was $7,234 and $7,012 for the three months ended March&nbsp;28, 2015 and April&nbsp;2, 2016, respectively, of which $5,605 and $5,283 is included in ending
inventory at March&nbsp;28, 2015 and April&nbsp;2, 2016, respectively. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Accrued liabilities </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Accrued liabilities consisted of the following as of: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Bonus and commission</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,557</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Compensation and benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,712</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">BioStructure second close payment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,965</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Product costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income and other taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,656</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,319</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounting and legal fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,801</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Amounts due to managed care organizations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research, development and regulatory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">939</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,465</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34,368</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">30,534</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-48 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>3. Business combination </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>BioStructures acquisition </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On November&nbsp;24, 2015, in order to increase its presence in the surgical
orthobiologics market, the Company purchased BioStructures, LLC for cash of $48,397, a $23,528 note payable to the former BioStructures owners, contingent consideration of $4,542 and a second closing payment of $4,960. The Company accounted for the
BioStructures purchase using the acquisition method of accounting, whereby the total purchase price was preliminarily allocated to tangible and intangible assets acquired and liabilities assumed based on respective fair values. The following table
summarizes the preliminary fair values of the assets acquired and liabilities assumed at the acquisition date: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fair value of consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">81,427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Assets acquired:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,677</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,924</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">73,350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total assets acquired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">77,773</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Liabilities assumed:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accrued liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,386</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net identifiable assets acquired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">72,310</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Resulting goodwill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of April&nbsp;2, 2016, the purchase price allocation for the BioStructures acquisition remains preliminary and subject to
completion. There have been no adjustments to the current fair value estimates in the above table. Adjustments may occur as the process conducted for various valuations and assessments is finalized, including tax liabilities and other working
capital accounts. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The results of operations of the business have been included in the accompanying consolidated financial statements since the
November&nbsp;24, 2015 acquisition date. BioStructures revenue and earnings included in operations are as follows for the three months ended April&nbsp;2: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,031</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Revenue and earnings, including the BioStructures operations as if it was acquired at January&nbsp;1, 2015, are as follows for the
three months ended: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">56,514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(19,798</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-49 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>4. Debt </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Long-term debt consists of the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2014 Revolver due October 2019 (5.33% at April&nbsp;2, 2016)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">First Lien Term Loan due October 2019 (3.18% at April&nbsp;2, 2016)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">106,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">103,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Second Lien Term Loan due April 2020 (11.00% at April&nbsp;2, 2016)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">60,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">60,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Unamortized debt issuance cost</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,322</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Unamortized discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,508</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">149,607</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">145,535</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The 2014 Credit Agreement contains certain covenants, including, but not limited to (1)&nbsp;a minimum fixed charge ratio and a
maximum debt leverage ratio requirement as defined in the 2014 Credit Agreement, (2)&nbsp;restrictions on the declaration or payment of certain distributions on or in respect of the Company&#146;s equity interests, (3)&nbsp;restrictions on
acquisitions, investments and certain other payments, (4)&nbsp;limitations on the incurrence of new indebtedness, (5)&nbsp;limitations on transfers, sales and other dispositions and (6)&nbsp;limitations on making any material change in any of the
Company&#146;s business objectives that could reasonably be expected to have a material adverse effect on the repayment of the note. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Contractual
maturities of long-term debt at April&nbsp;2, 2016, were as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> 14,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">57,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2020 and thereafter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">60,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred finance costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Original issue discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">159,910</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(14,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">145,535</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>5. Derivatives </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November
2014, the Company entered into three interest rate swaps, effective November&nbsp;28, 2014 and expiring November&nbsp;30, 2017, in an effort to limit its exposure to changes in the variable interest rate on its First Lien Term Loan. The derivative
instruments have not been designated as hedges. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The fair values of the Company&#146;s interest rate swaps recorded in accrued liabilities in the
Company&#146;s consolidated balance sheets are $286 and $634, respectively, as of December&nbsp;31, 2015 and April&nbsp;2, 2016. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-50 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The effect of the Company&#146;s derivatives on the consolidated statements of operations and comprehensive loss is as
follows for the three months ended: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Statement&nbsp;of&nbsp;operations&nbsp;and<BR>comprehensive loss</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest rate swaps</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Interest&nbsp;expense</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">456</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign exchange forward contract</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Other&nbsp;(income)&nbsp;expense</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">610</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="10" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>6. Fair value measurements </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Recurring fair value measurements </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There were no
material assets subject to recurring fair value measurement carried on the accompanying consolidated balance sheet at December&nbsp;31, 2015 and April&nbsp;2, 2016. The following table provides information, by level, for liabilities that are
measured at fair value on a recurring basis at December&nbsp;31, 2015: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;2</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level 3</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">39,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">39,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest rate swaps</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Management incentive plan and liability-classified awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,924</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,924</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">EPR liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">46,504</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">46,218</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table provides information, by level, for liabilities that were measured at fair value on a recurring basis at
April&nbsp;2, 2016: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;2</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level 3</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">38,292</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">38,292</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest rate swaps</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">634</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">634</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Management incentive plan and liability-classified awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">EPR liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">45,517</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">634</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">44,883</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Below is a summary of the valuation techniques used in determining fair value: </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Contingent consideration</I>&#151;The Company values contingent consideration related to business combinations using a weighted probability calculation of
potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include revenue, net new business and operating
forecasts and the probability of achieving the specific targets. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Interest rate swaps</I>&#151;The Company values interest rate swaps by discounting
cash flows of the swap. Forward curves and volatility levels are used to estimate future cash flows that are not certain. These are determined using observable market inputs when available and on the basis of estimates when not available.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Management incentive plan (MIP) and liability-classified awards</I>&#151;The Company values these awards using the Monte Carlo option model to
allocate fair value. Key assumptions used to estimate the fair value include </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-51 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
expected stock price volatility, risk-free interest rate, dividend yield and the average time the award is expected to be outstanding. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>EPR liability</I>&#151;The Company values the EPR Unit using a weighted probability calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash
flows. Key assumptions used to estimate the fair value of the EPR Unit include the timing and amount available from a Distribution Event. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following
tables summarize the changes in the Level 3 contingent consideration liabilities measured on a recurring basis for the three months ended: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Contingent</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>consideration</B></FONT>
</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>MIP and liability-<BR>classified awards</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>EPR liability</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Beginning balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32,215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">39,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,924</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,037</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Initial estimate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">278</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in fair value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">326</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Payment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,790</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,914</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="21" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Ending balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32,396</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">38,292</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,363</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="24" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The contingent consideration change in fair value of $8,971 for the three months ended March&nbsp;28, 2015 was primarily driven by
sales exceeding estimates at the OsteoAMP acquisition date, higher than estimated inventory on hand and the interest on discounted cash flows. The contingent consideration change in fair value of $1,301 for the three months ended April&nbsp;2, 2016
was primarily driven by interest on discounted cash flows. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The revaluation for the EPR liability is recognized in interest expense on the consolidated
statements of operations and comprehensive loss. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Non-recurring fair value measurements </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The carrying value of the 2014 Credit Agreement and other indebtedness was not materially different from fair value at December&nbsp;31, 2015 and April&nbsp;2,
2016. The fair value of these obligations was determined based on discounted cash flows using estimated incremental borrowing rates for obligations with similar characteristics. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As of December&nbsp;31, 2015 and April&nbsp;2, 2016, assets carried on the consolidated balance sheet and not remeasured to fair value on a recurring basis are comprised of long-lived assets, finite and
indefinite-lived intangible assets and goodwill. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>7. Restructuring costs </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In November&nbsp;2014, the Company adopted a plan to restructure and no longer sell a diagnostic ultrasound product in order to improve margins, principally through headcount reduction, which was communicated to
the affected employees in January 2015. Costs included in the restructuring plan are employee severance and other administrative expenses. For the three months ended March&nbsp;28, 2015, the Company recorded total pre-tax charges of $504 related to
severance and $43 in other administrative expenses. The plan was completed in 2015 with total costs incurred of $711. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In January&nbsp;2015, the Company
adopted a plan to restructure and relocate certain finance functions from Memphis, TN to headquarters in Durham, NC. For the three months ended March&nbsp;28, 2015, the Company recorded total pre-tax charges of $413 related to severance and
temporary labor, $81 related to consulting and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-52 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
compensation for departing employees that remained through the transition and $35 in other administrative expenses. The plan was completed in 2015 with charges totaling $960. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November 2015, the Company adopted a restructuring plan to improve operating performance in the international business, principally through headcount reduction.
For the three months ended April&nbsp;2, 2016, the Company recorded total pre-tax charges of $172 related to severance. The plan is expected to be completed in 2016 with charges totaling $944. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">These charges are included in restructuring costs in the consolidated statement of operations and comprehensive loss and all relate to the Active Healing Therapies segment. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company made payments and provision adjustments for all plans for the three months ended as presented below: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Employee<BR>severance&nbsp;and<BR>temporary<BR>labor costs</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Other<BR>charges</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Expenses incurred</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">159</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Payments made</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(477</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at March&nbsp;28, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">440</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">526</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">772</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">772</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Expenses incurred</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Payments made</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(267</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(267</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at April&nbsp;2, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">677</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">677</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>8. Benefit plans </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Equity-based compensation plans </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company operates
two equity-based compensation plans, the MIP and the Phantom Profits Interest Plan (PIP). The awards granted under both plans represent a non-managing, non-voting interest in the Company designed for grantees to share in the future appreciation of
the value of the Company. The total amount of awards available for grant through May 2015 was limited to 1,111,111. In June 2015 the PIP was amended and restated, increasing the awards available for distribution by 821,722, bringing the total awards
available to 1,932,833. At April&nbsp;2, 2016, 508,070 units were available for award. Profits interest compensation of $529 and $288 was recognized for the three months ended March&nbsp;28, 2015, and April&nbsp;2, 2016, respectively. The expense is
included in SG&amp;A and R&amp;D on the consolidated statement of operations and comprehensive loss based upon the classification of the employee. As of April&nbsp;2, 2016, there was approximately $3,255 of unrecognized compensation expense to be
recognized over a weighted-average period of 0.25 years for the MIP and 1.25&nbsp;years for the PIP. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-53 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The assumptions utilized to determine the fair value of the awards are indicated in the following&nbsp;table for the
three months ended: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Expected dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Expected volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Risk-free interest rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Time to exit event (in&nbsp;years)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A summary of the award activity is as follows (number of awards in thousands): </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>MIP and 2012 plan</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number&nbsp;of<BR>awards</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Weighted-<BR>average&nbsp;grant-<BR>date fair value</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Outstanding at December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Outstanding at March&nbsp;28, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A summary of the award activity of the Plans is as follows (number of awards in thousands): </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>MIP and 2012 plan</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015 plan</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number&nbsp;of<BR>awards</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Weighted-<BR>average&nbsp;grant-<BR>date fair value</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number&nbsp;of<BR>awards</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Weighted-<BR>average&nbsp;grant-<BR>date fair value</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Outstanding at December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,069</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">379</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6.69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Outstanding at April&nbsp;2, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,043</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">381</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Defined contribution plans </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">For the three months ended March&nbsp;28, 2015 and April&nbsp;2, 2016 Company contributions totaled $1,136 and $1,328, respectively, for all global plans. The expense is included in cost of sales, SG&amp;A and
R&amp;D on the consolidated statement of operations and comprehensive loss based upon the classification of the employee. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>9. Income taxes </B><B>
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The components of income (loss) from operations before income taxes are as follows for the three months: ended: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Taxable subsidiaries:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Domestic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">986</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">96</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">784</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,082</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other domestic subsidiaries</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,528</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pretax loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(20,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-54 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Federal income taxes:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">364</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(119</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(119</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign income taxes:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">State income taxes:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">276</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Provision for income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">603</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The differences between the effective income tax rate and the federal statutory income tax rates are as follows: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">U.S. statutory income tax rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">34.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">LLC flow-through structure</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(35.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(40.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">State and local income taxes, net of federal benefit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign rate differential</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Effective income tax rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company&#146;s effective tax rate differs from statutory rates primarily due to Bioventus LLC&#146;s pass-through structure for
U.S. income tax purposes, while being treated as taxable in certain states and various foreign jurisdictions as well as for certain subsidiaries. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>10. Commitments and contingencies </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Leases
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company leases its office facilities as well as other property and equipment under operating lease agreements that expire in various years
through 2020 and records rent expense related to the leases on a straight-line basis over the term of the lease. Rent expense was $787 and $891 for the three months ended March&nbsp;28, 2015 and April&nbsp;2, 2016, respectively. Certain facility
leases provide for reduced rent periods. As of December&nbsp;31, 2015 and April&nbsp;2, 2016, respectively, these rent concessions totaling $902 and $868 have been reflected in accrued liabilities and other long-term liabilities in the consolidated
balance sheets. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-55 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Lease payments are subject to increases as specified in the lease agreements. Future minimum lease payments, by year
and in the aggregate, under capital leases and non-cancelable operating leases as of April&nbsp;2, 2016, were as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Operating<BR>leases</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Capital<BR>leases</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,969</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,453</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,503</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2020</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2021 and thereafter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total minimum payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less amounts representing interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Present value of capital lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less current maturities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Capital lease obligations, less current maturities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,030</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">No particular lease obligation ranks senior in right of payment to any other. The gross value of assets under capital leases at
December&nbsp;31, 2015 and April&nbsp;2, 2016 was approximately $4,679 and $4,486, respectively. These assets mainly consist of software and computer equipment and are included in property and equipment in the accompanying consolidated balance
sheet. The accumulated depreciation associated with these assets at December&nbsp;31, 2015 and April&nbsp;2, 2016, was approximately $3,412 and $1,540, respectively. Depreciation of capital lease assets is included in depreciation and amortization
expense as well as cost of sales in the consolidated statements of operations and comprehensive loss. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Other matters </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On February&nbsp;9, 2016, in order to enter the three-injection osteoarthritis pain treatment in the U.S. market, the Company purchased the exclusive distribution
rights of a three-injection, hyaluronic acid product for pain relief associated with osteoarthritis of the knee for cash of $6,000. As part of this agreement, the seller will supply the Company products subject to annual minimum purchase
requirements for ten years. After the initial ten years, the agreement will automatically renew for an additional five years unless terminated by the Company or the seller in accordance with the agreement. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November 2015 upon acquiring BioStructures, the Company assumed an exclusive license and supply agreement for the use of bioactive glass in certain of its
products. The Company assumed a world-wide, royalty bearing license, as well as the right to sublicense, for the use of certain developed technologies related to spine repair. The Company is required to pay a royalty of 3% on all commercial sales
revenue from the licensed products. Royalty expense is included in cost of sales. The agreement will expire in 2019 upon the expiration of the last to expire patents held by the licensor. In November 2015 upon acquiring BioStructures, the Company
assumed an exclusive license agreement for bioactive bone graft putty. The Company was required to pay a royalty of 3% on all commercial sales revenue from the license products, with a minimum annual royalty payment of $201 for the period from 2015
through 2023. In March 2016, this royalty agreement was amended. Subsequent to the amendment, the royalty rate has changed to 1.5% in 2016 and 2017 and 2.0% for 2018 through 2023. Royalty expense is included in cost of sales. The agreement will
expire in 2023 upon the expiration of the patent held by the licensor. Royalties related to these agreements totaled $123 for the three months ended April&nbsp;2, 2016. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-56 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">From time to time, the Company causes LOCs to be issued to provide credit support for guarantees, contractual
commitments and insurance policies. The fair values of the letters of credit reflect the amount of the underlying obligation and are subject to fees payable to the issuers of the letters of credit, competitively determined in the marketplace. As of
December&nbsp;31, 2015 and April&nbsp;2, 2016, the Company had a letters of credit for $220 and $230 outstanding with two of the Company&#146;s banking institutions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Company currently maintains insurance for risks associated with the operation of its business, provision of professional services and ownership of property. These policies provide coverage for a variety of
potential losses, including loss or damage to property, bodily injury, general commercial liability, professional errors and omissions and medical malpractice. The Company&#146;s retentions and deductibles associated with these insurance policies
range in amounts up to $1,250. The Company is self-insured for health insurance for the majority of its employees located within the US, but maintains stop-loss insurance on a &#147;claims made&#148; basis for expenses in excess of $100 per member
per year. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As part of the formation of the Company, Bioventus is liable to S&amp;N for one-half of all costs incurred in the defense and litigation of a
certain pre-acquisition legal dispute for an amount not to exceed $5,000. There were no legal expenses for the three months ended March&nbsp;28, 2015 or April&nbsp;2, 2016 and there was no legal expense liability outstanding at December&nbsp;31,
2015 or April&nbsp;2, 2016. A settlement liability totaling $688 was established for this contingency as an adverse outcome of these legal proceedings was deemed to be probable and reasonably estimable. The liability remains outstanding at
December&nbsp;31, 2015 and April&nbsp;2, 2016 and was paid subsequent to the end of the three month period. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the normal course of business, the
Company periodically becomes involved in various claims and lawsuits that are incidental to the business. Management of the Company, after consultation with legal counsel, does not believe there are any unrecorded matters that will have a material
effect upon the Company&#146;s financial statements. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>11. Net loss per unit </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following table presents the computation of basic and diluted net loss per unit for the three months ended as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated and unpaid preferred distributions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(953</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,042</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss attributable to common unit holders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(7,091</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted average units used in computing net loss per unit, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per unit, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The computation of diluted earnings per unit excludes the effect of potential common units that would be issued upon the conversion
of preferred units, profits interest units and the EPR unit. The effect of these units would be antidilutive due to the Company being in a net loss position and these units only convert upon completion of a Distribution Event. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>12. Segments </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company&#146;s four reportable segments
include: Active Healing Therapies (AHT)&#150;U.S. business (U.S. AHT), AHT&#150;International business (International AHT), Surgical business and bone morphogenetic protein research and development (BMP) business. AHT products are primarily sold to
orthopedists, musculoskeletal and sports medicine physicians, and podiatrists, as well as to their patients. Surgical products are primarily sold to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-57 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
neurosurgeons and orthopedic spine surgeons. BMP is a research and development operation for future surgical bone growth products. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following table presents net sales by reportable segment for the three months ended as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">U.S. AHT</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">40,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">45,496</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">International AHT</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,794</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Surgical</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,926</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53,362</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">65,402</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table presents total assets by reportable segment as follows: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">U.S. AHT</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">289,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">290,440</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">International AHT</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">56,039</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">54,245</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Surgical</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">132,355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">131,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">BMP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,320</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,660</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">487,352</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">486,264</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table presents segment adjusted EBITDA and reconciliation to loss before income taxes for the three months ended as
follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March&nbsp;28,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>April&nbsp;2,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Segment adjusted EBITDA</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">U.S. AHT</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,006</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">International AHT</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,660</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Surgical</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,686</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,546</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">BMP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,491</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,535</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,394</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(9,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Equity compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change in fair value of contingent consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Inventory step-up</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(164</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Restructuring costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Transition and other non-recurring</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(20,649</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-58 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>13. Unaudited pro forma net loss per share </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Pro forma basic net loss per share is calculated by dividing net loss attributable to Class&nbsp;A common stockholders by the number of weighted average shares of Class&nbsp;A common stock after giving effect to
the corporate conversion. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share, basic and diluted:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Numerator</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less: Net loss attributable to non-controlling interests</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss attributable to Class&nbsp;A common stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,683</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Denominator</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Shares of Class&nbsp;A common stock held by the Former LLC Owners</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,904,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted-average shares of Class&nbsp;A common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,904,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(0.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Due to the pro forma net loss of Bioventus LLC for the three months ended April&nbsp;2, 2016, the exchange of shares of Class&nbsp;B
common stock was excluded from the calculation of diluted net loss per share and no adjustment to the net loss attributable to non-controlling interests was necessary since all shares were antidilutive. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-59 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B><A NAME="fin22578_10"></A>Independent auditor&#146;s report </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To:&nbsp;&nbsp;&nbsp;&nbsp; Management and the Board of Managers of BioStructures, LLC </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have audited the accompanying financial statements of BioStructures, LLC, which comprise the statement of financial position as of December&nbsp;31, 2014, and the related statements of income and comprehensive
income, changes in members&#146; equity and of cash flows for the year then ended. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Management&#146;s responsibility for the financial statements
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles
generally accepted in the United States of America; this includes the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement,
whether due to fraud or error. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Auditor&#146;s responsibility </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on our judgment, including the assessment of the risks
of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the Company&#146;s preparation and fair presentation of the financial statements in order
to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control. Accordingly, we express no such opinion. An audit also includes
evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence
we have obtained is sufficient and appropriate to provide a basis for our audit opinion. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Opinion </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of BioStructures, LLC as of
December&nbsp;31, 2014, and the results of its operations and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">/s/ PricewaterhouseCoopers LLP </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Raleigh, North Carolina </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">February 1, 2016 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-60 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>BioStructures, LLC <A NAME="fin22578_11"></A>Statement of financial position December&nbsp;31, 2014 (Amounts in
U.S. dollars) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">309,454</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Trade accounts receivable, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,600,391</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">999,884</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,909,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">130,488</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intangible assets, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">355,941</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total Assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,396,158</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Liabilities and Members&#146; Equity</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">740,379</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,674</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">400,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,144,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accrued taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">467,186</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total Liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,611,239</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Members&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">853,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Retained earnings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">931,331</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total Members&#146; Equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,784,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total Liabilities and Members&#146; Equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,396,158</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:120px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-61 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>BioStructures, LLC <A NAME="fin22578_12"></A>Statement of income and comprehensive income Year ended
December&nbsp;31, 2014 (Amounts in U.S. dollars) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net sales</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12,178,713</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cost of sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,256,853</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Gross profit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,921,860</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Selling, general and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,066,628</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">379,982</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28,753</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,446,497</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,397</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(16,335</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net income and comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,448,435</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:120px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-62 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>BioStructures, LLC <A NAME="fin22578_13"></A>Statement of changes in members&#146; equity Year ended
December&nbsp;31, 2014 (Amounts in U.S. dollars) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Members&#146;<BR>equity</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Retained <BR>earnings</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total&nbsp;members&#146;<BR>equity</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at December 31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">853,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">839,397</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,692,985</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Distributions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,356,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,356,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,448,435</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,448,435</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at December 31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">853,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">931,331</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,784,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:120px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-63 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>BioStructures, LLC <A NAME="fin22578_14"></A>Statement of cash flows Year ended December&nbsp;31, 2014 (Amounts in
U.S. dollars) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Cash flows from operating activities</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,448,435</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Adjustments to reconcile net income to net cash provided by operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">93,154</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Provision for bad debts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">191,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Changes in operating assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Trade accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(470,558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(502,341</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts payable and accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">673,025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash provided by operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,432,859</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash flows from investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Purchase of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(62,037</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">License fee and milestone payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(212,037</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash flows from financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Repayment of loan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,391</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Member distributions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,356,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,367,892</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net decrease in cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(147,070</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents at the beginning of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">456,524</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents at the end of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">309,454</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Supplemental disclosure of cash flow information</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash paid for interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,397</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:170px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these
financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-64 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>BioStructures, LLC </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B><A NAME="fin22578_15"></A>Notes to financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(Amounts in U.S. dollars) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>1. Organization and Summary of Significant Accounting Policies </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>The Company </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">BioStructures, LLC, or BioStructures or the Company, is a limited liability company formed under
the laws of the state of California on August&nbsp;22, 2007 and operates as a partnership. The Company was owned by two members until the acquisition of the Company by Bioventus, LLC in November 2015 (see Note 8). </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">BioStructures is a medical device company focused on developing innovation propriety platforms in bio-resorbable bone graft products for a broad range of spinal
surgical applications. The Company&#146;s products are developed to benefit the surgeon and their patients during each phase of the bone healing process. BioStructures&#146; bio-resorbable implants are created for best-in-class performance. The
synthetic and allograft implants are designed for proportionate resorption to facilitate balanced bone regeneration with optimized clinical efficacy. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Use of estimates </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The preparation of the financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses during the period, as well as disclosures of contingent assets and liabilities
at the date of the financial statements. Actual results may differ from these estimates under different assumptions or conditions. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Cash
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company&#146;s cash consists of cash held by a single financial institution in the U.S. in excess of the federally insured limits. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Fair value </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company records certain assets and
liabilities at fair value (discussed further in Note 5). Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly
transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs
and minimize the use of unobservable inputs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The three levels of inputs used to measure fair value are as follows: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Level&nbsp;1&#151;Quoted prices in active markets for identical assets or liabilities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Level&nbsp;2&#151;Observable inputs other than quoted prices included within Level 1, such as quoted prices for similar assets and liabilities in active markets;
quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Level&nbsp;3&#151;Unobservable inputs that are supported by little or no market data. This includes certain pricing models, discounted cash flow methodologies
and similar techniques that use significant unobservable inputs. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-65 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Accounts receivable and allowances </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Accounts receivables are amounts due from customers and are recorded at net realizable value for product sold in the ordinary course of business. The Company maintains an allowance for doubtful accounts.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The allowance for doubtful accounts is based on the assessment of the collectability of specific customer accounts and the aging of the accounts
receivable. When evaluating the adequacy of this allowance, the Company analyzes accounts receivable, historical bad debts, customer concentrations, customer solvency, current economic and geographic trends, and changes in customer payment terms and
practices. Changes to the allowance for doubtful accounts are recorded in selling, general and administrative expense in the statement of income and comprehensive income. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Inventory </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Inventories are valued at the lower of cost or estimated net realizable value, after provision for
excess or obsolete items. All products the Company sells are procured through third-party contract manufacturing arrangements and cost is determined on an average cost basis, which approximates the first-in, first-out, or FIFO, method. The valuation
of finished products and consignment inventory includes the cost of materials, labor and packaging costs. Consignment inventory represents finished products located at third parties, such as distributors and hospitals. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Long-lived assets </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment are stated at cost
and are depreciated using the straight-line method over the shorter of the asset&#146;s estimated useful life, or the lease term if related to leased property, as follows (in years): </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Automobile</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Machinery and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3-7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Furniture and fixtures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Finite-lived identifiable intangible assets are recorded at cost and are amortized using the straight-line method over their
estimated remaining useful lives ranging between 8 and 10 years. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The carrying values of property, equipment, intangible and other long-lived assets are
reviewed for recoverability if the facts and circumstances suggest that a potential impairment may have occurred. If this review indicates that carrying values may not be recoverable, as determined based on undiscounted cash flow projections, the
Company will perform an assessment to determine if an impairment charge is required to reduce carrying values to estimated fair value. There were no events, facts or circumstances for the year ended December&nbsp;31, 2014 that resulted in any
impairment charges to the Company&#146;s property, equipment, intangible or other long-lived assets. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Revenue recognition </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Sale of products </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company primarily sells its
products to hospitals and recognizes revenue upon notification from the hospital that the product was used in surgery. Accordingly, revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or
determinable, and collection is reasonably assured. Until such time as the product is used in surgery, ownership of the product remains with the Company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-66 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company uses a distribution network to deliver its product to hospitals. The majority of the distributors hold the
Company&#146;s product on consignment until delivered to the hospitals to be used in surgery. In these circumstances, ownership of the product remains with the Company. The Company does sell products directly to distributors who take ownership of
the product at the point of shipment. In these circumstances, the Company recognizes revenue upon delivery to such distributors as there is no right of return. Accordingly, revenue is recognized when persuasive evidence of an arrangement exists,
delivery has occurred, the fee is fixed or determinable, and collection is reasonably assured. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Shipping and handling </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company classifies amounts billed for shipping and handling as a component of net sales. The related shipping and handling fees and costs as well as other
distribution costs are included in cost of sales. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Advertising costs </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Advertising costs include costs incurred to promote the Company&#146;s business and are expensed as incurred. Advertising costs were $124,346 for the year ended December&nbsp;31, 2014. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Research and development </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Research and development, or
R&amp;D, expenses consists primarily of contract research organization services. Internal R&amp;D costs are expensed as incurred. R&amp;D costs incurred by third parties are expensed as the contracted work is performed. Initial and milestone
payments made to third parties in connection with technology license agreements are also expensed as incurred as research and development costs, up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval
will be capitalized and amortized over the estimated remaining useful life of the related product. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Income taxes </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company is treated as a partnership for US tax purposes. Accordingly, the profits and losses are passed through to the members and included in their income tax
returns. The Company makes periodic distributions to its members. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Recently issued accounting standards </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In May 2014, the Financial Accounting Standards Board, or FASB, issued guidance that provides a comprehensive new revenue recognition model that requires a company
to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. The guidance also requires additional disclosure about the
nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. In August 2015, the FASB approved a one-year deferral of the effective date making this guidance effective for annual and interim periods beginning
after December&nbsp;15, 2018 for private companies. Early application is permitted. This guidance permits the use of either the retrospective or cumulative effect transition method. The Company is currently evaluating the impact this guidance will
have on the Company&#146;s financial statements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In July 2015, the FASB issued guidance for simplifying the calculation for subsequent measurement of
inventory measured using the first-in-first-out or average cost methods. The guidance is effective for annual periods and interim periods within those annual periods beginning after December&nbsp;15, 2016, and is effective for the Company for the
year ending December&nbsp;31, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company&#146;s financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-67 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>2. Balance sheet information </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Accounts receivable </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Accounts receivable consisted of the following at December&nbsp;31, 2014: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,791,535</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(191,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,600,391</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table shows the activity in the allowance for doubtful accounts for the year ended December&nbsp;31, 2014: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Beginning balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> &#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Charged to operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">191,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Ending balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">191,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The allowance as of December&nbsp;31, 2014 relates to a specific customer that filed for bankruptcy in June 2015. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Inventory </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Inventory consisted of the following at
December&nbsp;31, 2014: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Raw materials and supplies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">176,255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Work-in-process</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">52,968</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Finished goods</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">770,661</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">999,884</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Finished goods includes consignment inventory representing immediately saleable finished products that are in the possession of the
Company&#146;s distributors or located at third-party customers, such as hospitals. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Property and equipment, net </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment consisted of the following at December&nbsp;31, 2014: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Automobile</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> 39,135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Furniture and fixtures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">29,753</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Machinery and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">134,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">203,533</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less accumulated depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(73,045</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">130,488</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Depreciation expense was $28,753 for the year ended December&nbsp;31, 2014. The Company&#146;s assets are pledged as security under
a bank loan agreement. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Intangible assets, net and royalty agreements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In July 2009, the Company entered into an exclusive license and supply agreement for the use of bioactive glass in certain of its products. The Company paid a non-refundable technology access fee of $230,000 in
exchange for the world-wide, royalty bearing license for the use of certain developed technologies related to spine repair. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-68 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
The Company is required to pay a royalty of 3% on all commercial sales revenue from the licensed products. In October 2010, the agreement was amended whereby the Company paid $234,000 as
additional consideration primarily to obtain the right to sublicense. During the year ended December&nbsp;31, 2014, the Company incurred royalty expense of $153,532. Royalty expense is included in cost of goods sold. The agreement shall expire in
2019 upon the expiration of the last to expire patents held by the licensor. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November 2011, the Company entered into a development and license
agreement with a third party whereby both parties collaborated in the development, pre-clinical and clinical evaluation and commercialization of a product for use in certain orthopedic applications. Pursuant to this agreement, upon receipt of a
510(k) approval for a developed product, both parties agreed to enter into a license agreement for such product. Upon receiving a 510(k) approval in January 2014 for bioactive bone graft putty, the Company paid a $50,000 milestone payment and in
February 2014 the Company entered into an exclusive license agreement with the third party for the developed product whereby the Company paid $100,000 as a conversion fee. The Company is required to pay a royalty of 3% on all commercial sales
revenue from the license products with a minimum royalty payment of $60,000 in 2013, $102,000 in 2014 and $201,000 annually for the period from 2015 through 2023. During the year ended December&nbsp;31, 2014, the Company incurred the minimum royalty
payment of $102,000. Royalty expense is included in cost of goods sold. The agreement shall expire in 2023 upon the expiration of the last to expire patents held by the licensor. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Intangible assets are recorded at cost and consisted of the following at December&nbsp;31, 2014: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Licenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> 614,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less accumulated amortization:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(258,059</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intangible assets, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">355,941</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Amortization expense related to intangible assets was $64,401 for the year ended December&nbsp;31, 2014 and is included in cost of
goods sold. Estimated amortization expense for the years ended December&nbsp;31, 2015 through 2019 is expected to be $66,549 for each of the five annual periods and $23,196 thereafter. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>3. Loan </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company was a party to a loan agreement with a commercial bank with a total borrowing limit of
$2,000,000, with interest payable monthly at LIBOR plus 2.75%. The maturity date of the loan was initially set at August&nbsp;1, 2013 and was extended in one year increments until paid in full. Outstanding borrowings as of December&nbsp;31, 2104
were $400,000. The loan was secured by the assets of the Company and guaranteed by the members. In November 2015, the loan was paid in full and all security interests and guarantees were terminated in connection with sale of the Company (see Note
8). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During 2014, the Company paid in full an outstanding balance of an automobile loan of $11,391. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>4. Members&#146; equity </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Members&#146; equity consisted of
the following at December&nbsp;31, 2014: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Members&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> 853,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Retained earnings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">931,331</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,784,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-69 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company is owned by two members and all profits and distributions are shared equally. During the year ended
December&nbsp;31, 2014, the Company made aggregate cash distributions of $3,356,501. On November&nbsp;24, 2015, the Company was acquired (see Note 8). </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>5. Fair value measurements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Recurring fair value
measurements </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There were no material assets or liabilities carried on the accompanying balance sheet at December&nbsp;31, 2014 that were measured
at fair value on a recurring basis. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Non-recurring fair value measurements </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Certain assets are carried on the balance sheets at cost and are not remeasured to fair value on a recurring basis. These assets include finite-lived tangible and intangible assets which are tested for impairment
when a triggering event occurs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The carrying value of the bank loan was not materially different from fair value at December&nbsp;31, 2014 using level 2
inputs. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>6. Accrued taxes </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company has
evaluated sales tax and medical device excise tax exposures in relevant jurisdictions and determined that an accrual of&nbsp;$317,186 at December&nbsp;31, 2014 should be recorded for the estimated amount of unbilled and unremitted sales and medical
device&nbsp;excise&nbsp;taxes. The Company&#146;s estimates of potential liabilities are based on its engagement of third-party experts to calculate the applicable taxes based on the Company&#146;s sales data.&nbsp;For the year ended
December&nbsp;31, 2014, the Company recorded $194,000 to selling, general and&nbsp;administrative&nbsp;expenses related to the Company&#146;s&nbsp;estimated&nbsp;unbilled and unremitted taxes related to that year. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Further, the Company has recorded an accrual of $150,000 at December&nbsp;31, 2014 for related interest and penalties associated with the estimated unpaid
taxes.&nbsp;For the year ended December&nbsp;31, 2014, the Company recorded $88,000 to selling, general and&nbsp;administrative&nbsp;expenses related to such exposures. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>7. Commitments and contingencies </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Leases </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In April 2011, the Company entered into an operating lease agreement for its office facilities that initially expired in October 2015. Rent expense under this lease agreement was $72,804 for the year ended
December&nbsp;31, 2014. The Company is also required to pay its pro-rata share of taxes and common area maintenance. On March&nbsp;10, 2015, the Company amended the lease agreement extending the term to October&nbsp;21, 2019. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Lease payments are subject to increases as specified in the lease agreements. Future minimum lease payments, by year and in the aggregate, under non-cancelable
operating leases as of December&nbsp;31, 2014, are as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> 71,722</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">78,331</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">81,457</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">84,709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">72,936</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total minimum payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">389,155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-70 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>8. Subsequent events </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Company has considered the effects of subsequent events through February 1, 2016, the date the Company&#146;s financial statements were available to be issued. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On November&nbsp;24, 2015, Bioventus LLC, a privately held medical products company, acquired 100% of the membership interest of the Company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-71 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>BioStructures, LLC </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B><A NAME="fin22578_16"></A>Statements of financial position </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Amounts in U.S. dollars) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Unaudited) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>September&nbsp;30,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,<BR>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">796,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">309,454</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Trade accounts receivable, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,597,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,600,391</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,245,542</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">999,884</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,639,712</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,909,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">134,706</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">130,488</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intangible assets, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">306,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">355,941</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total Assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,080,447</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,396,158</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Liabilities and Members&#146; Equity</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">676,784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">740,379</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">249,923</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,674</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">350,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">400,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accrued taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">536,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,813,607</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,144,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accrued Taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">467,186</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,813,607</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,611,239</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Members&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">853,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">853,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Retained earnings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,413,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">931,331</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total Members&#146; Equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,266,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,784,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total Liabilities and Members&#146; Equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,080,447</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,396,158</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:120px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these
financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-72 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>BioStructures, LLC </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B><A NAME="fin22578_17"></A>Statements of income and comprehensive income </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Amounts in U.S. dollars)
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Unaudited) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Nine&nbsp;months&nbsp;ended<BR>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,890,138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,369,328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cost of sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,815,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,821,234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Gross profit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,074,298</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,548,094</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Selling, general and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,926,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,010,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">157,390</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">345,550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">30,180</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">24,224</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,960,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,168,083</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,899</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other expense (income)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">16,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(15,943</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net income and comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,931,921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,172,911</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:120px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-73 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Biostructures, LLC </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B><A NAME="fin22578_18"></A>Statement of changes in members&#146; equity </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Nine months ended September&nbsp;30,
2015 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Amounts in U.S. dollars) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Unaudited) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Members&#146;<BR>equity</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Retained <BR>earnings</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total&nbsp;members&#146;<BR>equity</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at December 31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">853,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">931,331</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,784,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Distributions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,450,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,450,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,931,921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,931,921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at September 30, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">853,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,413,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,266,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:120px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-74 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>BioStructures, LLC </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B><A NAME="fin22578_19"></A>Statements of cash flows </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Amounts in U.S. dollars) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Unaudited) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Nine months ended<BR>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2014</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Cash flows from operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,931,921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,172,911</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Adjustments to reconcile net income to net cash provided by operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">80,092</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">71,988</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Provision for bad debts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">59,435</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Changes in operating assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Trade accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(56,773</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Inventory</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(245,658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(428,759</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts payable and accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">252,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">448,521</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash provided by operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,021,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,271,518</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash flows from investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Purchase of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(34,398</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(56,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">License fee and milestone payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(34,398</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(206,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash flows from financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Borrowings (repayment) of debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">143,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Member distributions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,450,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,856,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net increase in cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">486,987</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">208,689</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents at the beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">309,454</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">456,524</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents at the end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">796,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">665,213</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Supplemental disclosure of cash flow information</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash paid for interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,899</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:25px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these
financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-75 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>BioStructures, LLC </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B><A NAME="fin22578_20"></A>Notes to financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Amounts in U.S. dollars) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>(Unaudited) </B></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>1. Organization and summary of significant
accounting policies </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Basis of presentation </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or
GAAP. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results of operations for the periods presented have been included. Operating results for the nine
months ended September&nbsp;30, 2015 and 2014 are not necessarily indicative of the results that may be expected for the fiscal year. The balance sheet at December&nbsp;31, 2014 has been derived from the audited financial statements at that date,
but does not include all of the information and footnotes required by GAAP for complete financial statements. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>The Company </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">BioStructures, LLC, or BioStructures or the Company, is a limited liability company formed under the laws of the state of California on August&nbsp;22, 2007 and
operates as a partnership. The Company was owned by two members until the acquisition of the Company by Bioventus, LLC in November 2015 (see Note 8). </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">BioStructures is a medical device company focused on developing innovation proprietary platforms in bio-resorbable bone graft products for a broad range of spinal
surgical applications. The Company&#146;s products are developed to benefit the surgeon and their patients during each phase of the bone healing process. BioStructures&#146; bio-resorbable implants are created for best-in-class performance. The
synthetic and allograft implants are designed for proportionate resorption to facilitate balanced bone regeneration with optimized clinical efficacy. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Use of estimates </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The preparation of the financial
statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses during the period, as well as disclosures of contingent assets and
liabilities at the date of the financial statements. Actual results may differ from these estimates under different assumptions or conditions. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Cash
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company&#146;s cash consists of cash held by a single financial institution in the U.S. in excess of the federally insured limits. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Fair value </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company records certain assets and
liabilities at fair value (discussed further in Note 5). Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly
transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-76 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The three levels of inputs used to measure fair value are as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Level&nbsp;1&#151;Quoted prices in active markets for identical assets or liabilities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Level&nbsp;2&#151;Observable inputs other than quoted prices included within Level 1, such as quoted prices for similar assets and liabilities in active markets;
quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Level&nbsp;3&#151;Unobservable inputs that are supported by little or no market data. This includes certain pricing models, discounted cash flow methodologies
and similar techniques that use significant unobservable inputs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Accounts receivable and allowances </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Accounts receivables are amounts due from customers and are recorded at net realizable value for product sold in the ordinary course of business. The Company
maintains an allowance for doubtful accounts. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The allowance for doubtful accounts is based on the assessment of the collectability of specific customer
accounts and the aging of the accounts receivable. When evaluating the adequacy of this allowance, the Company analyzes accounts receivable, historical bad debts, customer concentrations, customer solvency, current economic and geographic trends,
and changes in customer payment terms and practices. Changes to the allowance for doubtful accounts are recorded in selling, general and administrative expense in the statement of income and comprehensive income. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Inventory </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Inventories are valued at the lower of cost or
estimated net realizable value, after provision for excess or obsolete items. All products the Company sells are procured through third-party contract manufacturing arrangements and cost is determined on an average cost basis, which approximates the
first-in, first-out, or FIFO, method. The valuation of finished products and consignment inventory includes the cost of materials, labor and packaging costs. Consignment inventory represents finished products located at third parties, such as
distributors and hospitals. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Long-lived assets </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment are stated at cost and are depreciated using the straight-line method over the shorter of the asset&#146;s estimated useful life, or the
lease term if related to leased property, as follows (in years): </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Automobile</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Machinery and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3-7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Furniture and fixtures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Finite-lived identifiable intangible assets are recorded at cost and are amortized using the straight-line method over their
estimated remaining useful lives ranging between 8 and 10 years. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The carrying values of property, equipment, intangible and other long-lived assets are
reviewed for recoverability if the facts and circumstances suggest that a potential impairment may have occurred. If this review indicates that carrying values may not be recoverable, as determined based on undiscounted cash flow projections, the
Company will perform an assessment to determine if an impairment charge is required to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-77 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
reduce carrying values to estimated fair value. There were no events, facts or circumstances for the nine months ended September&nbsp;30, 2015 and 2014 that resulted in any impairment charges to
the Company&#146;s property, equipment, intangible or other long-lived assets. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Revenue recognition </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Sale of products </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company primarily sells its
products to hospitals and recognizes revenue upon notification from the hospital that the product was used in surgery. Accordingly, revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or
determinable, and collection is reasonably assured. Until such time as the product is used in surgery, ownership of the product remains with the Company. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company uses a distribution network to deliver its product to hospitals. The majority of the distributors hold the Company&#146;s product on consignment until
delivered to the hospitals to be used in surgery. In these circumstances, ownership of the product remains with the Company. The Company does sell products directly to distributors who take ownership of the product at the point of shipment. In these
circumstances, the Company recognizes revenue upon delivery to such distributors. Accordingly, revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collection is
reasonably assured. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Shipping and handling </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company classifies amounts billed for shipping and handling as a component of net sales. The related shipping and handling fees and costs as well as other
distribution costs are included in cost of sales. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Advertising costs </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Advertising costs include costs incurred to promote the Company&#146;s business and are expensed as incurred. Advertising costs were $102,384 and $107,558 for the nine months ended September&nbsp;30, 2015 and 2014,
respectively. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Research and development </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Research
and development, or R&amp;D, expenses consists primarily of contract research organization services. Internal R&amp;D costs are expensed as incurred. R&amp;D costs incurred by third parties are expensed as the contracted work is performed. Initial
and milestone payments made to third parties in connection with technology license agreements are also expensed as incurred as research and development costs, up to the point of regulatory approval. Payments made to third parties subsequent to
regulatory approval will be capitalized and amortized over the estimated remaining useful life of the related product. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Income taxes </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company is treated as a partnership for U.S. tax purposes. Accordingly, the profits and losses are passed through to the members and included in their income
tax returns. The Company makes periodic distributions to its members. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Recently issued accounting standards </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B></B>In May 2014, the Financial Accounting Standards Board, or FASB, issued guidance that provides a comprehensive new revenue recognition model that requires a
company to recognize revenue to depict the<B> </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-78 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>
</B>transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. The guidance also requires additional
disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. In August 2015, the FASB approved a one-year deferral of the effective date making this guidance effective for annual and interim
periods beginning after December&nbsp;15, 2018 for private companies. Early application is permitted. This guidance permits the use of either the retrospective or cumulative effect transition method. The Company is currently evaluating the impact
this guidance will have on the Company&#146;s financial statements<B>. </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In July 2015, the FASB issued guidance for simplifying the calculation for
subsequent measurement of inventory measured using the first-in-first-out or average cost methods. The guidance is effective for annual periods and interim periods within those annual periods beginning after December&nbsp;15, 2016, and is effective
for the Company for the year ending December&nbsp;31, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company&#146;s financial statements. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>2. Balance sheet information </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Accounts receivable
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Accounts receivable consisted of the following at September&nbsp;30, 2015: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,848,308</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(250,579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,597,729</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table shows the activity in the allowance for doubtful accounts at September&nbsp;30, 2015: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Beginning balance at December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">191,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Charged to operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">59,435</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Ending balance at September&nbsp;30, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">250,579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The allowance as of September&nbsp;30, 2015 relates to a specific customer that filed for bankruptcy in June 2015. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Inventory </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Inventory consisted of the following at
September&nbsp;30, 2015: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Raw materials and supplies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> 226,318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Work-in-process</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">73,694</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Finished goods</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">945,530</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,245,542</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Finished goods includes consignment inventory representing immediately saleable finished products that are in the possession of the
Company&#146;s distributors or located at third-party customers, such as hospitals. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-79 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Property and equipment, net </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Property and equipment consisted of the following at September&nbsp;30, 2015: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Automobile</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> 39,135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Furniture and fixtures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">46,775</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Machinery and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">152,022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">237,932</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less accumulated depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(103,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">134,706</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Depreciation expense was $30,180 and $24,224 for the nine months ended September&nbsp;30, 2015 and 2014, respectively. The Company
assets are pledged as security under a bank loan agreement. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Intangible assets, net and royalty agreements </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In July 2009, the Company entered into an exclusive license and supply agreement for the use of bioactive glass in certain of its products. The Company paid a
non-refundable technology access fee of $230,000 in exchange for the world-wide, royalty bearing license for the use of certain developed technologies related to spine repair. The Company is required to pay a royalty of 3% on all commercial sales
revenue from the licensed products. In October 2010, the agreement was amended whereby the Company paid $234,000 as additional consideration, primarily for the right to sublicense. During the nine months ended September&nbsp;30, 2015 and 2014, the
Company incurred royalty expense of $150,152 and $101,194, respectively. Royalty expense is included in cost of goods sold. The agreement shall expire in 2019 upon the expiration of the last to expire patents held by the licensor. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November 2011, the Company entered into a development and license agreement with a third-party, whereby both parties collaborated in the development,
pre-clinical and clinical evaluation and commercialization of a product for use in certain orthopedic applications. Pursuant to this agreement, upon receipt of a 510(k) approval for a developed product, both parties agreed to enter into a license
agreement for such product. Upon receiving a 510(k) approval in January 2014 for bioactive bone graft putty, the Company paid a $50,000 milestone payment and in February 2014, the Company entered into an exclusive license agreement with the
third-party for the developed product whereby the Company paid $100,000 as a conversion fee. The Company is required to pay a royalty of 3% on all commercial sales revenue from the license products with a minimum royalty payment of $60,000 in 2013,
$102,000 in 2014 and $201,000 annually for the period from 2015 through 2023. During the nine months ended September&nbsp;30, 2015 and 2014, the Company incurred the minimum royalty expense of $150,750 and $76,500, respectively. Royalty expense is
included in cost of goods sold. The agreement shall expire in 2023 upon the expiration of the last to expire patents held by the licensor. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Intangible
assets are recorded at cost and consisted of the following at September&nbsp;30, 2015: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">License fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> 614,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less accumulated amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(307,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intangible assets, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">306,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Amortization expense related to intangible assets was $49,912 and $47,764 for the nine months ended September&nbsp;30, 2015 and
2014, respectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-80 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>3. Loans </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
Company was a party to a loan agreement with a commercial bank with a total borrowing limit of $2,000,000, with interest payable monthly at LIBOR plus 2.75%. The maturity date of the loan was initially set at August&nbsp;1, 2013 and was extended in
one year increments until paid in full. Outstanding borrowings as of September&nbsp;30, 2015 were $350,000. The loan was secured by the assets of the Company and guaranteed by the members. In November 2015, the loan was paid in full and all security
interests and guarantees were terminated in connection with sale of the Company (see Note 8). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During 2014, the Company paid in full an outstanding
balance of an automobile loan of $11,391. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>4. Members&#146; equity </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Members&#146; equity consisted of the following at September&nbsp;30, 2015: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Members&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> 853,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Retained earnings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,413,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,266,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company is owned by two members and all profits and distributions are shared equally. During the nine months ended
September&nbsp;30, 2015 and 2014, the Company made aggregate cash distributions of $2,450,000 and $2,000,000, respectively. On November&nbsp;24, 2015, the Company was acquired (see Note 8). </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>5. Fair value measurements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Recurring fair value measurements </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There were no material assets or liabilities carried on the accompanying balance sheet at September&nbsp;30, 2015 measured at fair value on a recurring basis.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Non-recurring fair value measurements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain
assets are carried on the balance sheets at cost and are not remeasured to fair value on a recurring basis. These assets include finite-lived tangible and intangible assets which are tested for impairment when a triggering event occurs. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The carrying value of the bank loan was not materially different from fair value at September&nbsp;30, 2015 using level 2 inputs. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>6. Accrued taxes </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company has evaluated sales tax and
medical device excise tax exposures in relevant jurisdictions and determined that an accrual of&nbsp;$370,384 at September&nbsp;30, 2015 should be recorded for the estimated amount of unbilled and unremitted sales and medical
device&nbsp;excise&nbsp;taxes. The Company&#146;s estimates of potential liabilities are based on its engagement of third-party experts to calculate the applicable taxes based on the Company&#146;s sales data.&nbsp;For the nine months ended
September&nbsp;30, 2015 and 2014, the Company recorded $49,150 and $133,000, respectively, to selling, general and&nbsp;administrative&nbsp;expenses related to the Company&#146;s&nbsp;estimated&nbsp;unbilled and unremitted taxes related to that
year. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Further, the Company has recorded an accrual of $166,516 at September&nbsp;30, 2015 for related interest and penalties associated with the
estimated unpaid taxes.&nbsp;For the nine months ended September&nbsp;30, 2015 and 2014, the Company recorded $16,516 and $62,000, respectively, to selling, general and&nbsp;administrative&nbsp;expenses related to such exposures. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-81 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>7. Commitments and contingencies </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Leases </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In April 2011, the Company entered into an operating lease agreement for its office facilities
that initially expired in October 2015. Rent expense under this lease agreement was $57,690 and $55,997 for the nine months ended September&nbsp;30, 2015 and 2014, respectively. The Company is also required to pay its pro-rata share of taxes and
common area maintenance. On March&nbsp;10, 2015, the Company amended the lease agreement extending the term to October&nbsp;21, 2019. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Lease payments are
subject to increases as specified in the lease agreements. Future minimum lease payments, by year and in the aggregate, under non-cancelable operating leases as of September&nbsp;30, 2015, are as follows: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:2px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"> 18,878</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">78,331</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">81,457</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">84,709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">72,936</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total minimum payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">336,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>8. Subsequent events </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On
November&nbsp;24, 2015, Bioventus LLC, a privately held medical products company, acquired 100% of the membership interest of the Company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-82 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Until &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016 (25 days after the date of
this prospectus), all dealers that effect transactions in our securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&#146; obligations to deliver a prospectus when
acting as underwriters and with respect to their unsold allotments or subscriptions. </B></FONT></P> <P STYLE="margin-top:48px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B><I>8,823,529 Shares </I></B></FONT></P>
<P STYLE="font-size:96px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:36px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g22578g30q81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B><I>Class&nbsp;A Common Stock </I></B></FONT></P>
<P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:44%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="6"><B>P r o s p e c t u s </B></FONT></P> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:44%">&nbsp;</P></center> <P STYLE="font-size:60px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="5"><B>J.P. Morgan</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="5"><B>Piper&nbsp;Jaffray</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="4"><B>Stifel</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="4"><B>Leerink&nbsp;Partners</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:48px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016 </FONT></P>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Part II </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Information not required in prospectus </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Item&nbsp;13.
Other expenses of issuance and distribution. </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table sets forth the costs and expenses, other than the underwriting discounts and
commissions, payable by the registrant in connection with the sale of Class&nbsp;A common stock being registered. All amounts are estimates except for the SEC, registration fee, the FINRA filing fee and NASDAQ listing fee. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Item</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Amount&nbsp;to<BR>be paid</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">SEC registration fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">FINRA filing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Listing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Printing and engraving expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Legal fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounting fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,070,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Blue Sky, qualification fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Transfer Agent fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Miscellaneous expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,607</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,900,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Item&nbsp;14. Indemnification of directors and officers. </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Section&nbsp;102 of the Delaware General Corporation Law, or DGCL, permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages
for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a
stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our amended and restated certificate of incorporation provides that none of our directors shall be personally liable to us or our stockholders for
monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of
fiduciary duty. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Section&nbsp;145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the
corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#146; fees), judgments, fines and amounts
paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or
proceeding by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable
cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been
adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is
fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our amended and restated bylaws provide that we will indemnify each person who was or is a party or threatened to be
made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or, while a director or
officer, is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons
being referred to as an &#147;Indemnitee&#148;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees), liabilities, losses, judgments, fines and amounts paid in
settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best
interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our amended and restated bylaws provide that we will indemnify any Indemnitee who was or is a party to
or threatened to be made a party to any threatened, pending or completed action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer,
or, while a director or officer, is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other
enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees) actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal
therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such
person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the
extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#146; fees) actually and reasonably incurred in connection therewith. Expenses must be advanced
to an Indemnitee under certain circumstances. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have entered into indemnification agreements with each of our directors and officers. These
indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#146; fees, judgments, fines and settlement amounts incurred by a director or officer in any action or
proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or
omissions in their capacities as directors or officers. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In any underwriting agreement we enter into in connection with the sale of Class&nbsp;A common
stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act of 1933, as amended, or the Securities Act,
against certain liabilities. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and
controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. Please
read &#147;Item 17. Undertakings&#148; for more information on the SEC&#146;s position regarding such indemnification provisions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Item&nbsp;15. Recent sales of unregistered securities. </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">On July 15, 2016, the registrant agreed to issue ten shares of common stock, par value $0.001 per share, which will be redeemed upon the closing of this offering, to an officer of the registrant in exchange for
$0.01. The issuance was exempt from registration under Section&nbsp;4(a)(2) of the Securities Act, as a transaction by an issuer not involving any public offering. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Item&nbsp;16. Exhibits and financial statement schedules </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Exhibits.</I></B> See the Exhibit Index attached to this registration statement, which is incorporated by reference herein. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Financial Statement Schedules.</I></B> Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown
in the Financial Statements or notes thereto. </FONT></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Item&nbsp;17. Undertakings. </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the
underwriters to permit prompt delivery to each purchaser. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Insofar as indemnification by the Registrant for liabilities arising under the Securities Act
may be permitted to directors, officers, and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registration has been advised that in the opinion of the SEC such indemnification is against public policy as
expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling
person of the Registrant in the successful defense of any action, suit, or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of
counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Registrant hereby undertakes that: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance
upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared
effective. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">For purposes of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Signatures </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement on Form S-1 to be signed on its
behalf by the undersigned, thereunto duly authorized, in Durham, North Carolina, on this twenty-seventh day of July, 2016. </FONT></P>  <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:arial" SIZE="2"><B>Bioventus Inc.</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">/s/ Anthony P. Bihl III</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Name: Anthony P. Bihl III</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Title: Chief Executive Officer</B></FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by
the following persons on behalf of the Registrant and in the capacities and on the dates indicated. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Title</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Date</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">/s/ Anthony P. Bihl III</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:arial" SIZE="2">Anthony P. Bihl III</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Chief Executive Officer and Director (Principal Executive Officer)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">July&nbsp;27, 2016</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">/s/ David J. Price</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">David J. Price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Chief Financial Officer</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">(Principal Financial Officer)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">July&nbsp;27, 2016</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">/s/ Gregory O. Anglum</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:arial" SIZE="2">Gregory O. Anglum</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Chief Accounting Officer<BR></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">(Principal Accounting Officer)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">July&nbsp;27, 2016</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">Philip G.
Cowdy</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">July 27, 2016</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">William A.
Hawkins</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">July 27, 2016</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">Michael R.
Minogue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">July 27, 2016</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">Guido J.
Neels</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">July 27, 2016</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">Guy P.
Nohra</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">July 27, 2016</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">David J.
Parker</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">July 27, 2016</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="21%"></TD></TR>

<TR>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Title</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Date</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">Cyrille Y.N.
Petit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">July 27, 2016</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">Martin P.
Sutter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">July 27, 2016</FONT></TD></TR>
</TABLE>  <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">*By:&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">/s/ Anthony P. Bihl III</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Anthony P. Bihl III</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><I>Attorney-in-fact</I></FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Exhibit index </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exhibit&nbsp;no.</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Description</B></FONT></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;1.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Form of Underwriting Agreement.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;3.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Form of Amended and Restated Certificate of Incorporation of Bioventus&nbsp;Inc., to be effective upon the closing of this offering.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;3.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Form of Amended and Restated Bylaws of Bioventus&nbsp;Inc., to be effective upon the closing of this offering.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;4.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Specimen Stock Certificate evidencing the shares of Class&nbsp;A common stock.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;5.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Opinion of Latham &amp; Watkins LLP.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Form of Tax Receivable Agreement, to be effective upon the closing of this offering.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Form of Registration Rights Agreement, to be effective upon the closing of this offering.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.3*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">LLC Agreement of Bioventus&nbsp;LLC, as currently in effect.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.4*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Form of Second Amended and Restated&nbsp;LLC Agreement of Bioventus LLC, to be effective upon the closing of this offering.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.5*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Form of Stockholders Agreement, to be effective upon the closing of this offering.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.6*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">First Lien Credit Agreement, dated as of October 10, 2014, among Bioventus LLC, J.P. Morgan Chase Bank, N.A., as administrative agent, and the lenders thereto.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.7*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Second Lien Credit Agreement, dated as of October 10, 2014, among Bioventus LLC, J.P. Morgan Chase Bank, N.A., as administrative agent, and the lenders thereto.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.8*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Amendment No.&nbsp;1, dated as of November&nbsp;20, 2015, to the First Lien Credit Agreement, dated as of October&nbsp;10, 2014, among Bioventus LLC, J.P. Morgan Chase Bank, N.A., as
administrative agent, and the lenders thereto.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.9*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Amendment No. 1, dated as of November 20, 2015, to the Second Lien Credit Agreement, dated as of October 10, 2014, among Bioventus LLC, J.P. Morgan Chase Bank, N.A., as administrative agent,
and the lenders thereto.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.10&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Amended and Restated Exclusive Distribution Agreement between Seikagaku Corporation and Bioventus LLC, restated as of May 4, 2012.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.10.1*&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Amended and Restated Distribution Agreement between Seikagaku Corporation and Bioventus LLC, restated as of June 30, 2016.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.11*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Continuation of Product Partnership Right of First Negotiation between Smith &amp; Nephew, Inc. and the Company.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.12*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Amended and Restated First Lien Credit Agreement, dated as of the restatement effective date, among Bioventus LLC, J.P. Morgan Chase Bank, N.A., as administrative agent, and the lenders
thereto.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.13*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Bioventus LLC Management Incentive Plan.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.14*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Bioventus LLC Phantom Profits Interest Plan, as amended and restated.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.15*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Form of Phantom Profits Interest Award Agreement (Executive Waterfall).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.16*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Form of Phantom Profits Interest Award Agreement (Executive Termination Form A).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.17*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Form of Phantom Profits Interest Award Agreement (Executive Termination Form B).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.18*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Profits Interest Award Agreement, dated as of December 2, 2013, by and between Bioventus LLC and Anthony P. Bihl III.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.19*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Profits Interest Award Agreement, dated as of January 1, 2016, by and between Bioventus LLC and William Hawkins.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.20*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Assignment and Assumption Agreement, by and between Bioventus LLC and Bioventus Inc.</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="87%"></TD></TR>

<TR>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exhibit&nbsp;no.</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Description</B></FONT></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.21*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Amendment and Termination of the Bioventus LLC Amended and Restated Phantom Profits Interest Plan.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.22*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Bioventus Inc. Director Stock Ownership Policy.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.23*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Bioventus Inc. Non-Employee Director Compensation Policy.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.24*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Bioventus Inc. Senior Executive Incentive Bonus Plan.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.25*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Bioventus Inc. Employee Stock Purchase Plan.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.26*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Bioventus Inc. 2016 Incentive Award Plan.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.27*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Form of IPO RSU Agreement (Director).</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.28*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Form of IPO Option Agreement (Director).</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.29*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Form of IPO Option Agreement (Employee Form A).</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.30*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Form of IPO Option Agreement (Employee Form B).</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.31*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Employment Agreement, dated as of April 20, 2012, by and between Bioventus LLC and Henry C. Tung M.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.32*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Employment Agreement, dated as of September 27, 2012, by and between Bioventus LLC and David J. Price.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.33*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Employment Agreement, dated as of November 4, 2013, by and between Bioventus LLC and Anthony P. Bihl III.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.34*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Employment Agreement by and between Bioventus LLC and Anthony P. Bihl III.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.35*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Employment Agreement by and between Bioventus LLC and David J. Price.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.36*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Employment Agreement by and between Bioventus LLC and Henry C. Tung, M.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.37*#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2">Director Offer Letter, dated December 11, 2015, by and between Bioventus LLC and William Hawkins.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">10.38*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Form of Indemnification Agreement.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">21.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">List of subsidiaries of Bioventus Inc.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">23.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Consent of PricewaterhouseCoopers LLP as to Bioventus LLC.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">23.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Consent of PricewaterhouseCoopers LLP as to BioStructures, LLC.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">23.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Consent of Latham &amp; Watkins LLP (included in Exhibit 5.1).</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">24.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Power of Attorney (included on signature page).</FONT></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Previously filed. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">#</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Indicates management contract or compensatory plan. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">&#134;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Portions of the exhibit are omitted pursuant to a request for confidential treatment, which portions have been provided separately to the Securities and Exchange Commission.
</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-7 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d22578dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 5.1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g22578dsp_3.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">53rd at Third</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">885 Third Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022-4834</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: +1.212.906.1200 Fax:
+1.212.751.4864</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">www.lw.com</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">FIRM / AFFILIATE OFFICES</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">July&nbsp;27, 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Barcelona</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Moscow</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bioventus Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4721 Emperor Boulevard</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 100</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Durham, North Carolina 27703</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beijing</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brussels</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Century City</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chicago</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dubai</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">D&uuml;sseldorf</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frankfurt</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hamburg</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hong Kong</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Houston</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">London</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Los Angeles</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Milan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Munich</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Jersey</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orange County</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paris</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Riyadh</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rome</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shanghai</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Silicon Valley</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Singapore</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tokyo</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Washington, D.C.</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top">Registration Statement No.&nbsp;333-212329; <U> </U></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><U>10,147,058 shares of Class&nbsp;A
common stock, par value $0.001 per share</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B>We have acted as special counsel to Bioventus Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and Bioventus
LLC, a Delaware limited liability company (&#147;<B><I>Bioventus LLC</I></B>&#148;), in connection with the proposed issuance of up to 10,147,058 shares of Class&nbsp;A common stock, $0.001 par value per share (the &#147;<B><I>Shares</I></B>&#148;).
The Shares are included in a registration statement on Form S-1 under the Securities Act of 1933, as amended (the &#147;<B><I>Act</I></B>&#148;), initially filed with the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;)
on June&nbsp;30, 2016 (Registration No.&nbsp;333-212329, as amended, the &#147;<B><I>Registration Statement</I></B>&#148;). The term &#147;Shares&#148; shall include any additional shares of common stock registered by the Company pursuant to Rule
462(b) under the Act in connection with the offering contemplated by the Registration Statement. This opinion is being furnished in connection with the requirements of Item&nbsp;601(b)(5) of Regulation S-K under the Act, and no opinion is expressed
herein as to any matter pertaining to the contents of the Registration Statement or related prospectus contained therein (the &#147;<B><I>Prospectus</I></B>&#148;), other than as expressly stated herein with respect to the issue of the Shares.<B><I>
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of
this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to General
Corporation Law of the State of Delaware, and we express no opinion with respect to any other laws. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>July 27, 2016 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Page 2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g22578img002.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date
hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers and have been issued by the Company against payment therefor (not less than par value) in
the circumstances contemplated by the form of underwriting agreement most recently filed as an exhibit to the Registration Statement, the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company,
and the Shares will be validly issued, fully paid and non-assessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the General
Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is for your benefit in connection with the Registration Statement and may be
relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement and to the reference to our firm in the Prospectus under
the heading &#147;Legal Matters.&#148; We further consent to the incorporation by reference of this letter and consent into any post-effective amendment to the Registration Statement filed pursuant to Rule 462(b) with respect to the Shares. In
giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations of the Commission thereunder. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">/s/ Latham&nbsp;&amp; Watkins LLP</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>3
<FILENAME>d22578dex1010.htm
<DESCRIPTION>EX-10.10
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 10.10 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CONFIDENTIAL TREATMENT REQUESTED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>PURSUANT TO RULE 406 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED EXCLUSIVE DISTRIBUTION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BETWEEN
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEIKAGAKU CORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIOVENTUS LLC
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTATED AS OF MAY 4 , 2012 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED EXCLUSIVE DISTRIBUTION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amended and
Restated Exclusive Distribution Agreement, as restated to include all amendments in effect as of May&nbsp;4, 2012 (the &#147;Effective Date&#148;), (as so restated, this &#147;Agreement&#148;) by and between BIOVENTUS LLC, a Delaware limited
liability company having its principal place of business at 4721 Emperor Boulevard, Durham, NC 27703 (&#147;Distributor&#148;), and SEIKAGAKU CORPORATION, a Japanese corporation having its principal place of business at Marunouchi Center Building,
6-1, Marunouchi <FONT STYLE="white-space:nowrap">1-chome,</FONT> Chiyoda-ku, Tokyo 100-0005, Japan (&#147;Company&#148;). Distributor and Company are sometimes referred to herein individually as a &#147;Party&#148; and are sometimes referred to
herein collectively as the &#147;Parties.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>RECITALS </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Company has developed and has produced in Japan over 20 years a hyaluronic acid (&#147;HA&#148;) product and has obtained or is going to
obtain the following marketing authorizations in some regions outside Japan for the Products which is more specifically defined in Section&nbsp;22 and now wishes to appoint a distributor to certain regions for such Products: [<B>***</B>]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Company and SMITH&nbsp;&amp; NEPHEW, INC. entered into an Exclusive Distribution Agreement on January&nbsp;1, 1999 (&#147;EDA&#148;) and
amendments and supplements to the EDA thereafter (hereinafter, the EDA and any and all amendments and supplements thereto shall be collectively referred to as &#147;Existing Agreements&#148;), under which the Company appointed SMITH&nbsp;&amp;
NEPHEW, INC. as the exclusive distributor of SUPARTZ, the Company&#146;s HA product, in certain territories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. SMITH&nbsp;&amp; NEPHEW,
INC. has assigned all of its rights and an obligation under the Existing Agreements to Distributor and Company has consented to said assignment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. Company and Distributor desire to enter into this Agreement as the Amended and Restated Exclusive Distribution Agreement which supersedes
and replaces the Existing Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">E. Distributor wishes to obtain the exclusive right to distribute and sell the Product throughout
the Territory as specified in Section&nbsp;2 hereof, and Company wishes to grant such right to Distributor, on the terms and conditions set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">F. Distributor also wishes to purchase the Product from Company, and Company wishes to supply the Product to Distributor on the terms and
conditions set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">G. Unless defined elsewhere in this Agreement, capitalized terms used in this Agreement shall
have the meanings set forth in Section&nbsp;22. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants and agreements of the Parties contained
in this Agreement, the Parties agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><U><B>APPOINTMENT AS EXCLUSIVE DISTRIBUTOR</B></U><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of and
conditions of this Agreement, Company hereby appoints Distributor as its sole and exclusive distributor and grants Distributor the exclusive right to market, distribute and sell the Product in the Territory during the Term of this Agreement, and
Distributor hereby accepts such appointment. Distributor may appoint as subdistributors wholly-owned subsidiaries of Distributor, upon prior written notice to Company. Distributor may appoint other third parties as subdistributors from time to time
for the sale of the Product; provided, however, that Distributor shall notify Company of the name, address and outline of the business of such third party subdistributors and whether Distributor has an equity interest in such subdistributors in
writing and obtain the approval of Company in writing prior to appointment, such approval not to be unreasonably withheld, delayed or conditioned on terms not directly related to the third party subdistribution arrangements. The terms and conditions
of the agreement between Distributor and each subdistributor shall conform to the provisions of this Agreement, and Distributor shall require the subdistributors to observe the duties of Distributor as provided for in this Agreement, to the extent
applicable. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><U><B>EXCLUSIVE RIGHTS AND TERRITORY</B></U><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Distributor shall have the sole
and exclusive right to market, promote, distribute and sell the Product in the United States (the &#147;Territory&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Distributor
may submit to Company a business plan to market, promote, distribute and sell the Product in [***] within [***] of the LOA Effective Date. Company shall promptly notify Distributor if and when Company obtains regulatory approval necessary for sale
of the Product in [***]. Distributor may submit to Company a business plan to market, promote, distribute and sell the Product in [***] within [***] of the date it receives such notice. If Company approves of a business plan that Distributor submits
under this Section&nbsp;2(b), then the Parties shall amend this Agreement to include within the definition of Territory in Section&nbsp;2(a) the country ([***]) to which the approved business plan relates. Approval by Company of a business plan
pursuant to this Section&nbsp;2(b) shall not be unreasonably withheld, delayed or conditioned [***]. In the event that the Agreement is amended to include [***], (i)&nbsp;Section&nbsp;4(a) shall also be amended to provide for a Purchase Price equal
to [***] percent ([***]%) of the Average Sales Price per Unit for Units sold outside the United States, but not less than (US) $[***] per Unit in any situation ([***]), and (ii)&nbsp;Section&nbsp;4(j) shall also be added to provide that, with
respect to Products sold outside of the United States and denominated in a foreign currency, the Net Sales attributable thereto shall be converted from such foreign currency into United States Dollars by utilizing the &#147;Noon Fed Fixing
Rate&#148; announced by the Federal Reserve for the average of the first and last day of the reporting period. At Distributor&#146;s request in connection with its preparation of a business plan for [***], and [***], the Parties shall negotiate in
good faith a reduction in the foregoing minimum price per Unit based upon market conditions applicable to such country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) During the Term of this Agreement, [***] unless (i)&nbsp;[***], and (ii) [***]. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><U>GENERAL TERMS OF SUPPLY</U><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) During the Term of this Agreement, Company
shall deliver and supply Units to Distributor, according to and in conformity with the shipping instructions of Distributor&#146;s purchase order for same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Orders for Units placed by Distributor shall be made by Distributor issuing to Company a purchase order which specifies
(i)&nbsp;quantities and destination(s) of Units to be shipped, (ii)&nbsp;delivery dates at least [***] ([***]) days after the date of such purchase order, (iii)&nbsp;particulars of warehouses in [***] area, where the delivery of Product in question
shall be made, and (iv)&nbsp;transport means (air or sea). If Company becomes aware of an event of Force Majeure, or any other event that it expects would prevent it from supplying Units ordered or forecasted to be ordered by Distributor on the
specified delivery date(s), Company shall promptly notify Distributor. Provided, however, nothing contained in this Section&nbsp;3(b) shall relieve Company of liability for failure to supply Product as required by an actual purchase order, except as
excused for Force Majeure. Company will try, with its best efforts, to fill purchase orders placed by Distributor with delivery dates less than [***] days from the date of the purchase order, however, the actual delivery dates in this case shall be
decided by Company in its sole discretion. In any such event, Company will confirm in writing the purchase order issued by Distributor, regardless of whether it is with regular or shorter delivery dates and each such purchase order shall become
binding on both Parties upon and according to the confirmation in writing by Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) During the Term of this Agreement, Distributor
shall provide Company with a [***]rolling order and delivery forecast [***] (the &#147;Annual Forecast&#148;) in Dollars and Units ([***]) each [***]. In accordance with the terms and conditions of this Agreement, Distributor shall purchase at least
70% of the Units indicated on the Annual Forecast in the forecasted year as a minimum purchase quantity. Company shall use its [***] supply Units [***] of the Annual Forecast, if so required by the purchase orders of Distributor. Notwithstanding any
other term of this Section&nbsp;3(c), to the extent that a failure to meet the purchase requirements set forth in this Section&nbsp;3(c) can be reasonably attributed to [***] (&#147;Negative Developments&#148;), including [***], then the Parties
shall negotiate in good faith an appropriate reduction in the minimum purchase quantity or other appropriate means to offset the impact of the Negative Developments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) After termination of this Agreement, Distributor shall cease promoting, distributing and selling the Product anywhere in the world, except
for its promotion, distribution and sale of any Products remaining in its inventory as of the date of such termination within [***] of the termination. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><U>PRICE AND PAYMENT TERMS</U><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) During the Term of this Agreement, the
purchase price payable by Distributor to Company for each Unit (&#147;Purchase Price&#148;) shall be equal to [***] percent ([***]%) of the Average Selling Price per Unit, but not less than (US) $[***] per Unit in any situation ([***]). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;Average Selling Price per Unit&#148; is defined as (i)&nbsp;Net Sales for each Period divided by
(ii)&nbsp;&#147;Net Units Sold&#148; in the same Period. &#147;Period&#148; shall mean the period consisting of [<B>***</B>], which will be announced by Distributor for each [<B>***</B>]. A [<B>***</B>] consists of [<B>***</B>] ([<B>***</B>])
Periods. &#147;Net Units Sold&#148; shall mean the total number of Units sold by Distributor to third parties ([<B>***</B>]), less reasonable returns of Units. The purchase price hereunder shall be settled in U.S. currency. Notwithstanding any other
provision of this Section&nbsp;4(a), to the extent that Negative Developments can be reasonably anticipated to adversely affect the market for the Product, then at any time thereafter Distributor may request that the Parties negotiate in good faith
an appropriate reduction of the minimum purchase price or other appropriate means to offset the impact of the Negative Developments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
For purposes of calculating the Average Selling Price per Unit, Distributor shall provide Company with a statement (the &#147;Statement&#148;) (i)&nbsp;describing the calculation of the Net Sales from the gross sales, and (ii)&nbsp;Net Units Sold
from the total number of Units sold; with a description of each numbers and amounts of the items reducible pursuant to Section&nbsp;4(a), which were accrued during each Period, for each of the United States and the countries outside the United
States no later than [<B>***</B>] ([<B>***</B>]) days after the Period in question. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) (i) Within [<B>***</B>] ([<B>***</B>]) days after
the [<B>***</B>] (defined below) in question, Company shall provide a written summary on [<B>***</B>] for the [<B>***</B>] and the [<B>***</B>] (&#147;Adjustment&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;[<B>***</B>]&#148; shall mean [<B>***</B>]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) Within [<B>***</B>] ([<B>***</B>]) days after Distributor&#146;s receipt of Company&#146;s summary above, Distributor shall
<B></B>express its agreement or disagreement to any Adjustment by Company. Such agreement shall be expressed in writing with a signature of any authorized Distributor&#146;s financial officer. If Distributor disagrees, both Parties shall enter into
good faith discussion to settle the Adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) Upon the agreement to the Adjustment, either of Company or Distributor, who
[<B>***</B>], shall provide the other Party with [<B>***</B>], which shall [<B>***</B>], for [<B>***</B>], for [<B>***</B>]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) The
notices to be made under this Section&nbsp;4 between the Parties may be made by e-mail with work files, which shall be followed by written notices satisfying the requirements of Section&nbsp;17. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Company shall have the right to appoint an independent public accountant, reasonably acceptable to Distributor to verify
Distributor&#146;s calculation of Net Sales, Net Units Sold and Average Selling Price per Unit (the &#147;Audit&#148;). In the absence of any intentional misstatement of material fact by Distributor, Company shall bear the cost of such Audit unless
Distributor&#146;s calculation of the Net Sales, Net Units Sold or Average Selling Price per Unit is more than [<B>***</B>] percent ([<B>***</B>]%) lower than the amounts determined by the Audit, in which case [<B>***</B>]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Company shall supply Distributor with Samples of the Product (&#147;Samples&#148;) [***]. The total number of the Sample Units shall be
[***] and shall not exceed [***] of the Units ordered by Distributor on the current purchase order. Distributor shall [<B>***</B>]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Purchase Price for the Product shall be based on sales terms of FCA (warehouse in Greater
Tokyo Area designated by Distributor) (Incoterms 2010), subject to the following provisions of this Section&nbsp;4(f). Title, ownership, and risk of loss of the Product shall pass to Distributor upon [***]. The Parties shall cooperate in processing
all claims for loss or damage to the Product. For purposes of the foregoing, the Parties intend and agree that &#147;FCA (warehouse in Greater Tokyo Area designated by Distributor)&#148; shall mean that (A)&nbsp;Company shall bear the cost, risk and
responsibility to: (i)&nbsp;[***], (ii)&nbsp;[***], and (iii)&nbsp;[***] and (B)&nbsp;prior to each delivery by Company, Distributor shall bear the cost, risk and responsibility to notify Company: (i)&nbsp;[***], (ii)&nbsp;[***], and
(iii)&nbsp;[***]. Thereafter, Distributor shall be responsible for all costs it incurs to ship the Product from the designated warehouse to the United States or other locations, including, but not limited to, freight, insurance, terminal handling
charges and U.S. import customs&#146; fees. If and insofar as the Parties&#146; intended meaning of &#147;FCA (warehouse in Greater Tokyo Area designated by Distributor)&#148; is inconsistent with or contrary to the definition of such term in
Incoterms 2010, the Parties&#146; intended meaning, as detailed above, shall apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Company shall invoice Distributor for each
shipment separately and shall reference the applicable Distributor purchase order number, mode of transportation, date of shipment payment terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Payment terms for purchases of Product by Distributor shall be net [***] ([***]) days from the date of Company&#146;s invoice by
wire-transfer to Company&#146;s bank account designated on the invoice. Distributor shall pay Company a late charge of [***] percent ([***]%) per month for all payments made after the payment deadline as provided in the immediately preceding
sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision of the Agreement, SMITH&nbsp;&amp; NEPHEW, INC. guarantees to Company the complete payment of the Purchase
Price for the Product by Distributor within forty-five (45)&nbsp;days of the delivery of the Product. If Company has not received the Purchase Price for the Product from Distributor within forty-five (45)&nbsp;days of the delivery of the Product to
Distributor, then SMITH&nbsp;&amp; NEPHEW, INC. is obligated to pay the Purchase Price directly to Company. This guarantee expires two (2)&nbsp;years from the LOA Effective Date, and is a continuing obligation of SMITH&nbsp;&amp; NEPHEW, INC. for
such two (2)&nbsp;year period regardless of any permitted assignment of the Agreement by SMITH&nbsp;&amp; NEPHEW, INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Distributor
shall have absolute discretion to determine its own sale prices for the Product. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>PRODUCT SPECIFICATIONS; QUALITY CONTROL; REGULATORY MATTERS AND COMPLIANCE WITH LAW</U> </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Company shall (i)&nbsp;manufacture the Product in strict accordance with the quality specifications described in the Registration
Dossier(s), which is exactly disclosed in ANNEX A attached herewith, or in effect from time to time in the applicable Territory, and other additional specifications agreed to by the Parties from time to time, when additional specifications are
written as amendments to ANNEX A as provided in Section&nbsp;5(b) below and (ii)&nbsp;package and label the Product in accordance with the packaging and labeling requirements decided by the Parties as provided in the Section&nbsp;12(c) and added
later to this Agreement as ANNEX B (collectively, the &#147;Specifications&#148;). Either Party shall have the right to request a change to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Specifications at any time during the Term of this Agreement. In such event, the Party wishing to request a change (the &#147;Requesting Party&#148;) shall notify the other Party (the
&#147;Receiving Party&#148;) of its request in writing. If the Receiving Party agrees to such request, the Parties shall cooperate with each other, in good faith, to have such change to the Specifications approved in each applicable country in the
Territory, and Company shall maintain sufficient inventory of the original Product to supply Distributor until the change in Specifications is so approved and the new Product can be marketed and sold. In the event of a dispute between Company and
Distributor concerning the change of Specifications relating to the formulation or the manufacturing of the Product, then Company shall make the final decision. In the event of a dispute between Company and Distributor concerning change of packaging
or labeling, then Distributor shall make the final decision unless such change is not cost effective or feasible, in Company&#146;s opinion. If any regulatory agency having jurisdiction in any country in the Territory requires a change to the
Specifications, Company shall use its [***] to make such changes, with respect to the Products sold in the affected jurisdiction, unless such change is not cost effective or feasible as determined mutually by the Parties. If Company cannot make such
change the Product shall not be sold by either Party in that jurisdiction. All expenses incurred with respect to a change in the Specifications required by a regulatory agency with respect to the sale or use of the Product in the Territory will be
[***]. All expenses incurred with respect to a change in the Specifications required by a regulatory agency outside the Territory will be [***]. All expenses incurred in connection with any and all changes to Specifications except those changes to
Specifications required by the FDA, or similar regulatory agency of any country in the Territory, shall be [***]. If [***] is the Requesting Party and such change in Specifications would [***], then Distributor shall [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) All changes to Specifications allowed by the provisions in Section&nbsp;5(a) made subsequent to the Effective Date of this Agreement, must
be made in the form of a written amendment to ANNEX A or ANNEX B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Company shall conduct quality control testing of the Product prior
to shipment in accordance with the Specifications and regulatory requirements with respect to the Product as are in effect from time to time in the Territory, and such other validated quality control testing procedures agreed to by the Parties from
time to time (the &#147;Testing Methods&#148;). Company shall retain records pertaining to such testing for a minimum of [***] ([***]) years following the expiration date of life of the Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Company shall provide Distributor with a certificate of analysis of each shipment of Product made to Distributor. Nothing contained herein
shall waive Distributor&#146;s rights with respect to latent defects or with respect to Distributor&#146;s rights under the representation and warranty provisions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Distributor shall notify Company and all applicable regulatory authorities in writing of reportable events involving the Product for which
Distributor receives appropriate notification, as required by applicable Laws, including, without limitation, Medical Device Reports under the Post Market Surveillance program of the FDA, and maintain the files of these reports and investigations as
required by applicable Laws. Company shall likewise notify </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Distributor in writing of any of such reportable events, including, if and to the extent required in connection with applicable Laws in the Territory, Device Vigilance Reports required by the
countries of the European Union. The reporting Party shall notify the other within a reasonable time in a manner consistent with the requirements of the Law in the applicable jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Each Party shall communicate to the other regarding any complaints received from users of the Product or Product-Drug, within a reasonable
time following receipt of each complaint. Each notification of a complaint shall contain, but shall not be limited to, the lot number, expiration date, indication for actual use and description of circumstances involved in the alleged failure of the
Product, to the extent such information is available. Each Party will provide additional information to the other Party as it becomes available. If Distributor receives the Product associated with a complaint relating to the performance of a
Product, Distributor will mail the Product to Company via express courier for evaluation of the Product and investigation of the complaint by Company. Company shall investigate the complaint and report to Distributor the results of the investigation
and decision made concerning corrective actions and detailed information concerning the corrective actions taken, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Each Party
agrees to notify the other Party as soon as practical of any information of which it becomes aware which relates to the safety or efficacy of the Product or Product-Drug. Upon receipt of any such information, the Parties shall consult with each
other in an effort to arrive at a mutually agreeable course of action that is consistent with the obligations of the Parties under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) (1) If a Party is notified by a governmental agency that a Product or Product-Drug recall or other general corrective action with respect
to the Product or Product-Drug is necessary it shall immediately advise the other Party in writing of such notification by such governmental agency, and proceed with the recall or corrective action as instructed by such governmental agency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) In the event either Company or Distributor believes in good faith (without notification by a governmental agency) that a Product or
Product-Drug recall or other general corrective action with respect to the Product or Product-Drug is necessary or appropriate (&#147;Proposed Recall&#148;), the Party advocating the Proposed Recall shall notify the other Party in writing regarding
its belief in this regard, and provide the other Party with a complete written explanation of the reason(s) for its belief regarding such Proposed Recall. As soon as reasonably possible following delivery of the written explanation, the Parties will
mutually determine what actions are appropriate regarding such Proposed Recall. If the Parties cannot agree upon such actions, then this matter will be decided by arbitration pursuant to Section 16. Distributor will keep detailed distribution
records for each lot number detailing the quantity shipped and the location where the lot was shipped as required by Law so that in the event of recall, Distributor will be able to contact the consignees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(3) In the event any recall or general corrective action is taken with respect to the Product or Product-Drug, whether ordered by a
governmental agency or otherwise, Distributor and Company will jointly determine in good faith the cause(s) of the non-conformance(s) prompting the recall or general corrective action within the time required by the applicable Law, but no later than
[***] ([***]) days after </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the date of such recall or general corrective action, in order to establish preventive measures for the future and to assess responsibility for costs and expenses arising from the recall. At the
end of this [***] ([***]) day period following the recall or general corrective action, the matter of costs and expenses will be submitted to the Presidents of Distributor and Company for their joint resolution. If the matter cannot be resolved by
the Presidents of Distributor and Company within [***] ([***]) days after it has been submitted to them, either Party may initiate arbitration pursuant to Section 16. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Each Party covenants that all of its activities (and the activities of its suppliers in the case of Company, and in the case of
Distributor, the activities of Distributor&#146;s subdistributors under or pursuant to this Agreement) shall comply with all applicable laws, ordinances, statutes, rules and regulations (collectively &#147;Laws&#148;), including, without limitation,
Laws arising under the federal Food, Drug and Cosmetic Act, the Safe Medical Device Act and their respective amendments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Distributor
and Company shall have the right to visit each other&#146;s facilities where the Product is manufactured, stored or delivered [***] during the Term of this Agreement and for the purposes of performing an audit of the operations, facilities and
records concerning the manufacturing procedures, and storage and distribution (including shipping and handling) of the Products of the other Party; provided, however, that such visits shall not give access to the other Party&#146;s proprietary
technology and shall be restricted to only those persons who are directly involved in determining compliance with the terms of this Agreement and who, as provided below, received a prior written approval of other Party and that each Party shall be
required to furnish to the other Party only that information necessary to make a determination of the other Party&#146;s compliance with the terms of this Agreement. Such visits shall be conducted upon written notice received at least [***] prior to
the visit and during normal business hours; provided that the person who will perform the audit received the prior written approval of the other Party prior to such visit, such approval not to be unreasonably withheld or delayed. The Party who
requests the audit shall select and retain at its discretion and its own cost the auditor or auditing consultant who shall conduct or otherwise assist such Party in performing the audit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) (i) In principle, Company shall obtain, by using the data it holds as of the Effective Date, the regulatory approval for the marketing,
sale, distribution and use of the Product in the Territory at [***] and Distributor shall assist such efforts of Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) If
additional clinical trials must be conducted in order for Distributor to market, sell, distribute or use the Products in any country in the Territory or if FDA Approval contains conditions that [***] (&#147;FDA Conditions&#148;), then the Parties
shall negotiate in good faith whether to proceed with the additional clinical trials and the responsibility for payment therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii)
If the Parties are unable to agree upon the need for or payment for additional clinical trials or the satisfaction of FDA Conditions, then [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) Even in the case where Distributor [***], Company shall assist Distributor for completion of the clinical trials and satisfaction of the
FDA Conditions [***] and shall, under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cooperation of Distributor, file the application of the regulatory approval or satisfaction of the FDA Conditions for the marketing, sale, distribution and use of the Product in such country and
obtain such approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) The [***] shall be [***], may be [***] and may be [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi) If the Parties are [***], then [***] to the other Party. If the FDA Approval contains conditions that are not reasonably acceptable to
Distributor, but are not able to be [***], then Distributor shall have the right to [***] to Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Each Party will be granted
rights to access, make reference to, and use the clinical data and regulatory filings owned by the other Party relating to the Products or Product-Drug other than Confidential and proprietary clinical data or regulatory filings of Company related to
the manufacture of Products which Company shall not be obligated to provide to Distributor, but shall be obligated to provide to legal or regulatory agencies or bodies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) Each Party will inform the other within a reasonable period of time as it becomes aware of any new version or amendment to any Laws which
may materially affect the procedures, process, practice or activities with respect to the import, marketing, sale or use of the Product in the Territory or the manufacture of the Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) If despite reasonable efforts of a Party under Section&nbsp;6(d) or Section&nbsp;8(d) below Product or Product-Drug is offered for sale or
sold into the Territory by an uncontrollable third party in derogation of the rights of Distributor or outside the Territory in derogation of the rights of Company and its other distributors, Distributor and Company agree that such event shall not
be deemed to constitute a breach of Section&nbsp;6(d) or Section&nbsp;8(d) below, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>COMPANY&#146;S GENERAL OBLIGATIONS</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) During the Term of this Agreement,
Company agrees to provide Distributor with the following at Company&#146;s cost in order to assist Distributor&#146;s promotional activities for Product in the Territory. Company shall have the right to hold a meeting with Distributor at the time
and place to be agreed upon by the Parties to discuss alternative activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Reasonable quantities of promotional materials and
literature in English as requested by Distributor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) Medical and commercial advice and information to assist Distributor in responding
to inquires and questions made concerning the Product by other Persons, including, customers and governmental authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii)
Technical and marketing training on the Product at a designated facility of Company for reasonable, but limited number of, Distributor&#146;s competent technical and sales representatives at times and for durations to be agreed upon by the Parties;
provided, however, [***] out-of-pocket costs for such training of Distributor&#146;s representatives and employees such as travelling, lodging and insurance are to be [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Company shall maintain ISO 13485 and Medical Device Directive certification to support the
right to continue to use the CE mark in commerce on the Product, but only if maintaining ISO 13485 and Medical Device Directive certification is required to sell the product in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Company will maintain the CE marked status for the Product for the countries covered by the CE mark and maintain all certificates and
approvals required in the European Union, but only if maintaining CE marked status for the Product is required to sell the Product in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Company shall [***]. Company shall [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Company shall not, at any time during the Initial Term, directly or indirectly import, supply, promote, market, distribute, sell or
otherwise commercialize in the Territory [***]. For purposes of clarity, the foregoing is not intended to and shall not limit Company&#146;s rights to commercialize Gel-One or the Gel-One repeat treatment label expansion or to commercialize any
Product through Distributor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) In accordance with Distributor&#146;s request and pursuant to Section&nbsp;6(a) above, Company shall
prepare and file all regulatory filings as may be required in the Territory to replace SMITH&nbsp;&amp; NEPHEW, INC&#146;s name, logo and other identifying details of the Product label with those of the Distributor. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>COMPANY&#146;S REPRESENTATIONS AND WARRANTIES</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Company hereby represents and
warrants to Distributor as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Company is a corporation duly organized, validly existing and in good standing under the laws of
Japan and has all requisite corporate power and lawful authority to own, lease and operate its assets and to carry on its business as heretofore conducted. Company has the full legal right, corporate power and authority to execute and deliver this
Agreement and the other agreements contemplated hereby and to consummate the transactions contemplated hereby and thereby. This Agreement has been duly executed and delivered by Company and constitutes the valid and binding obligation of Company,
enforceable against Company in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&#146; rights generally or by general equitable principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Company owns all rights, title and interest in the Product necessary to grant the rights contained in this Agreement to Distributor. To
[***], the Product does not and will not infringe upon any patent, trademark, trade secret or other proprietary right of any person. Nothing contained in this Agreement is in conflict with any other agreement to which Company is a party or is
otherwise bound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Company has not granted and will not grant the right to market, sell or distribute the Product or Product-Drug in
the Territory to any other Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) At the time of delivery to Distributor, all Products (i)&nbsp;shall have been manufactured
(A)&nbsp;in conformance with Good Manufacturing Practices (as such term is generally understood in the medical device and pharmaceutical industry), and (B)&nbsp;in accordance with all Laws; and (ii)&nbsp;shall be free of all valid liens,
encumbrances and security interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Company shall promptly replace any Product which fails to meet Specifications, or is
misbranded (except to the extent such misbranding occurs as a result of the acts or omissions of Distributor) or which is otherwise defective, whether the Product is owned at the time of such event by Distributor or a third party not under the
control of Company. This warranty shall not apply to any Product which has been misused, improperly stored, adulterated or modified by Distributor or any of its subdistributors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) If CE Marking Certificate is required for sale of the Product in the Territory, then Company represents and warrants that the CE Marking
Certificate for distribution of the Products in Europe has been obtained and is in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) At the time of delivery to
Distributor, all Products shall be &#147;merchantable&#148; as defined in Section&nbsp;2-314 of the Uniform Commercial Code, but only to the extent such warranty would be implied. All other implied warranties at law between the Parties are hereby
disclaimed. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>DISTRIBUTOR&#146;S GENERAL OBLIGATION</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the Term of this Agreement, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Distributor shall, and Distributor shall have its permitted subdistributors, transport, store, distribute, market and sell the Product in
accordance with directions for storage and use as indicated on ANNEX A including any amendments thereto (as provided in Section&nbsp;5(a) herein) which are in effect at the time of such transport, storage, distribution, marketing or sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Distributor shall exert its [***] to sell, distribute and promote the sales of the Product in the Territory in order to achieve the annual
minimum purchase quantities as provided for in Section&nbsp;3(c) hereof and agrees to provide Company with the following information in English (subject to occasional missing or incomplete information or delayed or undelivered communications, as may
occur): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) Safety information relating to the Product including data, report or other information relating to its side effect in the
Territory, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) [***] sales and inventory records and marketing reports of Products in the Territory with substantially
comparable detail as are currently being provided to Company as of the LOA Effective Date, within [***] ([***]) days from the last day of each Period (as such term is defined in Section&nbsp;4(a) above), including claims, complaints, questions and
comments from customers relating to quality, performance and effect of Product, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) Except as prohibited by applicable Law, and to the extent consistent with the information
being provided to Company by Distributor as of the LOA Effective Date, any and all market, marketing, business and technical information as may be reasonably requested by Company from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Distributor will provide Company with reasonable access to records for purposes of conducting quality control audits and to effect a
product recall, if necessary, as provided hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Distributor shall not, either directly or indirectly or through a third party,
sell, deliver or market Product for sale outside the Territory without the prior written consent of Company, and shall promptly refer to Company any and all inquiries and/or orders received for sales outside the Territory. Distributor shall [***].
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) In consideration of the exclusive right granted hereunder Distributor shall not, during the Term of this Agreement, promote, sell or
distribute the Product in the Territory, except for Products purchased from Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Distributor shall prepare in good faith and
provide Company with the first draft of a business plan for the Product for the following business year no later than [***] of each calendar year. The Parties shall enter into sufficient good faith discussion based on such first draft. After
considering such discussion with Company in good faith, no later than December&nbsp;31 of each calendar year, Distributor shall complete, and provide Company with, the business plan for the Product for the following business year. Distributor shall
discuss with Company whether it is appropriate to amend such business plan on a [***] after providing Company with relevant information pursuant to Section&nbsp;8(b). For avoidance of doubt, this paragraph requires communication and discussion as
provided, but does not restrict Distributor&#146;s discretion with regard to all decisions and matters concerning the development, amendment or implementation of Distributor&#146;s business plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) In connection with the re-labeling of Products, in order to prevent any occurrence of problems such as shortage of stock, Distributor
shall [***] sell off any and all existing SUPARTZ products in the inventory that are in proper condition for sale and convert the packages for SUPARTZ products to Distributor&#146;s packages at [***] cost, and use [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Distributor and Company each agrees that they shall hold the following meetings in order to maintain good business relationships between
them and to further expand the SUPARTZ business (subject to occasional postponements, missed meetings or cancellations as may occur): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">Top management meeting ([***]); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">[***] business meeting ([***]); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">Teleconference ([***]) </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>DISTRIBUTOR&#146;S REPRESENTATIONS AND WARRANTIES</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distributor hereby represents
and warrants to Company as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Distributor is a limited liability company duly organized, validly existing and in good standing
under the laws of the State of Delaware and has all requisite corporate power and lawful authority to own, lease and operate its assets and to carry on its business as heretofore conducted. Distributor has the full legal right, corporate power and
authority to execute and deliver this Agreement and the other agreements contemplated hereby and to consummate the transactions contemplated hereby and thereby. This Agreement has been duly executed and delivered by Distributor and constitutes the
valid and binding obligation of Distributor, enforceable against Distributor in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&#146; rights
generally or by general equitable principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Nothing contained in this Agreement is in conflict with any other agreement to which
Distributor or its Affiliates is or may become a party or is otherwise bound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Distributor shall distribute, market, and sell the
Product in accordance with the Laws of the Territory. Company agrees to provide Distributor with all information and assistance required in order for Distributor to comply with the foregoing obligation to the extent reasonably possible. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>TRANSFER OF DATA; CONFIDENTIALITY</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Parties acknowledge that Company has
or is in the process of conducting studies on the Product or Product-Drugs necessary to register the Product for marketing and sales in the Territory. No later than [***] ([***]) days after the execution and delivery of this Agreement, Company shall
deliver to Distributor copies of a detailed summary of pre-clinical and clinical studies on Product or Product-Drugs and other similarly detailed data in Company&#146;s possession or control as of such date which Company and Distributor reasonably
determine is relevant to the safety, efficacy, regulatory status, sale, marketing or distribution of the Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) During the Term of
this Agreement: (i)&nbsp;Company shall provide to Distributor any subsequently acquired data which Company and Distributor reasonably determine is relevant to the safety, efficacy, regulatory status, sale, marketing or distribution of the Product or
Product-Drug; and (ii)&nbsp;each of the Parties shall deliver to the other Party all relevant data and Registration Dossier(s) relating to use of the Product or Product-Drug, and results from any studies being conducted by or on behalf of either
Party in connection therewith promptly after such data and/or Registration Dossier(s) become available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Parties acknowledge that
discussions between Company and Distributor in written form and orally will necessarily require the exchange of information that is considered confidential and proprietary by the disclosing Party. The Parties agree that any information on which the
disclosing Party designates the mark &#147;confidential&#148; in the written form or in a written confirmation made within thirty (30)&nbsp;days from the oral disclosure shall be considered &#147;Confidential Information&#148; and shall include,
without limitation, (i)&nbsp;the Know-How; (ii)&nbsp;earnings, costs, and other financial information; (iii)&nbsp;drawings, formulations, samples, technical data, photographs, specifications, manufacturing methods, testing procedures, clinical
studies date; and (iv)&nbsp;marketing, sales and customer information relating to the disclosing Party&#146;s business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Parties agree that both during the Term of this Agreement and for a period of
[<B>***</B>] ([<B>***</B>]) years thereafter each Party shall keep, and shall cause the directors, officers, employees and agents of such Party or its Affiliates or third party subdistributors to keep, confidential any and all Confidential
Information acquired from the other Party to the same extent as such Party protects its own confidential information, and shall not use for any other purpose than to discharge such Party&#146;s obligations and exercise its rights hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Confidential Information shall not include information which (i)&nbsp;is or hereafter becomes available to the general public other than
by reason of any default with respect to a Party&#146;s confidentiality obligation hereunder, (ii)&nbsp;is demonstrated by documentary evidence to have been known at the time of receipt thereof by the receiving Party, (iii)&nbsp;can be shown to have
been developed or acquired independently without breach of any obligations contained herein, or (iv)&nbsp;is required to be disclosed as a result of a judicial order or decree or applicable Law or regulation; provided however, that the Party whose
Confidential Information is the subject of such judicial order or decree is given the opportunity to contest the judicial order or decree prior to any disclosure. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>PATENTS AND PROTECTION OF DISTRIBUTOR&#146;S RIGHT TO DISTRIBUTE PRODUCT AND PRODUCT DRUG</U> </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Patent Prosecution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i)
Company will file, prosecute and maintain patents within the Territory relating to the Product packaging, use or sale (but not manufacture) of the Product (&#147;Patents&#148;) as Company may elect. If Company elects not to file, prosecute or
maintain a Patent in any country in the Territory, then Company shall notify Distributor. Distributor shall have the right, within [***] ([***]) days following receipt of Company&#146;s notice, to assume responsibility for filing, prosecuting or
maintaining such Patent, which Patent shall be considered a &#147;Distributor Sponsored Patent.&#148; Distributor Sponsored Patents are considered Patents under this Agreement, except where expressly provided herein to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) Company hereby grants to Distributor an exclusive royalty-free non-transferable license to use the Patents (subject to the
Confidentiality provisions of Section&nbsp;10 herein) in the Territory in connection with the marketing, distribution and sale of the Product. Distributor shall acknowledge the Patents (pending or granted) in Distributor&#146;s labeling and
promotional materials relating to the Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) All costs and expenses incurred with respect to the filing, prosecution and/or
maintenance of Patents (other than Distributor Sponsored Patents) shall be paid by Company, including all reasonable costs for the prosecution, issuance and maintenance of Patent applications and Patents issuing thereon, and any divisional,
continuations, continuation-in-part, reissue applications or Patents, Patents of addition, Patents of revalidation or the registrations or any Patent or the like. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 14 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) Company shall cooperate and assist Distributor in the filing, prosecution and maintenance of
Distributor Sponsored Patents. Distributor shall own all Distributor Sponsored Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Patent Enforcement and Enforcement of
Distributor&#146;s Right to Distribute Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) If any of the Patents in the Territory are infringed by a third party, the Party
which discovers the infringement shall promptly notify the other Party in writing. The Parties shall [<B>***</B>] with enforcement of rights against the infringer and the division of any awards or settlement payments. [<B>***</B>]. The Parties shall
keep each other informed as to the prosecution of any action for such infringement. The Parties shall cooperate with each other with respect to any such action. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>TRADEMARKS</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) (i) Company hereby grants to Distributor for the Term of this
Agreement the exclusive, royalty-free right to use the trademark &#147;SUPARTZ&#148; (or such other trademarks as may be mutually agreed by the Parties) (the &#147;Trademark&#148;) in connection with the marketing, distribution and sale of the
Product in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) In the event the name &#147;SUPARTZ&#148; is not available for Company to register in a country in the
Territory or is reasonably judged by the Parties to be inadequate based on special reason or situation of a country in the Territory, the Parties will select a new name from candidates proposed by Company and verified by Company to be available in
the country, which mark shall also be considered a Trademark for purposes of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) Company shall register, and maintain
the Trademark in the Territory as Company may elect [<B>***</B>]. Distributor shall assist and cooperate with Company in connection with the maintenance of Trademark in the Territory. If Company elects not to maintain the Trademark in a country
within the Territory, Company shall notify Distributor and Distributor shall have the right to require Company to register and maintain the Trademark in that country (&#147;Distributor Sponsored Trademark&#148;). In that event, all costs and
expenses thereafter incurred by Company with respect to the preparation of Trademark registration application for, and with respect to the filing and/or maintenance of the Trademark registration in that country shall be [<B>***</B>]. Distributor
shall not use any trademark confusingly similar to the Trademark within or outside the Territory without the prior written consent of Company. Company shall not use any trademark confusingly similar to the Trademark within the Territory without the
prior written consent of Distributor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Distributor may not sublicense the Trademark to any third party, however, the use of the
Trademark by Distributor&#146;s Affiliates and subdistributors for marketing, distributing and selling Product is permitted and approved herewith by Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 15 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Distributor and Company shall work together to develop a mutually acceptable package and
label for the Product, which package and label shall include the Trademark and other design elements as are mutually acceptable to both Parties. The use and presentation of the names, Trademarks and logos on the packaging and labeling of the Product
are to be attached hereto as ANNEX&nbsp;B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) If the Trademark is infringed by a third party in the Territory, the Party which discovers
the infringement shall promptly notify the other Party in writing. The Parties shall [<B>***</B>] with enforcement of rights against the infringer and the division of any awards or settlement payments. [<B>***</B>]. The Parties shall keep each other
informed as to the prosecution of any action for such infringement. The Parties shall cooperate with each other with respect to any such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) In the event of the institution of any suit by a third party against Company or Distributor for trademark infringement involving the
Trademark (other than Distributor Sponsored Trademarks), Company shall defend each such action [<B>***</B>] with attorneys selected by Company and reasonably acceptable to Distributor, Distributor shall assist and cooperate with Company to the
extent reasonably necessary in the defense. Company shall [<B>***</B>] with such third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as provided in Section&nbsp;13, upon termination of
this Agreement for any reason (other than breach by Company), the license granted in this Section&nbsp;12 shall immediately terminate with respect to Trademarks (other than Distributor Sponsored Trademarks), and Distributor shall immediately cease
all use of the Trademark (other than Distributor Sponsored Trademarks), except with respect to Products acquired by Distributor prior to the termination of this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>TERM AND TERMINATION</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) This Agreement shall continue for a period of five
(5)&nbsp;years from the LOA Effective Date (the &#147;Initial Term&#148;), unless terminated earlier as specifically provided in this Section&nbsp;13. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Distributor has the right to renew this Agreement for one (1)&nbsp;renewal term of two (2)&nbsp;years upon expiration of the Initial Term
if and only if the following two conditions are satisfied: (1)&nbsp;Distributor provides a written notice to Company no later than one hundred and eighty (180)&nbsp;days prior to the expiration of the Initial Term; and (2)&nbsp;Distributor makes a
non-refundable payment to Company in the an amount equal to the lesser of (i) the purchase price for the number of Units by which Distributor&#146;s orders fell short of the required minimum for the year and (ii) One Million Dollars ($1,000,000).
Such payment shall be made no later than the commencement of the renewal term. In addition, if Distributor fails to order a minimum of [<B>***</B>] ([<B>***</B>]) Units from Company during any full calendar year of the Initial Term, then (subject to
the remainder of this Section), such failure shall not constitute a breach of this Agreement, but, in such event, Company shall have the right to change this Agreement from exclusive to non-exclusive upon at least sixty (60)&nbsp;days&#146; prior
notice to Distributor and this Agreement shall be amended accordingly. Notwithstanding any other provision of this Section&nbsp;13(b), to the extent that a failure to meet the order requirements set forth in this Section can be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 16 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
</B>reasonably attributed to Negative Developments, then the Parties shall negotiate in good faith an appropriate reduction of the minimum order quantity or other appropriate means to offset the
impact of the Negative Developments. In addition, Distributor shall have the right to reinstate this Agreement as exclusive by making a non-refundable payment to Company in an amount equal to [<B>***</B>]. Such payment shall be made no later than
the expiration of the 60- day notice period or 30 days after completion of any negotiation of reduction in the minimum order quantity. Insofar as any payment in this Agreement is referred to as &#147;non-refundable,&#148; such reference shall be
without prejudice to recovery by Distributor from Company of all or any portion of such payments in connection with any rights or remedies that Distributor may seek as a result of a breach of this Agreement by Company, including, but not limited to,
recovery of the same as an element of damages. The Initial Term of five (5)&nbsp;years and the two (2)&nbsp;year renewal term, if applicable, shall be collectively referred to as the &#147;Term.&#148;<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding the foregoing, this Agreement may be terminated by giving written notice to the other Party: (i)&nbsp;if the other Party
commits a material breach of any term or condition of this Agreement which is susceptible to cure, and the breaching Party shall have failed to cure such breach within sixty (60)&nbsp;days from the receipt by it of written notice thereof from the
other Party; (ii)&nbsp;if the other Party commits a material breach which is not susceptible to cure; (iii)&nbsp;if the other Party shall commence any case, proceeding or other action (A)&nbsp;under any applicable Law relating to bankruptcy,
insolvency, reorganization or relief of debtors, seeking to have an order for relief entered with respect to it, or seeking to adjudicate it as bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, wind-up, liquidation,
dissolution, composition or other relief with respect to it or its debts, or (B)&nbsp;seeking appointment of a receiver trustee, custodian or other similar official for it or for all or any substantial part of its assets; (iv)&nbsp;if there shall be
commenced against the other Party any such case, proceeding or other action referred to in clause (iii)&nbsp;of this Section&nbsp;13(c) which results in the entry of an order for relief; (v)&nbsp;if the other Party shall take any action authorizing,
or in furtherance of, or indicating its consent to, approval of, or acquiescence in, any of the acts set forth above in clauses (iii)&nbsp;or (iv)&nbsp;of this Section&nbsp;13(c); or (vi)&nbsp;if the other Party shall admit in writing its inability
to pay its debts as they become due. Notwithstanding the termination of this Agreement pursuant to this subsection, the non-defaulting Party shall retain all rights and remedies available at law or in equity against the defaulting Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Company shall have the right to immediately terminate this Agreement if Distributor fails to pay any undisputed amount due under
Section&nbsp;4 within [<B>***</B>] business days after Distributor receives written notice of nonpayment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The termination of this
Agreement for any reason (other than a breach by Company) shall be without prejudice to Company&#146;s right to receive all payments accrued and unpaid at the effective date of termination or to the remedy, in accordance with the terms herein, of
either Party hereto in respect of any previous breach of any covenant contained herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 17 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Upon termination of this Agreement, each Party shall promptly (i)&nbsp;on request return to
the requesting Party all of the requesting Party&#146;s records, materials and Confidential Information in the possession or control of the other Party, or its Affiliates, suppliers or third party subdistributors, except promotional materials
reasonably required by Distributor to promote, distribute or sell Products remaining in its inventory as permitted by this Section&nbsp;13(f), and (ii)&nbsp;discontinue all distribution of the Product, except as otherwise permitted pursuant to
Section&nbsp;3(d) above and 13(g) below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Termination of this Agreement shall not terminate Distributor&#146;s obligation to pay the
purchase price for Product which has been received by Distributor under this Agreement, and upon any termination of this Agreement, Distributor shall continue to sell all of the remaining Products in its inventory. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>INDEMNIFICATION</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Company shall indemnify, defend and hold harmless
Distributor, including its officers and directors, from and against any and all damages, liabilities, costs and expenses, including, without limitation, reasonable attorney&#146;s fees, arising out of: (i)&nbsp;breach of Company&#146;s
representations and warranties; (ii)&nbsp;any claim relating to the manufacture of the Product or delivery of the Product to Distributor, including without limitation death, personal injury or damage to property resulting from defects, contamination
or other condition of the Product; (iii)&nbsp;infringement of patents or trademarks of a third party; or (iv)&nbsp;the act or omission of Company, its agents and representatives. In the event the Product becomes, or if Company reasonably believes
the Product is likely to become, infringing upon the proprietary rights of a third party, Company shall, in addition to its other obligations hereunder, under consultation with Distributor, use its best efforts to take such actions so as to allow
Distributor to continue to sell, distribute and promote the Product in the Territory without infringement on the patents or trademarks of third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event Distributor is enjoined, prohibited, restricted for a period of at least six (6)&nbsp;months from selling, distributing or marketing the Product
in any part of the Territory due to patent infringement, then Distributor shall have the right to terminate this Agreement with respect to the affected portion of the Territory by providing Company with fifteen (15)&nbsp;days&#146; prior written
notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Distributor shall indemnify, defend and hold harmless Company, including its officers and directors, from and against any and
all damages, liabilities, costs and expenses, including without limitation reasonable attorney&#146;s fees, arising out of (i)&nbsp;any breach of Distributor&#146;s representations and warranties or (ii)&nbsp;any claim relating to the sale,
marketing, distribution or other disposition of the Product by Distributor, Distributor&#146;s Affiliates or subdistributors, including without limitation, death, personal injury or damage to property resulting from the sale, marketing, or handling
of the Product by Distributor, Distributor&#146;s Affiliates or Distributor&#146;s sub-distributors, unless such damage liability, cost or expense is caused by Company or breach of this Agreement by Company, in which case Company shall indemnify and
hold Distributor harmless as set forth in Section&nbsp;14(a) of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 18 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If Distributor or Company intends to claim indemnification under this Section, such Party
(the &#147;Claiming Party&#148;) shall (i)&nbsp;promptly notify the other Party in writing of any claim or loss for which it intends to claim such indemnification, (ii)&nbsp;cooperate fully with the other Party and its legal representatives in the
investigation of any claim or loss covered by this Section, and (iii)&nbsp;allow the other Party to control the defense and/or disposition of such suit or claim. Neither Party shall have any indemnification obligations hereunder to the extent that
such Party&#146;s ability to defend such suit or redress such loss is prejudiced by the Claiming Party&#146;s failure to perform the obligations set forth in the preceding sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>(d) Both Parties shall obtain and maintain a policy or policies of product liability insurance coverage that shall: (i)&nbsp;have a per
occurrence and annual aggregate limit of not less than [<B>***</B>]; (ii)&nbsp;include Distributor as an insured with regard to Company&#146;s policy or policies, and include Company as an additional insured with regard to Distributor&#146;s policy
or policies, in both cases for occurrences arising out of issues related to the responsibility of each Party, (iii)&nbsp;provides for at least [<B>***</B>] ([<B>***</B>]) days&#146; advance written notice to the other Party of cancellation or
material reduction in coverage and (iv)&nbsp;have a policy scope of [<B>***</B>] which will provide coverage claims. Each Party shall provide the other Party with a certificate evidencing such coverage upon reasonable request.<B> </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>ASSIGNMENT AND SUB-DISTRIBUTION RIGHTS AND RIGHT OF FIRST REFUSAL </U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except as
expressly provided herein to the contrary, neither Party shall assign or transfer (whether by operation of law or otherwise) its rights and obligations under this Agreement to any Person without the prior written consent of the other Party, such
consent not to be unreasonably withheld, delayed, or conditioned on terms not directly related to the assignment. This Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything herein to the contrary, this Agreement shall continue in full force and effect in the event of a Change in
Control (as defined below) involving either Party, <U>unless</U> as a result of or in connection with such Change in Control, (i)&nbsp;a Distributor Competitor (as defined below) becomes the beneficial owner of more than 50% of the voting capital
stock of Company or (ii)&nbsp;a Company Competitor (as defined below) becomes the beneficial owner of more than 50% of the voting capital stock of Distributor. In the case of such circumstances as described in the immediately preceding sentence, the
non-transferring Party shall have the right, in its sole discretion, to immediately terminate this Agreement. For purposes of this Agreement, (i)&nbsp;a &#147;Change in Control&#148; means a transaction or a series of transactions as a result of
which a Person or group (as defined in Section&nbsp;13(D) of the Securities Act of 1933, as amended) acquires control (as defined in the definition of Affiliate) of a Party, (ii)&nbsp;&#147;Distributor Competitor&#148; means any Person which derives
more than 50% of its revenues from the sales of orthopedic medical devices and has in excess of [<B>***</B>], and (iii)&nbsp;&#147;Company Competitor&#148; means any Person which [<B>***</B>]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 19 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) As of the LOA Effective Date, SMITH&nbsp;&amp; NEPHEW, INC. and its Affiliates shall own
forty-nine percent (49%)&nbsp;of the voting securities in the Distributor. Notwithstanding anything herein to the contrary, in the event that, within two (2)&nbsp;years from the LOA Effective Date, SMITH&nbsp;&amp; NEPHEW, INC. or its Affiliates
sell or transfer any of their voting securities in the Distributor (other than inter-company sales or transfers between SMITH&nbsp;&amp; NEPHEW, INC. and any of its Affiliates or between any such Affiliates), then the Company shall have the right,
in its sole discretion, to terminate this Agreement upon written notice to Distributor. For purposes of this Section&nbsp;15(c), &#147;Affiliates&#148; of SMITH&nbsp;&amp; NEPHEW, INC. shall mean Affiliates as such term is defined in Section&nbsp;22
of this Agreement, excluding, however, its clause (i)&nbsp;with regard to &#147;control.&#148; For purposes of clarity, issuance of additional voting securities by the Distributor shall not constitute a sale or transfer of voting securities by
SMITH&nbsp;&amp; NEPHEW, INC. or its Affiliates. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>GOVERNING LAW AND DISPUTE RESOLUTION</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) This Agreement shall be governed by and
construed in all respects in accordance with the laws of the State of New York, without reference to the conflict of laws rules thereof or the United Nations Convention on Contracts for the International Sale of Goods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>(b) The Parties shall attempt in good faith to resolve any dispute or claim between them arising out of or relating to this Agreement
promptly by negotiations between executives or other representatives of the Parties with authority to resolve the dispute. If a dispute should arise, such representatives shall confer in person or by telephone at least once and attempt to resolve
the matter. Such conference shall take place within [<B>***</B>] ([<B>***</B>]) days of a written request therefor at a mutually agreed time and location. Such conference is a condition precedent to initiating arbitration as provided below, unless
the responding Party fails to confer within [<B>***</B>] ([<B>***</B>]) days of the request to do so, but is not a condition precedent to initiating an action for interim injunctive or provisional relief necessary to avoid irreparable harm or to
maintain the status quo.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the dispute is not settled within [***] ([***]) days of the conference or time to confer described above, either Party
may submit the dispute for arbitration. The dispute shall be finally settled under the Rules of Arbitration (the &#147;Rules&#148;) of the International Chamber of Commerce (the &#147;ICC&#148;). The place of the arbitration shall be [***]. The
language of the arbitration shall be English with simultaneous translation into Japanese at the request of either Party. There shall be three (3)&nbsp;arbitrators, one (1)&nbsp;of whom shall be appointed by each of the Parties in accordance with the
Rules, and the third of whom shall be appointed by the ICC. The arbitrator appointed by the ICC shall act as the chairperson of the arbitrating body. The arbitrators shall decide the matters in the dispute in accordance with the laws of the State of
New York, without reference to the conflict of laws rules thereof or the United Nations Convention on Contracts for the International Sale of Goods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
arbitration shall also be governed by the United States Arbitration Act, 9 U.S.C. &#167;&#167; 1-16, 201-208, including the United Nations Convention on the Recognition and Enforcement of Foreign Arbitral Awards of June&nbsp;10, 1958. The
arbitration shall be commenced and shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 20 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceed according to the Rules, except as otherwise provided herein. Any Confidential Information disclosed in the arbitration shall be subject to the confidentiality provisions of this
Agreement. Any time period specified in the Rules shall be extended or accelerated upon the Parties&#146; written agreement. At the request of either Party, all time periods specified in the Rules may, at the discretion of the arbitrators, be
accelerated or extended to the extent necessary to comply with the timetables specified in the Rules or for the reasonable management of the arbitration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>The procedures specified in this Section&nbsp;16(b) shall be the sole and exclusive procedures for the resolution of disputes; provided, however, that
a Party may, in addition or as an alternative to seeking interim relief from the ICC, seek injunctive or other provisional judicial relief in any court of competent jurisdiction if in its reasonable judgment such action is necessary to avoid
irreparable harm or to preserve the status quo. The Parties agree to submit to the jurisdiction of [<B>***</B>], solely for the purposes of any such action. Despite such action the Parties will continue to participate in good faith in the procedures
specified in this Section 16(b).<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The decision of the arbitrators shall be final and binding on all Parties to the arbitration. Judgment upon any
award rendered by the arbitrators may be entered by any court having jurisdiction over the Party against whom enforcement is sought. Each of the Parties hereby consents, for the benefit of the other Party, to the service of process by certified mail
or registered mail or by an express delivery service providing a return receipt at its address set forth for notices herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While the procedures set
forth above are being followed, the Parties shall continue to perform their respective obligations under this Agreement. Each Party shall bear its own costs and fees, including attorneys&#146; fees and expenses, in connection with the arbitration,
except that the arbitrators shall be empowered to assess costs and fees against any Party who the arbitrators find to have acted in bad faith or to have maintained a frivolous position in the arbitration. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>NOTICES</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All notices given under this Agreement shall be in writing and shall be
delivered by first class mail or overnight courier or by facsimile transmission (receipt verified) and addressed to the Parties at their respective addresses set forth below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">SEIKAGAKU CORPORATION </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Marunouchi
Center Building </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">6-1, Marunouchi 1-chome, Chiyoda-ku </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Tokyo 100-0005, Japan </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention:
[***]. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Fax: +81-3-5220-8975 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 21 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">BIOVENTUS LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4721 Emperor Blvd. Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Durham, NC 27703 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fax:
[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">With a copy to: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">BIOVENTUS LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4721 Emperor Blvd.
Suite 100 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Durham, NC 27703 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Either Party may change its address or its telecopy number for purposes of this Agreement by giving the other Party written notice of its new address or
telecopy number. Any such notice, if given by first class mail or overnight courier, shall be deemed to have been received on the date actually received and if given by telecopy transmission shall be deemed to have been received at the time of
dispatch or the next regular business day if received after 5:00 p.m. local time of the recipient. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>WAIVER AND DELAY</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No waiver by either Party of any breach or series of breaches
by the other Party, and no failure, refusal or neglect of either Party to exercise any rights granted to it hereunder or to insist upon strict compliance with or performance of either Party&#146;s obligations under this Agreement shall constitute a
waiver of the provisions of this Agreement with respect to any subsequent breach thereof or a waiver by either Party of its rights hereunder or otherwise at any time thereafter. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>FORCE MAJEURE</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>A Party shall be excused from failure to perform its
obligations under this Agreement, including without limitation Distributor&#146;s obligations to purchase a minimum purchase quantity pursuant to Section&nbsp;3(c) above, and from sanction for failure to meet minimum order requirements pursuant to
Section&nbsp;13(b) above, if any such failure is caused by a Force Majeure and without the fault or negligence of such Party. For the purposes of this Agreement, &#147;Force Majeure&#148; is defined as causes beyond the reasonable control of the
Party, including, without limitation, acts of God, storm, war, riot, earthquake, tsunami, fire, flood, terrorism, pandemic, nuclear accident, cyber incident, biochemical incident, explosion, governmental orders or restrictions, shortage of
materials, power cut, power shortage, or strikes or other labor troubles. Upon occurrence of a Force Majeure, the Party claiming Force Majeure shall immediately notify the other Party of such Force Majeure and its effect on such Party&#146;s ability
to perform its obligations hereunder and the period during which such inability is expected to continue. The duties and obligations of the Parties shall be suspended for the duration of the event; provided, however, that if such suspension shall
continue in excess of [<B>***</B>], the Parties shall attempt to arrive at a mutually acceptable compromise within the spirit and intent of this Agreement.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 22- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>ENTIRE AGREEMENT</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement (with Exhibits) contains all of the terms and
conditions agreed upon by the Parties hereto with respect to the subject matter hereof. No other agreement, oral or otherwise, shall be deemed to exist or to bind either of the Parties hereto, and all prior agreements and understandings with respect
to the subject matter hereof are superseded hereby This Agreement cannot be modified or changed except by written instrument signed by both of the Parties hereto. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>SEVERABILITY</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any provision of this Agreement is declared invalid or
unenforceable by the arbitration or a court having competent jurisdiction, it is mutually agreed that the other provisions of this Agreement shall survive. The Parties shall consult and use all commercially reasonable efforts to agree upon a valid
and enforceable provision which shall be a reasonable substitute for such invalid or unenforceable provision in light of the intent of this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>22.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>DEFINITIONS</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the following terms shall have the
meanings set forth in this Section unless the context dictates otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148;, with respect to any Party, shall
mean any Person controlling, controlled by, or under common control with, such Party. For these purposes, &#147;control&#148; shall refer to (i)&nbsp;the possession, directly or indirectly, of the power to direct the management or policies of a
Person or to veto any material decision relating to the management or policies of a Person, in each case, whether through the ownership of voting securities, by contract or otherwise, or (ii)&nbsp;the ownership, directly or indirectly, of at least
50% of the voting securities of a Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Annual Forecast</U>&#148; shall have the meaning set forth in Section&nbsp;3(c) of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Audit</U>&#148; shall have the meaning set forth in Section&nbsp;4(d) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Average Selling Price per Unit</U>&#148; shall have the meaning set forth in Section&nbsp;4(a) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Change in Control</U>&#148; shall have the meaning set forth in Section&nbsp;15(b) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Claiming Party</U>&#148; shall have the meaning set forth in Section&nbsp;14(c) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company</U>&#148; shall have the meaning set forth in the first paragraph of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 23 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Competitor</U>&#148; shall have the meaning set forth in Section&nbsp;15(b) of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Confidential Information</U>&#148; shall have the meaning set forth in Section&nbsp;10(c) of this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Distributor</U>&#148; shall have the meaning set forth in the first paragraph of this Agreement of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Distributor Competitor</U>&#148; shall have the meaning set forth in Section&nbsp;15(b) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Distributor Sponsored Patent</U>&#148; shall have the meaning set forth in Section&nbsp;11(a)(i) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Distributor Sponsored Trademark</U>&#148; shall have the meaning set forth in Section&nbsp;12(a)(iii) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Dollars</U>&#148; or &#147;<U>$</U>&#148; refers to United States dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>EDA</U>&#148; shall have the meaning set forth in Paragraph B of the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Effective Date</U>&#148; shall have the meaning set forth in the first paragraph of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Existing Agreements</U>&#148; shall have the meaning set forth in Paragraph B of the recitals of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDA</U>&#148; shall mean the United States Food and Drug Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Force Majeure</U>&#148; shall have the meaning set forth in Section&nbsp;19 of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;[<U>***]</U>&#148; shall mean a [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>HA</U>&#148; shall have the meaning set forth in Paragraph A of the recitals in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Initial Term</U>&#148; shall have the meaning set forth in Section&nbsp;13(a) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Know-How</U>&#148; shall mean any and all technical data, information, materials and other know-how, developed or acquired by
Company, either as of the Effective Date or at any time during the Term of this Agreement, which relates to the manufacture and use of Products or Product-Drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Laws</U>&#148; shall have the meaning set forth in Section&nbsp;5(i) of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 24 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>LOA Effective Date</U>&#148; shall mean the date of the closing of the transaction
transferring SMITH&nbsp;&amp; NEPHEW INC.&#146;s clinical therapies business, including the Product business, to Distributor the principal owners of which are SMITH&nbsp;&amp; NEPHEW, INC. and/or its Affiliates and Essex Woodland Health Ventures
and/or its Affiliates. For purposes of the foregoing, &#147;Affiliates&#148; of SMITH&nbsp;&amp; NEPHEW, INC. shall mean Affiliates as such term is defined in this Section&nbsp;22, excluding, however, its clause (i)&nbsp;with regard to
&#147;control.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Net Sales</U>&#148; shall mean the gross amount invoiced by Distributor or its Affiliates for the sale of
the Product to third parties in the Territory, less (i)&nbsp;returns of Products; (ii)&nbsp;sales, use, value-added, excise, or other similar taxes, which taxes are included in the gross amount invoiced by Distributor or its Affiliates for the sale
of the Product to third parties in the Territory; (iii)&nbsp;trade discounts; and (iv)&nbsp;freight and insurance costs. A &#147;sale&#148; shall not include [<B>***</B>], or any transfer or disposition of the Product for pre-clinical, regulatory or
governmental purposes prior to receiving marketing approval. For purposes of calculating &#147;Net Sales,&#148; Product shall be considered &#147;sold&#148; upon the invoicing of such Product by Distributor or Distributor&#146;s Affiliate to a third
party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Net Units Sold</U>&#148; shall have the meaning set forth in Section&nbsp;4(a) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Party</U>&#148; and &#147;<U>Parties</U>&#148; shall have the meaning set forth in the first paragraph of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Patents</U>&#148; shall have the meaning set forth in Section&nbsp;11(a)(i) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; shall mean any natural person, corporation, firm, limited liability corporation, limited liability partnership,
business trust, joint venture, association, organization, company, partnership or other business entity, or any government or any agency or political subdivision thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Product</U>&#148; shall mean an intra-articular, injectable solution of 1wt% of highly purified HA in a syringe for treatment of
osteoarthritis of the knee and requiring three (3) or more injections under the FDA approval PMA P980044. It shall include [<B>***</B>]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Product-Drug</U>&#148; shall mean the Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Proposed Recall</U>&#148; shall have the meaning set forth in Section&nbsp;5(h)(2) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Purchase Price</U>&#148; shall have the meaning set forth in Section&nbsp;4(a) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Receiving Party</U>&#148; shall have the meaning set forth in Section&nbsp;5(a) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registration Dossier</U>&#148; shall mean a written regulatory submission or document describing Product Specifications and
manufacturing methods as submitted by Company and approved by the applicable regulatory agency and Distributor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Regulatory
Conditions</U>&#148; shall have the meaning set forth in Section&nbsp;2(c)(i). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 25 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Requesting Party</U>&#148; shall have the meaning set forth in Section&nbsp;5(a) of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Sample&#148; shall mean samples and [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Specifications</U>&#148; shall have the meaning set forth in Section&nbsp;5(a) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Statement</U>&#148; shall have the meaning set forth in Section&nbsp;4(b) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Term</U>&#148; shall have the meaning set forth in Section&nbsp;13(b) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Territory</U>&#148; shall have the meaning set forth in Section&nbsp;2(a) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Testing Methods</U>&#148; shall have the meaning set forth in Section&nbsp;5(c) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trademark</U>&#148; shall have the meaning set forth in Section&nbsp;12(a)(i) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Unit</U>&#148; shall mean a <B></B>syringe containing 2.5&nbsp;ml solution of <B></B>1.0wt% HA and blister packaged. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>23.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>PUBLIC ANNOUNCEMENTS </U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as required by applicable Law or any securities
exchange or the NASD, neither Party shall issue any press release or make any other public announcement concerning this Agreement or the subject matter hereof without the prior written consent of the other Party, which consent shall not be
unreasonably withheld. In the event of a required press release or other public announcement, the Party making such announcement shall provide the other Party with a copy of the proposed text prior to such announcement. The Parties agree that if
either Party is required to file this Agreement with any governmental agency, such Party shall delete the unrelated parts, provisions or words of this Agreement to the extent possible in order to keep the terms of this Agreement confidential. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 26 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>24.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>MISCELLANEOUS</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Parties agree that each Party is an independent
contractor. Employees and agents of one Party are not employees or agents of the other, shall not hold themselves out as such, and shall not have any authority or power to bind the other Party to any contract or other obligation. Nothing in this
Agreement is intended or shall be deemed to constitute a partnership, agency, employer-employee or joint venture relationship between the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Except as otherwise expressly provided in this Agreement, each Party shall bear all of its costs and expenses associated with the
performance of such Party&#146;s obligation under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Captions used in this Agreement are for convenience only and shall
not be deemed to affect the meaning or construction of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) This Agreement may be executed in one or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) This Agreement is
neither expressly nor impliedly made for the benefit of any party other than the Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 27 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>25.</B></TD>
<TD ALIGN="left" VALIGN="top"><B><U>SET-OFF</U> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Party shall have a right of off-set against payment due from it to
recover any amounts due from the other Party under the terms of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 28 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the Parties have caused this Agreement to be executed by their duly
authorized representatives. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SEIKAGAKU CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ken Mizutani</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ken Mizutani, President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BIOVENTUS LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Augusti</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mark Augusti, CEO</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement is also agreed and acknowledged by SMITH&nbsp;&amp; NEPHEW, INC. for purposes of Sections
4(h) and 15(c). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert A. Lucas</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Robert A. Lucas</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Assistant Secretary</P></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Quality Specification) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supartz is a sterile
aqueous viscoelastic solution designed for intra-articular injection in order to treat osteoarthritis of the knee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>The product is [<B>***</B>].<B>
</B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Product Specification:</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt ;margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>[***]</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><U>[***]</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt ;margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt ;margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt ;margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt ;margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt ;margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt ;margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt ;margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt ;margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt ;margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt ;margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Shelf Life:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt ;margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[<B>***</B>]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Storage:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt ;margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Direction for Use:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt ;margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[<B>***</B>]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used above, [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company
shall be responsible, as the Requesting Party for the changes included in this attached ANNEX A as compared with any prior ANNEX A, to prepare and file all regulatory filings as may be required in the Territory as a result of such changes, and,
insofar as such filings are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required, this ANNEX A shall not be effective prior to the date such filings are made become effective and, insofar as future regulatory filings in the Territory become necessary as a result of
changes to the [<B>***</B>] where referenced in the attached ANNEX A, Company, as the Requesting Party, shall prepare and file the same. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Confidential treatment has been
requested with respect to the omitted portions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties acknowledge that the Existing Agreements do not include an ANNEX B as of the LOA Effective Date. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d22578dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in this Registration Statement on Form S-1 of Bioventus Inc.<B> </B>of our report dated April 19, 2016, except for the effects of
the revision discussed under the caption &#145;May 2016 Revision&#146; in Note 19 to the consolidated financial statements of Bioventus LLC, as to which the date is May 26, 2016, and except for the effects of the revision discussed under the caption
&#145;July 2016 Revision&#146; in Note 19 to the consolidated financial statements, as to which the date is July 19, 2016, which appears in the Registration Statement on Form S-1. We also consent to the reference to us under the heading
&#147;Experts&#148;<B> </B>in such Registration Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Raleigh, North Carolina </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 27, 2016 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>d22578dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in this Registration Statement on Form S-1 of Bioventus Inc.<B> </B>of our report dated February 1, 2016 relating to the financial
statements of BioStructures, LLC, which appears in the Registration Statement on Form S-1. We also consent to the reference to us under the heading &#147;Experts&#148;<B> </B>in such Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Raleigh, North Carolina </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 27, 2016 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g22578dsp_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g22578dsp_3.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M=6M=W5FWJKV5[]D]-6]+/F5E"S3AUTMK9Z==.MW:^R6K:_$#X:>--3_X*+?
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K 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g22578g16j40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g22578g16j40.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "D 2<# 1$
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M%N&CP0D\U$N^U)-6KS1=PR4<Z+M6NVJW'>Z/&E6)Z/%=IB\:?;B[I-DI9"C
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"N_5=Y 9[
M^EOC2.9E!TEW[F8Q]%]V]$B5#Y)JO]7<*^&AF1XWI>\JQ+0MQ(F0HP!@# (X
MG/\ ,E/^L<A^T]H95B>CQ1'C6GP9(^0HP!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , KOU7>0&>_I;XTCF90=)=^YF,?1?=O1(E0^2
M:K_5W"OAH9D>-Z7O*L2T+<0]UCO6(BC2YTK^&MPX:01-8PVF_4?)>E2#.AA0
MZTCCKB96[$Q!TRT ,]37!-:+(C'NLT=L&<:Y9$E""0I]#)><">QD?="#M@:@
M4]D(+FN$(JYGVH:)CJ=ZJISU85FB($1&,.WCP3*9X"BQ"$'U9,:D(F10$?%H
MZ,8I@@YC4<N],O2Y0&I?Y4C[F/7-7KBPAU4E(#8<5G[JS2E6OP,J.48(3#&1
M0>ECZS]0]M="T:D:;@5?E>+L8M S,NLMVLY+,4H'R0$KM=@D_/G,9'3G6I2-
MV29A#8T1)!9049_>8T%+MXX()OQCZ&P6Q(L]9LFTC(N76TT@D^82B/C4$E#3
M9F FC&4#(X;B1D4W!J6'SV[I;B7YT4&:S:G ^Q%AJ74GA%^F*V=M^"2C'BK+
M11Y>:,>5.^MFG"VFR7+C5+E'A37;3G?MN.>.*L3T>*,7C6GP9*V0HP!@# &
M, CNV^9%X,YQK$HL5FLG4CA%$#%0DS5KLH;*+H\HLV;6<MS,?=Q3[5M]5%C;
M$RP(,6Z:JP]79[J@DH&PI_6T6ZO8-9U8FY5N?L>H8WTS.8(6"+SR/M+#*6GP
M5I-="73:)DRC^*O9JXW3M!#DNA=<Z8,H:&3TUD+N7&GN\X%P2[]2P]I%Q&I>
MM-\ 4G4'E-CP.1\SRTRO@-GD[:SD:QB1VLV0P"!%SQ"[2JQEHZD 'AZ+='C
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<99JGJIVZ"GVI\[\:]KMSKOK5 DYX2.-M2P'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g22578g30q81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g22578g30q81.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1>44&AO=&]S:&]P(#,N,  X0DE-! 0
M     "H< 5H  QLE1QP!6@ #&R5'' (   (  !P"!0 .0DE/5D5.5%537TQ/
M1T\X0DE-!"4      !!_,'<T-T<%&#5?^,C-72?>.$))300Z      $_
M$     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN
M=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M      MP<FEN=&5R3F%M951%6%0    N %P 7 !0 $@ 6 !& $( 50 M $T
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M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #
MP     $  0/      0 !.$))300F       .             #^    X0DE-
M _(       H  /_______P  .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              /(   07          $
M 0             $%P   /(                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   /(     4F=H=&QO;F<   07    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !CA"24T$#      ,DP    $   "@    )0
M >   $5@   ,=P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ )0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
M],S^HX/3L<Y.=>S'I!C?88D_NM_??_(:N3ZY]<,',]+'Z?G"BEY NR+&W5@
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M3\[%^L7UEOR<>RFG*R*W8]CQ#;&AV3+JC^=]-BZM,7 $ D N,#S/*1GOH!8
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M^C_S%\LI)(?_V0 X0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S
M &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !?DU- "H    (  P!   #
M     02P   ! 0 #     0$L   ! @ #     P   )X!!@ #     0 "   !
M$@ #     0 !   !%0 #     0 #   !&@ %     0   *0!&P %     0
M *P!*  #     0 "   !,0 "    '@   +0!,@ "    %    -*':0 $
M 0   .@   $@  @ "  ( #SA\   )Q  /.'P   G$$%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,38Z,#8Z,C,@,#@Z,C$Z-38     !)    <
M   $,#(R,: !  ,    !__\  * "  0    !   $%Z #  0    !    \@
M       & 0,  P    $ !@   1H !0    $   %N 1L !0    $   %V 2@
M P    $  @   @$ !     $   %^ @( !     $              $@    !
M    2     $X0DE- _T       @      0   /_A 8!-30 J    "  , 0
M P    $$L    0$  P    $!+    0(  P    ,   "> 08  P    $  @
M 1(  P    $      14  P    $  P   1H !0    $   "D 1L !0    $
M  "L 2@  P    $  @   3$  @   !X   "T 3(  @   !0   #2AVD !
M  $   #H   !(  (  @ "    \     !   #P     %!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*0 R,#$V.C V.C(S(# X.C(Q.C4V      20   '
M    !# R,C&@ 0 #     ?__  "@ @ $     0  !!>@ P $     0   /(
M        !@$#  ,    !  8   $:  4    !   !;@$;  4    !   !=@$H
M  ,    !  (   (!  0    !   !?@("  0    !              /
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ .@#\ P$1  (1 0,1 ?_$ !\
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MG49;HV:3=L\94'/:Z_%&V/DP_L.&QZ:FGM#V1UUU%T5>^P^V$V!>O]=L@W[
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MD *S(WFK(2#GY\:KLU:>"0Q2Q.K@XP5/Q?53C# ^A&<ZRK_4&=X:#V[.Z-Z
M]5"4'=]KB[;&VFVDZ#)8L(B1L60,*T6BZZK9<>X^..E<8MYZ59W8$AV 'DY#
MP')JI[)J*,ZQ[/-@L;1'?ZAW96H1&F\4*6%:-Q6#)8L6948!HT_(QK$& 9QW
ML!V]A>Q['3>KXVX6E,4:1$)WC#$'EFP<$# [0#YD\>6M6?5W2;>B.KNBNOY5
M40QG6.F:)K<ZM2<2AY::!J@\,><PAY'M?@$)S4U:&G6_:N*\EM:/3U3SDNZW
MOX0W6_N*=R>]7;%F/T9%DF9X^1R&52O.<Y&<ZK4TIEFEF\C)([_;N8D?LU_G
MU]]:3N7Q9]H^YW5S59B?6]-=G:;%AC6$)=4V?T;;+7%MP&! =PI&?R%;D#;-
MJ<C.6AQ<L2NWP\,X;-(?1^B=@L4NK-KV3=K:"6[M4Y9L8'AWX86BE++_ +LB
MM%;1?1Q"WZ&#=Z!AW.K4L3\RTG^)B0/C1?-B?T2.USG](?+D[4_#STS3TGZ.
M:PHAL7@?M+8#&-M;@RZREJ<S=;E"A/,5R9GTRO"Z56XX.INM?<6SDB*(S6<(
MS.<QGB'6>]_PYOUJQ&W=4K?Z'2P<J8(&8>(/Z^4R3 ^?:ZJ2>T:J>YVS<N2R
MY^ 'PXQZ!$) Q_2Y8GU)^7 S:>:+5@/JSY>]8=N-UZKA;;ZR[ME:^L-MKA@2
MV7 G&J56 VL-E5!<6;_R,BQBZZ.$W4)$E.-,/32@Q25I1$E+9Z9T19?=NCK6
MST;;4]THK9CAD1^R1#/,]NK,"H[A$TK/#(P!.%8?I :GMID>SM<]2"0QV8>Y
MHR&[3\3=R\CT)!4GR&1G6B'5'3;PQ[PUP.VWJO073VY:])#6RN+(,KM3^*-C
MK8Q(>8L#3ZF95<)0$9R@H*.L#R0M]MV.0BQWFG$)YO;WGK6A9:G;O[S!91BG
MA/)+EB#C,9&1*K>:/&61P05)!!U!R6MUB<QR36E<'M[27SGZ?/Z8\]) [7]B
MO&+1>X6E^KG2_P <W5#M],/65BK;.?KE>',1)]EL)"&+K]0UC<Q4<F!?+!%9
MF%+=8)@X[5HC#C SY463".3!-\VC:^J)]EO;MOG4F[;,(XC-4$DC$K%&"TDU
MN!RL@5QVK#$'CE8Y?!!0-+5X-Q:I-:M7[%557NB[F.6P,Y9200"<!1PQ(SY:
M<_YO (BK>(+LE6  J$!!5RIZ6!!08U"6QP82(W)JP>.%0&TH;2W"'0X[,2*A
M*$)2PRVG"$XQZ8H_0LCR]9;5+([2223W9'D<DL[O2MLSL3DEF8DGZG43M1)W
M.J2<DS9)^9(8DZ\I]/!C&/%?I/.,8QE5SW7E7I_WSC;%K1C.?[_:E./\,8YG
M]HYSU9>_J*/_ &<.OO>_Y3L_>/\ NTUX3ZDS&,^- S_=N[4^<?W9^^=__/7'
M^&<XYF]FGYSI_P #;_LCUEV#^4H_ZN;_ *#JWGAD_I?].?\ XQE?ZPL_(CK;
M\Z=Y_P")7^XAUJ;I_*-S^O?^W2 ^AW]I4[8_^Y.TO_W8?.A]0_[,MG_J=G_Z
M'U-W?S?I_P#VO_ZT]CS?:L/[<\87:(!6(,DF:KU?JVQFH,1I3\AX;KB]5FY6
M1;;2$J<7F)5PYJ=E+:<K5B-[4XSG/IF@]"VHZG5.U/*P2.62:L68X :S7EAB
MY\N97C7GYZA]HD6+<:S,0%+E23QCN5E'[R-4P^G?[CZ,M71>A=;9VP:M7=QZ
M4.; &DJ18#8X,<.UZU7NQ7P+9ZW#(26'#@G#5I<#3W!V)#PPD*>009C,RQST
MR<]I&RWX=^L;H*\TM*]'799XXV>..6&".N\4A4'PV_(B1>_ ='RI)5@NWOM2
M9+LDPC<Q2]K!P"R@]H# D#X>1Y'52OJ;>V^E;?IK3W5*A7JO7G:3>Y1^TK:'
MJ16'8/T>$KM.NE4'C["\+=E,0#A\I=$NC0KCN">(8F7+DQ6(\F N7+^RW9[T
M-V[N]B"2"F:35(FF0Q^.\D\$S-&' +1Q+!\;CX<L "<.!M=.U9DGEM.K1Q+$
MT>6';W%BK' /)"A,D^7(Y]-/DZ[$ZIT5\;VBIO84]"U\$T/UKUNC99 ME2/Q
M!H?41*3 =F,GW29YEZPR' @H3#;>GE2SL4=!8>E266E4#<UFW_J;<%VZ-K#W
M]TL^ZJ@_'&9G\-\^2H(@)'=L!4!9B #J$F[[EZ7P5+M/._8H'GECC]6.23Z<
MG2N_(%UP\5/D,Z@[ [RU^\:YHMRA:V,W0/O:IF!-<L$RSC +\T71MO4[Y#2;
M'9)I&+#K$H(;&8V)'D?8%U\JUC+,>3:NG=SZMZ<WFML,E>S8@-E(&H31O)&L
M3R!6GI3]I,42H3*'C;W8KEI$]5DJ-G<Z%I*A21U\0(T#@LO;W %HF_1&#D,I
M[",=P/I^?IE-Q;2V1TLV+3;X3*GZKIW;ZZCK$L6?>EN#:\3J@.P3Z3"DO^Y:
MAE:(3OR ^,IQS\?'LJ!\?#(^-!CLO:C2J5M\K3UT2.:[3\:TB *&D2:2-9V4
M ?%*B]K-^F8BQ^(L2ZAABBNJ8P%,L0>0#_>[F7./0D 9^>M(/.9Z@=<:PUVO
MVX&4K-K!![-6SD-X<: 6 ;",A2X^0GV2(),619D09T1]&<I=C2F'67$_LM&<
M<]!((()!'((X(^QUE@GGJS1V*TTM>Q"XDAG@D>&:*13E7CEC*NCJ>0RL"#Y'
M5$C7C Z>%6(@V#KMZO5V$XZN#4H!!!FK@VWWG9#T*D"KM#MB-6#7GWEO/C=4
M.4:#(<SE;\=Q2EY5+4]]W:@6-6[-"6_%VL0KX  ,J?@F(  !F63&.-66SUEO
M5\E]R:MN-DJ%-VQ7$-Z3M':&M6Z+5)MP<#@/N37' X#   5X[4=!\4Z*%V=U
MF $'G:J%AAK1KIL@4.EC 0,SB.*,5V68ED"Y(N'%ML!W@KLR2_."CQ;09OYH
M_,,IP3VG=&[AN>Y3=9;+%[QN<H5]YHP11I)>,2A5O5HHPB/<6-52>!%S95$>
M,&P&$_2O9W[0:RUSTOU-.L5.25WVO<I.U(:;S,7EIVCPL=665FEAL$!:\LD@
MG/@NKP0#J'R V/5$-022A@D/A/.LS*R?3)9=@3&W%(EM1G,9:F"Y:7DJ1(CN
MH<82]]Q3T++^5+Q1=C]I]O98S7=4EBC)62I9#J874XD"G*R0.""'0AE![BT9
M;G5TW[V65-\D]YC+0RR*&CN5>UEE1E!1G',<T97!1P0V,!9,<&)>Y/DN_C-2
MA^OQ6NQ<-MJQ!3K$*49D6R.6L@*>R0JDET!@4*AE7@5CCCCH447;-"%'H R=
M+$3Y< >J-\]0^W;<WK2TM@VZ&E=LHU=;0E>]83Q1VDU8_!A2.8@X621)NW.%
M7N(82G0_L5AVB\^Y7]TFL1B"6-NVNM'PZ\B%;2FP;$TB)-7,D,\D)KR^ \J+
M-&CR!V"^*+JO>-&:TN^U=NPIXW:N_"PP\1"F?O*/ *L)22>!1K!B3E4F/8C$
MTX7.&8DA7RXR)(R(30R5BS8[/0/8]T??Z<V>YN6\K(F[[_-'9GBFR;$-=/$>
M(6.[+K8GDGEFF1CWJ#$DH$J,J\R]MW6NW=2[SMVR[%)%+LO3,$U:*Q7[?=K-
MV<Q+9:KV81ZE>.O!7KR+\#E9GA+0/&[6!\@'1FC>0C1$?0FP;G;**!CWJO7Q
M)NFM!WBZI]=@FX,>$I!N%.A?#?;./K>SAG#V%LM>Q:<>_"N^].[]8Z<W [A6
MAAGD->6OV3%PG;*T;%LQLK=P,8QSCD\>6N-TKCT9Q/&JNP5EP^>W##!/!!_?
MI3>VOIFNG%[H%$"4;8>R-6;%IU7@5DML(=#!'1FQ'!^%MLV2ZT1]L7!39%,?
M9CR)U3,U9B>EI4HM#(D7ESN6^I[4-ZAL6'L5JMNM-*TL==B\;5>XY,<%@=[&
M/.2%F24KG",J@+J3AZAMQ.[.J2QNS,(V+#P^XY[4?DA1Z*0P X&->0Z\_2_]
M6];VP;:-[[HV!V$A")C4UFDQ*[ U/33"F5X6B+:&QQZW6DB/SZ8RY&#VJNJ?
M4G")#[L53L5W+N/M3W6S$\6WT:^W,XP9VE:Y.GG\41:.&)6^KPR8]!G!&2QU
M':E4K!$E?/!?N,KC^B2JJ#]2I_QUI9KE< 5  %JE4"BJW6:V+@A*_7P<",+#
M! XR,W#'"Q8V$VS$@P(,1EJ-$B1FFV&&6T-MH2E.,<YC)))-))-*[RRRNTDL
MDC%WDD<]S.[L2S,Q)+,223R3JO$EB68DDDDDG))/F2=+ Z^>)[4_7CO/N'O=
M7MG;#/7O<<O:,PS2S,>MHJ0E>T[3#M15 QZ",8,*2-E0D1A_RIKN51UJS)RX
MYZ*Q:=QZMM[CL5+89*M>."D*H2=#*9G]UB:)>X,Q0=P;+8'GY:D)=QDEI143
M&@CA*E7'=WGM[O/GMY[CY#Y:OKOOK_I_L]JZQZ:WG1Q.P->6EE""0,KAYIQB
M4QG*X)<.3A.QB@(Z,=SE\8:$3(9*"[[LL2$)6XE<!M^XW=JMQ7:$[UK,)/9(
MF#D'AD=6!22-QPR.K*P\QY:TX9I:\BRPN8Y$.58?O!]"#Y$'((\QK-3L+Z53
M21>ROSM8=L=E4:JO2E/(KMPUS7-BE(L=:O=F)'L@RRZZ;RAKURB.]* RGDM8
M;Q(7*=2MYSIU;VLWDB"VMHJSR]H'B069*R$C](Q/#:.3ZA9%&?+ P!88^I9E
M0"6M'*X_35S'D_,KV./V$?3&FA^/_P +W4GH <3L:KLV+;.[,0WX4;:FR5#7
MI598FLJC$6:#6A<.*'JOY&,I<:43=R9L^8;TP<BQ(%3ID!ZJ]0];;OU#'[K+
MX5.AW!C4J]P$K+RIL2L2\W:>0GP1=P5C&756$;>W:U?'8Y6.'.?"CS@D>18G
MEL?J&3Y>6&[<IVHO5!>V_CFT#W,VWUIW%M>,3Q8^M-R_5 >*,0,R.O(M) 6<
M9I=W;G0I3A"L,V - *(BLK9<PAXS"2M+!J;E5AV?J7<-DI[I2J%?#W2#PG9B
MW=7?M=#/!VD!93&[(2<^2-YQKK<K7IZL5B*(CML)V-G]'^<OIW=I*Y.>#\P"
M+]<KVM/5?NS75W1_;_5!G3&_J1!N](+N-366G7'H)BO'(K;S8^RU8Y#6T1 V
M =B0^F,0A/)^[&?ECI[4P5.G09,CM>ZW]FMI>VZ=H)T!4D89)(R06BE0Y62-
ML#*L." RE756&:O8FJRK- Y1U]1R"#Y@@\$'U!_MUF\N'TJ&H9UB>DT#M_LB
MK5)R1[T@;7J^MW<ZB+[_ ')CYLPFUT& XZC'JE$A=4],9]%*85G&?=TR#VM7
M%C L;-6EF _'#:DKQY^?A/#8;!/F!,/ED>>K"G4TH7\I4C=P/Q+(4&?0]I1_
MV!A^K39O']X=.I?CY(N7BC0C^S-T2H#PYW;FR7!TPR&A3&L,D1]'"C(4$+4(
M4]'O:E26&2%DDQ'GQTRQRAKRX?*AU#UIO'42"O.8JM$,']SJAECD93E6G=V:
M29E] 2L0(#"(. VHJ]NMJ_\ #(0D0.1%'PN?FQ/Q.?N<#T U<'N3U>J_<_K=
MLGK5<[&>J5:V8Q6XY.PUAL<Z<')K5PK]QC*@ME8TN I4B97H\1_Y$=S&(S[V
M6_:[A"TPNR[K+LFYU=TABCFEJ-(RQ2EA&WB0R0GN*$-PLA(P?,#TUJ59VJSQ
M6%4,T3=P5LX)P1SCGU]-</HYU!J'1;KE4>MU%M5DNE;J!6VE8=@MC0MDW*=M
MUE)V>6U);#Q84##<643=CQLM1T*RPVWEW*W,J5G)ON\3;]N4VYSQ1P2S)"AC
MA+E (8DB4@N6;D("<G&3Q@:^K=EK=B2PZJK2=N57/:.U0O&23Y#U)UQN^W2>
MD]_= 2NOE_N%IH]?EVZM6]9VGM"7C*9E97,<BQ4H-0YT'XTC,Q>'\Y8R[C"$
M_;6G/KS[Z?WR?I_<!N->&*>00RP^',7"8E[<GX"K9';QSC7U2MO2G6Q&JNRJ
MRA7SV_$,'."#Y>7.I/ZI]>*]U.Z\ZLZZU,\:L]=U57G*Z*/6)$%LT3CN%"!7
M+Y! UB-!2]ATBXUC$9AI'VVT9]ON]V<ZN[[E+N^XV]RFC2*6W()'CC[BBD(J
M84L2WDH/)/).L5B9K,\L[ *TKER%S@$^8&<G'W.J5::\3NI]+]^=E>0$+L[8
M9?8&S)^Q9Y.C%(];33ASFQW6G22(+T08R:4B IK&(/R)SBLXSG[^7,^F>3E[
MJZY>Z?J]/25:R5ZJU46=#+XS"J"$[@7*9;/Q87[8UMR[E+-2BHF.,1Q=N''=
MWGMSYY/;SGT&FI2([$MA^+*89DQ9++D>3&D-H>8D,/(4V\P^RXE3;K+K:E-N
M-N)4A:%*2I.4YSCE3!((()!!!!!P01R"".00?(ZCM9K^T'TR_5;<=W-7G1^U
M+EUK78ISY(A2858%[%UT-F27/NR/TH#EF*D<KT%YU3KN!.;21%P<N)C!H@L:
MQ'@-=-VOVH;M3@C@OU(=S\)0JV#*U6TX'EXTBQS1R,!@=XA1F RY9B6-@K=1
M6H4"31I8"\!BQC? ]"P# _?MS\R=2ETD^G@ZI=4-BUW;^P+I:^R&P:<0C&*@
MS:P@FJ:[ G8+K<@?8DTB!).S"QL7*;Q)%J.6DD'AOX:F8#+(Q8<Z/J;Y[1]V
MW>M)2K01;97F5DF:&1Y;4D;9#1FP1&$1@<-X<2NPX[PI*G'=WVU;0Q(JUXV&
M&",6=A\BY"X'S"J,^IQQIT>^]!ZG[.:HMND]VU"#=]=72$B(9"S5OQW6W8[S
M<H<5%$8CC$\0;$3F6)XHL/D,3(,MEMUIST]Z54G;]PN;7;AO49F@LP-W(ZX(
MP1AD=3E7C=25=&!5@<$:B(9I:\BS0N4D0Y5A_80>"#Z@C!UFJ-?2IZ+DWG\D
M [8[4$:X5,^ZNH$J!5#=P3"RY[LQ&+^R8#"$/);SEMJ8_KN3A.?:MR,]G"DK
MZ<GM9OB#MDVBH]G'\:MB6.N6QCN-8QO(03R5%H??5A7J:<)AJT328QWAV5<X
M')3M/KR0' UHRZN=7M.].]+U70^C*ZNO4:K(D/>^;)_('K$<(+2\8M%H+9:9
M46L)F0E+LV5AF/%89;C#1<(<'@#QT3FV[;K=WJ]-N%^3Q+$V!\([8XHUX2&)
M,GLCC'"C)8G+.S.S,T!8L2VI6FF;OD;S/D !Y*H\@H] -6$Y&ZP:.--'&FCC
M34&;)ZS:!V_,R2V/J6E6@LK&$N&Y0AJ&>>0G'HEM\Z,S!+R&D8_9#+TUQI'[
M^U&/7/*[NW2/3.^.9=VV3;[DQ\[#P*EA@!@!K$7ASLH'DK2$#T')U9=HZQZH
MV&/P=HWW<:4 Y%9)VDK*3YE:TWB0*Q]66,$\9/ UQ]<=1NL^I33=EU]I2AU^
MR,*RJ)8L!TE3T!2L>BE#3)I9(D-RM.<I7F!)C^].<I5ZI_;F#:>B>D]CG]ZV
MK8-NJ6A^&R(?%LI\_#GG,LL>?(^&ZY'!R.-9]WZ[ZPWZN:F[=1;G;J,,/5-@
MPUI1Z":O7$,,V/,>*CX/(YU8OEIU4]'&FCC31QIHXTT<::.--'&FCC31QIHX
MTT<::.--'&FCC31QIHXTT<::.--'&FCC31QIHXTT<::.--'&FCC31QIHXTT<
M::.--'&FCC31QIHXTT<::Y!\W!K0,Q827R<CP@V:5F)A17YTUR/ CN276H4&
M*AR5-F.I;RW%AQFW)$J0IMAA"W7$IRTU24%M?>M7CWAO98 E32=BLM8M8HY9
MQPZYUC6M+LBY8(R/9@:^L$EPH&HJZ\!8FSYY8/(_-WU=N/,#ZS%G):^L#TY\
M_P!9]/,<9^7TXR=?.3CG@\>?W^GR^_WP-?6=L^T#=EH,D7=W+!7'@P$866!I
M5SHD"P)O.]Z;78EB0TJT))Q9H:FUZS3V9[4A8N7#;F$HC?Z8MN8>''/I^PD8
M4_3U)XX^GF-,G/S^WER< _L!/^.OGM&]=]"J8#L+]1$57\A8(]%-$3@:>J(#
M-U8*83>+(EJ04@)8!6>]15577KY5QL;)&A<'FYQO-UK$+ !<XY/V_=YCT\S_
M (8TR>?+]A]!R?V_Y/&90/V'<Q.N=>'Q4$'#O9^SI)7@6N=80E3>#1=8WN9+
M1/=8'&#(\>_8%U>4P'FL2WHI%<09+F2%QURW''/R]/GYC_/VU[SQGS_=Y?Y^
M?[LZ@8%NOL1#-4^LN!0*)-D(3K*U^HF#Q#]5-6[;5[_Z;KQ=Q\<^."4RE,@8
ML=Y(><2!1WQIFP"X@!N-$*^X'/GQ\L<<#S_7GU^@UYD\8Q]N>?MQ_G.3CU^D
MQN[:=DD"0+!EB$JT04XO%9!:[NX.S:?>G;!UU2$U^1?'3#D*38A4:]RR)&0@
M9 D$XM?D6@#%@UQ]I6/,#TS]"<8. 3G&/IR,G&>=,_8^AQY@Y ^?W]!Y:[5<
MVMO8+3@EE>#P3,*%B"'=HCX2SO60O.;ZU,[=-RUWHY:"4N(IN_1R-3'X(B2:
M4H3D9+F/SWXKP]@?/]XQ^+'R'ISZ<:9/ZOE@Y\L\G[\>1_;J3M/[%L6R+;?Z
MJ3NH&Y5H11::169J=(N&M944[=2-X@%!4.<3LA.<K\'%JS6&9 ^3%,A2$QV&
M1DI+CW/M",8/W\\'RQ]->@Y)'T_]^/GG_/&H2H[FVZL)"6*N6>US&XFIZ5?C
M +9$W8.QG[0?W!=9K(ZIPI=@N.'JU(KX6J0@ZY*62:P7Y=1-P:IR>9_+^GDG
MCU(X &.T<G@ <YSCC7@].?0'GG\7[/+'_P :]"[NK>,,3"G$)-=B&K#21VQ-
M?U?^%MLF2+^1LLTY^(T_#G1+1]L.<K@H: 7;;!+0\\U)N31YX0#K=9GM$?,#
M]AP>1QCUQ\OI^K.3ID_3TQP><^G_ +G]W&O2V#?U]@9)C1@F*HU6[-L:/<US
M*C:)8^F52-M$?1]<&B4:([$D%ED*D;8V7@>+FMR[:  &,!G1\=U)",[?+ZXQ
MR.3C)_?Q]SZ^ON?/Z9_5\OW<^>?EJ.6MN;GM!VW3*K>J^9!ZQ![8+0[% UC:
M8P>X*J]'TK8A0^56UW.+^1DDY]\L$004AE'!\\:)D3 D%<E]@G#]P.!@Y./4
M?,_3[<8^Y'EKS)QG(\B?(C/EZ9_?J?-J6#+1FCP=A'K10M=$ZL7('2=0GV(*
MF7>6I%?0,K)2[U=+!^MPVX<LQ*%1X1 (]:I[.(OSG$CG!!/Y'K@9/'^/D/7_
M  UZ?KY?L^7KZ?Y^FH1FV#>YNJWZK5FRG*S7F:^'B42PVFI'Y6T2</:>PK51
M*A+EE910$1"RJV-%-E_E%1;MQ0)(5DQ99,(T@LJ9[Q\LGSX([>.2/(Y^OE\M
M>?KQY>?/T'R//U_=SKOQM@;QI,:<0ESH5L'6(MN8C'3-I-GFRJ6&K>Y0-0#6
MF4H=9'I1L#!J-A=M3M-%#@TB8$$XC!RC#T6<3(L#^SUXY!./IR,>?ZAY:9/]
MOI\CCZ9_SYZY!'<E\?/TYJ7L,<#K*".QWQ&T6=57:15[Z.#@=9QQ#.:M"L6$
M?)E6&ZVH/7ITDM(%6=^J+>K8Z43DCWVV!\C]LCCS^GV^W.=,_P!OG@_V \_?
MUXP.1K]HFZ=M1XLD@=:CZZFV%,PO%>,4+8EZ9,6@!2]=#?X=UVJ,6>.[7B)2
MRKM,O\##D-$RD9AQD1"GGHMGL>&!]\?(CYGG./ECGTSID_;[\\\>6#^[/VSY
MZ_"=Q[A%QSKSS2:_8"+UJL57JA^IVF\.7VUC[?::4SJ6I$AA85"K<43&I@<C
M,G(:GID,7J-;&V88809>),#[CYCCZYYS]O3RQYG3/ZOU$\YP?V??Z^0Y_E:-
M\[!*SI5:%& CA>Q*V8$E:Z@TN\C++3H0IHG6*P1D;$&V:&G,Z=8"]/).S1,4
M4N<+(X*4Z>S @J-S/<#&?MSD')\R ,?+/SY&#SQKW//_ ,?X_P"?,>G)]).W
MC?D5>W'F+75X!\4/^[-U[/U3?%D->2\6@6/2&-6W)Q8@C8U!G"<(9DM$" [<
M><%6$3-'4MJ=(D^8&0.?OD<\?;]OGCR\]>9^H_9S^O)'[\9_?JY &5)G@PTZ
M:EQ$R8*'2I:'AKP=Y,F1#9>?2Z(D2Y\@4XEU:\+&OSIKT%6,QG9<E;2GE_.O
MK75XTT<::.--'&FCC31QIHXTT<::.--'&FCC31QIHXTT<::.--'&FCC37SRX
MD0A$E0)\6/-@S8[T2;"ELMR8DN));4S(BRH[R5LR(\AE:VGF74+;=;6IMQ*D
MJSC+37@]:5*J5("^Q5:S7JRQ.*$7YK-?"C0S4Q^-+>@1WI38V-&1(=8@Q8T)
MEQW"UM1([$9&4LLMH2SGSTQCRU(G&FCC37"LX8/8:^6#GQ0TX(FPW4S!9B#%
M)#I:6?20UB3!FM/1G\-2&6GV\.M+PAYIMU/HM"58::Y]%  JU5 HRN!1( ;\
M-J9^/"#88J#\P@G$R?*^)!98C_)FS'GI4M_[?W9,EUU]Y2W7%*RTQCRUZWC3
M1QIHXTT<::.--'&FHSJ5'I0"VW$V"I]6"FILI#<TN)KXD:4EH)-QRQ%$J?#B
D,RY""!7.2<U+KJ\2B&<S'\.2<Y<XR?GIC4F<::.--'&FO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g22578g45y56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g22578g45y56.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1>^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     #(< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @  ' (%  Y"24]6
M14Y455-?3$]'3SA"24T$)0      $'JP!@<O*#A:B@V$2="CWR$X0DE-!#H
M     3\    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O
M; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E
M;D)I=&)O;VP     "W!R:6YT97).86UE5$585    "X 7 !< %  2 !8 $8
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M8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M     $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"
M<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M  !2<VQT56YT1B-0>&Q >/            IV96-T;W)$871A8F]O; $
M4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M         %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O
M='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!2
M96-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#
M[0      $ /      0 ! \     !  $X0DE-!"8       X
M/X   #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M   )           ! #A"24T$"@       0  .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              (<   )&          $
M 0             "1@   (<                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   (<     4F=H=&QO;F<   )&    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !CA"24T$#      ,O@    $   "@    )0
M >   $5@   ,H@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ )0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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MU%TO3?JU59TK KRNI6=5^S$VT9<M(<QY#ZVUN!M<ZMK&M].QU]W_ )Z]$F
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M &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P "  0P!3 #8    ! #A"24T$(@     !?DU- "H    (  P!   #
M 02P   ! 0 #     0$L   ! @ #     P   )X!!@ #     0 "   !$@ #
M     0 !   !%0 #     0 #   !&@ %     0   *0!&P %     0   *P!
M*  #     0 "   !,0 "    '@   +0!,@ "    %    -*':0 $     0
M .@   $@  @ "  ( #SA\   )Q  /.'P   G$$%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I #(P,38Z,#8Z,C,@,#@Z,C(Z-#(     !)    <    $
M,#(R,: !  ,    !__\  * "  0    !   "1J #  0    !    AP
M   & 0,  P    $ !@   1H !0    $   %N 1L !0    $   %V 2@  P
M  $  @   @$ !     $   %^ @( !     $              $@    !
M2     $X0DE- _T       @      0   /_A 8!-30 J    "  , 0   P
M  $$L    0$  P    $!+    0(  P    ,   "> 08  P    $  @   1(
M P    $      14  P    $  P   1H !0    $   "D 1L !0    $   "L
M 2@  P    $  @   3$  @   !X   "T 3(  @   !0   #2AVD !     $
M  #H   !(  (  @ "    \     !   #P     %!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$V.C V.C(S(# X.C(R.C0R      20   '
M!# R,C&@ 0 #     ?__  "@ @ $     0   D:@ P $     0   (<
M    !@$#  ,    !  8   $:  4    !   !;@$;  4    !   !=@$H  ,
M   !  (   (!  0    !   !?@("  0    !              /      0
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M @,$!@$'"  )$1(3%!46(@HA(W<7)C$R-CA'=K*UMO_$ !P!  $% 0$!
M           ! @,$!08'"/_$ #P1  (! P($! ,&! 0' 0    $" P0%$0 2
M!A,A,10B05%A<? '(S*!H;$5D<'Q,T)2T18D4U1B<N&B_]H # ,!  (1 Q$
M/P#VB=.]P\T<A1Q*-W;%C!K'8F')-8H0(<1M5^L4=I;C2I@^J@H\PA'%?8:<
MBY/E\#*^B6C,1TJB3Z-9G@IIZ@GE(6"_B8D*J_-B0,_#J3Z#75<-<%<1\6O*
M+);VG@IR!55TTD=+04Q(R%EJIV2,RE?,((C)4,OF6(KUUPYV+YEF@NENAP(+
M=&Z[KSWR>Q$RIL)9:":85=#N?AC0Q%TDQPMSI 4'->>=*33]D;DY"-#D0Q9
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M<DK*1A&5QAK$AYMV=(3AQ&5,Q4.N)PM&<IQ[L>L*QR.'9$=EC&YRJE@B^[D
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M;=S$CN$)9,A=53I#*9<MB24PR5C=7%Q9P_;Y'K[-PK'279@_*GGK9:FFHY)
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MMU[Q^. UDZ/!HT>#1H\&C1X-&CP:-5KL'9,2@/5]M\$?/),37FYV*^)*%GQ
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MOC0#^7SQ_OJ-#.B9Z8ORV/6A^!GZ8(G^D,)"'ZVR*-0AB7B4XL?DUN2-A!+
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MZ%:C.!0Q&-'FG"3LF,#01@0UE5+M/UG_ &]/4]M&?Z^WIU]__NIC1]WB[H2
MB&Z^7'33;1'US)EU]S(^2)@(F36"0R,:D'QOR^["X"YXF.V_"DC)CKD?]6 T
M\A&/T]_7\L:,_73Z_OJ[_":71X-&CP:-'@T:/!HT>#1H\&C1X-&CP:-'@T:H
M<C_S)5K_ "C/?_3P?"^A^8_8Z-7QX31JAMN?\<:)_P"_Y?\ Z*7X7T/S'['2
M>H^1_<:OGPFET>#1H\&C5%;R_P"D/^=]!_\ ,EX<O^;_ -3I#W'S_H=7KX;I
&='@T:__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g22578g59w39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g22578g59w39.jpg
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MU"4F.5)ADIC8@4-%8WBW_\0 &0$!  ,! 0                $" P0%_\0
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M&?R2;NL=_P#91G8G0I:Y+AQ;H+Q!>N$[MTM#O># HB%H>PXW ZOMD6&JDK$
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M-5PS>#W/EHJHW62<L""#5\R<MW"*S=RU=MT5T%TE$U$]=M<XX"<W1SW ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' *B$>B?51
MY=53W\/I>O8O8U.D9L9C1")0:$QYN4-3H<T'D#4IU81O1Z;+B-F>I*-DMG[=
MX&+KNB"*VZR^W!,N&ILX]/ST,1KKP^:4KF:Q62-C]E2J&UF^L\I2M(S,['BU
M/4D1N-N='6"Z@ 9I$ADI=Z$P4JED7#L)],)P+AD3E!V-0AC' S[+/03M8V5\
M7F_;%39*YA0OPWX-"H@=#P*W[R]W8WUUL_K?U@(2Z=I.6W4N#V.%%C-F=-$8
M@"B$T;.A.\7@S<;,9?*IC90@%#@X('-!H_#I!T(F7+C%-[X_,K;CFYWX=%56
M,BZ;2.T+Y3:3FGZZH[L6P%3@.DU[6P&M&)(:':7J\+10U(G1@L//207+)579
M^O99*P4@?QV0'2(-(<P8AM<,96Y[NBQGN<]/_#_IFPI_*Y<]D=G1^'V7*ZRG
M=R49%C\>&TQ<LTIY"+,X!(IT$<Q,A*VZPX9!(*%-BH3,X='9N$AH /.PTE'M
MEF[@-IQPP>:6GKIP/<]Z#5 ^M1Q8:DIM-.(O[O#]F"E HR,#K1Y3L* P,<"+
M:=A]XIO.M#320!0TVVC3*P6E=O)\,;3=_"W4ERX)+A-NJG.'EIF\I+O\$$-T
M!]2:,_94I_+ _P %:/*N?=DR<%AP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P#4/3/B%7A;>_7DWBFZH!PSO!&[R5ZH*JV7+W4C 32K(;)I[%(_V%8:
M5UHU!#YO%(F<)2)_!%I$_KHR.4B>14P<.4C*8LZ4ISV8VG:+Z7R=M^[ L3U8
M[%7S:]U=DZ?MZ U '2Z[_!>#)S:FYS-9E&GUD3Z/D9L8KI169P2#N]3D*@;V
MNI.>4:M5FK=.Q@C#"BCQ @FT$-0D]9RBV$YYRN1CC[L[V5BW:X5UGD]6T,9?
M6O4M_P!HTRK"+=GCPE&&M/%(B*B6_8'0E4:*L1B5H.YJ,&:3&)B)+K&9*.,Q
MX:%G6S9(BJ_.PA1.D3STX>NXPF"]K>WTX/\ 9:K&-==44++ZLS"O6<^FKZY+
M/946^BT_K<A/W;!I(&]2E9&&LFO-4!6)K&S S UM'9"!DF2K'8HB)3$PK7QW
M7QC"?<M-TMO*9]E^L=47U.X6*@)>TA1>5B0 0B7*"G,%>R8VG6DL8N3P<"92
M;SZO$8Q.T6!,2S?"TY'H-=)^O:[[9$-0VM"T7! X X X X X X X X X!#=
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M(.1X X X X X X X X X X!#= ?4FC/V5*?RP/\ !6CRKGW9,G!8< < < <
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MNYGXF7/V-#?.DS' ' -[_@V_)R^_MW7_ . 2SG-X^-/!]S3P\^7N;J>8&@X
MX X X!UQ/%V_?+Q#^12,_EK8G.KP/(_ZGV1E7CR]V:LN;%!P!P#L\^%U^]'C
M'W6SC\>*\Y/&\_)&M&'/V1L/YD7' ' ' ' .I'WB_?:7K]VR_P"+V'.SPO\
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M8U^9\NR*I\T*C@#@'<8ZR?O;>O?\A]3_ )! .<-?GJ_JJ[LW6"X+L3ARI(X
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M.?LSJX<[#(< < V;^$W^^C(?R52W\<Q7F/C^1?U+LR]&/+W1V4><IJ. . .
M. :6_&1^2M$?=!.OQ=&N;^!C5P7<S\3+G[&AOG29C@#@&]_P;?DY??V[K_\
M )9SF\?&G@^YIX>?+W-U/,#0< < < < ZT?C"RZ*BNV$$CI*1@V$@(T('+,
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MKZ?!@T?D^19!_#I#*XD9&F8A+8I,8V>CLC*C"T:D@ISLHT(>WC&(AJ.=T_\
MV,Y7(KK5OB.599!^"9(U[9U;53=,?LJ5=>KXG>:\2KB[8]4PEY)I84!-(Y/I
M#.X@@]@PPM9$-Q8\/B.\JK\.5.ML-73/85L$;TWFE,KTUM:;\CBX=XF=1DQ>
MLKM"M[;Z_5[(>N\_[853/K6:0/(:V:!J\;'#LXEX$9!9W,Y/&#H6,S*(2S:
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M%<$D^%-R[B;>$,1[B/L8N(9 $9,+F"JCEH'<J+$#3J0 @3Y0A[4T:M\B6^C
M8SPHXRJV)<UO:<1A"B9_)8VX7RK9O.,WAK/<S?\ ^ Q1,)J%#M^=BJ"R;BPY
MU61ATDJJY4T%LQ\2*!6H5IE=TXRLU37&NRN'*^/:\N"KAOLKLV;M=$\/%I5+
M49R^&"2Y075;J2G]J2XW;.PGS(L. . . . =*C^Z,._3CJWWBKFO4JK1F^I3
MJ_!9?DLI--X[LAL1M"YA&1^&.L6-X4PC@#AQ[5[7IE3+K*7L^GJ?6*Z4>(Z%
M"2=Y[?8M3X'Q5M;6S#B-F=_U+4T!N_& V?H^SONN(UXW]:W7]0ZLO+A'US1P
MD[:K>J5KO?3UK9T@BY;J>CZ2*Z22R>=5$]=L7^,W^U=66_2?ZG]O_8^G].,>
M_P 7MK_M25_Z?<?'?TKJQ^D_U/[/^P_3C'O\7MK_ +4E?^GW'QW]*ZL?I/\
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M/+W9IX>?+W)EY0T' ' ' ' *[VU\I&?VE;?AI'FM&'/V1E7CR]V1?RY0< <
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M@K]#^<Y_>RWB-_7KK;_M.E/_ $WY;8JT]5]SH_4^'_FZ?R/[V6\1OZ]=;?\
M:=*?^F_&Q5IZK[C]3X?^;I_(_O9;Q&_KUUM_VG2G_IOQL5:>J^X_4^'_ )NG
M\ES?#M_N?OO;UX[S=5;RGQ:A5H75=UPF:R=*/V#(B)M0.$*)NGFHMBY@8]!V
M]REKG"""SUJGOOY8V6TQ\?#I:NUV*U?_ */#JI=*VI=E;^3^@CRIB. . . .
M 8'97R0(?Z9A^&H<M1YES[,K7Y7R[HK'S8Q' ' )*JKY3[_:MW]]:\I7AS]F
M7HQY>Z+'<R-1P!P!P!P"&[@_:H/[(??>V_-/#SY>YGXF7/V(+YH9C@#@$YT_
M^UCO^G8?>W7,J\>7NS3P\^7N3+RAH. . . . 5WMKY2,_M*V_#2/-:,.?LC*
MO'E[LB_ER@X X!9>L?DFV^RWOW[/,:_,^79&U'E7/NR0>5+#@#@#@#@%4)M\
MJSGV;M][3YM1Y5S[LQK\SY=D8MRQ4< < M[&ODY'_M(*_ $.8/%\7W-U@N"[
M'-\@D< < UJ0/P^S8@%V,KFS;R:6G47:A&[-+I +5 "C%CS5Q=*)H6N\.VZA
M*3!E^I"(F82A$&:8#-QD:B ",@ 3 2+!LVFHF7*>D1R_)>^YPC[PTT[,"3QG
MV4OJ27%(3G6]#JU7\O P>/5F5K:OVTK 3_WXI-T"$L8R6WB,]A%<2PU*G:(V
M(N2%?1Y 97@9BJ8;$Q,QAQ>:>7N^N)SQ/I[V)8YM.V@G:/5[VVM!IUOK!&Y!
M]40Z)Q>!T+3UMNIA(8I':U.JV4->%9.%GEL$Y.1(EE%Y(<,!AX-2"L1(M8<$
MK"+7XRU&.[+L[S]!#P]4'T\+(XN,HCUPD/:@+W//4%[R ZA![>H25!+*221M
M'8MAVA5Y*X8Z*MHS"5X@]-/95A\Q1F[2)OMXZF&UUATI[G;#@VC\BOAZH1N:
M05BM<90IUNJ?L=.^UU7T#M!P[-]'[>GIFP):LS,6BF65(2"LXE/+2F<W@\,3
MBP<N),J1]F6F)\#'6HA8)ZM1.ZWK:[ST/VD/#V1J&74)J1N,I-:9ZC.[&?=5
MJF6@X<$]KQQ80"0PE'WYSMJ6?.+%2KVN9?*J_KK1O'(9N/ FE'4H4EQ]HS,(
M@ZIG5XO7_P!<-[S9!P5(;H#ZDT9^RI3^6!_@K1Y5S[LF3@L. ?S$.S/@1^*)
M.NR'8&;1CKJ-(QJ8W=:TJCQ#:Z*,9;/@<AGAXL)>;,WUCMGK39TP=MU\MGC=
M!TAG?U3A%)77?36VS5IZHZ*?'\-))MRDD[/%*"$?[WZ\6#^+2,_VXT%_U.XV
M*M/5?<G]1X6K_P!K'][]>+!_%I&?[<:"_P"IW&Q5IZK[C]1X6K_VL?WOUXL'
M\6D9_MQH+_J=QL5:>J^X_4>%J_\ :S^J0";JM @=JOKZ"[84/;K:8VUV]!5%
MHBFIKZ6F=M=O1WUSCTM<YUSY>>,YQ\?*G,<KP!P!P!P#BCO[B&?M40_!%N2L
M5Q7<AX/@^Q3SFY@. . 9)#_E0"^V3;_?Y6OROEW1*Q7%=RVG,3<< < < < P
M.ROD@0_TS#\-0Y:CS+GV96OROEW16/FQB. . 2557RGW^U;O[ZUY2O#G[,O1
MCR]T6.YD:C@#@#@#@$-W!^U0?V0^^]M^:>'GR]S/Q,N?L07S0S' ' )SI_\
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M+J))(+*K8SE%-)117&J6ZV<I::9V4QA%/1117.=<9QA)/3?=3/ZG73;;.,9
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M]2:,_94I_+ _P5H\JY]V3)P6' *<&/W6*?;%[^$J\W6"X+L8/%\7W..Y) X
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M3,*FDDA!C'+I\N+#R8S"'LA%BU7[_<:Q)H,<OGGL_M*M2S4/[[[P6YX(' '
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MN'$'D$N!71B.:V<7LNU;=M6PY7K"_4[0/5S;%D3N4VBPQ7;ANB1KKW(F _:
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M^ZQ3[8O?PE7FZP7!=C!XOB^YQW)(' ' +JI_XM/_ ,FO^[CG.=!Y\ < < <
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M7;@+.X-)6; ;-HUH#+@&^)$!=QB;2MJN]58"[5I3E3&$>Y=#@@< < < Z_\
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M(WE-VD[]OBQ+0614]6DNE[*HY4:N\;-%/7>L52PGC.RJ*&WIXQIG&PHU.;7
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MT=-\.&3Q7R:(.DV>GI.-\93;ZYUPGIZ*6DR]7U954I*(3WP95\"%+?-#5_T
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M?5B%HNB-9'Z5:6^?=#_9^Y_YVY?XF[U_@I\/?Z?R;A^9F@X X X X X X X
MX X!A4ULFNJU:,']C3Z%0!B5?:#!;V:RD'%6A(DIY93'L')U^P1>/M\9QG1H
MWW47V\\>BGGSX![3MA0"+%XR DTXA\=/35ULQAH0[)@H@O+7VGJO39QD:0>M
MWAYUIZ]#TFXI%VMKZY+STQZS3S R#0L*W*+@]"8_<TV8MRCD/H\;;%&XQXNY
M:M"*X_"F7:3%TY9O&[=VHCJW77:N44E-E$%==0/F'R./%B)L.*.AB9>-.&C2
M1BAY1D](@'3]KJ^8MC;%LNHY%.'K'?1XT1?)(*.&N^KA'7=';&^0.9X X X
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M@_4-L6>?7H>3ERQ21SZY+RW_ %S3S",\CZ -@0*5&I)&HO-XC))%#':;"8
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MA=HU;.'#A--)%3?4"3^ . . 8O-IK%:WB$DGTY.,HS#(>'?2&4R0GLHF+CX
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MIDVH8/'??">]G23P3-; 8^"#J$W>%7BHX.,:*K;HLF^J8&3^6/BSY?L?L?\
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8M===<>6-==<8QC&,8QC&,>6. >7 /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g22578g60n31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g22578g60n31.jpg
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M)4%14U21DI/2T__$ !X! 0 " 04! 0             !!P@" P0&"04*_\0
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MZJ>*JYUVJ11,R;$/3^@31?U+:F_#F'_HU*KG7:HHF9-B#Z!-%_4MJ;\.8?\
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M$9VD4FBF4'98V=25JNG=258IX9X8PZ)MKY(9Y NIPE;-OGA=;#_#BO@LA?\
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MX29I)X^6NWLO=RV ?0CQB.N--O&WL1Z9&F/T=IXS=1G$MY46O50RMY.=J87
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M 4 H!0"@% * J;UR#CEF_0GH+TMV3:Y[GAJV%RKVKWF^F1.Q.XVS4$B@% *
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MQ8JIBVCZ\?L)(QE\ABZ?%D9("S7&#\%7^0\*+ET(ON5:(3,H0* 4 H!0"@%
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3/GMU_P"VW_\ L4__ *UK-!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g22578g81g02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g22578g81g02.jpg
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M"?KN0K3DG:;EZDF)C.*<VQ
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M<D:%A25ZBLK8U&?0W^*21N:I&P+]3$#RUH5A9A&I)B8S;+
M
M&E+SOR!T!&&Y\EWKEY?9.\$Q6N*WAK=A_LFUINL(/4H(77L7U/3&/#T>G3*5
MZ]6J4MT=B["B=)9,GR.Q)F>7U 6(KYG*.:=6#FZ>=".K79/;F&=S;4*Y(^U_
MR%'G+=ZI*ME"11HM:':V%GF)DW15L-IQ:=7ERD2'2IH0[$)]J[A)KZTZV7(!
MR^?/F=%Z:ZZZZXUUQC777&-===<8QKKKC'DQC&,?!C&,?!C&/@QCX, C^@
M              ))M[E=')9@IN^C9890?2>J1&F/L=B:L.L1LY UZ;:-T2Z$
MK71>T-%NQ,HG.R)O<5*UELJ%)3E&:WL*'[J5V%I:[LX]N6GMK$TA[='=(JII
M*7"D;IB15.=,1AGW?'>O=W79YB=A15,I)0&VG1$R/2-F+$K<U:H2)W4LUN:9
MO7CFO0,5CQ:.JW)A5/PF-\7C7SQZ\Y56"
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MVVV+K6T(3.3=,:>7V3V0J,OCF87DOS=L&ZF:Z[%[:[:F8UVUSC I,9Q+=0(
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M)V"MHDCESDIU\G^FO$NPU;29Y<-O-U\]P=758M,\W7)A^V<8 K,YS*B00
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MLWOC(KSL8E>8Q)&LS.3F:511[3.,:E3&I\BMDD32YM*S314C.TU),4FC9H
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MFA:QL7I%119VH2@97O3G+_\ I]*R*0=4TJBQC990=MRT@^^HDV%Y\F2J2O\
ME:PC6PM4A/EV30+H]V5O+L?GR$]!QQ$G2,9Q;3G:==W2/>.BDJ4ORLK_ (\X
MOM=O2DU9'73:.SJ%R)J<8K8M:2PDDL]5#[(@;\G0R6&25,2:6IT0/*!/HY-I
MZ1[95#FQ.#<YJQ,3&;<H(    T5?E^1BA(PU.#@U/4UG,U>BX=4M2PXM(JGM
MLSU4D4K4<5BJ-:I2(4Y2="C6/4HE+VL;HI!HHW.\NESPTQ]I6K2RQ%>'%J>H
MN;Y,ZS1KZ(ZI<V6P[]2:*C8+%F?=8MISF9M=4^R=5&J8:G0A+NZS ] ;NV36
M^) V)9_./9%Z)I30* *D=>-@KNC+WY^,LM]UF@@                 UQ;%
M15Q>,(=*ZM2*-TOB3J8D5&(%NRE,K;G5M/T6,TBCKTW'HWN+RN/.!1#K&I9'
M'%KDD;=TR5V8W1 XIB%)8R29$[*L;E691JF^CY2X6#3LT>F^)T/U.^ZIBWM+
M(G53A''*3Z64)"4K:FG+J=NG:*RN8A*VQ^V'#9-#I:DC]KJ6 ZU"YWBVL?F/
M&[/*M+Z!       1/)-?;KX@U7-!OV5LH7ERR;"-2Y^$O28WS8D1@,+>_)_Y
M537$JDN)F3;8\F-DLL<L;8VSC3.A=W.?;/\ "V 0      '^<NGZ05VIXUWB
M"SQRY^J"U&*H;DX\<4]KSRWYQ%K%I1;IR37+^VG596S-7<DBTVRX/:)(O<=7
M^;PDM(>5[-KHXYSMIN=)F(P88K,3,3:D4G]4YS6OODE>*^(/UGO4#S9;=TR^
MSFUK3\/?Q2KZO6GS6VJ%2/ARWN834R2C=XLP,4*0RF#$L[VO<:\71^V'*6:S
M5T9='U:6J<B%9N[^^R[,5I2VU@BM:5B<ZQ7VI13M[3OJV((>9X<T=L= IU5]
M<.=T==3F6DL]!$2)+/:VKSF2>P"(1/&M);,\9K6)/3_)D;8T(VK>4*&&2O#8
M[3!R.,2KDA(B/U6BV+#&_?6)W[[?A*\H[Q[<JZM7M;IT%/)[M</(_A-]#R2:
MRI!2$=4\^*^P;BD4 OETKAZUKF/0*%0W2.(6IJCCE:+;+6N!.2DF6O#LK,)<
ME2H1AB=V_'%(W[,1,;ZS-9W9Y*F@EJ]FV9->,.=Y'UG)X7'KSM+OEB/M.EYS
MS+<%K.=25%$JWL*GVV3V2PUS,:G*LR)+5S[!Y.YL<.1N*U@R:H<2"Y$X%O9!
M*129IE&'6FD[ZJF[EMB!TYXH'A3R>T;,B570'%:^(8E=Y'/YFS0F(Y7&PGG\
MAG(<W>0N+6RY6'*CMBFTI4H]F,4G;:)=<F&9QDD1^G%3]V'VQ?TQ#G/HNI8_
MXH7BC,KA>%4-KY:S5X?&U ,$FL^)MNEHN+YSR^>IBJS0+WPC>8DOKD]QW0K,
M2*<<N!CRU>Q9-,7H_91,3LX;?N]V!>"0T<B.]1U+;CS)8 ]>);/(K:Z?IA9)
MK&PNZ9<IFCLMRUM-JL&#.<CWDJ--%GI$S($Z-=&TZ"--.K*4T81M[D1NM-8Z
MUF(^FOZ:1;T\[\W^@<',      $3]5:^U6W>(+;3_83(_P!&K*EDBC7R8W4P
M6_ZJGT,U9_.^#S2E-Q-]*/1GESMKOM'BR_,R9N6866,I[<Z^*K8!       1
M/;=UV+85A/',_*RMM36"QE(/=QO=U;"9!".:&E[0E.#<UIF@_?5OG_0<D9U*
M=VA=:*#?4D295;?8EJ[%1Y;#8C9A:6K/I&O]1WRC?3=U'T!7//T<<62#(G)8
M\29TS(["L.6N9TFLNU)B<06G5S*R)FOQZSDS^>246E2X-R0T1]H(11N*-+#%
MVMJ94(F:MU @                 E>].9R+"D#?<542C-+]-15KU:XM;K2V
M>LD$E84ZC=;I6=V1 I8V);8J5>K,.V-CCHN1/\44K%DAK.4P>6&>O,EKNSCY
M>-)^35[W/O0IUI*I16MD176JNC:O);?=1JDYRR[(LMSKNJ3L%F5E(C$K?F?4
MW.#6]?M$I@2WH%R1:B=(A,V6,3J/2".-PIT4T" # K1LR&4U7<RM2PW?1BA4
M#8'"1R%RR2<K.+0MY.3/1F]O2Z&KG9X<3\DMS(RMQ"ET>G=6B:6Q*J<%B9.8
M,[0FOFNJ)D^R-RZQZ$9MVZ]['8]FF'P!<<G7I^9:67*T[JSTVR&$;&HO;P];
M)6N2W[*VXPW,NL!.ECZ1Q70.O*^(0%FF49:Z\?']RM$$
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MFG:G ?H7^[;'LG:=%$.?FY^#;&?4)KMC;S?]8O.^F_V/;<%C/TQ>TK4!
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M3FE*6MSB@5D;;DJD:U(>2I2J"=]BCB#=#"]MM-L9R1](
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MGLPC&I2PM+NI2N\7D2735IF\(>(Q.H\8ICLE:E1XF*?CC#? (
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MX.DEG,_DQQ6A*J6V-/I*M=IE8$L5E%EDJ)'+GMX=MDY1"/55HC3)DY1EN
M        0'>NQW*URYZ^;B3O<5GC7'X)V.WI"]C-(DWQ[V9%674>B4O_ /9Z
MV)7'P:[5A96RDRGUL>F;BJU::-(0+2Q>W3QXX\[7N0>0J()5)3BE*9246>G4
M$&:'$'D':8,).).+SL6:4:7MKN69IMMIOIMC;7.=<XR"/*
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MVJ1K9&1J3:)$"!&3C.<X+))+UQL:;N8>H-SN>I--/-,-W(RP
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M,WDZD(FQI:6\E.B0(DQ.NNA*=,267IC'P:^7.<Y,LE
M !_-M==M<Z[8QMKMC.-M=L8SKMC/P9QG&?@SC./@SC/P9 8,Z5=6;X9DYZKN
M"NYNWEQL:Z1%@<#-O+_'Y=U;>=MGR^3X?+GX?]X#G1X3=75F?P#S:\'5W!3G
M<^/RPP]T-B+ 8XG&:6/,BM##5V[?E29OH5IH7KMN;G;4O773&<:ZXQ@N+.><
MNI*9(E1$Z)D:9.D3EX\A9"8DL@G3'_#0HK7337'_ /+K@$>P
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MR)NC%6Q9?OKH:L@M/1>OH(>HTU5;QK97YRC85W91I'R_JIP$
M            <Z/"6^YX<T?BY+OG*FH+.<\Y]W1<$
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M^8Z# UC^O%]V+WE: ,@      YU>''_)[L3_ +BO9OSH' UB_P ?MAT5!D
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M.5*?5:M(KN^1+_0.#              YT>+5]SNZ:_%B*_./#0'1<
M         !K>Y/YH;5_JWG/Z,.@"=_#>^YW\%?D7\N?,=!@:Q_7B^[%[RM &
M0      <ZO#C_D]V)_W%>S?G0.!K%_C]L.BH,@
M         .='A+?<\.:/Q<EWSE34%G.><^[HN".?R[Q(J!WI+L2[8RBL&0MG
M%=@6#4=D1Y1"WF-/4BM.!X;4N(E!\OJ=,E?-)*_/3.P,;QJ86BRJ<"%:W"9N
M,(5'FMF8V<OU16+ZI]>O$,MG>M:ED4'C=42NXUE\M'/UR<S+&:Z(K;.+.7N]
M>/$E@E6MLGCC2[;D5C3L[]UF5VG-8PWPQ5#$3;*5C;$F=]WPSBG.E*Q-8IOY
MYS%,^%V7]4^(++N?.P*AYX;(;"W"'S0OG[$AE3^X2 HWT^]KT>ZD.9E,H:R-
MX-3KA$HTPN-APW-P+&XKHEQ1NM55#Z5.65>7J^?/G(C#6)G2NFZG&L[ZTBUI
MG-J:F_%KW<':-Q_I:O\ 6B71:\HW26FJHC:ZPJ&PY\IB,3A,PO#:5%W!Y;Y'
M"+0>+!J^>60[)6^G4*;GFW)$ZOL07FLL8*$QNB]JSEKNYQ28C.ZB.@/$^HGG
M*_':BILS2E:HB,.89E/Y,R*8NH]JZ&51FRY8Q^B0Q2_)9Q*D2=JK!P]M3XP,
M2EFBA\IA.BY6<6YO)L>$89F*_,Z,=D?B<MD%980\6#S?;45]L-;I+VF"+VRU
M*]J:TH)WF4 @K'93_LT3I02\+%[W8)&ZF$1<QWD3>WQ.9*M]#]TT:(E1*;HF
M)Y?.^7%\-/XLM?JG1<QDT7;?K=Z??:C3B,QSK;3%ORTKK-;QFN;$!^LSW*A:
M%!;:8I<<ZS3+5J9"O3WTA(8K1D-#@^?A=FU:QOKG:U;VWOA,OBUP:1OC#'J\
MYHN"2/D@E$$@LC3$O-01[6-6U8\OZ"K!CA3PJ=9ZE+=5*2R^9[%C+_)VG+BQ
M(FM,VR%(M<R5B9 :*:S'?2)TXO'7_BH-5B/48,@E;SRPG"]F/F(ZB*93M,&A
M4G1/-S4I>][RHJ762_V<IBBQ/'8-2$I4N)F&MC3MKHU(&=C43+:3%KFDFSGE
M:*]Z>[?'1/;..<K92L<CC<ED;,HJ&JY%I7<:C\7S)E$TN#J>KN:HW[%/GFQV
ME@+T;7ZS6W#HPGL9;;LA3+7LB;9W)(9E3^N]BEJ\^T53MOXO+&@,D,LD5$3*
M.59 :"M2S["<5DF@:F5,]A5GT[+^455<H$Q<H(8%B9;:D ?6='*3'4EE4)'N
M/R%>M8F9([F%EINK>VN4QGE\NRI!XN57K&"6RG6G+,/C564S;=\7)(VE\K)W
M8(57M,RBS(;(7./.*>:%YL_VS/E>I#:]-@Z=P0R%EES2YNJR.&(G1"F&S/"\
MQ&_.:<..\A'BV5Q/I;6L#:*ID**3V)*YG!T:M]LRG&> +Y=%4D%<$44KRRU4
MUQ$K<EDB06)'U2",05:O>2<I)$B,2[N;)NA4C9FGXO7G,;HC77+59O%U^/\
MU+RK0W14D@^*Z<KHK*)V/K%-'9&]$(F^6LZ5Z;#TJY&>H\J1>WK$ZU,G6;%N
M24D[1.Y)TRTLXG0F**3,:313P(          #G1XM7W.[IK\6(K\X\- =%P
M               &M[D_FAM7^K><_HPZ )W\-[[G?P5^1?RY\QT&!K']>+[L
M7O*T 9      !SJ\./\ D]V)_P!Q7LWYT#@:Q?X_;#HJ#(
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MHDS6:SG+:(           .='BU?<[NFOQ8BOSCPT!T7
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M-8_KQ?=B]Y6@#(      .=7AQ_R>[$_[BO9OSH' UB_Q^V'14&0
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M,9Q*E00               !SH\6K[G=TU^+$5^<>&@.BX
M #6]R?S0VK_5O.?T8= $[^&]]SOX*_(OY<^8Z# UC^O%]V+WE: ,@      Y
MU>''_)[L3_N*]F_.@<#6+_'[8=%09                19TM]L5X=OY2MK?
M^B7JD%C*>7YA:8(                            BJ?\ W1#E/\CKO/YY
M/#L!=T\X]I6J"                .='BU?<[NFOQ8BOSCPT!T7
M        :WN3^:&U?ZMYS^C#H G?PWON=_!7Y%_+GS'08&L?UXONQ>\K0!D
M     '.KPX_Y/=B?]Q7LWYT#@:Q?X_;#HJ#(               "+.EOMBO#
MM_*5M;_T2]4@L93R_,+3!                            $53_P"Z(<I_
MD==Y_/)X=@+NGG'M*U00               !SH\6K[G=TU^+$5^<>&@.BX
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M@:Q_7B^[%[RM &0      <ZO#C_D]V)_W%>S?G0.!K%_C]L.BH,@
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MW3SCVE:H(                YT>+5]SNZ:_%B*_./#0'1<
M   !K>Y/YH;5_JWG/Z,.@"=_#>^YW\%?D7\N?,=!@:Q_7B^[%[RM &0
M <ZO#C_D]V)_W%>S?G0.!K%_C]L.BH,@               (LZ6^V*\.W\I6
MUO\ T2]4@L93R_,+3!       <V>[N(Y_P!2V9RC;5<3>E8[(>87NY'4J+=
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M /5S?_04?YL3_D /5S?_ $%'^;$_Y #U<W_T%'^;$_Y #U<W_P!!1_FQ/^0
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M5KU?-F##@D]=:LNZO=!H[[-?LOIV&O=<68BU<,D>B;*]-T^#<G:[:8#Z@
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M)6V/%@V!(%Q$>8X\^NB$B&ZF^U16<K-=7-G7/&V7#)*SVIE&2R@0
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M/\1LNQHL0YI3)34,;D$7BZGU O-B[^*Q28FE:VI%LN%KY<,W^@ &
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M:4:()X75SW//:_96SGJPKLD4(G$5GD/1N29XD+G$\Q!EJ&PUBIET7;IMW)1
MU$?KJ4S9"GQ)ED3.:HXX/QS1NE2Y$3BB*Q6D3%]T3%9B/>:>KQ0J?^%I4TUM
M.RX98?.L/G<;TTK"R9.3.49+U$F^0JW=V.C239>[FF1*./:VN9!('G>*E-C
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M0MRK>:[H(!$(GBVEL0>W/2.$VLYWZS>MJ7O3WS?1E/@_6$JK/E&+M:*N4SC
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M/<%HS[S%3_)U#_H<"LZSUD]P6C/O,5/\G4/^AP*SK/63W!:,^\Q4_P G4/\
MH<"LZSUD]P6C/O,5/\G4/^AP*SK/63W!:,^\Q4_R=0_Z' K.L]9/<%HS[S%3
M_)U#_H<"LZSUD]P6C/O,5/\ )U#_ *' K.L]9/<%HS[S%3_)U#_H<"LZSUD]
MP6C/O,5/\G4/^AP*SK/67/;PJ*8IYY\/WG!S=ZHK5U<E<>EFZIP<H+%URY3M
MI8\R*TV4*U36:>=MH47H7KDPS;.I>FFF,XUUQC!9F:S><YWNA/N"T9]YBI_D
MZA_T."5G6>LGN"T9]YBI_DZA_P!#@5G6>LGN"T9]YBI_DZA_T.!6=9ZR>X+1
MGWF*G^3J'_0X%9UGK)[@M&?>8J?Y.H?]#@5G6>LGN"T9]YBI_DZA_P!#@5G6
M>LGN"T9]YBI_DZA_T.!6=9ZR>X+1GWF*G^3J'_0X%9UGK)[@M&?>8J?Y.H?]
M#@5G6>LGN"T9]YBI_DZA_P!#@5G6>LLAC595O#%QKI#Z^A$4<STIB YQC448
M6)<<A--(/-1FJVM E4&)3#TR8XQ/N9DG<U.09MIG<HO.I*S.<U9N
M                           #6]R?S0VK_5O.?T8= $[^&]]SOX*_(OY<
M^8Z# UC^O%]V+WE: ,@                                        #
MG1X2WW/#FC\7)=\Y4U!9SGG/NZ+@@
M                  UO<G\T-J_U;SG]&'0!._AO?<[^"OR+^7/F.@P-8_KQ
M?=B]Y6@#(                                         YT>$M]SPYH
M_%R7?.5-06<YYS[NBX(
M        -;W)_-#:O]6\Y_1AT 3OX;WW._@K\B_ESYCH,#6/Z\7W8O>5H R
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M%1XCT<D[;TV0R5W;6A%DS70C"E65D\XDKSS-0S,
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M#H_R9"M6K7Y9OLJ==]M59V?.,\F"3-9F=94Z"
M         -;W)_-#:O\ 5O.?T8= $[^&]]SOX*_(OY<^8Z# UC^O%]V+WE:
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M$*Y*M*5)$SJG(<2$YI92XDI3H;IJ99F
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MUN#(_(\$NB;.Z+9Q3N39J=LL;%I1(F)C.,_^>[>X(
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M2N2OTA32QQ9'='.DM+,\XPW)(LTJV=^D;\C,=75"2@VT),UI:E*Y97F9_*S
M0                              &M[D_FAM7^K><_HPZ )W\-[[G?P5^
M1?RY\QT&!K']>+[L7O*T 9
M   '.CPEON>'-'XN2[YRIJ"SG/.?=T7!
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MU?ZMYS^C#H G?PWON=_!7Y%_+GS'08&L?UXONQ>\K0!D
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M(X/'YE'UR+:<(4KLZ)A.&E;UF)F)Y12*^LS2'6<&0
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M(V9S6$G_ )Q;Q
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M$](43HWJTI1,FQ
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M2(PY&X-KBA4$+$*U*<:G5)CBCR3-R]]=LD?7
M                      &M[D_FAM7^K><_HPZ )W\-[[G?P5^1?RY\QT&!
MK']>+[L7O*T 9                                    0]?%DSBU[ 4
M\B\]2)=&I9LV-KKT9=S'["8;SI6L@*W-0,L95&EGHM^B+3;M%!5;-9Y:@NOH
MWLMN&4)#4R*"1JP2Q2E9](KGQY1OZ1OF*IK6MH/3\"BM8UM'4,4@\*:$S''&
M%O\ 9=B4:)/YVVQAZE28>M<7)<I,/<'=X<E*MV>G56M=G9:L<EJI4<3.\LX
M     '.;X>!)W_1^&K5E?_RT;N/+9F+O_P#@4U<RVM)7'_[IMHRRG7_ZFK)K
M_P#18^?/G9<^?O\ W[\XOT9!
M         !K>Y/YH;5_JWG/Z,.@"=_#>^YW\%?D7\N?,=!@:Q_7B^[%[RM &
M0                                  27T?>$MCCK&J"H5.TOW35L-ZU
M;&"GA.:XQ2GX C4EMTEOZU4J4],=F&Q10HT01:,:JT#G:M@'-4&9EC<W[2N5
M1(L1OG+\Z?,FSZ'H^)<_U^F@T74NSVM6.;E*IU/).H*<)Q:%BR(W17+K'GCN
M40FT=)3)E^N#5&2$Z1J:&XAMC4<;6>+LC(S-XF:MR@@      /D2!@8I6Q/4
M7D[.V2*-21I<6&0,#VA3.C,^,CND.0.K0[-JTLY&X-KDA4'HUR)42:G5)CC2
M#B]R]]M<A"=3O[[R-8<8Y=LUX<WJD)TNW9N0;=D2Y2Y+6=60E/6Z<IV?(5QA
MRA5+(^UI%*BB9F\*=UME05M40M]5K+(A/KJQRS>_6.D5]=\:\,N@8(
M                                      UO<G\T-J_U;SG]&'0!._AO
M?<[^"OR+^7/F.@P-8_KQ?=B]Y6@#(
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M)DIJI8SV;%FY##YF6QQ0LZQRII/B=W2^<VL"
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M+//5ND&E*"25M)U)S_%CUSB*;]TY>.<;_$PJD$
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MRB<\?NR!2=9[>#:_CAZ.-WC+>#S</0-35,8B[JM9YKJK)K)+%N.PNR; KY9
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M@[S'IDP&&-3TG\T3%..^)X?,XW-]@@
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M<6EQ3E*DAFF"9-G
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M!NAFFV<;8!&0
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M17HMKMKOKKOIMKOIOKC;7;7.-M=M=L>77;7;'EQMKMC.,XSC.<9QGRX!'Z
M
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MG%=\9\>/#CUBU:="P9
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MQ7I9BMX]8T_J=W3C-O@@
M                      -.7M=\0Y_KY9/)82ZNYYSBVQB%0B,)2W*;V;84
MB/RAB%<0)E,/38>);*G/.J1 08H2MS<ET7/[^X-$;9WEX0%B*S3ONCC+5?.%
M(2]A>))T%?IS2]=,VJV(V]_T:%1CG%*6KM*JW<X[0%6+%!"<TR+QM2=ERFLM
M]$0.5LV%NX3-V2-S,GAD2AXF=T91WXS\M%N,UN"
M       -+WU1T4Z @!T)DBMV8')O=6V6P"P(N>2AG%66/'MS%$3L:"NIY"DI
MODD=6&&9U+5)EC.^M*IVBTG;'F*OSXS. B:-:\X7C*Y0YR:A[W2-,=Z;J5 @
M52](SD'((I;,%7J#D$8OZJ$ZP]2HW@LR/2G(W^.[K'!TJR>IWB ORQQ(31R3
MRLLQOW3\HK($
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MJ5S:CDK&9NV2J(OJ%2DDM?S9NU*;YA#W1K=M$S<X;.;,UDF)C\?/?BJD$
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ML?U3Z>T.A_N$TA]YNJOD\B/T0#)[A-(?>;JKY/(C]$ 'N$TA]YNJOD\B/T0
M>X32'WFZJ^3R(_1 ![A-(?>;JKY/(C]$ 'N$TA]YNJOD\B/T0 >X32'WFZJ^
M3R(_1 ![A-(?>;JKY/(C]$ 'N$TA]YNJOD\B/T0 >X32'WFZJ^3R(_1 ![A-
M(?>;JKY/(C]$ 'N$TA]YNJOD\B/T0 S"-0R'PPA2EA\4C442K3M5"Q-&F)K8
MB%9^FGL>AZDEK2I2SSM"_L>IANN^^NGUN-L:_  R4
M                                                           <
MXO"/^YV\U?\ 0IM\Z4Y!K']4^GM#HZ#(
M
M      .<7A'_ '.WFK_H4V^=*<@UC^J?3VAT=!D
M
M             '.+PC_N=O-7_0IM\Z4Y!K']4^GM#HZ#(
M
M                   .<WA)ZXT\._FG&/+Y,QZ8[?#_ ,=[-FV^?_P\NV?)
M_P#(%Q?5//VLZ,@@
M                                                  .='A+?<\.:
M/Q<EWSE34%G.><^[HN"
M                                                      YT>$M]
MSPYH_%R7?.5-06<YYS[NBX(
M                                                         #G1
MX2WW/#FC\7)=\Y4U!9SGG/NZ+@@
M
M .='A+?<\.:/Q<EWSE34%G.><^[HN"
M
M     YT>$M]SPYH_%R7?.5-06<YYS[NBX(
M
M       (X[]M/HZC>1[FN?E2'P.PKAJN,'3UO@EAM<E=F65QB-&:.4W;$":)
MR.,/69*3%"75TCA"=:I]:.K<G9,(3#70I0F-88B<41.4YT_Y+D7_ .S5=)=1
M])<;NZVVH56$0HFJY"=6=&.468Y>AFL[=RW)WEMC/DB<7V9/+*J8&-;)V>/L
MIK%'V[56Z%/R12KRH83]%!K_ ,F'#AQ4B9F<YX5R?Z.P<P
M
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MF.*E 0
M$*E]47E*IM;D<J3DU=8<=J2S'*K'"7K;N@,*U>)"SQZ,R%P-0L+P@4N!"$HB
M4(B"CE!GE.-*.VUUQKC +2-\\;1KZP^M[N/8GQ&?\357?1(%M9Z1Y:'YA=.U
MJ%H*KZ?>.,$+\YP&-Z,BQX;>E*U3H5YNJU8J]G3$*FGT@LOS5.NGFF_7>77.
M?XLX!9I,S-9OPCRWQ[N/8GQ&?\357?1();6>D>3W<>Q/B,_XFJN^B0+:STCR
M>[CV)\1G_$U5WT2!;6>D>3W<>Q/B,_XFJN^B0+:STCR>[CV)\1G_ !-5=]$@
M6UGI'D]W'L3XC/\ B:J[Z) MK/2/)[N/8GQ&?\357?1(%M9Z1Y/=Q[$^(S_B
M:J[Z) MK/2/)[N/8GQ&?\357?1(%M9Z1Y/=Q[$^(S_B:J[Z) MK/2/)[N/8G
MQ&?\357?1(%M9Z1Y/=Q[$^(S_B:J[Z) MK/2/)[N/8GQ&?\ $U5WT2!;6>D>
M3W<>Q/B,_P")JKOHD"VL](\GNX]B?$9_Q-5=]$@6UGI'D]W'L3XC/^)JKOHD
M"VL](\GNX]B?$9_Q-5=]$@6UGI'D]W'L3XC/^)JKOHD"VL](\GNX]B?$9_Q-
M5=]$@6UGI'D]W'L3XC/^)JKOHD"VL](\GNX]B?$9_P 357?1(%M9Z1Y/=Q[$
M^(S_ (FJN^B0+:STCR>[CV)\1G_$U5WT2!;6>D>3W<>Q/B,_XFJN^B0+:STC
MR>[CV)\1G_$U5WT2!;6>D>6R^<;T>+S9+$.DU;KJKEM76H^U/*HFMD[-,-"G
MEECT4DOIR%_8BB6]8A5MTN;_ &/S2M#"CBCRS,?6XSD3[_\ %$@B*_#J^TJY
M^_%%=^D[\"SG/.?=:@(
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M^D[\"SG/.?=:@(
M      BSP\/M.::_Y:;?.1,0:Q_5/I[0M,&0
M          15X=?VF-&_]&DOZ=2D!:H"+./_ .5/;/Y:<W^9VC 6<HY?F5I@
MB*_#J^TJY^_%%=^D[\"SG/.?=:@(
M                    BSP\/M.::_Y:;?.1,0:Q_5/I[0M,&0
M                        15X=?VF-&_\ 1I+^G4I 6J BSC_^5/;/Y:<W
M^9VC 6<HY?F5I@B*_#J^TJY^_%%=^D[\"SG/.?=:@(
M                                  BSP\/M.::_Y:;?.1,0:Q_5/I[0
MM,&0                                  15X=?VF-&_]&DOZ=2D!:H"
M+./_ .5/;/Y:<W^9VC 6<HY?F5I@B*_#J^TJY^_%%=^D[\"SG/.?=:@(
M                                                BSP\/M.::_Y:
M;?.1,0:Q_5/I[0M,&0                                  15X=?VF-
M&_\ 1I+^G4I 6J BSC_^5/;/Y:<W^9VC 6<HY?F5I@B*_#J^TJY^_%%=^D[\
M"SG/.?=:@(
M  BSP\/M.::_Y:;?.1,0:Q_5/I[0M,&0
M      15X=?VF-&_]&DOZ=2D!:H"+./_ .5/;/Y:<W^9VC 6<HY?F5I@B*_#
MJ^TJY^_%%=^D[\"SG/.?=:@(
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MS.T8"SE'+\RM,$17X=7VE7/WXHKOTG?@6<YYS[K4!
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MY(ELCMB63&L72:O=U0ZQ*^G9LUM2XIB@UA%MN*1VLN+P9DDL_=&2IF::N"!
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M=^D[\"SG/.?=:@(
M       BSP\/M.::_P"6FWSD3$&L?U3Z>T+3!D
M            $5>'7]IC1O\ T:2_IU*0%J@(LX__ )4]L_EIS?YG:,!9RCE^
M96F"(K\.K[2KG[\45WZ3OP+.<\Y]UJ @
M                       "+/#P^TYIK_EIM\Y$Q!K']4^GM"TP9
M                           !%7AU_:8T;_T:2_IU*0%J@(LX_P#Y4]L_
MEIS?YG:,!9RCE^96F"(K\.K[2KG[\45WZ3OP+.<\Y]UJ @
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M%N2DYBU&F4&:%XW,(+VV\W F\S/%0P(
M                       BSP\/M.::_P"6FWSD3$&L?U3Z>T+3!D
M                            ''WAWJ)TB/+-4QDGEKJV7E,J65(=)-#J
M_ASG%WO4J=2CR+F->NL=K5JD!OE^Q'*&](9MY,^<3KY/A-;/'#U5A[\5Y^)O
MVE\F,#_:L!L_RP]7YXL0S'='TG-)=74VK#2TNH)A8$5C5AH6MLE6\455W5<<
M1N;@W-#P^I$>JMSC3OH05ZQ--R4GU-WTTP9K@$G=%:TC=SF?RM0$
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:                               #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g22578ifc.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g22578ifc.jpg
M_]C_X2GF17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-CHP-CHP-B P-SHT-3HQ,    Z !
M  ,    !__\  * "  0    !   "J* #  0    !   #<          & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0 "/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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MH!@M;O:VYE^QSF3L_2^Q:3HWM.YI+)#G'6)&_6'>S\U1:UH<=Q=^]$_2)/\
M6V.21;G.-ED!S/4+P2&O#=Q&CMO\]C>WV^F_]':S_AU-S<AAW;6AK7>YPKVQ
MK+K#^M5V?G;_ /"JZ0W8UNOT] XDNU$>WW>W;N3O8 TR X:;B3N$@>W5SO\
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MY^WG;ZCIXYV3]#=_*0S:U\ULW/LW;7M>2\ \[3N_D_Z-B?U=-VQLSLVP_?\
M^3]/9_)3>/U700__T>UL;99::YJ:;'0ZNK:\. %?Z&RQ]%;Z7ML++J_Y"3*F
MTET8HKI#0YYM#2W>(]5VM;[=OI_0M];T_P#@5-XBZN7&AC2&P&P0';GMVO?4
MQU'L9OR'_P M5Z<9_N%=;36\.:Y];6L(9^=N;;C^K?\ H]KO]%D(!<E-=3P<
M<V;'5#=5CEA]-K)W,:QCJV>]GI?H[?YS^<_P::M@OO-C2,6REK7/8RL76MW
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MBD>E#&,]-KHLLJ:!)=[-]E%H_J5>VU)]5M<$,=6T'9+VL>]P(=[-_J^VNO\
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M(])K!#V,JK9=LI_?];^=_P )^XA_M 2U[G%SRV9+F;@ &[65,IRVMW-=^?\
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M (+&3M VY$07%K;K&N(V[GLLI99^<&[Z_4M_EHOIN]&=UF^=OI0S?']?;O\
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M\P      "0           0 X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300$       /' %:  ,;)4<< @   @   #A"24T$!@      !P (
M 0$ .$))300(       0     0   D    )      #A"24T$"@       0
M.$))300,     "C,     0   'P   "@   !=   Z(   "BP !@  ?_8_^T
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M;*?3C5YM!^P6,Q+2RRVDX-OI95U%M=-K:/6]!MOZ.ST_4_5_T2Z)EY#6!YD
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MVEK6U6/V$65AAW.=N:^N,;W7?2?^D_/2=9]G?; D;W.=:0P..CK+/T-5'O\
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M1_\ T%8R,G=8'^H3#W-;Z):]L$/]3U&NLVO_ .#_ -&]*RD,VEME3[J?;:>
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M/3_G/\(M*K#:UY;;6YM9=L#-KMOZ0,8[U7LC^<_L>G_X(BW8PA ;?:TCA!P
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M^X_T:W;4_>ZOU/4?96NDZ7U_IW5\QS</(:[*? MPKG$#VG;^=_2?8W=['/\
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M$-+O2]2SU-CGV?HW[O\ T:L'ZSY5=V2]M#G>E0ST6U"8BLO8_P!(AQV5,?\
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M    !@             #<    J@    . $0 20!& $, 7P!B &D ;P!V &4
M;@!T '4 <P    $                          0             "J
M W                       0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M W      4F=H=&QO;F<   *H    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M'@      !      X0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S
M &@ ;P!P "  0P!3 #8    ! #A"24T$)0      $,W/^GVHQ[X)!7!VKJ\%
MPTXX0DE-!"8       X             /X   #A"24T$*       #     (_
M\        #A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))32<0       *  $          ?_N  Y!9&]B90!D0
M  '_VP"$  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$" @(" @(" @(" @,# P,# P,# P,! 0$! 0$! 0$! 0(" 0(" P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M __  !$( W "J ,!$0 "$0$#$0'_W0 $ %7_Q &B    !@(# 0
M   '" 8%! D#"@(!  L!   & P$! 0            8%! ,' @@!"0 *"Q
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MN4IHQC%VGO#)M3O&$J8ZRFI!,2T3E#[][\N6VI+16O-T%7:*C(ZB&81R*%!
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M(U4X:ICD(D+>_73I':06\4/ZL1#'14AUE( H:>0^(BE .K/=7(:6YBO&#R
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MU<;1]#X %)"^JHK\(!'F/,YR!3J2.7=FBW2'<I6B$CP^'0%R@"L2&<G2V!0
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M>YZ+%9W+R5G\9@2?'YNCS*Y2)&9IG?'34TL25*Z?;>Y7,EW#<V=VBW$8D1M
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MS['"MLDEN0VD*V3EJ?A)ESPJ.#8-:]1Q"F]79OIX(Y'CB!=CII12P%31<"K
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MVWQ-_C\4"M4#]1T7.& &IAG((IQKT366V\^W09=JW*\DP?[*)V)!P?AA.H$
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MM=;2)-'A$!A6@U@BG&@,U2,BOEG%#T!(S>/;O=K"YME8 L%JH)!(!-* D*Q
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MY8[NZVUY)44H"SR@!:UX1SJK&O'4K9^6.D<]Y=6LBQ)+\2UX#_#3%>D=+M[
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MM_<V/V[]G-6T HJ^CCR?DB6GJUE!A8LFYHWJPGGDCY/NYMMCE2-)G6.2*?Q
M0&MXEE\:6CD!&944."K $ E9!RSM]W'<I)S19M<FVFF6.%RLL1ATD1W!=-*E
MU#&BLQ"D-6E:C_U]MK%]L[NW9A^RMG=J5.V\9USM;>&)I]W=:9;9G1$6--+)
ME:G,X3?F+IJW_2OVI"*NG7)*T-#3T],7BAIY6C\Q:V:[NMUO9$YKV'<$V.$R
MZ'N1"H9X&5-<D<<WB1"0,\D#O0R(C,R)@$O>WO[&.*3E_>K8[G.8HQ'"U9/U
M]?8"R"-BC*JS4;L+H,ZB5,3LKX:]!TM!1UD/5&T9<-FLM1[]%10Y7?\ #5Q9
MFFHJREVWF,32RST0QKQXS)->$" 02N656<*P%M[M'*NY6P%O9?H-I*BH","
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MW6.-I1IT,JZ2+=M#ZHTJ'<UR<]&D^-&R/DH*CL[-]O=Z[KJ=J?9=?[%PF0[
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M;N7FV=EFVR'3(TPEU("[EP]:J&30?#KVHW:JD5J#7HVO=ZNMQF6YW&1I"J@
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M;9O<\TEY+/;^*[:@2=*D9[B /Q$DN0%+-4D"@Z\>?-@?7;BRN#;L.ZFDL2*
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M-)4T6@44+'W2*SGV^SW[99X^79;8 HK 2>'H?2(GUA5 D9<<56M.XU*3W/\
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M/;<&-D\M,D[J1(X0%(I>&RO;/=+2":UF6(AW#:X'B)!$(PK+< @3>(K&H B
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M)ZR3:V-QCSS5&DR_<#2 U*ES&_,&P\Q<BS[+M>Y-=6M]>1,6CC>L2D.R:H6
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M:JWMB^W']VR12#<C,H)HJ5[R8U8.DC]M%<E'&DEAW8P.D,7*UC>6BF[\197
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M19Z'=^1U-6U."R;&NK*A2U#J1M,9WL^X2;A>3"^:\*S:7CBBA261G&&52N@
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MU)DFFJ)9;T E9'A2GE7W+6V;K%M>VVB7T1-UH9G9%C)6,%JLU:Z-7:%% &)
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M;M^/-[8Q--3P187&>* 3_L:A*; ;W:WI+%]OY?L#(;>&1G\:OA&94&@82C*
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M:^<N:=[WJ\OMT\&>:5GE^G:.,:(5+PRQVZ!80JLD8T!2NAF3BU.@MW_O'8F
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M?W-G&VJ%8E# "NDAJA=+:@*T-1QH?+H@WP20;?;O +A9GF9F921&4:H16;4
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M^G!:K&J5!I3\0\Z_Y.@.W;L:OZ Q6(Z<INP-S8S-;RV/LC8$G:<'6E'5X?\
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ME)=<M8M0ZE5.AO,Q  ^GM*+ZW:X-LD@,]"=.?(T.:4Q]M3T_X$Y07:Q:8B]
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M3[K=16GAS-K)8(5C()RV<%S2I9: D"@%<C?8/W5;;MRTV^749VA+E/%!93(
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M5M/78_,8G;.1JLU3Y+(5TV-R]!65DM*9JS(Y>2&\K1J(Q3N)++S82S/9R3B
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MAM1U?IU\BQ%*OI!X+TOWJ%YK06UM:+62(:% (\1J 'ORVFM:4]!BM22;]?\
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MU! &6*: $B%B)"TB@JP+Y%77 "T'0>WF&R?0-IDE$+6Z%EE*ZA*5(D1F4 !
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MA)G^Z$B.R HA['NOTMM+:R 5KK#4J*$ %5-,FH\S7/[ \G+?U5PE_-*'+!4
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M+]OV=9(\I0[J4[IP64J'K-IU\E!34CI4$RPY"NARTM4BK)"(\E-C2\3AO)"
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MT&!D5KG^+TS7&.GZM9X*J)<@1_#,70*V-G:LJI:VKD7'U,.0;*00>09-*>%
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M5:H/B56G$;CP4[%G!N/;5O)'%!_BR'POL)-":8^7^ =/SQW-Q.3<$&>AH:@
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M? 46;-74#'B2"NGHWDFK!24#9"&AC-9YJQBJLX(77?\ LJ3[>2*9P.T9)H>
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M>&R%)%%&U+'%%5)E*>CBHJ>6!1CLC0-.":1UAB98W(9K7)5V]O:,L5TQ8FA
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MM2"(.JAPOOTMRIS 8V?(*LI9:,*:B*CN7XD-?B'I7I_Z"YLO#:^MI$1Z%6J
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MZT]H(I%\"_DD*.-*DBE:@8J5-20,"O"HZ+.=;*VCN]JM(4+KI<$D#0-1#",
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MO44F(AB8A"M'$92IL2"CVO;+RVM-M;=[YKG>K:(H\P 592QS(8U"QZV55KI
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M\B,XP./6+Y,9+<>,VF#$N1DW52=J5%#AJ[&8.%L[DMTTN03+;>JL;5(IKZG
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ML5'80*4 :I%2"*4\C7UZ<FM9X4=YJ:P0"*Y.H5#?-3Z^O66;<&223[>N%)A
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M2O9DMXK*P_""2!U=TO7BMKU;)OW;(SJ),(JL%#Z A(:I!! "Y_(TKR^4_6F
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M2L@D=JB)1H4J5U@U<:A7HO8VME<0)"+F39@BTAD*J 5! -0K*Q#=P+JV@X4
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MENQ,:^$K]I8*#;.4W15Y 8"6N\PGQ55%)(J2,P$?IC!+MRRP77BSR6ZN(PI
M21GTM&\C4%8E[FH"&/8*?%T2S;#^[;:XOT?2R7/@@LE059 RR !V-68T"D4
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M#:=4D=(\7DS1I<S6",2$+HDEY')]Y.>^R6:\M[7-<U%P+X*H6A)U1OJX\%!
M+'B<=25SO;Q365E1OUC,!7B2H5B>.?G4^?'I:_\ "A11/_.L^+8.F6.HV!\+
M=*?[K:*7Y'[L0K:[>AR3^3P?;'M,/^89;R".,MU4<1_N/&*?ZN/5.6:?U9W
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M#^5V4W/VA%L7KS=4,^W\I+-D]A_QD[-V]GH7IX*J0BEIIF>,2!O3[/[;W/\
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M144F-CRBRU4<)H80)*Z-XA(T0:4C1QJ]X_,Z*"S$*@XG)H/,X!)H,T )/ET
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M?]*Q^P$X -+:_AY_PJ,J>N]EP]0_S!>A>T-Y=L]=ZMJ[C[2ZJHML8G=^X*O
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MD=[_ &X.2JEBNFJ@A=G+^;]NV/(_RF?GU25?V"R?[+SO*LB,'@IH4ICD,'3
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M\<_C)U%\;]C?$S=-)M;OK;O7-?29K;V_-RUK;9W=/OB3+YS=PR^";96$KJK
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MM2[>JZC/5=1453S&BSCZ*2HQU.:<&.>0@"W/.2H\=O%:I);HY!D5V-:D4[>
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MMW/;S[76;=51BJJCPN3@HWCQJ]4U]5+-EJ2"3PO1ULSR374Z!$UVT1JR#Z<
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M'SZPY*CK"[01T$203T]ECIX)9:M#1M&:/]]F<- [ AHU6,H22;^U$2I$ZE*
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M.S GAR72T*%BJD&FK20*YXKG!;CGIZWN;FYF-J;=H]):M54E@ S,1I!(;!H
M: ^=!U:?\<NU\#MSXZX[=&X.R<[O[<]9C*Z7<E;5Y[(YC*KO#[RJ0;)P^-3S
M+M)<!CWI*>KIXT@AI4B$TK7224K;!+1)K<7,NFW:507;4PHY&K32K%1PH, ^
M>.BZ_2[OK?59(@F\%J+VQTT FKGAJ:AH2=3 "HJ0.BDP;^VM34.R]M4L6V:^
MFQGR'ZJJZ>JQ>?P]?C]UP3]G8#!4M-A:?"5M3)4YS 5^<>0QF6-)%B$LAD *
ME_>MFV[8.:]&Q7IDMXHE73(=;1K("22[ !@P8:-/ZB,"' \SRTW>XW/9;S<-
MQLHX[R>/4 $(74JA#H132,@ EM8T&M5J>K1<[V%EU[CJ.L),'_$-O9S!TZ93
M,2&HITQ\$\,T@I(!H>&K:OIJF2)RKH8F4.;W"CV@&(OJR#P]1_L=!K7WA-/E
M6O\ L=%@[?\ D?E.L.UJ'I1ML8S,;HIMN[/QVW]SU\K0X[.Y+=V1RV.V<^19
MYH9,8:+^"/%7JTC0>6<5 <JO@-3NL]DD=K"REVUL5-0 B %B/(L5! 7B3YTJ
M>AMRW[;KS7LO,7-<]S)%MNUM"DI4K4F;4$505/<7*DM\(3M%784X8WY79#+[
M\CZQQ'6<]'NO(X[&'"9K'[KQE*^8JMR8G.55+)B9<K0314+5E=@VIY!5PWI8
MR)PS:@4M#N,MZ@$[-$CI1E93J1U.$(!((H058&G&OD.B2\Y5L=L222.]>62*
M0%6H-#QG30TP5<=^H4(-%TD5)Z'+8V_,EN3)8A*JCRVP<U6T5#)GNL^R9,IM
MG>V!M3>>ND3<M+G,G2=CY&HE5J>&;$5,F-A5 \BZW/NCHXD(5E,8\Q7/S\J8
M]17HJ*4)(-4]1_JJ/V=!QM//_>]T=]9/-Y2:?%8C:/579.U,ON;;CQ5>Q\?D
M<-G8(,:^(F>6MJ=S;;@2H225R*VH_B"Q:69?4@EN!:;G&&A$H"5*@CUH"&.!
MD\?3[>C%;22;9KAX[HQ.9O#J*]W;J8$+Q4@4IYD?+I99VLR/8^T<SB=O4E%N
MBLK\$S;-R=;6S8_'9*O^\IJ7+8Z&:>FHLAMC-)'2R4];"VFIIGD)(TD$^&XW
M'[Q2TN4:&WE4D@U()'<@!SD#4%IBAR#U5=HM%VEK^UN!+/&Z @895X.6 XH:
MJ1JJ00*9QTT=:[>S.Y-DY3#U^:;:57LC=-5@]O[;HMPT>8I,)N;%PR'(83*&
M>!H:JBGJJM(Z>"H,\K(GW"$+(4*/F#>+?9=Y@VVUMIGB9(Y*X)T2*#VZ*ZV4
MUK0!:@K2H/22-8Y[=&**'6HKZY/$>7^KUZ<-I]N;DQF5Q_4.7I)\?F*973^\
M&3J:)Z.17DK,F$T8A*"6IJGIV:&.*%"O^3EF72?9PL;7$TT"7(1535J-,@4J
M,D $@@YR,]7>*.WL8+Z1"X9RNE>-> )XX!!K]HZ&'%;MKZ7/[-V_)D8<K5Y#
M&;CSE36*J:*JBB1/M<;!&U1-]OD8)ID:5E'IB&GZ$V\]L]M13<ZHT?XCDLIJ
M!D8K6F?0?/I@30S:R(-)(& <*WG2HK2E<>1STN:Z/)9"D1JBL2"I?'UKSQ0Q
MSI05'BDG6E,ZVEF6&*-M5E(9G'/''M-;I=&./ZJ4?4JS5TBBL*D*:$DTI0TK
MQX]:N5B=F^FU",@4!-2#05!( \_3HK=='2U?>='%53Y;;T$^YXL+6FNK,M)#
MO'(202U,E7CHJ2=J?$T>1@DCIXXAH"M3B1K-9O:@H&(&"1D_YOMZLCR(JK0D
M4.:#A4G\^A5Q59-D:W=>-V[N;*TU32C%4>WZ 5QJ9H*"F)3*Y*2DKIHX\G/7
M/&L#5$SF0,;JVNY9ME)4E&(;Y9^?V9_;TJA>.&Y'CPHR FH; J5('#NHIS2A
M%0/(]"EG=U9N';]=D-K[>.=R]'%)*F,DJ4I4J1%Y%=::1#*U1('CX0 %E/'-
M@7SYTZ8M8X99TCN)M"'%:5S_ )/M/#SZ!G8FRMM[BJ,INO=='.NZ]XR9W^*8
M9Z@4R[15X/'F,:B"4UAJ(!.BO-,BNDRWC"+8G5 ZBHZM,%B=_#>J D TX@$Y
M].N)-%U-5/1T4TV=Q.9J(JK"BJJ6GJ*"@JJ4U3J6F>226G1*%HTD&FS2ABI(
MY\)/I@TI<UX?;\L</MZ4V&US;Y?P;='02N6IY4T@DD\:CSIQ/ =/Y[3^QI\5
M6U6#@GI\M()*6JBK1#'2TDM.U?CDJHF$KI++3QW<JSF-ULPYXM]3*Q*."&!'
MV-ZT/R^S/5)=HM4DTBX9HZD'A4$>HQ4'/ UX=)G:6/ST&['I:R"';IW?2U^=
MGEI\RDU5G<(TC22(**S2PU].:^**\#1^%5:7D-I]L[G/!86 O%#NYD*8I3*Z
ME)KE5XC(.<#I'$%):-E!Q_@X_P"3H1MIXV?:V:R@J,K-68$XBG&,KI6HYGE"
M5#.RNU%3+4U-9'ZE+,S:^+ < ,V5S]5:I.4*MY@@^7F*\01P/52E&TJ,].4%
M125DV6<_: Y"+RRR35-.%IB(B\D5:^HO"/%!=R0"H!!M;VON((4:%H7))&K/
M^3T]:'RX=6AE<K^JH!4%<?;\N/V]$5VSV_W75]SXGMJ79>]*GH'L#'[GZIZL
MP]7N&EQV.S,>W\&VZNM-\U&T*NDI]T[:W=W#O'!9N@BK<HD=#2867$1\35#^
MVI"IUU-#CA\SP_U?/IJ@(H1T]TG96]L_TUNS>,OR"@S&\\[\=>Q][9+K# ==
MXF&HZ_W-4X5)L%2[?:EIY=SX7+[%S.17#S46X&KZS*S:I?%3R1D)4T)5:5 ;
MC_J_U?RZ\ !P Z:Z;>W:?3%/BJ+:F#R'8N3EDQOQEK*VHVYDJG*[A[TP'4>P
MZGKG?F[\Q22+34FQ8<U)F\=F<BJ08^"EBCD>5ZFWELP!I4<#CK?7.D[2^01[
M(S6SZ?*X"BRFU.QMH=?X?;N?R6RML4O9N)HJ':U3O#?^9P-1A,YV+1Q=AT^4
MRE9@),#5)B<8*"G@D::]5IWU[H3NS<YW%C^[]X[FZRR^V_X!U?\ &^3)9V@W
MQC=[Y7 U68W+N[<6X,>F+QVU\EBH*G/08'8FF8Z)ZJ*"IA1%7R%7V //CU[H
M!MA=E?(+&T&UM@8'-T. R.V-F]!4^VTW]N#!01]B;AW_ +=V[NS?&:WG#O#;
M^3['R>!JLYG:G!T<>W)XZC'RT,[U+ET6)/?;U[I=R=]=IFHV'N,=BTV.SVXN
M^-T;:W7T#)L&DRM5LWJ[9,&]<GG*#(U])3G>6)W6-L[&.07/5]0N(K'KDBI*
M,B:D=O>77ND+U=D>W*.DQ>'V_F:KKAZ'9&[,WV5O"IV;4;OWAN7%]7=,=2KM
MVF-7O!LEC)J^'L_LK*F1Q2O/58W&FAB"-&:B+1X9X=6( X&O4_=OR&[@I.L-
M_P#865[$QG5&ZME=;]1UNTMBS]7'-X_L#=G86TMJ5[[KRL>5II<_7[8R>^]U
M-@:>CP];1/@YZ!WR,S,XC72HH(H,]>9CZU'0\_)39.#[!S?QUP6X:6OKJN'M
MP0YNMH<AG\13R;1V[L3<^\-]4^7; UU#1MALS/MZ@CD@J T4Q98E!9@IL",G
MJ\L(BT#54E0?R/#HM>WMX_(C8?4/7YPN[Y\MN;M3K;L+<N#Q6X-B?QJBZTW'
MNGMO9R]69&1VABW)F'P^.[+DAK:+*5I2HCH_+$M*D#HWL$\,=-# P>AA':_;
M%-N^KQ4_8$DVX=H]X[!ZDP_4F3V+@Y<YV=L^J.&_O7VQG<CB\129+#0YC!YZ
MLS-#E,7%1[?Q5+A133I4SR3V]4^F.O 8)\^FK._([M=]MTE?M:CI-P[VVQB/
MD=N?L+:#;2K:C)[;QNU=]2[.ZOH<WA*)ES>.FH8LI39.2EB'\0SU#BJAZ8>.
M3R)O0K*2?LZW4C Z3VYMX]A;GW#!TUM7O/\ TD--O+XPY'(;SH-A8W&U.VJW
M+;OWAO+<]0TVUH,9M;/;<SVU^KW,%)*LPH9I/'63U*N(&]PI7A3K70L5787=
MZ_''Y(Y/"SUVX.P^O-[]J[1V/GX-KTD&Y,IMG:^8@I5W1%MFBHZ3#YO=F$Q4
MM:]*E%1I2Y6IH(2E*QF,3:%">O= CNZIZSZQJMD[R^,F6SF\=^087=>]-_9F
M'=>^M]P[FZOQ77VY\GEZ[N@Y#+9#'5>Y,SO*3#)AZ>JCI\\V6E,5'%'3K6(N
MZ4)##KS>6DT'^JO^QU"[4P'>E2:[;==VCN+-;SR?QTZBZUJJJGVU%M_;%-VU
MWGW9C*3,[EH<-M6FQ;TT6UL-M>HG2F:KD>GQ]UJJ@K*7;?;PIV=>^9Z%ZM[4
M[(IM\-UQN7LO^Y&U*3LOL?'_ .FG,[,VU!D,IB-I[-Z_SU#L6!J_$2; PV<K
MLSO+(R1Y*JH=-;C<*T%/&]8\LB;0Z!353\Z=>(J:GH(\!VCO7</8."W)OGNV
MKZ<FPGQ4W%D%RTG6TU#!OI\QVWNFDVEOG'[.W73Y7#4F;RVT^OZ#+U.VZ>!\
M]-'EDAIQ3PZ=6GIQ#5-?\@_U#_+U[A@<.E%L?M'>^8WA+6;KS-!\=ZG?M9FI
MM^]@S;5I*6NS&<ZCZ[ZTP5-L:FC[ _B^W-MU]7E-T93,"2JI)ZA\?0?PZ$/-
M3U52EC5HT SI)\O7SZV<*OI_J'_%=,&W.W.SLON;:.X-Q9^7K>NW1@>J>M]W
M]C56VIJ/!;5QU?!VWV?%GZ39^Z'DVSMG<O;^/HL'2I/E%J*?!35QIYD>;[:
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MT2KN6Z7,:BCO$.Z@1F45 5G\P*T 8^>*](OL.HP6X]X["Z-W[3]E0S=H[0[
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M9.W(KJH=)H33I/=[WN-PBMLJ#5'<LC%HZ@D*0PH:&E3AF%*@D8R4=G>A>O\
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M5^^JJO\ B-<K9"KG=$(6)2&#_-FQW^[;2EO86U;MKE6(+BBHM27J3Q)H JG
MSQZ$F[7]A<)/;VH402"I%""2*4I7X0 !P_R=.O4^R/DULO&UVUMT=$;P.'RB
M)L:II:7?'6$F!&V<A69.AR&\<:F/WG/EY:EL;DY)FQTR131Z01K/I]C/=+BY
MN-@5K#:UDW>)% @EE$88!>Y?&563+"H^$]W'%>FMGFL+*%;2^O6,<=L0&2(L
M))5%44J6#('/:7.K12M".!=^V/Y:.^\A)V;MK9FQ,GOUQL?.TW4N^>Q=[[,H
M]I8#<6YTV5'%14FRJ-UKL5E-N#;M6\N:,%1)4O5*D?[09 0\N[AS$FPV\6^;
M D=XTSDQQF&NC"KXA60H"R@&B2/0U+$,<H[N*RN;I+R"[,<WAA&UZVH Q<$&
MAQG3IH*4K4UP+$?Q+[IV/M39M!C-KU^7DZC[S;L+8&;[([/P.4^]V]B.V=U9
M[:N-W]7RYF:IJ*.JZ]W94XL4]*&DHZ^6G5&:CB,04+]7%NKWEIM,K*UL%I6,
M'6'J*#Q* *N=7Q8IT^[V<MFOCW2I=BX)KWT$1!/'3\6LG'"GE7IXR%!WG/49
M*"?XD=C_ '&0+RS8[)]R_$_[VC$]5)5F)U3MB-&=!-X$F\*NL(&D*UBL=O[1
M[TQ-/<.UH'8C_%Y_Q,6],')!;B:FO2-%"*B#>9?#!- (Q0"M0%J<-6M7H21B
MGGT%_8O3FYNR(L5A^PL?O;XKY645XHZ6;.=<[NE[$I:B2!HLI!N/K#<FY8=M
MP[2DD>EIUK*F&;R5!EC1E0L!)MWM[[DV&WPR<O[C+NMK:W#RR- CI$DDD8C$
M<\+,/%J@UJ=)':N589&6P\X\N\OV.]V.]VEG?7-^D8$]Q&$GMXX9?%/TLM7\
M$N:)*X^.*J$9KTFLW\"]S[OPV\4PG9&,W[33;:R6TLC1[0BH\%NN+<E+M@3X
M,4V\L#N1*C8N>GKXHJVKK9%6FJY)Y)I4L=7LNV/;^;=MN[">P:U22WDC4N0[
M2+X997U!G:LC!CK\57JRH:&E":;QS-M%W;Z-QVR^6*97DCB\5?IW\;24<1^%
M0HFBL01E&DLI)4TZ!/ISXA]U[:^/79^)[$H<YLCY79PB7:*OWQU=F]@;YR>,
MRNU,GA_M2N]JS+]89K'8/"5$-;34K4&/KZ&D:H,LE743(P\OK>XO(;4W4[27
M,,,BH"(U5-4DC:-2!2[=^OQ&4.FKPU8(M.BI=ZA5[<V]E (Y)-4\@A?7*PT:
M"XIH\-!&JI&"5)JSJ6((/%\!NG,M)U+OZLQL6:PF:S?=!W5N7^\'<%%O7:?9
MF5_NDN)W'14]+M[<._,EMOJS*5<LLYVU4/2I6O&*M(X8959UUG?;C-9V5ON,
MT3R6\8B4JB:@@-0'9 GB./)VJ=/&O'HDWV3;I;L3V5D\1D0M+J0H&D9B2\:D
MT534 4  )H .C;=F?$G#=A=5;JV9N.JKJB#(8F)\=LKK.LJ^LMNU67PM(QVQ
M3Y_)XO*TFYMZ4>+R212F+,9.2BJ!"GDI_2![4R3,4E1.#(RU(U'N%#2OPG_2
MT/SZ)HI1#(CQ( 1YD G^8H/V=57Y?IKYF8#,XG9V\.R=Z9/)U>&_@NQ]MY'O
M3;L6:HZV>LIZ.FHHYZFLE>BI:N3&P3BHBJM=73*BR:)0T)"^Y[;=WL:QP^(5
M XE@"!ZC-?+C6OSIT9V][;VZ2E2%E8@]M?G@@BGG7A^5>C0P='?(_I:BES<$
M.7W;BZ&C_B^]=Y[@[)V[MK+8; UJ";?,&WZ^"=I:&GP]+3O5TD<\4\,Y+I*'
M+EO8:V39-TLKWZR\M=$"*^"ZM6N23D_%FI%*'/KTI6^@?=XI?[2%U"D:?,?"
M M*G-*>8Z@?'_NC?_:/:W8^]\O*1UML.NQF)QE/EL[09?>M+U]44&2>K[$RN
MV8:#'S5L6;W8L-/3T^.IYHX8J,!R9C(?9O)875]O_+]WM1#10JY=@ZMH=P0B
M@$@L M"?)JTX=)=[C,9A2YM3';I("JD$5"D:@2<UK7UIT9^E^0_QI@W3%U%_
MI>V[A=_T Q$='UR(*K#92F^WI8,G08C*4&8IGH)JNLR4AK((7D69&G46+! 1
M4T6]W=[/-NM]XDY=&6@5'KX85Q-1B'+.-2\-((6G;D@%OMEM;VUMMUN888P1
M0,66FLLH0$ A0IHPS4]U<TZ9ZR3<N5DHH.K^MNT>XML[=CGQ#]@9#=_7V/R&
M2S<>;RU?N'$9*+?^Y-M;LEJ\545B4DD[TJP2011K"[!"WL,[YR;N.XWD<T/,
M,=JBP"/0Z.[89GU%DQ0ZJ$5SY]6L($@M4CCW.84U"I!<FK%AJ:H) K2GGCIC
MRNV>W\E1_P .;XY[GH*Z6MHLA@WR>^^FA1IF,/DJ7/TDK0XO>D]5Y*9L<1'X
MT(C!#,=*N379.5=SV.^AW*;?X[N*)6#1)&Z,X?M-&<:5I@]V*"@(-.EK4>,Q
MG<"<8!CP""&K56KP%!@@5%>%>A3QNQNP-[;<BV/OS:NZ=KX^HDERZ[EK\OLV
MOGQF<IJIUH\0E#B\W7QU--**N33, XF50!H)'LZYDDW,1Q3;)ML=S,0-0+JA
M4UXZ9"%<$ !CJ[:U 8BG2Y;JR^G;Q9&$WB4"TH-!![@XX$'M"TR,]%GR/1&X
MIZZ/"TVW=RX;>=&VY9<ME)=R4<^Z*RH;KZGQ6R:R@W-CY*>BI<-D]T423U$$
M#H*2E>2-1Y59#I]\B6=+&XLY!<)&H.E>S"CX"Q77C!(![JBO2 01(TS6\Z^&
MS$T.H4U>7 C'K7/&@Z,3N#K#/9FORV3KJ/,;3VSO7:CX;.;AI<Y#29G&50S]
M)N/;E3BH*2=ZN"H&2\\5=%.B4U3!+&H5&#!K6EYO-DBS;#;2)?-(S1L= (1J
M%@=1.@E:KG(\LYZ<G%CK5KN91$$&NE3^IGA09 -"#T#F<VKO3:?8E%3]8524
M^UY>M(J#+Q'+T\61EW72YA((-U5C-)/DI*_(T5+##]P;4L;/I(%O;\C[U.\2
M[Y/HW&4G3J=:L,8%,8-:'CY>?5HKBS,4\UB3+;1$:NQB%-#DFE<^8X4-?+HX
M?5N&V[@*'$8O*S#<&_<W2Y'<.2JX:&:NK%ILG6S5,HR66$*Q-!2M*E/%).Z,
MQC4*"0/=IIHDNWM9)B;A&6J@<#2ND_;Q/^'I"D\<Z5@.J-<5I3/^?[.H79^W
MZS-[1R<G7U=N[^\..J\?0Y3$TV3;&55=!%)45$]-E?XV8BT-4M:"SQMZD"E=
M2K;W>"^BO+B:VMR#=*06!&FE<5S04QY=>#QHU7D"E2&SYD9 P#QITE]CKV?1
M;5I<%7[$G0TT.6>.7$;SQTV2@K'=JC&TT2YJKGI)\2U3$L;*CNL ^B6O[M+M
MK"\:6:*JG31O,<*U P"O'.3^SI?-N\=V5O-:+=&M8^ZE *"AXFH]2>/D!T,U
M%M_/9''X.NRU/'1UE;BL2N1P>XJU,XN&S,'DJ9JH+A8Z?&93-)+(R25:R1I+
M$@3]')4G2C,BM5030^9Z0B3Q%#E I.:#R^7V=(K?W7%;F:''Y7:-?GJO=FWL
MA/1TM10Y9,%1X>-/(,G%C\+%48_#035+,EGT-))& AD*F_MN0LR:0>!KCC^W
MC_DZNCTJI TG_5]O0;4O6O<U=,:7,UNX":FJJ4KLM#NG&5""E^V$8D:*22.:
MIFG"1K$)(V$5KD#3<D]]:7$RR&-2:C@2!6OKGATKBGC0QC50#CBH^W/1H:+
M5%+%'%>36E'2I45?H2OJ9Z7'T]'2S-5!S%]S3,LA9[6<N3;Z>S!3>,D$3S_X
MNBD::"H# 4"M7R8$DD&N/3*$QVH,SK%29J58&E2"<D>NG X4^=>F/)X+<=,L
M3;8ECKADIZ6BRM/E<A_N/H\-00UT:RXJGI@L<-56SU(^X N)@#JLUC[<TLK
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M6EP\==B\[D*L4TRR4;546&ER-)#%D*96C6S&55N66]O9M;1FVMU26Y672#W
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MK;@ULTV-,90"1O%("E*K517BP.-)5B-F!^5>1R_QXZFW3MVIS^Y]ZQ?'3?\
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MA)601(L5345*S2>S>(12(CBC!A6BUIY9+$  'B#7]G0+FMV61TA;4H9AD4(
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MH#LTTL*B-@ A1XD[F!)*FI,C@L:-7RZ.4TGF"WLHXCX?CHF@BE>"F@XU8]U
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M$-9]_%( ")XI)%]FFS[1S5ML$4V_[R)-YK'KN[=Y!];'&%UK<)*/@F('B1@
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M%>)BH']D[2R,23P>K\2*8 X<".\M[GF"3<+[ZB",P6Z.%<M5W1D6B#-:D@Z
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M ICI&]C=/]L[EP^TZ/:/8?QAZ@:@[3I.MI=K[]ZYJ^S]J[NV]MG):=G;'P>
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M0":VM&E>WMAN<;RJXU'334%(#JH&5JN!7 XX)/0'N>8$CVY8[?:KBW(!TLI
M15([:&@)9FRS$]U ,@=&&ZP^//=]!51=PY'M;8E#@J;H_';/Z$ZZRL6\7VCU
MKEZ''86# YS<L514R4]7%BQ1U-77-#%!/DI)U@GF$"<JKIK6VMI[?< G@9#5
M.D$ ZN/$"@%?E7UZ#GCW5Q=+<VDKBZ9CGXG.M=+#'%C4D$>>:=0<'\.._M^;
M37J_N?OG9':O7]3N6?M'%U]%2;RPN[,9GLO3YZE=\3F*6N@AJ=OS5V7ER,5
M08*>>!8EM32>,&FS\Q[CLCR7.P7$44LUN8B6ABF0Q.!A%E1E5J %)%[DI53T
M]:-:12R'<K9I865QIK0ZP>)-:X;XA7/#ACJ9V=\'#D,OLG"1]XPYBGQW6(ZK
MW)@MZ8^MH\IEZ)(@:'<N%.S:K%RXBKJ*BKIVR=:JE8U@0*Z:W0DMO<S;;>;>
MVW7217L3(ZZ@'J8JU9D8%7!U]P<%2:$U(%!+M_,_+Z+N@YEVF2X$MB\,01Z%
M9FH%F9F;4JI0:@G$8%!6JKQ72W3R9?;M&=[PS9^;$5V(3<F(WO63T%1!!M##
M#)5./5GK9&PF<QM?X(U+2JJP,=1* @)MM-Q)>75VN[A9I+EKAB%&DS,"/$
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MUJ&,FLAR^:U[JBHX$T/KCCTC]P>=MTYUOMOO]PM/IHA:(JHK,06!8%M9HS*
M2%! H,&M*]<.S/C-OS<>8W%B\-V1B:*DWALI8,C7;K.?R+5E1C,U'65N=F"Y
M&2GIL[C:6I6+_)7IJ9H*EV>*ZJWL[VYCMU['N4$A%Z@J#0$:@0RDAJ@@,*E2
M"I\P>@%)<7-U#:64@#P1SQNOJ I[E   )88J:D<!QZ2M%\'$K>I7H.JNYHXX
MLKO7;?9>T@;[IV##_"J?[4XB/,"IDW#N';.1N:Q'EJ)/\K5?U0C1[WN5]>[]
M<WF[7]Q'+N-R26=$2)2"A0*B1!5C4 U 0"A%1G/0JM]TLMJW>UM+[:)4VNVO
M%9X6),@4,#)&5<A=9-<MD&@.!3J/'\4MN;+6@V%GXYMX[@WCNC,YN@Q6W-T9
M[$4-#39:2GR68RF0;.U-<::"GK*"28&$AD6...%/2![!W,LM[N&XV(OK_5>K
M9"!2BI'2&FAE;2 &U@D,6J6%2QST_+SC#;7>\;=R[MS0<OW%Y]6(I")"K*6$
M57^+4@)(5"%J:D''2LW?\8*'*S[LV[E,_N+!RY2E&X(-P5F6.X:6:JHJBF$>
M[<)2QPXN>#=N&G2-466: *C\ET;WK;(MSBW_ &_;A?R+)*&T$:"CA8PC)@5I
MX8I3 [0:5"]$<^^VX9I'VB'Q2M-8!!(#F32!J(J6)-2":%A6AZ"W?7Q*S6[-
MP9G,4G9]-4X#*;0H=K5M)G:+.XVH67'45+'7?>TNU,T*"?&UU704E:UV%2LL
M6EFLS:Q]'MN[65Q!-8W<0N8J%2RZAP*B@=2#@E34$9KQ /6HN9-ND[;RQE:%
MNUPK $QZE9@">!-,'%"!P%>CA=!['I.O]IYG;^[LQB,EN;*[WW#O7+P[<I\L
MD+#*FABII\EC)UJ:FE7PT"D:@E/96:/@,0GD%U#!MUI<W7BR00*BL,:5U,0H
M;#-2M-;U=AAB<=>YEW/9=\WN]W/8MH>SVR30!'(59W*(%,DH6L8=V!8K'^FI
M/:!PZG]];&VYV1T_V+L*'<5'C<GOK%-C*;,[FKLO1TIGJ:M:JAH9*^D2ER+X
M]907@I:>2[E1I!&H^UNS;A<;9NEG?V<@CNHF)0Z$D"MI(#>'*#&QS7N! -",
M@=$JO!$1+=6YFMUKJ0$@LO#34 GS\O\ !7HD6^?@?N?>756&V3M;MO(8C=)R
M])G\R^0HFCZ]J<@^%P>'R4N&BVS-#NBFBBCPK-1/-*P+5$QG]9 ]LI;WMK,+
MXW$,DHD+&J<21W8-%J#W4\FR :]+)^;+._$UO+92+&VDAM7=VA0H:FKM(7B!
M4C%0.E[@/CSN;&UN)Z^[LRO6?9G5N]8-YBIVOMWJS,M5X:L;(TNXI2.P)-Q2
M9VCPM3DJ,,],D+-+4A8 !&FL /FK:=]W6>-]JW=K*_B:,PS"1Z(L<9#*T2KH
M%:Z5R:U+,=6.C)+NVW!-QW6$TC)&N-RM9"[T[10!J4U." %Q0'H/^]NO]M;P
M.<^.6TMH;>Z#QN(BP4G7W:>9P&/P'7^5PD,V/K=W[7P-7C<_%N*KSF1P]00J
MQQ-2U2>5:KQ2K%J$%I9;R;7Q96D5]0,S1&0P2L<(9->=8-2M.# Z20.F8S86
MC65U^\[=YI%)$*-_C*+D,1@*  .\5^%A7!ZS]J=-_$+/;=RF\.N/[A)N'8.S
MI:3S+@,]D^I\C4YR [=QT>[MN;8IHUI,_"'C-#5TLM-4S.?WVDCUV5;>S;?)
M'*M_,KT(=D(+E6(+:==0I) SYTJ:]+'W"\D>8-80O&X4('H=&@U%""#G(/$A
M"54B@Z-M\?FI]G=*];[7R$=7O')8K9U'13;FP>*K-NX7*1Y U,S?P#%9*2EJ
M\700)4"&-'BA8*NM1I(9CJ/:H[N,W=O=?XO.2X\5V>05\R:8)R>V@_/H#[KS
M$8MQNX;N$FY1]+:=(6M!PSD4H!7[/+H0=R9&"NPM5%@]KYV'))104T7DS$^'
M5:2A=IS1C(+5L\4<IDM)X?7,38EBH L^RD!O$W.*):#O*NX]!VJ-6?LQQ/KU
M3;]]M[B[AA^DD9G-  5!+>0R:>7G]G'H@F,Z(^0L_:FZ<QGM_8C%=;5-+3)U
M_P!:;,IXYMP;"JJ.NHJN:K;*YJFCK)Z6*KAD8,9'DUU#'4%&D>W'9KJYL=LV
MZTYIMD^FU,#)!*4JV"5"L&->%7-!2GIT:67,>SPW>X7]WM]Q+'.0.TJI9AP#
MNP(!IG2HU9X4Z%CKGXC]8[,_N7D<?7T\F]NK\L^;QFX,?E=P)41;AK*7*"K?
M?5+A5KL)EZRJ;.2/415#-^XT8)/IU$_AB*.2-;GQ)BNDR $*U#6JJPJH/'3^
MWI0TZ2W/CBVT0:JJC4U*I_"S*<D'SJ3TW;X^/&TMO5V,S-'V9%B\=35=-G)M
MK[ERM>T,N_\ &/%C\/O3"4-='0Q/-BJ;)7R:>&8FEBCO8 >T5W# (T)&K0X*
ML^2I^$ "E""":U%0<CI;:W-U(]VL&I#.M)%C! =?B-3EE.H*!0TH37)'2/[2
MV:_8V P/8&'[VVE'G*#+9&EJJ3>&6K:3"-BF&3V+E\#1X7#Y2' -LR2:O&1J
M_P#(WJJ*FL4FA]+>VHC:K+;7DCT:%U9 HX*#0@ FG</,"H' =:/[S6VOK&.+
M5:W*,CA@:%CP;4!J)##X:T8BAX=&GK-M46<VAU%MVH89RMZYI-JT5;GHZ3)2
M8[<E)BL+34>7EVU+C<[1K%-N!Z""JHZFJ^ZIE@5@T;LXL+?HG(FN#*@652P&
MKX=1J">TU K0@4/GPZ((Y5B0121L6C&GB!D8_9CATW;H>C>C[&I.W-\P5'3N
M=Q?7>"V5LV?:J[8RFT<WMO\ B$FZ*FOW53[@-1OF'>&8AH:J*A:&ECH8*!T+
M2":WLLOT79[=+VZN46.H (JV2,8IZ5\L?ET=;+97^\[A%8[7;Z[H@MEE "@9
M))P.-!ZD]"!DNLNO-][;EHNR)8^U-J;KQ[U>2P>XYL!#L7=-#E8D>6KR>R\-
M#1;<W'#7T;(K?Q&.MUI^1<^W+?Q6\*:T8@8*LM:\*@@\>'I04Z+Y[HVLTT$B
M>%,C$,-0U J:$5!)!!'D1T5W?6Q]X]186NS&8[DR S%3_&8<+E-H;!-'3=;=
M5Y2JC6/ _=X&G=XL5MK%4%/!CJJ<PLIH5+:R&)IM1@M3<'<(I+B1@X'=BM"%
M<@T 8$DG3C  %*]/[A.][(LMM'%$-49H%H %I50 3AJ9J34EB>O_UMR;MR3>
M^6W9TE683<$.VTW-M[.SY[ T&0JQ4[G^VVNN9R^'H8&PU=!7T%%CR9&+ST,S
M&-!$[2$I[5E$"WI4:HDP"12E30$BH()X4H:5SUYDD# *>Q3FAQZ?GT 7R%W5
MNG>=958/X][7W]NG-=<]Q087M^!=LU.'QN)WSA=F;3W5!6[:J=^0X'#[CI<G
M3[@I))LABFR6*JLC#)',WW"2@@OF6\VJR>QEW"^AAN"D@C$APP.G5VZ6# $+
M4$<:8)ZK*D\L/A01$L9%8L/PA:_LK4YS^SI)9;L#Y4U_QQW)AZ#K'=.W-Y;9
M[#_B5'6YN-*XT>VMOU6,W#D2,VV2Q=1$U!4I55,-;3%1)H%' M@6)=!S?8QQ
M(5NXY=,G>Q9@N0=(U%:@,]!PP*^E.CVXM+.><012OX$\2IK4%9(]6E68K4KX
MBK4TJ8V/=@'!5]J?S@NPNS-M=B=EX_H_-;>V?TY$N[:"GV=DJ_=%#W9C1N=]
MD8W!Y'=F2V']CLO"YR3+Q9.22FBGJL='1_N2E&9?<B[V^VVUY!%LF\_6[?';
MPR3RFV> K)( )(%CD+,W@NU/&&) A*H PZ7V')=FEKO9NI0UU5UB)D 54\5!
M#.P$G<7 8/%72@:NKMZ6E-WU2?.0U>^LEU7GMK3=9U>"Q/6F_=B;T7<6V<_)
MG]NKN/<%7N2@RF+VY6T\.U-SQR8B*CJ:=_NJFG>LIY4!1?9;])#N$FW7T5_I
MF7Q4N;5T_LS')^FK2?"WU"!94:',:G1(0V!;F#E[>?;V:+;+RX4O<6UO>6TB
M482Q3:N\(2X B965UET^(!55*G.?(?'38>Y,EMI=R;GWR^UZ>HQE-N':-1M/
M$5E=N;&R93^)UNW:3/XNOH9\1M]\B\7V,<2F3$Q1%J9EDDD<J)K&25(&><E5
M&D( M"'-&%3Q!!(;56H)]>B&+=YVN#29(M;L[R4(HQ#'40I.FAP@10%Q04'0
MEY#XP]$]<=@[8K<9/\AYL%F=\XNHAP/]_MQ[KVG@-P[?2LJ]L5<V=K",KMC9
M-?45=4F8,LYJ,E5_93/4B:%2Q7=>V7*)ELX/ZN62[,D$L+01PZ(BD@TY1' )
MTEXR7#J4<J1@=*4Y\YBO=NO8;S=[F?<I;B*<23.&DUH"&)9DR3V,*4(9 0:$
M])C<&Y,;\/O[P]4_&KX^9Z#K>@PNX_D[G<GLK.=R9W'U'86$S4<V7V=75L]7
MGUQD>[*:!:ZJA;(HCQJ[-1LIU%7>;9LVPM:6^RV:6;2A2_@QQQ*RP*D4*,%0
M+3PT$9HJE(T4 GR..7IY-W%W>;]?+<NJ2P(LY5RGU&N1Y8S(2VL2R,Z\:R,3
M53TR]1_S1NY>R=]=9;:S'4?4>UX]][HZCVW2+%O_ 'GF:JLR&Z=_KM[?<V)D
M? 8FACH*';=3#6X)I5>6KJQ+!5Q4ZJLC*[/>=CGFLK%I[@W4S7*OHA4B-4AU
MVSBIU.'E!CN<+X"4E4R E>CFR]H;O<.7.:N:;.\1;#9;-)I#*VE&F+=ULK"H
M5Y%H;0,=4\@>,@$5ZL5W+C]\2?)*.BQ>X_MMJ2;4QF8EV?3UU2\N1@BW%BL6
MV<R&/EPTE,M'C\\S*ACKTEM([O"\(U!_P_\ $S)H_&!J]#QIQKD9X4^=<=1M
MIEKKK^CPX^?V<?\ )UBVKN3;O:NQ=L[PZSR.]6ZHSTF]4PF.SNW\MM'/#)T.
MY\IL":AQN-WE1[=WGM>@VQD:>NR%"&A2*LHUC$#F P$H9-\.RI/X>QM=705'
M1T>,.M)D#JL<ATR50ZF)!THC!06(!9?9SNLT*R;Q]/9'6LD95M+AHF"L9$&I
M-#< I[G9:D*I/0?=C=?[SVM1[GWEUILS8&0S>.JI]Z1U7\1JX]PU.:VYL"JV
M)UQ4[/R=11U&/QE;592)5RT=8:BGEQS2) K.Q8M;CS%OUE8W-WXD<J0QS4C&
MID=')=%*K0D&8AV H-0&FE.F]EV6RNN8.7;.^I;\OR7D(NY4H;B.W1 ADM]=
M4$ZH"@+5!!R35CT3.O[:_F/0T%9)74-<E=39>..DI]KKUU-&^$$$TTU'6-FV
M\:[E^ZBBCAF)-&U/*S2HDJ@^X\//F_R&)I+)H6"1!Q';1R*9,_4,OB,',8JO
M@H:-VL'<U'4OW/*GMQ#+>Q[5>_46K23&'ZRXN(7\.I^F$K6Z%4D*YG:/4@8@
MH"JD=)#N/:^[^Z^H: ]YM7=E=M-2=TOL7#X+"4V&W'M;#4-3MAMO8BNHL%6Y
M"@KMZ9&25:.1TU41ADFGU:4 ]BRPEEWI;3FSQ9+*."2'QD:#4P>%7)F*H& 0
ME/$2(MEBG$UH7[-=[ER>_,%CR9&URTUN\<KQSNL<\$@):(F0(2L(+*[KIDID
M5'2-Z7QF[9]P=^R5/4N6I,#N^IV5UHNX-C;CI,?N?!]<;*ACK:[9W]R<S')N
M"7;4VY*J=L3FHHE%5'%(WW,:R>L8_ONZ]SN7=IV[F'FP0[OL.WNTID9Y)]RE
MN;@R*_B!1"T\4>@R(7[0!168&@-N]I_JO>[C=[?M1%I+,JP&,T2$+&@90P.K
M06+:3G4<XID<?]'(-0V0H-E]MT4+X^DH/%4G;6;Q5?/3*\4=2<569&!L554-
M(R0!&<%F4R,A:1F]D4O+"RQD#< HK\>DU:B@?%P%/09\SB@ZK#S#>6X189)O
M$*G4H([:L3C54FHS7%"2!7B3)?'/XMXF>JW!V(IW!MW!YG*SG#;7ST6TMP-3
MT"0B'[JFR=-1O54N7Q&5266.K64SFRK<Z(]'GM[NWM;;;FF61;<_IR$CN#-5
MR12H(& , _+)Z9GN$NB]Q(7^HF \0ZL]OP@^1IYGSZ$?MZBGZI_C7:O8&SMJ
M]A[9W!B]K;2W;#@-OYS(]BR55%N%Z+:,.+I1)6Y+<V*H(JF&IK4$D,T!%761
MJY4(=[I#MLMN_P!1"SQ&:-@&- I6A1F8$:0)!J)S4E5H>MV41F>=7NQ&$A=Q
M4%@2H_LT514/)P!-%!RQ Z!>B[4P6PMC[3ZMFV7N^CK*G);HAVSN/'X;:,E=
MM+9&Y*J;<>UI,K0;I&81*2MK)C3!C%%(7I8Y/2TA*GLVRM?F#=MRLXU>6<ZH
MR2:RE07R!4*Q KI(HU5(]423@&:UBN-4L5NK!J5)0-IH"3ET7R-:J,=%HVM\
MP_E/E=_;[^/>UNIMT=C;)Z_KUVI6]@[#J-Q57;L>U<GL?.[SQ'9&XLCC*0;5
MV=O2IW)@9=O)@H)IU62HCF$NH?;^U',R;1!^Z;/9+B>.ZDM5:?5;A(K>4ENR
MVJTAGA50H\5U36['2-*$D6<L[!MZ)MV\[W>0N99PZB1AX;Q>&]1-0@K+K /:
M:!:*4U$, &P?\\SM.+ [QRNZ_CSL#&[AV?O?-;,I^M/](>^Z/>F=.)P>)>E-
M165^R9J#%9#^]%7/BZH/3S:9J9B@9F**YM0Y>NI=I&Z[\UI8SHIEF%J\XMF+
M-K0QH5DF*@*H*44LQ)(1:E#-R:+BQW)X966]B=O"4E562BHT>HEZH'+,3DT0
M*14D@#G0_P UW?\ @H=B;@S?3^:KZSNC;NX<MC=G9E\YM/;/7%?L2OR>VJ'
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M97.Y3?FT=C9V:L@PO]VJBLK\'+C*!JFOVY5]9[UJ,7M&IR<U0HBKMS5$51+
MC$5* 0EI 2/8.V/9GDL(K>^E"F587M^(>,M?1:I.&6$=7TG!5@?+HOW[>XWN
M;?Z(MX4<A+T/;XAA.IOF-05=6:4( %2.@*AZ<VC6XBNPU-4]D[0V]65'\4Q&
M.SL6'W'D<;65D\LN0HMS2U%2,EF,'-(_W*T32ZXZMED>1V@@*SG!830P&%KH
M&=T=6<* 2K4HA7X:H!I++35QKT$)MWN-;(L@E@CEU1U4 5 "ZPPHY5@*A')
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M\,\6ZL4LK4$.XMM4&%Q+8B2BI*VGE2LC/A6E6GDC :;2"3W.])'>_111:29
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MAF6CIJ.JCR.+5QXUDB:HA?4![#.[PW^YPBXM=)2V68R!#I\.-"H9V44;2LC
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M:>JRN^ACMQ0X^GRVXMPICZ*CV_T)F:*C9*#K3^ 4DG\:JX&GJ7KF^V1HR\K
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M!7).EE-%TTJP(!<D"F.E*>W%ON[75SMF[21OVR:9UJ&1T!8AHCV%92P 8$Z
MI-#Q,MU3WSANQNR-P;(Q>V3BJC:.UUJ,A09/&4LFY/N*'=DFV<Q3N(Q!!)C<
M77TKQR_:HP$H216=7"A-;7\FX6QO8(-%KK*D5HPD J5T^0IYD\:>1Z]OO(EQ
MR28HMRG\2^FBAFC"@-$]I<1&6&99*U9I /A  '<K4D4]++"?)_XXRY+&X.G[
MGZOFSF9@FKJ/%-OSKQ<W'1JIJ13O@Z#._P 5I_M:92[1M3F2,*QDTL& U?SQ
M;987FZ;O(+6TMH_$F:<^'X,>*O*7H(XU) 9V(4$BIR.@E=;GMNU[7)O&[7L%
MCMBJ&=[AU@2,$"AE:0JJ'.FKD4/;7HG'6S]Z=BY [P[$[!WUM[K; ;QK,B:+
M#;?VU@J?-;?PVZ,H<9O.#-PT^3JJ>"KHD7[G[6U;-$!XV D+#S/'<W%A'83^
M)#/&I0C.MJ!CI/#31@U?X2#P(/1S'.$MT;Z2%]8#*U=0\-U#1N,U.M3J4Y!!
M!&,=?__0VL-H?RUNIL9T_P!H]19O>.Z>SJ#MFAEQV$WIN_9G7$^X^I(9:>DK
MGK=E5E)M*BIJ=ZK,T%'DXVG2:/\ B%/',B_J'OUREO)/+-9VXME)0J(R3H9-
M!#(S%FJ9%\6I)HYQ@  30<U[I%?[=?SA)/ =&:-@1%+H<.$F12 R=JJRX! I
MYGI.]D?R]-G[2Z[[03#;D["WK%OW:/7NS\GM>;*;=VM&L6S\!U_LR;.4.XL9
MMJHJMOU>6QFQ**KR$L=/,M1,DD154GO&GW2;=KR]O-V.X/)NMS/)+*[A6:66
M:4R.[$CXBS,<<3B@ZM^\K+?;RUCWJEO:(')DCU%E[68  M\.H*H ("+\-:4Z
M#7O_ &33]=U^PL5LP;7J.LY>QU[$[6RV4WU)MCL/J^?.=X?WFQF1ZHP'7.U<
MW2^*M[%W340XQOO*8Q+ ^/JJJ.G$A9V+E??+V]$ME*RW(B9.]$C%(QXYPY'?
MH!;.2A&D$D=$\._\IQ;)=+O.XSB99@\8A7Q4=I 8:O+6JH):*0 *,2:U5@!R
MS&T,;V-6[MQV1WGG-T;EZ9WSL3=V*S.#PE'L+"4&"RBT.Z-O[5PV4VK/483L
M7:-=E</+45T\KRU25J3TTP"61 -OV^7$NX[9N=[M$2745=-)'*GN!(;N8,*Z
M3V\#PZ/MI2ZVK:[_ &Z"YI8WX-:H-2E!H+H2%930LA'<K FH!'3'VE5=*['[
M/AK^PMX=H[H[.V]A*>FK,EUWL#&4.9J<<^6FK<A2T4V+ABQ=$IJLDLN5AC]#
M4\R-I57O[%D6YOOL=SN#6_@P6SB)'4DEE<5(<L6SJ!P#QR>B%-LELX[6W:9/
M"NE,JJS"@*]I<*HP=(TY\N%!T ._>N^LJG=W0.Z,?L3Y$[:&]*3=^'QU/B:#
MK69\AUKA]UXG>F6DRJ9F9\NV7R,VW:&>,9*KGFQV+@J#2".2>-2]#)'9RV]S
M':-)<4=!7&H2#20RX#8)T@XH>'6VLY+BQO;/]Z1"TU1N>).I#J7PV(.FIPVD
M"I R.CPX;YW=*Y[=>Q]EX_:^;K\_V%3UFY=@RXNFV_EL%-MLXJIRV)W1GLW0
MUTL>T6R6-HY#+!+&]72:-,BDVO2QGCO&@L[&#5="BPQ@8/&BJP&B,T'PDK3A
MQZWOFVWG+T$6X[[&UOM[VRW#2OBD35[PI.N05!&I P/$$C/52ORWWW2_('Y/
M]/;5;XK=B;^[!FV;N3#8+:.P=\[<VYLO<W2FZ=SUL^:KMR[APF*FWSA*S;/\
M/FFK52LH:"?(496!9Q*/(NFNMW_<UMM=S]1!92.TXA\1_"<D>&6$0.C4  #-
MHUE**#IZ6;5N:6D-Y;;=<6K$2!9'(J\99 :$C@I%#X9\SJPW2$P'5?5.QOF%
MO;>=#U3\I.ANU=LY"7?Z;'WUD=G[[ZI[5VEL+LVDSGVNT,UE=O1=N-2;ZW;C
MJ2>B8:XX8CI71I5?:&3>[JSLKA#<R^!$6D9-9549EHYQIJ'7B2*%013)!,;R
M^NK@74\HMI+BZA,9?25+ ,2#0=H"-Y 4KW<17JS3M#%;8^0^TXMZ;JZY?+8;
M*;KH:?LGJ[&YS!9BGP'9.S*:/)X'*9+(8[%39O?4\NVXX8'H4"42QTPC,8E0
M:BG?MZW38)9X(+**]C\4&.5"Z(T,J:X'*L"^INX-@**8(J*$][M)LYH(?K8)
M5:-27BD$D>H8D4/090X((!&#YCI0;OV#T;O#KJG[>WALO<>Y\Q+G,;U]M^#M
MVKW/M5<&TM0(J;&U=//6T>2BV!C9GFJJ?RP-6U,3!-0CTLI1=-NNZ;='O!N)
M;6<HJ-;I'$T>O@S+)+&9&0U-?]+0>?5-KL$O-YM[)I1%Q/C'5J4 %A0 @ DC
MM)(R02>EQU]\>>HMT;8Q>T'QFWI<AL?/T#4V:VQN&NW5CZ2LJ5FRE!EH*7/5
M>1I_XFBB2GD-9%/H7B/BUGMEVZ=+JWFN;UGE@?21I31)&RDTX!E4U.K33(P>
ME_,$;VMTDBS._P!1&2';M=64Z6!T]NH_$#Q*M4YXI?O'+]J=9Y&79/677.W=
MY]/];8/^]'96 SF[Z'9V8WK1;L_B]5E,-L;"XO#%\A40XVGEB2C:IIZ2LKJ@
M1R($ ;V9[MS!;65['8RVS4$:&JD!0&;10BHKZGCC..G]HV.:ZL1>)<Z9I9'1
M!H9S5%#EB0I"Y( )I4@\0#T+^W,=UI\?\KMKJ[9>U<+CZ#>V^<SN/:.W!C5G
MJ-K;JWWC<MO+)19C&84^/:V)R#X2L%+6U49ADK4>+S:]/OV[[MNNWM,D-HC6
M2HN6)P%H*<:T4D4)]:5-*=%%I807L?U>IA-$C,Q%>#&A;TJQ;A@>G'H0L)DM
MJ5-'M79V6PN$VQGMY;MWI-M^FV]0/),,G@145^4SM-+4QS>&N-#52&>:0FRS
M$+P;>VMFYIO[R^L'^EC.K5KRV HHM/EZU^76[G9$:TW!HY#X$(0\5![SY>N?
M3I/[GZOV_C,G6[^Q6YMT5.7V;CZO%P;?_CB28#(XRO%%F-R5DFW51Z&LSM-B
MH9WHJC0)HA'(MF0M[&[[G*7U^ BO3RU"OVYH:=$26J(F@DLM:BM#^PTK3U%:
M=5/_ "0W-L'JKYU;%V[D,;\EL#FM]B@.)WYM+='4<>RNR*?>5'MW;^V,AMG%
M5D55YL1B=T0P4>4&7BE96@1Z>(K+&_LENY==\+DVH=BW"NFE5H2IXUI\Q4U'
M0MVJ]N[6SB2WEA"1HP[C)7+'XM-.X9*T.!2H/ C#UAT#L3?GR32LRF_?E52;
MAVEC\ENFMZBWA1;3J]E;$Q?8.W:_:-/3]B[@I\56-2[IR-/MZ:/&8_'U\F/I
M$IHQ3QK%,69!-;V]W%>6B6S(9I5F<T.D^'ITH0304I4C\1-:D<#_ 'CG#=+V
MRY<BEBLH[;:K1[2%8:JSB>1YIIW)):5Y)6+-*3VD*JA1TM]V=8Y_!;YSO5E=
M5X+L7!P8G!]CTN8WKBYZ6MV]_=K)9+);=I\#@]M553-1OM#*T2ST4Z: )Z@Z
M(!$'60HW;;H]L6XO)]JD<34/B%:*[,-+!&^'6H'<N<@4%:=%.U3W.ZVEL8-P
MC1#.T7AJWZB>'I<&12:>&Q/8U:_%4C/1H>J-G[=[TZ]Z([O[!P==D=][9DK=
MW;%I=6+R4FP<SGQD]M9?(8K)4./I)9Y,OC!+]_YI7C8RE98P550?3[3;W6WR
M;5?W?UFVRQJ' -(Y10.-1 !8@T[L$,#2AZ+]RNTAN;B"';+>.X1B&<:G;5@'
M2S.408IIC4#R))Z&VGZ:Q6W4CDPV1S-:L,%93BDSE4^7CDJ,E719*KS4L\Y%
M7)EUR$(FC82)#&Q(6,*%4*+3:-JCLEVB.UC@VY4 58U55!4AD)%.ZA4$UR<5
M/08W?<]RME.X;;;H]YX@[3JH%((;30U&#Z^9ZG/L]OM$HGQ.(K(%U:H\M0?Q
M%:A9:BNJ:R&I:M:H>2EKY<E*)8[E=#E5 !/LSL=DY>L83;P^(+?6[::@FLC,
M[@%@30LS$*305H,8Z!][S)S=>2%[K9;5F*A>X..U5T#SI\- ?7SKU6YVM_+U
MZ][5EW;#6P[HVQ5;C[;R_:N2KJ'=^,S."EW#E<6<%F*+'[0SN.&/QNVWHX8D
MIZ4M*]*RJR,& L<S<L[/(7GBW6\U2=V5!8 @ +JH:]N/32 !C'1Y9^YW,-G;
M6UG)LUH4A14I20 %> J&X#R'D<CI+Y'^7?B<7USW/M6#LS<.V-O]F]+]C]5Y
M^NFQ^SE?:FV.P\AA\CO#<&"J<-#10T53!'B$D:2K'VQ3R251:0AQ:RVO:MJ.
MYSWN[[G=_4+"A)< J(5=86;Q%8.8E=E1C4Q1]L8T5'0KW/W4W3G78^5>2Y^6
MMNL;7;[F:Z$T>LRW%PT95M;N"(ED0:?"C(2:?3+(=?24[K_E]5_?^%Z P':/
MRRW52[6^,FU=CX_:HQ^W-E8#"5XQ>5PO\#["W=EZF*3&56>SM/A:&@#T++2/
M2+>*+SREV6S3<L%E6$W@G 65@)86+M7#4\(_%1@ "*,6P!P!D+[A+$DO[K?P
M)'>%&(("T52R&F1H5E+,1PH:GI+;0ZCZEQW;_P E-Q]?]G_+'.=_?+[,4NV=
MS[WP.P]DX2DV#4T6\*RCS4&QI-PTM!B]M[LV]B89\91Y;)&LDPF/"O3*DLC.
MP4N9UC<0&V_38B149=5 22A(/FM:U_B%?3H6V\#20K.NXHE$*%E=E+ A=:U4
M"H<  KY@\!7H).MOC#U=US!E>I,=VI\NMO;-ZS^1-9G.M<=O5?CZ*&#M3&[9
MRHWW2XS/[CH'BQK[OV_29&KJ:+1]G64\IFL<A42L4%S?PF.Z6XL0S=H60G3X
M;:JU!)H2RZE((;!-*-0]";E^PW7Z^VLMC>.:_NXV01HK.0 "P*J!4$4H",@B
MI&D5 K=C=>?%CY&TV_=_] ;6WSL>5MDQ?%EMM;7VQU[U[MW(LF1VWNVCW3M]
MZRFEK\GN7 X3;=+C,/,)Z>CHWE@5],/D=7()-SNK"XL-G\=]JNI;59XQVH9+
M<RM:ZT8 LR>+)I93I"DU- >F(^<I=FMTV;=S;K<JTMTKRN3(88XE@D0R*^D6
M\=0S1/0F1M0K04R[4^6G8_R=V7V;OG:WP\[^RG5G5M1LV+"U>R^RTH.R^Q=[
M8+=>,Q65P^/J<+@9<%G(\%BYA7Y:&)7Q\L+3Q_=2,I3VJEWBZ4)&]JFF(D,3
MK#IHP1@T)!%&'#TK3)%#LT1E>2/<%I*:@&A#"3/:"/AS0'TIT.FPJ?K?^8)M
M>#>V;J]_=2X?:L]528+;.1;9T>^,?N(5>8Q6?IZ^K@IJW%QRB7;,@QYI13S>
M(2^6S*540[!SW/M%MND#[9:3VETJ:UE#.&$9+BBU /\ $,$@BHI3HBWOE87E
MUMTMON5S#=VS/H> Z64N C48#6#0Z32E0:9KTL_C9T1\>/CSMOL_#==;]W-G
M3MW!5\>:7?&3V]'C-H8S?M3EZBN-578%TC@Q<DTK32S,94IT52AU,X,:23;;
MN^][[O5F&C:1M16C"(>)4EHC(:LI-0[58*13%>AV]UOD'+/+_+MW&#9P%FC8
MK^K)IHBH^G =1A%"H6!!H10]8OC7\4/C?2?#O;WQ^[#PF-WELC;V\9Z3:57O
M_/[>.X*O?\N5J=VX^JVWN#;_ /#Z?%;XI<M4M!$V.(K)8:54G67]P,KMK".-
M)IKEHFE<BC*PQ2E*-Y-49H16@!X=,IS;N2W%G>;-XEO-:&JBF2PJ:L&'<HU'
M0'!"%FT\>I_QQ^+VU-CY_L3>^_NP=P;FW-V-OK;.[T@W!@]I4M-MAXL=5UM'
M1X2#!8''46W</2FC9Y7I#"GDB,M0S32.S"F2"V5_\0VR-70#5(-3N[' +,Q)
M+9[5'D:**#HCO]VN;J2)MQOF9J4"_" JBM*#\( [F/GDFI/0@]L87XU]L8F?
M:?:?8=%VCE=_T^?W3L2ADH\(,ECL+@)]K/DMW]?T<=*,1#B-I1YC&2U&2DBE
M^Z*J#+)+=?=I-DW*W-]/+:R1M:G1(SUI#*58!6& KD _IGTJ1T@M^8=ONH]N
M6UFCE@GI)&J9\:,,#J!R2@)PX(] ?+HH!ZCV+UW'NG96S/D1OG+TF[\Y4Y*G
MHX\_3PR/DI<=!7;BCV4V'QK9C:)I D<@*F*DR1ED21E,8#1A>\QVT<=Q;6-O
M;W$+)WL"_!DTDFA JG%)"* BE#U-?+\FX6NX6E]>;<"]I<+/X$X8QNT;!T21
M%8:D8@56H8#\6DD=!!2_!ZBRE3D:^C^078]+EX]Z;?PV;W#N?!;7HNPL9D=M
MX*''4.U.O8,1'0PC84NUHH)O&LCS02TAE<^)I"S4W-5];2[>=NL(&L(XXXY(
MF6622CMI$B*KY4UXM5@U2P5*, SSGN.Z7G,M_OM]>E=XW&>6Y::*1D(:5R\L
M2  * Q-& -*#%36MANY_C=F=M]>S9KLKY0[VW%@<1D9-UU'\4V=UYOB?,;?Q
M>&KTR&U<-D,_MROW%!1;NVA!(E33XZJCJ3*6:DF0VN,=MM+B#;9;"8(TLL<D
M0I7M60Z04."&"F@I@'UZ#5YN GNTN[.'Z9UECD;2U%+1D'N4XIJH?7'D2>BU
MT6R/AMO8YJFVE\==_;HQN"VKN/<>YZG&;-QNV,9)@,-CY:JFJ=M2YK.0QU]+
MD)X2D$+I/*PE5XM)4DA5N0=CAEG@\>\&DZ6 >E-&!4@"A%*@_%7(ST*_Z[<T
MS^%<2[^C2.2P+DNS%R=18LK%M7XBQ((P:CHT'Q1W7U!GNJML=%4.+S77^X>R
M=F;Z[$P6R<W08C)S1;+PF8Q>R*C=>$FKH]PXFJQE!F*FF&-AS'GKG>#S/3&E
M6,>SWE^WL-E5-NL_%8EFFI*Q8D:@"2U:T)QQ#<3CCT5[[:;UN-M-S1?O%-8)
M/':F1=*KXGA&18@BA?AC7)4!!A0Q; $_OWX[;$W?U3/M7<O8>_-J[0Q>U=T4
M.;V]MJ;;,.#W_2UN Q-!,FZME28!\9N6;'1X,5%%1TJ4=,E94S,8RCA%$D>X
M7.W3C<[2\FMKJ%O$66&1HY8V7N#1R*0Z,OX6!J#3/1#M@G_>-D;2W6282KI0
M@E"2: .!G1GN'IT0O ?!KX9]L=88$[$WQO\ ZLKMJ=Q[H[0V]D\'NZFAJ\%O
M/-T>(I-TG;NU,K13[:Q.V<ABZ.GCAI:.G$>'L5IWC;4?9/%<0\R6ET]U?R-/
M</*97GD#2R-(H5VD9R3*S"C$M74>-:'J0Y^9MU]M><MHNI["PNXK:5+J.'PV
M6&05S$VFC"&J^'I5@0I:A!;#WA_Y4GQ=K>PMJ]MOVGONMJ-BU-1!LC:NV1UI
MM7#TN7CS\&_<U0XR/&[3>OK7W+E*/[FMIEG!J-3,UA]#"ZWFXBMX]FO.:YY[
M.:[B=8I;KQ5FN88@(L%J2RI"NE% )2+"@ =!V?FV_P!VO;O?K?8+6&DLTVB*
M%A%"DLYE=$74Q2$R$+W-W4HQ)STF-N?$KXG](]D47?LO87965GVOVKN7M#9$
M^_<=M6OH,9W%O9MS[)K&@RU!LZEW<Z5)K)L7+E)YFH11^.,2J )"BV[=I+%]
MPO\ ;[R>-)P]O.M"JW$?B>((G%*F)9JNA4+5JU8B@Z9N>=QO7+\G)=UR_9M-
M/?I+#=A9%N+>2KK(D7<$T21C06DU!41%2A%6'_%]I=(96LJNRJG?&Z<1F\+C
M)MN;+H_OJX['W1-N7;^*R]**["K#74E?73;N^\H:;(K&D<,:"/RB23U&8WR5
MTEG:QTL@(- P Q@.:X[L"HK^71!^X9X!%$23$V14IFGQ:.&JBTU::@&H(KCI
MOV;T#U!O[=F\^^:3=.X-];8[[Q=#_>';U>M1MO:-97[8V\FTLK0R9W&RX?<5
M+0XF6CG@>$F &:)M;31\>SR,ONNVV@O&"P1NT@0*NI#( KY(U%3I!H685J12
MO1=<<V[IRXU[L=K!&%&D%S4L?QC )4DAM)P,4Q7/2.[?_E^_&S>>V,9#BL,G
M1&%I9*7$SY?:%)!NB;<LM?0)M3:6*$N^)<_!1R8+(R4]1124:+4LR(-84L"[
M $V>XEFL]TN(+F:%[=FCE:%]$M*QAX^[2Y%'0]CBJR J<UVSG#F"ZN&6';(K
MQE5Y"K(7"A%)>2@I0HH+%N*@5 Z:=_\ \KKXW=O[=VEMV//[RV1D=F[GRF[*
MG>FW-_T^ZLEG<SF,GB,_GJK<>W=[T^2V[20Y+.X6GG"TL$<M"(Q!&JPW]ED-
MO#8Z;O;=WEUD.#E0&67$BZEJ>X**_"#0D$<.C"XYPW^65['==I10D@<(T3!D
M<%6!-=!88%*DZ>.3GHCF[NN<_MSY.8/K'86U/F7NG)93 ;JH(=[[%J/CE3X[
MM_KF#,1&3>YH(\*^W\5L:/<V6J*+,Y#<L4%?D$2**&.21H'8@N4M9Y(Y5LE>
M4',NLL[=H4MJR"5 "@"G"GET.TYTYSACVU/ZP26JV1+6T1#J+1C)XOZ2.-:.
MS@2?$<-D48CHT=/U!TQUQVM48CN/*=U[N?9.%@EI=K5^*ZWVQUUB\9W5D4V;
MU]BM^[QP$VWI*C-Y+<N'J3C6CD%-3&IFFJ4!=@A=>V@6&X^G>6WF9U9I!HD-
M*T(_5JH+DBK::"@IP/6N8N;N</<)-NVWF+>VW%1<ZHT848S241G"HJEB%HE"
M:Z=*J*4'0K;6W!\4G@[:HNI>K]T5.Z-F4F!QVXL?N+.56,V$N?R-36T5)!39
M^AS%3)GHXLQ3DY!Z;FJHZ<M&6LJ,7P[#/>PW#V>X7=RX"ZQHB72"VE&H(@).
M^@&@M7 QCH([C+/M%W!LF]R?3E9Y(HT<Y\2,,\L8%2T>E59B'TJ*' -1TOME
M_&;:>Y:;K_?M)MG>>R\C1[,S=)M;9==A*?(XW8<6X^Q-H=IYK%B:BQ^4P]?4
M4>\-A4B8[(Q5,DO\)FD@#2"8LH\@V":SAC@O]ZE$\5 ZNML6KPR*J=0K0@@
M 9]>@_\ O6&X+-;P+)%)\+QNVEQQ!'D02 :C /#H;=F=1P;!W?E^P(%W559+
M,;6&V9,?6T60QNWUH<3G<SFTJ,^*1*9ZFIQ\V=KCC:^IFDGI*>58XG6!= ]M
M_+UI8Z8?WV9($!!!\($ZSJ#!A4L030K@ 8X@=7W'>KF]E,XL5^K=EX:B#I
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MFN;F-)I[MH?IP=4H 17$Y./TY P*5%2"#7B 6KY$==;;R7?^V^\^R=YR=?\
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MT$<.U1Q,WZ-#2BENXD59_P"(MJ.>)Z*;S>;AP91"OC'2 *$#T)XGCQ^=?+I
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M?O=)*;([X@3<&1R,]+N[%J(,5154TN6F+/6SO%3(D1-;[8-MOMSL=REE($*
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MB6R%*UU ^3!>E6X<R<T\O<J<P[!MUK_C,R(\:LA,@=9$D%!@NKZ=)1JJ5)H
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MIC9::MI))$H\?E*QZ9?W&#%7=R6!W"6*VDIXTTQ2'5XC1(LI4(S@4D*"BEP
M'(U "H'0-FL=P_=MW?06K2;-9R*CW07PXY!)4VY(9R4::,:U4T915&KH+=(+
MNWO/LG>G7WRKW/\ &#:._&^1.Z/B;M+-8/:^P\+58ONBEWYE*[;.WLGDL9@Z
MZ"D-#68F&::".H21GBJZ%Q<&,,*6C"*29KN!XZ%7".K*9$1BKA*@:B&.>M;]
MM3V3QBWN(;BU#!/%A=9%C:5#)&KE2VAO#%2*D@8.:]%H^1&\>V,3WK\(-L_$
M?87R9S>Z.B-D];?Z=*;$YFMRFX*S;N\M[;9R6_\ :O:>)JMXUF7W?G\*RUT^
MXH,BM9#135Q5"&Y"U5VRVNV:(HSRSJS%6U!4U&BL?)QJ)-,JM!B@ #5T-RO+
M$"XA81"!E%4"EG"!<4QI(4::\34YJ:F?V1UIWIB^T^VLIG>CNYJC%YNLIZ#;
MTM$U#4;=R^ H<GF*_([:H:+-[BHSLVES-#!#":V$&GE\UBH<@^P[=[='NMW=
M27[DKK;2=3)Q<]Q**2R :=*8H*FA%>I>V??TL=O%I;WT"7#QP@&1CH23PPIF
M90K5:,FK&@8Z1DZ0.BL[JQ7RLDW?+D]O?%+Y)PU&UJW!YK;U!EMAT6:QFX<O
MB]Q[@QFYXAG_ .)U6/AHZ/:#XI8EK(XHLXT#R1 D!FI!MVX-M.WQ1W44-S$D
MK-J:I)D!1*  UD05'G0.<UZD[=/<#V_V7>_=+:[+;Q?['N<5A':RPT2)9;01
M/.1'+1X[6></)I0JYP NG 8=X]7=I[THM\G!_&7Y.TE=N..]%0OU=AZ;/X6M
MAW"*^HP.6S6%SLF!Q50K9RJFH*F.!8$HFE%U++$?0P[A:R[;-!13$ CG574:
M %M)R5*U!K@&@H2*CV^>X_LQO7*-U8#D-X>=#MLD/U4?;&]SH9(KI5+:58L?
M$D9D$AJVDX%;[*_;6Q^MJ7 8J',]<X6:#9M/LC86+W=FZPQ9:B^UQ6/KFS3&
M*.NJTU4Y!FC U2E?(0WZ3O=-]$UW<7.Z[@JS74FMZD+1R30QC52E3Q()' $#
MK%;9MB2WLK:TVFP+6]G$$CT@O^G05\4Z22V/(T(!)!(QEJ>EQCCMC+[,Q^S,
MCNWKR!-O8K=E5A\9ENS&Z]W!7KF^P>M<;OC+BDK=HX3>&2I:9%FHYE-+34D4
M@CEFCC*M^-XKF1VU2$=V32H  /XB?4@\3Y]+(5AC!14'A4-*4%*U/D*8KY4Z
M1&6^+^X,E@\W%MG=%;TGD\A04<$V^MF5\.Z>[*_&X_(09>KP4N_]TXRJPV I
M,ZU(M)734>/FR%53'6U8*@"0.&Y6-6+0>,H5NRA(J01VH"*MZ5.3Y=.Q&.%U
MD50SC^+A^SS_ #Z+?UGU1\F-B;ZVON-<MU=54%/N?+97,1P;OK)I4&9I\G-4
M8^>?)4<+8W#NE<D;T=#'Y:Z>**5Y (B2 +.?=5DMY8.5=V$0%-+VK)H0  FA
M:H_I8I6M*GJ]D]G%:7\<]TOU,KA@RN"IR3H8$>1-58$<2M*=#WU+U/V)09KN
M'/;TS2[Q&\NR\5N7 4\.X:JOH*6@I=D/C!M[,M3T,-%EMO4>:JZF0QU"R H8
M O\ F$ $.V[MS'9VUU NU^'>L)$(NHVB#%@KHT$BAF4570\HII^%>)HGO-OV
MG<[B"YN9&4HT1)A(((C#)IEC)5) %:H0X9J,V0.E#VYU/NO(;)W=)B<XU'A*
M?!YG(;EP,&V<>QW]M3:VSMU87;/7LU0SR-2_:U5=35M-74J1U,LM.BL0F@!8
M7NQ(MS<WLKQ+*TC+3NT$'5&*$$YS4D%SQIT5W.W7$AMDL[M(8D<54@!61590
MCFA"H"5:H%1IH01CHIVSMW;NW_U[6[&S.U>T.OYNRZ0[3P>[]P]?U^WZ'8E!
M11T62@H]QYZ6LBDK<= ^-:",8^H>D220 N.5]EG->]65MLQW#;8'NQ&S1O#"
M0&C=0"0T-0X.1K6(.] 6H<5'%J;&2"X6ZNX4940QA@29JG0/"904.FI?O*C1
M4 9Z26Q.D]_U6T*S:^[=C9#?.4VYO?/P83LC-8JHP%3)AXJBFKL,W4\SG+5^
M0V5-$5E2MDJ5-9-Y]=.BB,^U&P_1[M9;+O\ ':M;7+VP)0,'!8ZB-="0Y"L0
M=575E%:4Z(KK19-=PV]P[*TBRU4F/PQI"G*T\-O$44"]NECW:L="33=(=?[>
MW+B>P=]].9W&X? RU+U[[FWA4U_4F(I<K&]'79S<6V-P4-;3YC_**Z28K4S,
MCUE2TS R,7]G0MK:.:"YGE8:"M2S$ **Y!K@@>6/V=,&[N+E985D9@8V"(M#
M5C\((- 0QXDU/I4]8Z+;7QJVOV#7;GV3TUU)'B=K;NS.W^U,IMG$T,F,ZK[.
MDQ"4$.3RFQ_[O9"LR/8F6V^6P]3'3JWV^-,)FM!XO:M(=MN=UEW**Z2>>.(0
MN% +* PD6I5:@J3@J0P!H2!0=*VM^8;?:-MVVYVZ:W@NY#=6QD;2)ETF)VC+
MR %#I((8 ,RMI!8,>F.H[O[BW7VYU'T7\4NM*:7XSY)M_P!3\A>]]G]:8I=G
M[9SE)2YJ6/8.%I,>NWJ2ES= <9&F9CAH)\Q-65L%-3M'*&D#.Y6]G=_O"UF-
M0R-&PJVI7*D4:IU5!H3GA^SINREN]LEVO<#"PHZ3)4"CQ!_B3BI5@& -*'.#
MY@O)WE\A.]INZ/C#V7\0OD+T]U#W1B\=0]([Q?;U.N^X<;L:JV]4;VH-^TL&
M7-7C%WCA*5JBBG@=_P"#^<4DQDD=9E)+&PL>7[(1))XTM2S4%6D. =*#.E 1
MI7B%R?/I;N6XWF^7CW=PH0$X H%0,2V2,:B?B/ D4%0*GC\<_C9W5T_M_LG8
MM3M'M?;>PLCNC=&>ZYV[@=NT]92;+ILSV+VULXY2EEQM9#793.97J#*8/.5*
M,T-0TD%/1F6.JA;V7;G,ES^[[BVMKKQ8[E&H8GX<&.1VI_I<FF.)Z<M(XM-Q
M;W,L2((6:JLE&<5** *9-:9X'/3[DX?YC^W.IH,KM/K+*?Q+J/9/6FW.I:[+
MX_9F]=_5-;)MJCVKVEO#);=RN5JMS;CKJNJM70T-6:2JT>6-F<*)6,Q.LS07
M,5C(D<2D -4-4DB1@N  ZT500P'Q5S@WVMMMAVV^V^ZO4$]Z%$W$J1&=</=2
MG8>X_P 1.@T Z4?2G;O\PJO[-VNG<>SM]IMR2;=NX:S"TO2F)P. J,?A^D<E
M+@-LP9R5ZC-0YVH[7Q\>3CF=T9OO/X<R-!&)"=;7NT=S)/93;;+&/W>1XTDJ
MH/J/J5/B! M'1[4F$P EDD7Q]9!*A;S!RGR?;\BS<T[=O]J-]_><44%A&[2S
MM$% G>12:QHC#QXYV!20,;8*"H8D0[1H_ESEOY=O1.'VYT[\WLA\X]Q=E[L[
M@[+S356<@[0V%N#%T6<Q32UN87=$.3QVU<SC<I0T."QV./V4D5,WFIXT#:K3
MP[?XO[U2)?'>#PT4&I7 UZT\JE3IQ0EJBIK2/%N-P:+]VLY%JLNHDK0$$DC2
MU<G@')S0!> '0GX7YI?*_L'Y 57QGS.-H:#K3$;2V-A.U=LUV+HMF=O8O*U_
M6>'S':<^3W;_ 'GH7BQ])G<BY26BA@J:2IJ0\M2T:Z6MS'?[+;[5:O+<W=K>
MR73K/=2-$+00,@\!;< >,)P=0D>0E2P 1=-:"CDW:M@2ZVNXD$+W20(6C8NQ
M6X61VDDD4"CQ.ND"$ZE!.H9I3GNCY;?S5<]0X38FW^NO]&.^9VR^6J-HR='/
MGM_9G9F(KZ)<+%UK7Y'>6?PF:IDQ#24N?S-=%'X*R6FFH[*S$UY0YCY5:ZW:
M'?K"XO+E+!F@B@N!;J)60C5=/(C/125E@B@5C<)569/,\N.1N7QLFU\R0\RV
MJ,]Z\4]LZJ9DTJ)$*(BC]%LPRR2%-,C)HJ.[I7=N;Q_FO]03=55VSML8/>V[
ML[NW%8;O[(]8[5V?VSV/%L"@W?6S;,H]TX*2EPU-MN:'JLRLF3B,BU.7J7N2
M$Y0[<%6::>]AN")8Y!V$:5E5?T"=5550&+2A15FT@4'!)?W'*]Y'ME@EQ"EO
M#<LQCD)C AEE!D$;5+N-*JH<_P!B!Q<UJ,VW]E]E[VVUBW[AZYWUE.R>X8<-
MG=Q8ZHVCMW!;SVM/@]W0UF0S$N#I*JN."PN4HJ;'PY!:18_#,JZ)0LLD3@C>
M]GDW#=+^6PA,*-."JDZB(PJ!VUD*6+2592H  HIR.CB/<X-L3;VAD,EG;ZE$
M@)\/62S1Q5R 43R.6&J333H?/C=G]GXU=T=4;L[<ZRW9NW9V:SR93*XS=^(S
M&=CV]7562SV/QVZ-JXK-35>"WSD<?B:O^+((DH*U:!O 'M)&BO:+&7:[B2"9
M(71Y-19P& 5P!)$,X+,-1#@HZFA5NBC?A?75NM_/:W<"R,=(960R4JRRZJ48
M!&%"IJI&H$ CHP1[)^/\>QMH[SC[6Z]?J[(8?&U6S]R&G^[VU58W:63^YKMR
M4F8BE_AE-0XR2.44U46%)3&[:F5"/9_M%C;0;=:VNSV]=KC'Z01695"EF(P-
M-%SIP H!H"!T0;Y8[K'N>YVV^Q>'O*-&TR2E5E#N%T$HS!B[56F"U2*Y/58.
MR?CW\W_DOLKO_<U%WUNWJ,1]U;OJOC1L+<^!VS+T9N?K?!YNGRW7G8D&,I,7
ME=SK1;KFGARN(RU+.(:2>G69:"0,-2,?674*6D,2#;T+.K."7+%]:$25U:5.
M4%"@7M((H.A1-<;1MLR7%W:*N[L@@E6+M"HJ>#*7B_L_&8!EDJ$=FHX8=QZ>
M>@-I=UUG;W9_5GS,Q_9?=.R(-E;9QNRLW\IL!UW2]9Y_N!*BEIMWXKI=DHZ"
M;+U)IZFM>+,0R4HKL>!'%3J$U,/_ !H7AM+H0VMG#I/;',TDM?674-.D?A4+
MJ!-:TP 7OIV2)!;[+#<2.)FK+("I,?X%%&(#L*&0C!-4R%J3'4>Q^D_CIC=\
MUN_ND>L.G>K\:=JQ8K>.[\;LO,X;([=H)8:';VQZ+%5^&K*C;V V!D<BU#AJ
M<I+,8ZI! !&ITENWV.W[>UZ(Y$/BS/*64A:&0@N*H$8BHKI-0/P@=(]PW&ZW
M#Z22>H,5ND-&U'4(P0C'4S G3^+!-.XGIT^)/5^8^.'6O92+A>Q]]4_9?:TG
M9F"CBQ>5S&69]TU'^3XF>2LFG>CV%CL72TPHX'D^RQ5&RPPQ)%&D8+Y5<,Y$
MB.Y. O: HI2I.*^OF>ED+QNZL&95T $NQ<\#D4R*>5*4]<]?_]+9$WMOCNO-
MU5-G_N:_*I2[OSNW,YM3!4=.NZ)=N8O![@S=--B*Z*>BIZG&[CJ46"FH-+M7
MUL:"2:.2 >2(MPN+RXG'UTYEB<R*O:-(",=5"/)#0&M:C54^DQ;9!M-G<(D-
MN8U\!&/=W%G44K6M6?- *4JH ZS5_P 3.I?E9A.H>_-U[CS,VVMMOMS-;2V1
MALO/+B-X;@R]?C:62&62N@.9Q5)_%MOF!J. HTTR5"S JBV.;:^O]FY.WR_M
M7"W4D15M09F[2\;: 30:@:H0*K2N>@?O,UM?[IM<%Q&#% Q*,-*JNK2RDD"K
M%!\8;B2.&>E9NJKPO]T=J]5R[,IJ^:IW-5;ARF.Q>6:DAESE2FZJS-U4T-55
MODJNLPE/0SM$D_F69A&KE"$ C798+J[L=S1=<;P6\TR24)!\,0]@%"*G4 7X
MKJ ..A!OE_%8QV5W!(K7-QX29^)5!<4IPJS#42>(%!7CTQ?'SL7%[?\ BE\4
M=X[FSU-L'<_8?7.T:7./5X2>JKL_6;>H#38Z+L#<V)HZS+X/ ;/3*?8TN0FA
MEH:"HK8HRUSI]SEM.\7(M]QL=OVM+B621M,A<*R!20RA?B>M :@T %!YT"',
M>PV46[6$NY;M(+*&-"\:H60F2-6#+6B(1D'51GIZ:03#;;R.^!E-B=D-4;@V
M9+L?(=BU?;O7#YW!:-S9',8O&[>P$_951F:O&Y7-5N$IZ-'P,T)<233JTH$3
MQ/[IM>X[ANY$EY)*DUK<2HT1H!&C@-"*5KI U%!FE:'R/1MN6W[1R[9;AMEG
M%;7 W"ULY(KO3(79X2XN##12HUU3ZFM*^&"F=2]2?EY\B/E9UCL3#[[^-_QQ
MVWW3A()V_P!(^&W)N_\ N_N/!82F::HRU?244$R4IQ+X>%S]Z9I7II+EZ5U7
M2Q]K9'@9%J/$%?4+7)'S]*X]<=%&QV/+5_8[R=[W>2VO(H':(!08Y"%."WQ5
MKP0 %Q@,#T4;:?SSS^=V;O#LG ]=XG<6!V!B8URFT:G/4>V<Q4;AGVD>QZ>O
MIQ.M0M1B:39,J)!2K3K%+74ICU1I*\T>OZRWDKIV)]',SJ)%6K1HI*+)("P(
M+R4#!0QT&H/  8<S^RNU<I26>WWFZ3'=VL[>\:,.K((IE20VZOH'ZJQ^(1(2
M4+C32@JV7$_S,NO9,C)C=W_'CL'.5E#M6GWT<MUY-CLOM7"[3KZ&.JW)B*Z:
MNR^%R-1O[!U59KGH(:::FFI_WH:B/3I(@AOKA=@DW<[W:).+E87M==+LT74M
MPD14ZK=:!3('6DA\*C$'H#'DL+>W,6V22?N\0Z]<M*&84_0JM=)92"KGMPU0
MM5Z=:+^83L3LW<E;T'U=UYV-M#Y$9G(5W46TN^*[K893XW;.[]K-M;BRNUJO
M)29C?V%W/N'!T-?A*BK%!-20UN2AI9(T%V5RZJ;TW+4._7=U#'MEQ+-$D;2Q
M^--) T:7*PQ %R(3+&78A!I<,FKJMWRS<6E[>QQ*?HXM3"1P54JNH\:$%R5,
M= 659.QF!/1N,]N_=[X#9I2IV/G\U!BZ2ERG8G8E?N*@VCEM]TK-@MUG:W5=
M3-4YJFQF9KJ6:JQ4@AR*RTD^BF8:5D)"D:-4L2:"N*&@I@D\/M!S^?14R2@Z
M56M1ZX_U>O5/?RS[<[XI/D1@LKL'8G?'5G2&)WEL;9N\ML[MQ).Z^_MOXNBW
MAN>6EZLV9F,KEL]MC;E7B]C9.+!3RU&.R-$X6=XZ503[I)9K;S1WD%T#= *=
M43E2H 8:6; 90KL3'E2:'NH*+X[Z[B2&P6[0VO>0I4. 77O )6H8A%!-2/X?
M.MJ?7GRAKLCO_K':U/B=SS8;N#%[OW5MC=66SL=8V"V_1]<[*[5V-L?)T$T6
M4DK]Q[@VMGIQ%^\:R4TU14QFIB4M[#.W:[;]]_4R'Q8+A09')9A#VL$3B#JH
M06T\6)4$].7BEOH?#B_Q>6.L84 !FII9ZBA-&_#JH"*$BG1D,GA]Y;II\;'N
M/.5>-R<]7O$)'A*:OH<=7;<%!+_!\9N**%*C[C&0U-2/NQ>*6K\*Z +Z3:RL
MMX_QE-ZW$/.E[))"T2^&KV^#%'(FIZZ=15^X-(5U4 .D(MV6PN5M_P!VQR0C
MZ=0ZLVJLP#!S72O8QHP4#M&*D@GHBF]OAEM&/L[*?)S<^>SV\^RMU["H=HXK
M:^6BJ<1MC9>T,!M[";<S63PN/H%HLY]D]()YH%K)K4TN09;C6X]A[W'W"[MM
MAL=NAD'TT]T"XIW$@%ER?A0$4TT_A)..C+DZWM[3<6N9G9IQE6)PJD*#&JTR
MI(+ G*BH ->@6^9^]5RG7FZJS;VRJJ;)=<[0QCX27&9JG1,5AO\ 2KT]@H)\
M/102E%ASDN4J)1*\4;00E--X_80V..9[>PW24/#X,MNC!@?U5:WN6U T[ OA
MJP4'2W'B34:7C1KO4&QVLL9^HEDUOD]S2)D@5PJL%HM2*$U\@<;>^^:79^ZI
M-G[%K8JK=5?MV+=F,ZPVM0U6VY,B^;G;.9[+XO-X6BJ:6LWOFZ1*K-5^*JFI
MZW(T9:;U!P'E0;WNC;"D=CLH<P(29%;O<L#X;"/!4BH*L:Y&JF*=!./E_9I>
M:)1NF^-$D\P1/$74D>A@'1G)H8VTE-*84-IH 2>DRT>-Q]=)BJF?(5^V<W)5
MY7&X#;>]SMS"8V@SV*QM!B<33T:U$./BQ]"^"GJ*J&",0_<ULSNI\KGW$_/7
M/?[QW3;#<[P$-KM4*2IWAIKA];2R2F,C(<J&)[FTT!48Z+KZQV_E[?-RVV18
MDM8)6TQNC/JBD)9,DU6( KHS7305H,@EV)L&MWYN7K_+;=J=P8*BV6FZ3)C)
M.S*G/8O<C9S:.2PV)QV4IZVLBQ8HJ+/8^CJ*'[N)):.21V1D9E8FGM7S7)^\
M-WVE-V-\UU#%($9G(B\&0>)(OB$L&,3MP[2%%03TW'MO+UXERL,EO;2)!K4P
MQY$@JL<5" Y\9B 30*,5IQZ9.POBOO:LQ?4N.P^<V3D=P;PVCC*W=FP^Q,CB
MH-_93<I@KFRHV[%5SXG!+AH(Y*1*A%2:>&L=3#J1@HD^ZWY^7-QL7CW^8^.X
MC6LFGM9B&E$H"Z3I(0(#20G32O2GPK:XM9Q<;;#8W,*ZO$B!4AV4*ELRZR&$
MCZJN*LO&A!-$OTI\E]O]*;9V)L^MI,30577&P,7@,EAZR2*/*5NX:',[A_CF
M%R6*Q<4F0SV6>F+8Y$JWCBHYV$TDKJ;@@N[1%WB3=;B-I)"[E""RQ^&U*&95
MH)2IKX;.:BI+:J+1#8+)=W\=C""5,08A::@X!KIKQ/ Z<,0#ISU8!NOY35>=
M[TZKZAZH$&2P_8NR<SN+/[DGJL6N)VQMG"T4&1S&6QE;05YJZ7=F&@R%- :2
M7R*PF\D<9$#LPXV:?:+J[OX;N1JPVK/&%6NJ8T\*,X-$85#4IF@)'17O2[I#
M9V#;9'&TC786XUDJT5M0ZY$J0"X:E%(P#6A.!EW3-W;G*';M!ANT<A#G\_V5
M2Y2MV_BL9MB"6NZ@PVYJ&/*4%!/E)9(HL&^-E9*^O!.9J( W@"O(%0Y2[VJ.
M1'_="^$MKX9K)(2+BA_5?LR]3B( 1K0=QH22]+'=6BN!)NC-(]UXB]B ?3DK
M2- '/: "?$),C FJ"H +/U]W]AMP?*/(];C+;IWIB<1#OSJ7"9'#X*JV3M3'
M00KC9L3#V3MW<N4_W^F?PE7MJM>GW=BHHJ62GR*PM & <QQS/M,#V%W>1%?J
M]09L9+$G4F/Q$M4:CY!1CJ5=BL[>ZY:W&Z$^F[MYT #$'5&JC"BFNK5JI4%<
M$,14'HR^;ZCZG^16;H=@]P8K.;MVOLG"[8EAZNW%AZJ+8=;D:""9:3>51524
M,'WT]3!F0E-"E8R!Z(SJNJ-KE5EMOTUK%<[O9GQ3($0-4: %%348U<0M&J,G
M["7<8;>[V^&,102QF0RZN+ACJ&FE?A49J1Y@8\ZF_@_M*AW?WC\EZ7?.#DW_
M !_$:K3K;;L.$V/D:/=L6_6[;[(S8FV//49N".LI#L%*3'5&/=?+/0TL?#2(
M[2K>8[>WO+K;0MA$^X7F?$9E+ND<*)&22M!(M-*DCRX^B0*MPEM)=RNZ6,?A
MI5?[$%W<JG$E 36N#5L]66_(#>.3VWVUU?-M[/82CKJ[JRFI*3;=;BL=D=Q/
M19#,TXR$\N'W!D<328Z1(IX75"5EF,$B%3X[![=/#6\VU)H4,RPD#4<C@&5L
M&N.'V'H8\C6GU%GN<<%W(FN8%@.# 5:-E8$$$&I:N/A\R>DIV+D9J_<7\N[%
MY"*AWAB]Z;R[BPV:E2CQ4V R>)J^H=UP18O-8RADK<54XW)Q!,?-2QEHRS:6
M  8"D\GTFU[8P #F550<:Y.E3YG I0Y\CTDBM(+GF/F9!<,((X99&?X6++HU
M,ODI+$L#Y4J"32KU3]ATF:W%DMHX'*P=@X7%;HH]N[TI)Z2IP6$VQATJUQV'
MK*C%+12;;WCU=!D\.F.I\E33O##4Q.CA"X<&.]<S;U'%9[G9;7]';*R+KC<2
M:%5P97)%% *Z@RD5(;344!Z*.6.5-@NYK^PW3=C/?>'*_AR(RM/JC(CC4_VG
MBJ^ET/\ $ P+&HZ"_&;QV1VQLS=.=I]LXW:^S,?N.IH^O,QO;=&8R_8.\=Y;
M9W!/4C>&,VEM2ER>8Q*8>FIY:R@Q5-0SI7T?AL0?TD&]W',7-B7[:VL]E>,>
M$HD;3(!)57DC05+$"H'Q%2%U<*"'8MMY,Y)O-F628WW,T4_^,'2JK%6.CQ)+
M*=#@L0I8%0KAB!QJI^A-P[2[&HNQMJXBLB[<ZYW=B>LLCC<_EZ>AVZ,CC,AE
M,Y4Y7/5N"GIQ2TE/M?+;>R)J\9)$E=$<>L<D2U&L >6?[E3EG8;;<=P\*UCA
MD13(&)DDB5I"C DE"^DFK&D:Y8T'4>;A=\P;=SIS)N&S6:_7O<HU(6"K#%-^
MGK0@ 2+&C%3HS*:A:ZCTI^Y>O*7=\N(R^XVJJG,4E-MC"=>Y+:/66'W#7==[
MNWGV10RR;WP6Y*ZAKL[0[1J-KK1+EZJ/(Q+00:IE$<TK65VO,&R1RVEQ8;-'
M=6QEB9'>LJR1S(H4K6B,BN3,L@%5.D9 %2.^N=_VZTNMNNMUO8A(ZI)'; QA
M9/%**[*IP%0B*8L31=5:%J!K[&[UQ6^]V_*SKK:'3,.X,)\*.K#5;SW7N'=,
M&/VEO7>N?VIB^S8>I,1A<;'4YNAC3'X^GJJS-R&GEI*A(?#',I)]H.8=HN=]
MDL;HZ99I;H5#-I.E2I-?0TH<4X<:T'0EY<W:UV6PW.V8! ]L.X)J ;OH:C!7
MXEH:UU#% 3U5?\D/E9VO\F-C=1_)GXP8G<'2])OFEJ-M]KF6HPV\_P"%YFA[
MLP747^C^IH(:&3&[SK=WU^YZ&IIC' D_VAMI25@ :;E&]S#M,QF+3P*ZQE6*
M.%61)!I8$:1J0:O)E[:TJ"6;%=W-E/N=M;3>%:S3PR,K*KJ9#&R5-034*YH:
M@#CDT/5I'77RLUT_24F'VQV#CMF]S;GV%UUM\;JW'3IN'IW'9W$;^VI5UN[%
MR$F>BJ*Y^Q^OY<7"E1.\<N0EAAAE:0&#V$;-91O>[K<DR,(XWC+L>U7)#E:4
M!+&G$4& :]'UV2;.UECC"VS,48JJT:1:FA/EI!R :TSP(Z6^W-[[RGR6#I>Q
M]LR] [WDKI]MU.U.X*^7,[0WE/0UE735>]L%WKMC)28W>E3E,30QU6.P?EV]
M6P/D&>HIW:,1@_DB82!89@T0\])JV!@BHTFM:G(Q@D'I 8EU#PWU)3TS^SR^
M?$=,V^OD)UWUSN?<O]YMY[K,^[8*/>V/ZQWWM'-OC>M.J^K<E)LCLK<.W<SA
M<M%!E4W960MF:.>>NFJVCJX66)HRL2*OK;S:DB%I)%K=ZFI'P@+K-=+&J+@(
M0 [X&03TOVSENVWRXG:^U_31P,%>-E_MRK&&,AOPEJ>(<: ,L*])3,?S#?BC
MO39.]MO]9;F[.3,;OV318_&9G&=:]A4#X3,=CY;(]?[6:*IS\..I\5GL'NR>
M.3(TZ!)L3$\576+#3NLOM:?%OHK9)G1A*]Q&BZXU>1H(?'F55[7)\',1<CQ2
M"D):3MZ2VW(N^.L]W#9EX+>!+B9E!98H2^G7+IKI"L/U1DQ+WN AKT5?';6[
MG=MI=E[=3<6ZIL!M_);:S6RMR[AAZXZMW'ONJIX]OYO=5?04T+OGJIJ.:3(5
M0K%F\]5 %1W++.0[96L6VWBPN/WGM8IXJPLLEO+J0E 2%^)'9&F/X""IR" :
M\QRV>]6MG<6=O%LM_P#2)&K,7\?Q(3IDF4/10)E#(B9J,@M4$F#VKGL#!\1\
M_DL'0GJEZ'Y+4M%N2/?F'GQ$N6W9@VV]B\QEL/B:ZICI]P8G+9*C@JL?4ZQ#
M6XY!4L%DU-[;YJ3;H]MLX+>S185A@64!B0\BTUN*UH20.W(HM10FG3O*<;'F
M4RC=7=F+O$WA>'X=0:0LI-65%+ 2:@S,1@ 9?NP%/;_Q'^4V'[$WEC<%B-T[
M/VWB]QUT&V]L>;;=-EI:1&J?X=B\]/0RC*44<<5-65\Z4L,A$\S?;PR@%.V4
MU7DB1J$;03I\VX XIQ  .,GHXYRACL;[9D%P[3@-EOPHS+I&22:L6(J>T&E/
M5GI_Y>GP9WS\>:3J#;V&@V_3X;>&8VYLGMK&9^DR.\)^Z<KM.DP61W=7UNVJ
ME=M9_<<E/3+%5P^G'/4TLAAA@;2_L[ELRRFC%)L$L0*G.5(."#P ]3C/0<^I
MFBN'AB_414:JZ3V@#46& W;D]P%*'4* ]0]H]M4G67672O3$&QI.Y>R_D7W#
MD.A,>V.W#1;?PVW/]%>U8,[NC>.[,Q4_Q#)MBMHX[;SUCTM-35=153Z(G 5F
MD"]H);W8_P!WJ/\ %XXII0A-*DN13T!P!GHJM;F.PYD@W-SPDB0L!JHHH6-!
MQU ^7 YJ.D'D>P>M_EIVW\BOY8.[]E9#JG-[0R^>W;B^UMM9?$YNBWI@AN?!
M[BW1DJ' 96F1MG;FK&RRRU<&BHQ]WFD@9'*H%&PP3;#LMS8^(!JMM1'D"7!1
MZ5Q74&T@BE:$XZ*][FAW??+7<%BK_C-&IQ*A#5"U*L5IHUG-030UZ%G9>T]@
M_&C8,VT-G[=E;;:[-Q6V\/EWRDQW'6;5>'*UV6W!75^4J:>.=-Q5]35HKTWA
M&J2)K/(%(QGFO]PW7F/=I[F%II)Y2K:!I44EC0&@K1,* A)4U /IU,-DMC;[
M%;NKJ([5]21LU<M&^D%AW,8R-1P":'*\2./5T_:%%U#LG";<BHNLZ2HPVPZ'
M8^+Q]32;BR4F"R\>V-R;OS,D&2J&H:BMDJZNMHX9I50TU-*91'*]B<BN5(MI
MVS:-LBN==[+#<7RW!?7&@9;BXCMUJJZPH0(^G.HBA9032%=WDY@W>]W=DN5M
MO$%O],Z!'=XPD+3N4=@@:NN*I^%>X*[4JP;WW)V=M^/LW?U+O_*;NQF-W!@L
M;U+3?:8 XR;%TV$GPW86+QF@2Y.IR=+4TPKZJ;)C5+5V@I+Q@$M\QWG@<O1"
MSA%O?1?VLN26+2 HVEAI7':JKJXU;..A-RS8QW/,:B_9IMOD!T1@T HC5!(-
M2 PJQ(7@:5&>BQU^]MW[8WQ2?Z0<C/N3KW+U/6M#'N+&BJP^WH=R]@G.C(KE
MYX*N6MCJI,O/_#8\M*D8FRW@@GBC"B1H9E:Y\6<7(=[N.4:\:7R:NHIQ;0:@
M\:!JCTE6UDLEVQC JK*S=M2&6@-$8@_A!% *TJRUZ-YLVC[3ZVP&_=C;UW3C
M^SY8,T<EUAMK'R[AV!1]?])9*EQV(I=O=E;VJ<N<9V+OC#[@BR%9-)#)C*JO
MQK*D4>F%G>8;"V6"SMK=I*Z5TUR:D>@)U<*"N17]G45;C.]W>75XJ8>3A@'@
M*X& *Y%/+Y]8-N=@Y.+.XW!5_65?O%]Q;3W[)E]]=5T^1P/0.(VSCJ3'TNW-
MG;MW'N#)8[$;A[0W1D:W^'X>.AH\A'2Q--+4U$8TF0R,6WQJTM_?K;V89%8N
M-14.P4L56I*J#6GQ'@ :](7^OAA:>PA$NXQ]T<8;2SLJEP%8X0D@"IH!Q/#I
MM[+V-MG(;(H\9O#!4^;Z\VE!G\_5[ VSUI@]_/7Q[;V164FVUVI_&<9FH$W_
M +>W9131P04\=.E2T2HR&!"'3+O6P1QN=MLENX44Z7J9$U0RLK@ 44DJOA-$
M3V]YKJ!HAN=PYDL#?7U_?WD-Q+&[R) I29XI(O$*%AW,_B5D4XU'3C2*D .I
M^YX_]F'Q'3F;S&]-\3[5V]E.GX:ZEV_/LK&8N>HVWMJMQ^-[7V]N#,S0[VW-
MMBLP528]U8=8Z:..M^W:&XU$.\U6%K?V^X;G9PQQ32OX@10 %UDGP@!P/<%4
M$T 4+P'0^Y7LX[CE&ZNI;US?0-":RL"\B>&&)89?6^HDE01K!UD5KT,'=?9V
M V7_ '47*8C?.\*\-M7KW:_5J5,^SMD5^=JJ'(9B+?NX-\RXZ,8O!18UY(6\
M=4\<[4UM*V9O93M+[QL-J]_#MIDW2<""-6.E44+J+.U"M 1@ U\L5J/)L^T;
MY:QP[KN<5OLL3FYEE52\[=WAB%$!JU2=7"E#7RH0PWY6[5VOGL9/4;FVQM[L
MG-XFCQ=3@MFP9K/P;Q[&V[1Y+,XKK_*YF2CJ]I;8R6!VS3SE9%R*5V5;6((6
M8D%1RY8;E#S5R[O&^[G-+<A-!5V=R&;4$#.:*%0'()8NU /4N\Q7.P/R1SCL
MO*^VQBT,PD5B(U(C729'CCIXM96%!@+&E3JIT'?Q$['Q4'Q%P_:6YLB=FU\_
M:_:NU*3<3;9?=&Y*_;%?V/F,[C\)%'CX9L]'LFM-(N>K8Z-9134R/42*JW/L
MXL]WDM-VWVVM=O2YG:9T%7"&-R?B!.6XD:1G->-.B7==EBFV?E::ZW62&W-I
M#.Z*K,K)0BCC@&7'>PH :*::CT<C;WR,ZNZ5P/8/<7R#W)M[K+;U#+MO!TF]
M-P9:JST^Y<+EJJHDV5+M>KAQHSV?P6ZDJC/C:>GIG)NRA T4@6FT[KNM]?;E
MM6X*\8@"/'$?A IHDD6I)H[J"U2:M5L5ITIWO8=HV[;=BW3:+E9Q<+*LDB@C
M.H21Q2#X2\2$J"/P=N0 >D)L67XP;=[BZ*@S-=LG8F_]\;Q[*W7TI29'"8/:
MW8_857-0YM,@F5RL-/0;@J!/2;GJA'2US-%D)HU0-+41E03[1M.Z0\P[E-<*
MRV\,DH)/PL7(H%SD@48D"BC''HVWW=-KDV6PAM)3)<7%K;L5#,!$$'\)J*$+
MI-""2:\.D1ENV^_*2MR5/'WIUA+-4;ISE%'@7WC2T<U/@1-6QLL%;64E/-!5
M[<>GB$H<(\SRZ5*)&^HZ&W;_ $E699->IBF@CN6O;4\%P?4^G$X#L6Y;8XUF
MSMFA30#74N<UJ*DM6AX"E<FGF*75V\^RJW8W>&2E[/\ [T' ;5PD^/Q<.4QV
M:R.U\-C\KF)-TY56I2:*2JRVV())* ">275"JMZPH]N[;#NT+2+N=L\<9II)
M)->-1G(ICUKQ^735_=V%TL7T-O#&%)J$))(Q2M?]7'H&^H^Q9]N?S$J'KC:U
M=BL)M3>_1F4W+O'9^(QV1Q>VXXXWPF1V!NZ/^*UU9+2[JST^8GI98)3%,8XV
MTAQJ(.)!BIX]%AX'H4>]=XY7;/?^X,?B=S[=1\GL':F.K<(,=A<_F<;@Q#FW
MKJJLI\[E:"FH7AG0R&",.7AF65D-R2#]U\%MTD66&-F, 6I.2I))%*'/F*?+
MJ3N1[,S[*!#>21,)]; "@#JH"L"&!TTXAO,$="OO[-=CX#;W4.8P'6.Y^Y=M
M9[!?PKL6LV-F,+KV9%/MJFRNSNS8>NSEL%)VECI*VG-#54.,RRU$<$H:"&;4
MSQB+;8E^D5I9=$PC2BT)#8_B' @<"<&F2#T +M;4WVY+#)IB$SZ*CB-1XT^&
MO$8I3&.DJ=PC-=;;IQF*[/GBR%:U=MS$]@]=8:J?LK8M=C\5D]Q9C<O8?6^X
M'Q&,V=2.V(?%Q4,F,U4+5%.LDDHF-0BVWAD9U,DB#N&6[5%6 R<X4'4Q\E#'
MRZ2^&^F@IJH:>C>0"^I-?^*Z*K_PYST=C-CTO:>0Z#[4VOUS1X#!;BR&"RFW
MH<MV!N' ]D-G*/8!V?08S=<VV4R=)F-L989R#(5T8Q]/'":>:5Y="GDT^\W/
M,D/+VW[A!?7DEY';I+;R*89I97$5N8966-62>2BJS:%^%FPP/1P.3[F/;YIY
M0QOQ%'((54LZLS.)(6%"Q=%4%2@825(&G23T='X^?)[9G</5W8G:&Q^L.RNN
M\!UMF-R[?WKLOLK&I@^PX,SM?;U)E:M)=K8?+;NF2F.'K()(1K6JFC=7BB>Z
MJR;>8K]=QDVZ2ZM[J_C.FL4JM%K+$-%XH 4/&X9)0117! 8C/1+>65WMMJLO
MA+)<.I98]5&(!H*D@*H<=R$%JKDZ2:=.V(^3/4'<VVMY;,VK)N^NP$VTZ_%9
M?<N,V/V;A\9CL/FJ&IQE=DX,WNC9F"I8%QD4[RM/YF$4:>5K(+^P_P Q1G:[
M%X[Y)T$TAMB8XFF,<C@@,ZI6D:BK/*U(HP.]Q4=))[ZUL[C:[=HKJ>YNYUAB
M2"VEG+2,0%#")7$:$FADD(C7S8= 3M';_3N+VQO3K_<&\-KC9VRMQ;6RW4>8
MJ\AMK95)#CMSX>+%5> P6=I(LHV 2HW!0H]7/3QZ*B26&H]0J"2EW;8+7FE5
MO+I_JK]5B6>55I^K%^GXE5%!XJ:*A<$J%KPH(+_<KZ>Z1-P@C6Y0LBA$1 50
M84JE$+1D,"X%=.<@=%5[/[XS?6&[-I8RMS65VEBMGRY'=0S"=CUO8.WUVXF7
MIY*K(Y7-F1/MI8H*!I'@A4>*D7QQ40\AU/WG(=_96W+4O+RS/MDDLD(<H5B@
MN5 ?3-2OA1,@J'/Z= X8Z^)IRIS9M=IMG/NW[A';#<A:^,(FD DGA92FJ&M!
M(R2L 8D_5!*LJE:D+3O7Y';Y[=^%'R#WM@ZW&YG'4G3M7N&?%T<%92[@R]%F
MLGB#MJ'%X]JMZ/#UE7$6$ZR&8+'(GC;6752&'?;Z_AFA<VPAC5O$(0@D4H#&
M2QP.%6R>- >D\O)^X;+=\NO=76OZME((U  ZE!#CR(K4Z:XZ,CN#?-!M&MVA
MAMO96"FWGO+:%%N^@V1B,;480[QW9E\33:J^LWOB*&H^P[+WU+BPM$,DL+91
M:6412&^H+]OWR^?9(X;+9DE*$2-('JSIQ"F,48@9!).21Y4Z:W+8-L/,MP-P
MY@D2!W:",E24B<-0NK&JJ@P0JU*_PUU$%M[5Q.[MX;G?!;.R6[=OU>[.J<=-
MM_&[*AHH:[:>_::OS55O*O\ XM(I.VLSN+'5\5/G',4%=-XXV F*L(Z6%Y)O
MFV6.[WE^YWF B"5"ZBX>0,VAD!!U+$@"S,ND+05!J*GMYM^W<O7'-.Q0;+;R
M6%XBSVUPWBB&!(RK.: _!,2WA(:C)*GT1>$IM\+N'8'6^\MK;CP^Y9J5NN>F
M>XML;C_OYNG YW#;/S\\G:N^=V9(+0;/S^3CKZZ#$)D6DIGR-J:5_"\?B$:P
MVDVWWIDVYXMW-F8S(]%D>XUEA,   Q1"%0M4.:U(& $MK,6V;S9WTF[076UP
MW\4ZVIC,ENUNJJKV;NIU1Q,P:60@-)0Z5 KU:30;^[1Q_5U7M[9.VJ7?G;>S
M-O4.%H1O/=&.Q6(W5N#"8ZAAKHLYN#%5&66GW#7D-Y0H$'WS.K21Q@.4\8*Q
M1J:E@HX\:@>?SK]OY]*4&UW&]L=QG:':Y9F):)"=*,Q*E$;22M*$8^'@*XZK
M%V/_ #"/DSO3LO:OQ]^0'3>#^/G:.\:F.D9)\L^:V[BIGFRV7V]3T^'HZM]P
MUFZ]T[=HI5CHTR4T<7VPJ'BM)XPF@BDW"XN;6?<ULHX[<R:R/-*%EJ67XE84
MJWD<$XZ..9=JV39+<[AM+/N=F;I8D57"LVK&LD#X48'511Q KVDDY'6G<6;H
MNUOCGTRN\J3>59N;:_;>\<MNZKEHI9\OC\?0O4XW:L]/%6UTD69Q&2R$$]7/
M"8Y/!3K#8)K!5C9_W?JC@W S6L3DJSD2.\;$@5<>8)!!_AHO03.Y07IE<[=X
M$S  JM519 !4A2-6DJ#V5(#$M7AT3/Y%=IY_8&YOC9O7"U]'@NT<SW/@]M5>
M5H\371YK>^?@WOCMH]@[3WE(,E-12[3BQ==DZB"L@A>G$-'&':-%+LH([33A
M3IOH?]__  ]ZLV7WMVW\@1DJ[>F\.X9L+N/.1YJ98]N[*V9493;N,K4Q-/AO
MMHJF#)1;>B'W%;)*)HQ,C!D](BCW2W2^^EVG:HW M&UO0+G6JD LWF#J[5H*
M,*UZ%O)B6T.XFX(TW!8 M7B"110I%!2F6K4B@QQZYY;-R[Z[-R.YL-ALIMG)
M]7[2P^1DR5%N?[0Q4\.]LC@Z#830T%7'#_!=PTU4]1,LOB5Q2QB52H0 .1;G
M/LFTWO,3$V\DD-Q9TD!.EY;2!EN-1%5,>KL -5UC12G7N9;F"TCGVJ.2,PJ@
M8MQ#.)V5G8BAI@F@X::$FM>IU74X!J0O2XW<LE3DJ"G&4R-5V].TN6?&R&"N
M2II4J%FJ**IA+K3+Y5>%FU(HB#>P'-S*%93;<UO%+"JDL&F#,ZD,'^(("2 H
MU @J3JK7H-EM@F0_51VAEC4!I6B(DH"&P#5%#4HI/J<$9Z$'I?8];M7KSI[%
M[DISD-W=<=?XO9$F_,[E)MR;LR^ ?.5NX8<?225%5)G:[<--L[%463FDGFEC
MJ9*A=*R/';WE@^^<KWT<&\M?*VY7D8T0 Z9 [VXN %Q236=;"),Z(S4@$=);
MAN84%WM-E:&+ER-Q/J%'C8!S&P"*:1M'&VC6<%I-*:B*=$S[=VS3=?\ ;'QK
MR>'Q^8;/[F[YV.O<^5H^M\'L/:&^I=]Y3LVNI=TUM;@\1BER^[-MX_;L=#E\
M>Z3^"GK8U!6265I$',&^6$NUW,-OM4=JOBPRJ^DZP&7P_"UL2S#561D/PL?/
M%%O*4FY;SS*MC?[M>W#0;<Y_6),)4%M C7X5F14\+R"H5#?,UV;WQAZ+=NX>
MK\'50[AH\%5X[;>>Z]Q>*EVW@]E[%IA%0Y&FP"T5#4;7W;LC:*545#F*43QC
M%3RJLHNATE^[<R;W%M<-]MVTFW-MI_5B8,X8:2TFD4"=H-0P-%)4<:]&W+?*
MVP7N^366Z;P97N2[JLRL1*K!@L18_J,Y9E9'7BR@D@@+T'.9[:[OQN1RL>&[
MPZFH*)=XF'!;6CW32TM,FSF:>B;"X^66AA?'U6#I%%1H*ZBD?BA8$"1GQ;;U
M<A[BCF*9C)$5/Q(RZD']$&HXG %<\.DD=S:6HDMYK* O:JL4@?4&#H^@EC6K
M-449E!K4D@<>BS?(/9O=??&RX(J.MV#WCBNJYMP;[W1UMO#>,,PQ&(Q^,X[(
MVS6[?%9#D\GBYIJA\915#5!DFB:-D42(0:<K6#S;S;VG-5M(FSRLJ E].7<*
M2SLK*JHI+L2"&44%"!TQNU_8SVZ?NVS@C>-BQT$DD4-*C&"?(9K\J]"3_H=W
M%V]\>NN.Z-O]UYW/]T9SKLYG:W\%[$HSC,[U?G*R+)0[3Q=;N#;0^[S.T\14
MQPC+Q8VEJ!4F6GF4%T<1MMW/$UWS[<\JQ[%>)802R0/(0=<;QEU29D0F-+9M
M-0S%G8,IJ:4Z?OXK>2(7:VT2/H!H,UKGB:=U#3  /IT&5+LKN'<E)C*FGW-V
M1G<OUKOLY3=T9W"NS*#?%'0Z,QM_;F_=YT4LF0SCI5!L<D\4II6H9B0D3J8%
M'SVH@N$GV^XDE2==9CB96>.,N5>*X2A82D*2J$FJ$."5/2Z>2QN-EL;&[VZV
MMKBTEE4W$AD'CF4+)$T52(P(N!8 5;! (Z__T]N6EP'2]!)M3?&1VM+BIEIL
MZE-E/[\[QRF$Q,F/JYJ7<E1OG,[;;-;)VUDI,S')"]"U56UBY!T@"*]UB+S8
M6%LRHT3!@[: Q8D5KP\Z$9-<4Z7ON.X34\60:I$6HTA=50*5  ^5#C X]3]V
M]I]'=/;\P6R]S[,SV*R>6H<7V3M?/8BMS>7V7E:S*RY;$^7;^2R,&.QU?G\3
M!C6EK:9(/\@@K()W*FJ1F0;E:;35;6ZB.BZ)U ,5#%0!4Y'=0T%*>OSZ<@\>
MYB)>]1!;"BAJUHYJ0**:BH_%ZX.>@SSW>OQ>W178'>%-LG=68_AAIX:'.X+(
M9&ER.,R>=W%//.E91)4TU.9ZC*Y.22:1W\\J:58>(V!+%9[#:006!L'C@(8"
MLI!/C4#U):IU@+4DG@M!@'HU;;;F7Q;@[O;$H0:9.8\I0:?+R%///$]*+!?"
M'I[8_;'5.^,?#68SM/KW:&XMA]24F2[5RU;2X[84M9][NN7:NQ<I*])E,A!4
M9>.NK*YX'J(*EH6,@M"1(<6T<JVMO+96Z3K:2 L1XCZ]?'XRQ(4'R7UKQKT%
MKK?N9MUNSNU_&DEW&%4GPD"4. 6C4:68@4!:N%ID#H-/DM\@=Q?%WO38.)IQ
MU!7IVUMP;K[3VUV+62X_<78";(S.+VAA:K865GJZ;"+N?$8$PS54E8B4D%/
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M()&0,64,0VUQ=RQ.[QJ450U=0"T R0>#'- H-1P/1C+M#4A\*Y!C9RH JQJ
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M3;DM*^V</5Y=<FE=G-UB"JKI:>0XP.QD>-824+U&WPPWMOM<;*SLK2=Q8,
M585IIJ&!!&&!%>C$[?OH>SW'=;246P#*KL*4)+*5)S4ZHV722&!4TJ >C"[L
MP74^/[&ES^^Z;;&WMU[@S5)+MB@WAV)F-Q5$&\*W&T^"CH,'M["?<8_96 W
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MC C11+4%@.P+4DX%:_/CZUZH[7$LUM%;,WB,=(4?BX *>'$F@KQKT7/'=?\
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M]/'-(_BD6ZQB)N7-FY-Y9YINKU-[N)MVFN)%A5-?@1+("621A4RBE0))#H!
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M:J34FH#412*]VD$::D]1_O6_;7<0DL[^&UP&TA#Q8C@ <FO[<G )HCL5U/\
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M-J2/!+1?9[WEC2#$25Y6*)(JB"6-XDTC:TM=XDMXQO-W'-<+9>":+I3M90@
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MLE;:-TVSZ<_7^ E"3^FRZU#$MD:E II %3FM#T=-S'MN[0/]!+WLBI*K*5<
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M9ZTV_P"AWYG.P9\#G=ZM+552)GZ7+R;BHUP-?D*:HI8#32N%T70>MK2VFO\
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M1!7*QMV%)#0*"N"LC@+J!)*MPQGH_P"4UVW;+J6U6=6MU<Q^*.TNF:LQJ05
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M*'<K9!:_=N[I)83##0P02N]+&\C:(H5<N[3O^U;UN=[M\>^QO<6\>OPXB&]
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MK6W0J/%C)+E&4@H=NY8V:2QL]RW6_P##7PR7C.L&65I"(DB(&$$0+SN2Q4_
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M" %B2!.-_NVRV_)'*\7+^VK;;L+F]CO9J(DMRQ\!UULNKQ(HU8"+7I>IDJ*
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MY/<.Y9]Y[[?(T+F;-3&ET)"(-$06[%.XQ6]CM\-K=;A*42*1 ?J'CD59* B
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M+E-Z-AZ3+LU944<\TZS9!O($6%!I+><O;S<_<5I^8+[G867,DMS'*M[KNS>
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MY6(U@::I,L\55"@1XF5B0^;R\V5(+S9MTB2_>*6%W2-&8PS)ID6DBL%U"@U
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M-)2X6EQV1QF%J6>:#TM(PE;R,ZD6W;;5'M;SO8[D9Q. DB%OACKJ#*!J%6(
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M@ZT)(<$C064G5&2W'@*C /W:TO;?>Y=VNEA^GD672Z.A4:Z#0 #K4%*JXTY
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M)X/']_,NN-:*P/M EU;K0B://])68D\13@!7A45IZGHV:%#_ !@ 9H#6OGG
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M?[R)'U1&P^EN;:]V#EF2RLGA\<7&NX\8EIE$Y0E8"BM:O /T]+$F4GQ1VD
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MC8LKC1&T;RQTJRRL"J:"NA%[@Q<4C&79]LGGN-U>];69(Y88)%JL3AG%(F'
M1AM;ABVIC16 7H"M^;9?KC&08?(]9X3M#;F\<+A.E-IXK86T:>HW!L? 4-/N
M;-[SR^YLGD:NDIY]LUVXFH9L9)3Q0-B:LH2)8]<AI/>;F+NTN[R2.2Y^H5X6
ME)73<Z"K.&;NU2*"HSA 03YG6V;6I7=!=3Q_2BWC2*...K4UMXP=J@!!570
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MNEI),'2#%?>5HO44X@1EJCB-8KE8)WT^.0'(4DZ&X::G.,T]0:]$\<\\4=O
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M&6A=DLNCGW*\M+A+.*0R6\3R2*VL(L2D NC4TO5F%%(2IQ6I'0.W:S.P;O\
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M5I=S/*%N@>F@IY441RE7+AZUW/<MVVRQO'DACO@&%O2(D'^(, 3J^0\B*T/
M++6ZN(+6Z@E17$ZH75BQ2(\5$0+51<^M3ZCH1.P?@)\9.QO[H=\]K;K[H[0W
MKE:6/$;,P>\NY(]O[6Q%1D*^IWI4XK%5& V[B1MS;./J(IZF0KK@2G6SJX(]
MB#E[F#<>9^7;26[G>))0HGAB=U@DEMV=%D>$,4=QFC,"5#%00.F]LWBZLX3'
M"J%EE<U= Q0L1K5214(=(QYBE37H/>C^H?B)#VEW=W1DQOS"=K?'[?S=Q[SV
M9-V94]A=:5&Z<GB\M2XKLW"T-?C#55T5)%D*_'&>.<"A030JZIJ4+[B,6K7-
M\MQ(CO'*DE&H)(IJ>)!(!0-!(P5FB/:S*I-:#H4Q<Y;Q>[/NW+4]I82V]_+%
M(7:%1)#)%)XBO;N3^BYIH9A4F,E, TZ-9LKY>]42X;-9'.QU$&$FQV K,?F,
M7C/O:/,!]KXW'9?)FEQTE?5Y?$X#.T\RM/$BK04"Q2,/"JRDNL+6&V%]+#MW
MARN$\8JJKJ\*,1HS@4RJ@(M!72%!';@GO-OOY19++,&MB)/"U.2/CUNL>JM:
M,07S19":Y->A1VSVMT/VYU_%OG.9VLH*:BBJ-N;QA@BK<12X3<>)J8,+EJ>/
M&0QSY)(,MFLBR8^:#RBN0ZXF:Q;V,-E&[7=M:06=CK$[,%!449@-3@,3I[0*
MOW=OXJ$] [>I=KVB6ZEOKY4\&-9'*M4HDA'AEE6K N3VC35C6E<]!/O'=/Q5
MZZV)N+83]J;YZBV;UO@<)4[TWG_'&Q(ZDP6[<EE*7;576;IWEMW<.$JZW/9?
M%_9>*JDK)HHZR$RA3)!?U]8RW.S,-RL8)MENM47AMW),%TEEH&#:14&N*D$
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M21X[%6\,$$>(Q=J')U.2&8DDT8Y]:]&49N+^*/<-WNH_KY0QD,<>A/$#D41
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M2]I;G[-P/:_8>[MK9#%8SNWL?*Y##5F[&VQ4X_)1]"8]][YG-2;1I*203U5
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MUK5G*4757/1W?;AL=U9W6TV/Z-)EE50A\'4L<<3.D:D-K=58G4%2I9Z!B2;
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M?]NXU#CVW':VL!%IM<++9IB-"26"C@/,D_GTCFN)[AWN+R75<.268@"I/'
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MN?K2L[8W/M;M/M3:F\=I[DZYKHJJAI]D9+"8?!P;TQD.6TK+73*V)R:4<K)
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M,P0401H69@LLS^$5C!J0)9*4QFM3@5Z%[>WRBI-F;<W7N)>M]Z[AI]GY+;>
MKHL/_#8HLCGMPQ[>FF3%U^4JZ"C3 [=@S4TF0R%6U,B+0S>))3I!$EOLT=Q)
MMT9W:V0W"R-5F_LU0L ),8DDT@QQ@DD,*E>@T^[R*-T(VNX(MFC6NG$C2*K$
MQ^9CCU:7D("Z@0*@$]1:OLZJ2NS"9CNC:.UZVBJ)OOMJ-_=L9C "&>>-:8XZ
MHKI<[//4T:I*(I('E&M&T@, 5Z?N6WVN"\N]M_3$=7E=W537@Q--*BN :@&A
M%30]%L]MS==[H]MMD<SK+*5B5%#:B *JG;5BO%J5*@YI7K%FMS87-8J6AW/W
MKUY6X0UD$%:F1JMD/0&KHO#DH*6LBCS4?DR,!C6H,!LP2S-'I&KW:>WV*>&X
M278B\2CO77*!2H%6-!1:D"I-"U!6IIU6R',RS1M<&1HS4"B@U>E0H"BI< %M
M [@!J(H*](S-P; WT@H-X;FV!E:2..NW!+4UNY-EU5#CX:C'3[8&Y?XA29RC
MCDB? U<L*K]Q(::!R/&-:R$/Q;)[?6DLVVVFSP"Z$BR-$/'#EP3I!K7N5E(4
M&F<BF>A")=_DMX[LM(;,A@'["E* L 1@@!@6/"C DYZ*H>AOC[VG\B<]49C8
M':6[MKU&3@P57F.L.S^T*?9=9N>HQZ4[;PWN^#[/QE%AL"^.H5_AR8J(4GG1
MQH:1 /8(M]]W&#>][L(4$.TV+:([=8XJA3FE7C,CL&))JP:H%<5!-]ON=U>
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M,0#[/#<S+*1)<$W$A)))&IV'Q,?4YS08K3 QT@26*06JHP.M28U'&AH6*KQ
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M:'9O:ZX>*JS<NY=]K0[.EI,9NO)U&)APV3HUIIL3DZY:845)"1+5'S-+ K2
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MM_W";;K6[ O$-"9-:F0>0KQ9>W&*8_TM5.\I/L-M;W-Y8$6\BZ@$"$1F@-&
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MF;>S%3N7L4[BII_%2M' C-33&1O @=BZ^YCM;_;I=O;8KQ+9(B_B2B(  8%
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M6NS[_ML-W0WH4$ T6B\.ZA9#6AK'0XXUZ622[=)?[/<- 3#:Z@:JI8*QJVD
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MKVZS3BX:.,1$$@T(KYJW$-Z$''#SZV-QV*3EV*P;9 N_I<*PGJ65TJ31U9B
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MJ;S3$*<J31\QW.Z/,&L@VM/)FD*@$"APJ$L"3\1H*8/59N:+>?E^RVRWM_\
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M1M5<Y#VW[3ONTNJWUO/'#-$NDR((VDS0,48!@'#5J %-:@@4ZY=RY+8/\O\
MV!\KOF)T?AME[/R</Q[I:C:FT=W;4EQ%!MW<DFZ=N8Z@BS$%/6XW+5&W4J,H
ME;_#S- 8%NBE4(LNY+7>VY?A3FQ8UW)'3Q71@Q\$LVAI"*J)!JTO0D5IFI/1
M#N:A+B%4#5!<(#7^T"TH/R!'0+_)7^8!N?XH=L?"G9V'[_Z>[.Q?;FU-@9#Y
M18,X#:+8_="=L;KQ=)B-^85\--33;#H\E292L_A4<4\U+/2TT;RT\C-YF$5G
MM<&U;C)*)F2XFNET@#00NHA7!SA@P \B5+"I)Z2;ONT^^V,<4D>J**STU)#
M%4%4- .X,K,2>X:@M1I'5IN%ZOW)U7ML]5[,K^T<9@]I5^9IL+OBNJ9NW.YN
MR\7NV>KS]7*N[<CBJ--DT&RMQY-L?BX:W)-#+B(D4M3I B,QJB>1GTC6S,:'
M 7N)^UJCTR#^WI6D7Z,"^**A #Z"@IQXGUP.B^=X[,[4IMR[2J^SUS%!L:DQ
MU-2];Q[,GH]W=SY_,XJA:3=^=^1.[)L7B]JU%-1TE3#%@:'#-+#"&J'FF<Z$
M5N?;(-S-L]O<F*YB9BU0-+AJ *HR12F2<YITKBW&2QB>.W:0F6@<@@<.&//S
MK7CZ=$'[([.ZPV)0Y.BJV[PWU48VGS61I]EU&WZ2/,TV/7'Y/)[:A&[Z3.OB
M*K'4E9'$N3C:-YJJDUQH4+@):+D/=+B6TF2\B@BU1G(J<$5!J#6N<XI7!Q7H
M^BY@O3))&MU,8R]0X516IX@'N7USGSXXZT_$^;'S@[ZZ_P ]LSKJFZWP^!E_
MC5%G-R;+DV[L7<V8J,OF7SQHJ:/<>3CKZ"KH<95K2^6C&F:BIE_=\NH')""Q
MM(MZ_?5]<S2RJ"HB<ZXT0*545:H(7)4M6I8UZF(<Y;D^S[=M=OM4$6X1E==_
MJD,T[+(6'B*P9<H C:>*4;BQZ*/7[^[>[:38M1E]W2RR=?Q5>U\)C*:BI:;:
M]+3T61QN1;;N5&1J*F7=N+JY8%?*P.T<@O' [O'*?9M-=1-+XUE!'#<D!I-*
M+WBH95=::::D5@0.[2*\.@9S->[MN4NWB]W-I'B#4P0JAFJRH<&K?/*K@<:A
M.;BZPCSFY\OO;+TE'A-Z5.9?<=;N?;]+BJ;"+EDR7\5I:W'[!JZHX/;6+2M7
M]JFI)&AI8G\: A1[*[NVFW"<WD\[_5N^N0T!#L?BJ*  $^2Z:4%/3HDM)9+5
M2GAQN=("EM54*D$,H! J*4HP8$$U!.>E!C^E,GGYI,IG<8W84FXQ2U<$$]3-
MD,J:JD%1#)E<=48^77_$JQJP_<3.DRR.!P;>ZO:6Q$FH!20!45!%!2H/K\_4
M ]/2W]Q(8S/<^(JOJHP4K4DDU4 5!J00>(-.%.ASZ#Z<W/7?(GK[IP5=8F[M
M[[7VOL+J+%=B[<FH<IMRGKM]Q09RBVCD=G8*2HJLEB<6E0E-6STT=;#3Y"=A
M,/"[@$[W:6UYO&T[9<.)XV@D"AE#:14T+::%M+=S-\5,^70MY$O=JMMZW#==
MUVPWME:6-Y<M"H72-$# 2D.RHL5NSI(07![5"ZF(!.;\S?Y2_P R]C;^@K*'
MJ'&;JZXJ]W8O)U?8&R][TVY$I<GFMRU68SL&[*G*Y*,.NW<768_%_<P!U=8T
M C_MD/R6LFU;_875L#):A(@SHK!,  L=7>*-C(%2:TZ(.9>:=HYBNK>^VZV6
MUMC:Q1-"<.9HX@LUP5JVE;B4-(*M4DG X!:XO^6U\A(,52T&0V#19:CK)HYJ
M:ERV3QLP*4TNJ+[>LCDBRM"L;FP6*=%*GD6)'L>S[G:7BF.ZMO%'S4GAPSQP
M14?/H+VFZ';Y!/971AE -"K4I44/RR"0?D>/2;H?Y=_R)VMO6CDV-MO<VT9M
MOY:/>6'F3?%-G*O9.Z*BJ^\FR&QX]S5&3H\3%0U4*55#2R"6FBJ0&8$&PVF[
MP0V\T"J>\FNJIKY $\=(X4%!3@.MIN&B]M=RCG;ZN&42*WQ4DJ&+ -J%:BN:
MBO2.S'\O3OR.OWMONNV5E*_=$F:.YX-Y0;NVUMS.KE!208H?Q!L-3TE-#6[B
MC5ZC)U".D\E;-(T$D:,R,G-[:O+'(Z@E2-(H=-.+*P-04+'4!0# QCI]=W9_
M$5Y:B1B7) +:B:B1"*:90*J6'D2!0'H/\O\  WY*TL$643'S+0LT^3W7B:NH
MQ6Z_[WT2TKI2XWP5IK*F">"JD:1*A -0#(QL_)I^]+6<QAE4Z12E* "E*#R]
M,<>O17003+!=,NO+5SJS6A]"3YCAPX= )0[$[OZ-WU4]J[,V=NVDR_5B;>K]
MC;3FVADY>H\AOC+05T=70Y_;T4M-3Y?()A*Z:O:B:6ZM-&T902E&30OMO[TF
MGI&CV\>H/^*L@[U!K4*5 +!<5 \^E:WUS*]J@!>4$*E #0Y(&D"C&I/$'CG%
M.B1Y#=>5R.\=P;NRV1IJ'-9K<NY\_F((LH\='C<IN6NJJO.4E%25.0EEI*.*
MMJ'C2)M?A3T#Z7]GUN-O_3G@BB:X -&&6[P 37/X<=4^HOD%S;+<2I:S,GB
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M:>16T*A!?6 %<+VZLZ=91BQU5TG/4CWEG<[O:[?N=_([Q$&")WDHI6(C5&K
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M6,!BPV')5SM.Y7EC=WTL]E) \<MS %ETR5CE4K%(R%0YJ&!)6BLWQF@O[/\
MDYC?B_G-R;#[\ZNK-I=N=V;^W9N#867A[)G^1.1[/Q34Z[4VKE\ENNGVUC=K
M[&W%D*RGIL=-@_MZ7%XRCD6;S3HE0Y4;/M/,)N(-OWG;;)]ZN@@B\-Y77Q2A
MUQEKA%;0):)'( NM:NZ(1IZ;>PV]MNO-VVS<[C]V6I;QWE1%(4,-#JL4C5)C
MJSIQ4@*I:M>C&Y7N/-[.VCEMP]B;(VAC:FH[-Z]VCUQAL?38B6LS^8S6X&Q6
M0PN5R&#QSG YB@IC!435*-]NQC$$3DLP]FG]7=UL9)X[^QM'F8)*BQHJA0V2
MC,0=3"FOQ *' &1T5I?[+=> +3<9RE&5F<&M10B55!^%B601GN!!9L$='4R'
M8.V,+D<B^?W'382GV_0T39T9$0T5'029J:J&(>MJIJB\-160T,CI&H8: 7+!
M;>S- 9)F@13KJ*5!"FHKVLU%:@&:&JF@(!(!+(9!//<6T8/BQ!=5<#O%5 )P
MQ]=);2:!J$@$DWR9^0/8F![&VWANK=U[<@VI6]<Y;<5!FERM,M(G8^-S"Q86
MBW.]-M[<U3D-FYG%5.@T\1IB]48OW!J!"!_&O$NY]LNHY(K(_P"-:6U"VK32
M;@(KF/5D!9-!J!Y]'7+\G+=^^XP7VY%IO!D2 0>'-KNU566W)$J^'(003JU%
M4J3&0:@G%3\E.V][X[86%W9V3N?:W>NW*[!24514[.3:W7N^NP-SY1/X9L;:
M>W\A2KC.Q!/L&NKX:ZD4B0P1U$FJ*JIXG]G.T0[!=/'N>Y[E.J6\-Q+<1Q?V
M:B*AB3N[D:90VHUD*@@@9H"Z6WWJVDNX?H(!84B:-Y9525HR&-PVD !VA8*(
MT05?.KHY&:W759VMI\_5;QHZ2LPM?N''8;$T?6,U;0TM'E&@BQ<^4?'BF2J&
M32FA$4W[BP$Z@55Y![Q^'N%SB$6>WDCCO)-6E=-NX2-J%:^(<-\*TKJ(4U.>
MGEVFVOH(XKEKA)]0($4J+J[:IXE"-/&H4DC%3T6_";SWUN_>F4H>RL/USOY=
MA=A9[<NS*+>RXKK#'9GKG*XG;=?LS%[CW'0X/+_Q7+;4K:NH(@EA>+,24JK(
M-2J?8M_>+<P;ARU<3R(K/M@DG$5=!ND=UF;2&7M8H",]E: $5KJWVN>.\9()
M9)7C@C5%9M14,:. Q J U3W# KY9Z-;+N?:FT^WNP*5-O[!Z<VT^SZ'<&3[
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M 2K!^JT*6H'=Y!<M_I1DGRJ<GAPZ-"DFHHP.H8 -:G/ ?ZJ=5*'?_?\ O?\
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M,>N21#4D:0Q4 <12A-00/2IZ6<M\OQ;_ 'VYK)+X,43"@!!85J>#5JJ@'/\
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MP&2K! $A6IJ*'RZW@U030F)B5D1O<F;1<W2; +J>[+S--5:UH82HHXH305)
MU4.#T =W:S.XR20;>3;K" RB0U$U35<D5Q2I6H%1CH5L7A,]3]P]*+7]P8?(
M;6VQL7<M#N/8N7VUL&@RVX]\/&TN;V[2TF)VQ4TT:G#O2R24PG%730TT4<#R
M-/+[,9?WC6$Q22'M1S6HU*[4^?$:B !4Z:"E:]%0N+31<1-M^F5A4'4Q"4X9
M+9(.#7%#7RZ,=7U.6S]'1U.V=E;;VO+-EMPXF2DR&'PM=D:BAQ=(*O'Y3"/%
M20"FSF3$D:TT4Q:&G<MY@Q L4V6X;_?K>B>R^CFM[UXRK2"7Q(%TE9$9 H5I
M48$*:^&:JQ+##&Z6Z6Z6QV^_\=9+=7)T,A5SJ#1T8_$C"@;@P[J4(Z!?<78_
M7VV-O9)^W\]U\-W0T%!-3].8+$[5W?VGN''Y:CPM#AY_[AKDHLKF=UY"N:L2
M>6FI4H)*=!*IB2%W]C.VO[C;-HDW"]MI#:+*-,W> .%8RP5E9BPK13JK44(Z
M+-JV;?-[W>&PLY#]5(*KW4"JJ L7);#+W:W-$X4-: M&>ZQ^$.5HI<(\'QFS
M>8J8:VAQV#VAM7J!M\UF=I(BM?\ PS'T$M=E,E58VGG\M;0K!,RQH69?HI-X
M=VW&X,JVGB -Q)=F0*<@'M %3\+5'&GF>F;>.]LITFG$OAQGNJ#]A(H2:BM2
M!6G'C2M9G:'\O/K_ 'SU/5=6[5R-93;&W[GL 'K,O7XG9F_Z3#YW)YO=-;OO
M%;WQ6VHM]T&*QU/"E/4T=6T=-0T4R*_B2G1O:SZI=GKMV\;G*;L++A6KJ="#
MI$FH!UJ6JZ:@BKP/D,++W#O+G=8N8;#:;-894C4:XT$8B:/PVD%L5_3DC55D
M(;2Q9F<T[JT$_/7XB;K^.O3/3?=&>RVUJ;9O:.T:?J_/TNR8:+M'9-3A]N5.
M2J>O.Q,!O>7'UV\-[KD-C+2U&3J*RMFRM75Q%U>8S>$-[G^Z=PAEO]AW.8;?
M,\::9I'>5ZJ#^D5T@"H8N"N132:&G4D<B\ZOO$5G'NJVDK^!-.DUO$BP."QI
MJ4BO?5!&5(49U"F>J5LQMK;^6KJGK')9^*MQ:[PQN,@W-MK;61V_D,O24.4F
M:CRG\*KJ;#[_ -H8C,Z$DG2JCIZV&G!1XPS6%N6]@W*UWZ*ZDOF^FT2*"'D=
M_@-#X+'(8YR=:C-.A'OG-^S;QLYVV&S"7[M&Q!2-8PVJK+]0O!D&"R@HYX&E
M3TD,S\5\1NWM/L+;&,S64P]33[&VOEX**F;+1XK$YNN&2QM5NFKFILGE*C;^
MV<G58.(I13F3)PR5;AZ=%>(D<V!%PT4%UN;F21R$U"A8D:@IH2!0&@TU8@'%
M:@!F6PO)TWVZL=I9[*UA62?06_0 =8V>M*E ]*G2$0L<Z37H!<]A<#A*S![9
MIMKT^-BPF:QV!J-TXW.0-5[@W!39IZ7+5^7KI(\CEEJ-TU,=)30TK0-':#[=
M2&J=2%UKM]Y;[E*+S=0\OC%BI5M.-(1$5C2BM45K5BP)%13HG?<+.1Y(O"6*
MWU'N)(K3AW"O<<5 P> R:]#QM.NV+2[Z7.5U34]'Y+.['R!S>8JL_2;AR60W
MGBJ*JPN2AH.O]IXBBR&"VINJ1):>GPDM53S0SH9WFFTV]^W#E3?%M)(+>X;P
M7?2$\0B4++4N2^HX4YSP'8.%>E$=[9W5T4DH%4Z]0!H65<#@/7&FM:YST+W;
M_P P-]=N8;K'1M?8V7R/1L<F#VKG7Z>V]UWB-];1IC2;E-1OS<\%=N;%YK<V
M&R>'6),=5PG+55 )JJ=FI_HLN=DW6<6.WW>[ZFB'8ZZFDB;2J*FMJAJJH9I=
M*KJJ&J68ERT"6EKN5W9"Y59NV1:E(I8Q4MK(.DD/\-LVHE5\4(0H(16]OF?O
M[O*.#IWL',[:ZWV!0[JW/VIB*_']=;6;<O6.\4VGFY8^OMO;]I*&?<>7V=G\
MU*M/Y*N%HT2I0A(XH5L82[?NL^WS6\VX*82X9(V6CJ2V6,BT96:IJF14TJ!2
MB."';8K\3%9-9C8.T9UHQ"]H52,@$ :Z A:XZ1VW?EWWSG-K;:ZM38NP<<*9
M&JLUO#)9&*HS.Z<12T&*PN#VKN#=DD4>)CV%BJ*"YQ\<%8U?6!*B5'D@5@PC
M_NFW%INMQ+-:JP(\3)4$$:8GI0 9XDD5%<=6BA\63ZY(XDED5@P5ZDL"&K(M
M*Z3P0Z:-F@!'1E=[?)W(YSH7KWJ3);(ZNI^[=CYO<60VMMJMP.UZ6BS.R\[1
MK_$#!VH9,?7YJK?/4RS87;E11RP_8R25*U8+I2^QG'N/M-$%N[/EV^$LEI&C
M!YY&C6Y!)UC2GP%#21F H0%\/&KHG0<WG>%5OH1L]"=5*3%J@&/PV&@J1E6U
M!R?*AZ175WRLWGTB.OLUM_MR78&>QF?QN'GW#L?>N]<5LW:6[,-5/DZ;"Y;;
MV(_@^"SVYLC'YG05&ERJZ7LT<9,*[5[=<O<W[SN<N];I=[981B::!PPB-S.=
M1AMF8E@NHZ=+(:\!1E.#Z_W*W-K L\:/(O:58]JBM"*'YC(% S8.0.MP;X7_
M ,\;I/O[<6$ZC[4ZKVM#V,M;%B3W)D\?@\?@=[;FFPOWF77)5,^S*?)BLW!C
M6GB2MI:::EJ\E'+13*[2(TK6];)NW+^W6EQ<P&6XD)C%NKLQ5E +9>@U $%0
M!0U&DK2O00;ERUWJ\G3;]Q^EMX5\0R]ZJ*@Z*$,&TD@JQ+@T6E#D=&T[#_F,
M?&+>'2W8(Z[ZHW-5393;'8&R:C-X?8>V:[#;:P-=@)]M5&[J*HQDD64Q.(K<
MKF3)B!)#3/DJ6G>0PQLRH'.547=KD7LT\<4-JHN")&16K%24ZM55D5-&B0BI
M5R% (J>D;\C[SMNX+:S7)721W/XH"JQ&A_#8:E21&66(4!9<K6H/5KVU<UN>
MDZFVMM;%8G%+E-H=4=7S4VX,Q LVW,UEZG;E'BZNCDQD\$>3I:*B?PS,^I)I
M8SXUTE6]QA?[QO&Y[[N<<>UBV2:W^IBE9E*^+)(X>!XD *>$=# @Z9*T04!/
M2:_M;86\US:[@LES]7)&5*%:*!5):UR'-05&4I1C4]!)V-W;L;IW/XO'?(7L
MO9O66-W1D]S8WK^ERU-"^\>P\OA:U<SFHMO8W%"227:V$V3-%4B!8S64<6NH
M=S&I"BS8H=W^DW?<H]NEN+"TBC-Q*%8I 78HCR,H(19'[8U>@8@J*YH06UAN
M&XWT-E%$))9-81>#,RU;B2%">&"0&(-?,D@=);*?+_X=4U;0[7W!\D.MMK;W
MW%3U7]S-I;QRNT*7-;^QN:BEAV9NO:V&?*5$=3M_=R:*O%SGQ_=P2AY8T)("
MJSW"XW"*_GM-HFEMK=29&17*Q*OQ,SJI4(1D%B 5H02,]&,FQ7MO<VEL55YY
MHXW15J6/B#M72:'6#VL.(:H.>BP?''X5=Y;IZVW=N?L7YJ[SI^].VMO[9W'C
ML[MG&X7=VWNO-NXK<L\Q9/[P8'$8[/U^Y,90SX;+R20_PZ6*)7H=<<:2.#OI
M:GZB(IXN2,8)/K]I^1H<C/1KXL$95)+6JE@2-1U4(&%7S!J"#\\TZ.%\0HNQ
M-G[9[&I/D774&[.RMEYH8C?/8<>*QTU#DX\-A,M(FX84QN)PE)CZ";;$=,"L
M5%3H0"CKK)9JI:P&.62XM(W<9("!B3Y@ +J<^@ +'TJ>B_<+Q+>.2<.R6T:%
MB!J:BC. *L30?" 37 KCHS.0WCT]C\3D:;-[BVMB,QB]L5&X:^9:';]'N3#8
MR'&SU,>=H\8*>N\=5C:(!X42.=U9570Q.DWFBVRVMUN[E;:*U9PH=_#1=1("
M@EJ:230 -2IP.'3$]ZME'#-?WR00LP4&658Q5N"]S#)KPXTJ>J2_@QOWOOL_
M+?(K.[P^3F[\[TU18S#;YP^ZMS?W%3=>^-OUF8GQ&(I=T;;I,=0Y?9L>].OZ
M"F@=Z%:!L977,.B?RH:O%*AGE+R! V@UR"P-" /(U.2#Z>71I!+9W,H@M[8&
M96(-=:TXDGNH"JT)[LTZL$ZN[>QT_46S-Y?(7N'KO$[MS6W,AN_;FR/#A,?F
MI-ET-;F,;@,-M3'UNXHL]OS+UD6'AD$\,4LD]?,8 C!T53_:9KBSV_<YYK9Y
MK>/+2:*+$M*T9@K+\/J0:4(SQ)[JPDW:_P!IM]JCHTU(U[]6N2HK@D%:U%10
M@4.=-3TJ]YUO4O8O4NZ]F4':G6>.W;V?UWN+9^$V5O;/;9VIN"FWCV1M"MAV
MOMC<>(3/5N6P>X:6IRD<=30I35%3='58F86*Z'=!?1^):V=49%8$+JTH!DTT
M<#0Y-*'SQTCN]IOK&[N;696+Q2,II\)()&&#4H:54BM5R!3HEGQ-^+>-^(>!
MQ&SNS,MC=]97:=/N[<&9A@P-%DMCTN[=SU5#M^DI<-'EZ?,5]/\ 8T&.C2LF
M2EIUG:>.60:D14QRYQYG>\YPGE>-H(($\'37Q%%(W)8H*(VIC7(QCS'4J<O[
M1;ML,MN)0XUJYDTTD"!QJH*ZL?"M&S0^72TV%N3%; V =E=;;7Q>:7>V;["[
M>R^1I!2]>SR_P/=>=BW)+3JJ08.&@I*/:<(AJR''V<X33XY2OLSAO]SVRVO=
MNEMU#Q2(HE,K:Q&T4,J]]2>#5.HXX$5X.10V>ZK^]/%,8$A3P@BL&.IEUL:#
MN)[0%XE2V>H?77:&Q,CM?)=F[ER6S.N-C;1HL3NOO [CPU!6;/VALC)8=\OG
MWSDN9%93;=2C^[I:N2GJ L<=/6(T2@>E1!R3%O6Z\T[9M.UQ7%[>3RH4@0/)
M)-J)5HT458D/3" LQ^'B>GN:XMNL-KNJ:5?P>QTJNB2@*D! &+,O"F% IZDB
M[_LT'P7Q^!GW!DNW>I=N[ CA7&U'9&9VOL3;&R,?NNH^WJJ#;M;+D(:2J;<.
M>P-3%EZ.G>E--+C--0DJB1 99:_ W [8FU.UT'-8QK<]K:/"I0L'!!P!J*BI
M!45ZCN79-YL;4WLTK1 R(K+K96/B()%<Z30J0P%2:AV"&CDJ'7:/<GPSW34[
MXW/UIW1TMG,IC>MZ;<='D]LT>UMOQ9K"97'9E\!7;?R4"XREWA0S5M),A-%6
M2F.MB$<H1[7UNFY163WNWWFWM!N-N:2QR@^)'@$!@X#A@*42@TU%*5'0:N^6
MK^:]BNVDDB@N(E,=&<*YJP$F#3XOQ&I)4\:=.'1_8O2%#+TWU[B<GM)]Y'8^
M0VY6XFB.VZS=.-W[3X^'<II,MD$ER%75Y+-X^*=H_M*JHD25"LC6<WBFVW+;
MEW;9-NAD4*Z21D?BC;^T6N6IK /!B0135D]#;Z+>(=LN!=7DCH-!DI(3'*11
M=;*-(9E-"&9 >)%,](COP]5+WM197+4L$F+EA?;N[*[!TM0*6JWGCW_B=#B=
MPRX%:9ZRIHHZN.DDJ)JG7CGE6%3%ZA['^Z<I7LO*O]8=OW0 M((O!+*&'=4R
MJY8 -H#'PCW,%[ 2:=(-BW.U%_+M%[MKI>K,LJS'50PNA58M%-.DR499OA!/
M<=.>EG\>MY[;Z_\ C6_9.>Q%=DMPXWLWL#9VZLQ54%'6[[G_ +M=I[AHX]M?
M>4\,N6K*6BBHVBH:9ZF:2*,(A=G)(8M L\-F$MUC;PP"!J-2!1F.JC#606(-
M*5I3'3N\R1Q7]]'&6$"M2FH-P \U[#GS4D>A/0T=A[GW:-C;R[.ZVVWMO+YS
M*[=?/]>5'9E+5MMW9>[Z.BBPU7)N"&AIZK.X6BS^VGB=S0J[K4P2PS AP79O
M&GBMKAH-'CJ#35\((/''$#C\^GN7HMKN-ZVRWWKZ@[7)* X@T^*00=(360M2
M: DD4%?/I6[L[YZ\V3UCENQLAMS-[G;;6-%9N+:NQ=JC<NZZ:6F'CR308>%*
M=IJ6@F4F:74$AC(9]-[>WB552YX 5X9_XOJFV[5-NNZQ;5%-#%<2,0ID?0G'
M'<:\?P@Y/1*.F]W4_?F8Z][QHI:RGZO^6>&W+E.M*?=4.$QF\.IU_@+?P+$8
MC'OB\U-M?+[AJ]M5\E9/2UU119(3L%C+A2Q<+&;<+*XE):WOX9Y!'.DA\5[6
MX5:K0DJG@R*FE4%2K.2YU$=*]U@L]D?<.7)[(/N4<YUSB1C&SQXT&)E ':6[
M\-J45%3ARS,6\NFMY8/:& ZDQ'=U3N&KV[C-S;6K>L=G]>XC%;'CRF.I-W]G
M9KN3><6+V[N#&=5T1DR4>(@IUJ<NBE(668 DMY<Y7W+;X[K<;O=S+"^A61V+
MLY4%4(0DE ":DTR*5X5Z))IX!-#;PHWB:6-0#Y^K4ID8H.AZJ=T;?Q&ZLQC]
MLX2NH<'!$V(W'OW:^PMC;#Z\ZZPM'B1F7SVX<IN:)Y=Q[6GIY/NS)+5)BZFC
MDU4?F<%P*)+;ZE$$Z)(RFL895<JW"J5#:6^8H1PJ.FE)#:$4ZZT-/7T/^H]!
M3V'V=MO.=<_'O<VT*G"]J=*[PVSD]TR[EVE7#KKKS>5)"F/3 Y+&"CFFJ8,$
MJUTU51TB%Z4PMYBTE@WL/\Q0%)K6TN1(C%B'5:CQ*#X'*D-BNH5-!^70TY.V
MV6>XW1Q#$\ZT50]"T19C610P*FH&@@=PKY5KT&/S.[/W!M?X@[1W-2=L=J='
M[RS.^5V!U]F^K%QV[J_=F[\G1[@QFP]F[JW#N'!UJ[=Z_P _5I'_ !//+#3S
MT45(K_<K<:W=I1WME!E8F-&!+GN(4TK4^=,5!U&GF>BS?((-OWW<(FC00L Q
M1-15"RJQ0!.)!R 1HJ> IU)SW5/=?Q6^,<L^2^4.^^UNWMN;AZJH=LY'>&$P
M=?M#9V7W+F,/M&7$[6V\M%%7;B7&XK*5=12RY6IK*BLJ])F8:A'$L:!TB(CG
M<MD@_$17TK6OR!J/+I$DT#/ 6M(UA9@""Q%:$<37M'"M,@9&.C=9S(["V?C8
MZC<6^\=GLC.\&)J*#$8&#)[QRF4DS%!A:ZOJ-K[5S/[$N,R=:),F:>C@AHAY
M'81QJ5 E?>-OMK6%I+:%50H"2(SW&BT_LBQ+,145(%<^O1#:;7NVY[G=6EG;
M2U4R-QHJJJM(*EB FI%/AZRK.*: W0M;=VULRGFR57D,IM'<,-%0SC)M/38>
M6''PP5#S_=53RY#(14,=-2624LL:N5UDJ?3[K=[A552VB$#$U[:*2*4-=*(2
M-0)%:T./GTDM%$SOXJAU %*D,*_+)I_FZ)UU5TW#_IPPG:FV>RMS3[@J]U;T
MCW?6)O9LIL+L'KX)FYJ':6W]B-10;8I\=13Y#&30U6.9A2/0%HO3)(YC3;;_
M ':\YDOK6[DD>.-Y=>O)1*T0$D%J!N"UH:U Q4REO5EMMCR[926XA1)8(&B5
M 06D-!([:7TAF :IT A0JEO7-!\POBED:O<(P_R/P.ZZ?;>:SE/OJLP5?2QX
MC86-VSE*W%[JSFX<I79+&TM)@MB[EIQC<I+2F>:DK:J&GDBL_$O[Q+=;!<6M
MCNNPR6MZ\<;*DJ%7*2IJCE*.H.B1"K*WPD,C ]RU 5EL-_?6TUY @%N%D8%B
MP#^&P5D7%=8+ @$"H#%=0!Z__]'=%R1PW8V2V;F<-)B*_'[:ILOC*<0)@<KD
M<]256/?!H:;)9"G?+;?&'R$$M5&:*4BOGA$4Y\8/L[@L+3Z9E&XK(S(*L. &
M:'M;2==",@!<TK3HGN;^_LW,=_LDD,NHC]0.I!%"P *BI 9:^E1YGHHWS)^%
M-5\H]MY?:^ZOF+O_ &GL;:O=./[WS>R8]N;,STNW<2NSMM[5V=U9A*>AEVX:
M/:>-K\'7YF@?+QYBKESV6DEUF*"*'V7!A;R#0RM*",>8'D2/F>'J!TLM9Y+N
M(N]HZ0$$!B#I8Y#!6X-IP&I0@FA Q4%H?C1O7L;YOU'9> ^7._\ X\]B=/;>
MQM?LSH:?K#;59L&EZ K,E#%N';=72Q;S2BW7B-XY2CFFS]95 5O\4FAJX?":
M: 1Z:14+,D$:ZG+MI%-3DU+&F=1/GY>5.E(5RH$L[R2!0NIR"=*@*JC  55
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M(Q&/K(:&EQ>3J:'*Y+"9FMPD%']L:VEBI(JH RF")F*@XCW*+<;*R1+(Q+&
MR@OJTL 5(&!\_7'  8Z#-Q93;?N%_%+="24,5+ 4#5[M7KW5!SFO'->AAK,E
MB(OX'6183&5<68SU%AZHD1+5TF/BK):'%UZI)&?)%29J"E1HA94\JL#J"AMZ
MJ]YXDU_/U/5"N-)&.JV-Q_%'JG*[JWAFJGHVLK,X^X=TU=;EL<^9CJ,C)G<A
M7MEJZCK**IB;[/)TU;(CF)A'4)JBD6UA[2CV=VB65;\<[O#-<L9C1-)6205J
M2)!5U!T9%0N!VDCH^D]W.9'AM-ON:2VUI MO$'(D$<,1.B) ZMIC#5?0M%UD
MM34:]5K_ ,QC8WQ[^,&SOC[V'V/M3=>W]FX3O7+5A-!E=J9'?Y@QVR*VOW!2
M[&J.QZ\3T\&:Q'EI1'B1(D3R"1HTT@^UNV\H[IR?#NEGRKS#N.Y3[K!!!-"D
MK1Q^#%(9(TEU.RE%90!&^E00K=VD &&T<YW>\7,K7.VV47@AY5<1I$%E<]\E
M412SOJK(V6()X:B3K(_+WYJ]4[K[(Z.[!Z?ZX[(Z"ZCZJVSE=C[-R$V4J?D7
MOCL39V"P=9L3:F1D?+8O [8ZOR=/MW,Y!J[&462R5/-4N\IEN0K"O;M@W_:A
M+"%4))%''(KLH*B-O$4:D#$E6.I64@$T+'M%!3:74B-M6XWK)+<('$1C5U%&
M4Q,O;\3$',GQ,.P@@]+[XZ_RL_AEN'.;%V)MGOGY"?(7=G9^6V[DMK[2P'0>
M4VG283'[EHJ:OJ<SD<S09S)4-3N;  4S5$F1%,M!+2/XY2S@$?;IS!"TRR7=
ML4<H&8:CJ8L*L[-0,==268_%4ZB?-+;7;V$#26WA1A&859UH",,HC\,+48&>
M]2!3217H_P#\!_\ A/?L[Y [G[\WNWR#[?V9M>@WW-M&APV^NF-OP[NP"[:F
MGAP>,.6K-VU)RE=]D-5=#+3T\M-'X&DO).RH'/Z^QV@DMK*PU1"E*DA1QK3&
M33!]!3HGWK<[B-XY99$>:7N-&!I@# "C2",Y+:C4^9Z.UTA_)AZ)J>U,+C*_
M;>[MMP;QPVY'V1V/FL=USOR3=5#L6LBFW)1;YV=A,V1U[_':.3_(QY9>9)(7
MTS %@M:^YZ[U=36D-HR2#5^,BFEM-0>/Q$$8H1D>?2;=[*]VVW-S,RG24U*
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M(8TTJA "Z38K)&E7]^P$*P\N*FG<.[-*Y6M<&E:=*&O&9O%$*@U\C05 'H*
M^9_;T >3Z:IZG>6]-YQ=@;TP]1N6OQ&;VMMW(U@Q>$ZUEIJ"AH,1)@-L0_:Y
M#&2&6@9UIFD"U52\TZ0J))#[8VS9+>QO'NYB+EQ)A11E]60/J*NK4!^$*@JN
M2>D^[<QWEX#;2H%98?##>J@DAL =U6-6)+$D5- .LVR^H(.H:&J?>786YMS[
M.R=+F-NMMO=N9GJL5N&MW[,M+%BJQZW*5T9D@E9A3HT$C)%-XQ9?JY,EI*/!
M-Q&A:8D,0%*YU!5SDU-%R.'3<>Y7US*&MMMDEG2$,PC#-VQJ TI 7   +$#!
MSYUZ&7;.S-F5*!,W@&W1C,12::2;=NYX=U[>Q%+11Z:>BIL":6BVUBJ2BIV;
M[=EH]4(NJZ0.$TMG''$DD5]J#4.%H2#YUU&OSSPZI)OMSJ=/H"DRL014@Z@:
M$&J@@UQ3UQQZ(-WSL'>79>?RF]MJ=J]@/MWKK,5M1UYMK8VR<76;*I,%BX*2
M+*;<VFM!7X;&9VIFQT9C>J25YXDU>EE3Q^P7OMOM.VK%N&]\R/ID#R01K%6N
MA=11734 2.#R$:L@$T/0UY<W[>S<"QV/E?PKR-TCN)'E9=+2/I#2)( 0 W%5
M'8:$T)!Z4?3FW'[*Q^<V'OGM.@WCL' 9#<O8=+A,UL_&[CBVA3RY,1_W:H,S
M]Y%F9Z"AI-P-%+!4*\X9RH$:V0/\N6L6X;9;[U;WLL]A/(T:V\L2H4D7+%9
MU2@X $4XFH(Z]S9>W6W;_>[/N6W1VV[11K))/%.T@DCDII#II #GB:$'AVT/
M1ENPMG]5;LHJO8G:W:FTMP]=UJ[?ZTH>MI*+^'P3;AIHYZ6BV_+E:3<OWF:W
M>U322-34I*U-)I8LC<O[$4>VWLT\,PM916,S4%57PZU648JJ*>#UTD8Z#C;M
M8"WN8(Y8B1)X3'#D24HT9XC40<K@K4$TZUZND.H-B9+O'Y4[XZ\Q?R_WY2;2
MP/;F*WSOC8>R.IL=5&OCVT-I839^$Q=+E<O/N#>N.VE5&LP-/*T,V02,.Z13
M,Q)??;CNEY%M5C?W;7%E8130P)I55MTD+,^@*HK21F8 L6-<-@ 2#!O\R-/-
M%;0"2XCCU%Y7JY$8CB8^K1( %KA3BG'KCLKXA](=S]3[FV]M[Y+=F]3;>K6V
M]TWOC([YZ:P&T=_U6WMA[R;<$O7.>V[@-X5&&R^(V;N7<+YRHKJIYZNLJO\
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MJD:H9B">P.03D"N#G)P#4=%GN^=DMN>-ZVKEJY63ENVN2MMH9F@IX4 D\#6
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M]S10WT[0J@2S92Y0-^H3I+/10#(>V\K[+M]M>IN?TTDU[:J8JKWQDLA,8HI
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M&?9\=(N5RM755U-38N.OJZ.FDR5:SU%5X(VC5*BVQ:&(OW!<]P[LY89K]M.
M ''I#.0L*@1LM">YB>)X+7A0'@*=!EN+^8$_0/R1CZGW+U;NC</5]%@=S[3[
MM^0=+L'/T^$V9W#G77*4$&WZB@I),5F-F[7HU6DW4N/K9FIJJ5Y:0RP4$[2!
MG;]GV;:;C<;V'<XFE=W*?J*/#346TU-#XAPQ_A 4$ UH>[GO^Y;TFV6CVCI%
M''""H5B9'554LR@LI0-J"DCN#'B*$E(VAVG\Q.W/BOM/O7&?+#I*F[BV-N2K
MW-'TUO['=4;>CV?@ES&8V7@YL1O#)9>-\GNT[:^X>AAWI*^+SL=1$("DOCF
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MFD7>K#QR*4B/\.G437I?)R5NMFJ7*RQW,2NJNL>K4"5+.ZBA+P)0@2XUX(4
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MQW23=MF%G&X,T;(I4D9#J69@I!"J""2W;2HXGJW+-YM]ML.ZO=W(3P;J-R*
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M"\V<!A=?"IJ\L+DXIY $GU\^)Z?^NG?PF8J0#\(4&E*9(ID#B:X(!KU,Q?\
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M7PA,HD@(8H(W,@6H5&=E! <(W0FY2VWEKF3>K[9[O?@TVWW$(NHDBE4Q^)4
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M9NLRM%E\KL3(4\$E34Y-FHLJ"5$490(Y4.5]@Y<%GMMK=M(WU=Q<3QZ1X?\
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M6%K9-OR8[[RFVA-11T=;')KH,8#%4F/]I+%D+%=]R/N7NUS=L.W;7:>/N%Q
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M*\*>M>GC??=WPFZ<['RO6W:/;U3M/M!<I@]MR[(R&:R-9N*>6NQN+KL;DZ?
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MDZ4#YNKJ9*$0K3@Q$R:]4T0X_ *4#7$I\12K$9P<>5:?Y.CA=,2 "K 8&?\
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MU:P(XTBT"K%0!73PINO-O,.[;G/;L]M-/<7;R$HNF.:5JOJU*5TK7*@!47%
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M+/.YSJ/O&E["^/>\<ELZ)NM9>RM\2;\Z_P"QEVU/6TVV,AVK01U>Y,.^2S.
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M4TK@=-NS=SY[+0?Q2F7#9[$UE>^(.6P61P=/%3'$S-0Y&9JB"NJIZT4%?%/
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M.18[R1]@1;>CQ\1($DDCQ_=5#*&>0BZ\,MAX+7,1+&A"JC59<X.<(NKN.!J
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MS+8N:RPP.QEF'8TX;Q%\.E:%P=)':/A&>ECC.I_@!@\C156V9^ULG38S<O\
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M?%4<-3-3.X>2&813O(Q1_H?:]MAM!;_4#;--M(NIM+K0ELL:!BU=5<4QBH
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M4Y'=%;N*%:V7"15%51TX8)#221:[ LQ=''OUKS3,V]6L%O%$X4*D"&&)5H:
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M[R[:ZDW?5[;R_<+=<=O4/7>YMF9' [GJ\PM!LJ/<O8&*K%KHHZQ,J\)58<Q
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MP5T$E92K*9162KS$G,I)C'%4  '1$-ON!#-$FYW#/)=>-J9E(\*JD1 : $B
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M@1^*2552#XC  FE U2*#2:@8P,]*N:-[]P+P+;<\[U-?K#:B&W,C12JMO$2
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M4YZLQV>W]6[<W+09#<F;B:3-XG.;QR$0FKS-X]%.H(4)8^VS;)7O28B%NI<
M+JTJ"2S!10D BM0*\2.!ITWN6Y036[13>-):H-0UE2Q8*JJSG\9%/.F IPPZ
MM0EK]E5:4(JAO2KHGR]56Y.EES&V:JBW#521K11X;=-.F4D@RF.C%1&T-.Q"
M"0J'Y])$IV2Y'BA985 H0 )1I\]2 IV\#J_,YZ#J7D05/C8BM20I+5_B]:#
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MC4TCE6B>6*5<J^70L"#''I&J-"ST+%.BUMEG*/=7>YK<&BZ(JL@C$D5)(R
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MIIF0(E$96T\<>R*QV*SV_P"K1=<T<EU)<KXC,YBD<"JH7+, &U%:$! 2J@
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M7(-CL;D:?$0T$M$RI+0Q25%55M"*F9U5VO:QYHVRV@N8+:]@=UCJB1D!%\P
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M8TFV%JJJ2/*XW=.<>NRN8W;NK[V"/<:)$@/C2TNI(=(;CV"Z@YGW6^A<+8/
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M=R.#?;0I!N:KKQ64SN*VCB7[@((YEG)7QB0,+Z@0R7$<06K,U /4G@.O$.P
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M7?._-V5NZ<KB*6CSDL<&,QN+Q>U-LTR1O)CJ>C9VHEFD 8R++N"=+.8W=SN
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M"H\C%25,&#JH:=2S&:K6.+2Q-U1<PS[GMVV[?<7^U36\<S51G$D8E50"[(K
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M86$0II>,.P!.H!G+@FAR..*#@.@UN-RU]>W=Y=@2W\I[I$:BL2 "0 H%#P.
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MV/RNRI:+=V3W?M*KVGN3MS9G7N)PM%NKK?(Y#'[FKZ#,[XARN/VW5[2GK<'
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MIR%<VT=LFFQ\,SU6+?(4T(^ZT#3&ARDN@,153Z<2<4-6(% 3FE"17'KU&+K
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M4A!&7"J&!P"S$*A(-!U-V#G>V^T>RLQN_I[LSIR;K''=<;87ISL7;%314O\
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MLD9EH" S)%4F,D8=B5U*,CU$ZJ[9_F4;'V!G^\]Q5^,[,W=M#M':/7FX-[;
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M+%M30[BH,9DJB%9I*2-D::P]OW&]0RI8#<:,$1$#R.J+(L51$90I":HD8*&
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M3'C-VUM O:%7V5BMN;OV_L3<6*P<4^W:D9C<,&,Q.1R$B&80U$L[I'#X0!J
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MWC((YVRVN6B$]Y!(DK,1H$E==,Z@XP%UU&FFJJFIH>G[J[L$E:!]N5&1@=5
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ME_N6^MNETWTUN+<,I* 49"\8<$%>SPNY2QTAHEK6K @'FU>S;;C#]+-=^'S
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M[V5S;7-N8M<I \6%M#*)&*DQ,%H4!8$GR-.G)K+EV]2<6=M9+<2))A$H[/\
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MKK/E4T45^0].AHZUV7C.OJ;.X]\0F'J]P3Q9!P<U#6/5?P_'" 2K)),)J:.
M J'M^=1MR06[C]")$>TDJNDZB:@X.*D_+]G2J)G$6F1SH4U )H!7)(' 5/'U
M\^NLMTKUENW:^RJ+<.%J)X=C;AQ>]]GU WEN&:OPNZ\%@\WM_!90;ACS#5FX
M)<=B,_5I&F0DKJ9GF\CQNZ(RHI&,C2,U-3<> X_(8'[.E"L=8D #$$'A@Y_P
M=54]J?#/J/J+<>UYNK\UOG;.1[-SE$,_7Y;LC-96IAJJ!8I,'D<+6%*,[:,F
M:!!=I?MG<".**.Y 9N]JWB;:CNUMMYFV_;PYDD! ,-%J"0*%P:=P 8J,GHTV
M7<+%[[>;.2XBCO+@1%8#&666LFEE7N B,8.H9H_ $$="I\?^PL!MG/=_[$WE
MVOD]U5V)[5CSEMT9/)[\S\&$R6T\9]]N'<%+*N3Q.S]IY3(4Y,-/1>+&":*1
MI0DI>WK6[V:_V/;9>9GBDET/&4D6B:30",T4F1'!#%GTZB5 J5H%UURYNQW.
M;^J]N\AHLC^$Q[')--!<K1E"GM2NG).6R[]Z?-GKW9NR,!7=:]R=7;TW'NG-
M[%R,-+3Y; Y:BR?5/]]L?)V'"U-++,:E,IL>:MJJ%Z>&:H>FIWDI@Y$:N/=H
MV;:I5DO[J!AM-NC*Q+L-1T,B,LE"NF&72KDFFHK&V6P6[5L6[;E>QV[6\K1L
M&+%5%5!1F5JU I4 _$*^73'3_P V/XDX[>N6V16_(_K^OKMJRNFY,5A89(JC
M:E,9YX\1%4)]C'3U[9Z2C>&FCC8S1(OD=1]"17$W+JQ1O#;RA2Q4L34#(578
M*2P5R:K0&GXJ#($UC[8\[7ZMX%HAGT1D(6 +-)QC#&@$D/"0-0%B%0L3U2/O
MO^;A\::Z#Y!;\[$Q>XNQ_D0]3D<U\=]^9+IK%;M^/=)E]CYW<*=+4V0P<^X*
M3!/V!L_#R2^'<BR?:-3Y-:LQZXO&R/?8MMDW>Q&U\K7<#?0Q,LE))69M+CQI
M4;0ULS2+F!E/AA11R&ZD.XY WW88-NVB:]2%$:&6Z57"N+@+W"*;(90"I[:+
MQH33JLC=?S>W5A,)W3M3=^RJ3I+Y,]\X3K_MCJ?:NS?!B*C(83=>0QV9QV>Z
MPV/LW#OM#$?W[VY55^5HZR>I41)2U$\T1G?6H1%CN2/N5U>;;X5Q%:N\-P)2
MIADRZ,8Z=VMM+,20H%4 H>I L[1;W:-J]OY]RBDY7?<S/+ ZH\TLC I5IS^I
MA58(@ 7Q.\@L*]1\;\K/YD/5?>N6I:7Y(]S2]9[!K\X:C:6[MI;"W]O=^JI\
M;B:C)4>Y]B;B_@7\3S=+3U\=0DM?+2Y)<>YJ59T>SA:\VGF3FO9N7-HY^V[P
MMUDLU:1T9K<J^IZDFW8MI8 ,$*\"&!"BH&D_M_[71;'O9V">2:<7P*PK.VN3
M21HTR2#2%"LP9@^DL-)5GH"5S>FWMV;WP. ^6-5NS.[,[VBWSN3;FY]O5VZ<
MV-^5_P#>#-IM+ 'K/<6)KJG%8O9]%M#-2"AQ-&8J;Q2SR1WD;1['^X;?=;+L
M>W6UINT2V$15&1DU>)2AC6-R[%&%*M4MJ)U,0V>GO;S9-BW.YYHV!?;:]W+?
MOIO%MKJWEE#;>J@1R37B!4$ML:DZY ")2JD::]1MIX?K+![>[;V]V[65^/VA
MUKDZO"GJ7;N9RG7>X<7M&AR,6,SV6WUO+'"@.[YZRKIH:F*CJZ6H:AJI9))E
M2:=5]VV*Z2:PW.\-V)KP*OZ8'ALE#A]0.H5) J*:=.2?)1OG*5WMJ\M(.4I=
MKY?DNIDCW65)WBO6,7B);*I[,)W*\2J9=98L0#3)1[V^.-91;.KZ7KS:6T.A
ML128W>]/D=BU7:+=X;6WWF\+68C(3U>8Q^5@I4HLS2X>F:KFJ&IHZ>CHIWHB
M)5>)U:1B9EM[JR""29]:!C(=( #%]5164%0JE6SJ8@UKT56MU/L%S]?8W#RW
MUF\;PRLJI:-<NI C0C^U-OH+7"!P-!C6G<U6+JSM#L/J'M?"_,CI'KJHZXHL
M;G<MMW^^])V%O7:6%W=BJ?;F,JMYTE?@\3+%4OA)J**FSE?AVQ@A&/K!%-J^
MX:15JP236TH^F><A%AF/BR,S-  RH)6+.P12&8J?@ #=HH2G>))=]W3>;^Z:
M R7LS7+*L,<4:M(Y=BL" 114?,:+A&^&A->DM4]BR]_[JP6&I<C745?\D.V<
MOFM^Y+9W;JX?KK=E3O:MW%1UV8W=@LXE#LW94.W,OF(ZJGJ9*J6KIPI@AC9X
M75DTFVRV(6]TVD:21NA!7QF8T454D_IF,T[E%0U"U:4ZI;7EW:Q%K6ZE,) T
M@%0A5<,60+5C3C4B@^')KT8KL/J3>/?7177^S\WE?C?3=A5-'0=I=$;BZSZB
MPW3V]*JMPV=R>/WR^XLKCX,9_>W%[BSNW'K\I,PJ95JHX\@41Y%"O;=MEU$A
MW:6^06T84&W#,7*RMI8ZL+1*=X-1(5H1Y]'>^6D&VV^V,=TEG6\A>>%SW1HR
M]V(Z54R.$ TU*K4'RZ*UF-]])[@ZGV]MO+=/;?RW== V/KH^YH>V^R,SFLKC
M[39;=>%W1UI0M%M>7?.3RVM:;*T>1B,,@,ZB5Y /:7;X.8KBSFO[:RA6(LSP
M2ABKTULHK PT% HSPKZ9Z0[VT.V\R2VB;@4E4H'0 ,06B1Z:T)R':H )T_#Y
M4Z,-UGWUTV^5V9LSL/KWLK>O:72N)PT.SFJ=VYGJ;K*AZ\VN:');5JX)<W42
M5]?MK*YC?]1/EY\I1QP1X6)JLQ&8*2MVJUGN(-[_ *R61W)$MYI$M[?])UUE
M49WT5 16[FDC7 6@!Z/>4+>Y/./+\MGS"=J6UD\9+QE+!);5?'C\%6*"65J#
MP[=W43LRJU%-#P[\^6_3&5V/_HQZ5ZQZTZ]PW2VZ\+M[;>XG[\3MFLKLEM^?
M.1Q1[':;:V*R7</6V+HY)J2GRE=4O%0R975'&VIRC^U6K/=;6-RV&<Q7.&*E
MQIU=A<8(H JLY)5C4&GGTIWC:T>XY@OF]R(;Z&(2W(=[2.W\62BR"WN1XK/%
M=LTKI'#&)(U93'K(&%AB,EUEVW\6\9B]A[:V E3U;4[?W)W/OK [*W!C=Y;<
M[#K\%FHI*2HW15S-@\CNG>U;44>'J:G)3)B)*:J<'34) C$O,\MOM[[O^ZP&
M>*Z,1U%@BD'N#?#1@M2"2 2*!M1%4_)W*^\;_OMGLAM;JXO;FT::UMX&6264
M=M*(FIZ=U0B S"H9D\+65*UVCX<WU+USMO>F.W!-N/M9\37[QJ^NL]F!U%/4
MK+EJG"X$Y_/QR4_^D["9G'1O/A5CCCHM/DI99(4O[IM+6=KL\N[;?'"6N8E_
M4 9UTJS=B$E2M"2S*592],>?1IS]:\VP[K9>SO/5C+9V?+URS+8L(8;@7$L2
M@3W,D/B)=%HF$=O-KU_3]FJ@(&;Y2AM\Y_9&YM\;G$.X^M^N=L]=[$PVQ:C*
M8O;VQ,5UW0XO^#_W#7!TT-!UIG=O4L$.4:JCKBF6RJ-/-,:K3I%MQ#O]YL-K
MN^W>*\L<0TK-'HBGH"2 VBL3Z0'K\(H$;B*1+8;1R-;[W<;3N=@D$4MPRL89
MWEDA.L -0R?JQZZQT(J"Q:.H4]&NC_FU_*O=-;L+&[U^0N/3;V$?;WWV_,IU
M?M_:TE+14N,7%0YW<<]/F)Y-X91*.K>.H3(JE%D*BI>I=#.L.E/MW+N]W4*R
MR;["CW" T:-#&@9=9!8+J]*%:M6@K0M6DVT<I#<I[(;:ZP++(C,SG 5B!QKG
M&:T\P/+H/?\ AS/YA9#)=IUV_MR;-Z[W1F:?KS*[%R%1U;1[D3M3M39$4_5G
M75#LW:E175VW<DFU.N\H((Z7'4U-45<%2]35PS3\ COMJO5FVX2W#&=6<J/#
M&EF$?P2$"@60U/$ D!<TZ9CY7Y4N[>\(VT*CJHJTQ!H'U,46H+%  =!S2K*
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MG)U6V8Y)*A#ES-5>5 X +.[%NP;1RGR]NFZOR^9UWJ5C(Y,[W$319C9%$O\
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M<,&;VQYGVV"2SOX+<;>%,C:B#(BE*@HR$AV(RP<U!(44(Z]N:[?N-M,]K/\
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ME-#U327QV1H:O-5ZWBBE6I*Q022#4-(O!:7TEQ<M;0A+JJ>"5[B"0P<D5SH
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M-F]O[/FRF2V#O#"[=R,$">6.(TSZZ>&6Z&Y2.9^7"QOUNB\J(L9**68 G4$
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MW-MNY?DFDE:X6W>8+*D,@A.F-?$8,VF-M)% YE*FG0;]+=,8#M/(9+)X3N?
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MY+)+45%6$,+U1B:.3V%=^Y9WJPO)X;NW5+F6%&*I(A72P.FNDE03Z#(!R*U
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MA@]!'C,ENW9O<=5C>KMNX*HS]1AY]Z42=B8G:FXMF[9W!L[";YP>[JC)[:[
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MW>#^=9\6M^8O<7Q]W?LW=S=[9[+8_HG=>6V%UU1U_4&'[%[%EKXMLRT55/O
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M&*HTL, :GU+"]F%&S_2<O746]\EW[0W-F\=U%0*S)(H4.\B2JP&ONUAET^8
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MKRVMS;[@MO8HH2?PJ*2PR6:,+0*#7M' $TKUXW$.VN=NEMF:?Q?% +,<LM$
M8%FU%3VG!TL13-.G7</<9K,/A.J]V;!Z5Z8VEA5W6VR-^;DZYR>$W9DMMOLG
M<E9L+KA\?/+D:JNQ&7W%DB,?1?NP+FJM:F::,H(X]V-K^[V>TN=SEUL3.6G9
MF :@0R:CVAF"(H SA:#U4B]EB$6Z?31R6<3?3QJ[1NA,GP1>"3W!O$.FH(#G
M!UBG0U]1;\Z;^-O274A[IVUL[-]N[LW=%M Y6?==.>QZ:;=N%6?([AW?F,_N
M?%4>R,7MC/UR4*U:.(IJ2":9I*71J<)_7;[NL,#I<W4D=[*XC?6%1%C8+0G
M#.3J(8 A '4$'H3W^W;'R_//97$]HMW900^(FG6\DTJ%R%Q5M"@*2 5,A96
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M>:7V]MSM+T21!4U!B4KJ_M%4&N8SV@BNOB:  =+&FY8CN&VV5)U^,+(M&R%
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M2S>:F,)#V\[IL_*W,2\K;CN5D-W6;PB*J]"=!7410(C*X*M( 6#*=(!KT]+
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MP)/H3TV(W>UM[A*Z7H144J#D @T(Q0&HK6M>C&_Z.]B[.^".X/D3N[/9N3Y
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M)!U=/&?[M^&5'VCM;X15F/V[D]V[FVTV5Q/6B;,R4FSSM+8F%_BWE;*2XO\
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M3\S7%[MVS37MG?31W=IH<2"4TDU,H*%=*EL'20=-%K5F\Z3?O*RAN);=YHB
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MC1Z=:T[8T#%C60$!J]JC/'HHN+'9>5GG_=>ZK=[@"!&(M2 QNM7=BR*]0K:
MI(U$,U,+4P\76-()\E,FQ>[:2"I>B1\7DGVEE:(M!%1QY2NHS-/#-BJC<@IV
M+V)-,)2(T0*J^PU/R]#.BB/=$1JGAQ8$G)(X'T' <#4]63F*]@ 2*6?242O<
M!0@9 J#6AQKKW#-!PZY=T=O]4X.AZ'V9B*;>N.K-DXB78.9FDP6ZLGM_8&1R
M3XBGQ.&R=52QXV+/YMZRG^UDFI9VC:-KF0M8 AO[B(36MC!=/*\!,<A (!(
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M38#<[ &FVNXADOT)20:@T,PC) 1&QJC>A,4HH6!#8!IUGWC\HMXY/9&(ZU[
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MB5&2IB\-I!X@4+XAR)"5Z>V3]Y6$][^^=_;<K=R]%<UT?J:ETN*$.(OTRQ+
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M62.$,HJ,O0\.G=WVQK3=WO.7(8X]B:ZE!>[D7_<=E8V94H&$#LY3Q*:M*!@
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M2/9S7-W-8"::2-H3%)4*#(FDM1:T\,$%""1J'1)=;7M]U(\4@3PECDJX%-0
M(5E#G4&9JLH<\2 :'K<S_E<_SJ>@/DUW7N;XWYK&8;K'=^+ZNQ'86T-\SYU)
MME]@FB_C#=EX?(U$Y-!L;<.T<-CZ7(+13S*IH9)69_VU4E\FQK:2-<H)&A)(
M6I)8J02#Z$BG<!D5'&N(4YHV/<8;75&/&AC17E("CPV8Z0JYJPK@XKP(%-5#
MO;]ZUZH[K[JK.T]N]E4T^YZGL#K&/K/N?;':6X3B=K2J^"AIMF[2@Q.>J.O<
MM4;@7&55&(#3Z*TY*6,B>9[^XZOGWE>;XK*%I! ?"8K0Z3$%J[<#0$!JGS84
MX].6EML\7(R[C.\>NEQ&PHGB&8'2N#1CI9D  J0.XT6H)@=X]_5-)VIN?J5\
MQG=G[RQD^W\ILYMZ8+,[#ZRWGM?<6-_B"T76.\Z>CJ<+VEV!CIZ:IQ\V'GRN
M)FAKQ&S4X@ \PXNX98M3AUD):GQ $4H._P Q7B#D$>?48A&T!A0GTKD?:./V
M'A]G2@W-ORO@R.TJ3?F_=H=<[7Q%!+N'NG:?:68P0SV*QV[$R>)ZCK<%NNEQ
M&&VNJ5N[</4)DDK9RRB/Q(P8*TBO;#=Q7,#V\1:>0E$ J2S4J0@7N9M-2  <
M5-#3I-?02M:7$D4+O&BEV*C"JM-3L3A44E=3L0H!R14==8'LKH//5E7&F_,!
M2XK'TF*BQV]<GDML8'9F]XJY,I-4X_9^8GS,1S=5MP43"M"JC4A:-@71[^U4
M?,3RS7-M&W=&P)R2 S5X&E":J=0S0X8!NJWNP;QM]I975Q:M^N7 3(D71HKK
M0T8!@X*DBC*"P)7/0>U'R/\ C)59O<6W=L][[$[-W?@TFVZ^S]M[OV4*A'Q#
MBJKML+N (F%3,[7P4M1D7HIIY:E,9%)-S'^X#;<MSW#9K2R>[V>:V:9%GC+I
M*OC*[:3/$LA DC<BI9#0E21@'I[:-AO=V99(T$=J)3$TK5*I*(S+X;::D,5
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MUN!/>//*_B!J^&Q52&&@AE4H70"I*5 %#3@.FTW,2L;/P$BP!^HV 52OQ4<
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ML/E,%DMB;HW,%Q#0PQ%&@>,F,+XG!7MHWZ[YBV^/EC:C=[O>-(FDZEC#,_\
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M/I_NZ*@II8'>6)9(H?'H'D8Y:.QEFLX&V^5'55E56UN5=M9XFI+Y8TI2I_(
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M62GDRF7JZ7:F0V<=P8TU]&TM;%+!(V*\NN&69921[.=H%M-=V%BT56>0AG)
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MMM?Q.BQ>%J-K5O8=#55^%RV7DW!.K4^.1:7)14]3HD(1#(3R"""ZTWBW=M+
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MD3X5522PRW<2>HUVA-WEL-IL[BXCBBBDH5F=V"+I56B.I=;Q-34Q9>TGL(4
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M=J>."SOA.&-(BZ^ -0K(=98/61@.V@TBHPN>F+L?!8;JO8/4^]NKOAYVQM;
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M,.1AJ:O;1Q^/GPD^,:HCJJAG:)(9W#:H+_;[VZN3X>YB,A@:G2(\K4#('$5
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M:3<'P66]VTK?7Q'Z#2U2SU&H_#]N?/%./19<WNV;A;/;65E;QW9 (*!]9IQ
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M\3$EZBO<4<+JJ0=*ZACJMUL6T1<O;=S)R_<_47:S.LA:B,D4L858"6QI+IK
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M:G@ *4-;[CODMIM3[9#:Q,\4UL8[D!?$!\2LAUE=3^*@5-(*A")&<,S@*,^
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M'.*F$1N;*>:=MM-T&PW,%I$3;L5%67]&(E2*%2=#Z<JHS0 8Z!,%QM2?N_\
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MBVV1B4PL=+G*?&B2;(U.5P%)3T_C=:>>AFIH594U/(0E;65\\][<W]JRMXI
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M!E>SMC[_ ,_7Y"IR>S*':N*I0]!N^FI,@E1A-M;VKTF?;U=+5R^:9T@FC"3
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ML :+P2Z8*&MR3?98>L6=8:@++4UE.C11K,C3$>V-UDYFFVJ>6UWA(K_4NE4
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M?LOOMQ_=]AO>XW]R/IK6REF R6>12JQQCT#LP!-"1Y UIUJ6"W%K+-"C*ZL
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MIVK3202J+DX!8\2.EV];C!($^BVGZ60Q*%#"0=ZT61]4A8OJ8$L5[0>P4T]
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M"+;^2@WG!34]!NK<F<SO\5,F1J<ECL92+-&8:=XA&DEY4E5@W;\Y<NVUW+'
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MU<7DL94.^0EP&(2JHL=5&*-8I05@E1@K>PA^\8KO<IQ?WMQ<7!GE"N5*HID
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M1))4N*V:NG0FC0QH#.5%I8_U?@BEL)1;WQ\2.J!98O"D4(XT2*4UL/A[2T9
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MJBRF,'S*HRGUIG)Z'[ICY.];8[ 8+:^![YS>/^-W97Q4RG^FWKR:GWWD</\
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M;.7HIII<@(I=N4-$%6B\\-"E+B:!Y9T*JTLA8 \(B"E]9M#-;2B*5JG@C!6
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M$\]I>VT>V3F.=XT :(F-BX7O5=)#=I)S4T&.A9:\W[]:V*BXN;]KME&H?67
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MP%# G/1IL>UP1W,HW1[>XA90J@1Z>X@L,@Y&D5/I45Z*O\2MF?#/M#IT9KY
M=K=Q5G8N-J-W9'+38S-=IUN/;I^CS.-PVVLTLN.I5@KJ"@R-3/01U<$;5M/.
MWC=1J4^QQS7S3M>R26$:VED]A-;+*L@C4,6E+:PQT:S1@=(<"@)*@+GH#R;5
MS!NEQ"-E@4VST"8C5F>C%E&HBH4 T)QB@)) Z":B[!W#\<.U=_879^:W#L[X
MQ_(+L3-]<8X93KG9?;6]MM==;&KX>N<[F<9A-^FOS6*['V5'DP88EEH:VJK9
MO.[O* WL,>X*Q<P7/+%YLF^P6WT^WAKJ.U1?"DE<AN_M JRIJK'72!0 UH3&
M>W^@2RMMRL!]?*J@Z2%TL"%8=N!W$ C--5:T%>@EQ7R&[!Z>WS0R=9X67M#K
MO*SIBLU'W-5KNK,T^WL?FLCL]=PUFUXXJ&2=WV\O\8:D6$F',L8)'>.(EXNE
MY=EV[ZK=?WI?3A$=RL,C]PTUT2(31GI332@ R<UZ4?46MWX-GX443R!@6D95
M","5-'I@=II7)8@<".E#4;3J*_*;HV#@,UU1LG"]=[_@BV7N/<V1_N]G<OLO
M:\3;@H\!54]=%4XG;.XLM%7TY7&T$=/1Y*MKO*\$4?DD:M[R!O?*=UM:1\QF
M>WNK&62YEL;YY+>WF:&&<PRR*41)XX[B-55#(%<%3(#CH/;??V6ZKM]E]%>V
MTPB>D=Q'HI%XLD:M#'J+",LC,%(346JH();I#[)Z'W!O.7<^X<[OW)4<%1MS
M*8VHQNR^T,I#C=Q+GJ7,XJEJJVFPTNC<F>VE74,.)I@:E)(HJ6RF2F6-1K;;
M>>TMPEAN9$TGA,0ZR/(NJ$2FOE\%#-J)*,X)-*]'FTBSG^LN+B%[@+179F"Z
M6T^'&"S$LQ^$IQJ%T#RZ37PL^'^>WQ7_  P[D_TB97.[TP_R7Z%W1N?;59N/
M,Y/KS=^T5[CVA05NR*R+*)%!C=WX_#U4%:06GQ^1IG>":(,4D)K?]VW[GX-\
MNH0%G0ZR=!J"-1.EZY&!08]>G[Y+NPV>PW9MNGA$LKK'<!E"LZ*'!4#OBEC!
M5@=0)XT&#UOB?+SY ;EZIVOO;L[:U=F,+5]5;TJ,%B]F"+;T&P,SBL"8)LKC
MMQI.BUZ9?=>*IJN6@B $<L4E,(R7;B+4%(PBFB>@X8X8X8ZC^266:1Y996:1
MC5B2223YDG)/S/2@[W[][2VINO$475,&'VG@MP]'[=[2V=35=3M[ 8P[[SN0
MRU-4X3?--+M[,5=;25F'^W^VCC^T,E7"X$I957V7W4-Z4:\M36UB7]5C7PX6
M)[3*0I.EUKI%5)88/1ML]OM-TFYP[E=217S0$VJ*FMKB52*Q(=2A6SEF#*%X
M@$@]%#WWVYWM\A>M,?TR>X-S[,^1>Y,"-K^2@BK.HMC[HWSNAY,A#LO;FXCB
M$GK6.R(YWGK,2QK*=:>26/PSQ,&,]MM=NNUBW.3=2MW'%,\D*@O$&1T6"*AH
MRM,"S,69]  .*X)+B+=[=[RT.UULB8?#E=T24QNI,\I4<? ?0BK& 7#$&M*]
M& ^*^R=X?&_;^/V_VSW+O+>6X,/MRH&;K<SN'<>7V[7;PW?N*MC-/'DMS9+.
M5^1IL)044=+#Y8X$II$<QD&7WC[S)S,U_P S;M*9);:S"21A"[$(8XP*%8B!
MK+:CJ7X25;.FG4E[/L\!V.VB.AV25&:8)W%"6JP!&L:CI K7'Q=O ,Q\F^JN
MB]G46-KN\.R,CVKNC:N\]_X7%4>X,WE0M97[BW+0[;R.7V%/-EL]+M^=L29D
M6-$IGHHKPE4.H9*>WG+E[=<B7VX;SL4$R6VZ3V_BEC]7X4<<;]LYE08$BI&2
MLE'(# G4IC_>I1N.[&>RN/IX!#$XCHJK*QE?7H'ALNH ?J#M 45!X4,1U]W]
M@=T?%_96+^16X<;FNP]TT5/B=XM!N^AQF.JLO7[NW!-AZO;\%+-35];*U+M-
MJ_'4:054ZI%]J\\\D<A,:SI=W/+M_;WD?C3,6HJRZ9!";@B)=<;*6FCAT>(Z
MZ5DD5OA5B@-=RV]H=QOI6N(E@UR:/#BEBCPGB(FF4NR,H(C8LYU.&D5=#+16
M_&RF^,.XZ".J&P-B4^?PVWZ[>]$^3VSCZAL=MNEJZ5ZR6F:MI===)M:IDA*U
M4,*4L J]%$0FL>VN7=JM;*.:*ZE2:9/$ -&"K$S A'UL=<M!61J:1\*409*D
MN9[FV@EC8A)&%!7.H>8/&E:@$8J#7(Z6.VN\^K-YXS:N>VYOO [:VSN7,;HH
M)4QF0V_3;;VO7;+K)_[Q#/UU5N/#B.ES.0HI?M)XZ6.7]]=:+H(]R%MMUM>W
M6UO9Q[;7Q0[ BND%JFM0A"#A12:,PH*$GI%+L6Y[F-\W-)F$-FR@AF(>2K:*
MQ@'O ^)FJ J=V0.D9\O_ )&;>ZKZ W3EL/V;L;>>_,?NK9N-VYM5I-H[@R6X
MLME,OB:G$[(CVA')G*C)9#,4-7%9UIC4+3U"U0T1CRAO<+>._A)M;0""B,VG
MO% XJP9U*@-0J.(!J%[AU7;5O=LO%GO;.1@JE=+F2*A=&"FJ%3J4E7%<,*%A
MH;).?AI\BNIMY=+Y'L+?.R.FMDY*JR^Y\WV1LJIVUC-\;CZDH,/2[GWUM5,W
MG)::HS&;H=S0;>K\IB*6HB$F.IX6C@NRH%#6[WE[<;AL\%V;95E(B>2.!$J4
M5@"(Z!-3*%7"]U&9N-0(OJ(S%/=HDJR!4HAFXBE2Q8"M,:N/$BG U-7C-_T6
MYN[\54X7:^WMS]98Q=K8;9^UYMYT>QMIX'&[JI,?F<9OO$;,R5'#C=Y5<M'6
MZHJ7[:.HHGD$@5&(D0,122KS#OBJS+!:!!'&"R)2@&DJITH34ZJ@KDUQQ++6
MVN[E[V\DD>5VD)9R2Q50OQ5)X'Y9)/SZ<JSN##[8I>WY\CMG^[FV-M[SVQCH
M:7=65I-Z4U/M=JN(Y/<N!EP[;IKZ;"56IZJGQ!T3TE6);Q0ZO;FP7267.UU9
MRE9=OEL%F,4DC.B2!C70SCX@#VJM5-1DTZ\^TW,]V;+ZN:UF>V>1&059V2A5
M!1UHDH/<Q8 !2:5.<NT?D)T-1[1I=\8O:PI,1N*DGK,?0XS;.(2#(154AAP5
M3EY!CJ-J 9V:G84.L>=@I1UU@*PW;FC:YF2V^A9+C4 3X8TA^!57!TMD@'-/
M/'1J/:;FZ?ZN2QW&*YV^*%YV=9)*BWB&N68Q$&0"%"'EHIT@@9%6%?\ \E,)
M1_(>JVUO')?"O?Z4-)N1=Z]?]T].SX6'&[VH,MMN/'34^<W%LVJH<[GX][&*
MGI<,F:HJBIILE4K#-1V5)T#]U?\ N%L=[N%WMFU6%M8^,L:+'<CZB5)04D\5
M&B%O"M6H2VMEH)$;- OM=HY1=7VR]YBO;K<4M)C66VDBCBGBH\7@R+*TL@*J
M2<BM62E0#T97J?9M<W<F5WSWWT;F]F;<V5U1C\G1=\[][.VAG\9B]DX7!5>7
MWKU/BNN*&KGW1U7M/"F4U&0?)2UDV3DHRU0Z:4B"GDK:^8-@GW*:\Y9VVUVJ
M6*98TBE\5U8RQ+#-*#"D+O,FMV\/48&"*7DUDJ$]V3:KFUM4LM[N7O?%B)'A
MM''0I(9E1PY8>&0@4L@\4.=.D)W3]R=R_$//P[-W=V)VQC:GJ?Y12;HVAT)N
M/=NT,VG6V[\G_$,'0;07;57F:">EV748F#+-CL16K!04&>HII6UR.$+'NQ2;
MMM_-5V\[2-:1Z-4;+1"6:AIJ[=2CM\^->*UZ]S+;;-<<L;6MC$B[@8V8L&JU
M0&H&(J?U*:\]R@ &@85?-O\ 9=7UI2TN+H/B)AZ)=D9%=D09[%]>T<&6IJ6K
ME$51N)EQ].U9)2YS<L2R5+Q,OW4[F:70#Y/95>[C<2WF[>':H%%S)Q4A2BEM
M+5X-B@%/7'1U8/$=OVRV?<KT0K K!0U0LCA1)I4-120.XX)H-6.A9Z'[3R<N
M6W57GHS;&W,;B]JUS46<VGMBDVQE<]N'^,44TNRYIGH<<D4RTLT<L@D"0ZD5
MV8L#8NCWB]-ON+VVV-<W4,#R"-*(9&7X8U=V" L>T%BH4\>/2B\M-L+V42[Q
M,(GF"L\JDHBGXG 4%CIXD*"2.'#H;MT;H[0:L6OPU.L>!BDVAFDH%\46:@DR
M^F6IH<S+)+#0C:.,I[??,C?<O,2J,%M[,+.XW"[2ROFA$=I-;J_AG^T21Z-I
M<_#I1:JU,D_+H+;E%<6]S+!;R+(B2E0RU[M)8!C_ ,+- 33NS3H)]I_(_.[M
MRVX=I4.9&XNS>MLC-@>[-B[*Q,>*K>OLSCJ+'/(FU=G[TPS;T[+H-QSU\$N/
MRM+)'@VI9VE:KC"!2:ND\,<!DCJ[JI[2*4/$\<4SVGN' CSZ?6*58;9I5&MD
M6M#C40-7G@5K@Y IY]?_U*G,=TW@L6V-DP_\P/);!GS6W:"JQB8GKG*339VD
MH:DP[4@R<XJ9*:MI=P33320Y1_)!+)$(IV4E !'&8[R 7MI9QNK*:D$4UT!;
M/\2\3_".(%>LI;@- ?IKK=)"D; 94CM%0!3^$\:?$QIDTZ%QNF-K[W["^.NT
M*_Y9[DWKUY6=J[BK=U9:MVO7]>9K:W9VPMM8'*3XJNR>X<I75F+;(Y/>E-A(
M&IY(J*45$<2!8IE!+)]WDL=TL9KBU,MQ$$TUET@K+AE# $=Y4$FAX=M*]'?+
M\6SF*6WWC:$O]A-QXT]N 8WF^G#:(GE6KI$OB%F5 K-159J ]6 =?="8786!
MWKM+HG)],;.K-U1;B@W7%N;>9@WKMS([*EK<7DZ/-]1]<XW=-?E,SCWCDIJW
M)Y7,MXWD"1A(Y)&4-<V7L/,US:&"SAAVVVD[ BL3(&(\0O.:-IDTT50 5^.N
MKJ1^9.>K#<[:UV[;^2['9[**'"0*IF$FD*K/*0#(J+32I! H:DDGH3/C)2[Q
MDZLJNF=Q8W XG;%)DL3OR7LA<-]E-1?9T44,.UL1AJF2JC1:V>"8+.N01*>!
MI(FC<*LOM-O.ZV5KM5S:0V\0DGNAX:+1?#4 D1KQ/A@44DFIH"U22>HJMC<W
ME]8W,Q=I88'5W)+&9W8'Q']9:\,4 PH '14/EMG=ZXZJVABJ#8V1W/LGKEM^
M]Z[5RN(_O3XMV[EPTF(Q.W]CI!@Z?)4D\^8QI;)Q-''++%#0L&1H&O[/]LLH
MX]F7;ELS)>7DT4JL-/BVY52&TH03)&0M6( !U?Q4/346[W*;I<7_ (BI;VUM
M,DB,7"7 8T\/4M/#D!-5XT*FN*CI9;CHOEQ\RLKT/W1G/CSC#W;N?.;?K^W>
MYDRL>-RNS^MLS34'6?6N0[;R5904^T)C3[ J9LEA(J<J]77PM'411U,[2((M
M[EL+6Z7<MSY7>UL[6XB=R\A:*X,NEHHU6A*QHP#,%JN1XA4"G1'R]9WD>V0V
M6P;C!=WM_'/IB6@EMUM"S3NP^$O(FH*3E14H&)J+:>F?Y4]5\0JZ5=F_-G+'
M^]-2FV*3/4?2]+23R)#7T:8JFI_X?OBMBQ-?E,A54Y@,*?<2SO\ JT@GVWSK
MN/*V_77[RW:PDM!K';#*A36:*.TQ]I:H 'G74,=!BUYP_=<*S_3I&CJ/B)(S
M3' :A4@?;T=KK7^7AL_M'I[?'5/9?==(FQ-][@P>3W=L?!;'.R=SXO<D$<&]
M<7)F,GC]XUT6)S9?!+FDK**2)F:\DC$EKD\7@64[)L+W$8\,K*'99';Q!X94
M%551&Z,$9-+:]1!.:=$U_P"Z&WWKGQ]E26\C "DRM''&*>(*Q(HU-I#-J:0!
M0 0OGT=J+IOJS:N^</N!N\5K\E+G\#N:;:TD>$JL=%A]HU5/0/EJ#!OE(CB-
MNIDJ=Y,CF0E0TM?.TC2EB% =Y8Y#V#DNSNOW'L?@Z=7B3R%GF\W\-IF%0H [
M8ET*%4 J=->@A>\Y2[Y-96837+/1(T1V;6SMH4@4SJ9E4>3$BG'H?CUETIWI
M'M3O3:%6T&8W!@Z/*[1[DZPRE1M7<N<VMEH8ZFB2;.XHQINC;N0I&5HZ?(PU
M< 1]:*K$-[.X+E)(HY8:-"X!'H0>! /K7I!?0W^TWEYM5_ 8[J"1HY(V-=+H
M2K*?1E8$$ X(ITY;EV5TA3]?9CI??-#ALSLK.XNHIMR;1S$$V07-464D:KGE
MR-#C(%T29&JI&E3P1P S(?"JL+>U,%]<VMU%>V\S)=(:JPX@C_#^=:C!Z0O*
M\C^(Q[N@UZ>Z/^*'166P\_5WQPVYU)D=Z9$TN)W'2=8T^+R&6RM''6U-)3Y#
M*K%7[APM3-1-4S4W\3%'J3R $.2A0[BEONK6+;E:13M;W+7$)>-&\*=U*--'
MV_IRLA*%UHV@E:T-.BN[VG:[^YVZ\OMLMY[RS=G@>2-'>!F72SQ,P)C=E[2R
M$$K@FG22WKV'U5UOWMC-T[EPF5H<'NW=6W]C0]D0X/'4>W8.Q!75.,2FK]T_
MQ66ORRY*O>EQ\U/]G!#1O0ZUED,LJA_Q5\)8O,,36OKP%*4%,FM:FM#PZ,*
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MF=O;KQCR,:ZCD198W9=8'E7VLMKV>^EL;&^V66TAN"0Q!\62..E4D"+\8<T
M4$D5J<=*&46MN^X_4I(8\T'PD^8+BM*>9IT7G?>U^Y\9E]G2;ZV;6=3]B]F[
MB[#RABW=MW<.$W]O6@['QE+2O]YM7+8RE,FUZ#&X1,3CIZ&F5ZR?):M0DY26
MI]@VC:X;6PM=UN[W>#&#X"6A333^*5Y/#)!K71J"T.HCR#\5_%N'BWB2PBS#
M4+APW$>8&0>  .6J".ARZ=SV.VUU[MK8@P>]J?L^AH-UXK 4U%38[/;5K]Y]
M@U51B\]-40I+DLMC*S8U!22XZGAQL,\L]:K5'[)G8I&MWN>^7!NC;\M-+L(D
M,GB^.BLLB$!HY(V[B-7;5"0N: UZ%FW;?]%N%E!'=H-[<>%X7A&74L@(!B*A
M@S$&H(H3QJ*= !LC8NP-P8[+XO9?8[[@[>P\$;[7ZKK]K5N&PVZ8,=/41[DA
MK^R*FO%-M'<6W\=#'4)2U5"RSU#-3F16TL6+KG6_L+.\NMTV-([2-HE[)2[!
MI"06-$":%IP5F<XP.F1M%O'X#VE\LDQ$@ :B*&CH&1B265A49(P<=-^W=L5$
MN'W3D-N[*CJ\7MIJNLJYVW1156,R=-0"#*[RRG\3G\%<U;M_%9$5]4TD=A"T
M<2%W*QB]GS!<-]*MKL<K"632!4UJ5+5';D:NTT)R3PTGIP6 =78RHJ!PH;4*
M,YRP!K6JJ=1J . !KT>;XL]:=E?,3?/47QQ?(8G%[(Z;RN;W9M3&)L2+(9I:
MC=FX*#'Y#;/9^<P>57^/4.[S*@II:UHJ7'(RL^K3J]E?-G-5KLNQ;;O;[=&\
MEPX CU&/@&:1F>E6 48!7C2GD>@:;ZY.];E8+-)$;:6J,&.3\(4K72-6HF@\
M\FII3>4^)G0,/Q7[.^+_ $#6;S_C^P.@NA>T#D-_9K;DNT-Q;BW%O>KIL-AL
M#EE6IR=(TFW,5-5TM,M'.9JCQQNITA4(2VGG+][W]QMG[N2$2/KC*OJJ(X@6
M#*0,KJI7@P (P:=1MSS>S;QL=C?7183HGAD%]0*F2BM$132&IJ91E69N'5E^
MY=V==T8@J]O[3WYN.+;F*KXFW)M_&[EJ,1C\=5M'59A:..NRN*7=>7IZ:$5%
M2E#!D*F"G#@6-XV%<2A@P--&K410#/R]/3'451!]2/KR%TBIJ=/#/K]I-?GU
M3'WG\:OC]N+>%-N3;>.WGF\UW3G<CNW9\U1V5GMJ[4HL/B7IZRFRSTNXL-65
ME'%&E0BXZDFA^[1I6FD:,6N3[U8[ZDB31;E"_P!0[!%^F4-&*5HTAE[CY551
M7B13H4<J6;WFXWA@N%MW@BI(SG7K5NW0(Z493Q()ICUI1YW5O[JGX>4M3\OG
MZR^0'9E=5=;[@ZYSN/Z^F/:%=MC:-,T&XLQ5;RJ:V>AQ& ZSPV2VHHJ\O.9U
M1Y@Q!UD*:[#;7D;O?378EBN(Q5#&JL'%!5G#-P *TI2E#7 Z;NK-TO;S:F:,
M2P2&K!NQAQ&@4'Q5! X^70:=<?)7XS[GZH3Y.R_'SY _'OJG/[BP'^F):#;F
M7P'5.[LAF6A&*SVTNN:.GR\78\V3W9+3XRCKZ/&X63*5):2*5WCC8B4WLL4;
M.L!\0#R-3CAI8>1'[!BG3@VZY+) +J(L^%JP!SCN8_"/4Y'ET:''[OS6Q<;N
M7 8KK#:]+MRFK\E75B[PW5G\?D,?1[FFK*]L?N7 5.!J),%DZBDJVAEHJJ25
MXJI9(;R-'<R#8<M<L2VL=X=YGB,1\1_T5I'))&I9U=Y?@*D#70*1PIGH-W&]
MW'B;=']*9[B\4K"L15VE$<C1! J5/B!U-(Z:])1B*,.@?[MV-5]VUFR-GP?'
M+!5&_MX[@@Q<N3V>ZY2?$;>Q&$2JH][[O_B%/@,5MS;.R::".LQDU=#-39"N
M1:2."H(T*7[_ +=8[3' UAN\\L@!+\;=A&X*E%D1CJ,U3&\9IJB+-6G2[8-Z
M2\D:1PJ6GBA*R@2()%(;4R4) A-'UTH)%"?%0=5T=C]E;;%%N/9>]]M)O.;
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MF;NDJ *:5\,,0"I).F@8G2U1UE/[8131<L;/%=R3"..>5T4%4TG55G[F7NJ
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MBK*P$&^^W99V%HDL$J23,ZS(=4RJ4=5C:0=K:=55U5D4H*]I%;R=E8C^8/\
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MS5N5QNON#S)>SWCW$\VLM(S,[R$P@59FJS%J4&HDT%.A-L=G%;>S6U6]K"$
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MR-- ])6*M6696EBCIP]QZ3D78Y;N"8QMX3GPY"DA*EC_ &A9.T-4B@K4"@(
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MS +J;54T 44  J0 W 'I/<S6(,;I:/\ 41:?#9B.Q17&,DL<$DU J14XZ?\
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M 8[LG%STF*W]MZAR];2XG<>7QV&S<-0<5_$@D511,LL;5,R/&KB0J3WN0*5
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M9&=1*-:GP#( 2J%BK$DEF*@'!Z6<K6T^]<R<J[#961GNKV\1$"L$#/1M-6)
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M0G,R1TT!IJ;'SSU_VKTL$(5="FF"*#'9B3[3W7).T)XGT/,.YR'Q,%G_ %
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M2[6P46TTSW1'8M U9*#2M G<&8T &:X^?1P-S:)O&D=$C3N9B=(55R6))
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M7Z]D&I6XQL'8!",B0% K*ZT%212J]%]V_P#"3:O>?9/8<71^[J>;I'KI.O\
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MJMRGK':]9N"GKXI!/7)+51@:6D6?!1Y'<E708VIIICQ)!'%?45&FY)%_TFR
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M_=&WXMK[*[)KM[;NV?NR)JO96?P$-3644,TO@IAH0R*SL$#U[N?+EJ8K=M]
MGG\30'8M))6A-7"XU$"FK2!GCQZ/-I@WBXE7<QLOB;?92PF9D33'#I:I(CJ
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MMKIX;Z.[8+&^$^G(=V=GTLRR*X *:&#*V*%2"5_#_P SO<E)3[WI=W?%+L[
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MN2H2IJ)Y 2HB\:B0J-WFQ;^JW*H?#MSQ8.68+44(HV3Y$4(()'2 \P;?-:-
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M^I2KAJ$*!V@%:-5B9F6.=]VLK:PC!61D,32,Z>&K:2L9PQ*NID,A(U%@""*
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MXI\&CRU(=0.JM!TDVO9OHM^L+">Z,5E-%(NMRBQ@QA& P2-+ TR0U> Z,_\
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MQ^*V?ALQ3MDV;"5SR[I%7DL555S/C5P^V63[G1(SSU/^3T<A&L^R#FOE;?\
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M&R\Y74?>.T,;78O9N6I-X[^IL/OC ]NSY'%8;+4V$JJG9IR%9,U'C:D97[=
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MZC"YO'M%E=F;YJS6R9O'QU.VS2XBKV[-CF*1TE6K9..2/S<1/<E-G?7US'+
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MIZ\UU(J/4R4RSK[7S[197,%S;;CN\8ADAG0QJ"P<KV^&Q[=*S9T.I/:*T!(
M2Q<P6R[6MK#RDCWKNA^IED=)$BE%04C#%2\-#K4Y.HCBM>ESN3LNBQW<>[Z
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M-5DMD8#'X;-5N&DR^U*"&B9VR--!+CW$4I)72R38;3G!]^-UN=T+G982_C
M*I0M57K2HDX:5U'#$-7!Z+KR2UAM=1ET3O\ #4@'AD#-#G\1QT8/&]A'*Y(8
M/']O;.K<N^!J<]32455]UA7IZ?+G!5HGS2X\8@+2YF,PI *G[[]1:-D75[D%
M[S8$E\/Z5J?$03G0#IU#N.2W:WX0V 0<=,?0;FEO]4\<@@$@C)/:0Y3Q *$
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M#%*T3QO42+O'O-R]S*W-VTV'L[LJ+-:RVT:%XPMHTT+)!+$%LU5I("5=G#5
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MD--'*IADL6!W[HL(GN$9)5G,FM0>"L"&44J#I#C@"*BH/0?.]SO%;PQ2(\(
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MR ^UKWU@[Q_4;<M2,D@4)(!)>GSKE@:&OK7KT=CNNF58Y6)9@:FA(K5AI/$
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M>Y(TI,U1Y6FCIDK9'$<T\(ETL[U<[M]?8;E>;@MTT-S'+/$%\-E(K&!H4T
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M5TD8>A:EI6D$E,L$ZMJ@E5Y>VW9[\VVR&TL(OW4+*BQ,NI$8%M(!*DL":/4
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M!F\?N*BKMX[&FI ,%1U#R4E0!!YI'A#ASODBWNOZY[:]](["XV5YI:L[1ZQ
MC,5U$**@AG8 ,K:B #TSS%93+R_*8[21+9=R586$>@NI=M"AP,A\A4U$,M!G
MCT>79/?'9^[-A4/>/??5VQ(>[<AG-A=&9O?'66^-KCI?=-!M:6U-3[Y^/^.6
M1L3V540355-6-2)%BIJR>G2FE2GIC @VYB_<<RM-;R&9?$0BJH0M0&:-BO<R
MLA!4L8S2A*C30JN4[3>8IHK&XM_"C,<OQF0N]&*J\3M^FOAN*,JJY/<-1#5
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M!KC"2@&JZ6:@-1G62JDM4YJ*2%NV^[5?/<^WUS;2;7N-I>R/-N7UES+:O%&
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MWM9S7N-WM,G+>]-+O$L@1$,DD4ZSEJ*B/J*LQ)4(RMW.U 13H!MG]@[*[_\
MDSWYL:DI)*/9W7W7?1/:=%L7!;GS.S,33;LVSN3>TF(K]WSX23%T\6,S<0D&
M8I0&ILAC4IVJM<*K[*KN>T7<]N;=(V3;)45SI.HF*H*R:$XZ3@1YJ !E>E*V
M/,&Q6.XW>U[AXN]Q:XVED2A$\B21S0UFU,68(Q:<A7#$E0L@'0K;HRO7&XYI
M=\;SS&VL%D<+MFK[B_TDT>1S&1VC!1XJ2IPG]\AG-M9:KP>_]KT1J"D>/2*1
M%J?&KQ^1E 42<X;-:[MX4D'^(,KNQECH5$2@PM&FDL'+DJP;47!  JO139<G
M<SWW+H-I?%IBT=O&D<@;6]RQ%Q%*6-0OA .KC08]))8!CTR96AJMZX3:^]ME
M9K=E%B9\[7;>QS]EPXOK':N[H,A0TDJ[FK8,E6XK<N#DP+"]&J>>>82,4@8^
M@@W=-_YFWF2.XVU([/:H[PT+01PNL=!_:EF[Q'D_"&>H% 0>A=LO)/+&RR75
MKO=TNY7TFW%BL4LLX$H)H(C$K*K28XL!& <D4/054GRWQ.P*['[$H<OA,+VO
MOC^\U-L9J['P];[;WA-M/>DVU,]B-U?(#-;;R^WGS> SZQO2[3@>ERTF,G65
M$FED14F6^LT-RUU'"I@\- -(4,Q*U!T"E W&HP#4$CJ+^7(;AMG(E9VTSR53
M66HP/H3G3D:O\_3;WE59KL[9:X7<F"VMD]^;KKMOU?96T>Y-J]:8;L=OC]M_
M<*T&Z^QNO<C!MZHW;G6VINR;%P8_$U;4$D<=<SN4?2KFFT1R)<6K.K+;%Z%0
MQ*:BN 0.QJ@5J1^'/1M<0%87G\/@O$5P3D#_  \//JE]NI^P]N=R;-RV8['W
M-0=@=B=PYW$9[X]T^1V5N7H>MV;%E*FNQ\^,P5922;BI\K0=;TR35!D5LI)D
MZN2I2I"))<F3?;A^9/H!;*+<7!C'91@O  +2@4TU"@H%SY]#K^K#/RK)ODF[
M3-<^#XIK.61C0=S.Q+%U6B@$EB>T86G1H]EX38>.[/VHF6Z8Z&[*I>N<K6TE
M%1=I4>S\''55NZ]QM*NZ),U7;4S<V^]R8,5C)!15Q<F)E96"QG23;])>/SIO
M=K%N4T-M#;1LB([A =()&E755#>;4IG(Z"6P[;)/]=>(IDD=@6+.:A:4+ L?
M*GEGH7MW9+8&+R/R#H^K^C.G>IZK#;LV//AZS;LG7F"QV.QN.R-)4;\[%QV]
M=H[??,;$QU3BQ4S5^(@_RB01,J(T<PN&H8]TEYH&W0[A)*]S8B5D>21X@T<H
M?(=B"534=2_T1Y'HRBMK;;^8-OFW*26&R-O.:QJ)&=O";P0%!  DDHK$Y4#4
MP) Z)9+_ #(.ENV=Y_(+IO;]#CX<EM#:%93P4&7DAVSVQFL=5];Y'*+N79@K
M*::;-?Q/>5?BX=OQJ::H3'3C(2!+.B2H)YIYXIY&IR[/*$@EUD&0DLCE<E=:
MR  @96C$DBG5KFPCM8DDUD;S&FN6$H&45*LBL5/P^$2[$U4DK&*$GI";&QQW
MVM=VQ78;KSH['[\Q>Y]U[1J,SW1B=RT79F4HMH4>(BVM11;DGCQ$-=4UNV*Z
MJHH<;-$U7EVCA^WU&:YG8\C[:E]OUI[A;KN4<T$M8X[*0LAD KX*2U+$ ^%2
M4J(]+3!ZMHZ++KF&:V"-R^R3[6SA5></&Z1EETR-"A(5A^H&BU'BC=H!/0F5
MGRJPE5T/N[!9'8.'VA54>V<'G]CYG%XG%PU0K:)8UK(=TM48^3(P;BK:/(D:
M::9,?'61.U0IB"L!I[>\IVO+6^;1<?52RVJB0S132RRK5HV+:=;L"NO%6 -*
M4(Z%O(&]IN7-TMO/:*;?Z2X/< ZE$*$:E-:-2E"OJPJ!DIKN?O/:_4G6F\Y]
MM9;>.-W!L/=B+Y]Q;ES.1AW=LO?^VMJYCK3* 9++Y%Y\9AJZLK,>1.\4BR$J
M :<(P%FXQB:SYLV/9DM;.W,4;(3#$8TEN'\/4Q=&?2S%:J&"@\*9ZRAY2.U)
MOT%]S98))R[!#;-*8XXT=-4K+.(FTA=31E67!RM*@] -T=VAVGW3\Z.A\#U7
M\I=Y/UOG\-0;-W?E-V[5ZBQ/^A[<QV]GL]VCL;J?;FY=HU']^=O[!W#04%7B
MZMHZJ?*KYX1-/31N6A6[M=UV][C;Y[V1KFT!6012OX%4)C.E:Z/"UA@%*T'&
MG#K'7W 3E6/W(YYM.7X(+O;#NDQM9?#:,S1:OTG)**8Y6%*@"BM2A\^C%]M]
M]]V["Z8J=V;0[!V/G=G=;_+>DZ]Z\V?)U#M;<6/W72KU<V\.P-^[WR-=74-:
MF%RV[LG'#0X%S)BS35/@2$M3PZ2L['<;G/:Q6NXM9R(-:Z=0 T@J0$6@96#U
MT,0*@9K2@5NYH83,TEH991(5E?Q"S GRSBJT):127.:XXDZW[\G-_97=/8&\
ML32[=[4KNXJ[<.*WCM.;KS<^*HMH;'RM+@LD:OIK:.X((G;*5&5I:NE3'TE?
M#/24I22)K%58ZMN7FV_<K;=(=\EG52/$C* 1LM NMXPS%Q5264-4L.)%068+
MFVB%J;S:(I(HI X65B1+HR82X1?C#4U \".!Z$/>?<YIZVER>S^TNH(\@NPM
MO]E;HJ>P]A9:FSN,K,I1146U]E4.UQ*F2W4**H,E+G)ZJAAABR<<#%E%2H]K
M);QX-P^CWNQEB6>1C ,4\-4\0LY';%K4UB%<U -.G[R</(!MEHL:/73&J,RQ
MZF.B,R$"H QK(J0#6I'2TWCNCLSH#:O4?;/>>7VIV;U)VM2QX?KO:.T\=M/K
MJJVCV?E<I%6[GVANSLK)9"@PV[L%C]M459;)">7%4U33O"Y# EO3;<;R 3;=
MJ7PZ.Q$E-2,=(H2 6H::@!VBIR!E@22F>2&XN$%>%8_05K05 !%=.:L0.%>@
M^P_S8Z<SFZ=F=0[(ZAW=N#L/?=9DMJ8#;\-#MG"PIV//5UT^/SL68S&$J5QV
MS7Q@CJIJ.LDCFD4M4B9(@Q]ED^VWUK/=V=V:F)0 \-SXD<KL101/'2M <EM(
M!P>CBVVY;I;5[:^B'B!W(FA,1B2,$LTNJH4&G:!J,E>VOF(/<^9Z V9U9G\M
MDM@YO9OR)H3L+;V\]L9*#KG+S8/=F8SE74[YHMW;(R>T5R<.P,%MW&??S5TM
M;4-]OE(*ZC6148@;<J<M\V<T[7M]_M$7T6Q;@S6UM?2&1K&XOXW8-MKO VKQ
MV2,O'XJB.1SH0LP-2>>YV6#<Y]JFW5Y]U@4RRVJ@K<);Z%87*K)VF)78*VFK
M*H+$ $= MU+NK>U=EODIMK_0[UWE>D%VSL'-4&Z*/;M-BMVX#%8BIKLQN:#9
M.<V^U/692HW87J8ZF"-5D>DB!I"*A@Q!?,&_66P[KLUKN-RUNEU-)&A-1JD6
M@HVD'@2H[Z $^G1[R_R_N',.U[[<6"M+/8Q1R.BYJC,0:5(I0!G[:D@<*]%T
MWMO?KO:B5.U):6LV!VCA\76ULFT\W4Y[&9;,1+F:W$T8Q%3E,A54:5"04RS2
M:VC4TSQS%WU, )+:[OI88+F**2:SF4M&T?>QH.!C U!B=0 H:Z3C/1/<;?%#
M*83>QQW<<FB17.E5-31Q*249 H5F:HTZA0X)Z2GR7^-5?U3M/K#<./[@W1UC
MMOMWXM9_NW<NYLEG8L;@^Q]WYO?&+CDVGE8**.CPU(>O-HUD/W&-(FJLA+ID
MCCD"3.A-%:&:6ZN61!=1@Y4&K(AHP5:C0:Y! X^0/0@O9+5KJWBC2J2.BM).
M7?2TU"C/(Q<L%'Q$L:(*@D=;%7\KSXR4_P 5=@_'_MK!;AV_VIL'O/&R[[[V
MSVX,50YW)35FT=A97'[$RO5^;AQF0C@QU2,HE9G5JYR75 ('# *X>YFW"ZBN
M[&R@NF:!M0DULQ([0P55).C/QBM<?.G1;<Q[5<6?-4,T##=;<1K:&(KX+KXQ
M2>:1J*91(H!MF0%*,213(L@_F ?S$_CE\(NAZ[L7>.PNQ-TT>^H,KM+:F1ZF
MZFHMRT5+OO)4<U+A*+<&9KH\5B<+DA6&*HACJ6+S1J&C24V3V&IG'A:6+>&Y
M"XJ<G@2.''^?D>DW)7)NY<U74\EI>0Q_1@/('=A)X8R3&B@NXI525[5_$0,]
M?.^WE\H*_N*+;O<W;'9_9?:_RES.ZJ';V[</F*/$[=VC087:N%1-F;]I6VA@
M<1M_.;GR-:'I,A2GQU=52--5SR,8XS[-+_E*"YA6*[WR::\BKJ9SH(C-152@
M%6SH!8ZQQ->LG-EDLK!;:*'8U2SE) *\58*:+0U! H&-/PUH00.BN=M?++>^
MZ:CKNE[GV9LV1-K-21;7Q&R<%A-N[-AV_-E/O]W9G-38&)ZS?NX=P9=&+_>5
M$ZK&%"LFE4*26RELXVLHEDC*6[1H7+%CWZM88D^)QTAS1J8-!TIAW6UV^7;7
MNHHI%ENEEE"FJJBIH,<AT@AZC5H6H*T);53H\7QA^47QMVM@NRL_G<O0;8RV
M_P#!9S:&6I<+C8I<YA-KXB2HK,5G.K,.<;(VV\EA*.MEA&8I)QDY*L0/(I6'
M6H<A.XQ;ILR2^*+6"XC=G0D,O<">ZI#'3E05(#"AQCH8;E/L-SLV[7=G<1-?
MW5K<!(GRC! R@JF"%#,%<K1F&FO 4E_RD?CG3_*GY,5DV)W)D]T5N#VMD>X=
MW1]CRUO8.Z/X#0=RQX[:CX&BJU=\GN/=^VLM''E4@>NH0('>H EE@C4>66YV
MME?SWS#67D9V+J';4LC-">%%=D8AAD<=(7AU! V.YNMMNH!N;0AHU"HKR>&(
MG#!F34Q.D$"NDK4TU$T!ZWO_ .73W;N'(=.P;>_T%9SH#KO;8WYC,-NC?,6V
ML_5[J[/V%N;<>U]W; ZYZPPV1P6[*[P[<VE!N.GGQF-?$S)45%+3&=Z6:4D^
M\7\>\7HOHEB[5"@HJXSFA% ,FC5H010\.H'YCVF;8]UN+ R2MVAVU:O,XK6M
M010@U(-:@YZ2?\R'O;$[;^%?;66W7NW?O72YBBQ.V=@9/>V)P\U5WQEMPJ,G
M+LWKG:>U%AW#LW,UD.,9X,I10^"AIP_W$I8N8PMO>V+=;=.3"DMO'&S2*55E
M*#+*5(T\0#Z8IFM"IY.FD&^VA4,(M53F@% :$YS_ *4_;3'5*'\O7^9=FZ+;
M&(DPN/R6/H^R-^;CV5DZ;);LSF>QG4=;LS*[;K]M557E=W4E3@<IA-_;<W%6
M-D:M'CEPF4I-%/3RQSQO'A[NFX?N7>N8#MLZPWUS! \:-&HMHF8F- 2H*Q+(
M5-"0,C4U#UDO>V=CNVR;=/=;*9+?;_%,[VR!KN5'[JA*J9#&12@/<.T=;(%1
MN/K;>G86U(,-7TF[]][JVUMO-8.GZ]Z[PM5N?:F S!KJ9-U97L>?'5,.V\<*
MB.<8T1UADKXJ>0\J]_>37+W,%[L.Q6?+UG:*=_\ K29OT1-"%D",P)U*M'/<
MCZLA-17.,5]MVFS]Q;:XY]AW5K3E"2V=8/$F:*9Y(6*.OA5UE@PTR1:: NH#
M&@! ;.[EV=T0U-NON&+:N[MGG<M=B=R9VOPNT]W]A;NKZ2CFHZ/+=AT-)3;C
M2ES><EKZ>)Y)G:I:G2626)8X02,>1)=V_=O,2\P744ES')J0,$_33NJ=2DL@
M<_ K,*4[B 2>GN=]GVR;?.1[#EBWFMX[U$CD=3-I:9B@TJC!?$,8-695.IFT
MJ": CECOF_T'@MMU&;K)-R[;V-BJ[$8*@J]L4U2,9)F):G'X'+4-'A<#'Y<1
M2;2S=;'C)Y#3F%:P0QK(IE10=KS%9,?I[>S*W!CUJKH@U1 @54Y!U#4XR"R!
MB!7B]O/M%S5R_?-9;Y?PI>QN5F&MV:%]+&,2<</I5>S4(V=0Q !('K/;OZTW
M]\9LU1;:S6-V+C]X5^<V[14.2DP^TLUE\W0;I,FZ\71TT%,(JW<N=\-3JFHH
MJB:62H\ZLTAU^RGF"29MLW"YL!24PEUTBNFHJ33-",DJ>' TZ2<N[?\ 1;_M
MVV[H\<H6<(Q#$(]?A[NTZ22%+8)H>F?XZ]0;5Z@HM[9?"4=-E=I)NC'':&$W
M#/2;NW3UW')M^CAWQ2Q[FJL8VY$DS^2JUJCCI9C' LA\02*2Q*.7I+R^VMY+
MB#Q()):'5I.J,$5PJ ,%D4T!%,5KBI,N9IWM;E-L3<7,<8ULB-((1,=0#JC2
M,JNT3 ,ZT8J<\:=+3>,.9W538W-XG9&UL16R8'=L57CZS$;9R^ZD3$RY:.EI
M=KYZ6D%)3G,5;0U$YE9Z=(%:P$A9C[:I-UO+2VNI=J3;YDGE2:"JR,/#+(OA
MRH A#]CZLC1V@UKT'-Z22VF>';MS-S 8D8. R%M2ZM(5C561B00WH2!GI!;[
MCH:;$X.BW%M/!8/-;YV]NW<NX]Q]:X7:V+S6Y9,!DZ8X#"4.1R='.^2JL5@'
MAJZP%GED^V'@ X"B6%2160 OGR\J_GY=(+<W*(K324N Q-4)7@3I((-00M,U
MX] M\2=T;=^1O2&XZ?M+:VPLNW3G<T^V*K<S[>VM68O*;.P.-QG8>*FG>''&
MA6KP^W\RD.015%JB!R06))-=LEBLI[JX\)2? DI@?$RZ >''.#Q'D>F-Q-S)
M"B17,JLTB@E78-IK5JD$$CB2"<^?2%RW?OP?VY2[-[SW=N&AQG0/R#S.\=F=
M<[XFZ9R%-L'= HZ#'S;>J,A1';KUN&V[@Y::JAP&<CQ]-!7)+4_<3>)T=R6R
M7>K+F6XNI9)6@B52RL"5)JI"G548!P1\53Q*FAWNDFUW'+.W6EF?"G<-\#T
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M2,?=U;HR21F1GA[W7L]TV*]6_P!PO9$O28&MX!%&YAD,199?$#_J!HFKH84
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M:!V 9&IIZ$QW"X,@W:UBE:9BPC&I5<M( %2M'4&II0"AH-+"M>EWM+Y9?';
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MZV[;E#S+MZ7NWTC_ '?"(0TQE+0ZI"NH@?$I)4*6:FD#4>K??D!UXFX_C?\
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MR.*Z@HBBRT!OXC4T).IF!#&M::<:<9(QT#>>[1VK@]TUG8F+V9VE-6Y'"O\
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M*Y1R)%- 22OM$2;A;7DNXF=HSX(:B*52*A#+I U:ZG!K0BBGH\7:?8F!WO\
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M[4QN"T9G<.+PU%BY9/X5!-*U/(T<B11U!,C ;<KMTVNVLH9(ZRD-*L*.0TE
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M;/@=RRH8\[L:K^V\,%:%CBG1!%I4J4 K6?EC90O+MAS-'<[? JQQLS"WGE3
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M,"^:1'4A2,M0T+ MBAQJ-.*V.[D:"*WNKA?I8R^FJ(&K+ASK #$BF [%5SI
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M.U]N8KK;,;WR.T'RM?B:ZGR>*CQ?EI:NBKHIL1')!4)692I@I(YQ,[71%O[
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M3MS>C]7;\QV;VAB=X;':BWAV"VS=R=EY!8.OMMYG<.U-GUV(JZ_>%.U-4K'
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M*.DPM-D(*;>U+(,C/&V3J7G>*=Q'&![%]EM&[P>"+ZZ,L"3 QJQ+T7!-&-2
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M4KR#LT5HMD+EW5S4UJJHWEX07X%'=@Y-0<9ZM^]!&+J9; B^J-!#J5*"I82
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MXZKS>"I.M<MLN)L[EJ3*R9*OFILY!%4S3U53]_4222Q,Q@8!1/'8[=&Q\&!
MG@M%4$AF5FU,I;C1L5([B,:J8Z@R/?-W-G")[EEG,JR:"$* +$$6B%=/:U:<
M &JP6O=TZ]3]RX+;TBYC>(J9XZ#&X$8:GP>XDQ*U62V8^/2EI\K@JBMHZ7<2
M9''S5;U*416NEB$Z1JI*M[VNR<M[E<75MN^U+(K6KM "*0/=+5E\5N <*&:,
M-V-($2G=T_:;O*PGEO;FL\(5A++(H/AC!AA#$%Y,59:?V>HUJ:]-V\.Z<=NO
M?.5SF VMLC>."J=K[EVANNKH\-3[<P=5%OVGEDR61V+1YVEJ]S4NU:>7[B:&
M*MDAR<4LHIA-(D84I9K#;[%'9+!&,VKPR KL*41?%  0.,&J^8U+2I'3PNWW
M,Q-:"*2U"LLYJL(D$E"_@(1XFC3K5PS9U:*, *2NB*BC[J[/P'31VE@I\=F/
MDCLC>F)V_O;+QY#9N#Z@Z^V%F,73=<5=7GI#O%Z+!;7\28ZC284SA1"4538$
M-_LUU!<2ZKTB46QB)H0P=M)#"F %/%::O3!Z5;3?[="UQMAV>(;4-Y2Z2WHG
MA);QPZ3;D$:ZB@=1\))HV.)T_P"755[2J5Q6/VA7=A=/KU_\@>[]X97OBKWI
MO:@ZUR&Q,Y2[3V[L/"TG7>S,O483;O8'7<]-59&NRT,;5$U%7QTB231)P]-:
M&5(;665)+AM6.  4UU'T!(^TGJ N?IC"9[J.RU6SROIT(E$#3/AC6K,JZ4TZ
M0HH3J);&^-D>P^L?CU\F*BAK>X=V[1ZLZSZWS>ZMS8_)[XW'4T6Y]]3U.SJR
M"#)U>2FR&=S&S-J8;*Y#(0X02O1T4-3)XXTA2.*,DO"8K6]FC+ET4T )/H#4
M9JHK^+A^?47/$7\!)HH5DGBU:S&% 0$T (PLA(%=(\Z'S/5(G\Q<;%['RVYM
M[1UG76Z-C]H4^Y<IMSM=-OP9JBQIR$6<SV5R-!ON.H,]2:FNIJ2C'CEA:@J*
M1KE7* 8K;]J',6[W%X9!.KL22V%.H: /E0U)XTX<.LW^2HMD7V\VAMONK;Z,
MPJ-31@=NEO&:1ABH88_A\ZUQ7_V!\VN^,MW;U+V%6[C[%BZ+V]N_KZD[#SD&
M/QN]MY;@H>LNM:O<4<W5]31))DL5V-B=M[:RM;%DDDIZR%JB-JV2ZO(37E3=
M);BVGWVPN[B.43S0,0Q0D1@HVM6[98CK+KY%@K9*@");L2V^K966![/2[!2B
ML2LA#L RC4"P055F[02!I#$];=?QA^8>6[1[2Z^Z^FHMVY.N[)VAVGOG [BS
M%5A8,1!MSKJHVF^#P=9&T"UU-NG=6%W_ $U?#4PWD%(C--'(@#B5.196OI99
M[W5)?I>LA=V:JJ$+JH3X:?%F@XT!(H!"G..WQ[8SVUO%X=KIK'I&'5B!J+U[
M@*"@R-5>&>C?[L^8'176F]*W8G8F^8-M[XBKL/AAM6K_ (QDLQ-)D,=CZZCR
M46)P^'K$BQ5>V32..L!,<\B/;2$($Q0;?N$X5Q9N(W+>&W$2!14Z2*@'C56*
MD4J<$$QNLX"WDERO@Q1%J$T.M% )=56I .: @-VD4X=*KM?M^3;/54?8VWJ&
MLR*#,T--38N:GKL?45\Z9&2%*=VJX*:6EI*J:D,9DDB\>AP_J3ZE.TW]AOEO
M#>;;<^)9N6 ?1(F58JW;*B/A@1E:&E5)!!*7;]WVW=K&+=-IN3<;?(#I?1)%
MJH2I[941Q1@1E0&XBH(/2*WC_IBW3USF=V]/939NR-[;ZIMO/45._%S=7A,#
M682MCG60OM]%JY*C*8&48UJA4T0S00S^*5"\7OVX[?N&Y6MUM^U[HUG?,"$G
M6))BA4UU"*0JC5 X%A3B*D4Z.+*YVZTN;>ZW;;/K-N4U>#QG@U^E)H@SH5-#
M4 UI0T!KU6?@_B_WAD=^=CYW.[8^(.QNQ]Z[=WQ)O;L7&XO-[FP^],_N2HDK
M=FYX[=VUB=E[GWWBQE9\Q7;JQKY6@CBR-0(==52.K1A67DWF2^N+[;AS7(+1
M# ZRO;1R2/J(-QHUZ((79$\*HB(0L)4#'M)_?[SR]+MVPW2[.PN-,\<B"8+A
M&U0:V",[(/$J"#J9%,;,IHP7&)^7?;?6,.?Z;KX>K\UO/H+:5)#N!NM]A;IV
M]MG?U)C*"-J_-;6V?'55C==XW#4C+4S4.NNC@T"&-S _D]G=I>-M7TNPO<&>
MZBD$-72-&)"%F8Z"$"KJ55I\85G(4D 2EM7W?(N:H/;[>+"_AB;FJ#Q8!),8
MH(IC<- MNTKHQ9F$32,Q"F(RQQE"::A!ZL^;F]NVNW,!UIN+K/$P;0WCL3MY
MLA4;7W15UHJ:#:0R+4.2I9,MB<>HK]TI204]-3RU$*(U5-J9S$&)K;7UM=_4
M6]Y>+;:'"L7%(U#!07+#("%M)'X@:C..@I[A>S?-7M%:[=NNY;4#>R7/A0K'
M*LDOB1Q?4-&0"(PS#1(M>Y2&4\"Y7_;O5W7.8ZYQFRNS-M;,R_4.R?XGF\AL
MNJV!_I1>BP^S-BUPQ&4VYC\I%E*5=TXS<-&U%+BZ*ED6N2/[5H'C,S%6^[<O
MPQ20P(UTB18[_$CU0RE74:,,- T>&6#JQ8X(H(HEW_FG;9MPWB?=IK6ZG5WE
M,",DSQ21F5J\6,AEJXTK1P %J*L:GML;1PF;_F"=7X+*;JWUUKB)\[@>I]Q'
M/[M[*Q:]^;APW7%7D\MN3KV@P>9-#UKMO?F*%$]%AZ8T,&-J\2\@BI)1&H2W
MBVFX[A<75E D=K02!%) B5N$2D]U4!I2IH/Q'HQL+Z[6QL%N5DN)I8%<SNB5
MD+#5J<?Q,35R0"23C'5I7QK[IZQV9E/D+O;?7>*8+KWKRHQTN-P^\]Y4N%VO
MU]UC28' 4<V]\[2US4-/6Y#?6\YWOE*@2U-97B1(R&:19$]JG<&0LVH9%:J*
M9'R#&OEQ J?7I9?U'C6[*BO%+3X:.QI0@$]Q10, T Q2M<3=KX;XR9_N'9';
M-/DME8?</8W=5?N/JSLBJI8=J[\[,S-7M6NSPV+BLODJO&9W*8.MP.0UBB:F
M9:VA$*D&/P!PM:V.Z+S=?>)'(MK&Y=C4E &C 4&AI4U#*!4BA)'0JW&]VX<I
M[6$N5-Q+:JHB% :K,:R5*:FJ5?40P4 JH^7>6_F"?$FHW?O/;&U-\-N:NZ[W
M%N2/Y"U;IN7:&,Z4VUM2>KQVZ]WUTV<VQ%/NF''[CB@HDHL-]VDTDQE+QHMY
M)?W^WYDY67E\;SM<D27ML)[>K(VNUI07'9(P$52%!:C5-*8- )M/*4^Z+O4[
M7"PM A;2U TC,00B"E#VDNQ)"J *FK =<,]_,G^'^&CG79.[:GL'-I@]L[OK
MMN083<VU\K#LS=\-<^U]PXN?=FV</CJZBS$M&5%,M0)X05:6.-1P2;CNZ[7M
M-GO>Z7+IL\U\;*.5*2J;E31T<!ZH(O\ 192-"#))%3T_9>U?,7,U[=;1'LX%
MU;;>^X.L[K;TM44'Q(]0)=G!_2A0:Y""%6N.D16?S0.J(Z**OH^K-RYBBKMO
MU>XJ2EH=U[.;-5U#3Q5EL6F K,A1Y+^]55)CZF&/$Z#6LT=PA1U8D-KSQM\]
MT(Q+,EN)67Q3].% CF$+2D&X!\'60RR"H:.D@[<AB_\ 9;Z*V[UB:]8*!"([
MMM;/$TH02+;E ^A2"'*@-V5U=I-OTEV#NG&4^<DWUD=V;HI^Q-S578O7<=7@
M<7CY-H=?[IQVWZC;^PZ>*AK$,^,VDE28ON:B..J>;[@2H&BNRF(3"2\,T[2%
MIG96-*%&RND^:TX-^+CT;;Q)MS)LL>W6,%NL-C%#*L;,VJ:(%))7U 4>0C4R
MBH7MTFA '__1VC<;_*^^,L6S.\,+1;L[>BH?E%GL3NGN'<%1VW(NZ]U0P9W-
M;V_NL,XU&)<5M;+YK<LL^3H*=5-=''%#*YIT,3'T>@+06\@) \G^RO&H/$5!
M&"1Y] F>\YB-R@1[=O#+</#SG&.! (R"&R*U!'1./D#\>_A/_+OZT>@W8W86
MZ.JNQ:/>&-I,%V#NO*=O=;[<SV6FV_49BGR'5E)%C*O,8/?>1QM!)F(J6MI/
M*U LI(<NQ*=TALA+8?4[-+/"I8N@E:)W5=-%1F#*":DU- *>9/0UY+WO<HHM
M\CW+=88EN$B0:(@W:6<N2Z,"C+12O8VJI&*='-VW\.?B[VKNW$=MUO7N[.L-
M];KV;L.@W;1;(WY48+;&42FQ^.S6S\Y-@Z>JK8JO*U.#QE'&9@164U!'##,2
M8V8!VYBM-VW>\@\!Q% 2VIW"FC#1&=.=3%444K05R":@299^XG,FP\L<S;##
M>02VF\F!IF>$R2Z;9B5\.0T$(!PY5:N%IJTA:V$]/]OX+N38R[]PV+W!MBA;
M+;FQ=1AMY8X8+<6/_NUG\I@7K<IC9)9124F53%&MI'ULDM%-'*&LW!E:W NH
M%G6-E4DT#"AP2,CRK2OV$= S?=G?8=VGVA[N&XFC6,EX6UQMXD:R=CCX@NK0
M30=RL*8Z+5V]UKUY\CM_8'>^RM_9_/9CJZ@K]IY=^G.VMIT]#2U>5K,?F?[N
M[WPH3*QU%<L,<553+.8G@1S(BW*M[/=JCM0[7,VXNC(:>'0M&<5U, &&H''D
M:8K0]$VXF_V<Q)-M[0R3I4,Z%'9:T 4L 2M03BHU"OEUBE^-]2VPZW8+9K?]
M7BH]VQ;\QN\ZGL&"JWQB,[C<W1Y:*GH<_2R4U;_!8ZNB5)Z"X2IQZ243/&).
M M=\D<HP[G<\UP;A?Q[JD4A5#)));HY1N]8F&JOD$$BH&(;3@].S\T;M?3K]
M2\#,T:14"1J"BKI4,J@(S4RS%=3, 2=6>F#&]787Y%;GJ)NU-_TFZDIYY()-
MEXW 4.&V+N>':F7\DFXJ/;]?+79J3=>U\]X8HLG/.PB@9H1'-':3V1<LWO,=
MTA_>5TAB#@J_A(@G1D!_24.SJ%)&IF_%5 #0MU>D/AN50DJ2I(J-+5\Q\Z&@
M\^/ETD>[-B_!6CW;N:E[6P57F=TY_9>[]G9"H.0RJUFV]IA(Y-UXRCH:7+8R
M+%0Y"6-<G%.],T3RNLT3E?3[/KJY@2["W%3*8R4TBA"CCY]QU D8QT;;9-?Q
M0R):7\,<?B+J1F&2P!!(TDT*D5R,=%8/2WP&VRF-F2K^1&7P-!5XH0S4N^,C
MEJ'=?W-9!73T6:I'@@2M6OA"_<QAQ/4Q:D<JP'LF'[G%V)KB!PR@FCD::Z2H
M8BHRE>PUH#Y$8ZDC:N<>=]HV#F+9]NN]NCBW6/PY)@ +E(C02Q12#^S6<!5F
M%"6"K0J17I4;5W?\5\UMJ#'9;9>;I^N]O186CVHNRZW[BIR6XZ$Y$;B%,K5E
M1D\])@ZG%Q5=)#/4!Z?'TKRP"2.(W%>W[MN"65S9K;+H9$+M10^E.[66J*DL
M033)/IPZC&?8Y!+9WBST[W5,L5+,H!4 *>[00#7 K^?2MZ\^,_Q[[_WQU9\N
MZ'";\R.Z>@Z[.8/%G<?8$^WNO]L[WVCD,A6[FRR[/)BQF:P=9F<LV46N^[,$
MM130F5-,)7V;6%W#?0"[O[DI=5II5<%:8(9:Z3FA!%:''ET'MRMY["Y6QAC5
MX6"D#!.<TSYC'E0''3;2_P OSXR_&G=6X_F3NC,=Q4>9P^.WANKL7?.Z>^LC
MNW';VHMV>2#,XK?&/;$R46Y-N[OJ:FED\4L;4E(R4[ 1+31E2[F5]G38]YEN
MY+BXM!$2R1PN\CH &8(D89V*T("**L!V\:=.[&FZS;KM]EMRP1W;2*J&25(D
M5CVJ7D=@J@UR['%:L>@#I.X=FYWMC>U6F_OC)V%\>\GDYTZYP$?55%B-\;4E
MHMKXK=FY]C[^WAB<EE:^K3:N!CR%?D:E,?-EIA4X^.EIIXZ@2&%+R^Y#CL)3
M-RGN,5_19JR073W$L3* 8DLHT<DL[QZ7+!B*@ :7TR4;#G>S7;KFWW]#XDLL
M&B.XC\*.2)NUOJ3(JA"NK@ JD$DY4D>NNNK_ (X?+WXC8G:N[NWL]OS9_=$&
M\=JQGJS&[AZ#V[NI)1+EI>O,'M++[>CSF%H\#3X[[</5T])-4>,SRQAW" [V
MN?E[;FV^WN(9K*_;<)+6&WFB:$M<K'XIC5*,I#1U<2AC&XKI8D$=)G;F:>QN
MY)9([J-K07,DJLDQ6"1](=I ^H$,-.@CQ%_$@J.J&?F=U?\ &[X1?#SM;/?'
MOHS<FV]\]/T&.CZ=W#VCN+(=@[CPTN:[5?9.8WINNBKVQ]-E=D5>(J:]*:I<
MBH0UL3JH"\1KNFS[4^[W6YRVU\)FF9-#R]NDG3J6(+H57 HIH6-17CU*G+'.
M&ZW-AM>P>!"EH="%EBI+@N1(TA?6$U)6H/G2F:BAO9'07RA[SV;4Y?![<[#W
M7O\ WG5X_=G6FV,)_!DCWOA\U0U]9O:>#-39^'=&+WB]%2QBCH):JFER%''X
MO&[,D;1'=\\;+ME]:[ -S@39X7>&>5B?$AG4JT290QO&U2'<*U#0!A0]9"0[
M3<*=U]QKW8[1-U,<<\5N8*V,ENR^%-/X'B:D= H8*6T@ZI"FDB@L=,;E3<6Q
M-W8;<76]/N/=&^.O:C;E?EX.Y8ML9>FK]X9:3KG=F-JMCY<5]55;XSE7#!3Q
M335%/5X*JC9I1)'*H A;;[<;@EW;;;KNSI,90_IA(UUU*JA!%*M0D"0FI/"A
MWM7O3[D;3R&/;3;-WLH^4-<SR(]JLEQ)).^IG>=I*EEJJ1]@$42*B@!35 ]N
M386CVM1; ZIP>9I*C%4>R/CA!LS>F_JON-*.DVKN/,YMMIP92GH,1ATI*&MS
M\]6*>9932>-G5I$NH>W^[W.]O+C<MWG@AMXX&?5$S),I(4LXEK0!M*QLBJ,
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M_9KJ/0M[T_EL]7;2S.R:QY]X5==N'1GM^Y;<O;"X^ISN8S68Q^+RU%29>I2
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MJU6W\MN7"8F44>->J2O-0!P*>544EO\ =-RBL-PW6UM#-S-/)*R0I0))X<:
MU&2@$:ZJ@U8X4:ZCI%8V%OO_ #?%M6[[M%%LQ\)KBY*.IC,I:I"L?U&\2@9L
M@:BY[>CY;&_E8;-ZHFVR=J]T2224,6-H\9UF>U,A25F]L%O#:&(R?8^/5:!*
MRKP. JZPP4%749>.):JEI(9ED"1%2]L.YOLVZ;)?V 3]Y>+',J-5T$VDT0ZC
M0$5;N6A-.[..@YO(M[_Z[8[[Q$MRTENKT(.@O34RJ-7>%4Z"33@/FI<%\/,%
MUQN_)]F1?$+*YK<M'E-O4&$GB^5%+,V>Q$#?QZLRVX-OU&(K<7DMOX^42O%3
MK*TU1:-@5B5Q[/>9IY>>;W;I.8+.$W%JS$-&?#=DXE78$AUSK ()Q04J>E'*
MMIOG)$&Z0\N7RI:WL?A/K#.JUQKC#!3&X^#!! .:@8@=B=&_'+M+O.#O_(=J
MT77W8_?VR*;HG#8['=IX+,[>W)C^K\,V2HUVW+DJ'"4^([ DQ:U-4%9XO/%&
M8(_N)O+$'[#EOE.46PWO;)7F21FC=;MTC!.%1U\.@(4U); )H5J!1*W,.]\M
M/N+6$@>_2*(N@@+:H&!K(F3J"R 1L(ZM1@Y;37IIW'U_TMTOC\)V">U<KNK?
M?5VQ]^=A=6]:5V?Q<E37P;?Q^/VV*C>NS<'4GS[0PM;5T,BP5)AJ3'#,T1D:
M.9D$/*O+WMOOF\[);D7%ELU]=1)<W$UTR)!%&SBK:XF"-(U8(U(.MY8FPN>A
M-]5S?O'-D>T\T16UO*LL2,\2=E)HUETP2*2JLMNI;51DC92DE6-.A3[IP>*Z
M>Z2ZV[PR@^QQVYMW;*K^RZ2.LS.9H&R78N!2OW!7;*QZKDLQ%DZO=B1M!%&\
M\#4H.F,,=9%?*/*_(>[\Y<U<H7"36.TV%M>R1SR7!ACBBM&J'NG;](1+$/U&
MHH#YK3'1SMFP;7O^_P"X64LS-*(KB6*0R'4K1DE/$8U !7XM(%&X#3CH#?N.
MO-UY?J7YTYGL'=%7O#H7:/9W9O1.)VUOW,=6;WW'2;F8XS/8BOPLU+48/<U+
MO&IP,,5&M:::-Z>19&]!+J8<_>W5ARMN,L5GS0+.SLI9;?3<1Q7%H7"(\Z^*
M"DUVBZPS^'&X2I"%QIJ%N8MDFL>9]TV5]N,D2RVGBS1S,?#$RJ4DU*GATTL6
M2@ <#!XGH-ZSX6_#[!_&>?YF]<[N[KV'V[\E*;JFHR^![*[-W+W=F8]];P[%
MW#O6G3=N!SN%P3BAI<QM*HDJ:MXF:CI'E:-FC$+28OM?WG,FP2F53'/=O^K&
M]11(YF*MK75I$JKXD2T!"%48*10+K&._Y;W];FVVEXKBV>1(A.8V-7K%0JCO
M&S-K2FAV_M%S4$!H^.7:U#\;NW]Z[[JNU9-][W[MW!GNS=\2XO,4G;&6I9L9
M1T^%J*S T^YEQ5!L/85;E*V/ SXNFIQ+E(:$.)UI("A46O+N^WTUMM]ONB6W
M@!2BE%HR:"2'<5\1F U#.!6@#$GHSO9TM+;=-WOK%GCEE97+*2R.CK&X1&96
MA\*=EC< 5K0U(ITP=J;CP5!O#/2;=VKL)-HUVWZ&NZ(V_79+-[OR65SF_:;(
M19?8>\5K^Q-O4&W]TPU5=J6&2#(4E/CIJ1 \AB(5>))=IBW'8!O$:+8SZ$@$
M0I)*VF1VH&(42.PH[ $:?GT[L<_+^^;A9W7,6[Q637T@-Q<NQ,@@8M$)!$J%
MI3&J#Q0I':X;B*=)S:E9UC001[D^2?3V_P#9VT<+N5-GT\&R-S2Y+L_<^>W%
M2P8;JK>FU.LUS40VU)M3<3UDE55/4S08B7'TE6VMI5 -EB&T3VL@WG7']'(T
M\OAM&(BK$&-F-2_B(05H!DF.E14AZ0K<VH%K;S_O&2Y6)+<E6)1U #>+BIUA
M@U0-"!7J:D";6?"[X[;MQ-3LWLFC[M[SQ6\:G';VV_O[$?(.#:F=AV9G*=:C
M:L;;LW!MK(YS?61I]$457704^.KYLI-602I)'%[*.6;?;=P7;MSO+:+;C?[L
M;&UTDRDAX_$:6YTL!%%1:C43DDCNZ/\ F6VOX$O=NVW=)-U7;]H%U>:U$)B$
M<H46]IK!>1M39"4U8&5/2)[2Z#_EP]PTG<>Y9L;\K)/D:_95%B-K]<8SNKL"
M&K[@SNX,EA=O[@R&"Q6*ZSJ=I93=J+0$SXN&JGK*EB9A/J*H%LV_[CM5QN/*
M#QSH=IN9H8HXF8I, P)EUH!H+UJBR]U *%E-0&+(?O.VV[<X WTMXBOJ."I8
M5H030D$4-#0?(] +@OBC\ OXGU/M? 5_;>XJ;,T.[=P=RY*#N[,Y#<6Q]Z8S
M^(4V"ZZKMKX?;5?412XC,X9F:KFGCJZ=QXVID\Z2 ><E7NU;_82V?-&Y3;=M
M:JSA)G="TC, 2\O>&4C^S6E#D@ #*H[+NQCN=RY>M8[K>H)4B2-0))3&X+/,
MB8 1"H61]0TL4'G7HP,WQ._E]UU!5[CW!O7M^IR5(V6%)DAWQO"LR.-R7V]7
M44GVCTVT9Y!E8ZB61(IU.I)Y)%U*?(OL1OL7M+K-O%S=2,"C SN!0_$'!C T
MGS4BG#'#I0J^[JW,=\.6YC=!PRR>"A/B5JKI)XIJRL:AP<&N>/05]H=)93Y%
MU?5F,W)N7:E'G.O.@:?M!<KV_O3/[(ZCVKB8:3^Y^+VCC,3LS&RYW=_:.YX<
M+55F0,U7XZ"@H_OY$+>-/<8;_;;!RO/-:[3;22M.S482DEHU>J4:BU!--!H*
M]'FW1;QS-=W8NKQ(XK>8EF=*CQ6!5R:5JU*Z_EDCI,=)/\+>O.@=B=F[NV#V
M=+LK*9WL/I3<NRL7W31U.Y^M^[=M5#U-)#+N'(Q86M["VMDLY4TE?3!5@EJ\
M-615#A/&S>UEK;W=Y/9[ER[M%Q>[K>,$= 2[JB@,:5( (4&E3]@--)#M\]S;
MQ2;+->6UO:6A9@S*J(230T84%&J&P,^?61-Q]?[(ZYI(_D3LGNV;*[R&Q,OL
MW ;6J\WM';^/P.4SV/;,T60PN6I<=C\M//MRDR%739F.HJ#')74"JGE+^T]E
MN.[I<7:7]E$")&1'  9G0592@R#IJ?0:32M>ELNSS^%'=6MQJMEA2249(C24
MA8V9J4 ,A5!7.IJ&E.DI4XGY.XKMS8O6.0BZSV/LG*9C<^7W9'F]IX7.[U78
M%3F*;*=1X7;9I0Z2;JS/7V7QE)+E\CXL;)G)7\SQO9'?VS=-QWJ&67;MPL6D
MEE:&U#AHC+.J:S"58UU>0)(7S)'2N[V#]T/MG[ZL[M( @FO'C4.(K9I-*SQT
M)!4(<DU.K(7RZN&^$7\N3=V8R'8O8'S+W!U[N+9>%H-M9WKZCV)!3]?[>PE%
M/D*L5/\ I*WA',V)WIDJN@K*2EKJ#&Z_X)D*9U=Y14+II/NVB_O]KWN=8T@A
MC;Q%5D1FD#B0*6^$1,E*RZ0X-5.0>@QO5E<RV6TW7+KFXFO+R>&.WT%KD+$
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M)G6GC97<J=NWKW.=TM;B';H)XI%#TM_%1@:U!<-J1R #HSH+>F>C2]V/VU2
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M\QFM!Z=%][)_E=](=RY7K+(;LQ?;5#+U!L;9NP>L,3MGO"LVICNK,3LJ-*C
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MVFCW[9F^NA=A&[21L61LEET'2I+$U1J,:5*Z>FI]^LVN8YX+Q2G:7&EAJ*X
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M>@HOM,52[@\$[TF5KG,5:V.98SY5CTJ:%MNBOY+]+@M(T?AM4N=2@E@&!J&
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M*BSXP-;%/2>:;[N>F<% R\>U-MNW+7,T5S:)(WAJU'UQ2H=49(*'4!P8$..
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M5D2JM(%*U*@+ISW$5B^P2WW6QL8(GDW,R2%O&NS1W52 RHR-I=4%*4)U9TT
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M1/\ <@U#2.N60CUTG@.A%LILHMKDM;_;-;2!'BGK5XPH:J(OD)2RZR?AT+0
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M=2;5+HE',5LO@(T8U>$-9$;(PH?%8%HSQ 6IX]:Q';GSI^4FTGW=-\E?D?\
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M%'-%;QGQ:Q*)$BK(*B-R6<M')I==(+)\/6UMT?EZ;,S=14&8R'9^2[_W=N?
M; WE5=D=6[@-+@-A;CH)<SN'!9W>-1MS"X'LW<6Q\[BGB.4JC0M54M8ZTYE2
M*)O99OO([0>%>R16<-K%($D1+N&43Q/B0)%'*\@9A0E:8"\:CK'_ &OF7<MJ
MVO<K:7=-<G@&:%@I$UM<QT,6HLBJ4%6 9:@,:T /2/\ D9N/&XOI;<0@ZJZG
MQ7QYZ)[DW-2;S[+[(EIMU[8J]F)EQ59;<'66V<#D\IV3A9ZS=M.N/K*258JF
MC@II%\\M-HD$-^Z4&_;ERI</L@26\6Z "*P1)8D; DUD&BD+K0'N( '1ARW9
M[E9\S[9MNQ;3*=[EM4:))&",DLL6LS*P<(Y 9G36RAM0)3&CJE+<776<R?8N
M[/D1\>]N4>%^.5!GJON3878>>II)<%C>JJW/8[:N7R5%M/>U'C,[E8J;+9?)
M4,&#JJ(Y+P/&\<3(D3G'7?=UVFUW19-^GC7W$FV@!H*,55BLBQB/0"A>484D
MDU/$'K*SV\VOENVY,EVGF>22/FF:]E2'PCXAB90LL;(8]4:@JK>)(Q*JE1C/
M0#]>=+5.1^7>Q:+L_'4N1I?DGW0^(R])MRLHY\MN7:.2VY6Y; 51Q%)+24V%
MI\]L_#TDZB9HO-3Z4X>Q]FGM#-M]US;R7MVW)*EYMSJO>CH8) A,D9:2FHJ\
MN5S4-J&.G_=6#DJS]FN<MPE\"?=I;/Q#-I<EW,L8+U7B10H:5';3'6ZO!@,U
M%T=MWH>APNY?X#-U;D.OGW[DHJ/RX?:<L$5#MV@&/QN;2OKL_1XB.)2RI%3.
MB69]?I]Y])L6Z216XMUB8$"I:1*YR6"UR ?+]G7,F/F_E9/'2:]<4-0B1ODB
MH*ZBN*C@<_/H*.U/C]WAO_\ EO[[^/VV*Z?>G:4>)FV[UYG_  ;:Z_J*N';7
M9./K-IU<=/(,3B,!68O;-$%,\CBHF> N\\DLA8D%W8;AM_,)2;;T^F"C5I92
MAK'0XU$D-6OKW4/#H[MMPM-QL(KZSO6=G-58AE==)/F0*%"H44QBHQU$I=@X
M[I;X@]7T>Z]Y8/:]5TKUYUAM'<E7N#=.,W-L."LJD\&X*O?^+PTV:Q%;+3;E
MDG:BR<<0J(:H%TG:+R@H=EV\-<[G+OFVQE)+AV3*D>&0:"H-2OR:N:4X=*=Q
MN%2" 6%V^H(->#\6*FE/0>73%F]HY"GVKCNQLUFOCMF]H[LP]*NUMS8;;T&8
MEW5A<=2U.2HJ?;+;7R,&?W=.%,I@6G1YY&F6'QDLH)_]#L%W$/\ %M45:@AJ
M >5 >%*CS%2?L'1<][=1B,ZT4! IJ*EZ$U8@BM34=JT44%!4D]$BZF^-'?/8
MGS&W/VSV#G-Y;3^/6X\WN'?.Q,[2Y[*8"GP8FGV#5X2EW%TA5[HIYAB-V4.+
MS%!3X+,XB:+;SSO5-"7J8R#QK7?;O:KC9HH5'+4EO;1PQF*(EDB+L$1NUT\-
MF)=R?UPP5U(0:1'8<P[3MUG8W D5M^MS-I&EU*/+I5Y-8!#LR@:5(!CIJ5JF
MA0N)^,_S3ZV[DW1N'"=F;CVKL7(=W[AINNMY;P[IJ7BW7A=ZYR7%8BBSF#;,
M[O@VO_>[;32XVCQPQR1T[04[ T,X\I);^;F.S2<7UL([&6W6$ZRA[M:N'!J3
MKJ,R<*,RM4$#HQLMWY9GC2,0J95E\;2D35UB/2QK1:J!6D? Z5.G54E78E/Y
M@-69NR=O;X[TW)TE+OR+>.P,#L3<>&Q>"SG6NSJG(8V3&S4N;&*WUMOK'+X2
MJGEKH*I:>JK:V@IIJ:58@5D1VDV[R65S'LVTH[SV[P0LS",PR,1X4L,3/&I>
M,KICUAD:-FJF5;H5QIR(.:DL>>MYMK6)98[B[E*M<?IZ&9XVDMXYZ^(&!F5%
M<K*%J1I=1;+U!UGO[M3X<_'6HE[Q[7ZP[-79VUMRY[M:OPFS\MV5EZK)X*MQ
MV5I=X4'8NVL_@ZW*5=)E0D=;4435D$T4<L3AF;4?W-Y:7%]<W=WL=O&64TB0
MRHL$A4!S$7(D7N!&EZ@@E2"*'J-N8;+9;?F+<1L,\L^SP74WT<LIC,O@,S"-
MG,),1=H2JOIJ*U\^@A^3/1_RWVIT%'MOXA_(3N/M3Y#4W8VW<7DMZ;[WETOC
M,AM;:V12JS&=:?&UFS-L['J8X:-*:"FHY*.HJ$2K$B*[*3[0V$MC:\U67,6X
M6EQ?;3':- ^W?5O!:RR,&TW<A13+]1&Y5@$=8W5?#* ,6Z(K/;[23>-TO]TY
MBO!#/:K#'"Q5[>"8.C>/%$JJRW,D8:,NTC+I<Z4!/53FW/E-\K<YL@;FZL[0
MKL9G\'LW<&$^1^Z,;%AHNQ:'LJLRV1V]T7DZS;O9NTOXEOZFQV%D2IQ>/PT=
M2-R,9(("44!"=[C]T-87US+%<23MXDD0DULZ13:3;U6OT\CQ51&.0:2,&*D&
M6=N/(&\WVV[1S%>2[3L\:2J9%M9@EL\JEXY!''1[A"VB1E4FK,0M 3U;MM3X
M_P#>FX,%L'/=@;0Z^W9NN#9F#FRF4R6VL5A*W-9?)X#'_P!Y\INK$S5L44.?
MS.9\E5/26,-',%\2H4L#1(MI5KR?;[5X(+B36(]1?2E2T:,QH79*FKD L<E1
MU&,LDOB0%:,T2:0W LP)!=0*:%8::(=16F6)/1</DI\5.R\/0=6Y#J3X]K0)
M-V@F4[3H^H>W(=@9#?FV,=MNLQU/@MZ5M?O.DH,YM=)JZIGCHGD-/39&*&<Q
M:@S^U2[S9;#8;X(I;6$7=NL1$EL)I'_51R+:0AA:R44M)(-)EB#1!@2*G?+<
MULEX;K<8'FN(SKB?54*X##N5JZM5=(.0I-2IK4!GW!\(_DC+V=@\3U+WI\A.
MQ<%LSXZ3Y<YC$=MU_2-#FN]-I9G TVVY-\8S&[GQ=7OW(=D04U2^<KJTR2,/
M&CU)%@I7L?/&R[)9<PJFW6EW?SI;:+F>,N;:DD@O66-NQI+J)HU5R"87C5T-
M:]"1DV/<+&PN-T#0[C#((5A +1M;K&SAZ@$:EF"HD3=@0R5!!ZE[*^#/=V]>
ME.P,C\@/D-OCH#Y$Y?N#=F8ZSF_TR2Y_9.WMIU>32+9-$-CXO-0X7;T>5HIW
M"Y>AECSN+K)/.DSD-'(6P6]ZT-G%XJI80HK11FC -76&/XJEC4G4&(++0 ]:
MNM]VZ2_>^FL1=7%P^FZD2/PGDMZJC0Z@ JZHE"A6C=5(1]55H/_3W-LU0;ER
MXS]<0<1N";%5=%/2[!A\>Z!5)AX-O0YB@K<] D6,R.U]YY*;[=HPL%704T,Q
M\G,?O;;SL=NPBV^RDN=V%79'4K_8SA'T'M1XBI4'4VNK.4&D!^D$UIS#)'+)
M=W5-LC:D2PE3K66*JE]7>DH8,U!V!50$U)4D=[.[]W1\7M\45'@>A,YV3ENS
M7Q.W5SW8_8M/C<5DH.GNNZ#+4^\=D;?;"9NN;(=CY[<%?B!0TGVLZYN-)IH2
M]0(Y#Z+=Q>;1O+WFY"RGLI1]-;QV\C?5K<-JF_6C 2);<#M6<LSC2D8-&HHY
M6Y?EW?<=U>9)8;2+PQ)*[ZS(!"?#F1684#2=DN0<,QH:=(W/?S+MX[/W_)UK
MN+X793)X_%XOKO<&]-];GS>(ZNI-@X'NZOIJ3:>&_N/N#:51GMS0XK*92+ O
M7T[11UN2@D:2.ELZI[;(KF?9;W?KOF*&U9+Y+6.)FE,LT[P_4I4*"(HDAKXE
MU(WAK(C(!6@Z%DO*1DGM?HG8V+QKJF!5UUJJB4(%93(P9E;PU[D610Q+ U9\
M3_-3Z.GVCG=SU?1.\^NL-M+'8G<68VOG,7LO.;DW%MVNW'D.N*78\E/C\ZN$
MVCO1]XP.R>6I--#C(&)<.QC5WF._W';M_GVJ'F*UO_ G :YMIFEMY-3!==O*
M1&7!D(JS+I*JTE:4/7K'DN5]MEN[YY$NS;%Q&25,,HDTTE[6U@H">T!@SJI7
MM+=!1O\ ^>>R_DGC]B[QZ]ZUWOUOM"FQ./W/F:K=]3@J"O:3.K)5XZJJ(]HY
MW.4YEH\=MZ6&:"=8ZR5VA6!_4&*7?N1]_P"8-LLMPM)EO3:;D;6:.!Q(ULLF
M@BX(P&BU%F.AB="%QZ&_+'-.V<C7M[8[K>PP2;AL[75N\ZN$E:+Q*V9;2"DS
M=N@%2C,VC4&Z.'T-\H<_W[L3+=@4V\:NEPN"VAN+LVHCK]MXV;,9/:&!&7-/
MB*D1U:TM%DJNEQ J7 1)8A*:9R2&E$>Q;YO)NKO;8-U1VMG<:Q$H$FDD<*!H
MU)%3_HE"1\73-]R5;V.T\N;Q=R2>%N!7Q%HH:,. S*C58,0K'2U"M0*XZ+U_
MPXMW)4]?=+=W8;X;;MFZF[FS.&I=GUVW]\;;KL9NC+[QK:;!;3_O+5?W9JZG
MHNB:I R%/]V:VGR"L(/.AT,POAYC^IOMOMVF1+=1HGDD20H"RY8.K:M*."M"
MFIE8$#!/2)/;*"4[A:6.XM->3.SV@)CB;PH];MXJOV5,(J2LFE71E(U%5'65
M^>_8F]-TXNGV[L[:/3NZ\?O*@ZFWGM+/[XH-S8?:[5>:KLE65]/F*2GV]MBA
MWM+2P&&>AJHIXO'+#^\QF 2F\;F899!M6XS2II0ZZ.B.U:@:)%JR D!Y ,J"
M !I(Z-]CY0VFS@M[#>;6VNI7F9F8!@Z+)&%">(CDAD ,R*/A9JG4. E]W_,C
M?6Q:-Z67)4T8H,MMFERFU.OZW:5/VVN0W%N*NV3@=OK39/,UF#K-TU4II,S2
M4M4TM+64K&&6(Q7<$\%U?WEW?[;O5U'X26_BZHE.EEK\/>!57."5 !!-*8Z%
MFZ>WG+FR\EQ<\;3;RRQON4^WH)RY0R):"Z6>WD&@.R$F&C? ZHW=J90K?AWW
MQA][4':*5E!A<?N&;L?!]@QRY7?6V(=W[^WEEX*/$5M%D=@?Q"/';*W?756W
M8JNOH,5(^(^ZK'-*6#CV&^8]E:2]VH[6O?(&&DT5=*Y# FE>.D "M*8 '1-N
M!VH;3LUU:W8:EJB3A6\3PBV2TE/[-B21H.* .&R1T<?:^[ZK;G2F\-_;=V;V
M/NEL9FMWY#-;)K,55;M[ RV5K<_03;AH-KX.BRZ5.6QN!2IJ8L=CG,=7)%1J
MB6#BXPVC:9X(+/;5D2&=M-7G.A"334QH3H!%0I- #0M05/00YAN)[JY:2SN;
M:5U"*I6H01JP!#$+4R".IK0@N0":5Z!3?7>>[/D1TSV[LC$_'SY$]50/B<7C
M<1NGMKJF;KN@AE?+T;PY2DH$WG5[EKJ?&246MEIZ19 'C]++J'M[<+B3:)]I
M==ODNUENFB?PFB<0Z%+^-*!(#].:!%:,22-(:"/15P17-]X6X;-MT6W7CK>2
M,C3QB+PK4!:^).7DC8(QPOA)*Y;!0"K!0;1^(.%VEM'<.%K.O=L[ISO9&"RN
MS-V9NGEDCGCQ>6"U<^X8:S/"HGQ\+R4RRM14YL]:Z:BRHJA-&@F;<&X#2&0L
M#W%Z$J :4"<37((H*X/1P]Y=@QF.Z;MI0'R(Q5J&A)_*OV=.JKN'J3XIX#&[
M!ZYSFQ,ULS-4^-;;642#)R22P9&2LKMV9"LH8:27,XVIR4JU,U;HIY9CJ)M=
M6*CZ>!)A"C Q5Q3B<?$1_$3]O6GFGN)&FD/B3$9J":>6/L\O3HCG\RVKR6?^
M)6:R.=W+A,7V9F<)5UV>VC72T5!D<MU]UKV9L;=6?W!CL)75IW(F/ZUKJQDG
MK((:E*2&O%-6-&'21(C]V["XNN3-\CL8))KHP.JJ@U.P# BB@5) !.*X&.'4
MO>R%_;6/N'RU)?W"0V*W<99G8*BU5ERQHJU) R1GK5M[HW)N;>^Q/D/MSI/)
MIN;O6+L3XQ[FVW@MKQPYK<6W=K;)V]V)@.P^QJVD>AR.(BVOLI=\4"U=;*3%
M$E8"#=D+8J\F;;N$,-I?7]C*FW^'/J9D8JXHK+'C(UZ2*D !J5/'K,'W*F\3
M?;:ZVFY0R(JQJRLJE)*E"5U8)[L4K5=3#%#T#W1'<V4VG\>=E_'K,;HR$NU]
MD;>K=O=A4F(IJNOK:W<N<WGV%NS,Y&@Q$E)35<>W,)N;=E0D=0[+'521R* G
MCC)2[QLMG><][CS!:V\D>Y%A*GB+2,Q^"D2HV:-* JM@#PP0174>I!]N.0;#
M?O;RV:QGECYUBA#F1EI (9IYH5CC-"6H(B99R6'PQJH"D]*+JCL#%?(K$T68
MW+6T-3F-HR;HVONBBAJUP]17["?:.0VK@LO)DX:^CDQV3S.0V[#2Z:+P3J&L
MLIO(?<D\M>WLFV[_ &FPW-]/<[9=;7+>12H-,B7$H,S1K)(0LD4)8@ZP24'=
MD*#"&_\ ,MC-:W%Q:01QQ[7N4=F8I6UQS01.4$CK&-0:>0:T"G&I5KEB%S1=
MX[03Y"]B['H>N,/O>"+$1YNJ&8W[E(-A[9K)-B8'<E!MW!Q;6I9:-JW&XNI_
MRT4I%*M5KY\K.0T;=K+;]KC>:V;Z<.A9NTSJ)3^LS,P:I%54$5% ,](O#V_?
M-QN8I+BYL8C T@,*EPLQ34MN0U5TER%#J::>&<]"W_+!W%MK>VZ^\,QE%H-L
M=A;EH,3V90X_"?Q;#T>TXJ1\C@]XX3;\$#3S4DHS*P(]-4-4L8)&EC]:+[#/
M-_BQWUE^H$M%$B:UH0Q6CHJYR&7@1P&/7H5^WHMH=LN(IH&>9_#DTR98!RR.
M7-.*,:TI4D#AUBZPP%;N3^9'\@?[E3T'7E7M_ISY!?W8G[#R=#4T\V=/4^*I
ML?N?)#-BIDJ*G+Y^AQ[Q4F0CJ9JNIT-4*&U*#KEC=19V^UWJVR7 8'6*Z$71
M+K*YIK7266B%2=5%QGH.\]637O[Q@"3K%#>1:0H\1W5T$;2$@_IJ#1V9R0JJ
M:YH.F[X-9_L;IK<^_P"+Y1;Z2AV/O/K7K3<N(C[>V9L//4^2[6IJD8X8U<=A
M\>46;;V/R$]%4@%J/)54M,JK!+&L["#FRZVV^O$?8$CA47,J(JM+'2%U(-*U
M+.3F,5;32I)' (;>952<;K,[@QKFBGN5ZJ!Y!13NK0M6B^A-]55E#L':N/.U
MM[[6J>RO[QUU=6]A=C[;&W3N;:6#KYZGL>OQNVZK,XVKV_N#*T%_'2>:6?'Q
M0R:4D;2?8)BAN=TN(;&,ULP?#*@L"Q1@*,:5*D@_-CQH>CZ\>P%SN-Z+9H8W
MU2*H*DQ*ZU!!P#I)J:"E,4IT!=%V;M;NSXWTV:Q^:QFYMT;:[2.+R'8Z5L$]
M'NR+<^"KMT8Z"2LIW:F2;:QS-/C9:>)%6$0!G4.6)D#GCE.>+E?E[]RZ9I?K
MAK!9=,85"P+MGS8 G+ T Z+>6;"[YFYPO-KVF-3KL2S,2$C4!TC9S4FBG#4%
M:L309ZA_+/LF'LW_ &6U=O-1J4ARN\=W9"HPF?PE130)M2/8M13Q5>=R5=-E
MZ;^\,V0:H>&+_*X5II@S*F@1CO&T27^Y\^,9DDDEAAB#ZL-.*2R%L:@:@!'8
M\"?(]2'LW)F];G<[1LL-I':3[;.XD\2H0C^SC$3+6D9!,E*5 88Z.O\ #&';
M.(R?5W80DK7["P&-JMW4^9GR,E/LV7,YS;NZ-I189SD88*;&18NBJTE@2!TK
M9:MEG9@Q7W-D^TPPVFP[[<LGUMG%!X;.P5(2(50A 2%97))=F-=8# J!3J'=
MG^H&V<P<N1-(+3<'G6Y"#4TNBY=EU,%J5C9>TT \$E6P:A*]H]\?-;N:EBZS
MPOQ]IZ6?9V5PFT<O28>AH^M,]M[KO-8S-TU1D^KZS<^XJ*IJZ[;>9AAK9:^9
MS OG$48=Y25*QS1MC;;)NUSS)5)+KP0(T:9 R#Q'4A064L%TJU#&P-0Y)'0>
MMN7)+7<BEK:^+;B!F:LB+W:@BLA4Z2 #4 G4>.FF>@WEP7SC$.TLCN3XJ[FP
M\NV=Q8[,;NKLOWMM');.W/@L;+%C6Q3;='9LU6U;)BXWR%4$=J&M\Q32DZCW
M27FSEM(7>;?IJ D@);2"@!#+G14L/A)\Q6H'1I;;;-/*L$>S(784),OF014K
MJ  !R 33R'GUL,=2IF]A['3K:;>%7NO=_7>3+3]Y=\;1P;;SW(=[4S[LVH>O
M.N-CU&4Q^7J^L*#)0[8J*A<7#/5I3134[U!\TS9&[1-'-;*P7)16 X,-0![J
M]J<<4-:4X''6/.\64T4X=6!+,X(!PNEB,F@K6E?]0Z'7%+VS/MKOS(9/JRLV
MU1IL/KZNI.YJ^MQ.WM_=_9+#MEZ_?% >I<&N7J.N$QV#@7&T)K9WK\G4Y LT
M2"($GJK!X2R1R$RL3J%#0 <*$_%7U _/T))0@5 )07J:@ T'V$\:_+'16]A]
MA9/#_P Q;)QM]UB=ER?&W(U^^'_@N-VYLW(1Y X;-]?8*M>!(,#1;\^YFR0]
M<S&IITM9=.DNQ(SRQHKA6+ 5)H!GB3Y <2?+CTQGRX]!3@?YJW1M;M#-[FJ.
MAMZ]:8?:N-Q^Y<QMC/8S9>>W)N';;[HJ>MX]BR4F-S<>'VCO*MW@]Z9I:DTT
M6,B=G=7)C EYEW#<MLY@FVJ'F.TOW@F :YMIFEMWU$*6@E/AE_U"H+,-)"L]
M=-.A19<D3O8275_)(ER;9V$9)0PRK*%'BDJP=62K=H#!F5=)H6Z*AWC_ #H-
MJ5N4VGG^JNM,WL?9TG7>V]Y[KHMV4&U:W>KYGL+>[=<;.KJV';><W'CZ?%[;
MIXI:MHZI8I&JO$/'4QR"VKS<MWVT[=MT6XPM>7-Q)#53XRPJ@U/J % 7-3"4
M8AB&)HH[A[[4>R^T^X%MSQNF]W3BVV78EW-4#-'),HF"- GP-6A'U!57,2%/
M#[Y*J7[Y"_S)?E#M6NR'463INGZG;-=UMV1'29S$X?+RU^>S^ S5=UU6RY&K
MILT1CZ?/>>29(X7IYL<DWAFCUL7"_9]WOKDVTNX1#Q'HLJH5.N*6C1E#VA90
MO:YH5U=XR!T5;O[;<I[>;DVT4S50O&3*28I(M22(5R)(O%I( U'TJ$)HQ/51
M_269BZ[R%1N/>O6FWNR,-B-NT&-Z_P!DY>KS&U-HX^5\OC#7)/D<'515VS,3
M3XD3U$E30S1O'*' NKR:A,O*'+EM:M;V^T6D9&/U%:4N:AB%4G0TCE14R JR
MU!R:]!^REN;B>X:XDDDUI74C)"D(J%::4:6+PQJU2JG6#E:Y'5B_=F"ZMVUF
MZSLG:^[^]>R^L\#MS'9[/;'Q&[-F[FVSWK3Y'+_WTQ,VP<[0T=3B=W;:EQ<.
M/H\::FDI:N2I,%&Y=89#[-+-)DW/:^9=TVVSGO((&"I+&&1HS4E)%8=BIEDT
M#4C!60@])]W2UM[R_P!OVN_E6U$@"RPR4KIH5=&JP8L^2Q.ED+5J*+T4K-=S
M[PQ.TNW_ .XVX-V8G96X-J=G8O$;$WG5*]?B]F[LQF36#"[FI*2>3'4^^<;C
M\@\%7D:5EJ(ZL/+%(C_02-80[U]3<SVD)W&[=I*1HL2>))E41% 58AVJ(Z!0
M!D<3T1P7=]#<V<<,[>"@CCH3XF%&DFKU+,35M9HQ)KZ "-_*,W\^.Z;[FZTW
MAO.':V.R-%)DH7R6Y-SUM-B(LA E&R0YO*9*JJZB>LKJ2G8PT,CS"%V-E9O<
M \];')LN]VWUEBL5R!I=*+]HX&E*'_!U+FS7TUS9SVOBOJ20,AJ%[O,<!4UI
MQ]37KAWCN?Y-S=GY[_1?O/L;;^*[!ZOP^T-[;4K)X\90UN!E?*T>6VMN3'4R
MUM+F*6IHC&B3O,\JT[(R.DUV!WRURWM5_;G<YYI_J@Y35&XC#*JT56(4EU4,
MU%)TY-*$GH/\TW$T>ZQI%;6Z@+&Y4@NNH,68_$ -9 #@4-*@&AZ16"WM\@]@
M;UH-P[RW+M^7H[:V?W+N[=>P\=BLAM/;-'CQM"HILS+L^JI:;,UNXJ2M&.@H
MA0YV2)P]1+4Q2++ZB<?N/;=AM-PN(!HM) #(9&J5<LJ>(37P\=H4*% .34]6
MO-[O]]WG<9=JL19RW[.AM[74(3 0'-O&I'B&,%&<ZJF@Q2G0)_#KY;;H[9R_
MR7WAENT>J.H.]=A=-8[LSJ+&;YQVT,-TUF:>*KERF8ZZSNP,_-1U^^J:NP$"
MU6/RE)/5YKSE6:.HI])C.-PY5Y4@W/:[Z\VRYFN@!%(L9&IU>F@J:=S*[ @$
MC *UH*=(;'F'F*7:[OEVTOX$VF>7Q*R$_ILE2Q# ]JD"CBE"2#0L>CK?*/\
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MERY+Q @DU':5;&0QU$FIJVG@>JVNXUD@ACME86R+H)[4;0U7C:M2?$6HQ@
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M784-5RO95A1JT/'J;_8_8[2XEYAO[9@;JWCB5*G3F262@!\BM360T(7\AUK
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MMIY7=%+?;M73-BY3'34DC4U0GW3QH@M?;JVDNKZ*]W7<5L1<^(D27+(CKX=
MLI4"=Z.S/4R .\<;L#0AA%N7-$=PFS3P[3;&9;%8'+(6TF*0A64%BE3&% ;)
M569?X2L&MW%N?'5%?20_)/-RY"/=492*KV1N5X:ZAIO+C\]BLT</+54459+1
MJ\YFIQ#3259L D16,+8>6-RM(%LVNWGC7".[DR$*NE#,V-3GB[  LV0*D],M
MS$D\UU=BVMHAC],0J$%9*E85%6*K7 J2L?$D= WVQV?+L#:=1'4;RW-OJC["
M_O!U]GMKXV.W7B[5R&+9Y\EV)G-WT6%S6Q\3F*JN<_=;;C?-TM?2TYC$D3S@
M>M=ENK=V&[1H8#3PPK5.L&II0G&D>8!XUZ,;'>['<-WV6.Y2%+);E3(0IA54
MH:%W]*T!]*U'1Y-D]M;=WITMM;<U-33@Y/K7;.+W9A>N.P<'NS>6S]NTV6I\
M3_'(<U2Y"*OJ*BI6AII(:B5 3]UJG8$/8*0[!=R[U?0VRE[(2A30*'I6I4)7
M'#3J-!YBHZ,[J6SL=X=H+Y/!5GDAEDHT;D\*OW+(@+%=2CNT\!6G21^/GQ:@
MHZ.E[:W'M7#[RS%%E<CG-E8K*PY"7)8S%TF?R%1AMLRP9^>NQ#YC'TTB".O)
MD2.1G>$LJQN!ZQCN+RTC^G,4*#PF#!J)X0'<1YEJT4@D$@_:0?+// )8X[TM
MJ=F8KP?6:T4@X0>0(X=?_]3;S[=[-R6)[%PVW:O_ $D[>B;9F!W.*?9TV-Q\
MT^]\W-7RPT6Z,MDJJ&CS%'BH\9XTIXG>FC*R&346%@SN[2&[$,%\\"Z-=%XF
M0FBL20:I0491CC4<.AMREL\=Y8RW-WMPN:R@*2:@1@5=:!UTR58:"V:4(\ST
MG/D;0=/[YV[TWG.U>G:'LK=3T<V<ZBCK,902Y?8F[W?;U;59# 04[-XJU\UC
MZ"K18&DC\U' 3=5][O=_NMOVLQH9GANT5G2-@J%HJM&S@\=#L6CID$^A/2/;
M=EF.X;M"MW%&EI(58-DLK,1I!&#V"CGA\J]%M*;"[\W%OK<^5Z\PV]]XY>FQ
M.Q-[8KLZ";^,[SV[USOAA1[;>BQE324^._@.X&ER=)CDD*Q9)YGB9E!5 A9[
MMN9O0Z2M++I+JK ,:IAE4#!<@T KI\^'0WEM8++;;2$W316<BL1X;45"X!+$
MFI56TJ&( <Z5%<#H_*;1ZAP/7&].H>JND=H/L>KK7AW/U_4X#%X;8F]&WVM<
MF:6:7QU=+5"3(Q'^)3R0.-:$#4S!P-9=UEOK_?;"':I#N$2)+JF54AN/'U9C
M<%M2HZLDIT@!UTBHH>HSNFW!;:PW9=Q66X=F51XA,D9B(H)"1V$A@Z&I)!J:
M'H@NX]K=6],[@Q?76S/AWT?MK;>X-N[BS]!EH.OMLXJAW=N;9^=RF(CVC7XK
M.9S;L6UZ.JPM-#'1Y4R5=1(26C2,LJ,)[/?>:-HMT79=QEM[5Y06",$!=5HN
MNI 5:44,,XQZ=%^U[1MG-]U=IS7+"#;6<GT[SH[EJ$L8E558ABP 1#02$ABR
M^:.V#W;2;DVK2[%VM1=&_'+?]8V1W)O[9&P]GQ#:0V)2R5.'V_3;OEK:K'T^
M9BW5MB3(JU#33HT\C(8QY(9$D9L=K3>=PM]P>[MX[FZG82H>]I3&H):22,*^
MF4GP@2JY8MJ)%>KFYW:& ;9%ME[<V-E:J\#*-(17=O$2*.1SH, 7QI#JIIHJ
MK44Z$_;7R$VEL3<G17Q<Z+R^W=T]4/DZC9W8^SJK:^V\2>NNH*.I&!ICBZ3&
MFFH:C;M1453Q5DD\J34\,FJ$32WA]GW/_+4_*)L(;#8)[*[>\C4Q.TTEN86H
M;AA)./$4PJ:PB-I4=JJQ4 GIS:FO]RCW"]O;ZVN;I[2.6)BQC96U@-J$2MJF
M,8'AQ.L=6IK<$] WW/\ &3+;N[QV1U%\/MD])]#?'C%[-V]V3W!O?<77.T%J
MEW149V:2DQ&WA53/NK)5U5MVEHJ:NCACBH:$9&GJ))I&D\;AR]NMQW.2.6[G
MF:<1]CNW<JDDT%. !S0C!(/2RUB-@ABCG;^U)(B:@[<$\!0G\+5X CCCI)]^
M?&'ON+=V8V!V7U3\;^R\=O/;&^8/BMV7UOUC@-B=F;*WM0Y2DJ-@[-K=Y4M1
MML8O)TF+^VK)*UZ.&F:II%EBJ5:)D]M1277U4<4[$PED#DT/B*M3W>=%J>V@
M%6) STJN]XO9K"*V7=;QXH YCC>0LD+L14QHU55G*@EA@E>[YJ7X@_#S&=,8
MV+$?)+#[$SN[Y(<YN?>%-GJ6;<C3[AS>=./V9A*W<F1FH,?455"]!/5:X)#)
M_$)O(9&%M<2\T\VO=<T2P6MQ-;[9!$T:QL2BJPC8LQ"DLI+'M(:ITI44)'0E
MY?VZ6/9IW66-KV:9&FF !#+JRS H:Z00*: "6(H>/1I_C[3;!^-_QRWIO-NW
M=F]9;8WAN_>]9MRNRFX'Q>RF[,WCN?.8R:DH*;)EJ_*[JJ\EBF2&EC^[J)YU
M#K%+R&E/E[<MPN^5)K._B9]\M[F:,S3 -((HTB:)B10:=+Z@U*4^70!OXMNN
M>:8GM5>':'$;-'%VZY))'#D**T)P"NK!Q4=(WOGY ?Z/>B.Y<7MWY/UDG>7Q
MGRF(W%N?9M9NA$['PNQ*W<6RY<8F_L?64=%4[OQ<-)N=(9L[%1I1UD%3$DC>
M56]J-EO'EY7W<7D*O=-'*8I:4=#&Q^)@ -5!0T '"@J3U3=K..+FW:8["9C9
M/<1HT=24D#B@:-#5M+L:A2S-D4J!7HP]=49G9&(W-4[BWAVMF-O[IW;4]AUN
M\L[O'*83&[)ASWVE5CNJ-K9/;C/D]O;2VS 95A:95-7+)&LDLA9 J6UW/9;?
M:A=S[DC[A,]6C<,YC%,L$!4!, J-6068UQT<WUOS#>;Y#M=ELD4<%C:>&@B2
M-3<G4>^4N':2>ITLVF@TJJA2&J^;/WIM';G6NXMD[BJ-Z?(7PY"'*;LH=^34
M&Z*NH7LW,');1VM!/N-*+!UFU\;BM<BQU4K"EI*47,LIT^Q)MMI%NUKL7,,#
M)8;?N7B/$7=G\/P:K+IT*SZ?$&F(*#\0!( )Z"6];I=;)NF^\O- ;O>-E6&*
M3P(Q$TGB@-$SF1U7Q?#8M.Y84TG2#@=$#_FQ[ER._?B-\JMJ;5Z-K\9OWKGJ
M_!8 [[P]%MC*;^39?:^\J.'L#;FP):.6HWOAMKY*3;E%#G6EBIJ;,QNZ)'/'
M3M*([]THI-M]M]TW?9]P4;H65450X>(>+$&UD#M,B,X C9C0]Q%:=2-[1RV]
MW[G[!MV]V(.T!BTID(\*3].0J%J>[0X5B7 R, TKUJ2['Q. ZVPZ;^ZTV1OC
M9.Y8L7N7K?.U&!V_O/ ?WDI\PE%'N7&9*>6GBFS4%7,],M7 -5*76#3RD=N<
MUW+[J)L%YN$?.-WX,+I+.1-&OTUN\ABC9L@JCR@QA<L"#J4#/72/;XN1MPWJ
M':SRY;/$*K&"A*O*$UL!7!8(=6JM*$T/1BMHR]>9?JC<O6F7V;N#851U]LS;
M/8/;?8&]=KXG#'<T60G;)[AP_7NX=TY#$5.3W=%MZ6HIR]-'4UV&:5Y8:>6H
MB*&4=OEO;[EJ+?9U6?F"='#3O1Y&(9E#,*DLD:J*XU%5)4, >B+;9-_M^>[#
M:]DYBDBY?ENKB"TLX;DQ16RL0M)33PH(IKAETI(X@DDE17EB$@;H"NJNENN>
MP>O\IM&NZOPG8&-WINS<[;TSW6NWL/C,MMRDVINJBSG6/4%9@YTFSW929&+(
M-7P9B*&(4444B3PD6=A5:;YNO,&R;>8MY875FP1#.XC6,Z0LIC) 6,2H 5!I
MJ%!Q!Z(O<GVUN?:KGR+8>9]KBMY-QV^*YE%BYO4N Y<LY9#I\>UN 8KF!&=8
MI=3>(0W1L=EP_%3;.[]Z[=E['WCUAO7KJARVVZS=.X=A[>J):V;!/34C[5R6
M!HX!-M/*?Q."DQ^*IU>>?(-/'+4/#XF4$E]R5N=U!9H\-G?03,7(%71:\7U-
M04(J P-"<K2M>@S;<TK9B1HI[FTO8:*X)T,1K"A4514LB]\BL!@4&KH8OCSG
M>K]F=A;KW%B\WLG";^W'UYN&;!=E;KJMLX+<&[5I:BDKZ^J:BK<OXGR<F3/\
M/@2G::22L5R@?ED1[/M.]7._[U9;AMDUUL]HK1@:-5M;SZ58*IP&DTG2NC5I
M9S6G'HS*32[=MN[;:;GZ62Y"RRQ(Q:6+4P'B"ATI4!W#:< 5-<&/L+>?QA[2
MS>X=_;XZ]VOV)O7;IAQN_:?+[6FQ.[J;+Y&IK%Q>0-7G:&BGK\965$M3<(OC
M=ZF50&0QL=6%OOO+FXQ1[Y8SIM%S#*T=N&323VUQW:"M<ZL@'%/)=S-RY>KX
M995ADD8:)Y#J#H,Z3H;B<%5)R::ACI4XR;8&]-Z1X0[$AQF\-G5%#!CZ+L6)
MQ0_Q?^[QW%MM_P"!U$M738Y*&CJHH(ZI7%.:7PR2Q1.0Q>.[[A=7-JTD[&+7
MI5'.$8U"FH/:*=M016H4]$T>S[;!MWULL*&LG<R %B!QH#Q8'NJ00HX8Z+?W
MEN'J+?M+NZKWOU_L'L_&=29+)XO>^P]V[5ESU3M_LW;6W-R;LRVXNL,+6QR9
M26&?"XVNIZ_.17@IZBB8S*T<D3F3K"#Z:VMKO:[6*RE\"-)V 92[R-J;4!4T
MI0GC4\>HIGM9#>;C%N&ZW%S#+>2M;CM=8XHQ0=U5!KW4%:46@'1O?A?TW@NM
M-_;XZK[&^-^Q]NX3/?$]OD-U9L?^#XS.[!IMQ;BJ<$8\SF<'2^-I.QH),O0P
MU:R2RQ+3.%N5>_NIW.ZAAW5+J0216[$%3\);1J1M/S4#-:@8P.ENUPWMON.P
MR\K[Y/;W]\%1GCK$Z*9M#PLYJ"*@.=( !-#5A7H-LA@=C]<=\=<;PW!2UFXN
MO<#-4XCLSKGMML#F>H,=UYEZ;<!K/X;1TE-/-M+^,[LI),KA:RF9YZ"7AD\#
MF+V&=LGB$-UN5Y%;-K[I30 :M TL3PU(**6\J =2[S:O,&R;;=W&V;]N\5Z0
M)-?C"K:&$9+G-=0PE16G&A'2OD[8ZYH,!C]T;3^"GQ/I8MS=AT=!NK![LVQ5
MT6.V=AZ2O@R6/[ IZO;G9DNZ=WU^:P*QY%)FHZ6.FFI?#3L@(C(Y#26\-QMT
MUA!)M#A08FT")PZ@JP#>('!KJ-5 &>X#J%)=KE?9]LWVTYQN_P!_SW%S'*B%
MS/&!3,M%1$24,T8(=M>0XJ".AEH-Z[B[IW[N?Y%=4UW7O8F H]EU[U\F+Z]P
MDN]ZOJSK*I@J<'M[!0Y7(4=5C>NMS'*235Y$4%8]93KD::9Y4DA%IO;3E3:;
M?]P[:UE-L\^X75LALT:V\*9K=#'N-:,!%XM(B*NTC* 0J"O1;R_N8LEVW<=W
MVG=;#:#;F5E5H9-4M2#;,)#21XU =J!=$;*JDFH!G>[J*JV"M!V/+D.IY.I=
MTX';&^]M[=['I?X)MJ/%[EPB96JVP:C9F/S><W'18B:K%&[S31S5@1'#+J!]
M@QN0]XOMUM+6UM(76D;&/PE1=0!62.05:L9;#&O<M&HK=,KO<]M#>32[M*H1
MG0-KJ" U4<8U59:-2F&-*D=&VV-_,JVUC:K%5C]1[HP-%E:"EVYB\CD8)*;"
MU,]-B(*S;T5']]24V2HL=EJ82BA65D+04YN+1L_N<]HYH?0VBS17C['&HA5\
M,!2!45T@X7)[:9)ZCW=N7+*=@3NS4)#5,1%2Y))^+/&IQQ)..C+XSY+;C[SV
MCO;#8V27IK<N%;:M+M??%)5X[*QYO,YK,U&+RN-VG'DJ7(8.IST9IUHUI9?N
MV62J8+^XBNH[V&YN^94OH+*(B>! [E03H3+-(0P%$"J26R *\#3H&WK[!RI>
M;7=[A<Q7MG)(R>&P:-7=AHC34IJ6:1UT@%=3 #X202M_(6*?:N-PF2ZKK-[=
M<X[KW86X>P,ETELG'=<;:V3\E-LU&_GP=7L+=V.WG1[LW=*)*V"LDR%)!/1R
MU^-JDBI9:29R5&T&TV;74"76](@,H6L0+T)0.A[@H*ER(L'4'U8( J']OW\P
M;??PQ\H0W-PX!22Z9HY$ <Q,J!7TZJTFCJ*FBC\15:-</_.3QFX=H9GH+J+K
MS9?4?5&]LCD=OYO&MT_MK:\5=DMV9FLER,.^]F;MW36R8?+;XCH9J19JVH_<
MHS"L?[S+,:OR3S+-/)<;AN.W,KYD>.*09J2Y",14A@48D!10XP.AC&BO)#<R
MW-S+=QXU,QU(5.,TRW!@ //B3T ^W>Y?BU6[]V8K_%3I;:N$R6S>QX>UJ?;_
M %6U+MR#I_:6X<%N;<N^GPM+E9)L]%L[=N&I:&CH:I:/,4F8FAIZ6EDB#R@V
ML=IW*S>2XW0I-]+(#&EN-.E2M$F(R-=&K&$;2$)KDX$]AN&Y;1]3;6^Z/;WL
M\;0%_$(UPR+6:U8US%(542J*EGI0]M.@A'R*ZF^7.*W9.(,K1;AC[ VQMWJK
M&;GJ]P4W=N=ZH7!XYM_&KQ>8J]RTM+L^LW]6PTS8*HI:A\*S^*G>&6H>9S^S
MV*1[NX:&-(HS#)(A&K3&8Q@^&:*"=6I:M4-W4&FG6]RW6T_<D>XR[Q-)N$4U
MO&UNQ&J59P[&K$:BL6G1<*$'&-&9BVH'EZWW5TWO[YN[$V6:W9.>VKM^CBV?
MOCHS8V.VAD-BT&]\31U.6['Q?:&,FH:O-;BWU&:V&EQE+19*#^'3"")0[^52
M4VU]N21(MQ<W#4A#ZR3J<5SCA]H(S4'A3IRSVG9KSE[F#>+CPX[^W#,B(=*1
ME2H TY+%]78 ?,C.2$+NK?/6F7WI4]08C,[1Z(W'T[EH^O<]L#;VX*(82LR5
M1D:_>VP*^C.#B6EHZS';9SD-/]HJJU#6^2%AK4M[E/VMW_EVUVZ[VGW*MH?W
MY/=AK<RH\L?@,E164BD=7PRM@OPQ3J%N88N9;GP=RY?@;Z>*(^,(G6NK5V]E
M:L0E*TX<#T'N_J'H;K?'4$._LW19P[PDI\7C]LXO;.Z<ED,XN8KI,6)*I#A:
M2EQ^!>I5TJLC++]O2J0[WNH,LWN[^WD,$UO;6L"W;TCC,*MK#R8C:-P<%3G6
M*Z>(J>B_EJTYGOMYV<78E^D,Z%]3 =BL-88?$&I^'B>E/L/9OPXV%-G*O,=-
MY6@H(8*JNQ;X7=V-CRM/54]+/3FFJ,+D)*BBIIERWB3P*OW#QOJ"6D2\2WUE
MS)?RK)M?,C/9_4I"#)-,SDL10*U&)9@2RM\-,FE#2<'VV>>\D>U%L;)I@JU,
M@<@D4!H?B(-0>!'V'J?2U*P= ?(?/[9[3PG2'8FT=LU=/L_#K387'8Y=T5T<
M$<.X*^IS$,V,IYA/6M3P-*ZR2U]-!"$:1E'LHYSM_HMTIMNY7]W:_2I)&7F,
MKME@55Z+V#3A0*<:5KU?>K#;EWK;[.UF2.SF2,%WJX4LS"M>(6H"_(YX=+G:
MV$P]5_+U[8S^9[-SGR%R.W=G1[P.Z=^' [@[.EB7,[1_CFV-PU>#Q. G; YJ
M:&K7 ID*$2)05$T)GGB]2%G+=I'S#O\ L^W;F@FVBZD19(I,PR@AB5(;!0,%
M8@GM*YH1TYS)9Q\J;I:IR[?O'N(MBRS*1XT$CJZ*RE1VE@3I.FNDGB#T*-+\
MJNM,_@L[N^NZ>B8=43T&0J-N;CZ@V-N3<745/4T]!B-L5E?4/MW,T>UX*NGD
MHZ''O3U,BT\"*&-/!&[>QSO&X\D6>[R[?-MS7+HRZ[B*CPZF-" ^H%C$*:@@
MH :J30]1_:>V/.AL(S-S(L$ZJ1X+RD246A6H"T"R%NPDY.&I4=$8K>Z^H=X=
MR_)&E^2&SJ&HQ.Z]U;5W9LG:W;)PM'3;*V_2T,ZQ;-H,50U5-B*G-UNXM-;!
M2TDDP6NKHRCAW'M5S!;<@\MV]FR[';W%I=IXK&V@,JR2Y#32L.+!"%>1S4A&
M%**:B*VY;YOOAMEE/N9_>=E;+$[32E&IK+I&AH=6D4  PK%1YUZ$S?<OQUR$
MW4U9%U!UML5]S[WP&[=P;QFEVK0)@]FXE<E'EH-WZ<Y/58_'[BSF/HJ.*68*
MGWU$J.XDL6!.YWO*USLG,K[3LZV/,$$&N,F-5D+OX>8#&2M?"?)'!6.#D R;
ME;>MIOH9-UOEN=M:-Z@NST ;2NO6%-0XQDTI4\1434;X;R9+-XW';5ZX["W'
M24.W*V%,-5[/?$2KNK!9/+X":@R5=N*EI,W1P4>)E:M-.Y>GKFBH=#U$Z $?
M+FQ\Q<R-/#:[[!:NEE<W :Z=XT/TX7]/LC=]<A==';IT!W9E5&/0$]P>?.4/
M;+9$YGYGVV_N-J.Y6-EX>W6C7MX\U_.MO (K9"I9=9J[LRI&O<[ <2>=.;>W
MU\A^[.P^A\]\@\#M;K_:'5F"['RVQGZ6[GW%U-MO 4L\=;74^Y=HX['54>Q<
M)C:+++D\X\]9]E05QE0/4,RGV$[9.8]WLII;F^O;#],L LJ,7.G3163@NKX6
M>FI=- *F@^O;+9+3>+O;K)(K^WC;2LHI$'!!.#(0 RUTNH- X-"10E0;:[VZ
M3W3L#(=3P]8]4]F;[W7VW@,]2]DUVS<O1S;=V_A\KXY8NN:C[XXE]H9+$4\H
MQ^/:GC:3[YF9K&-4''*7)_,T<MG;\S<R-=["A#L)3J9U32420FE:TK(S9[C0
M8'13ML^SR;U:M8UCN%$A/: H !+'4?+\ /D,^AZ$3J/MGI#:^[>U]B;$^-_Q
MPZOPVX]E;RZ\WIC>K]H=DX?>5?UFTN%JL9B=X[CRDE/B\O3=HRPU%;)C\14S
MKC8*0K*XD(T-[%L6_-SQ?6NZ6++RY:S2LI8)HD4, D;4_ ZL"&%"H102:]23
MNFV<F6>P[+?[/SU=7G,3/&;BR>*-80&#F=5(421+:/X<8:5W^J\35'I"GH/.
MD]R]9=S]Z=#?&/8O6.S>LYNL:7?E/V5NZE>BKLAWGAL'N)=TXM,91U6!J:ZK
MW5D-KUPQ$E!65%71M3I))<%!='N7)>X/O5U!"88MO2ZD*:3JDDCT@HC@J@1N
M-'9W514$FJ@  7T46ZWUI->.W?2K@A4R6(4BI(H5%*5-!Y ]1,Y\J_BQU%\P
M.W=L=@[<ZJS^R$V'VC0O@ND=G[0W5CMF[X;:<&(VY318QZW:F\\(-L;C::IS
M-#65E;""L45%,JQ,2JOMFM]OBO+.+8TO;N&[$9"HRRD:AJ8V\KJ$2,*0.X/5
MBREAIZ9FO]ON-EBT7MY;[^&U^*98VMWA/",LJZEGH:EA5'':0K ](&I[,Z#Z
MAVQO[X^?(G8G7.?[)WUU]L&IZDSN/VM@MU5^WJ?L';^+R>!W+0]K4,N#P>/J
MZ.&L=\C_ !6N:II6TJ=4LBS FVI=ZM;M8+ZSMF@)'ADE:LP).AU(KW @,-5!
MIID5/3LL-O\ 46MVJO+;Q,LDR=Q0Q56H9A\ ;*ZN-6KZ#I5=>9B@V=L'/[%A
MVS\6<Y@NR-G0P]=]@[R[5QN+W1TACYDJJW Q+EZG<-#B*;/4,%.E'78I8ZD>
M2N :=$U741[=S;)N&]3#<%3;)IW,:2<(UTZ42V5%9HD+$'+4JHR!6K>YG9KC
M<#<V<)AMRVM(T_45%RWAL[4#TI2H K6I].F797;N$EPW7.Q-\_$GX\_(.?;&
MY9MR[WQ6/W[@.RZGL;:E)YJ<83+8?K/![UR5&O\ '*R*2#,9#)4L%%44M*A'
MC9B;/MO-T=O#:R7R7-X9"0&5::"A4ZRVM>UB&5E6H^$H5)Z2(UK)XL\$TEO$
M0%)4T-:@X"Y-2.![:^8(Z05/M?!8':W<W8.]/AATUO[KO<FZ]X;5VIT'GNS.
MH)-X]#YS=.(S>8VSV/FL'N/==!M+:V P]!6P4DV2IFFK42A+"B@#M-[$:R<]
M1+#8S;OKY<C9VBM=89(&<#4\(HH4%F(R,"M!J/5XIX%A@FCNY5OM0#MG6X%*
MEZDUJ !_$:8QQ!/Y'[TVKU;M?9N"I,)BJ/>>Y=M8O<^#K*"APV?VSMKK;&UU
M+A]QG:VBM_A^;R@+(E"F/AJ :?3,&L\;$WY"VJZYDO+MKZXD;;H"T;!'[Q+2
MJ, !F,9J:@$T.0#T9[=8VUU<.+F,_3L#D#NU'*DCCY_( D5ZV0?Y7/Q(ZAWU
M74O8N*V;LK</7>_>M=K5>"WOEMMU44L>.R62I:U,I2BMIUJZ?<>86-U9*LH0
MVH,;\^P%S'>W^S7%_M]W-+'>VTK*Z%@2I&>ZE1\-&J.@QN4GTPD5XQ&8R:\!
M@#-3PP!4^76PULWX_P#QEPNUX:&@ZPZI3%R)5547V>W82,E03MH.1JONZ?[O
M(/5B[22Z6BNWH.FWL##<]QO"EQ!=2NCTTE22"2*@*1@U' #)Z(HUGOQ#-;(\
MB2*"I&0P8:E*^H8$%2/B!J.A#WCV9L?K;-;2PF<GCQ%+EZ"KI,#3Q0_MY.KI
MJ:G7%XJDAB#%A]O"\<8=42-PMV Y]H@LK^*]22N3Z_,])V.EM+M1ZTIY_P"J
MO19^^>K=N]T[6VEM#?.'BSFYMC[AW!N3KS<6Z,=55,U+75>%KZC:.\\7DH4@
MFI*['X'(3TE144\GW%%+%+<KJ1V3264-_IBGBUQE@I6E2P9A50//40,>=!T)
M^7.9-WY<%_<;9N4UNC:#)H;34*Q*D^M"33[>M2_Y'[!Z[V[U[\F-A9E\7+@<
M5F*?>U%UIDJ*GW-LW)T-/(E7C.P$P-;%DZO=-'#C<(4IJRJK(YH9$26:=!Q[
M--YY0W/D?F39IKR!!#I+>-;EE(B:FB$R&@20ZC5:$2"I6M.LAN5N:[3F_82Z
M[K>S*UNOBQRZ7)FUL9WT8'A:@M&;,;$5/#JKKY0]\_%/M_<,FXNF_CU3],P[
MLVQ@9>]]ETF<QM9C]R=C=?[GJ=XP]DPUVQ8((L[G9BWFI9LC5.DM4%6.$*FF
M0Q79>:>9[J-;2P7;+I(I96#NK1NB+K8]JU$C(/T]0U#3CNZ-]J3;;47<=S>I
M<+)(KX!+5C:IJ!BJL%(:N2*YZQ;BW;\2?EWT?73[#Z]J.E:;I?.YG<59N+$;
M*DQU#O3=O:]*N>R6W<U2SYBJW)78VIRV'BO7U%8U=7Y.KDT)XXU0D%^&3EI;
MR_W06%W:@.\MLJDU HJD2ABQ:HJIHP<Z@<"DI^SC\TCGNQY:Y'Y3CWR3>1(J
M[=<F2&&>H>:2>JM$J]H8O(=:R#5$35NB_=:=2]9T786TL3V)L3!,V\>K=M1;
M#P-%#25&R<QN[?&.;^"9[>+05=6L>4I-PR1_8TL,<7C$2O5)"8XT<KV3F$7^
M]2?O7=+B;=# RQABK!]2$H"VFI.A28B32M14UZ'',WME[D;;R-O]WMNQHOM]
M8748OY2]%@GM[E5G6VCUC$4N+D1I3PE+*.W4 +W/O3M2HZ\[:SF^>Y.VFV]U
MIB$^+W8&WH=T5,#Y'<N[-K[QRDV$J<;48/$03=:9OM?8='7SX*J1(6HTUD>=
M&5E\%I?K+ B7LRM-%5V*=J*:5BDS760W$&A&:=1+<1;2;:]:>Y2>*W*QE3-5
MY)C'(#(BM'H,32!9#&P\T%=)(*#S>'V1\<NP]Z[?SFUMG[FJ-V],=8]J]1YG
MLS"IO>BPNV-P[?V]O.+8V*VGN>"L_P!_!G?-6TQK*B6GJ*6*%?$460@F.U)=
MV23/>0*L\??''(!I=@Y%"%-&66FMJ$-I%*BIH@W&?8/WK<6IB:[@E$;1RM+)
M_B\>BO@QEB#(Z,L@;715)% 0J])'<./V!OO[/=U/MC"==9C*[CZXVUB\CLQX
M<)LO;IW121T/]YUHL=2Q4#4V"-4N0K%,*2U#4DB/)=BWM8-OOI-L?<H;T&43
M*B1E:NQ9P11JT70:Z3_"PK72.D]_N6T0W<=E!L)C$B!O%@D8+")!H\18V)U*
M%/B.H-6:-AP- )_5'7G\6J\I4[V[RW;64?76]M\;9R^ EQ5744/:]-C\[5;3
MVWD>LHL;64P:HP5AE\NDU1/!!'XM9\9.I'N%QS'8PM+=7<J1*&,NBKM!I'^B
M&@'>:!=/H:>G1IR9RU_6C=-AVG;MP$^[75\\$4<Y6&&\\1S%;:&RT3J*2N)
MRLY2,T4D]&TZJVOU7UU\>-X=B=C8?*=E5VU]^9?::[HW8:3([DRV9W/5>+K9
MY)C78_';7V[-BYJ*2N19S3T<\DRB1I) OLUY7WGF+>)[7;MHY@F6&;4[)JT*
M C 2IE2'DQVD AJ@^1/3/N1[>;_[:\U/R)S3 5WV"UAEEU2Q2^(D^IX75H0(
MT9XZ!H@.R16&00>MJ[^473; W3TIUI\A=QU]-69/H3)XW)=M34^&R=#!M+*'
M'M'@\?MRAB88W(8Z7&5T9IY:,.DOD)E)<%B).<;/F*TYBCY;M+JX&W[E'IB2
M0QCQ0/[9"VD, IH#J8$\1@CK%+G^]L.6DY@O9G==M2,OJ():E0" O'!H*?:>
M'5W_ &GWSC-H=:=M9:+HC+[D7K'KS*;AS>*Q-7M^BBRN1R%#GXZ3:.$JMRU=
M%34F2JY,1!!5UV4%)CJ45)8RR")[Q+<[)83V5K$=UMHDEF,(U>(PA0::RRD!
MJJU3H53(YID+7H#6>[WZ;E(#M=RWA0K*2- \1FU?I1@D,66@UEE117#,00-3
MS^8XF\NQ^R>S]RY3(;=Z[P==M#X?3[<RM;O' T#T.W<[B=S_ ,-V338G'R29
M[.1;EJLPD2U5- *&:K0U4K10LK>\-?</8MWE]P?WCLUVB;7:;7+'<:B4$LH_
MW'=>TEF4HP"C*JREL5(S[]F^=AL'*6VV]WNEY$\FYO(D<+,PB2156<Z-04!U
M*>(3AC'I4%@.@+^$/1<&Q/DO\89<#L+;V4AR_8&3I>R>T8,V*C*C"[UP]2<7
MMV"CI\13)ME=MYRF$6<Q=57R5$ZSP5B 1J59_EZ[W/<XMFM.8M_GFLED406K
M%? \1=2]IRTCBK5-5IP"D9Z+.>(;!9N:]VY<VU$AD1C+.JMXYC8([^,-0$:.
M0&6BM_29&J.KV/CAW3]UW/V#M&NQ6]I%BWS4QTV%1Z/&['3;=%F/[HQ>+;V2
MR-+DJO(R2Q-,]80U:]0-:>BR^QGRW)&NXW0$J>!X]!&$ 71\)4K3X]60Q-3Q
MX= #F7E2"3EFWNSMC?O+Z8L9R]1JIX@<-JH8] TLH''%*]6<Q;FVUU]O'"[:
MFWSO/%TX3*9^IV9A,J!@X0E:U/4)MK"TE/\ QJNS>;U?>K#.TL09*B5'4N(_
M<J6MM>B_2:UW"6&R5RLB&5UCTE*ZH$0 :ZC*M^,LY;2=)Q?O&7]X11_CG4%*
MTIQI0UX5]3CHTN[\]M:KBZ[ZLI\WC=V9W>&*.X=JR;HKOXL^9H,#3Q9)LWE8
MJ!%J'GGQQFJ<?5O3R4AK*;U(6109-VVUV]Y;&'<GDFM(E#&NEF<@40R!J!E+
M4+#%14#I@[A?;4S7MG++;W#LT2M%J4@LC%E5E-5.D$<>!I7.67'T%=FLK!MB
M/-XC)Y*+9]-F9YJ*GRT^)EVSE:BNQ=#D<)N2'"18EZZHJ:#3-!%,&DA#%ET,
MI F:^Y;6>2VBLU#C2X30@(4DBC*&IH-&"TX$#C3*!K;=OH/WC*\QLVE:(L7)
M)D0*[*P)U$KK5JMYD^8/1!^XL3\=NN>S-V]HTWQXPM!W)L+(U6Z>P.V-@XZH
MHLJF2J*/ TU/DQG*:KI,GC::LK,C0RRFH67SRT\8:*:+6ABCFC>D3<+VSVZ.
MX2#Q5JY914(O9J5#0Z"QH<T-=/GU(?+VURO9[8UQ>PM;W H(R"2!K-=18')T
MD@"F,GRZ4/Q_^/'06Z^T=O[K_P!"76>XF;^^.3J=R9.FR&4W?@]Q1UD.4ARM
M1&^07;[5F<FR!FEKXJ13][Y45U<,JH=A>;<WFL[^-)[761)45)8 %68\*$'M
M)!U$5'1AO[_N<F>PO)8-RB(5-#Z1H;! &2S+2A(/:*#HPO5FU/CEU\=Z[:^-
MO7&U]B;P@['K^P]X;<Z^Q38)]T9RBEF;(56YI*0^+*Y?=6WVJXP)&D$E6;R!
M"02/);*(M:S2P M&*1G/:!BB^E/V?;U'"74JK=1QS=LQ)DP#J+$$ZB0:U(!K
MZCI/)\I-N[&[>S'6.-PJT?6&T\?54E+1;2A-))@JBCQ=+E!0G$F+'SXJJ6:I
M<24+K%%3Q6^CC0267=IMMOWM9;&FW(J@!(ZO5P&4T&:-7%:"A#="R[V?;;GD
MV'?1>S2\R2W  76Q\0%FC\-00:LH742*FJE21PZ%^3L3 ]L9'%X6GJMS[>PF
M GBWAN/.99:W"823!4V)JZHT\F5R/BHIU6&0R5*J0:3Q-YM!%B+MBWW;#<;@
M+>UD>5+:HUQT34S*HHU<L"<@<*9ZC?<++<%,-O.'B;Q0&J3J':200>&,]%G_
M -(/26=W2M0?D/L'^[_?]9OC9'1U?1[DHDVONO=^T,ACZ##8CJ#>0I:3'+EZ
M:.KDI,C0)75D6<KW^YI"[Q-9'LVZ[JO--U'N<OC6$875&5!"%F JH"@@J"-2
MUJ"1Y$@GF_[7MT'+>V7&V,\6X2(69M1!:FH&M6((8J3&V!I!KPJ'';/=_P >
M8TP>VI-V5&X<M2U;;.RN3H,:^06+/;=Q<\>?R>3D@?[Q,?19'#UE/.TD+/\
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MB^AG H"JL> "U) IJ52!3CT,N>=CN-V@ELF:.SV22%A-/H#+&:.Z22(*U+.
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MM\5VY),%)3X6*>AR6'JJ(;:I,ID:%WJ:<+4S3%J:0F)C<OM]WNMAY=WS?DF
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M5%BLTM?V3@/M<% ^>B6ERKUU(E)(E&13"CE=V=?>-'N1;0?4QQR[?)-N-55
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M9D=@79@2HHQPHIT]M6P[ANX%U;A? ;Q%\9BV@O#'K:.J@G45*B,$:6+JJ5R
M7#Y/T6U?E[1].]3?'#YB;33&5W8.9S7<F5ZG[$IZK<%?U_MW;<E!N(IC^NIY
M<E72Q54D4$E152_PG#Y*HIIZH:I(D<.[O,;U(W>QT('%&(9E ;6RK4U7R9D:
MFHA#0D*2%6W6=Q"6:6U*I(&"$AE!9"NH!FTU(J%=0:K4"FI@#[M;XI=I]:#K
MCL_HWY.=OUO66#P?7.#[$Z8W7O*J6@W5UKC\1)MJIWF:6;[N2OW'N&JKZ*HR
MI9*&)@CM!X&'A)";:6/2J2?HDFIS742*'Y@^8)%,4QP6_4V[Q2D6B!@<%?AI
M34:'R.*K\JU\B>6^>W:VLQV(JJCJ_:DF IL]C>NLW/'18VO>*IQ^-J=R9C,5
M.WI8UJY*NGH,=!5_Q03P/""H19!*R>XVW?<)YKMK::.*&(%@-!(8D-Q8<"?4
M\14 >?4B[-MEI%):TO7EUPB2KC )6FD$9T@U K4$@GTI_]#:(VMNO</R!VQM
M_=>2J,=L+8>?QE'6[0J]L[NSV/W=E^YMF[YS^$R>RJG#TLD:5?5>-Q&,IJIU
M]%561US4I91'K*_;;V]W8W4KVL:VUL*,R%C(&%:$"H72RC@Q[FQ@"IUN5ML^
MRP6B&XNI-XNY>U&$8@-L54N2]&<3B0T72I54&HAB2 :?I6J[2KZCL\;LCZZK
M-N5M%@Z'9V3P.+W-02Y7(18VKJ=P0;HVIG*^6?&8N&2MAIDB6H\\RB0MI&DE
MJ^NOJ/I_I98Y&4E)5SKBF!&I7(U(5TE64JQJ#D^76F$-O"SFWN4+#Q(R^DQR
M0'".AHK%]:R"0%5"T4 5KT4'='8_8^Q]JY'^"8R';N'ZA[LV9/D#UIN.DV/E
M^RIL3N]V7:NY::#:F5VMB=C[@ILIHR](WVT\N.@1/NS/J?V1S;G<G=[3;KFT
M%JT[%:RZU50*4<%NYE?\+#!)IBHZ$EIL*7-LEQ%<QLC6R3#PF4J X8E69B '
M2G>O$'AT9GO[=G7G4,6[MP5VS,[NK8V$D@W!VGB\=O%,#M'!RUYBR51D*[:-
M*U/)NW+5M($GFBD$\;*\2R6!0 WCU@54T/ '-:>@]/RIT0B5P*5SZ^?V#TZ3
M?R6^0>#ZJZ]VIOK96UMJ;IZYR&P:>NVKB\5756 R6[:K?^2P^VMK['VC/BWI
M\+C9-V5.7I8A+.5C@8ER5"'VDO=EVW<["[FW35]/&DBL!4$I*A1P'!!0E?QB
MI%,9ZM;7EW;W,,5G3QW="M:$%D8%*@@AN[\)P?/HM>U?FKV%O6FWO1[P^*=)
MU)VWU=!1;DK,!O.:GW9?#'+_ ,*H]Y[/SN%IJZ#+YK#5D+RTH:#74\20RR*Q
M ]8Q[7=V5Z]I*6:V@+5 5CV1DK4M2K *,GB>)'DUN=E=6,\#;GMRAW?4 Z@5
M(:NI:5H*DZ2,CRZ36.ZRJ]WT.7[G3L[OC*[AW6V0V7V;M^LS.P,IE\+5Y3;J
MG:>2J/X-24E1+7T>'K(ZRCQE!"D=+-!]O+'$RD$"[J+G:?UV0W_C+"R3Q&BM
M#.@:)C45+AM:-I7PU9>WB.A_/NM_M"VUK:):+:RQ:F2*4R1AB2'0/0'&-2GN
M-:DD$'IG^1/R1K-K]2;?ZPW_ -&?(3Y<;%[#K=F;"RV=W+L_;VS<-EMX1Y>E
MJL=LFKQ]'08CL?>^_P"HI<$V4Q%5CJ-*9ZE(_)475_9ORU?;K+MBW%P\ZW^0
M1A:5!&D2A=3C2:-J'F58MGH@E-C+)(T6UVD+ZJU9I6'EW)&6\,)4')#'-%I0
M=&CS6_\ (3Y+8^#W)L3NGJW?/R$Q53)LC 55!M_LG<NV\_MC!%LF-Z8&BRDN
MQ:;:^RMOVDKJ>"5IJBIF=7DJ&DC+*MDY<V':X!LMCL\<%E=$K(00K,)*ZP\K
M5<"A('=1<44"G2&Y8R![AKB(^"A)%6"O3-!7)=ACR[1Q!KU!;XR]H203+'W2
MWAI9U6HCHOBGM.$JT4(,$E%3352ZFAB%E*@A+Z8[,2/=C[-^V2>'&-G84%%_
MQYZ <""=?#T]!7RZ#\=_8$!EV.#2N*5DIGU[^/IYCR/3C_LJ^U<H]#1=MX;<
MG;VXZ"::A;<T6T,EUSA:?;52OW.)PU!A=G5$^WZV*BK&E>OJ:B$SU!D4,2%L
MIG;>V^VVUJL>P\Q_N_9E6J6](+AO$X2LSSGQ5UX**&90 : 5J73N*:K>:"T2
M-XAI0*[C0 :C1W$@US6OV=9=[?%#X^;IZHJNM>Q]J[ZVQUQ14U0E=N,Y_<4M
M=@G@F@R--N"'*UU)+00QJC^-:V6GF\'JA"*MF&KCD^#:$_>*<VO)X*Y!$":H
MVJKQ]E6#$GX4RR'TJ.C6SW?<+G=()DMXWOF<$'.7\F*]HK\S3.>/16NR/@O\
M,]W[MS_9%/\ (3/E,WMW;^ ?%RT>RM_O1K08*'"X[+4U7N3 2UFFMH*:"I$#
MZZ05E-'-"HECCLC:[%I)%)9;I<6\ZT*M$65A52O%:'*DJ?5"RGM)'0UL=RWA
M9HC<\NPW42R O&<*Z*X8QFCX4D<1^*CC*@]'>ZIVUL+IGXH]C)LJHA^3F&J-
MW;[SV1I-Q8[;^"@WQN?=&Y88LCAMQ//BIL2:.CKZA$J:VHIJAS3Q%W61EL5#
MW\=ALEHWCS2VEE:A$JQ8A$+$)&#3PT!)"1K14&%QUKFW<KWGKGNXOIMFM=LG
MNVB5885HD:1Q)$C.U2TLA2,-)*W?(U6;)Z2/7.Q3W=UMV[T7VYU!!U5)M5-H
MM3XW:79&1[AZ_GVWE:^;<^+I=FG<(I\?A\Y02;5-/74,5)''3120&!PLNF-'
M!?6W,%A>)H(1: _"2#0.K"A(-#0Y/$>O0<N[:YV2[LKF&<GQ%:A(9#3*,K:E
M!&K()I\)ZKT^8?Q/D[4^)F:I\0L[=[T68V9)MC!=C]G[/QT>6Q^Q]]SU.V<+
MMK=E9MS(9C:^ZUIL,E0&Q\-'4FFBFIEDE6 JQ%><JS;SM,\S032$1%JX4*J_
M$XEH:4%"Q'"H&*BHMVC?-BV+FY('W_P=L6BZDAUL[NFI8WMO$ TL^I%U%AVZ
MJ$5 UDN[,;VUV7OZ;K_8.\MLQ4=5M;';JGEHMQ/M^@WKN6.3-[GWY)4;G;:E
M/+2M0;NSU308FHI<73_Q/'4=,TD4+L\AQYY^W*SV3FZYCW;ERW&ZV*I%(RIX
MSEF19%9BKZ90JD*#7M&,GK*;VKVZ_P!UY:MQRSS#<7&QW4DL\*3L($"*[(^@
M!7,#.P)= "'X=HH>DQOS=U;E%^+4V1V%B=H]@X.FBI,U65C9'&[KW+O+:&UH
MI<UNOM_*XBLR*9S?.XO!&V4K8B(JQHHW3QZ]"!^??MKBM=SNI]K!M5T 2V9'
MB$,QTF..<K'1JD-JHP'P@GHRAY:O+W=+;;Y;IH]Q=I6\.Z%5B8*"Z,T +5"J
M!'2JCSI7HPFV]H4^/Z"W1OG<.9II*:A[%J:3,8_)"JK,3A\#N;,1"FGV<U-4
MPYAZLY?1(L#T\8BH"YB?6%9E')UI:<\[G)#83;@D/T[2QZ/IQ,OAJ"QG9M4*
MB/)D85"]HP3TLYT-QR!R?;7.X_0RP"Y6)Q(9VC82-15@5=,K.YIHC.D_%Y 5
M'+=OQ'ER76O5XFWY\A]G8P;.V7GI\-TY@-C9#%[0ILFN7I1V?%N[,UL>70T>
M2GBK:V!G2H@JIJ:2*R12:M;OO1VCFVYV]-@VYIK:EO\ 47*R>)*BKJ%U<^ K
MQEV#%:QIIHHH.)Z!_+EY?W6T0O;WLQVN>1W2#5^C"9,&W@:0^((QIU%78D^9
MK0$3-P] ])=L;DZ_WA@MWX/9/9W5..PFX\)L#$;:PT&X>UIMO_P+ [H[/R^#
MH:[)-NW)[WJJ5,EE,]C*NNBJ,A6U$C2+J(C5,L^[M=;5+:[?%"R@BXLC,^(^
MX1*LJB-=88DZJ$Z0%'22SW9-AW"UW.>&:[*M*%$K1K1I@1JJ@#Z4*A. TJM,
ML02COC%VUNG!Y7>N^=Y;/WEV[GNV<QW/]UW3W#M/%1]<XS'5F4-'OOJ?:';>
MPCC=L['QV"-)324SY9ZC*15L5/1Q*J0%F/8=%]#%;+%):V48H\++59&52&<N
MQ*U]2ATAB=(ITNN^7KZPV67G"#=["\W,W?A+'%,5O;?4R-"3:!/%>*4ED2,K
MXC(C.^%H$CD:WXF;([UR&U]B_/3?VV_E_5[#P.ZL)M+^"[(VETOO?N_=$.1_
MB?2>Z^Z*0U51CNY,/!5!<A4Y2*!%BG20:I3/#[-QLL4>P_NM$=XEC2C:=90
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M@L+6?=-I2'<)FTK )"Q9J@ *]*9R14>6GCT[8;')N%Y-#;W*_1Q(7DFI58U
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M#20?.I[2 &R0"0,U./6A0]Z=A=&4O76.RW4N[=Q[OWG3_=UG:6-K,-+A=L;
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MALUF"+;K'5?TPK$"N%"X-3Q\ZCAU;;K[;;B*Z-G=&4^+W%92\:FE.[RX'!)
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MY#OS^ Y;.=9[>;"9;:W8CX U53MW,[GP%<E0<K5[0KIZB;$EV3QS3S&S.5
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MW17UEC93[-I-RL9IUMYMRA,PK^F66M?XJ'-1P%,?;TE2V,=O(R6[")B#KH:
M"HH,TH:YJ"<"E.D1VW\=_E=U?M'8>9K^J]YU'35>K/U/3Q87<=1M;%=D[DW!
M+MG?FV$RM/1T\^UNS=L4SQYF&GJJI8\K@7A^S:=8614TN^66Q1VR6:-'$L;Q
MS.AUNT3'Q%XM4"H<15-!("U<$="W9]SNIS=>-?Q&:D91'81K4DQZT5 /#:,
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MJE"2*#(U>GJ4L;V>RL+14+6ELK>'I7@KFIJPRYK4"OP#"\3U(H.L/D=\.*_
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M1W&6.2=(E1I'D4!O"#)#+(HHHD2,HM0O! <DM51]5=7(:2#P8(@H1HH#)(:
M!G5)&HX,X[I5# $D\10G90_X3^_&/9796R:3?.+KXXY\-W[GZ;$U&$W;G(X<
M2=MQX')5F%5Z:JDQ59M^;&5,#M%!$JM$RZAK0/[(9[>Z>"6&/<4EA*'2<MID
M% *@4#(H!HH-1C@*]1[SS>;+#;!;6QC@ C[EKJ4*2PHI))C!;%,"HIUN"=G;
M5W'UQ@<MVSL??4N>_N%C<Y-3];Y7'800[@V$ZP-1;"Q642-&P^1DR;LRY*K,
MD=/)4---&T4=@3;SX,.U7LDEHKHEN P.5.DU9FJ#4-7(H:T50*GJ"=M^BEO[
M2"=BJ2U4M%0LM0::%8J"U0 -34H23PH2'=K=_P"X=@]2;OI*;K/$Y^3M7L/;
M&\LIL^;>DFWJG9$LM-2X;>,M-D.NZ>C7'Y2N:C@J8((*LQOJJ!QY00$-VO=K
MGY=-QN&Y69E1X@J T8IG0"I-28U-&4B@^'%*=&O+]C<?ORV@@AGCB,<IU::J
MK<:%J<';\0S7N SU0YWQCNOJ3MS+=A5VVMR;9V'1X>$P[FR>_,QG:S)[^?:F
M[I\3MW;V]LO38_+OD:[=%+1QP8U8YI48+&\CAB?>/W/:[1?;S-?7$D4EI]+$
MA=:",!%>B@CM4@\?MS3K*+VP@YEFAL]DY?6X.\)/-/H3,B1$H9IG!-3%''4N
M2:*N?GT$O8&%ZFWIV_1[-V:=G9;9N"W#L+<.?RD38[<&$ZZI*_8M'-5-O\5>
M1AH,535^XI:^DJ?XE41QQY)6767"!P5N=K8KMU]=1&+Z)(10DGPZ#30,4-=-
M:<&J?D#T)I8.8=IN-ODW>TNX9KN1VA9E"F>A)UP:@0Q"D,&' $$]2LQU!CL=
ML_<O\*V5TSCL'GM_;KINN-RUN[=H879O8%=@8,8<DN0W!6;_ *Z49W&T%. V
M-I)_\E0%A#&7E(E'8$^[!#RWL%AS=S5N"F\VV!=U>".=EB<SF5EL@;9_!$<N
MD>,C%W T-*Z$)U#6Y<R_>.3F?F.]Y4VJP\2*]?Z".<VY=D$01&N3XREVE4,V
M@J%!((12">APZ2[HWST5W[TQEMET^0QFQW.V-O9:;I?8NU8J/%8/"14-;N79
M^^^QI!E\!V-@\?)F<C'@J035$V!H*IO')Y1(GLY]JMBO-VY2O1RUM-S?<N-=
MWZ6L[(["YB%U*L+:@JDLRA6.JA#8(!KT:\W;U>6=SN4G,EB7W#=;:T\=59-$
M-R85\9IE+$F/Q"WP%<H&5J"O5Y&3^6<W>6Y=N=/_ !RWAO/";R[8?-44F(QF
MSLC7Y;8VWMJ9";<.ZJ:/LK 99L'@Z+>&W$U0Y2EAEK'F00:HV#'W*UC[?[QM
M6Q74EW;7ED'\)9/%C\.21069H8W!KG)8(M1YD#J#VW5-IN;=[O:8[N6)I/!D
M!#P"1E"I+,O=J5#\(D-*< <]"KV5F]^]6XOK7"=;]=[:QNZH*W"TV%V!OS,_
MWZ[IWG3;MR4%/V!5T0FST-9MG=-)A(*LX_)U&&R4E5 N@>-R?>K78H;)+0;7
M JW-NQ=#+I:0U(+!79@%-!I#:0:#&>D\O-M_N<FYCF"21[*[C6)_!U)"NE3H
MUPQJ2R:SJ*A@"Q&JJ])GH+-]C=9-D,7F>DN^4QV(W7NS=_V%9T7O3*5>YX:G
M-PUNTZS 5$N*FQ$.Y\9@L=$KP32AZ)Y D5R" /-RGM;A-W>W5C=*. HAE*@$
MHC,0)5)/9W!:AC0'B$>5(4MK7;K.^N8HEEE-7>NF-&-%:4(I9"%^/#, 1D^0
M5?*3I2NQV8ILOWEV1OO ?&WN#-4>Y<]+-A-TXNFQ#0YU<O0]?=J[IS%9%2;2
M3)-EC24$%)2B>MJHS$1'$I4Q]RQODMW)O7U?*5] T3*L;S1OK)))8HE,T *L
M\1>.A3O)K13N=G92RQS6M[$OA2MBJJKJ5*5#G+#5W /I["* D](SHK8_9.(^
M(6Y]G0[ZWK24%!UC0#KC<NQMOSM@NHL'V'T<^6W;A=NUNSFCJJO$[.[BVTE&
MV3AG7[FORT]7#))3I*BM;AOFPC=-NN%W$Z[>5TF5@^J,."M)2R]C%R% _$2J
MUQT8V^VW\EM<0&U9/TPT(!4B20: 0@!R-(+U%2 .&1U9ILKK1NUJ"'O#KOM6
MNI-T=H;6V5D>P^B.Q-Z478W5L.1Q.RJ;9=?4[8;;U2NY>H=VYC"PHM5F]O54
M*U<D:3U-!),\H(L3<+2YMK$.BJK+6,.NAR"<5# %@"#2H..!I3HHECDB+P7$
M()C)!(H:$YRPP>/GZ^70[-UW'6I6XC<U=M[:^V:.#!Q[9Z^I,AM"&7KXX6-V
MRLFU=S1;=I\I+B][1>$U\60B=D\0,)A#DA68A=JMM!$S2+DZ:EN(I5<@4X8&
M0?7IN.]^BFCN $+BHJ]:-J!&0&&1Q%#Q J",=!YW=\8]E_)SHS</27;G:&7I
M<;N+&)]CE-H;YIJ+,[6R#P3T]#64<D<%-0YV"&.J\+4];#-1U"J"(PQU>W)-
MOO)4,9M):,:?"WEY</VCHPY<YF?E?=UW2S:"0 %2K4TLI],DH<5#*0P/ ^72
M1[.Q?7#X'XT=,;([1HLU-M.BPV'Q-)2YJ;+[ISFT.M(:3;]?OC,U>W<KC*K^
M[NULAM&6GSF11:BGIJZ=(98KS:"W:3VRRM;M.@N"C:5/Q,4PRJM"2V>&/MK3
MIJ:PW/<8=RWP6C_01R!II*,(T:8ED4MP!?)0$]P!/!20N,)VGU?VQD>Y^K13
M8_"/LGIC9,K=FY;/[5I=M[MQ&6I\W)6Y'$P09LYV'#=/;BQD,>5J\C0TU)#4
MUJQPM)^Z@;/Z7A^*"C$5 8%20IH2 P!(!Q7R..DDEI<Q*[/"?#5E4D$,H9UU
MJI925#,H+ 5J0*\.B58O8_8V<^4?0W?-/MI9MC[-V_N#-2XE\ VV=V]H=FTV
MQLSM:N385#4T4"X_"5=!GYLW!)4SK1Y>B,#P_N/+)[=:1"HHP.KATP 34@8Z
MLDV_TK1X;%8F;;>)H$;&;>W$V#H]WU-7/7/DMZ5%9E\G!N>>/'35,,=/5Y-T
M(AM(GC12&\:V,;[>+W<[BXN;V7NF"!PH( 6-55-*A@":**Z@<UI2IZ)]MV/;
M]IMK:ULX2%@:1HRQ#-65F>34Q75\3&FDC% U0!U__]*L#X0_S-_D!\+Z79O2
M_P <J')IA]L[OSF^H^JTQN3['I/D[VUV)0;;CW+M_LBDV-0Y#*4&S<13B.;%
M1;=$63H:FC;[B=@&3W/?-',S\T;]#N>\LT.W1SR:EMUA!A@9-$<<)EH-,358
M%BI)<ZJ@!>I,N>4.6;RUW%;>P>/<)K2%868M-_C*G7++1""HF+G5&I(55HI7
M/6X[\"/YJ?6--M3M'/?,3<'6WQIW#2;IZOVU7X#<6Z-QUN\*CM3M*IW7-C>M
M88*R*HCW;EZ.GH8EIDQ-.:NF:22FK%U4_D,/SW6Z[G!!;W5W)=1V[LL4A6-:
MQN:J*(HR*!<U! ! !K4EYYY:L.7KV.:PVU;**6(!X%+GPY(T4.U6-1XE?$(Q
MI9B*D4H;3IK _'?9O=6R\5AY]D;$[Z;J?N/<W7NU4Q.+V5OSLK9]1F:?#Y_/
M;M6BBI:S<4F!R&,61X*J*2IB9)JJ..0Q3NL<<L;;N\.Y;I-=AEMUD>,5)(,G
MB5.G)%%I0D#35@*C/1ASGN.TRV>WV]I*)9Y$AD<"H$:>#A2"OX@PIW5[23D
M=)E>Z_D5#1XB&N[GZLKI*YLS3YNEQV[L8*J"BEC%5B<OBJMXJ%YX*-]-(Z@Q
M2/+('<I%<!:+/F'P%CGAF%V%/:I!U58 '5P I7\\ >?06CW#:R7N&L[=K7Q
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M3C]NT&Z,YA*&DHZQ*W/TU3ETI<KD98"Z4RJ(WK'E0R(!J($NXFA*J4/P#\R
M*@UKFO'_ "]:CM-J??? W&^:WVF29F,B)JT*S,5HITG3PH:4T4-/+K6'_F4=
M=?)KMCO/X*]U?(#;V>^*^U/DGNW^ZO>^,HXZ&JH^INX=PUF5ZYVG@*[=%?29
MZ3&0;CZ]VA15F/@K*6J:3)Y5!#',UXDQGY@@@3F?G8SM"]Y,T+B*28PQM%%
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M6CW44T:^-'"JUH59Y"U2:#!! (4.30@M7ATKNX([:VL[VQEF>XE9W:'L=5B
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M;R5<<5G.O1EZXC=..DV/65=/4!342S0U+J(6E5?<GV\^Z;?MUMM&V[FS[1'
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M6ZMX)GJ&N@S\U3GUSM)OK.BFAACK,9,E''54\1=944:5DF\Y*V6Y5Y)H_&E
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M:[;E?BG#5Y:F:6C$0E0 @AB&X6SO+_>MNDCN$W&P!1V1"K:BOB!(Y'71+&X
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MISBI:7_)W^V*1OH ]R%8;YO=MRQR]OIW>-;BZC\4H8EKXH#JQ@/^A)I4504
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MF'PFC/<3$M1.K-0*=6@'!X=">2*XLHZ7/A2K<1KIEC8F-4>A93@:9: G0]&
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M'FC<[JZOX9% T, 2R+1JCR&10=([W:D@V_9-]>\C:ZO_ !F,:L?$@\&4Q 3
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M@:X%U=!=6D!@MJ)-6IQ(W=%&2%'=4H#T7#([2Z1W[UAM/"_(+NBLW'DHMY[
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MV7-<W<$OZJL(B=%2M>- *4-:G J .DD"%Y+DUC\-84E0@@#(9F5J_$R\65@
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MBH'XB.D<6S;FUW/O0V^5MNMI DLE"RPD@JB.W! Q_LP:!O+HS'\O':.,WO\
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M=AB$PLN8K*YNI) 9K?5JEMV- 0%!X(WXW (- >B#9M@YCW2YVN_NMMW"WB$
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M>[7Q2!(@R 4_"XJ!4UR12H&2.B>_<13R2Z&T-VL2!74>(.30$$4SGATW=@?
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M-K5$E.])40TU3N:O6%LA,):&2-S3U>4C#NZ-%3_JT'2?9=XENAE\,:%=BQ
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M&T@5R@S4$X))!Q^+)&.K;==[=/M6[[M=R7(LTHL<JP-)&9:FL;GXHUHP(>I
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M03Q#.P%9#@,2*@CS'2R!]YW*::WMX9;F]F#_ *<=="N:?J+'6@T@'4F :\:
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M&T,,J(HEA.6TYJV#<K':["^FY^VZ*&:6UU4BEL#*8T,3$F)[H,P8C4&= U2
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MM+M4UK*K&WSJ*$3-H08,B=P4'N#$@FAIUC_S/M>SWW(^Y2<LIX6_6M]"[K<
MCP]:F!#KPPCEJI<J=-!44;2>CFY?;6:%)@12R;FR$&!SE'75V-V;EC@<#E:K
M:>*JDRNR\B:AJ>NK=M;LW;E8OMZB2218EB@>9@D.EI63F&S\>[@V3; UK&]Q
M S2(5>-E*LH[Z%I-.E!+&#'W.5+ @]0;<;?NZQV\^YRR37<L<4M$<:&(1@1B
MM(Y7KV/W*%3Q *$$CU?!D=K)D<#3=F;]ZWS=+C<(E%LZ;!;DWM+UUN"KBI-P
M2[4S&X,96L=VT&-GS%125>3"QS5:HCZ@-1='<;?NN[W=UO5[,A:]D61D!"E6
MTT(-**%! K047R&10WV/=3:[3MUC].+<6]H1H=0^DFA,8<@M(X)HI8]U#5@.
M/+%U?5-)N"'<';/9N:GVI@JK^)T41I-W[:Q,>XYZ44.&SN4J<Q0BDQ^X<=G*
MF-,;XTGI=4EY+:58%/[CW*QEM;FXN_#B29&0PL/%\536,+DFC48/4#MQJ%:$
M1)OEWN7B)9,D5Q#&TVK0L)18QWL'_BHW:BU+$Z0#T+<^YNH:SJW8?76^,WB:
MSL"FQ&X=K8!MV;:WQO3;&0QN"RE3D,)D:V'$2X8PU>5PU5!*DDAD#1B:,+($
MM[$%QRQM^YW-IN<FVLMI(\FE:A7&IA*Z"OPZ6;%<@<#6IZ()=PO96OGFN5>]
M5$:1C^(OVAS3XBY!U4/Q&IX]%RV)\T^YER>^.J=E?'WK[=>+Z1R5?M&3</4<
M=1N;<64V[L[;=?N[%;Y/7;[8@.R]N[HK,3-M<4%6[S8S(52S+.\K1TSFN_-8
M;+;[=9\OWMQ(GT@>2%H9(1:O5M5NC,Y%PFA !<HJ1R2.--0C='.U\OVKV5MN
MF^WR*9V8K0J$:,QMW$GN619 *IP*#30.P("I/YNO8.4PFW\GGOB'L':N8[!K
MMECJS;E!VKC-U5W:5+OO>NZ.M85R&7CV7@WV/!C]Q;=F$U0WW54)%C44[*Q]
MJ]_>'ER?:8H>:XKX%(Y9Q")2D4<MNEQ&D4C$++,%D590%"Q.KQFIH>G9.0V>
MWW2PWR*:VW).R% %.FX#4I<=W8FC-%.KO4ZJJRD1.P/G5\J>D=[;UV_V!\0]
MO4T>'V?_ 'ZHLGNCM:*@Z?Q.R<-_#\76U.VNQ_[B>3LB:JKJ@5U;#/''EL6L
M92*DD1HKEFU;S#?S7C7]_);6QTO$JPO)*3E61!$2KG 8-5 0Y7)%>D'^MM!)
M;VC6.X0NUL1'=2.X569R[1OX+E)$"JK(Z@,05#$C4 1#WMU=E,YMC']RCY==
M@;8V7V!MZC[ RFW]VX7;NY,'UZW:6)I"=[;,W3C\5A\[55>S*//E<=3%*=J^
MC\8J7=X(FC".X>WUA)(VYVDM^MY<7:32NUY.66.HUQ0K('CM@!P55JO>E2&H
M%]CS<\*WVS36UD]HEA+:1F.UCC:32=44DQ1PTSLRC4[&IJK8*FJ>^3.V).G=
MKX_+;=WWVKOC#=A9G;&"?9F[]ZT,_6^P\7MS;,ST6Y>LMOT."QU9L1LL7#Y
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MSJE8P6J'$4E*A2^MU\09974ZFJ5:E*=%TVZ[>9947'&@JR&6,@5HA56T@T#
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M,JYJK*/A9@)<BNW\OMVII:UUB<O0UVM2\0;2(-NEN;BYMK$._P!4TB(N?-V
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MNMS?W6G<$HK-$AC\4J%!8Q@Z41C5V%:C@#Y=(C='R"7I#K+*=6X?&=:9^N[
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MM'KB!* 2!14:230,,@&E<5Q45)-NMK>ZM+*[VFY2XVZX7,J!M*EB0R." 30
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MIBK<?3WGHWJ/OD8QR,R.%"H]WV:[O]_AOTBBN+-8XI- [EU!6#*Q*T9D/&F
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M_:T^>W)U)NSM#<--FUW+5Y6JHI*C(4]-7/334R4M6RXER H8!I?:7=N9DM+
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MX]Q- "332*C-:=5.0_'';?\ =?JO<F[\AL+>RYF?<F4W/M/=^TLC6X#=6_\
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MH?Q&8FB:0 =)(H.CZ+D'9[I+RZF=(I+N$))F,L---(C# E=(4#O)J17H[/\
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M&T,M+7W,+WF+1QB?8>7[^_V!-Q@O5AWQK<B>.+]:+QXB))4#.^A:@,]5 <?
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M>1GD8M5E:CN6KERM:5J23J&>C;VZVRSM-B,8'@L[(%$5%:CJ6C _X6&^.E
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M:.H_;$LA"*WN5]O*6)GCL5:0E=*A22XU E0 3I9EKI+4"G)P.E0AMF.;@$E
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M.3%5NBOQ.Q_LI*^5,Q7.)_!)//2T1.FDCB2R^S%-JV&2U-K9=EXTFH2Z09E
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MUN!WS4[BIU:7$9BNGBIYSXZYJ: "P8^0R3R7SG*-FVV[WA5M-W-6>/XA&]2
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M1+2N&BAUZYO(T?[C&[K;KMRQ?JW\9@/FS=M/D3CS_P G52CO*C(I$RM7M!#
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M:B[4R6T^SZ*'>NWG)H]LU3[N2DPG\#S3)F<GBZ#$T5<V:Q-7B\A1(7FEF/\
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M D@O[;P)E^I2JR#6 :T'\1(J* X !J:U I7H-R[>\HC*Q-XS"B+I(+8)J#P
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MZ%(C15*,JT,'F[AT_P ,HT+-X0'CD)Y6RK[CUO9WG\LTQWW92*4S4T^7]B*
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M"5!(JI/\)P>(Z<?F>%+*&Q8$QDT>G %JAF*\7I4.*'B,C.'3(UGR%V#VCO\
MR&U^F.S8=LY;=&7RKU&S:?9U?2RMA<6TV QYVOFL]C(,[19>6=J2.>.I@-/.
MODD$D+M99M6Q[L=QWF\EVYUM[EU9 #&**?SP%/$%1ZTX=!"TYCY9L[K=;'<=
MT3M<@,1(6+U%:,(VH6%/\%:CH,M@UG<>:VD*WOGIC"=<9O>FXJS=T>![4IL%
M-A]N9.2N:EP>!?(;9ECP]3ON#;],):FL01Q3.TMI&(#,[M7*6Y-S9S!N&X[+
M<S[)X*(KH#(6,>C2^B(R2*H;4 Q0*/,BHJ3W._;;N>XK^Z=P@^MT&L="M$\Z
MB146M:5H:FO#H:L?T[N^*M.[%Z[Z?:L:NQF::;;M=E5H:ZGHEAI<4<UC,9N>
M5,IC*L1(M1'+3M354M[@NQ)$4NV\NWJNL[2-X>&4U5E#$FC(RZAJ!XD GB".
M'2QIK]"KQ6R)"0%J064LHS1ZA2:U(4'MK3RKU)^+758^*N#[O6' [MRX[1W:
M>PZO:E%2-591-XY"N>\.W&KLN^/H]BQXYXO\B\H2CIH=*17=HV-X=IOFBB:%
M&DC*A8SV@!%!"ZFKQX"I%3TE_>NV+,I-PD;*:-4LU36A"K3 &: &@]>@B^0G
M3'SXC[&S>ZOB=V-)UZ>Y\[DMX[EG@Z_VGELKMK.X#;M!C=H[%W=NK>:Y(1==
M[CDJ9==5C,>\V-JHFJ&1P5B*W9K[:-GAW:7?>4/WG=7-LT=O2[DMA:35Q<2>
M&&%P%J?T&TJXXL*=&^W_ +HW.6[MY=[,5O @D TM^JP(JJ@4H'4:=3&JDUST
M%6^>K_YJ/7&13KGIW*979&R]S]04N0PVY^IX.N.Q,9L#Y 9&6DSO:6Z]ZCLK
M#8[<&[)-V;GDK5QU.7EHQ#6-4R^.5!& Q93OM%SM7C[4VY60F5[B,RF$S*R-
MXJ"85:$>+1PRAB!^F@ -1*&WV7(O-T'-FX[YS/'M5[:[4&M 8FI-<1F-8[>.
M"(E3V50.Y1 JEY.[2>A;PO:O\PC.U/?6^^R?CCV/EMI=8'8&%^,W2]-3]=87
M>G<&XZG&UV#W#O+=N<H<]408B.CS-+'FJ^N:KHZ*AH*@4E'CZBJ(F#F[[7MV
M^6R1S?H$RB0!2S%%H:Q*S<31@FMJGMU8..HSVS>;W8KNZDL(U=)8GBJU-(!8
M$,P-2054]JT)) )I7K__U-L.7+=F8?-Y6D[7V8.IX<=O+-T>T.S,AEG[,Z@[
M>VS6YBFI]J;N[$W+2XX;^ZXW!#@JTR2;;R0Q>)DR=,H3(F$*HO)"M8EM[@D$
M FJ]U:97C0BO!AFG$ ]/^&AT&-JCB1P-?.GE3TIGU'6?<:9RF[2PW;>%[(WK
MB^@\32YCI/M+X]0;)Q.XMI=P[ER)IJK8?=G7?8&)W;69;8>W,:,U4MF2U5,*
MW&T(CEIH):9S4N% FD%UU$5K4BA\U/S\@/,D9Z?ME<2$)(!)QX\*>1J/BIPP
M>B5]M]38?+;6[.R6%Z0Q._JNGVON"FP_27QF<UNY1V!E!445#OO/=_Y'-83%
M8O!4.,K&GJ9:C(B>HQX:GCQGD#0NK@2$O'&\WAJ6!U,.('HH!)/EG!]:="BP
MWW=+4(LMP@@KQ<'53T%*?E4"ASY9U+#_ "R>V/X3B),IM3;?<TE30&)]SQ";
M 9/%RPTXBB?%U5?+)!-%51&PCEIY1XSI;@V]B&9+*X1QX7A.WG'V/]H(\_G3
MH=[?S3;(ZO>4<:O@F'B(PX4=2>Y37() ^?0']A4':W062DVFNSLSV#'_ '3W
MUNS#;6[EVO52[)ZJP5/@*'KO+9MHML9G:,V\\_MS,2QU6V:AVG?%O/Z89E_2
M'MYCV:#;;3:[E[A4CD>91%H2'P](5M:&I>;570Y-15C45 &5OM5SSS1N4^][
MA8;V%WO<]RL+47#AY)3)'&!%:>,JE1:SHJK- RUDCC(5P%))$,ID-]Y39LF:
M_@^WJW#4TN?PM5VHE//-NGL+<,$3Y7(U&Y,CDL[E9*JCP\LYACJGH*:B6B44
MY9Q=?9[L]YM&W<T-)97%SWUC0N4TERH<:E^(E2N"_P /I0]5W^QW[<>6]UL9
MWM&N+31?SHB.JQQ([05LW($$,3L]9(X\/3%-)Z/-MSO/8?17Q,R'8.-VG'N'
M+]FC:^(Q;;\V)C,YUSUEDNI\+AMG[-W(=L1Y/(;7R^'FRT%37TD_V,*C.2(\
M$JDO'[ NZ[;N6][W)N-U$UO96[:T:)S^K)(QEE=P"%2M0H90&4K@@4!-(=VM
M.6N49]Q:%V2^A6$--%&T,<<2B&.,%:G0@^$"J2%ZO0YZ,U_+Q^>WRK_O[1[0
MS7R0SE94;SQ>^>WZVO[!W/55TFW<YBLGC,36=>/)N>MFVMC=M9+^)?WBGH#&
MQ,*:*;0O'L;;CS/?2[=M8VJ1X=T73%+*S,Z,%+-XAC(*ZG&E&:A;SU"I'4*2
M\B<H;I<3?OG9+>>)H9I_"6,1.KD+&J),FED"9=(U.D:F)4G32V'XZ?SJ.S.R
M.W^F.KNSL/L1=M[Y^1VT>J,9G-BX"M?&;J9-U[:H\U7- :^6=Y,7AJ/(93Q4
M\0D%1''*CO"CQ%/MO,.\7]C*=UB\.8Q.2K"@(*M'2AJRJQ(E0UK74IJE  I[
ML>QO*/(V_P"];5RAO:;O86\$7@W4;EE:9HDNI$#5TM-!JDLY5%4*1"11XFH]
M;)N6[OS6>[QJ=D[;DQ6<ZZW30XZAKLI4I6PUU?-/-34[X+%4WV:T57YJ'(U-
M/4)(ZU$:E9$37<@G:W"P:F/ZM>'R]3]GE0=8\36=S;.L4]KI[*D_[/#'05;V
MZ'W/VUW?)BO[P2;NZHP&SMD4E/-@>PMU[=>H.-DW/A!GP,3/4;>J\KC*6F-!
MD?!(JU4D?D\<4R>,%UU.@M7@2-_JD/B56M2N%T#%":YIQS7IN%YX%^IBG":@
M4 *A@&K4GY'TK4<>@N^870NSL-UINC=]1\1,;W+)L_I/.];8KJ3<V+QD_2O9
M>5Q&2H:J@3LJC1<_EX=LY:?,3-39&0,Z5,#35"SC39U;6)98Y'D'AHJ'MJ2"
MU=0 _$4''U)H.G;?<]Q#M&+CM<U)KI8FO -0A0:>E!QIT%?QG_EY_"_IGXB4
M'8^#^/6R]M=O;JZGWIE=[[OBQ[8'>4'8<%+E\Q'UIC5GJV;;^(V)F?V,'04C
M"(Q8V)ECDEE>614EU-#W'!(QJ]/(^IQY<1T_'?7TWB0>.QHP&A3J&?G3-3@U
MH,U^75?D7PS[/W?T/L#.=(?)K8F)ZMP^P<3MSL/XY]F=9;JDR>YM[]>U%=6=
ML/-V1N'(P9!^Y=Y9AIB^8K:=<-1S5+P4K34+E?=[[8KO<]MGW"#>]PB=HB([
M>*1!9EE.M)62@8ER*$%B ]#IZ%/+W.VW[7O6WI>\O64LJS@27;HQNUCD3PGB
MU!@C0Q:NU=&HK74QQT%N_/B;\@-K]&_WUI/D1E*V"IZQCVKD]O='=5[ ;9_9
M%0-T4&<VE/2]@3UE;VH$VC3T=+045"DLV)C@IC3I3E'8L9V7*5E:SC>+SF[=
M)V_2)5FB2WC7P_"(,$4(7P]3FXG8$R:UJC!5"%/#S!#=,VV6O+UA&X$RAW$C
M2,VO6C>*[ZBRA/"@4@(5D(D#,0RERK]B]KXS/93LK [7C>D[&P-!L^OVWVAF
M&VSMK;>+HZDU6]*OJ[8^ P>&PU+EYLO1PI%034T-3&9W64QS*+BS;?I[-]RM
M4M8]TL6BFA28G5;!WHJWD2Z4Q& PB?0-1-2*$5-N;[ZQWW=AO%M%'LDTCV\Q
MLX@QFTH@62UD=R['QV D=-9(KH!QT">/S>]][]F;.Z?Q?06Z=E2]R=@KB_C/
MUY/M:<;_ ,))75%?N'N/?G8>TL9J@SE#E*8Y"N$M++!!3Y'%I-#JD4Q2K=[N
M-KW/<]T%K;1VVWP6ZM'&I<0H6 K5R2WB2,A-*FA8C"TH46]JFS6MO?K-).+F
MZ(:>:.)9I8XP &:-241$UE3D@A:U+UZ>]P=4[XZ_Z>Z2[%V5N/=O87<V[=A=
MG]>=_P#7<,W\;R&-[?K<IE6ZZAQ. %'++13T-+%2U^.8G1D\5>OG,921/?N4
M)H(^9VN?"\&TDL)98FHWAJT<9!4L:J&+4[2Q8G@*9*K?83]!'9O]*+JTNV\4
MJ%65A(%=:Y#/%" 54A J%B"37 +_  (^3NXNSZKIWI?<VWG[ZW?BNRDK)NL\
MKG)\;4;_ ,]4YY:_;/8V&R.,DQJ8;?VS,,^2QN0J)6G%7A,7'!3TOW:&8@?F
MR+<C"\T#*'GE2XDD(/B&:$@AC2@-5P:X.. !JOV*^2>;1=.SO%9S01J6&GPY
M2*J-0( 2K,,K0DT-<&^W=OSBEZ+^4>]\C1R4E3'L$T-!_"%*U$F:JY()<AG,
M;!AJ-*=*K^*TU4:.::NJ(H<7'()U*@6 9OK!7N8]UN83+=DED?O"HK!0"0M%
M>E3HK4)J/$Y 4FB-YO\ <[;$Q, !J*@,7 .$K3OX$*<L 1Q('5L%?\U]K=A=
MY]8[/V=.U;UCOCJK/[UKMU:ES6*I<_MR7!9U,?'C<9!)D\?N/&TV2EIY2RR0
MUU/K*:!"KNBW6>VGM;Z!P"\83C\(U ^?[.&030](K:TN3/$D5/$ D#K0AJ!0
M$ /E5@2U1@?/JDWO/NOKW;7R0[2Q5!G=H8]MQ8C*8'<VW<SECC=Y=0Q9&JEP
M% ^Z,3301Y<9O*XBK$E92B1I:>FJ8_'J5;D >YG+?)<FU\JW^QS2)N=RBR2U
MJ2[Q @"45*P'\:. P[0K+6AZFKVWW[?E6?:]X6-K>Q>2.-E"OI28JSM&#I:9
M2PTZ6*TK52!CJL;L7Y$[EZD^+W0>W]J]A9X[I["V]E,]7XC*X7%U6+QFUMV2
MY:''XZFH\I1Q0[=V]M^*H-)A:2F\M2*=#+6-I58WAKFN6XO)+:T>=)C*6FD+
M"NHI0!L8[:U6E*M3RQUE7]W_ )8Y0WJYY\YMYTY2>;;[=K:RMI%F\(17<Q_L
MA'VAY+I4)NF;MBM581+K;6 BR'9FZ?D9GOB+UO%USNF3M?!;C3%0;/Z^P\.5
MVYNKJ_>^T<M44_:$>RMO44F'VSNO&2X:GJH374].&HY*EO((IV'L\M-R3Z._
M.X6]95LCIH0-9;M0Q_PRUH=(^9%!PC?GGDC:=BO9KSEK=HI>4[W=)K:6!V_Q
MJRGB4LZ&1LRVD8($4I(HFA'#DANC0]D=K;CW-T/U'0;1P&[MT=C]8;;R6\L!
MUQMC(8;-[@V-3X:"##]CYU]N8[!_WNBP,Z3Y7(5TBY"=JC[C1.95C5$"_($=
MU;\Z[==P2C5%<59^X K4M@%J5-0!BH(U"ASU3W*3;6]MMTC$;1W-U;!45-(D
M$FG0"S*NK0B@@&N02AJ,!3_&3!;YEH-N]P;3VN,OM;:$RY'.0UE/2Q_PC$5]
M-#5Q4E+B*JLQ\E'%ES)#X9D\R4D,6J1!"RN0W;<JW\&[;_O26O@PF:4R*%",
M4,S&.5]0%%%=0P2U0:9'0K3GJRM-NY;VR207"?2PQ+)4R)XB6R!XHZ'+X 8@
MA5\R:$ UG2.YZ3H[.]F[IWMWKM?K'"[_ ,[)68'(;UR.=P&5R>?KZJ;,978,
M61VK'75%3CL0V2_B$,=-I@=@'=-14B2.:>:K#FK:]FMHN1TEO+.8ZH8U40/'
MX"QI-JJ)BX<,S"5CW.2&(TJ,=?ZK[EL.YWFX7/,7CVUZ2P:9SXL<ID>1DH"L
M6D1E40P@'2NEDRS$=,?\INH?L<R)_F!T)79VJCK9H<QG>UNUC58>M>*:"@R5
M-1PTV-#TN%=58TLRZ961A);62([FME*EO];=U?2P+*JY!'S+#'X:9K0YIT:,
M+AEC1=_C\/B*.0 ?*H+ $CR\OGT4GOF/>.Q^Z,QO*?LRNVU@=Z9C*P[UZ\VE
M58BIP.6@W/U2-]M2U.9Q)4?PK>]?MV++Y(F?_<;CGBF#I,WC,D;-#<<M75KO
M6\\HVMZ8K>W 6[+R*R/*L)E2($%I$C+BW11375F!44Z$$6X['-RM#RG8$0[M
M/=-=QWT,16Y.A'D>&1B2J1@C1)(O<54(30@]";\:>R]_;V^/?3]7L?<FX>T^
MR^M<3NS-8OKC?]1A]L9I<SV!FDI=C[ WSE>R:S$9K,]==9X4-5QSXR>KR^0Q
M,_C:76*8L(_<V]V#EKF/<_<%-O-ER+=7=S^[2D,FF\6WB"7!"0K($:)S5U 1
M%DIAJ,.@MR[#]1M$>S%XGW2X6'QY')UV0U$T0$KK$R,#5JMI3MXUZ#?K?=O\
MQ#?W0>,W-VATWW'U7V/M[O&E:JS&[]H; K=O5>!ILMN:63*=80;IS2YQ<C4T
MFZ(\.8YZ2*2FP-('HI)JN4J6N5]RY2WJQCW.7G/Q.3;B.21MRB'Z<;(VL1(S
MH0KZAX!PP PM2>F-RD>SW!5M.7X&W 40VS,U)59?##N(W!8 CQZU%9/C&D=/
MNU>R_G?4U4N4W!\1OE5B\+DH*O[W:G3]9AH\-M3([4K)L9B/[EQY7=E'3YFC
MWQ1-'6L:N.G\@B(\M.9.6(>;MFN7+1\W605I&-?!EJL;"J* 5^-3BO"F*5ST
MS)M262HEULL_BB-<>*N64T<UX%6XTJ#7.K30=&!Z*I.W9-LU>Z>Y-D]K;<WE
M_$)MF;HV_NS+9],AN+;]!GI-[X[.KDL+592EFK:XU_\ #(IF J(J6#PNQ0W(
M%]PN=]O?:=GV6RYD#1F]>XDECC8$LD2I'#3MH!5WI4J":_%TDOK2.QFL[F6R
MDMD?*C0)W;10T4<.XL15@!0&E2.E7WCL6E[$Z]W?LS%[2S^UH:N*3*)6;9W-
MO:IRU+'@ZJDWM&^-2>FAAH\[22[=$#5B,U/,:AHY.%DU ?DKG:TVGF_9-Y_?
M4QC6X(\!?$57213&T9)=E8'5730=_ UZ=*[%NTL%K!9V\,UQ(8UI R@F4!=3
MNP(_3PQ"E:D&A!'3]7=A[)[#ZUB[-W+M;9/5,%;6P[WZMVCLK&[O[6[CV=M+
M&TE;4[HW;6KAE3)3[TCV_/'%DZ2L,-'#).[ ".Q:8=YL=_YDCO)]XF-O;L\3
M+#"TDJA44@]FL+X@4T:ND&3NICH6<O7/)O*%]M-IL*->7L4<Z37-QHMTD=B
M &97)A,G<A74XCHH+$GHF7<6S]U[R3/?)3K&?86ZND^FI]CT^&[ WH^?K-_X
M/$]@U&"W)UWVOL*HV%ALI,JM1[EHY<S-0T:2T\,$YIW3QL/<S6J['=V%N]U
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MRW!O<[0FZZSU15_;Y]]M3Y&?#O2QM(W\-I4DJ Z2,1+&B".WENW1 [FB?A9
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M;@#:MQ&Z<QQ6<]MIM6M374 1XD)U(R DD!AJ4CR(4G(KT))(FVJS-WMM\ZW
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M.&UJ*5K1%4 D* >CZ/E7DW=$N;F]LQ8:E216AD<::H%>-ED+:RQ#2DDKWL0
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MQ.]JFHP.U_[I=03=@4&&^UG.(KQV1O3';53"[ IL#)E15S9.NG9H5 F9V +
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M*DJ*BNP,%50K-#/*]-IO(0Y#NI;AN? %W&+.%R^-3I^I'1J]C AEKYBM#Z5
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M[U_N?LOJC/Y'*U38[ 4VTX=L[IK):.HJ:/=.0WO045)5TV*CM)0U]7)%H5(
MP2;[;SWN\[5O,K6,-I:Q6<!#Q*I1+6-M+N  2C!3)))QE((+'%3CDWF&ZY63
MF:ZY?V>[DOKR*03*6-R'68$MX4CJ7A<,S %!IA1EI50:(SH?$9O<VX_D+L_$
M];]AXJ/M<=5](8W<V(HL=GML#!;*K,1NG<46YJ:KJJ":N[(VKFZDK3YW[<M4
MFGFCAD9;^Q>O-V^>X6V<OW]Q<6<F_P#+-A-=WBNT*3W?U$[+ UO;JH K'IU1
M1MV+ID<#AT$;WE:RV.3<X)[.ZAVZ69(K=LE$*1J94DE)HQ&N@8BA;@<=7E;9
M^,&Z-A]5[EZ\VS@=@;APO8V!GQ.\8*_#56U:3*-C8_XGA*\24GWU;)N*OJHX
MZ.7340P4]1Y*B,(Y5O:2T:=?W@LD96%]&@@5KJ(,M03V^'E0.!;(QT$;U87G
MBD2[D6ZC&,JVFF%P *U\S2M.GK:V.R?5JY6HSV%S6PZ_L#;&UGC7?E9_I7ZK
MZ>S_ %SBL'L_ [/Z?Z\QF!K\_B,;V+0T]37Y.23(U#TE8L%0PJ))O$!+:2P:
M%C"4 -!C\.>)]11<_BK7@.B*YL'DDFEBF,CDCCYU&37 &?+I[WSVYO[XX[6J
M/D/V91QYWH+K'"]C[U['WSVQ%!!WG+49J@Q&&V'LCH'96-I*?';:QFY]S200
M5K9_(TLU0#&B4\*NIC-H4AN*HBLUR0-(457^D235CCAI%/GT6LL<:.KR$R@^
M5-(]:GS^7^'HJ.]_YE'QRVUU1U9\B>[,+4[.V=\F-R[,W%A^I8-PQ[DW/5[8
MPV4AH-R]D;CQ=')14M3CNO)L)!+6"*&6FJIH4@QTU=,0X#-[RG>R<R#<7>FW
M!8F)X$RJN(@*UJ.UF+ :5:@&>A'!S+8)R_;[:ML'WA?'2I (CB<T#Y6@UZI*
M%6)9A4X%.CKY[$=G;IK<KVKU?7[%[I^,7:5)L[L?:F)ZBRU5LKM!*RLPD3Y3
M=<.[:7<D&R^]]HYHP4>2I,3638*HL/MA4SPZ82(I4A*>&H=):D,01D>5,54^
M1H2//''H-#PVC5"2']:U!_+R_*OV=!G\D>YLYT_M'8_=.-ZGW9\@MU;#SFVM
MD]=;?W)O#.]([KW'O/N6#-X/LK"[XPV<VKC]B9*##;8Q5++BU>/*-%*'0F!D
MBFJ#KE^SV&[W*&VW_FV+9=N\.1C=R0S7,:,BAHX]%MJFU2L"@:FE6IJ-#A^'
M:KO=V^AVZW\:^8,53%&"J32I( -*\: 4K\NBL0?S8MP[9I=A4^:Z&IMTYWNW
MK7<W<^QL5N&O3J6APT5-/7X[;GQ]QLV;V;5MNK=]3E-OS:LK4-!'%]PDTT*0
MM$H#$>\+#+$VY[AX5I)<1@2#4?!AED,0FD4$L?#H'D5.XJX5%)!ZD+:_::ZY
MNOH]MY-M3-?P[7)<R1L49I/ C>64J%8!00K !R?#5 [L=72_R?7.RNT^ML9\
MG-Q=I=\=6Y+M[;.*[8W[UDF]\=V;M#9ZY^CE@K]N[?KL9M1\D*[85+D:B7!3
MT,92"JB53JI=4/M!NGMMRK<7>X[MM2M-/<74<INT>XC,R(5!98Y&=H$D0'L4
M)I;NTZB:A.RYVWBPD38KN2![*VM)[18S# "@E!-#(H7Q2'*U,C.S*-&J@'2N
MS/P_VEN7=^V*S:&_.Z<[-N&3:<&1P^^M^5?86PL/M?;.UZS&8FNP?4=9'C=J
M=<_<15$<63FQ4=/)5)421SB1I-:J;'D_8.5GEW'9=N/U<YF220O+*Q%TZR3-
M(TLC:^Y4\/ $2@K$$4E26KOE_N%L+*_DC2",1LJ1QQQ]T(98PK*@85#,9*D^
M*:&3656AKMR?'G(X?KV/9.T]D[%W'B\7EMO]@Q;>E\FVZ.JWSMO)4/HQ<5+*
MM0E/6PB:I\M16"Y$=.W[+.GM3;VT;6_AW(*GQ2*"AK&*Z26R=1.D_):CCTF\
M>99?%CN7UDY)IP/$ 4H!]@Z#2BZ<Z[ZTSN<W!T_U]2;2RV5[*PF=[&:A+;JR
M.9[5W/392LGQ]7F:K[RJR VYN'< U?:5$5-"\CQ@1QC2L-^Y)W"]WNSCAE>2
M)8U5!7M60NO:@QI#!03\Q7'D,>4I["V#0W2JD+!P[ 4)C(;4S$5U-0D"M:#A
MU'Z*K]R]F;K[0W--F::HI<14;-_CV&P.WEJ,[N6KAP&9EQK5,N0G>:;%4>YR
M)X?4T$AH2J26U6'')=LMC=W<ES:1_OFXM+B(MK"I"T=\F0@X%X@ZZA^%@0,Y
M"G--Q/N%U9/#<R)M=LZ2>$J"DJ&'2BJ. \.2DA'FVJOET(>5^/LF7RO6AKAV
M)7577NX,KVCNF?)97.5N(WE+F<=O7#/AA.FYJ63-[NHL=N2>.DIJY)Z"A-1Y
M(UC<1,DI-OUR[WT@B@1+F!(*"- 8ECT4*46D:G0"S)W/3NKGH*V^Q6]I!:PB
M:9VAN'G),COXK2%R0Y?+TU44-0)P6@IT(6=ZSW;NO:6?PF0BSM1@]PX#;VVX
MML93*4X-#C*2LJ#/5)&]1-#1YBJQ,_@KIC+(TP('&GV TV:"6\N+NXGN6M)K
M1;=K:1PT0T.Q$RJ&(5I$8K(=1>0::TI3H92W<+V45G):P,ZSM)K5*,P= IC=
ML%D4C4JT 4UI6M>DC%T;C>N<CN+/8+"G&S;MS$6#S>=ST<6ZJFNVA#6S;HFI
M*>*BD@?;Z?Q U4>,DM*\%74*\D9 7V=136-BR-<[?<7"M5%$664A6:,D?BC#
M**IQ8D)4:J@GFMKVY9Y=ONXH+I>)?@T1D4O&I!&DD,V@FNBI8@Z:$+NW^M*W
M/X"H&>VUEMZ8[>5#L[:,\V[=\5N&\6U:S?E%OO<>[J+"($Q])OG86*G_ ,BI
M?M->0-"D3RK$@C?5OSANB)!N&VV:VL+M&\0T>%)I>(12^(GQQL$+:XF8@NS,
M<Y)9?\N7!-Q80VWU\R.JN7EUJ8_'$CLKB@8Q<8M.G6BJ,#!J:W+V'@'D%!L_
M>GR(_B)S.Y)I\]N/9]'58K(XK+R2R52)C<=/BFIZJ.O$+T@4?MPJZ@!BL@C"
MZVNZMX5LH9HWTJ0KL"*9'X1\34IG]N:=39MVXW#M)>75VX;Q$[ %:H"GN)II
M _"1\1J", ]5U_,G(U>UMO\ 5^X]M97=N8[$W;W514>4KMT;2K8<;&<!MR?*
M8K);8Q]6V4R&+Q]'4M')6RNK'RQLR/?2ON-N9N5=[%LV[WLGB;?""KZ*J8RY
M'>U *IY%LD$Y%,]3=[:\Q6$FXSV$BAKZ9:0ZD0A@ 6:)0:U9@,5XT/K3KGWI
MOKM[KC?G7O\  >RL!V;UEO7=VW=O]<_+7!4]##2;;S^?V[/E=_;*PFWJ6F@-
M7B-JU\GVN9&YZ>MGRE2$IO\ )Y2X4.W'(/-.QR1IX3R3NX$92.1(Y6"ZW4F0
MG48T)9G2B*%U5(I57MG,/*N\6N[2MM#PP1C7(LLRLR+KHI5U'Z?B,!&% +&N
ME0#D.OQ_[1Z*HOE#\LV^2>S\7E]GXS:G1VP()=S;#I>\=J9?;^0^XW+4[IIM
MB8V*>BZZR.?S=!'%2Y".-JU<JI\DJ#0Q-[.UCNKZ_%T(YH5TT!0EHPV<DC&J
M@<!?A)'=6H#F^S;_ ,N\H<@\R<LSWFUW-Y'>#QH)7M_J)()"CU*M^NJZO _4
M)0HGP5ST5#M2#MS<'\;ZSBWCV#F.N:_NW>='OW 4\V+J^R:CLNGW+'0[&^,^
MQOX72QYK'86GVM/3Y:?(99:RGV]051K Q;QHI1=NH!(:NXJ'4AN"Z6-6/F56
MH9$X$F@\^A1=6-M:[CM4J[):0;&UA9S03P(1]5:31"07$CEF#W#,LUNS433)
M&P==0J4GO5.TZ39_=LVV:#K6;:.^5WITSU'MW8$F3S796_=]38]=O4>&ZOP^
M,A:HW_C:')9"+'U68#BEGREHX> [J@V.WNE3;X=UNI9;Q)3(SE>U4#5 (45U
M^:@#AQZ3^X&Y\JR;K?W_ "9MDFW[&;>-%0R5)F*][DNS:17)7504+8'0BX[:
M?</QTVUO'HSOS9%;M3L#,=?=19RHV>J;DR)7+;\V1CMMY:GW57[0SE-B-KXR
MDR&-JB]3.]51862>MA,BA@&"?-(%US-+-=1+;RRRL:.%0*"W8^E@6!8'4Z\=
M5,8P,.1;NW;E>\N+"'ZB%06_0U,)7*DRI52%*EQA\BA-"01T7"M[*[V^->R>
MT^G>T]C;XV3W%MW:&Z9J;=&(W[04O5V/V/GVVGE<9)1?P>@E3>6'W?1+% DL
M=924<M++H$A]<1ES<MNO)KG:=V:QMKC;XUAA,\B%Y2:,* DA!I![=2,<GAQZ
MA7EJYV^#;M]VU;JZ@O9[J6Z\"-E2W#C3H<BAD9EJ1A@.!\J=,%!\[?E-D>F\
MYAL#DJW)=?=9XW,-5I7RF#<.(E7&4$%/04)J7I,AE,?M_;D]&,+AJ">5%J"D
MTAM(64);I8<L+=B*>U"WU[_9LM=*MJT]NFBQC%2345!(R*="FTOMZE0RV\M5
MA4+("H\21=7B=^JID<L>."10''0-=B_S&MP9'";3WENG<.U]W93"[PQF)KL*
MNV&VWG\IUSUXE5'E=Q;GV+#EZK#;,S62>NH::6:*K,RTBB*0SA3J1P<F.)[2
M&%)#9A %C8EX1)GPTK2LBN-184_4(!Q046#FB&""^HP-W),VJ1:I,8FRY45T
MQ^$P700:1:F &3T9^;L6BWKWS+NO<&^>NMJ]"8>/#92CZM-1N;%8J#-2;<IM
MP4/8^W,AB<G1Y-=S1C+Q&DEHXKO$\D%;4/#*T8+I]ET[<;?;=T:TY@3Q-#EM
M**LA'B1F, G1*%*L14BB%-)4U5IO>J[:2ZV_ZK:I&0R#2KNQB_LG#D !XB=0
MR 0S@U! $WIS'=";@^0>;V7TU7G(R?)O=>RJ; ;9VK38S<5-BMX8*8YRH;8N
MSXJ>!MLX>BFH9*NF:&5E#^> ((8XC[$.Q)NGUO(UH^X+N%[M=R2A4$R,A1@8
MI%))<Y55D-"P"$BO1-?SP0[=SQ-!M36=ANEFR3U/:IUHR31-I"ID'6BURQ(;
MK<_Z?^$N2ZGZ(K^K\7B.NLX>R\'44'8M4,&VSES%.(?XK@:Z6*(5]?)N>1HT
MI);30005!DJ45'LWO)O:ML-M:7D;Q^&TJH5QFK4+AJUTZ!4!:Y;ACK$;>-W:
M[W'ZA+J4/$:)4A@--0"*  UP:D$D>O#I7;4V%N#JV.J-?A,CM?)]@[8VYC:+
M';ORJ]I]7]1Y7K#%XO;6V\'U!USC\+7[BIX>S:(UE9FF.1GDI:F&"I<3O)X@
M*;6*)8EB"4"FBJ!0E<\3PJHI]M3T17!262:59BSFAJ1Q)'<3Z 'AU![%K=W;
M6PV#WEVYBZ3</06 W#F<_P!C[\[C@R%-VWALAEVQF$Z\H>C=G[,P[Y#:&&EW
M?44_\4K<G41UT5$&>&C53^RQN,.WSVCQWC2B77'H\,Z0'# BKDU^VE%(J":5
MJ]812&<B&Z5+A$9PQ.D#0I8@,H+%R!2, 9<A:U(JD<;V-U1BNNMN=6[KH\KE
M:^OW9O"BZ[FR>S*G?=-#M/<%6NZ,-6[BQ.Z*W&05453.?MDJ;.7FI0T>GR@E
M?<;%%O/@;O=[>4CDG/:QTD2.@+A: Z0^D-@4!-,5Z2F^F,DRO>^)<);ZB[-J
M+(K: 6)/>R5H:FI48K3HLE%_,AVCM/MU/AAA=F8?(;\VK2X_; ^0$&"VA0[,
MQF6W!AJO*T\:=30E=R8+*;;HV"5V,JFAIOMX?VYY&D1/9EN")8;39IM.YVR7
MDMS+;I8++(TMLD0!2:>B+&(I2=4:I(SGN+!:$='&P\HC<K[;KJ^N));*:WBF
M)2-5\1W9M=O&2Q"O&BU\4ZD84 C!-0V5OS_V;\U,/M_I7J[I_?-'N+<59G=^
M[?WQMW=&PJ>?%YWH?(X;<>+.?H]OYV'-[(KNRJ&FEEPC5;+3FFIY4JY(8QI8
MMMKS;]TMKL;AN)6UC, EC!)N7AE8EY;.,G3,UJZ#QE+H$+  EF'2^?DCF7EG
M;MLYR@M0=KFN'2VG8 V_U$='C@N'\.D9N%.I%H69%+:=(ZDT/6^1QIRW8/5N
M]-H4N6[8FCW3NG:].)]R1;^K,5]\^#VU5;]R^0FR> IFW@\ZUK7D5:>24$6C
MA<)]IMKJT:Y:.S@%M<JJR:@?&"JXD6JDG4[T"N3JT$L%J,]%7,5W9;SNL5_>
MRW$FXPW;SHL6F*V\65&214,8&A%#OX2Z?3B0.@L^/7S$R^1SGS4Z\[0W3D-E
M9W:RXK9&67K[=^+DFZA[)K-S5BY'8.U,I"L-;1U>'QLR2+7/-5-EVT3!O(65
M2B^W"\GY@W9+Z\>,7+%H@0!0"@UHJBBJ!@J%%"":5)Z..7.7-GO8=NCV^RI]
M,66XJ[2R-4UBA.JC22-GO8C4"22H%.G/N;YN=OT^\^Q-M9/8.P*'8.$W%F-V
M[0WMMCNG%T.YJ[8LM=-B5E[1V_78S)T6XMH9M*25=Q8:'[=<AHB1*NG/K#]K
M<K<(BW4FN$,T2X.K6H!*D^8"L*D!>-.%1TY=[=M&U7MHD27#W,,T9N-04P>%
MJ[V4*-8R"0I8T -:XZ-/U'\E.I]T?&S;>.?<?25758+K+<>V,]L3:6]7V3A*
M?J;;\\6*J:_$9#>T^VUP4B;>C21@]>G\.9@PE?26]A>3EU[GF:YB@DI&)$)C
M) D8O1B$P5"DX%<\0!PJ8;G<[?#N'[TV^5EVB;7+'<*K-&' -2H(#Z%. K@&
M@(J0*]'1[4S6]XML=%9CJNJQN)HLZ^VJ61US>W=PXI,;EL3C9*'"X.ORF7H:
M+<IRN)^YCBJ*!ZF>IC03QHP /N0((% EBDAH(T.!7MI@Y P%QDT'KQZCZ>22
M6626*0R!F+%J %@3741^&O$@<*TZ=1N?;F<R6[=C[*WMCJS?N'Q'5]3V[M.M
MI)]P+M<;_P 3.NUMUYZB+4=5CJS=&W=MUD<<R2R:YX899(24.MJ&YM+6:V>_
MLYIX'<+IC(!#$'2Q)!&@-I+XR,#)Z2W<%]/;S+MU[';W*J6U."00"NI10@ZB
MNH*0<-0FH%"&O;/6.Y=Y;/S:XG8F9['.Y-H[GPE+MS=N]*O;F+RM'O>LQ--+
MC<QCHU@H<3DMF;7HZA<=4/3O*TJ+"#&LDDC5L>:]WDAMMSV3;Q;#1#)$6C\&
M821$@ZT/?$V69QKH[$ \!T2[WLLUM#?V01;ZY'B#2\VN-O%*$H'&"B)7PF !
MQ0$5KTD_EY_%MB[4WU@L35YV7&9'IB@I\)3ME(//N2/:M1'A<ML;'4$=+4YG
M+9)L%6R9*>6CB$D!E,C@J%'M\2&5I9&(+%B3]IR>A B"-$10=(  _P  Z__0
MV56[CWQ@-Y[DR.=Z*VU2SX3*Y_*;;Q1V-1[BCS%)F:K'B;>>%R&+I:R2EVM@
MVQ):ME+15\=+.X0&9HHI2':_#NQ+) Z);:BI!C/8QJP73@M5!@K50#QX="&=
MK,E(S?3_ %("D MIU#@3K(*KI.6!(/"G CKKIWY:=-M+NF#N'*]6?'FAJMT>
M78J55#'0Y7?5;-0T^8WW@]NTM=CJ"IR6!ZVAJ*9S5T:ZJ6FJ&DFCB6)R17RU
M%.MGONZ0[&\UG$4\:98F\* .S)$)I A4&1L(LFG5Y5 )!9?VK;E<6%EMLTEQ
M<?J:5J372NMBM2 .T,Q-<D44$XZ,'#\C_B30Y:BV_D?D=U3UYO7<]94/BMI[
MJJ]C83=&]'JZAHL%O+';:7-FKS6'W;2PI7X^H;6*^BF24JE[*:6>XI>Q7<T.
MQ--9PJ?$(#$1QAJ$NX0A8R3VLU!2A!(-2EGV7<+6ZM[5@9+F14= FIF8NNH
M 9UC*L!W*00:$=+/);IZNW++3O6]G=>]D5L>X5H*[,4%#LG=^/ZYJJO#R9>M
MS^<?);NK:3;FU*H4T1GDI6^V6HD2*VHG2Y?[GL\%Q;V\^R@#X IK4@KK 8^$
M&!"C#N*GM-<Y;LMIW2[M[F]A4QVXA\:I<J)4\01?IT[9*,2.VM &\P1TV25_
M7^U^R^KZS:.W/CMNWK^:KW9E=[;VPV&VI-O/9U9BL/19/8\6TZK IDZ:I/\
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MQ;R[@ZIZ>';V]-Y8W<F0S_3.3[:V[G\[L?&X3>]!B,-NSK_9>Y(,'MC%;,W
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MJ/(T.$@W7#1NN-N]+_$(8)1=UII2KXYMV28MX5I66WTL\;HBNJ,3H;2I)-*
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M*^E7!U]'64..&3[%W1G3!_E]?6M35DD@:68%Y"?:/F^PV7E"WV@;3ODFXR7
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MTJ:>1Z#$T=Q<$S[;MMPNW1DTAN !(LB@++"2>[^U\2%9"*D*6I0CI>;RZ?\
MCUO7LK*S[1WT>RNP\MM_-Y/>>U<-O//[<SG:[Y;<M9)O?&/C*>HGEVYGNMJN
M&')5KPP23OCZ[P 1PMK*+<%OI[>6QV"5$O6"NTLR&10M:L!&Q30S^M>' '!Z
M:N3++!+/NUHT$!*QC10  802::ZQIJB\"&!9B3CI@VSUOL7K;>^XH\+T]V13
MYZNVG44.9H*7N+-91=-%6>*>GJ*I<?5967*EWC1**K7QQT@&@>2S>P5-:;_9
M236>X;G$KLM&18 @(/$TU$T) J.!IFO2FV,%Y96EM;7)DM(JF,!1V G*AOB
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M6R0*!M)(H3;;MKY;N-J@NMRM85EM'=O$!4O*I":(I ^H-HTDPL5!:IC+HI!
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M@Q6>Q66W!B<INC:T,\N]I-N;,D3<483+45=0;;2K;%+)CJ)I#4PRL%\+.X4
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MVJ/L,S71_P 'H<UG_MT\]8SB11)5*-1\9M#WN/937=QMT=M"[E%:-J!G)U?
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MQU5?"C" :@"!(&*!BC"FONXTZ!-CL-E9"W0H9I(+F2YCEDTNXEE9RVFH/AZ
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MSP)5;@S>%PP<4\=)+&9,BK3J3(S7)K&VEV%+C:[9)9YI+QW$MP06!E()1@"
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MR&&P])DI\M"=O9C<&/E*"OF,T,,L:AX2&.GW,U\NRS)%LL;RH75'U/IU&H!
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M780;'?5C)AMVC#2I&BRF%ED(,CA4=URNHU"@$CJI/Y1].=6?$F;JSIGI.H[
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M]D3)C!%7+D%JHZ*JG*L5>SAG=XC');!()Y4#QR^'&ZHA>%U"N5 )!#&I84+
M<:5ZA?:[J7=+2_WFSGVZWMW\>,1NK-<PVQ0AA(P"1NKI04Q67(2M!T"6W-E=
M&;;Q.9VIF*K*97LS>.Y*;"T'5,.Z$S^U:VKR=+5;=PNYGW)D]D8N2/<-#D(!
M*N(2HK:7^"0O50R.)8[J-PO@;6[N+JW7P;1"&\-F%40,T^EJE2NHJBGM=ZL2
M**.DVUR"VO-AO]KEE6>3PYXFGCC#([%&MTEA!K4Z'9UDJJ:8UXOT8W&?"K=^
M]IZ#>&9[C@;=6V<-0[<PV0Q><W #BL5CHHL=1TE&5DI*^*CI88$@@=*A'IXE
M6*+0I*D$6?.6SW5G-;1[ (XW97UO,YE#**+1S2B@$KII0@YJ<]#Z]YCYI-^E
MX)[5H0)5-J+"W%D_COXL[R6M"DDLL@5VD8E@5%* 4Z1&5^,6PMBXO,YOM+L&
M6'$[4R&:J)<Q3U-#C\#4UN8I\1!1X!(FH*U8,[6UV"AIJ6*)?,))FUARSO[D
M'D+F&[W&T6SVK:D37+X>A0TK!5TUDR030$LQ\\YR.B"]YZYJVC>[^59XIKN_
M<2S2/'0@E/""HB%56*.,!8U444"GET:[X9?&?M7Y:X+J3LZ@S78W<F;V+BL[
MM#8/1^5[0V]C=G[=V)35PH*OK+,[LKMN5\NQVS](_EJ9ZZG%?IB18 4,5Y4G
MV&:SYQM[$.LRB-02%HLB2*Q(;BI(!()4E1JTM5@>@%[A<]S6>W<Q[,]M8VL5
M[-#<R/:QLC-/&0R2$ZV!8&A8 Z>&*@]7A?"3JGL'>.TM[YO&_&^HZBZYQ$V[
M,!L_>U%V['/2>?:3/M+(4^R</3X.GR>Y*''C$5S5&=GJJ>DR%=$!1C1ZS..T
M;IN.T6,=A;65M]/$/TR4J5!H&45/ @ 8P0/6G6(^Y"*^O+B\N]PE:XG?5*N1
MJ-207\JU:M:5!/5GGQNW#%O/H_KG=VWNI(]M[+>CFW3M2G[&SN*R>ZI<532U
M\6/W3DZI:ZGIJ#^(TT]1/3QS F"G]4A5W])G9_17]J;V_E>*Z:1@5454#R:H
M4\?3B*CI%O.Y7L]_'']2LK?3Q1?"02J@ 1T-"=)7CFIS6G2M^0J8S.]*[VQG
M<*8?;'4$V)Q&5W3NC;V7QF/J*:GQN6QN;Q(HY*Z3*4+&JSU%1TXCEIJFGJTG
M\9NKGVBWJ?8-JV;<=VFO[E$MXV<Z4D9P$H:KX*,Y-*GL&H4P*]>V%]UDWK;8
M-HMX9=W,ZB.-V5$9ZT =G=54$^;,!\^J2=V]5]'YS=^>:CK>@MM=+;,W#NKM
MSJ'LS8>Z.Q^O^R*'.YVAQVX>P\?W-F\K6;FVA3;=F3'+D<^<;B*&IBJ%IJ7'
M4$B.S-%NZ<Y<MIMI@:*[B?0II)!<M+-'<>&JB.U$#2^*TKJ!(:ZJA@%&IQ+7
M+N\\^\F\S;#S5806EU?)/<F."0*;:.5'(D$LD<J*\6D:@K/X?:0Q- 393\6O
MCSTAOCX_]=;OPV\-H=Q8K=5!79^E[$VY0P4>UMQMD\K4UU2=OXVL\9AQ.*R$
MLE/2F6&.H:.%9'1'8CW)O*][!=;2C:;I7265'602)(KI(R,K*ZZ@592*Y#?$
MK$$'J!N<KOFQ^8KRZ>UL]=RD<PTJ"I65%D!4I(1H(:JKQ4=I (IT).^_CSM/
M:F)BSNSH\+19RES.&A66IQ&*RP$%77QT]2?M?$\DNF-[G]1 !(%[>Q,(K:Y7
MP7CF->&HU44/FI6AQ6GH<]$&W7F_M=1K?16Z6^:Z5TOP-*$.:"M <9'5=VS_
M )&]I[FW=M.ISGQHZ0J/CSVSO7,8C9N\,948,[PJ]PY*N_NI%N[L7J:5Z":#
M.YJAVZ)JNGAC-2<2J2&;4C A%;[:+K=Q8O!J<N8Z&N-)/=Z"IQY5&!U)'T>_
M0;/)?QR,EI0,6KDAP*#2?B7@30, >-#4=,W:6V-P=^]6TWQ/JIJO;>S:O?NS
M>LMSQ[2Q0PN$Q>(KMW1-MZFI-QP05$T6X*3)24_C@FE*4E#")+$E?:?F&:78
M[VUN=NM9;W<G=1*C4TQP2,8C,Q45 'PH#2M.XZ<]*N5(X^84WRUW"[@L-JM8
M)"DBJQ>2>)%E$"AFXN*L2N.(7N!'0L;M^"76O7W7&#P6X**BDP?7I;&[/SF!
MW)7Q]JY9]M2)B-FT6YQE#FJ'(8+>L42IES:GJGI[H@C)'L.[J(N7!?[VMT;F
M\)"B-SJA!D;BL2T"!0,T8UH!6G2'<>9+N]VJVV:V@B@<LB@I7QJ*>XM+JU-4
M9R!QX5QUAVO\4?CG@OCQU7@L'\D]WY?"45#N/I>GQL>?I,!65[[TW=/N_=&U
M^OGJL/2Y"FW1M*ISM1'0ZTJB:4/'(MV8A'OFZ[GMFW3;K;-&=TMXUG>,QN%*
M@"E:-33P4ENT@XIP*6X$IMY0K50AJ$Z221QIP(;%:@U#<:]#KV-\,\_U5U%M
M7&=(_(_O* 4$VUMD[&QV^LYUG5[*V7MW*5#+#4Y.IQO2-=N[)4&%IWT0*]4S
M%F022% ;&&]V_*5U:2<R[AR3MMQ>77AR2,Z/5VDT]S$/3 .!2@H*=&/+EDFX
MM!8+ C1K;EJE$>1A&I8 ZB-3$_/!->@'I^K-UX;9_63=V]D=F;[RNZ?DU!TS
M)BYMR[=H>ML[E*3;VX\SL_N#:!V]UYLO>V-DQ^:A5'HZRNJZ26%*Q6A=9(V1
MFQMN68;"/>=GY9L[*82E6:-6U,@8JR,78]C4J>VH!P0>C>:UGMKZYVF,"/Q[
M=68JBQLPHLBH^BNL!OPDE=0!XCH8\OT=#E*&CJ)-U[63N;:6VZO ;BDVSL:$
M]1TN\<K1M3/C,91Y>K&<Q^S(IX8HYJC[FHK:K0LK>,W"29/N8VK;]GDW>X1+
M= 7U1*!V2T[A&22P!92 &!TJQK7H(Q%-XW;?+;E_9YO ED1(XIYBT@:$$Z7E
M5536VF2A*:0S*@J*U,5A\+MG9VUZ3;E;G=R[9S&Y$I=CU&XH,EMW:6;W/F<=
M40G/1;,PE?M?/9BAV97UT$NFJR)B@BH&$GG"LD[E,\WQB;1I#'4::0QX5-"3
MYX&HG/$];21 WU%O&Z(V55SJ:,5J%)H 77 8Z14@X'#ICW?T=T)O_L/KQ,MU
MQ59OL;;> K=_[4E@W-'1C*;7I\CCMOU^XJ_<6R:O$4NZDI*O,T\:TM=622R+
M4M+%&2K2"UG9V%PRQ7DK1Q("P*D][<*,0K&M*@-2@X'B.G9=ZW/;3+<VA7QI
M.TZE#:5!K1 > U&I _+SZ >@_E5]34<5?B\!ENV=MX_(Y6HDB>BW;M>J?&TN
M3.<C-"D]115=768;"/GZKQP5!FET.+EVU>_7/+W+]PM9K^Z9:=RAJ!J,K:/[
M+MU4%2*4(J"IST+.4/>+FODW>K7>]KVO;IMQB0B(S1NPCD;X9ETR(3)$W>@8
MF.I(=&0E2Z[3W)M'=F:VYL7K3J;N3(14%'ANK\ON2LW/AME[2..V;EOX-D!N
M*E,<^)FS^.JL>:@5L5*V3F\R1+=&\8]++])>2%+0)<34E-.-#@%FKQ"T4Y->
C.22>@S(4W*W,E]N08ZY#0K75([&5R%X EF)& %% !I I_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g22578img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g22578img002.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ "P"H P$1  (1 0,1 ?_$ 'L   ,! 0$!
M      @)"@8$!0<! 0                     0   #!08% 00'!@<
M  0%!@(#% <( 1,5%A<) !$2&!DD,2(C)2%B,S4F"AI!430V)S@R0E)#8U5F
M$0$                     _]H # ,!  (1 Q$ /P"H384%"AVSMM]BQHD0
M,%OZ?R1M^)%/G@@0^;M.#NSK>OGS3;QXURLL^FVVWZ. 17OYU*/5S60;E$OZ
MFY=R656SY(%%UL(Y%JR:"209A/:JU73(2JP*)1@"4^.BTR6CLOILEZ;-VA0+
ML0^C50%<6L<A'2\!R.XM+*D;<@VJ515@JT$7S*+D_19-VIFFY1/E IBH:A%
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E?$?<S=B$)Z.'X!N);]YF/\N?;.?NW[S^P??>/_-_H^IU<!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
